

AUROBINDO PHARMA LIMITED

Financials of Subsidiaries for the year 2014-15



AUROBINDO

Aurobindo Pharma Limited

Financials of Subsidiaries for the year 2014-15



S.No.	Name of the Subsidiary	Page No.s
1	Helix Healthcare B.V.	1 - 20
2	Agile Pharma B.V.	21 - 41
3	APL Holdings (Jersey) Limited	42 - 55
4	Agile Malta Holdings Limited	56 - 76
5	Laboratorios Aurobindo S.L.	77 - 100
6	Pharmacin B.V.	101 -122
7	Milpharm Limited	123 -143
8	Aurobindo Pharma (Malta) Ltd	144 - 167
9	APL Swift Services (Malta) Ltd	168 - 190
10	APL IP Co. Limited	191 - 203
11	Aurobindo Pharma Gmbh Germany	204 - 224
12	Aurobindo Pharma B.V.	225 - 240
13	Aurobindo Pharma (Romania) s.r.l	241 - 267
14	Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi	268 - 288
15	Aurobindo Pharma (Portugal) Unipessoal Limitada	289 - 324
16	Aurovitas S.L.	325 - 344
17	Aurex B.V.	345 - 358
18	Aurobindo Pharma (Italia) S.r.l	359 - 377
19	Aurovitas, Unipessoal LDA	378 - 427
20	Actavis Management GmbH	428 - 447
21	Actavis Deutschland GmbH & Co., KG	448 - 473
22	Aurovitas Spain S.A.U. (formerly known as Actavis Spain S.A.U)	474 - 499
23	Actavis B.V.	500 - 525
24	APL Pharma Thai Limited	526 - 543
25	Aurobindo Pharma Industria Farmaceutica Ltd	544 - 557
26	Aurobindo Pharma Produtos Farmaceuticos Limitada	558 - 571
27	All Pharma (Shanghai) Trading Co Ltd	572 - 588
28	Auro Pharma Inc.	589 - 601
29	Aurobindo Pharma (Australia) Pty Ltd	602 - 622
30	Aurobindo Pharma (Pty) Ltd	623 - 645
31	Auro Healthcare (Nigeria) Limited	646 - 654
32	Aurobindo Pharma Japan KK	655 - 672
33	Aurobindo Pharma (Singapore) Pte Limited	673 - 687
34	Aurobindo Pharma Limited, s.r.l	688 - 700
35	Aurovida Farmaceutica SA DE CV	701 - 719
36	Aurobindo Pharma Colombia S A S	720 - 742
37	Aurobindo Pharma USA Inc. (Consolidated)	743 - 772
38	Aurobindo Pharma NZ Limited	773 - 773
39	Arrow generiques SAS	774 - 801
40	Actavis France SAS	802 - 824
41	APL Research Centre Limited	825 - 851
42	APL Healthcare Limited	852 - 887
43	Auronext Pharma Private Limited	888 - 938
44	Auro Peptides Ltd	939 - 988
45	Aurobindo Antibiotics Ltd	989 - 1015
46	Curepro parenterals Ltd	1016 - 1045
47	Eugia Pharma Specialities Ltd	1046 - 1082
48	Hyacinths Pharma Pvt.Ltd	1083 - 1108
49	Silicon Life Sciences Pvt.Ltd.	1109 - 1148
50	AuroZymes Limited	1149 - 1178

Helix Healthcare B.V.
Amsterdam, the Netherlands

Annual report
for the financial year ended 31 March 2015

Helix Healthcare B.V.
Prins Bernhardplein 200
1097 JB Amsterdam
The Netherlands
Chamber of Commerce: 34.187.780

Page 1 of 18

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountants & Tax Advisors B.V.

13 MAY 2015

Helix Healthcare B.V., Amsterdam, the Netherlands

<u>Table of contents:</u>	<u>PAGE</u>
Board report	
Director's report	3
Financial statements	
Balance sheet as at 31 March 2015 (before appropriation of result)	6
Profit and loss account for the period from 1 April 2014 until 31 March 2015	7
Notes to the financial statements	8
Other Information	
Appropriation of results	17
Subsequent events	17
Audit of financial statements	17
Independent auditor's Report	18

Helix Healthcare B.V., Amsterdam, the Netherlands

Director's report

The management herewith presents to the shareholder the annual accounts of Helix Healthcare B.V. (hereinafter: "the Company") for the period 1 April 2014 until 31 March 2015.

General

The Company is a private limited liability company incorporated under the laws of the Netherlands and acts as an intermediate holding and financing company. The ultimate holding company is Aurobindo Pharma Limited, Hyderabad, India.

Overview of activities

On 18 December 2014, Aurobindo Pharma Ltd. S.R.L., Dominican Republic was liquidated. As a result no liquidation distribution is expected.

During the year the Company received several share premium contributions from its shareholder for a total amount of EUR 5,212,557 comprising of EUR 550,000 and USD 5,350,000 (equivalent to EUR 4,662,557). Furthermore, the Company received several repayment loans from Agile Pharma B.V. and Aurobindo Pharma USA Inc. in the amount of EUR 45,600,000 and USD 20,000,000 (equivalent to EUR 16,241,676) respectively. The Company received a loan from ANZ Bank in the amount of EUR 15,000,000 and APL IP Company Ltd. in the amount of EUR 1,000,000. These funds were used to finance, towards loans and/or repayment intercompany loans from/to subsidiaries and shareholder. Capital and Loan contributions, which were made available to the following investments:

- a) Capital contribution in Aurobindo Pharma Colombia S.A.S., in the amount of EUR 180,000;
- b) Capital contribution in Aurobindo Pharma Nigeria Ltd., in the amount of EUR 22,500 (equivalent to USD 30,000);
- c) Capital contribution in Aurobindo Pharma Australia Pty Ltd., in the amount of EUR 322,000;
- d) Capital contribution in Aurobindo Ilac San ve Tic LS, in the amount of EUR 720,000;
- e) Capital contribution in Aurobindo Pharma (Singapore) Pte Ltd., in the amount of EUR 6,028 (equivalent to SGD 10,000);
- f) Capital contribution in Aurovida Farmaceutica S.A., Mexico, in the amount of EUR 1,940,100;
- g) Loan to Aurobindo Pharma Australia Ltd., in the amount of EUR 1,200,000. The full outstanding amount including interest payable by Aurobindo Pharma Australia Ltd has been converted into equity during the year.
- h) Loan to Agile Pharma B.V., in the amount of EUR 31,150,000;
- i) Loan to Aurobindo Pharma USA Inc., in the amount of EUR 16,214,025 (equivalent of USD 20,000,000), which was fully repaid during the year.
- j) Loan to Auro Pharma Inc., Canada, in the total amount of EUR 1,413,436 (equivalent of CAD 2,000,000);
- k) Repayment of shareholder's loan, in the total amount of EUR 9,299,735;
- l) Repayment of credit facility B with ANZ bank, including interest in the total amount of EUR 18,000,000;
- m) Repayment of loan taken from APL IP Company Ltd. Jersey, in the total amount of EUR 1,000,000;

Results

The net asset value of the Company as at 31 March 2015 amounts to EUR 82,125,306 (31 March 2014: EUR 77,414,426).

The result for the period 1 April 2014 until 31 March 2015 amounts to a loss of EUR 501,677 (2013/2014: EUR 1,548,114 loss).

Liquidity and capital resources

Liquidity has increased and shareholder's equity has increased due to share premium contributions from the Company's shareholder. Both are considered sufficient in view of the nature of the Company's business.

Financial Instruments

The risks the Company runs in relation to financial instruments are limited to interest rate risk and credit risk. The interest rate risk is addressed and mitigated by a fixed positive margin between rates on borrowings and lendings.

Credit risk

Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's investments. The quality of the Company's credit portfolio consisting of investments and loan advances to group companies is monitored on a risk as normal.

Helix Healthcare B.V., Amsterdam, the Netherlands


Future outlook


No material change in activities is contemplated for the coming year. It is expected that the result will be in line with that of the reporting period. Furthermore management has no current plans which would have a significant influence on expectations concerning future activities, investments, financing, staffing and profitability.

Subsequent events

On 10 April 2015, the Company sold its interest in Aurobindo Pharma Australia Ltd., Australia for a consideration of Euro 1,240,519 (equivalent to AUD 1,750,000) realizing a loss of EUR 6,846,765.

On behalf of the Board of Directors
Amsterdam, 13 May 2015


G. Phaneendra Prasad
Director


Intertrust (Netherlands) B.V.
Director

Helix Healthcare B.V., Amsterdam, the Netherlands

Balance sheet as at 31 March 2015

(Before the proposed appropriation of the result and expressed in euros)

	Notes	31-Mar-2015	31-Mar-2014
ASSETS			
Fixed assets			
Interest in group companies	1a	74,367,548	69,123,014
Loans to group entities	1b	32,708,807	31,556,630
Total fixed assets		107,076,355	100,679,644
Current assets			
Amounts owed by group entities	2	903,153	15,936,472
VAT receivable 2014/2015		39,213	-
Cash and cash equivalents	3	1,182,126	213,683
Total current assets		2,124,492	16,150,155
Total assets		109,200,847	116,829,799
SHAREHOLDER'S EQUITY AND LIABILITIES			
Shareholder's equity			
Paid up and called up share capital	4	18,000	18,000
Share premium		88,989,996	83,777,439
Other reserves		(6,381,013)	(4,832,899)
Unappropriated results		(501,677)	(1,548,114)
Total shareholder's equity		82,125,306	77,414,426
Long term liabilities (due after one year)			
Bank loans	5	6,000,000	15,000,000
Current liabilities (due within one year)			
Amounts due to group entities	6	-	9,378,207
Bank loans	7	21,000,000	15,000,000
Accruals and deferred income	8	75,541	37,166
Other liabilities		-	-
Total current liabilities		21,075,541	24,415,373
Total shareholder's equity and liabilities		109,200,847	116,829,799

The accompanying notes form an integral part of these financial statements.

Helix Healthcare B.V, Amsterdam, the Netherlands

Profit and loss account for the period from 1 April 2014 until 31 March 2015

	Notes	01-Apr-2014 31-Mar-2015	01-Apr-2013 31-Mar-2014
(Expressed in euros)			
Net revenues			
Operating expenses			
Other operating expenses	9	(252,531)	(124,039)
<i>Total operating expenses</i>		<u>(252,531)</u>	<u>(124,039)</u>
Operating result		(252,531)	(124,039)
Financial income and expenses			
Other Income		11,907	-
Total Interest Income	10	590,372	64,247
Total Interest expenses	11	(428,369)	(151,831)
Amortisation of arrangement fees	12	-	(112,500)
Release of loans to Aurobindo Switzerland AG		-	(152,478)
Other Interest Income		-	254
Currency translation results	13	(389,556)	(96,225)
Result of participations	14	(33,500)	(975,542)
<i>Total financial income and expenses</i>		<u>(249,146)</u>	<u>(1,424,075)</u>
Result before taxation		(501,677)	(1,548,114)
Corporate income tax	15	-	-
Net result after taxation		<u>(501,677)</u>	<u>(1,548,114)</u>

The accompanying notes form an integral part of these financial statements.

Helix Healthcare B.V., Amsterdam, the Netherlands

Notes to the financial statements

General

The Company was incorporated as a private limited liability company under the laws of the Netherlands on 21 January 2003. The registered office of the Company is in Amsterdam, the Netherlands.

The principal activity of the Company is to act as a holding and finance company and its place of business is at Prins Bernhardplein 200, 1097 JB Amsterdam, the Netherlands.

Group structure

The Company is part of a group headed by Aurobindo Pharma Limited, Hyderabad, India, a company incorporated under the law of India and listed at the stock exchange in Mumbai, India. The direct shareholder and immediate holding company is Aurobindo Pharma Limited, Hyderabad, India.

The financial information of the Company is recorded in the consolidated financial statements of Aurobindo Pharma Limited in Hyderabad, India. Copies are available at the Trade Register of the Chamber of Commerce in Amsterdam, the Netherlands.

Basis of presentation

The financial statements are prepared in accordance with accounting principles generally accepted in the Netherlands and comply with the financial reporting requirements included in Part 9 of Book 2 of the Dutch Civil Code. The financial statements are prepared under the historical cost convention and presented in euros (EUR or €).

Income and expenses are accounted for on accrual basis. Profit is only included when realized on balance sheet date. Liabilities and any losses originating before the end of the financial year are taken into account if they have become known before preparation of the financial statements.

The Company qualifies as a small sized company. Therefore, based on article 396 Book 2 of the Dutch Civil Code, exemptions apply to the presentation and disclosures in the Company's financial statements.

The financial statements have been prepared in accordance with the general provision of Title 9, Book 2 of the Dutch Civil Code. As allowed in art. 2:396 paragraph 6 of the Dutch Civil Code, the valuation of the assets and liabilities and the determination of the result is based on the principles for determination of the taxable profit, as meant in chapter 11 of the Corporate Income Tax Act 1969.

Going Concern

The equity of the Company amounts to EUR 82,125,306 positive. Management has assessed this situation and has a reasonable expectation that the Company has adequate resources to continue in operational existence in the foreseeable future.

Comparison previous year

The accounting principles remained unchanged compared to the previous year.

Consolidation

The Company does not prepare consolidated financial statements in accordance with article 408, Book 2 of the Dutch Civil Code. The figures of the Company are included in the consolidated financial statements of Aurobindo Pharma Ltd. that are filed with the Chamber of Commerce in the Netherlands. The Company values its investments in group companies, subsidiaries and associates at historical cost. In accordance with article 2:379 sub 2c the Company is exempted from disclosing its share in the equity and result of these investments.

Foreign currencies

The functional currency of the Company is EUR.

Assets and liabilities denominated in foreign currencies are translated at year-end exchange rates. Foreign currency transactions are accounted for at the exchange rates prevailing at the date of the transactions. Gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement. Non-monetary balance sheet items, which are valued at cost and resulting from transactions in foreign currencies, are translated at the rate prevailing on the date of the transaction.

Helix Healthcare B.V., Amsterdam, the Netherlands

Notes to the financial statements (continued)

Foreign currencies (continued)

The exchange rates used in the annual accounts are:

	31.03.2015	31.03.2014
1 EUR = USD (US dollar)	1.07290	1.37950
1 EUR = GBP (Pound sterling)	0.72540	0.82840
1 EUR = AUD (Australia dollar)	1.41070	1.49600
1 EUR = CAD (Canadian dollar)	1.36630	1.52300
1 EUR = CHF (Swiss Frank)	1.04470	1.21850
1 EUR = ZAR (Rand)	13.10640	14.62000
1 EUR = NGN (Naira)	213.59800	229.69000
1 EUR = JPY (Japanese Yen)	128.80000	142.40000
1 EUR = TRY (Turkish Lira)	2.80820	2.96500
1 EUR = SGD (Singapore Dollar)	1.47330	1.73750

Financial instruments

Financial instruments include both primary financial instruments, such as receivables and liabilities, and financial derivatives. Reference is made to the recognition per balance sheet item for the principles of primary financial instruments. Financial instruments are valued at amortized cost unless explained otherwise in the notes. Due to the short-term nature of the financial instruments included in these financial statements, the estimated fair value for these financial instruments approximates the book value. This also applies to the long-term loans receivable and payable, as terms and conditions are market based and the interest rate is variable.

Financial fixed assets

- (i) Due to the fact that consolidation exemption of art. 2:408 of Book 2 of the Dutch Civil Code is applicable, the interests in subsidiaries are valued at cost price.
- (ii) Investments in associates are stated at net asset value. Associates are entities of which the Company generally has between 20% and 50% of the voting rights, or over which the Company has significant influence, but which it does not control. Associated companies over which the Company has no significant influence are accounted for at cost.
- (iii) Other participating investments are valued at cost.
- (iv) Where a permanent diminution in value occurs in the subsidiary and/or associate valued at cost, the carrying amount is written down to its estimated recoverable amount.
- (v) The carrying amount is minimally stated at zero, unless the Company has incurred obligations or guaranteed obligations in respect of the subsidiary and/or associated company. In that case a provision will be formed.

Receivables

The receivables are valued at fair value and then valued at amortised cost. Provisions deemed necessary for possible bad debt losses are deducted. These provisions are determined by individual assessment of the receivables.


Cash and cash equivalents

Cash and cash equivalents includes bank balances, which are at free disposal of the company.

The Company has not presented a cash flow statement, as allowed by RJ 360.104, as the cash flows are included in the consolidated cash flow statement of the parent company and the annual report of the parent company is publicly available.

Long-term and short-term liabilities

Upon initial recognition, loans and liabilities recorded are stated at fair value and then subsequently valued at amortised cost.

 Grant Thornton
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountants & Adviseurs B.V.

Helix Healthcare B.V., Amsterdam, the Netherlands

Notes to the financial statements (continued)

Principles for the determination of the result

Share in result of associated companies

Where significant influence is exercised over associated companies, the share of the legal entity in the associated companies' results is included in the profit and loss account.

Where no significant influence is exercised or the associate is valued at cost, the dividend income is accounted for in the profit and loss account as financial income.

Corporate income tax

Corporate income tax is calculated at the applicable rate on the result for the financial year, taking into account permanent differences between profit calculated according to the financial statements and profit calculated for taxation purposes. Temporary differences between the reporting for tax purposes and the financial statements are recognized as deferred taxes based on the current tax rate. Deferred tax assets and liabilities are netted. Net deferred tax assets will be included in the balance sheet if actual realisation is assumed probable by the Company's management.

Corporate income tax expense comprises current and deferred tax. Current tax is the expected tax payable on the taxable income for the year and any adjustment to tax payable in respect of previous years. Corporate income tax expense is recognised in the profit and loss account except to the extent that it relates to items recognised directly in equity.

The Company is part of a fiscal unity with its subsidiaries, Agile Pharma B.V., Aurobindo Pharma B.V., Pharmacin B.V., Actavis B.V. and Aurex B.V. for corporate income tax purposes with its group companies and other wholly owned subsidiaries in the Netherlands. The Company is the head of the fiscal unity. As a result of the fiscal unity the Company is jointly and severally liable for the related tax liabilities of the entire fiscal unity.

Estimates

The preparation of the financial statements requires management to make estimates and assumptions that influence the application of principles and the reported values of assets and liabilities and of income and expenditure. The actual results may differ from these estimates. The estimates and the underlying assumptions are constantly assessed. Revisions of estimates are recognised in the period in which the estimate is revised and in future periods for which the revision has consequences.

Helix Healthcare B.V, Amsterdam, the Netherlands

Notes to the financial statements (continued)

	31-Mar-2015	31-Mar-2014
Notes to the Balance sheet	EUR	EUR
1a Interest in group companies		
a) Interest in group companies	74,367,548	69,123,014
b) Loans to group entities	32,708,807	31,556,630
	<u>107,076,355</u>	<u>100,679,644</u>

Movements in the financial fixed assets have been as follows:

Balance as per 1 April 2014	100,679,644
Share premium contribution	3,190,629
Loan and interest converted into equity	2,087,405
Converted into equity	(2,061,630)
Advance	33,763,436
Repayments	(30,600,000)
Desinvestments	(33,500)
Currency exchange rate differences	50,371
Balance as per 31 March 2015	<u>107,076,355</u>

1a Interest in group companies



The investments in subsidiaries and associated companies can be detailed as follows:

Name company	Registered place of business	Percentage in share capital		
Auro Pharma Inc.	Montreal, Canada	100% (100%)	3,111,717	3,111,717
Aurobindo Pharma Pty. Ltd.	Johannesburg, South Africa	100% (100%)	3,969,418	3,969,418
Aurobindo Pharma Colombia S.A.S.	Bogota, Colombia	100% (100%)	187,400	7,400
Agile Pharma B.V.	Amsterdam, Netherlands	100% (100%)	40,365,000	40,365,000
Aurobindo Healthcare Nigeria Ltd.	Lagos, Nigeria	100% (100%)	314,408	291,907
Aurobindo Pharma Australia Ltd.	Sydney, Australia	100% (100%)	8,087,284	5,677,879
Aurobindo Pharma Japan KK	Osaka, Japan	100% (100%)	1,184,006	1,184,006
Aurobindo Ilac San ve Tic. LS	Istanbul, Turkey	99.99% (99.99%)	2,686,822	1,966,822
Milpharm Limited	Hayes, United Kingdom	100% (100%)	9,337,988	9,337,988
Aurobindo Pharma (Singapore) Pte Ltd.	Singapore	100% (100%)	58,405	52,377
Aurovida Farmaceutica S.A.	Mexico	100% (100%)	5,065,100	3,125,000
Aurobindo Pharma Ltd. Srl	Santo Domingo, Dominican Republic	0% (100%)	-	33,500
			<u>74,367,548</u>	<u>69,123,014</u>

During the year, under review, the Company increased the capital in its subsidiaries by means of share premium contributions for a total amount of EUR 3,190,629. Furthermore the loan and accrued interest in the amount of EUR 2,087,405 of Aurobindo Pharma Australia Ltd. converted in to equity of Aurobindo Pharma Australia Ltd.

1b Loans to group entities

a) Agile Pharma B.V.				14,500,000
Agile Pharma B.V.			31,245,000	16,195,000
b) Aurobindo Pharma Australia Ltd.				861,630
c) Aurobindo Pharma Inc. Canada	CAD	2,000,000	1,463,807	
			<u>32,708,807</u>	<u>31,556,630</u>

 Grant Thornton
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants and Advisers B.V.

13 MAY 2015

Notes to the financial statements (continued)

(Expressed in euros)

Notes 1b loans to group entities (continued)


- a) On 31 March 2014, the Company received advances under this loan facility for a total amount of EUR 29,500,000. An amount of EUR 15,000,000 is classified as short-term loan and has a maturity of 1 year and bears an interest rate of 3 months EURO-LIBOR + 1.5% per annum and a remainder of EUR 14,500,000 classified as long-term. The loan has a maturity of 3 years and bears an interest rate of 3 months EURO-LIBOR + 1.5% margin per annum. In April 2014, the short-term loan was fully repaid.
- On 1 April 2014, the Company entered into a loan facility agreement with Agile Pharma B.V. for a total amount of EUR 35,000,000. The loan has not been secured, has a maturity of 5 years and bears an interest rate of 6 months EURO-LIBOR + 1.5% per annum.
- b) On 1 August 2013, the Company entered into a loan agreement with Aurobindo Pharma Australia Ltd. in the amount of EUR 2,200,000. The loan has not been secured, has a maturity of 5 years and bears an interest rate of 6 months EURO-LIBOR + 1% per annum. As per 19 March 2015, the Company has converted the loan receivable and accrued interest into equity.
- c) The loans to Auro Pharma Inc., Canada consist several loan agreements. The conditions are as follows:
- On 1 October 2014, the Company entered into loans with Auro Pharma Inc., Canada in the amount of CAD 1,000,000. The loan has not been secured, has a maturity of 5 years and bears an interest rate of 6 months CAD LIBOR plus 1% per annum.
 - On 23 February 2015, the Company entered into loans with Auro Pharma Inc., Canada in the amount of CAD 1,000,000. The loan has not been secured, has a maturity of 3 years and bears an interest rate of 6 months CAD LIBOR plus 1% per annum.

2 Amounts owed by group entities

a) Auro Pharma Inc. Canada	760,000	760,000
b) Agile Pharma B.V.	-	15,000,000
Interest receivable Agile Pharma B.V.	134,241	146,029
Interest receivable Aurobindo Pharma Japan	-	8,434
Interest receivable Milpharm Limited	-	7,102
Interest receivable Auro Pharma Inc. Canada	4,225	11,218
Interest receivable Auro Pharma Inc. Canada CAD	4,687	-
Interest receivable Aurobindo Pharma Australia Ltd.	-	3,689
	<u>903,153</u>	<u>15,936,472</u>

- a) On 31 December 2012, the Company entered into a loan agreement with Auro Pharma Inc., Canada, the loan has not been secured, will mature after two years from the date of the agreement and can be extended with rescheduled with mutual agreement. The loan attracts an interest rate of 3 month-Euribor plus 1% per annum. The loan has been reclassified from long-term loan.
- b) Further information was disclosed in note 2b of the financial statements. The loan was repaid on 29 April 2014.

Balance as per 1 April 2014	15,000,000
Repayment	(15,000,000)
Balance as per 31 March 2015	<u>-</u>

 Grant Thornton
INITIALLED FOR IDENTIFICATION
PURPOSE ONLY
Grant Thornton
Accountants en Adviseurs B.V.
13 MAY 2015

Helix Healthcare B.V., Amsterdam, the Netherlands

Notes to the financial statements (continued)

			31-Mar-2015	31-Mar-2014
			EUR	EUR
3 Cash and cash equivalents				
Current account			152,302	207,760
Current account	USD	1,095,166	1,020,753	5,092
Current account	GBP	6,139	8,463	309
Current account	CHF	635	608	522
			<u>1,182,126</u>	<u>213,683</u>

The cash amount of EUR 1,182,126 is available on demand.

4 Shareholder's equity

	<u>Share capital</u>	<u>Share premium</u>	<u>Other reserves</u>	<u>Unappr. results</u>
Balance as per 01.04.2013	18,000	64,709,505	(4,556,064)	(276,835)
Paid-in / (repaid)	-	19,067,934	-	-
Transfer	-	-	(276,835)	276,835
Result for the period	-	-	-	(1,548,114)
Balance as per 01.04.2014	<u>18,000</u>	<u>83,777,439</u>	<u>(4,832,899)</u>	<u>(1,548,114)</u>
Paid-in / (repaid)	-	5,212,557	-	-
Transfer	-	-	(1,548,114)	1,548,114
Result for the period	-	-	-	(501,677)
Balance as per 31.03.2015	<u>18,000</u>	<u>88,989,996</u>	<u>(6,381,013)</u>	<u>(501,677)</u>

Issued share capital

The authorised share capital of the Company amounts to EUR 90,000 divided into 9,000 shares of EUR 10 each. Issued and paid up are 1,800 shares of EUR 10 each.

Share premium

During the year the Company received several share premium contributions from its shareholder for a total amount of EUR 5,212,557. Additional information has been disclosed in the report of management under the overview of activities.

Other reserves


In the annual general meeting of shareholders held on 26 May 2014 it was decided to add the balance of the unappropriated result 2013/2014 to the other reserves.

Contingent Liabilities

The Company is part of a fiscal unity with its subsidiaries Agile Pharma B.V., Aurobindo Pharma B.V., Pharmacin B.V. Aurex B.V. and Actavis B.V. for corporate income tax purposes. The Company is the head of the fiscal unity. As a result of the fiscal unity the Company is jointly and severally liable for the related tax liabilities of the entire fiscal unity.

Guarantees

The Company acted as Purchaser Guarantor in connection with the acquisition of the North Western European operations from Actavis Inc by Agile Pharma BV. During the year, all conditions precedent from the share and asset purchase agreements have been fulfilled and the purchase price has been released in full to the vendor.

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountant for Actavis B.V.
13 MAY 2015

Helix Healthcare B.V., Amsterdam, the Netherlands

Notes to the financial statements (continued)

	31-Mar-2015	31-Mar-2014
	EUR	EUR
5 Bank loans		
Australia & New Zealand Banking Group Ltd.	6,000,000	15,000,000
	<u>6,000,000</u>	<u>15,000,000</u>
Balance as per 1 April 2014	15,000,000	
Repayment	(3,000,000)	
Reclassification to long-term loan (note 7)	(6,000,000)	
Balance as per 31 March 2015	<u>6,000,000</u>	

Further information was disclosed in note 7 of the financial statements.

Repayment of Facility A loan:

The Company shall repay the Facility A in installments by repaying on each Facility A Repayment Date an amount in Euro equal to the relevant percentage of the aggregate outstanding of Facility A as set out in the following table:

31 March 2015	20% (Paid by 31 March 2015)
30 September 2015	20%
31 March 2016	20%
30 September 2016	20%
31 March 2017	20%

6 Amounts due to group entities

• Aurobindo Pharma Ltd., India	-	5,371,801
• Aurobindo Pharma Ltd., India	-	3,533,371
Interest loan payable to Aurobindo Pharma Ltd., India	-	153,340
Interest loan payable to Aurobindo Pharma Ltd., India	-	319,695
	-	<u>9,378,207</u>

• The loans from Aurobindo Pharma Ltd. consist several loan agreements. The conditions are as follows:

- The GBP loan for the amount of GBP 3,550,000 bears Libor + 1% interest per annum.
- The GBP loan for the amount of GBP 1,000,000 bears Libor + 1% interest per annum.
- The Euro loan of EUR 3,500,000 bears Libor + 2% interest per annum.
- The Euro loan of EUR 500,000 bears Libor + 1% interest per annum.
- The Euro loan of EUR 1,000,000 bears Libor + 1% interest per annum.
- The Euro loan of EUR 3,000,000 bears Libor + 1% interest per annum.
- The Euro loan of EUR 5,000,000 bears Libor + 1% interest per annum.

Balance as per 1 April 2014	8,905,172
Repayment	(9,229,735)
Currency exchange rate differences	324,563
Balance as per 31 March 2015	<u>-</u>

The Company has redeemed the loans during the year 2014/2015.

Notes to the financial statements (continued)

	31-Mar-2015	31-Mar-2014
	EUR	EUR
7 Bank loans		
Australia & New Zealand Banking Group Ltd.	21,000,000	15,000,000
	<u>21,000,000</u>	<u>15,000,000</u>

On 31 March 2014, the Company entered into a loan facility agreement with Australia and New Zealand Banking Group Limited for a total amount of EUR 30,000,000. The loan consists two facilities (i.e. facility A EUR 15,000,000 and facility B EUR 15,000,000), of which the facility A is classified as long-term loan. The loans are guaranteed by Aurobindo Pharma Ltd., India. Facility A has a maturity of 3 years and bears an interest rate of 1 month EURIBOR + 1.35% margin per annum. Facility B has a maturity of 1 year and bears an interest rate of 1 month EURIBOR + 1.25% margin per annum. On 29 April 2014, the facility B was repaid. Subsequently, on 22 September 2014, the Company withdrawal of new credit facility B with ANZ bank in the same amount of EUR 15,000,000.

Repayment of Facility B loan:

The Company shall repay each facility B loan on the last day of its interest period.


8 Accruals and deferred income

Administration fees payable	17,628	12,166
Audit fees payable	12,100	18,000
Tax adviser fees payable	47,535	7,000
Other receivable	(1,722)	-
	<u>75,541</u>	<u>37,166</u>

Helix Healthcare B.V., Amsterdam, the Netherlands

Notes to the financial statements (continued)

			01-Apr-2014 31-Mar-2015	01-Apr-2013 31-Mar-2014
			EUR	EUR
Notes to the Profit and loss account				
9 Other operating expenses				
Management fee			4,000	4,840
Administration fee			92,688	67,138
Tax advice			79,472	21,695
Bank charges			5,003	4,408
Audit fee			10,313	17,348
Law firm			585	2,065
General expenses			60,470	22
VAT expense			-	6,523
			<u>252,531</u>	<u>124,039</u>
10 Total interest income				
Auropharma Inc. Canada			8,970	9,050
Auropharma Inc. Canada	CAD	6,404	4,635	-
Milpharm Limited			-	10,705
Agile Pharma B.V.			554,681	39,939
Aurobindo Pharma Japan			-	864
Aurobindo Pharma Australia Ltd.			22,086	3,689
			<u>590,372</u>	<u>64,247</u>
11 Total interest expenses				
a) Interest on loans from group entities			77,525	151,831
b) Interest on loans from Bank			350,844	-
			<u>428,369</u>	<u>151,831</u>
a) Interest on loans from group entities				
Aurobindo Pharma Ltd. India	GBP	35,084	43,845	85,880
Aurobindo Pharma Ltd. India			33,680	65,951
			<u>77,525</u>	<u>151,831</u>
b) Interest on loans from Bank				
Australia & New Zealand Banking Group			350,844	-
			<u>350,844</u>	<u>-</u>
12 Amortisation of arrangement fees				
Arrangement fee credit facility agreement loan EUR 30,000,000			-	112,500
			-	<u>112,500</u>
13 Currency translation results				
On finance activities			389,556	96,225
			<u>389,556</u>	<u>96,225</u>
14 Result of participations				
Aurobindo Switzerland AG			-	975,542
Aurobindo Pharma Ltd. S.R.L., Dominic Republic			33,500	-
			<u>33,500</u>	<u>975,542</u>

 Grant Thornton

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants en Adviseurs B.V.

13 MAY 2015

Helix Healthcare B.V., Amsterdam, the Netherlands

Notes to the financial statements (continued)


	EUR	EUR
15 Corporate Income Tax		
Provision for C.I.T. 2014/2015 (2013/2014)		


Final corporate income tax assessments have been received for the financial year through 2012/2013.

Staff numbers and employment costs

The Company has no employees and hence incurred no wages, salaries or related social security charges during the reporting period, nor during the previous year.

On behalf of the Board of Directors
Amsterdam, 13 May 2015


G. Phaneendra Prasad
Director


Intertrust (Netherlands) B.V.
Director

Helix Healthcare B.V., Amsterdam, the Netherlands

Other information

Appropriation of results

Statutory appropriation of results

In accordance with article 21 of the articles of association of the Company, the general meeting shall determine the allocation of accrued profits of the Company. According to the articles of association of the Company, the general meeting may resolve to make payments to the charge of any reserve which need not be maintained by virtue of to the extent such an amount shall not exceed the amount of the distributable part of the net assets.

Section 216, Book 2, Dutch Civil Code, prescribes that the general meeting may resolve on any profit distribution to the extent that the shareholder's equity exceeds the amount of the reserves to be maintained by law and the articles of association of the Company. The Company may only follow a resolution of the general meeting to distribute after the management board has given its approval to do this. The management board withholds approval, at the moment of distribution, only if it knows or reasonably should be able to foresee that the Company cannot continue to pay its due debts after the distribution.

The management proposes to the shareholder to add the result for the year to the other reserves.

Appropriation of results of previous years

In the annual general meeting of shareholders held on 26 May 2014 it was decided to add the balance of the unappropriated result 2013/2014 to the other reserves.

Proposed appropriation of result current year



Management proposes to add the entire profit to the other reserves.

Subsequent events

On 10 April 2015, the Company sold its interest in Aurobindo Pharma Australia Ltd., Australia for a consideration of Euro 1,240,519 (equivalent to AUD 1,750,000) realizing a loss of EUR 6,846,765.

Independent auditor's Report

The independent auditors' report is set on the next page.

 Grant Thornton
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants & Adviseurs B.V.

13 MAY 2015

Independent auditor's Report

Grant Thornton
Accountants en Adviseurs B.V.
Gedempte Zalmhaven 4E
Postbus 23278
3001 KG Rotterdam

T 088 - 676 90 00
F 088 - 676 90 10
www.gt.nl

To: the shareholder of Helix Healthcare B.V.

INDEPENDENT AUDITOR'S REPORT

Report on the financial statements

We have audited the accompanying financial statements for the year ended 31 March 2015 of Helix Healthcare B.V., Amsterdam, which comprise the company balance sheet as at 31 March 2015, the company profit and loss account for the year then ended and the notes, comprising a summary of the accounting policies and other explanatory information.

Management's responsibility

Management is responsible for the preparation and fair presentation of these financial statements and for the preparation of the management board report, both in accordance with Part 9 of Book 2 of the Dutch Civil Code. Furthermore management is responsible for such internal control as it determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Grant Thornton Accountants en Adviseurs B.V. is lid van Grant Thornton International Ltd. Grant Thornton International


Grant Thornton Accountants en Adviseurs B.V. is ingeschreven bij het handelsregister van de Kamer van Koophandel Den Haag onder nummer 28105565. Op al onze diensten zijn de algemene voorwaarden gedeponeerd bij de Griffie van de Afdeling Rechtspraak te Den Haag. Bij onderzoek ontvangt u een exemplaar van deze voorwaarden. Indien aansprakelijkheid is beperkt tot het bedrag dat is vermeld in de algemene voorwaarden.

Opinion with respect to the financial statements

In our opinion, the financial statements give a true and fair view of the financial position of Helix Healthcare B.V. as at 31 March 2015 and of its result for the year then ended in accordance with Part 9 of Book 2 of the Dutch Civil Code.

Rotterdam, 13 May 2015

Grant Thornton Accountants en Adviseurs B.V.



drs. C. Höllewijn RA

Initialed for identification purposes only:



Agile Pharma B.V.
Amsterdam, the Netherlands

Annual report
for the financial year ended 31 March 2015

Agile Pharma B.V.
Prins Bernhardplein 200
1097 JB Amsterdam
The Netherlands
Chamber of Commerce: 34.255.461

Page 1 of 19

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSE ONLY

Grant Thornton
Accountants & Adviseurs B.V.
13 MAY 2015

Agile Pharma B.V., Amsterdam, the Netherlands

Table of contents:

0000

Board report

Director's report

3

Financial statements

Balance sheet as at 31 March 2015 (before appropriation of result)

5

Profit and loss account for the period from 1 April 2014 until 31 March 2015

6

Notes to the financial statements

7

Other information

Appropriation of results

18

Subsequent events

18

Audit of financial statements

18

Independent auditor's Report

19

Agile Pharma B.V., Amsterdam, the Netherlands

Director's report

The management herewith presents to the shareholder the annual accounts of Agile Pharma B.V. (hereinafter: "the Company") for the period from 1 April 2014 until 31 March 2015.

General

The Company is a private company with limited liability incorporated under the laws of the Netherlands and acts as an intermediate holding and financing company. The ultimate holding company is Aurobindo Pharma Limited, Hyderabad, India.

Overview of activities

During the year, the conditions precedent under the Share and Asset Purchase Agreement dated 28 March 2014 entered into by the Company as purchaser, the sole shareholder Helix Healthcare B.V. as purchaser guarantor and Actavis Inc. as vendor for the acquisition of the North Western European business of Actavis Inc. have been fulfilled ("Actavis Acquisition" or "Project Crossbow") and the Company acquired the legal ownership and business of the Actavis' companies in Spain, France, Italy, Portugal, Germany and the Netherlands, including all absolute right, title and interest of the Project Crossbow IP, Actavis Trademarks, Retained Trademarks and Licensed Trademarks and Marketing Authorizations as defined in the Project Crossbow Intellectual Property Agreement, dated 28 March 2014. The Company has initiated further integration of the Actavis corporate structure and business into Aurobindo Group by means of various local mergers.

The Company as borrower entered into various short term loans from its subsidiaries as well as a EUR 35 million loan facility agreement with its sole shareholder Helix Healthcare B.V. to finance Project Crossbow. The Company has withdrawn EUR 29.5 million of which EUR 15 million was repaid on 29 April 2014 to its shareholder. Furthermore, the Company as lender entered into various loan facility agreements with its subsidiaries in the aggregate amount of EUR 62,648,581 to meet increasing working capital requirements of the operational subsidiaries.

In April 2014, the Company incorporated Aurovitas S.L., a company organized and existing under the laws of Spain. The incorporation capital amounts to EUR 3,000 of which the Company holds 100%. In November 2014, Aurovitas SL was liquidated and dissolved.

In April 2014, the Company sold and transferred its minority interest representing one share in the capital of Aurobindo İlaç Sanayi ve Ticaret Limited Şirketi to a related party.

In October 2014, the Company as borrower and Aurobindo Pharma Limited (India) as guarantor entered into a facility agreement for EUR 50 million with the Standard Chartered Bank, London branch. The Company borrowed Euro 15 million and repaid it fully during the year.



In October 2014, the Company incorporated Aurex B.V., a private company organized and existing under the laws of the Netherlands and invested EUR 90,000 as paid up capital.

In November 2014, the Company entered into a single currency business overdraft facility agreement for EUR 10 million with Barclays Bank PLC, London branch. The Company has utilized the overdraft facility of Euro 15,000 (due on 31st March, 2015).

The Company as shareholder approved a downstream merger between Agile Malta Holdings Limited as disappearing company and Aurobindo Pharma (Malta) Ltd. as acquiring company. As a result, the Company shall acquire all issued and outstanding shares in the capital of the acquiring company.

On 16 December 2014, the Company capitalized a loan outstanding to Aurobindo Pharma (Italia) S.r.l. in the aggregate amount of EUR 6,000,000.

On 31 December 2014, the Company as shareholder approved a downstream merger between Aurobindo Pharma France SARL as disappearing company and Arrow Generiques SAS, France as acquiring company. As a result, the Company shall acquire all issued and outstanding shares in the capital of the acquiring company.

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants and Advisors B.V.
13 MAY 2015

3

In February 2015, the Company received a distribution in kind (dividend) from Pharmacin B.V. in the form of the loan receivable of EUR 2,000,000 existing under the loan agreement dated 1 November 2014 entered into by the Company as borrower and Pharmacin B.V. as lender.

The net asset value of the Company as at 31 March 2015 amounts to EUR 44,429,579 (31 March 2014: EUR 41,843,875).
The result for the period 1 April 2014 until 31 March 2015 amounts to a profit of EUR 2,585,704 (2013/2014: EUR 362,837 loss).
The profit includes EUR 6,193,663 dividends received from the Company's subsidiaries

Liquidity and shareholder's equity has increased due to the profits in the year. Both are considered sufficient in view of the nature of the Company's business.

The risks the Company runs in relation to financial instruments are limited to interest rate risk and credit risk. The interest rate risk is addressed and mitigated by a fixed positive margin between rates on borrowings and lendings. The credit risk is limited due to the guarantee given by the ultimate holding company with respect to the loans payable.

Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's investments. The quality of the Company's credit portfolio consisting of investments and loan advances to group companies is monitored on a risk as normal. Based upon these reviews, management regards the credit.

No material change in activities is contemplated for the coming year. It is expected that the result will be in line with that of the reporting period. Furthermore management has no current plans which would have a significant influence on expectations concerning future activities, investments, financing, staffing and profitability.

Management is not aware of significant events that have occurred since the balance sheet date that were not included in the financial statements.

G. Phaneendra Prasad
Director

Integrust (Netherlands) B.V.
Director

Grant Thornton
INITIALED FOR IDENTIFICATION
PURPOSE ONLY
Grant Thornton
Accountants & Advisors B.V.
13 MAY 2015

Agile Pharma B.V., Amsterdam, the Netherlands

Balance sheet as at 31 March 2015

(Before the proposed appropriation of the result and expressed in euros)

	Notes	31-Mar-2015	31-Mar-2014
		EUR	EUR
ASSETS			
Fixed assets			
Interests in group entities	1	90,588,474	44,629,479
Loans to group entities	2	39,837,245	3,297,800
Other assets	3	-	48,485,750
Total fixed assets		130,425,719	96,413,029
Current assets			
Receivables due from group companies	4	100,000	-
Prepayments and accrued income	5	4,552,693	52,890
Cash and cash equivalents	6	2,151,071	1,192,308
Total current assets		6,803,764	1,245,198
Total assets		137,229,483	97,658,227
SHAREHOLDER'S EQUITY AND LIABILITIES			
Shareholder's equity			
Paid up and called up share capital	11	18,000	18,000
Share premium account		40,347,000	40,347,000
Other reserves		1,478,875	1,841,712
Unappropriated results		2,585,704	(362,837)
Total shareholder's equity		44,429,579	41,843,875
Long term liabilities (due after one year)			
Loans from group entities	10	84,745,000	30,695,000
Current liabilities (due within one year)			
Amounts due to group entities	7	6,342,688	25,090,779
Accruals and deferred income	8	836,670	28,573
Taxation	9	875,546	-
Total current liabilities		8,054,904	25,119,352
Total shareholder's equity and liabilities		137,229,483	97,658,227

The accompanying notes form an integral part of these financial statements.

Agile Pharma B.V., Amsterdam, the Netherlands

Profit and loss account for the period from 1 April 2014 until 31 March 2015

	Notes	01-Apr-2014 31-Mar-2015	01-Apr-2013 31-Mar-2014
		EUR	EUR
Net revenues			
Operating expenses			
Other operating expenses	12	(1,910,649)	(67,309)
Total operating expenses		<u>(1,910,649)</u>	<u>(67,309)</u>
Operating result		(1,910,649)	(67,309)
Financial income and expenses			
Dividend income from participations not valued at net asset value	13	6,193,663	-
Result of participations	14	(3,000)	(287,499)
Total interest income	15	497,843	26,102
Total interest expenses	16	(1,323,304)	(39,939)
Management income	17	2,244	5,808
Currency translation results	18	4,453	-
Total financial income and expenses		<u>5,371,899</u>	<u>(295,528)</u>
Result before taxation		3,461,250	(362,837)
Corporate income tax	19	-	-
Foreign corporate income tax	20	(875,546)	-
Net result after taxation		<u>2,585,704</u>	<u>(362,837)</u>

The accompanying notes form an integral part of these financial statements.



INITIALLED FOR IDENTIFICATION
PURPOSE ONLY

Grant Thornton
Accountants en Adviseurs B.V.

13 MAY 2015

Agile Pharma B.V., Amsterdam, the Netherlands

Notes to the financial statements

General

The Company was incorporated as a private company with limited liability under the laws of the Netherlands on 5 September 2006.

The registered office of the Company is in Amsterdam, the Netherlands.

The principal activity of the Company is to act as a holding and finance company.

Group structure

The Company is part of a group headed by Aurobindo Pharma Limited, Hyderabad, India, a company incorporated under the law of India and listed at the stock exchange in Mumbai, India. The direct shareholder and immediate holding company is Helix Healthcare B.V., Amsterdam, the Netherlands.

The financial information of the Company is recorded in the consolidated financial statements of Aurobindo Pharma Limited in Hyderabad, India. Copies are available at the Trade Register of the Chamber of Commerce in Amsterdam, the Netherlands.

Basis of presentation

The financial statements are prepared in accordance with accounting principles generally accepted in the Netherlands and comply with the financial reporting requirements included in Part 9 of Book 2 of the Dutch Civil Code. The financial statements are prepared under the historical cost convention and presented in euros (EUR or €).

Income and expenses are accounted for on accrual basis. Profit is only included when realized on balance sheet date. Liabilities and any losses originating before the end of the financial year are taken into account if they have become known before preparation of the financial statements.

The Company qualifies as a small sized company. Therefore, based on article 396 Book 2 of the Dutch Civil Code, exemptions apply to the presentation and disclosures in the Company's financial statements.

The financial statements have been prepared in accordance with the general provision of Title 9, Book 2 of the Dutch Civil Code. As allowed in art. 2:396 paragraph 6 of the Dutch Civil Code, the valuation of the assets and liabilities and the determination of the result is based on the principles for determination of the taxable profit, as meant in chapter 11 of the Corporate Income Tax Act 1969.

Going Concern

The equity of the Company amounts to EUR 41,114,218 positive. Management has assessed this situation and has a reasonable expectation that the Company has adequate resources to continue in operational existence in the foreseeable future.

Comparison previous year

The accounting principles remained unchanged compared to the previous year.

Consolidation

The Company does not prepare consolidated financial statements in accordance with article 408, Book 2 of the Dutch Civil Code. The figures of the Company are included in the consolidated financial statements of Aurobindo Pharma Ltd. that are filed with the Chamber of Commerce in the Netherlands. The Company values its investments in group companies, subsidiaries and associates at historical cost. In accordance with article 2:379 sub 2c the Company is exempted from disclosing its share in the equity and result of these investments.

Foreign currencies

The functional currency of the Company is EUR.

Assets and liabilities denominated in foreign currencies are translated at year-end exchange rates. Foreign currency transactions are accounted for at the exchange rates prevailing at the date of the transactions. Gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement. Non-monetary balance sheet items, which are valued at cost and resulting from transactions in foreign currencies, are translated at the rate prevailing on the date of the transaction.

Agile Pharma B.V., Amsterdam, the Netherlands

Notes to the financial statements (continued)

Foreign currencies (continued)

Balance sheets of foreign entities held are translated into the Company's reporting currency at exchange rates ruling on 31 March 2015 and their income and expense are translated at average rates for the year. Exchange differences arising from the translation of the net investment in foreign entities and of borrowings and other currency instruments designed as hedges of such investments, are taken directly to the legal reserve for translation differences within shareholder's equity. When a foreign entity is sold, such exchange differences are recognized in the statement of income as part of the gain or loss on sale.

The exchange rates used in the annual accounts are:

	31.03.2015	31.03.2014
1 EUR = USD (US dollar)	1.07290	1.3795
1 EUR = GBP (Pound sterling)	0.72540	0.8284
1 EUR = DKK (Danish Krone)	7.4693	7.4650
1 EUR = BGN (Bulgarian Lev)	1.9553	1.9550
1 EUR = LVL (Latvian Lats)	0.7027	0.7104
1 EUR = PLN (Polish Zloty)	4.0857	4.1720

Financial instruments

Financial instruments include both primary financial instruments, such as receivables and liabilities, and financial derivatives. Reference is made to the recognition per balance sheet item for the principles of primary financial instruments. Financial instruments are valued at amortized cost unless explained otherwise in the notes. Due to the short-term nature of the financial instruments included in these financial statements, the estimated fair value for these financial instruments approximates the book value. This also applies to the long-term loans receivable and payable, as terms and conditions are market based and the interest rate is variable.

Financial fixed assets

- (i) Subsidiaries, which are those entities in which the Company has an interest of more than one half of the voting rights or otherwise has power to govern the financial and operating policies, are stated at net asset value.
- (ii) Investments in associates are stated at net asset value. Associates are entities of which the Company generally has between 20% and 50% of the voting rights, or over which the Company has significant influence, but which it does not control. Associated companies over which the Company has no significant influence are accounted for at cost.
- (iii) Other participating investments are valued at cost.
- (iv) Where a permanent diminution in value occurs in the subsidiary and/or associate valued at cost, the carrying amount is written down to its estimated recoverable amount.
- (v) The carrying amount is minimally stated at zero, unless the Company has incurred obligations or guaranteed obligations in respect of the subsidiary and/or associated company. In that case a provision will be formed.

Due to the fact that consolidation exemption of art. 2:408 of Book 2 of the Dutch Civil Code is applicable, the interests in group entities are valued at cost price.

Receivables

The receivables are valued at fair value and then valued at amortised cost. Provisions deemed necessary for possible bad debt losses are deducted. These provisions are determined by individual assessment of the receivables.

Cash and cash equivalents

Cash and cash equivalents includes bank balances, which are at free disposal of the company.

The Company has not presented a cash flow statement, as allowed by RJ 360.104, as the cash flows are included in the consolidated cash flow statement of the parent company and the annual report of the parent company is publicly available.

Agile Pharma B.V., Amsterdam, the Netherlands

Notes to the financial statements (continued)

Long-term and short-term liabilities

Upon initial recognition, loans and liabilities recorded are stated at fair value and then subsequently valued at amortised cost.

Principles for the determination of the result

Share in result of associated companies

Where significant influence is exercised over associated companies, the share of the legal entity in the associated companies' results is included in the profit and loss account.

Where no significant influence is exercised or the associate is valued at cost, the dividend income is accounted for in the profit and loss account as financial income.

Corporate income tax

Corporate income tax is calculated at the applicable rate on the result for the financial year, taking into account permanent differences between profit calculated according to the financial statements and profit calculated for taxation purposes. Temporary differences between the reporting for tax purposes and the financial statements are recognized as deferred taxes based on the current tax rate. Deferred tax assets and liabilities are netted. Net deferred tax assets will be included in the balance sheet if actual realisation is assumed probable by the Company's management.

Corporate income tax expense comprises current and deferred tax. Current tax is the expected tax payable on the taxable income for the year and any adjustment to tax payable in respect of previous years. Corporate income tax expense is recognised in the profit and loss account except to the extent that it relates to items recognised directly in equity.

The Company is part of a fiscal unity for corporate income tax purposes with its Dutch group companies. The shareholder is the head of the fiscal unity. As a result of the fiscal unity, the shareholder is jointly and severally liable for the related tax liabilities of the entire fiscal unity.

Estimates

The preparation of the financial statements requires management to make estimates and assumptions that influence the application of principles and the reported values of assets and liabilities and of income and expenditure. The actual results may differ from these estimates. The estimates and the underlying assumptions are constantly assessed. Revisions of estimates are recognised in the period in which the estimate is revised and in future periods for which the revision has consequences.

Agile Pharma B.V., Amsterdam, the Netherlands

Notes to the financial statements (continued)

	31-Mar-2015	31-Mar-2014
	EUR	EUR

Notes to the Balance sheet

1 Interests in group companies

The Investments in subsidiaries and associated companies can be detailed as follows:

Name company	Registered place of business	Percentage in share capital		
Pharmacin B.V.	Zwijndrecht, the Netherlands	100% (100%)	4,790,621	4,790,621
Agile Malta Holdings Limited.	Valetta, Malta	n/a (100%)	-	5,075,000
Aurobindo Pharma S.r.l.	Milan, Italy	100% (100%)	19,973,000	12,748,000
Laboratorios Aurobindo S.L.	Sabadell, Spain	100% (100%)	4,866,000	4,866,000
Aurovitas Unipessoal Lda	Lisbon, Portugal	100% (n/a)	5,000	-
Aurobindo Pharma Malta Ltd.	Valetta, Malta	100% (n/a)	5,075,000	-
Aurobindo Pharma Portugal Ltda	Lisbon, Portugal	100% (100%)	7,463,000	7,363,000
Aurobindo Pharma GmbH	Munich, Germany	100% (100%)	3,691,000	3,691,000
Aurobindo Pharma France	St. Germain & Laye, France	n/a (100%)	-	2,438,000
Aurobindo Pharma B.V.	Zwijndrecht, the Netherlands	100% (100%)	2,518,119	2,518,119
Aurobindo Pharma Romania SRL	Bucharest, Romania	100% (100%)	2,089,739	1,139,739
Actavis S.A.	Spain	100% (n/a)	3,546,725	-
Actavis France SAS	France	100% (n/a)	2,320,300	-
Arrow Generiques SAS	France	100% (n/a)	19,240,433	-
Actavis Deutschland GmbH & Co., KG	Germany	100% (n/a)	9,516,794	-
Actavis B.V.	Baarn, the Netherlands	100% (n/a)	5,402,743	-
Aurex B.V.	Baarn, the Netherlands	100% (n/a)	90,000	-
			<u>90,588,474</u>	<u>44,629,479</u>



Movements in the financial fixed assets have been as follows:

Balance as per 1 April 2014	44,629,479
Capital contribution	8,278,000
Acquisitions	40,478,197
Mergered	(2,438,000)
Disposals	(359,202)
Balance as per 31 March 2015	<u>90,588,474</u>

2 Loans to group entities

a) Aurobindo Pharma Italy S.r.l.	6,262,245	627,800
b) Aurobindo Pharma Portugal Ltda	1,275,000	550,000
c) Actavis B.V.	13,000,000	-
d) Laboratorios Aurobindo S.L.	5,400,000	900,000
e) Aurobindo Pharma GmbH	-	150,000
f) Agile Malta Holdings Ltd.	-	1,070,000
g) Aurobindo Pharma Malta Ltd.	1,850,000	-
h) Aurobindo Pharma B.V.	650,000	-
i) Arrow Generiques SAS	11,000,000	-
j) APL Swift Services (Malta) Ltd.	400,000	-
	<u>39,837,245</u>	<u>3,297,800</u>

Balance as at 1 April 2014	3,297,800
Repayments	(1,070,150)
Conversion into equity	(6,000,000)
Increase	43,609,595
Balance as at 31 March 2015	<u>39,837,245</u>

 Grant Thornton
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Accountants of Agile Pharma B.V.

13 MAY 2015

- a) On 1 April 2014, the Company entered into a loan agreement with Aurobindo Pharma Italy S.R.L. in the total amount of EUR 15,000,000. The loan has not been secured, has a maturity of 5 years from the date of the agreement and bears an interest rate of 6 months EURO LIBOR plus 1.6 per annum. During the financial year, an amount of EUR 12,262,245 was drawn. On 25 November 2014, an amount of EUR 6,000,000 was converted in to equity.
- b) The loans to Aurobindo Pharma Portugal Ltda (Aurobindo Portugal) consist three loan agreements. The conditions are as follows:
- On 1 September 2014, the Company entered into a loan agreement with Aurobindo Portugal in the total amount of EUR 1,500,000. The loan has not been secured, has a maturity of 3 years and bears an interest rate of 6 months EURO LIBOR + 1.1%. As per 31 March 2015, an amount of EUR 550,000 was drawn.
 - On 1 August 2014, the Company entered into a loan agreement with Aurobindo Portugal in the total amount of EUR 500,000. The loan has not been secured, has a maturity of 5 years and bears an interest rate of 6 months EURO LIBOR + 1.6%. As per 31 March 2015, the loan was fully drawn.
 - On 15 March 2015, the Company entered into a loan agreement with Aurobindo Portugal in the total amount of EUR 500,000. The loan has not been secured, has a maturity of 5 years and bears an interest rate of 6 months EURO LIBOR + 1.6%. As per 31 March 2015, the amount of EUR 225,000 was drawn.
- c) On 1 October 2014, the Company entered into a loan agreement with Actavis B.V. in the total amount of EUR 13,000,000. The loan has not been secured, has a maturity of 5 years from the date of the agreement and bears an interest rate of 6 months EURO LIBOR plus 1.6 per annum.
- d) On 1 October 2014, the Company entered into a loan agreement with Laboratorios Aurobindo S.L., Spain in the total amount of EUR 5,900,000. The loan has not been secured, has a maturity of 5 years from the date of the agreement and bears an interest rate of 6 months EURO LIBOR plus 1.6 per annum. As per 31 March 2015, an amount of EUR 5,400,00 was drawn.
- e) The loan towards Aurobindo Pharma GmbH for the amount of EUR 200,000. The loan has not been secured, has no maturity date and bears interest at 6 months EURO LIBOR + 1.1% margin per annum. As per 31 March 2015, the loan is fully repaid.
- f) On 1 December 2013, the Company entered into a loan agreement with Agile Malta Holdings Ltd. for the amount of EUR 1,100,000. The loan has not been secured, has a maturity of 5 years and bears interest at 6 months EURO LIBOR + 1.2% margin per annum. In December 2014, the merger proposal is subscribed by the management of Agile Malta Holdings Ltd. and Aurobindo Pharma Malta Ltd. As a result, the Subsidiary will become the disappearing company and all its assets and liabilities will be transferred to Aurobindo Pharma Malta Ltd.
- g) The loans to Aurobindo Pharma Malta Ltd. (hereinafter: "Aurobindo Malta") consist several loan agreements. The conditions are as follows:
- On 1 May 2014, the Company entered into a loan agreements with Aurobindo Malta in the total amount of EUR 5,500,000. The loans have not been secured, have a maturity of 5 years from the date of the agreement and bear an interest rate of 6 months EURO LIBOR plus 1.6 per annum.
- h) On 1 September 2014, the Company entered into a loan agreement with Aurobindo Pharma B.V., in the total amount EUR 1,000,000. The loan has not been secured, has a maturity of 5 years from the date of the agreement and bears an interest rate of 6 months EURO LIBOR plus 1.6 per annum. As per 31 March 2015, an amount of EUR 650,00 was drawn.
- i) On 1 November 2014, the Company entered into a loan agreement with Arrow Generiques SAS, France in the total amount EUR 15,000,000. The loan has not been secured, has a maturity of 5 years from the date of the agreement and bears an interest rate of 6 months EURO LIBOR plus 1.6 per annum. As per 31 March 2015, an amount of EUR 11,000,000 was drawn.
- j) On 15 March 2015, the Company entered into a loan agreement with the APL Swift Services (Malta) Ltd. in the total amount of EUR 4,000,000. The loan has not been secured, has a maturity of 5 years and bears an interest rate of 6 months EURO LIBOR + 1.6%. As per 31 March 2015, the amount of EUR 400,000 was drawn.

Notes to the financial statements (continued)

	31-Mar-2015	31-Mar-2014
	EUR	EUR
3 Other assets		
• Third parties deposit	-	48,191,000
Tax duty on acquisition of Actavis Italy	-	294,750
	<u>-</u>	<u>48,485,750</u>

- On 28 March 2014, a deposit was formed in connection with the Share and Asset Purchase Agreement (hereinafter: "Actavis Acquisition"), by among parties, the Company acquired the North Western EU operations of Actavis Inc. (USA) for a final consideration of EUR 48,181,000, which amount was placed at a third party deposit following the execution of Actavis Acquisition. The completion of Actavis Acquisition was subject certain conditions precedent the Company as Purchaser, Helix Healthcare B.V. as Purchaser Guarantor and Actavis Inc. as Vendor, dated 28 March 2014 which have been fulfilled during the year. As a result the purchase price has released from escrow to the vendor.

4 Receivables due from group companies


Aurobindo Pharma Romania S.R.L.	100,000	-
	<u>100,000</u>	<u>-</u>

On 15 December 2014, the Company entered into a loan agreement with Aurobindo Pharma Romania in the total amount EUR 1,000,000. The loan has not been secured, has a maturity of 11 months from the date of the agreement and bears an interest rate of 6 months EURO LIBOR plus 1.6 per annum. As per 31 March 2015, an amount of EUR 100,000 was drawn.

5 Prepayments and accrued income

Interest receivable Aurobindo Pharma (Portugal)	1,403	3,795
Interest receivable Aurobindo Pharma Italy S.R.L.	174,438	17,441
Interest receivable Aurovitas Unipessoal Lda	144	-
Interest receivable Actavis B.V.	19,428	-
Interest receivable Laboratorios Aurobindo S.L.	33,254	6,871
Interest receivable Aurobindo Pharma GmbH	-	1,771
Interest receivable Aurobindo Pharma Malta Ltd.	36,668	-
Interest receivable Agile Malta Holdings Ltd.	3,912	3,013
Interest receivable Aurobindo Pharma B.V.	955	-
Interest receivable Aurovitas Spain S.L.	185	-
Interest receivable Arrow Generiques SAS	73,772	-
Interest receivable Aurobindo Pharma Romania S.R.L.	535	-
Interest receivable APL Swift Services (Malta) Ltd.	149	-
Interest WHT receivable Aurovitas Unipessoal Lda	4,028	-
VAT receivable 2013/2014	-	10,931
VAT receivable 2014/2015	-	4,268
Current account Aurobindo Pharma B.V.	3,115	-
• Management fee receivable from Pharmacin B.V.	7,044	4,800
Dividend receivable Actavis Deutschland GmbH & Co., KG	4,170,264	-
Dividend receivable Aurobindo Pharma Malta Ltd.	23,379	-
	<u>4,552,693</u>	<u>52,890</u>

- In 2014, the Company entered into a management agreement with Pharmacin B.V. In this agreement, it is agreed that the Company will provide management services to Pharmacin B.V. The Company resigned as director of Pharmacin B.V. effectively per 20 August 2014.

 Grant Thornton

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

6 Cash and cash equivalents

Current account	2,151,071	1,192,308
	<u>2,151,071</u>	<u>1,192,308</u>

The cash amount of EUR 2,151,071 is available on demand.

Notes to the financial statements (continued)

	31-Mar-2015	31-Mar-2014
	EUR	EUR
7 Amounts due to group entities		
a) Aurobindo Pharma GmbH	5,500,000	4,750,000
b) Laboratorios Aurobindo S.L.	-	2,800,000
c) Pharmacin B.V.	-	1,200,000
d) APL Swift Services Malta Ltd.	-	594,750
e) Milpharm Ltd.	250,000	600,000
f) Helix Healthcare B.V. loan B	-	15,000,000
Current account Aurobindo Pharma B.V.	3,115	-
Interest shareholder's loan payable	134,241	146,029
Interest payable Aurobindo Pharma GmbH	23,578	-
Interest payable Pharmacin B.V.	8,664	-
Interest payable Milpharm Ltd.	1,693	-
Interest payable Actavis Deutschland GmbH 7 CO. KG	421,397	-
	<u>6,342,688</u>	<u>25,090,779</u>

In March 2014, the Company borrowed various short term loans from its subsidiaries ("a" until "e") in order to finance the Actavis Acquisition. These loans bear no interest. In April or May 2014, the loans were fully repaid to the respective subsidiaries.

Balance as at 1 April 2014	9,944,750
Repayment	(4,194,750)
Balance as at 31 March 2015	<u>5,750,000</u>

f) Disclosure on note 9b

Balance as at 1 April 2014	15,000,000
Repayment	(15,000,000)
Balance as at 31 March 2015	<u>-</u>

8 Accruals and deferred income

Audit fees payable	12,100	18,178
Administration fees payable	24,023	10,395
Other fees payable	15,026	-
VAT 2014 payable	785,521	-
	<u>836,670</u>	<u>28,573</u>


9 Taxation

Corporate Income tax	875,546	-
	<u>875,546</u>	<u>-</u>

10 Loans from group entities

a) Shareholder's loan	31,245,000	16,195,000
b) Shareholder's loan A	-	14,500,000
c) Actavis Deutschland GmbH Co. KG.	53,500,000	-
	<u>84,745,000</u>	<u>30,695,000</u>

Balance as at 1 April 2014	30,695,000
Reclassification	14,500,000
Increase	39,550,000
Balance as at 31 March 2015	<u>84,745,000</u>

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountants & Advisors B.V.

13 MAY 2015

Notes to the financial statements (continued)

(Expressed in euros)

Note 10 (continued)

- a) On 1 April 2014, the Company entered into a loan facility agreement with its shareholder in the amount of EUR 35,000,000. The loan has not been secured, has a maturity of 5 years and bears an interest rate of 6 months EURO-LIBOR + 1.5% per annum.
- b) On 31 March 2014, the Company received advances under this loan facility for a total amount of EUR 29,500,000. An amount of EUR 15,000,000 is classified as short-term loan and has a maturity of 1 year and bears an interest rate of 3 months EURO-LIBOR + 1.5% per annum and a remainder of EUR 14,500,000 classified as long-term. The loan has a maturity of 3 years and bears an interest rate of 3 months EURO-LIBOR + 1.5% margin per annum. In April 2014, the short-term loan was fully repaid.
- c) On 1 April 2014, the Company entered into a loan facility agreement with Actavis Deutschland GmbH Co. KG., Germany in the total amount of EUR 65,000,000. The loan has not been secured, has a maturity of 5 years from the date of the agreement and bears an interest rate of 6 months EURO LIBOR plus 1.5 per annum. As per 31 March 2015, an amount of EUR 53,500,000 was drawn.

11 Shareholder's equity

	Share capital	Share premium	Other reserves	Unappr. results
Balance as per 01.04.2013	18,000	38,622,000	(1,822,838)	3,664,550
Paid-in / (repaid)	-	1,725,000	-	-
Transfer	-	-	3,664,550	(3,664,550)
Result for the period	-	-	-	(362,837)
Balance as per 01.04.2014	18,000	40,347,000	1,841,712	(362,837)
Transfer	-	-	(362,837)	362,837
Result for the period	-	-	-	2,585,704
Balance as per 31.03.2015	18,000	40,347,000	1,478,875	2,585,704

Issued share capital

The authorised share capital of the Company amounts to EUR 90,000 divided into 90,000 shares of EUR 1 each. Issued and paid up are 18,000 shares of EUR 1 each.

Share premium

As per 31 March 2015, the share premium reserve of the Company amounts to EUR 40,347,000.

Other reserves

In the annual general meeting of shareholders held on 26 May 2014 it was decided to add the balance of the unappropriated result 2013/2014 to the other reserves.

Contingent Liabilities


The Company is part of a fiscal unity for corporate income tax purposes. The shareholder is the head of the fiscal unity. As a result of the fiscal unity the Shareholder is jointly and severally liable for the related tax liabilities of the entire fiscal unity.

 Grant Thornton
INITIALLED FOR IDENTIFICATION
PURPOSE ONLY
Grant Thornton
Accountants & Advisors B.V.
13 MAY 2015

Agile Pharma B.V., Amsterdam, the Netherlands

Notes to the financial statements (continued)

	01-Apr-2014 31-Mar-2015	01-Apr-2013 31-Mar-2014
	EUR	EUR
Notes to the Profit and loss account		
12 Other operating expenses		
Audit fee	12,028	14,428
Notary fee	5,551	-
Tax advice	-	(8,000)
Management	4,392	3,630
Administration	213,959	53,854
Bank charges	4,167	3,397
VAT expenses	62,521	-
Legal and advisory	1,391,291	-
General expenses	216,740	-
	<u>1,910,649</u>	<u>67,309</u>
13 Dividend income from participations not valued at net asset value		
PharmacIn B.V.	2,000,000	-
Actavis Deutschland GmbH & Co., KG	4,170,284	-
Aurobindo Pharma Malta Ltd.	23,379	-
	<u>6,193,663</u>	<u>-</u>
14 Result dissolve interests in group entities		
Aurobindo Pharma Poland	-	287,499
Aurovitas S.L., Spain	3,000	-
	<u>3,000</u>	<u>287,499</u>
15 Total interest income		
PharmacIn B.V.	-	1,401
Aurobindo Pharma (Portugal) Lda	12,982	3,795
Aurobindo Pharma Italy S.R.L.	177,195	9,251
Aurovitas Unipessoal Lda, Portugal	40,427	-
Actavis B.V.	92,501	-
Laboratorios Aurobindo S.L.	35,676	6,871
Aurobindo Pharma GmbH	403	1,771
Aurobindo Pharma Malta Ltd.	47,292	-
Agile Malta Holdings Ltd.	11,345	3,013
Aurobindo Pharma B.V.	3,886	-
Aurovitas Spain S.L.	1,680	-
Arrow Generiques SAS, France	73,772	-
Aurobindo Pharma Romania S.R.L.	535	-
APL Swift Services (Malta) Ltd.	149	-
	<u>497,843</u>	<u>26,102</u>

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Armutants of Agile Pharma B.V.
13 MAY 2015

Notes to the financial statements (continued)

	01-Apr-2014 31-Mar-2015	01-Apr-2013 31-Mar-2014
	EUR	EUR
Notes to the Profit and loss account (continued)		
16 Total interest expenses		
Hellix Healthcare B.V.	554,681	39,939
Aurobindo Pharma GMBH, Germany	34,997	-
Laboratorios Aurobindo S.L., Spain	1,590	-
Pharmacln BV	8,664	-
Milpharm Ltd., UK	6,492	-
Actavis Deutschland GmbH 7 CO. KG	603,603	-
Arrow Generiques SAS, France	87,719	-
Actavis Spain S.L.	3,338	-
Actavis B.V.	18,246	-
Aurobindo Pharma B.V.	174	-
Standard Charter Bank, third parties	3,800	-
	<u>1,323,304</u>	<u>39,939</u>
17 Management income		
Management income from Pharmacln B.V.	2,244	5,808
	<u>2,244</u>	<u>5,808</u>

In 2014, the Company entered into a management agreement with Pharmacln B.V. In this agreement, it is agreed that the Company will provide management services to Pharmacln B.V. The Company was resigned as director of Pharmacln B.V. effectively per 20 August 2014.

18 Currency translation results

On other items	4,453	-
	<u>4,453</u>	<u>-</u>

19 Corporate income tax

The Company is part of a fiscal unity for corporate income tax purposes with its Dutch group companies. The shareholder is the head of the fiscal unity. As a result of the fiscal unity, the shareholder is jointly and severally liable for the related tax liabilities of the entire fiscal unity.

20 Foreign corporate income tax

Provision for foreign corporate income tax current year	829,902	-
Foreign withholding tax	45,644	-
	<u>875,546</u>	<u>-</u>

Staff numbers and employment costs

The Company has no employees and hence incurred no wages, salaries or related social security charges during the reporting period, nor during the previous year.

Audit fee

The audit fee of EUR 12,000 (2013/2014: EUR 14,400) including VAT and expenses.


Agile Pharma B.V., Amsterdam, the Netherlands


Directors

The Company has two (previous year: two) managing directors, one of them receives a remuneration of EUR 3,630 per year (excluding VAT).

The Company has no (previous year: none) supervisory directors.

On behalf of the Board of Directors
Amsterdam, 13 May 2015


G. Phaneendra Prasad
Director


J. van der Vlist
Director

Agile Pharma B.V., Amsterdam, the Netherlands

Other information

Appropriation of results

Statutory appropriation of results

In accordance with article 15 of the articles of association of the Company, the general meeting shall determine the allocation of accrued profits of the Company. According to the articles of association of the Company, the general meeting may resolve to make payments to the charge of any reserve which need not be maintained by virtue of to the extent such an amount shall not exceed the amount of the distributable part of the net assets.

Section 216, Book 2, Dutch Civil Code, prescribes that the general meeting may resolve on any profit distribution to the extent that the shareholder's equity exceeds the amount of the reserves to be maintained by law and the articles of association of the Company. The Company may only follow a resolution of the general meeting to distribute after the management board has given its approval to do this. The management board withholds approval, at the moment of distribution, only if it knows or reasonably should be able to foresee that the Company cannot continue to pay its due debts after the distribution.

The management proposes to the shareholder to add the result for the year to the other reserves.

Appropriation of results of previous years

In the annual general meeting of shareholders held on 26 May 2014 it was decided to add the balance of the unappropriated result 2013/2014 to the other reserves.

Proposed appropriation of result current year

Management proposes to add the entire loss to the other reserves.

Subsequent events

Management is not aware of other events that took place after balance sheet date that could have a material effect on the financial position of the Company.

Independent auditor's Report

The independent auditors' report is set on the next page.

Agile Pharma B.V., Amsterdam, the Netherlands

Independent auditor's Report

Grant Thornton
Accountants en Adviseurs B.V.
Gedempte Zalmhaven 4E
Postbus 23278
3001 KG Rotterdam

T 088 - 676 90 00
F 088 - 676 90 10
www.gt.nl

To: the shareholder of Agile Pharma B.V.

INDEPENDENT AUDITOR'S REPORT

Report on the financial statements

We have audited the accompanying financial statements for the year ended 31 March 2015 of Agile Pharma B.V., Amsterdam, which comprise the company balance sheet as at 31 March 2015, the company profit and loss account for the year then ended and the notes, comprising a summary of the accounting policies and other explanatory information.

Management's responsibility

Management is responsible for the preparation and fair presentation of these financial statements and for the preparation of the management board report, both in accordance with Part 9 of Book 2 of the Dutch Civil Code. Furthermore management is responsible for such internal control as it determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Grant Thornton Accountants en Adviseurs B.V. is lid van Grant Thornton International, lid Grant Thornton International.


Grant Thornton Accountants en Adviseurs B.V. is ingeschreven bij het handelsregister van de Kamer van Koophandel Den Haag onder nummer 28105555. Op al onze mondeling en schriftelijk afgegeven adviezen wordt verwezen naar de Algemene Voorwaarden gedeponeerd bij de Griffie van de Arrondissementsrechtbank te Den Haag van toepassing. Op verzoek ontvangt u een afdruk van deze voorwaarden. Indien aansprakelijkheid is beperkt tot het bedrag dat is vermeld in de algemene voorwaarden.

Opinion with respect to the financial statements

In our opinion, the financial statements give a true and fair view of the financial position of Agile Pharma B.V. as at 31 March 2015 and of its result for the year then ended in accordance with Part 9 of Book 2 of the Dutch Civil Code.

Rotterdam, 13 May 2015

Grant Thornton Accountants en Adviseurs B.V.



drs. C. Holewijn RA

Initialed for identification purposes only:



Registered number
98777

APL Holdings (Jersey) Limited

Report and Accounts

31 March 2015

APL Holdings (Jersey) Limited
Report and accounts
Contents

	Page
Company information	1
Directors' report	2
Statement of directors' responsibilities	3
Strategic report	4
Independent auditors' report	5
Profit and loss account	6
Balance sheet	7
Cash flow statement	8
Notes to the accounts	9 to 10

APL Holdings (Jersey) Limited
Company Information

Directors

Mr Frederick Schembri
Mr Venugopalan Muralidharan

Secretary

Verite Secretaries Limited

Auditors

The Corporate Practice Limited
Chartered Accountants and Registered Auditors
65 Delamere Road
Hayes
Middlesex
UB4 0NN

Bankers

HSBC Bank PLC
8 Library Parade
St Helier
Jersey
JE4 8NU

Registered office

1st Floor
37 Broad Street
St Helier
Jersey
JE2 3RR

Registered number

98777

APL Holdings (Jersey) Limited

Registered number: 98777

Directors' Report

The directors present their report and accounts for the year ended 31 March 2015.

Principal activities

The company's principal activity during the year continued to be a holding company. The company's performance during the year is set out on page 4.

Directors

The following persons served as directors during the year:


Mr Frederick Schembri
Mr Venugopalan Muralidharan

Disclosure of information to auditors

Each person who was a director at the time this report was approved confirms that:

- so far as he is aware, there is no relevant audit information of which the company's auditor is unaware; and
- he has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditor is aware of that information.

This report was approved by the board on 19th May 2015 and signed on its behalf.



Mr Frederick Schembri
Director

APL Holdings (Jersey) Limited
Statement of Directors' Responsibilities

The directors are responsible for preparing the report and accounts in accordance with applicable law and regulations.

Company law requires the directors to prepare accounts for each financial year. Under that law the directors have elected to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these accounts, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the accounts;
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the accounts comply with the applicable law. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

APL Holdings (Jersey) Limited
Strategic Report

Review of the business

The management has decided for the company to carry on as a holding company, investing in its two subsidiary companies APL IP Company Limited.

Future developments

The directors feel that the one of the subsidiary APL IP Company Limited will wind down its activity in the near future.

Key performance indicators

	Year ended 31 March 2015	Year ended 31 March 2014
	€	€
Dividends receivable	-	-
(Loss)/profit for the year	(700,098)	(16,086)

Principal risks and uncertainties:

The company's main areas of risk are as follows:

Financial instrument risk

The company's major financial instruments comprise bank balance. The main objective of those instruments is to raise funds and finance company's operations. The objective of the management framework of the company is to shelter the company from events which may hinder the company's performance targets and to ensure that sufficient funds exist for working capital.

Foreign exchange risk

The company transacts in foreign currencies. The risk is managed by monitoring foreign exchange rates.

Credit risk

The company mainly deals with group companies. Outstanding amounts are regularly monitored.


Liquidity risk

The company manages its cash flow to ensure that sufficient liquid resources are available to meet its obligations.

Interest rate and cash flow risk

The company maintain a positive cash balance. It does not have any borrowings from group undertakings or from external entities. The company does not use derivative financial instrument to manage interest rate costs and as such no hedge accounting is applied.

This report was approved by the board on 19th May 2015 and signed on its behalf.


Mr Frederick Schembri
Director

APL Holdings (Jersey) Limited
Independent auditors' report
to the members of APL Holdings (Jersey) Limited

We have audited the accounts of APL Holdings (Jersey) Limited for the year ended 31 March 2015 which comprise the Profit and Loss Account, the Balance Sheet, the Cash Flow Statement and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the company's members. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

As explained more fully in the Statement of Directors' Responsibilities, the directors are responsible for the preparation of the accounts and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the accounts in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the accounts

A description of the scope of an audit of financial statements is provided on the APB's website at www.frc.org.uk/auditscopeukprivate

Opinion on the accounts

In our opinion the accounts:

- give a true and fair view of the state of the company's affairs as at 31 March 2015 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the applicable law.


Opinion on other matters

In our opinion the information given in the Directors' Report and the Strategic Report for the financial year for which the accounts are prepared is consistent with the accounts.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the applicable law requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the accounts are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.



Mr Devender Arora
(Senior Statutory Auditor)
for and on behalf of
The Corporate Practice Limited
Accountants and Statutory Auditors
19 May 2015

65 Delamere Road
Hayes

Middlesex
UB4 0NN

APL Holdings (Jersey) Limited
Profit and Loss Account
for the year ended 31 March 2015

	Notes	2015 €	2014 €
Administrative expenses		(14,307)	(16,086)
Operating loss	2	<u>(14,307)</u>	<u>(16,086)</u>
Exceptional items:			
loss on the disposal of investments	3	(685,791)	-
		<u>(700,098)</u>	<u>(16,086)</u>
Loss on ordinary activities before taxation		<u>(700,098)</u>	<u>(16,086)</u>
Tax on loss on ordinary activities		-	-
Loss for the financial year		<u>(700,098)</u>	<u>(16,086)</u>

Continuing operations


None of the company's activities were acquired or discontinued during the above two financial years.

Statement of total recognised gains and losses

The company has no recognised gains or losses other than the loss for the above two financial years.

APL Holdings (Jersey) Limited
Balance Sheet
as at 31 March 2015

	Notes	2015 €	2014 €
Fixed assets			
Investments	4	105,383	3,705,383
Current assets			
Debtors	5	1,795	1,661
Cash at bank and in hand		<u>2,899,530</u>	<u>1,380</u>
		2,901,325	3,041
Creditors: amounts falling due within one year	6	(6,337)	(7,955)
Net current assets/(liabilities)		<u>2,894,988</u>	<u>(4,914)</u>
Net assets		<u>3,000,371</u>	<u>3,700,469</u>
Capital and reserves			
Called up share capital	7	3,637,824	3,637,824
Profit and loss account	8	(637,453)	62,645
Shareholders' funds	9	<u>3,000,371</u>	<u>3,700,469</u>


Mr Frederick Schembri
Director

Approved by the board on 19th May 2015

APL Holdings (Jersey) Limited
Cash Flow Statement
for the year ended 31 March 2015

	Notes	2015 €	2014 €
Reconciliation of operating profit to net cash			
Inflow from operating activities			
Operating loss		(14,307)	(16,086)
Increase in debtors		(134)	(537)
Decrease in creditors		(1,618)	(10,053)
Net cash outflow from operating activities		<u>(16,059)</u>	<u>(26,676)</u>
CASH FLOW STATEMENT			
Net cash outflow from operating activities		(16,059)	(26,676)
Capital expenditure	10	2,914,209	-
		<u>2,898,150</u>	<u>(26,676)</u>
Increase/(decrease) in cash		<u>2,898,150</u>	<u>(26,676)</u>
Reconciliation of net cash flow to movement in net debt			
Increase/(decrease) in cash in the period		2,898,150	(26,676)
Change in net debt	11	<u>2,898,150</u>	<u>(26,676)</u>
Net funds at 1 April		<u>1,380</u>	<u>28,056</u>
Net funds at 31 March		<u>2,899,530</u>	<u>1,380</u>

APL Holdings (Jersey) Limited
Notes to the Accounts
for the year ended 31 March 2015

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with applicable United Kingdom Accounting Standards.

Taxation

The company does not provide for any tax liability on the profits in view of the zero tax status of the company.

Foreign currencies

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the profit and loss account.

2 Operating profit	2015	2014
	€	€

This is stated after charging:

Auditors' remuneration for audit services	<u>3,000</u>	<u>4,500</u>
---	--------------	--------------

3 Exceptional items	2015	2014
	€	€

Loss on disposal of investments	<u>(685,791)</u>	<u>-</u>
---------------------------------	------------------	----------

4 Investments

	Investments in subsidiary undertakings
	€
Cost	
At 1 April 2014	3,705,383
Disposals	(3,600,000)
At 31 March 2015	<u>105,383</u>

The company holds 20% or more of the share capital of the following companies:

Company	Shares held		Capital and reserves	Profit (loss) for the year
	Class	%	€	€
APL IP Company Limited - company incorporated in	Ordinary	100	107,810	(3,577,650)
5 Debtors			2015	2014
			€	€
Prepayments and accrued income			<u>1,795</u>	<u>1,661</u>

APL Holdings (Jersey) Limited
Notes to the Accounts
for the year ended 31 March 2015

6 Creditors: amounts falling due within one year					2015	2014
					€	€
Amounts owed to group undertakings and undertakings in which the company has a participating interest					-	4,455
Other creditors					3,337	-
Accruals and deferred income					3,000	3,500
					<u>6,337</u>	<u>7,955</u>
7 Share capital					2015	2014
	Nominal value	2015 Number	2015	2014	€	€
Allotted, called up and fully paid:						
Ordinary shares	€1 each	3,637,824	3,637,824	3,637,824		
8 Profit and loss account					2015	
					€	
At 1 April 2014					62,645	
Loss for the financial year					(700,098)	
At 31 March 2015					<u>(637,453)</u>	
9 Reconciliation of movement in shareholders' funds					2015	2014
					€	€
At 1 April					3,700,469	3,716,555
Loss for the financial year					(700,098)	(16,086)
At 31 March					<u>3,000,371</u>	<u>3,700,469</u>
10 Gross cash flows					2015	2014
					€	€
Capital expenditure						
Receipts from sales of investments					<u>2,914,209</u>	<u>-</u>
11 Analysis of changes in net debt						
	At 1 Apr 2014	Cash flows	Non-cash changes	At 31 Mar 2015		
	€	€	€	€		
Cash at bank and in hand	1,380	<u>2,898,150</u>		2,899,530		
Total	<u>1,380</u>	<u>2,898,150</u>	<u>-</u>	<u>2,899,530</u>		
12 Related party transactions					2015	2014
					€	€
The company has this year taken advantage of the exemption provided by Financial Reporting Standard 8 not to disclose transaction with other members of the Aurobindo Pharma Group.						
13 Ultimate controlling party						
The company is 100% subsidiary of Aurobindo Pharma Limited, a company incorporated in India.						

APL Holdings (Jersey) Limited
Detailed profit and loss account
for the year ended 31 March 2015

	2015 €	2014 €
Administrative expenses	(14,307)	(16,086)
Operating loss	<u>(14,307)</u>	<u>(16,086)</u>
Exceptional items	(685,791)	-
Loss before tax	<u>(700,098)</u>	<u>(16,086)</u>

APL Holdings (Jersey) Limited
Detailed profit and loss account
for the year ended 31 March 2015

	2015 €	2014 €
Administrative expenses		
General administrative expenses:		
Bank charges	102	163
Sundry expenses	(24)	15
	<u>78</u>	<u>178</u>
Legal and professional costs:		
Audit fees	3,000	4,500
Other legal and professional	11,229	11,408
	<u>14,229</u>	<u>15,908</u>
	<u>14,307</u>	<u>16,086</u>

AGILE MALTA HOLDINGS LIMITED

**Annual Report
and
Financial Statements
31 December 2014**

C 42437

General Information

Company registration

Agile Malta Holdings Limited is a limited liability company registered in Malta in terms of the Companies Act of 1995. The company's registration number is C42437. The company was registered on 26 September 2007.

Directors

Phaneendra Prasad Gorla
Frederick Schembri
Venugopalan Muralidharan

Company secretary

Dr. Louise Ellul Cachia Caruana

Auditor

John Zammit
Certified Public Accountant and Registered Auditor
Suite 6, Isola Mare,
Bouverie Street
Gzira GZR 1220
Malta

Registered office

Vault 14, Level 2
Valletta Waterfront
Floriana FRN 1914
Malta

Bankers

HSBC Malta Plc.

Index

Page

1 - 2	Directors' Report
3 - 4	Independent Auditor's Report
5	Statement of Comprehensive Income
6	Statement of Financial Position
7	Statement of Changes in Equity
8	Statement of Cash Flows
9 - 18	Notes to the Financial Statements

Directors' Report

31 December 2014

The directors present the report together with the audited financial statements of the company for the period ended 31 December 2014.

Principal Activities

The company's principal activity is to hold investment in subsidiary companies and receive dividends there from.

Review of Business Development

The company did not receive any dividends from its subsidiaries during the period under review. The statement of comprehensive income includes interests paid and received on loans from related companies. As from 01 January 2015, the shareholders of the company decided, by an ordinary resolution, that the company will be merged with Aurobindo Pharma Malta Ltd (C42439).

Results and Dividends

The company achieved a profit before taxation amounting to €5,184 (31 Mar 2014: profit of €238,498). After accounting for taxation the profit for the period amounted to €5,111 (31 Mar 2014: profit of €204,621). The retained earnings for the period-end amounting to €4,223,903 (31 Mar 2014: profits of €4,218,792).

The directors do not recommend the distribution of a dividend.

Directors

The directors of the company who held office during the period were:

Phaneendra Prasad Gorla
Frederick Schembri
Venugopalan Muralidharan

Events After the End of the Reporting Period

On 1st January 2015, the shareholders have decided to merge the company with its subsidiary, Aurobindo Pharma Malta Ltd.

AGILE MALTA HOLDINGS LIMITED
Annual Report and Financial Statements – 31 December 2014

Directors' Report – continued
31 December 2014

Statement of Directors' Responsibilities


The Companies Act, 1995 require the directors to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the company at the end of the financial period and of the profit or loss of the company for that period.


In preparing the financial statements, the directors are required to:-

- adopt the going concern basis, unless it is inappropriate to presume that the company will continue in business;
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- account for income and charges relative to the accounting period on the accruals basis;
- value separately the components of asset and liability items; and
- report comparative figures corresponding to those of the preceding accounting period.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy, at any time, the financial position of the company and to enable the directors to ensure that the financial statements have been properly prepared in accordance with International Financial Reporting Standards, as adopted by the EU, and the Companies Act, 1995. The directors are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the Board of Directors and signed on its behalf by:


Frederick Schembri
Director


Phaneendra Prasad Gorla
Director

Registered Address:
Vault 14, Level 2
Valletta Waterfront
Floriana FRN 1913
Malta

Date: 11 May 2015

JOHN ZAMMIT**B.A. (HONS.) Acc'ty, M.I.A., C.P.A.****Certified Public Accountant****Registered Auditor**

"Isolamare" Suite 6
Bouverie Street
Gzira, GZR Malta 1220
Tel: 21332970/6/7
Fax: 21332991
Mobile: 9949 0357

Independent Auditor's Report**To the Shareholders of Agile Malta Holdings Limited**

I have audited the financial statements of Agile Malta Holdings Limited which comprise the company's statement of financial position as at 31 December 2014 and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the period then ended and a summary of significant accounting policies and other explanatory notes.

Directors' Responsibility for the Financial Statements

The directors are responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards, as adopted by the EU, and the requirements of the Maltese Companies Act, 1995. As described in the statement of directors' responsibilities on page 2, this responsibility includes designing, implementing and maintaining internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

My responsibility is to express an opinion on these financial statements based on my audit. I conducted my audit in accordance with International Standards on Auditing. Those standards require that I comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial statements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.

JOHN ZAMMIT

B.A. (HONS.) Accty, M.I.A., C.P.A.

Independent Auditor's Report- continued
To the Shareholders of Agile Malta Holdings Limited

The Company is a private limited liability company incorporated under the laws of the Malta. The ultimate holding company is Aurobindo Pharma Limited, India and whose shares are traded on the Stock Exchanges of India.

Opinion


In my opinion, the financial statements give a true and fair view of the financial position of the company as at 31 December 2014, and of its financial performance and its cash flows for the period then ended in accordance with International Financial Reporting Standards, as adopted by the EU, and have been properly prepared in accordance with the requirements of the Maltese Companies Act, 1995 which exempts the company from preparing consolidated financial statements as required by IFRS 10 Consolidated Financial Statements.

Report on Other Legal and Regulatory Requirements

I also have responsibilities under the Maltese Companies Act, 1995 to report to you if, in my opinion:

- The information given in the directors' report is not consistent with the financial statements.
- Adequate accounting records have not been kept, or that returns adequate for my audit have not been received from branches not visited by me.
- The financial statements are not in agreement with the accounting records and returns.
- I have not received all the information and explanations I require for my audit.
- Certain disclosures of directors' remuneration specified by law are not made in the financial statements.

I have nothing to report to you in respect of these responsibilities.


John Zammit
Certified Public Accountant and Registered Auditor

Date: 11 May 2015

Statement of Comprehensive Income
For the period ended 31 December 2014

	Note	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
Dividend receivable	4	-	86,503
Refunds receivable		-	146,086
Administrative expenses		<u>(6,709)</u>	<u>(9,453)</u>
Operating (Loss)/Profit	5	(6,709)	223,136
Investment income	6	26,582	18,413
Interest payable and similar charges	7	<u>(14,689)</u>	<u>(3,051)</u>
Profit for the Period/Year before Taxation		5,184	238,498
Taxation	8	<u>(73)</u>	<u>(33,877)</u>
Profit for the Period/Year		<u>5,111</u>	<u>204,621</u>


AGILE MALTA HOLDINGS LIMITED
Annual Report and Financial Statements – 31 December 2014

Statement of Financial Position
31 December 2014

		01 Apr 14 to 31 Dec 14	01 Apr 13 to 31 Mar 14
	Notes	€	€
ASSETS			
Financial Assets			
Investments in group undertakings	9	5,650,000	5,650,000
Current Assets			
Trade and other receivables	10	4,096,269	3,929,408
Current tax asset		25,918	768,406
Cash and cash equivalents		103,147	20,166
		<u>4,225,334</u>	<u>4,717,980</u>
Total Assets		<u>9,875,334</u>	<u>10,367,980</u>
EQUITY AND LIABILITIES			
Capital and Reserves			
Issued share capital	11	5,075,000	5,075,000
Retained earnings		4,223,903	4,218,792
		<u>9,298,903</u>	<u>9,293,792</u>
Current Liabilities			
Trade and other payables	12	576,431	1,074,188
Total Equity and Liabilities		<u>9,875,334</u>	<u>10,367,980</u>

The financial statements on pages 5 to 18 were approved by the Board of Directors and signed on 11 May 2015.


 Frederick Schembri
 Director


 Phaneendra Prasad Gorla
 Director

Statement of Changes in Equity
31 December 2014

	Share Capital €	Retained Earnings €	Total €
Balance at 1 April 2013	5,075,000	4,014,171	9,089,171
Profit for the year	-	204,621	204,621
Balance at 31 March 2014	5,075,000	4,218,792	9,293,792
Balance at 1 April 2014	5,075,000	4,218,792	9,293,792
Profit for the period	-	5,111	5,111
Balance at 31 December 2014	5,075,000	4,223,903	9,298,903

Statement of Cash Flows

For the period ended 31 December 2014

	Note	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
Operating Activities			
Profit for the period/year before taxation		5,184	238,498
<i>Adjustment for:</i>			
Interest receivable		(26,582)	(18,413)
Interest payable		9,485	3,013
Tax adjustment for previous year		5,141	-
Provision for impairment on investments		-	(23,371)
Investment waived off		-	24,999
Loans waived off		-	2,960
		(6,772)	227,686
<i>Working capital changes:</i>			
(Increase) in trade and other receivables		550	(3,510)
(Decrease)/increase in trade and other payables		(175)	175
Cash (absorbed by)/generated from operations		(6,397)	224,351
Interest received		488	1,028
Taxation received		752,922	25,873
Net Cash generated from Operating Activities		747,013	251,252
Financing Activities			
Advances (to)/from related companies		(167,411)	1,070,000
Advances to group companies		(496,621)	(1,306,225)
Net Cash absorbed by Financing Activities		(664,032)	(236,225)
Movement in Cash and Cash Equivalents		82,981	15,027
Cash and Cash Equivalents at Beginning of Year/Period		20,166	5,139
Cash and Cash Equivalents at End of Year/Period	13	103,147	20,166

Notes to the Financial Statements

31 December 2014

1. Basis of Preparation

The financial statements have been prepared in accordance with the provisions of the Companies Act, 1995 enacted in Malta, which require adherence to International Financial Reporting Standards (IFRSs), as adopted by the EU, and their interpretations adopted by the International Accounting Standards Board (IASB). The financial statements are prepared under the historical cost convention.

The preparation of financial statements in conformity with IFRSs requires the use of certain accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies (refer to Note 3 - Critical accounting estimates and judgements).

Standards, interpretations and amendments to published standards effective in 2014

In the financial period ending 31 December 2014 the company adopted new standards, amendments and interpretations to existing standards that are mandatory for the company's accounting year beginning on 1 April 2014. The adoption of these revisions to the requirements of IFRSs, as adopted by the EU, did not result in substantial changes to the company's accounting policies.

International Financial Reporting Standard 10, Consolidated and Separate Financial Statements, requires a parent company to prepare consolidated financial statements in which it consolidates its investments in subsidiaries. However, the company has availed itself of the exemptions set out in section 173 of the Companies Act, 1995 and accordingly consolidated financial statements covering the company and its subsidiaries have not been drawn up.

2. Principal Accounting Policies

The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

Reporting currency

The reporting currency used for the preparation of the financial statements is the Euro, which is the currency in which the company's share capital is denominated.

Notes to the Financial Statements

31 December 2014

2. Principal Accounting Policies - continued

Revenue recognition

Dividend income is recognised when the right to receive payment is established.

Investments in group undertakings

Subsidiary undertakings are all entities over which the company has the power to govern the financial and operating policies generally accompanying a shareholding of more than one half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the company controls another entity.

In the company's financial statements, investments in group undertakings are accounted for by the cost method of accounting. The dividend income from such investments is included in the statement of comprehensive income in the accounting year in which the company's rights to receive payment of any dividend is established. The company gathers objective evidence that an investment is impaired using the same process disclosed in accounting policy. On disposal of an investment, the difference between the net disposal proceeds and the carrying amount is charged or credited to the statement of comprehensive income.

Investments - loans and receivables

The company's loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They arise when the company provides money, goods or services directly to a debtor with no intention of trading the receivable. Loans and receivables are carried at amortised cost using the effective interest method. They are included in current assets, except for maturities greater than twelve months after the statement of financial position date. These are classified as non-current assets.

Impairment of assets

Impairment of financial assets

A financial asset is considered to be impaired if objective evidence indicates that one or more events have had a negative effect on the estimated future cash flows of that asset.

An impairment loss in respect of a financial asset measured at amortised cost is calculated as the difference between its carrying amount, and the present value of the estimated future cash flows discounted at the original effective interest rate. An impairment loss in respect of an available-for sale financial asset is calculated by reference to its current fair value.

Notes to the Financial Statements 31 December 2014

2. Principal Accounting Policies – continued

Impairment of assets - continued

The company assesses at each statement of financial position date whether there is objective evidence that a financial asset or a group of financial assets is impaired. If there is objective evidence that an impairment loss has been incurred on loans and receivables carried at amortised cost, the amount of the loss is recognized in the statement of comprehensive income and measured as the difference between the asset's carrying amount and the present value of estimated future cash flows discounted at the financial asset's original effective interest rate.

An impairment loss is reversed if the reversal can be related objectively to an event occurring after the impairment loss was recognised. For financial assets measured at amortised cost and available for sale financial assets that are debt securities, the reversal is recognised in the statement of comprehensive income. For available-for-sale financial assets that are equity securities, the reversal is recognised directly in equity.

Trade and other receivables

Trade and other receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for impairment of trade receivables is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of debts.

The amount of the provision is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the effective interest rate. The amount of the provision is recognized in the statement of comprehensive income.

Cash and cash equivalents

Cash and cash equivalents are carried in the statement of financial position at face value. For the purposes of the cash flow statement, cash and cash equivalents comprise cash in hand and deposits held at call with banks.

Income taxation

Income tax on the profit or loss for the period comprises current and deferred tax. Income tax is recognised in the statement of comprehensive income except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity.

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantially enacted at the statement of financial position date, and any adjustment to tax payable in respect of previous periods.

Notes to the Financial Statements

31 December 2014

2. Principal Accounting Policies - continued

Income taxation - continued

Deferred taxation is provided using the liability method, for all temporary differences arising between the tax bases of assets and liabilities and their carrying values for financial reporting purposes. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the statement of financial position date and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

Deferred tax assets are recognised only to the extent that it is probable that future taxable profits will be available against which the unutilised deferred tax credits can be utilised.

Share capital

Ordinary shares are classified as equity. Dividend distribution to the company's shareholders is recognised as a liability in the company's financial statements in the period in which the dividends are approved by the company's shareholders.

Trade payables

Trade payables are carried at cost which is the fair value of the consideration to be paid in the future for goods and services received, billed to the company.

Borrowings

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the the statement of comprehensive income over the period of the borrowings using the effective interest method.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the statement of financial position date.

3. Critical Accounting Estimates and Judgements

Estimates and judgements are continually evaluated and based on historical experience and other factors including expectations of future events that are believed to be reasonable under the circumstances.

In the opinion of the directors, the accounting estimates and judgements made in the course of preparing these financial statements are not difficult, subjective or complex to a degree which would warrant their description as critical in terms of the requirements of IAS 1 (revised).

Notes to the Financial Statements

31 December 2014

4. Revenue

The company received dividends from Aurobindo Pharma (Malta) Limited and are analysed as follows:

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
Gross dividend	-	86,503
Tax at source at 35%	-	(30,276)
Net Dividend	-	56,227

5. Operating (Loss)/Profit

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
<i>This is stated after charging:</i>		
Audit fee	1,000	1,000
Impairment of investments	-	(23,271)

6. Investment Income

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
Interest on amounts owned by group undertakings	26,094	17,385
Interest on bank deposits	488	1,028
	26,582	18,413

Notes to the Financial Statements
31 December 2014

7. Interest Payable and Similar Charges

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
Tax adjustment for prior year	5,141	-
Interest on loans from parent company	9,485	3,013
Finance charges	63	38
	<u>14,689</u>	<u>3,051</u>

8. Taxation

The tax charge for the period/year comprises:

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
Withholding tax @ 15%	73	154
Current tax expense	-	33,723
	<u>73</u>	<u>33,877</u>

The tax on the company's results before tax differs from the theoretical amount that would arise using the statutory tax rate of 35% as follows:

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
Profit for the period/year before tax	<u>5,184</u>	<u>238,498</u>
Tax at 35%	1,814	83,474
<i>Tax effect of:</i>		
Income not taxable	-	(51,130)
Income taxed at different rates	(98)	(206)
Expenses disallowed for tax purposes	<u>1,643</u>	<u>1,739</u>
Tax expense	<u>73</u>	<u>33,877</u>

Notes to the Financial Statements

31 December 2014

9. Investments in Group Undertakings

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
Opening balance	5,650,000	5,651,628
Impairment reversal/(allowance)	-	23,371
Investment waived off due to liquidation	-	(24,999)
Closing net book amount	<u>5,650,000</u>	<u>5,650,000</u>

The principal group undertakings at year ending 31 December are shown below:

	Registered office	Percentage of shares held	
		31 Dec14	31 Mar 14
Aurobindo Pharma (Malta) Limited	Vault 14, Level 2, Valletta Waterfront, Floriana, FRN 1913 Malta	99.99	99.99
Agile Pharma (Malta) Limited	Vault 14, Level 2, Valletta Waterfront, Floriana, FRN 1913 Malta	-	99.99

10. Trade and Other Receivables

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
Loans to subsidiary companies	4,091,443	3,872,443
Prepayments	-	550
Interests on loans to subsidiaries	4,826	56,415
	<u>4,096,269</u>	<u>3,929,408</u>

Loans to subsidiary companies are subject to an interest rate of 1.3% per annum above the LIBOR rates. These are unsecured and repayable on demand.

Notes to the Financial Statements

31 December 2014

11. Share Capital

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
<i>Authorised</i>		
5,000,000 Ordinary shares of €1 each	5,000,000	5,000,000
2,000,000 Ordinary shares of €1 each	2,000,000	2,000,000
	<u>7,000,000</u>	<u>7,000,000</u>
<i>Issued and fully paid</i>		
5,074,999 Ordinary 'A' shares of €1 each	5,074,999	5,074,999
1 Ordinary 'B' share of €1	1	1
	<u>5,075,000</u>	<u>5,075,000</u>

12. Trade and Other Payables

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
Loans from parent company (Note 1)	550,000	1,070,000
Loans from parent company (Note 2)	23,379	-
Interest on loans from parent company	2,052	3,013
Accruals	1,000	1,175
	<u>576,431</u>	<u>1,074,188</u>

Note 1: Loans from parent company are subject to an interest rate of 1.2% per annum above LIBOR rates. These are unsecured and have no fixed date for repayment.

Note 2: Loan from parent company represents the 6/7ths tax refund accounted for in the books of Agile Malta Holdings Ltd. This amount is unsecured, interest free and has no fixed date for repayment.

Notes to the Financial Statements

31 December 2014

13. Cash and Cash Equivalents

For the purpose of the cash flow statements, the cash and cash equivalents at the end of the period comprise the following:

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
Cash at bank	<u>103,147</u>	<u>20,166</u>

14. Related Party Transactions

Agile Malta Holdings Limited is fully owned by Agile Pharma B.V. which is ultimately controlled by Aurobindo Pharma Limited, India and whose shares are traded on the Stock Exchanges of India. Transactions with parent company and its subsidiaries and associated companies are related party transactions.

	01 Apr 14 to 31 Dec 14 €	01 Apr 13 to 31 Mar 14 €
<i>Loans and advances</i>		
Loans (to)/ from parent company	(167,411)	1,070,000
Advances to related companies	(496,621)	(1,306,225)
Interest charged to subsidiary companies	26,094	17,385
Interest incurred on loans by parent company	<u>(9,485)</u>	<u>(3,013)</u>
	<u>(647,423)</u>	<u>(221,853)</u>

15. Financial Instruments

At the year end, the company's main financial assets on the statement of financial position comprised of investments, receivables and cash at bank. At the year end there were no unreported financial assets in the statement of financial position.

Notes to the Financial Statements

31 December 2014

15. Financial Instruments - continued

At the year end, the company's main financial liabilities on the statement of financial position consisted of accrued expenses and other payables. The company had no unreported financial liabilities in the statement of financial position at year end.

Timing of cash flows

The presentation of the financial assets and liabilities listed above under the current and non-current headings within the statement of financial position is intended to indicate the timing in which cash flows will arise.

Credit risk

Financial assets which potentially subject the company to concentrations of credit risk consist principally of cash at bank. The company's cash is placed with prime financial institutions.

Fair values of non-derivative financial instruments

At 31 December 2014 the carrying amounts of cash at bank and in hand, receivables and payables approximated their fair values.

16. Contingent Liabilities

At 31 December 2014, the company had no contingent liabilities which affect the financial position of the company.

17. General Information

Agile Malta Holdings Limited is a limited liability company domiciled and incorporated in Malta.

LABORATORIOS AUROBINDO S.L.U.

MANAGEMENT REPORT AS AT 31 MARCH 2015

The Company's Board of Directors has prepared this management report in which it intends to provide a clear view of the evolution of the business and of the Company's equity situation, in reference to the fiscal year closed on 31 March 2015, according to the application precepts and the Corporate Bylaws.

Evolution of the Company's activity and situation

The net turnover of the year reached the figure of 10,950 thousand Euros, which signifies a decrease in sales of 23,4 % in relation to the previous year.

The average staff for the fiscal year 2014/15 has been of 13 persons (20 in 2013/14).

The year 2014/15 has been the year of consolidation for Aurobindo Spain S.A. in the Spanish pharmaceutical market, with a stable portfolio of clients, gross sales over that budgeted, being an intense year both internally and externally.


As regards the market, the year 2014/15 has been marked principally by the implementation of the fourth and fifth auction of medicines in the Region of Andalusia. These auctions, which will have a duration of two years, have meant the possibility of selling part of our product catalogue in that Autonomous Region.

In 2014 one new auction has again been announced (renewal of the 2nd and with a duration of two years). Aurobindo has been awarded 45 new presentations.

Internally, 2014 has been marked by the purchase of seven subsidiaries of Actavis Group by Aurobindo Pharma Limited, by which the first six months of 2014 were characterized by the great effort aimed at integrating the two companies and reorganising the available resources to achieve greater efficiency. In Spain, the synergies in terms of portfolio and strategy allow us to face this next year with a diversified structure in all the channels of the sector (Hospitals, Retail and Tenders) and focus on increasing the market share of each of the channels and being prepared for the evolution of the autonomous management referred to. This year the improvement of the service and supply will be a challenge, as will cutting the issue times of batches and adding synergies of the vertical integration and economy of scales that Aurobindo contributes as a world power in the development and production of medicines and that positions us in the European Top Ten in the sale of generic medicines.

The Company's Directors consider, therefore, that based on the plans and the development of the operations in progress, the signed projects and those in negotiations will allow the future results to be positive.

For the year 2015 we expect that the market will continue being stable. We expect that the synergies in costs and the new products of the portfolio will allow us to be increasingly more competitive in the Spanish pharmaceutical market.



Financial instruments and risks

The management of the financial risk is controlled by the Company's Treasury Department that identifies, evaluates and hedges the financial risks according to the policies approved by the Financial Management.

The Company is not exposed to significant risks regarding the interest rate. With respect to the exchange rate risk, the Company carries out practically all its transactions in Euros, for which reason the exchange rate risk for operations in other currencies is minimal.

Activities in R&D&i

The Company does not carry out activities of R&D&i.

Environmental activities

The Company complies with the regulatory requirements on the subject of the environment.

Treasury shares

No operations have been carried out with its own shares.

Events subsequent to the closing

No significant subsequent events have taken place other than those reflected in Note 15 of the attached Annual Report.

Director
Gabriel Díaz



RUSSELL BEDFORD ESPAÑA
Auditores y Consultores

INDEPENDENT AUDIT REPORT ON THE REPORTING PACKAGE

To the Shareholders of LABORATORIOS AUROBINDO, S.L.:

Report on the Reporting package

In accordance with your instructions we have audited the financial information included in the accompanying Reporting Package to 2015 of LABORATORIOS AUROBINDO, S.L., which comprise the Balance Sheet at March 31, 2015, the P&L Account for the yearly period then ended, the Sub-schedules to Balance Sheet and P&L and the Checklist providing Inter-company transactions.

Directors' responsibility for the Reporting Package

The Directors are responsible for the preparation of the accompanying Reporting Package in accordance with the Group General Instructions for preparing Balance Sheet and Statement of Profit and Loss, and for such internal control as they determine is necessary to enable the preparation of Reporting Package that are free from material misstatement, whether due to fraud or error.

The Reporting Package has been prepared for the sole purpose of carrying out the consolidation process of the Group Aurobindo Pharma Limited and the preparation of the group's consolidated financial statements for the yearly period ended March 31, 2015.

Auditor's responsibility

Our responsibility is to express an opinion on the accompanying Reporting Package based on our audit. We conducted our audit in accordance with prevailing audit regulations in Spain. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Reporting Package. The procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the Reporting Package, whether due to fraud or error. In making those risk assessments, the auditor consider internal control relevant to the preparation of Reporting Package by the Directors of the Company in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

RUSSELL BEDFORD ESPAÑA, AUDITORES Y CONSULTORES, S.L. CIF: B-96996079 - Tomo 6.727, Libro 4.031, Folio 218, Sección 8, Hoja V-73,978, Inscripción 4ª

Oficinas en España:

C/ Tránsito, 2 - 1ª B
Plaza de Carlos Trias Bertrán, 4

46002 Valencia
28020 Madrid

Tel: 963.106.046 recepcion@russellbedford.es
Tel: 914.184.537 recepcion@russellbedford.es

Russell Bedford España es miembro de Russell Bedford International



RUSSELL BEDFORD ESPAÑA
Auditores Consultores

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the accompanying Reporting Package give a true and fair view, in all material respects, of the equity and financial position of LABORATORIOS AUROBINDO, S.L. at March 31, 2015 and the results for the yearly period then ended, in accordance with the Group General Instructions for preparing Balance Sheet and Statement of Profit and Loss and with the applicable regulatory framework for financial information in Spain, and specifically the accounting principles and criteria contained therein.

This Audit Report has been issued for the sole purpose of informing you and should not be distributed to third parties or used for any other purpose.

Madrid, April 30, 2015

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
(ROAC nº S-1357)

Jaime Salvador
Socio

RUSSELL BEDFORD ESPAÑA, AUDITORES Y CONSULTORES, S.L. CIF: B-96996079 Tomo 6.727, Libro 4.031, Folio 218, Sección 8, Hoja V-73,978, Inscripción 4ª

Oficinas en España:

C/ Tránsito, 2 - 1º B
Plaza de Carlos III de Borbón, 4

46002 Valencia
28020 Madrid

Tel: 963 106 046 recepcion@russellbedford.es
Tel: 914 184 537 recepcion@russellbedford.es

Russell Bedford España es miembro de Russell Bedford International

LABORATORIOS AUROBINDO SPAIN SLU**Balance Sheet as at March 31, 2015**

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	31 March, 2015 (Currency)	31 March, 2014 (Currency)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	4.866.000	4.866.000
Share application money			
Reserves and surplus	3	(4.317.101)	(1.455.185)
		<u>548.899</u>	<u>3.410.815</u>
Non-current liabilities			
Long-term borrowings	4	5.400.000	900.000
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		<u>5.400.000</u>	<u>900.000</u>
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	7.303.874	11.727.080
Other current liabilities	9	41.647	106.030
Short-term provisions	7	2.941.830	3.125.050
		<u>10.287.350</u>	<u>14.958.160</u>
TOTAL		<u><u>16.236.249</u></u>	<u><u>19.268.975</u></u>
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	11.821	17.842
Intangible assets	11	2.430.596	2.283.977
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5	1.834.040	531.672
Long-term loans and advances	13	63.249	83.665
Trade receivables	14,1	-	-
Other non-current assets	14,2	-	-
		<u>4.339.706</u>	<u>2.917.156</u>
Current assets			
Current investments	15	-	-
Inventories	16	3.570.502	3.902.555
Trade receivables	14,1	6.333.954	9.206.451
Cash and bank balances	17	1.983.392	415.797
Short-term loans and advances	13	14.104	2.819.068
Other current assets	14,2	(5.408)	7.948
		<u>11.896.543</u>	<u>16.351.819</u>
TOTAL		<u><u>16.236.249</u></u>	<u><u>19.268.975</u></u>
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-66996079
Plaza de Carlos III de Borbón, nº 4
28020 MADRID

LABORATORIOS AUROBINDO SPAIN SLU
Statement of profit and loss for the year ended March 31, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Income															
Revenue from operations (gross)	18	1,806,451	2,379,390	2,955,646	2,251,556	2,067,808	3,429,460	1,652,692	3,059,586	2,972,072	3,301,020	2,516,212	1,856,287	30,448,178	30,002,202
Less: Excise duty/Rebates		754,906	1,138,936	1,617,033	1,105,604	1,273,103	2,485,008	1,041,757	1,933,887	1,705,937	2,739,415	1,851,406	1,851,380	19,498,373	16,276,285
Revenue from operations (net)		1,051,544	1,240,454	1,338,613	1,145,952	794,705	1,144,452	610,935	1,125,699	1,266,135	561,605	664,805	4,906	10,949,805	13,725,917
Other income	19	-	-	674	60	-	621	235	-	-	-	-	-	1,590	566,756
Total revenue (I)		1,051,544	1,240,454	1,339,287	1,146,012	794,705	1,145,073	611,170	1,125,699	1,266,135	561,605	664,805	4,906	10,951,395	14,292,672
Expenses															
Cost of raw material and components consumed	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods	21	1,362,456	773,299	622,235	621,446	819,909	1,568,301	353,691	684,437	397,507	273,582	417,381	802,991	8,697,238	9,930,229
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	-	-	251,203	79,223	-	-	732,266	437,777	337,526	563,805	164,089	-	332,053	921,060
Employee benefit expense	22	95,023	88,851	88,671	157,638	156,523	93,362	67,154	87,638	85,752	34,334	13,737	-	957,131	1,290,214
Other expenses	23	311,462	308,260	228,269	180,704	232,355	282,759	211,119	500,410	862,141	345,942	535,382	1,072,091	4,819,901	2,098,324
Exceptional items	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total (II)		894,976	1,080,456	1,190,378	1,039,012	937,003	1,377,754	932,992	1,710,262	1,682,926	1,417,663	1,130,589	1,412,036	14,806,083	12,397,707
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		156,569	159,963	148,910	107,000	112,706	-232,681	-321,822	-584,563	-416,791	-856,058	-465,784	-1,407,130	-3,854,688	1,894,965
Depreciation and amortization expense	25	18,637	18,280	19,190	20,112	20,667	20,601	22,051	21,667	21,667	21,667	24,727	21,191	250,455	188,241
Finance costs	26	556	2,780	2,683	1,204	3,822	3,914	1,251	1,828	14,494	9,070	8,467	9,071	59,141	47,221
Profit/(loss) before tax		137,375	138,909	127,037	85,683	-106,783	-257,199	-345,124	-608,058	-452,952	-880,795	-498,978	-1,437,392	-4,164,284	1,659,503
Tax expenses															
Current tax		-	-	-	-	-	-	-	-	-	-	-	-	-	518,861
Less: MAT credit entitlement		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax		-	-	-	-	-	-	-	-	-	-	-	1,302,365	1,812,338	-
Fringe benefit tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax relating to previous years		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total tax expense		-	-	-	-	-	-	-	-	-	-	-	1,302,365	1,812,338	518,861
Profit/(loss) for the year		137,375	138,909	127,037	85,683	-106,783	-257,199	-345,124	-608,058	-452,952	-880,795	-498,978	-1,437,392	-2,551,946	1,140,642

Summary of significant accounting policies

1

The accompanying notes are an integral part of the financial statements.

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
 C.I.F. B26996079
 Plaza. de Carlos III de Bertrán, nº 4
 28020 MADRID

LABORATORIOS AUROBINDO SPAIN SLU

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 1: Summary of significant accounting policies

- 1.1
- 1.2
- 1.3
- 1.4
- 1.5

Note 2: Share capital

	March 31, 2015	March 31, 2014
Authorised shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of 1€ each	4.866.000	4.866.000
XXXXXXXX (31 March, 2014: XXXXXXXX) preference shares of XXX each	4.866.000	4.866.000
Issued, Subscribed and Fully Paid-up shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of 1€ each	4.866.000	4.866.000

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-20936079
Plaza de Carlos III de Borbón, nº 4
28020 MADRID

LABORATORIOS AUROBINDO SPAIN S.L.U
Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 3: Reserves and surplus (in thousands of Euros)

	March 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	(9.936)	(9.936)
	(9.936)	(9.936)
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet	-	-
	-	-
General Reserve		
As per last Balance Sheet	(3.217)	(3.217)
Add: Transferred from statement of profit and loss	(3.217)	(3.217)
	(3.217)	(3.217)
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	(1.442.032)	(2.582.673)
Profit for the quarter	(2.861.916)	1.140.641
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)		
Tax on proposed equity dividend		
Interim dividend paid (amount per share XX (31 March, 2014 XX)		
Transfer to general reserve		
Total appropriations	-	-
Net surplus in the statement of profit and loss	(4.303.948)	(1.442.032)
	(4.303.948)	(1.442.032)
Total reserves and surplus	(4.317.101)	(1.455.185)
	(4.317.101)	(1.455.185)

Note 4: Long-term borrowings (in thousands of Euros)

	Non-current Portion		Current maturities	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)				
Other loans from banks				
Current account credit balance				
Loans and advances from related parties	5.400.000	900.000		
Other Loans and advances				
Sales tax deferment loan (Un Secured)				
	5.400.000	900.000	-	-
The above amount includes				
Secured borrowings				
Unsecured borrowings				
Amount disclosed under the head				
"Other current liabilities"				
Net Amount				

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
 C.I.F. B-96399079
 Plaza. de Carlos Trias Bertrán, nº 4
 28020 MADRID

LABORATORIOS AUROBINDO SPAIN SLU

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 5: Deferred tax liability (net)

	March 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis		
Provision for diminution in the value of investments		
Provision for doubtful debts and advances		
Fixed Assets (Depreciation)		
Retirement Benefits		
Others		
Gross deferred tax liability	-	-
Deferred tax asset		
Carried Forward Business Losses		
Others	1.834.040	531.672
Gross deferred tax asset	1.834.040	531.672
Net deferred tax liability	(1.834.040)	(531.672)

Note 6: Other long-term liabilities

	March 31, 2015	March 31, 2014
Trade payables (including acceptances)		
Other liabilities		
Advances from related parties		
	-	-
	-	-

Note 7: Provisions (Provisions for contingencies and losses)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Provision for employee benefits				
- Gratuity				
- Leave encashment				
	-	-	-	-
Other Provisions				
Provision For Expenses			2.941.830	3.125.050
For Taxation (net of advance payments)				
For Proposed dividend				
For Tax on proposed dividend				
	-	-	2.941.830	3.125.050
	-	-	2.941.830	3.125.050

Provision for warranties

	March 31, 2015	March 31, 2014
At the beginning of the year		
Arising during the period		
Utilised during the period		
Unused amounts reversed		
At the end of the Quarter	-	-
Current portion		
Non-current portion		

Note 8: Short-term borrowings (Short-term borrowings)

	March 31, 2015	March 31, 2014
Bank overdraft		
Loans and advances from related parties		
Working capital loans (Secured)		
Short term loans (Un Secured)		
Working capital loans		
	-	-
The above amount includes		
Secured borrowings	-	-
Unsecured borrowings	-	-

Note 9: Other current liabilities

	March 31, 2015	March 31, 2014
Trade payables (including acceptances)	7.303.874	11.727.080
Other liabilities		
Current maturities of long-term borrowings		
Trade deposits (Other liabilities)	(15.394)	
Current Tax Payables	57.041	106.030
	41.647	106.030
	7.345.520	11.833.110

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-95996079
Plaza de Carlos III de Borja, nº 4
28020 MADRID

LABORATORIOS AUROBINDO SPAIN SLU

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 10: Tangible assets ()

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment (including Computers & Software)	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation									
At 1 April 2013						17.738		14.095	31.833
Additions								4.242	4.242
Disposals									-
Other adjustments						(4.410)		4.410	-
- Exchange differences									-
- Borrowing costs									-
At 31 March 2014	-	-	-	-	-	13.328	-	22.746	36.075
Additions								1.938	1.938
Acquisitions through amalgamation									-
Disposals									-
Other adjustments									-
- Exchange differences									-
- Borrowing costs									-
At 31 March 2015	-	-	-	-	-	13.328	-	24.684	38.013
Depreciation									
At 1 April 2013						3.245		7.933	11.178
Charge for the year						1.618		6.399	8.017
Disposals									-
Other adjustments						255		(1.218)	(963)
- Exchange differences									-
At 31 March 2014	-	-	-	-	-	5.118	-	13.114	18.232
Charge for the period						2.051		5.908	7.959
Disposals									-
Other adjustments									-
- Exchange differences									-
At 31 March 2015	-	-	-	-	-	7.169	-	19.022	26.192
Impairment loss									
At 1 April 2013									
At 31 March 2014									
Charge for the period									
At 31 March 2015									
Net Block									
At 31 March 2014	-	-	-	-	-	8.210	-	9.632	17.842
At 31 March 2015	-	-	-	-	-	6.159	-	5.662	11.821

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-56795079
Plaza de Carlos III tras Betrán, nº 4
28020 MADRID

LABORATORIOS AUROBINDO SPAIN SLU

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 11: Intangible assets (Note 10 and 11)

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At 1 April 2013	42.487		2.114.195	2.156.682
Purchase	3.643		495.728	499.371
Internal development				-
Disposals	(25.685)		(16.454)	(42.139)
Other adjustments			(33.320)	(33.320)
- Exchange differences				-
At 31 March 2014	20.445	-	2.560.149	2.580.593
Purchase			389.116	389.116
Acquisitions through amalgamation				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At 31 March 2015	20.445	-	2.949.264	2.969.709
Amortization				
At 1 April 2013	12.820		122.252	135.072
Charge for the year	5.793		142.304	148.097
Disposals	(16.529)		(2.150)	(18.679)
Other adjustments	14.996		17.131	32.127
- Exchange differences				-
At 31 March 2014	17.080	-	279.537	296.617
Charge for the period	6.775		235.721	242.496
Disposals				-
Other adjustments	(4.748)		4.749	0
- Exchange differences				-
At 31 March 2015	19.106	-	520.007	539.113
Net Block				
At 31 March 2014	3.365	-	2.280.612	2.283.976
At 31 March 2015	1.338	-	2.429.258	2.430.596

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-95990079
Plaza de Carlos Mas Bertrán, nº 4
28020 MADRID

LABORATORIOS AUROBINDO SPAIN SLU

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 12: Non-current investments

March 31, 2015 March 31, 2014

Unquoted equity instruments

Investment in subsidiaries

Investment in joint ventures

Investment in associates

Note 13: Loans and advances

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Capital advances				
Secured, considered good	63.249	84.938		
Unsecured, considered good				
(A)	63.249	84.938	-	-
Security deposit				
Secured, considered good		(1.273)		
Unsecured, considered good				
Doubtful				
	-	(1.273)	-	-
Provision for doubtful security deposit				
(B)	-	(1.273)	-	-
Loan and advances to related parties				
Unsecured, considered good				
(C)	-	-	-	-
Advances recoverable in cash or kind				
Secured, considered good				
Unsecured, considered good				
Doubtful				
	-	-	-	-
Provision for doubtful advances				
(D)	-	-	-	-
Other loans and advances				
Advance income-tax (net of provision for taxation)			14.104	19.068
Prepaid expenses				
Loans to employees				
Loans to others (Related Parties)			-	2.800.000
Export incentives receivable				
Export incentives licenses				
Balances with Statutory/government authorities				
(E)	-	-	14.104	2.819.068
Total (A+B+C+D+E)	63.249	83.665	14.104	2.819.068

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors				
Dues from officers				
Dues from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner				
Dues from in which the company's managing director is a member				
Dues from the partnership firm in which the company's non-executive director is a partner				

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-66966079
Plaza de Carlos Mas Bertrán, nº 4
28020 MADRID

LABORATORIOS AUROBINDO SPAIN SLU

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 14 : Trade receivables and other assets

14.1 Trade receivable

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful			677.780	303.911
	-	-	677.780	303.911
Provision for doubtful receivables	-	-	677.780	303.911
(A)	-	-	-	-
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies			39.018	14.013
Due from others			6.294.935	9.192.438
Doubtful			511.277	-
	-	-	6.845.231	9.206.451
Provision for doubtful receivables	-	-	511.277	-
(B)	-	-	6.333.954	9.206.451
Total (A+B)	-	-	6.333.954	9.206.451

Trade receivables include:

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				

14.2 Other assets

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)	-	-	-	-
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)	-	-	-	-
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on investments in subsidiaries - long term				
Others			(5.408)	7.948
(C)	-	-	(5.408)	7.948
Total (A+B+C)	-	-	(5.408)	7.948

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-36946078
Plaza de Carlos III de Borbón, nº 4
28020 MADRID

LABORATORIOS AUROBINDO SPAIN SLU

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 15: Current investments

	March 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any (Please specify)		

Note 16: Inventories (valued at lower of cost and net realizable value)

	March 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)		
Work - in - Progress	1.030.455	
Finished goods	2.540.047	3.902.555
Traded goods (including stock-in-transit XXXX (31 March, 2014 XXX)		
Stores, spares, consumables and packing materials		
Loose tools		
	3.570.502	3.902.555

Note 17: Cash and bank balances

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			1.983.392	415.797
Deposits with original maturity of less than 3 months				
Cash credit accounts				
On unpaid dividend account				
Cheques/drafts on hand				
Unpaid matured deposits				
Cash on hand			1.983.392	415.797
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
Amount disclosed under non-current assets			1.983.392	415.797

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
 C.I.F. B-66996079
 Plaza. de Carlos Trias Bertrán, nº 4
 28020/MADRID

(All amounts are in local Currency except share data and unless otherwise stated)

[illegible]

LABORATORIOS AUROBINDO SPAIN SLU

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 21 : (Increase)/decrease in inventories														
Inventories at the end of the period														
Traded goods														
Work-in-progress														
Finished goods	4.776.522	4.866.446	4.615.243	4.536.018	4.807.802	5.374.471	4.642.205	4.204.428	3.866.902	3.303.097	3.139.008	3.570.502	3.570.502	3.902.555
	4.776.522	4.866.446	4.615.243	4.536.018	4.807.802	5.374.471	4.642.205	4.204.428	3.866.902	3.303.097	3.139.008	3.570.502	3.570.502	3.902.555
Inventories at the beginning of the period														
Traded goods														
Work-in-progress														
Finished goods	3.902.555	4.776.522	4.866.446	4.615.243	4.536.018	4.807.802	5.374.471	4.642.205	4.204.428	3.866.902	3.303.097	3.139.008	3.902.555	2.981.496
	3.902.555	4.776.522	4.866.446	4.615.243	4.536.018	4.807.802	5.374.471	4.642.205	4.204.428	3.866.902	3.303.097	3.139.008	3.902.555	2.981.496
	(873.967)	(89.924)	251.203	79.225	(271.784)	(566.669)	732.266	437.777	337.526	563.805	164.089	(431.494)	332.053	921.059
Details of purchase of traded goods														
Product A	1.362.458	773.299	622.235	621.446	819.909	1.568.301	353.691	684.437	397.507	273.582	417.381	802.991	8.697.238	9.930.229
Product B														
Product C														
	1.362.458	773.299	622.235	621.446	819.909	1.568.301	353.691	684.437	397.507	273.582	417.381	802.991	8.697.238	9.930.229
Note 22 : Employee benefit expense														
Salaries, wages and bonus	93.941	87.641	87.641	157.229	155.440	92.280	86.072	86.072	84.670	32.440	12.973	(32.080)	944.319	1.274.838
Contribution to provident and other fund													-	-
Employee stock option scheme													-	-
Gratuity expense													-	-
Other employee benefits													-	-
Post employment medical benefits													-	-
Staff welfare expenses	1.082	1.210	1.030	409	1.082	1.082	1.082	1.566	1.082	1.894	764	528	12.812	15.377
	95.023	88.851	88.671	157.638	156.523	93.362	87.154	87.638	85.752	34.334	13.737	(31.552)	957.131	1.290.214
Note 23 : Other expenses														
Consumption of stores and spares													-	-
Conversion charges													-	-
Chemicals consumed													-	-
Increase in VAT on finished goods													-	-
Customer service expenditure													-	-
Power and fuel	417	351	295	269	378	400	87	163	149	-	-	-	2.509	4.596
Water charges													-	-
Freight and forwarding charges													-	-
Carriage inward	11.558	12.442	67.036	19.174	24.265	21.375	19.019	43.193	32.062	31.586	20.818	13.512	316.040	343.075
Carriage outwards	44.211	73.331	87.570	42.846	23.629	48.231	35.851	40.286	46.171	34.332	28.271	24.523	529.253	1.002.458
Rent	3.260	3.291	3.294	3.249	3.438	3.040	2.730	2.798	2.730	136	16	42	28.023	39.962
Rates and taxes													-	-
Insurance	2.221	2.881	2.070	938	127	-	127	938	479	-	1.200	17.578	22.455	3.821
Repairs and maintenance													-	-
i) Plant and machinery													-	-
ii) Buildings													-	-
iii) Others	149	-	-	79	149	1.114	-	-	-	311	-	-	1.802	2.512

LABORATORIOS AUROBINDO SPAIN SLU

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Advertising and sales promotion	3.626	2.913	2.926	4.240	4.040	2.157	3.593	2.820	4.562	225	-	100	31.201	40.226
Brokerage and discounts	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Remuneration to Auditors	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales commission	480	474	419	1.830	792	-	-	-	-	-	-	-	3.994	55.046
Travelling and conveyance	5.030	8.505	11.131	16.198	10.167	22.772	2.230	9.713	7.975	3.227	1.002	-	97.564	177.148
Communication costs	2.027	2.792	889	3.295	2.182	2.037	2.396	2.213	1.413	1.690	1.919	1.662	24.515	36.913
Printing and stationery	1.132	558	575	853	762	328	1.245	3.314	449	0	225	71	9.514	10.875
Legal and professional fees	20.169	6.517	6.625	13.944	9.330	9.224	8.484	8.903	9.827	13.761	9.313	9.611	127.705	112.314
Directors sitting fees	9.535	-	8.000	16.104	8.000	8.000	8.500	10.500	8.000	-	8.491	2.500	40.775	102.578
Payment to auditor (Refer details below)	1.000	53	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	11.053	18.392
Provision for diminution in value of investment in subsidiary company	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for other than temporary decline in the carrying amount of other long-term investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adjustment to the carrying amount of current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Penalties	-	-	-	-	-	-	-	-	193.511	175.174	200.208	409.878	978.771	-
Provision for Expiry Products	156.946	135.306	156.946	20.537	93.683	59.035	130.536	87.860	105.275	86.594	178.807	623.201	502.411	-
Provision for warranties (net of reversals)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for litigations (net of reversals)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exchange differences (net)	-	-	225	-	-	-	-	-	-	-	-	-	225	-
Loss on derivative contracts (including provisions mark-to-market loss)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bad debts/advances written off	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment loss on fixed assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for doubtful debts and advances	-	-	-	-	4.200	53.963	57.907	68.357	355.362	111.860	97.526	177.678	901.142	247.425
Loss on sale of fixed assets (net)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Premium on forward exchange contract amortized	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Factory maintenance	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effluent treatment expenses	14.117	4.263	4.263	4.263	4.263	4.263	4.263	14.445	2.756	5.314	4.263	3.434	69.907	9.321
Vehicle maintenance expenses	6.251	6.251	6.251	8.299	5.576	5.576	5.576	5.576	5.576	5.576	5.576	5.239	71.323	70.224
Analytical charges	24.383	32.091	39.403	31.325	27.196	38.951	19.701	42.960	55.449	29.750	43.368	20.783	405.361	420.409
Product development expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Registration and filing charges	4.626	16.151	4.626	5.775	8.855	6.802	10.855	12.098	7.230	53.979	11.583	7.786	144.896	49.809
Safety and security	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Office expenses	323	-	323	646	323	323	-	-	-	-	-	-	1.938	3.779
Repairs and maintenance - others	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Management fees	-	-	-	-	-	-	-	100.599	39.438	19.599	14.010	197.081	370.727	117.112
Liquidated damages	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Donations	-	-	4.060	-	-	275	-	-	2	-	-	-	4.337	11.895
Software license and implementation expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital work-in-progress written off	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Miscellaneous expenses	1	90	-	-	0	0	0	-	139	2	-	1.195	1.428	20.551
	311.462	303.260	228.269	180.704	232.355	282.759	(240.119)	500.410	862.141	545.942	535.382	1.072.091	4.819.655	2.098.324

Payment to Auditor

As auditor:

Audit fee	1.000	53	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	11.053	18.392
Tax audit fee	-	-	-	-	-	-	-	-	-	-	-	-	-	-

LABORATORIOS AUROBINDO SPAIN SLU

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Limited review													-	-
In other capacity:													-	-
Taxation matters													-	-
Company law matters													-	-
Management services													-	-
Other services (certification fees)													-	-
Reimbursement of expenses	1.000	53	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	11.053	18.392
Note 24 : Exceptional items														
Others (Specify if any)													-	-
Note 25 : Depreciation and amortization expense														
Depreciation of tangible assets	623	531	715	649	649	649	649	649	649	649	1.129	416	7.959	30.084
Amortization of intangible assets	18.014	17.749	18.474	19.463	20.018	19.952	21.402	21.017	21.017	21.017	23.598	20.774	242.496	158.158
Depreciation of investment property	18.637	18.280	19.190	20.112	20.667	20.601	22.051	21.667	21.667	21.667	24.727	21.191	250.455	188.241
Note 26 : Finance costs														
Interest		2.055	184					998	8.558	7.943	7.342	8.129	35.210	
Bank charges	556	724	2.498	1.204	3.822	3.914	1.251	830	5.936	1.127	1.125	942	23.931	47.221
Amortization of ancillary borrowing costs													-	-
Exchange difference to the extent considered as an adjustment to borrowing costs	556	2.780	2.683	1.204	3.822	3.914	1.251	1.828	14.494	9.070	8.467	9.071	59.141	47.221

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B/96099078
Plaza. de Carlos Trias Bertrán, nº 4
28020 MADRID

**NOTES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31ST
MARCH 2015**

NOTE 1 ACTIVITY OF THE COMPANY

LABORATORIOS AUROBINDO S.L. was incorporated in Madrid on 12th February 2008. The registered office of the company is located in C/ Hermosilla, 11, Madrid.

Pursuant the articles of its by-laws, the corporate purpose of the company is as follows:

- To buy, sell, import, export or store any pharmaceutical products.
- To acquire, hold, developed, dispose or exploit industrial property rights.
- To acquire, hold, exploit, management, hand over, lease and sell the property or the use of rights, and personal goods or real state.
- To provide all type of marketing support.
- To act as commercial agent or broker.

The Sole Shareholder of the company at 31 March 2015 is Agile Pharma, B.V., legally seated in Amsterdam (Prins Bernhardplein 200, 1097 JN, The Netherlands), and registered with the Registry of Chamber of Commerce of Amsterdam under number 34255461.

The ultimate parent company is Aurobindo Pharma Limited, with domicile in Plot, 2, Maitiri Vihar, Ameerpet, Hyderabad, 500 038, Telangana, India. The annual consolidated accounts settle in India.

NOTE 2 BASIS OF PRESENTATION OF THE ANNUAL ACCOUNTS.

a) True and fair view


The attached annual accounts for 2014/2015 have been prepared by the Company's Board of Directors using all the Company's accounting registries up to 31 March 2015. In this report all the accounting principles and assessment criteria compiled in the General Accounting Plan (GAP), which was approved in Royal Decree 1514/2007, have been applied. These annual accounts show the true and fair view of the equity, financial position and results of the company.

There are no reasons why, in representing the true and fair view, any legal accounting regulations have not been applied.

The attached annual accounts will be subject to examination by the Only Shareholder, with the expectation that they will be approved without any changes needing to be made.

b) Critical issues regarding the measurement and estimation of uncertainties

The Company have prepared its financial statements based on the principles of a running business, without there being any large risks that would affect the value of any assets or liabilities in the following year.



Despite these estimations being made according to the best information that was available on 31 March 2015 regarding the facts that were analysed and the progress up until the date the current annual accounts were formalised, it is also possible that certain future events which may take place could cause them to be modified (upwards or downwards) in the coming years.

c) Comparative information

In agreement with the Mercantile Legislation, the Company shows, to comparative effects, in addition to the current period figures of the balance, of the income statement and statement of changes in equity, the figures corresponding to the previous period.

As explained in the following section f) in the current period it has been considered more appropriate the adoption of certain accounting classification criteria in relation to the items mentioned therein.

The fiscal year of the Company starts on April 1st and ends on March 31st of the following year.

d) Aggregation of items

No items have been aggregated with other items on the face of the balance sheet, income statement and statement of changes in equity that require details to be disclosed.

e) Items disclosed under several line items

No items of assets and liabilities are recognised under two or more balance sheet line items.

f) Changes in accounting policies and correction of errors

No adjustments have been made for changes in accounting policies or correction of errors during the reporting period.

However, during the current period it has been considered more appropriate the adoption of the following accounting criteria of classification of certain expenses and liabilities that in prior periods were registered in other items of the income statement and balance sheet.

In particular, the sales volume discounts consisting in deliveries of goods in kind, which were previously recorded under the heading of External services are now recorded as a Sales volume discounts decreasing the revenue of the period. Also, the subcontracted work of a third party relating to the storage and distribution of the goods of the company, which were previously recorded under the heading of External services are now recorded as Supplies under the heading of Subcontracted work.

In addition, regarding the liabilities, the debts to Servicio Andaluz and Servicio Nacional de Salud that previously were recorded under the heading of Suppliers are now classified under the heading of Other payables.

In the same way, the contributions to the equity made by the Single Shareholder that in the previous year were recorded as a current liabilities with Group companies and associates, are now classified as Equity under the heading Other equity holder contributions.



NOTE 3 ACCOUNTING POLICIES

The main accounting criteria applied are as follows:

a) Intangible assets

“Concessions, patents, licenses and trade mark” are the capitalized expenses included the registration fees for the industrial property. Subsequently, measured at cost less accumulated depreciation and impairment losses they experienced. Amortization is carried out systematically in ten years.

The “Computer software” is calculated first by the price originally paid to purchase the property or the rights to use the computer software and, subsequently, valued by the accumulated profit stemming from its use or any losses through deterioration that it experienced.

Amortisation of computer software is charged on a straight-line basis over a maximum period of 4 years. Maintenance costs are attributed to the year’s results in which they were incurred.

b) Property, plant and equipment

Items included in “Property, plant and equipment” are represented on the balance sheet by way of their purchase cost or production cost minus their accumulative amortisation and loss of value through deterioration.

For those fixed material assets which require more than one year in order to be ready for use, the financial expenditure that they have incurred up to that moment is included in the purchase price or production cost.

The Company is not committed to dismantling, removing or repairing its material assets. This is why figures or values for covering such obligations in the future, have not been included.

Expansion costs, modernising or improvements that represent an increase in economic capacity or an extension of the assets’ economic life, are classified as a higher cost for the corresponding goods.

The Company amortises its fixed material assets by distributing the cost of the assets depending on its estimated economic life according to the following breakdown:

	Depreciation rates
Buildings	20%
Furniture	10 %
Information processing equipment	25 %

The Company uses a straight-line method when calculating amortisation for all its fixed assets.

The Administrators consider that the accounting value of the assets is not higher than their recoverable value, causing this calculation to be based on the future cash flows that these assets generate.

c) Financial instruments

The Company includes in the financial instruments chapter, those contracts which lead to a financial asset in one company and, simultaneously, to a financial liability or a capital instrument in another company.

For assessment purposes, financial assets and liabilities are categorised according to the instrument's characteristics and the reason behind its purchase.

The assessment regulations applied by the Company to its financial instruments are as follows:

Financial assets:

Financial assets held by the Company are classified as:

- Loans and receivables: are trade and non-trade credits which come from the sale of goods or from services rendered, whose payments are of a determined or determinable value and are not negotiated on any active markets. Subsequently, they are recorded according to their repayment cost using the cash interest rate method. The Company records the corresponding impairments by the difference between the value to be reclaimed from the pending accounts and the book value for which they were recorded whether there is objective evidence of impairment
- Held-to-maturity investments: are those debt values which have a fixed maturity date, determined or determinable payments, are negotiated on an asset market and ones which the Company has the intention and capacity to maintain up until their maturity. The assessment criteria for these investments are the same as those used for loans and receivables.

Financial liabilities

Loans, obligations and similar operations are recorded by their received amount and their direct net issuing costs. The financial costs, including payable premiums for liquidation and reimbursement and direct issuing costs are accounted according to the payment criteria in the profit and loss account by using the cash interest rate method and adding the instrument's book value in such a way that they are not liquidated during the period in which they were created.

Debits in commercial operations that do not have a maturity of over a year and do not have a contractual interest rate are classified by their nominal value when the effect of not updating the cash flows is not that significant.

The Company suspends its financial instruments when the obligations they have generated expire.

d) Classification of assets and liabilities

In the balance sheet, assets and liabilities with maturity of less than twelve months from the end of the year are classified as current, while those maturing more than twelve months are classified as non-current.

e) Inventories

Goods for resale are valued downwards to their purchase price or their net realisable value. The purchase price is the amount billed by the provider less the discounts and interests incorporated into the nominal value of the debits, plus any additional costs so that stocks are ready for sale.

The cost of goods to the various units of inventories is assigned by applying the weighted average method.

The valuation of reversible losses due defective or slow-moving inventories are boils down to your realizable value, as well as those whose expiry date occurs before six months from the closing date of the period.

Advance payments on account of future supplies inventories are valued at cost.

f) Income taxes

The income tax due to be paid is worked out by determining the total of the deferred tax and the current tax cost which is then calculated by applying the current tax rate to the taxable amount and deducting the amount obtained from the general deductions and allowances total applied throughout the year.

Deferred tax assets include any temporary differences, which are identified as those amounts which are expected to be paid or to be recovered due to the differences between the asset and liability book values and their tax value, as well as any pending negative taxable amounts and any credits or tax deductions which have not been applied. These amounts are listed after having applied the corresponding encumbrance rate with which they are expected to be recovered or liquidated.

Deferred tax assets, identified as having temporary differences are only ones recognised in case where it is considered probable that the entity is going to have enough tax gains in the future. These assets should not come from (apart from in cases of combined business deals) other assets and liabilities in operations that do not affect either the accounting or tax result.

At the end of the accounting close, the deferred taxes registered are revised (assets as well as liabilities) with the aim of checking if they are still correct, and carrying out any opportune modifications needed according to the results of the analyses carried out.

g) Income and expenditure

Income and expenditure are accounted depending on the payment criteria, irrespective of the moment in which the monetary or financial effects derived from them occur.

The Company only includes the profits yielded on the date of the year's close but, any foreseen risks and losses are accounted for as soon as they are known.

Income through the sale of goods or services is only recognised by the fair value received or to be received. Discounts by way of early payment, volume or other discount types, as well as interests incorporated into the nominal value of the credits are recorded as deductions.



h) Provisions and contingencies

In the preparation of the annual accounts the Management difference between:

- Provisions: Liabilities that cover present obligations at the balance sheet date which result from past events which could give rise to a loss of probable realization for the entity, which amount and time of cancellation are indeterminate. These balances are recognized at the present value of the most probable estimated amount that the Company will have to pay to settle the obligation.
- Contingent liabilities: Possible obligations as a result from past events and whose existence depends on the occurrence or not one or more future events beyond of the entity.

The annual accounts include all the material provisions with respect to which it is estimated that the probability of having to meet the obligation is greater than the opposite. Contingent liabilities, if any, are the subject of information in memory.

Provisions, which are quantified on the best information available on the consequences of the event giving rise to them and are re-estimated at each balance sheet date are used to meet the specific obligations for which they were originally recognized. Provisions are reversed in full or in part when such obligations cease to exist or are reduced.


i) Related party transactions

In general, transactions are accounted for at the beginning for their fair value and, subsequently, they are valued in accordance with the corresponding general regulations. In the case where the agreed price for an operation differs from that of its fair value, the difference is recorded in accordance with the economic reality of the operation.

For the purposes of showing the annual accounts, it is understood that a company forms part of the Group when both sides are connected (directly or indirectly) by a controlling relationship similar to that set out in article 42 of the Trading Standards, or when the companies are controlled in some way or another by one or various legal persons acting together or grouped under one collective name by agreement or statutory clauses.

Shall be deemed that company is to associated when without in question of a group company, in the lines set out previously one or more of the companies that form, including the dominant entity or a natural person, over such exert significant influence. Is presumed significant influence when it holds at least 20% of the voting rights of another company.


Gabriel Diaz


DUC Romero

Pharmacin B.V.

in Zwijndrecht


Annual Report 2014/2015



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants en Adviseurs B.V.

3 MAY 2015



AUROBINDO

DIRECTORS' REPORT

REPORT OF THE DIRECTORS

The management herewith presents to the shareholders, the annual accounts of **PHARMACIN B.V.** for the year ended 31st March, 2015.

GENERAL

The company is a limited liability company incorporated under the laws of The Netherlands and acts as a trading company. The principle object of the company is to trade and deal in pharmaceutical products and other allied products & services.

RESULTS

During the financial year, i.e. from 1st April, 2014 to 31st March, 2015, the company has recorded Revenue from Operations of €9,024,689 and earned Profit of €643,898 after providing for taxes.

DIRECTORS

The directors at the date of the report are:

1. Mr. Ronald David Steentjes (Managing Director)
2. Mr. G.P.Prasad (Managing Director)
3. Mr. Muralidharan Venugopalan


UNUSUAL ITEMS AFTER THE FINANCIAL YEAR

No item, transaction or event of material nature has arisen during the period between the end of the year and date to this report, which would affect substantially the operation of the company during the current year.

STATEMENT BY DIRECTORS

In the opinion of the Directors, the accompanying financial statements were drawn up so as to give true and fair view of the statement of affairs of the company as at 31st March, 2015 and of the results of the business of the year. Directors have taken all the reasonable steps to prepare these financials statements on a going concern basis and that suitable accounting policies have been adopted consistently. Further directors are confident that with the support and guidance of the holding company your company can achieve better results in the future.

By Order of the Board on 19th May, 2015


Ronald David Steentjes
Director

Pharmacin BV

an Aurobindo Pharma Ltd subsidiary

Molenvliet 103 - 3335 LH Zwijndrecht - The Netherlands - Tel: +31 (0)78 610 18 36 - Fax: +31 (0)78 610 28 82 - E-mail: info@pharmacin.nl
ING Bank No.: 0006 8056 00 - IBAN: NL29 INGB 0006 8056 00 - BIC: INGBNL2A - VAT. No.: NL 8544 00 497 B.01 - C.o.C 61580481 - K.v.K. 04080505

Grant Thornton
Accountants en Adviseurs B.V.
Gedempte Zalmhaven 4a
P.O. Box 23278
3001 KG Rotterdam
The Netherlands

T +31 88 676 90 00
F +31 88 676 90 10
www.gt.nl

To: the shareholder of Pharmacin B.V.

INDEPENDENT AUDITOR'S REPORT

Report on the financial statements

We have audited the accompanying financial statements for the year ended 31 March 2015 of Pharmacin B.V., Zwijndrecht, which comprise the company balance sheet as at 31 March 2015, the company profit and loss account for the period 1 April 2014 until 31 March 2015 and the notes, comprising a summary of the accounting policies and other explanatory information.

Management's responsibility

Management is responsible for the preparation and fair presentation of these financial statements and for the preparation of the management board report, both in accordance with Part 9 of Book 2 of the Dutch Civil Code. Furthermore management is responsible for such internal control as it determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

Grant Thornton Accountants en Adviseurs B.V. is a member firm within Grant Thornton International Ltd (Grant Thornton International)

Grant Thornton Accountants en Adviseurs B.V. is registered with the Chamber of Commerce of The Hague trade register under number 28105565. To all our services our general conditions, as registered with the Registry of the District Court in The Hague, apply. A copy of these conditions will be sent to you on request. Any liability shall be limited to the amount which is mentioned in the general conditions.


We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion with respect to the financial statements

In our opinion, the financial statements give a true and fair view of the financial position of Pharmacin B.V. as at 31 March 2015 and of its result for the period then ended in accordance with Part 9 of Book 2 of the Dutch Civil Code.

Rotterdam, 13 May 2015


Grant Thornton Accountants en Adviseurs B.V.



drs. C. Holewijn RA

CONTENTS

	Page
Financial report	
Balance sheet as at 31 March 2015	1
Profit & loss account for the year 2014/2015	3
Notes to the 2014/2015 financial statements	4
Notes to the balance sheet as at 31 March 2015	7
Notes to the profit & loss account for the year 2014/2015	13
Financial statements	
Statutory regulations concerning profit appropriation	16
Proposal for profit appropriation	16
Other information	



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants en Adviseurs B.V.

13 MAY 2015

FINANCIAL REPORT 2014/2015



**INITIALLED FOR IDENTIFICATION
PURPOSES ONLY**

Grant Thornton
Accountants & Advisors U.V.

A handwritten signature in dark ink, appearing to be 'dw' or similar, written over the printed text of the stamp.

13 MAY 2015

BALANCE SHEET AS AT 31 MARCH 2015
(after appropriation of result)

	31 March 2015		31 March 2014	
	€	€	€	€
ASSETS				
Fixed assets				
Intangible fixed assets (1)				
Intellectual property rights		177.005		55.392
Tangible fixed assets (2)				
Equipments		35.770		64.788
Current assets				
Inventories (3)		659.101		360.503
Trade and other receivables (4)				
Trade debtors	938.775		1.087.646	
Receivable from group companies	441.997		1.801.881	
Taxes and social securities	20.686		87.557	
Other receivables	18.310		34.838	
Prepayments and accrued income	14.685		19.100	
		1.434.453		3.031.022
Cash and cash equivalents (5)		627.244		749.680
		<u>2.933.573</u>		<u>4.261.385</u>

 **Grant Thornton**

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants and Adviseurs B.V.

13 MAY 2015

2.933.573	4.261.385
-----------	-----------

PROFIT & LOSS ACCOUNT FOR THE YEAR 2014/2015

		2014/2015		2013/2014	
		€	€	€	€
Net turnover	(8,9)	9.039.624		10.275.558	
Cost of sales	(10)	7.061.920		8.239.048	
Gross margin on turnover			1.977.704		2.036.510
Management fees	(11)		245.170		401.916
Expenses					
Wages and salaries	(12)	733.491		721.627	
Social security charges	(13)	89.221		100.107	
Pension expenses	(14)	38.143		56.348	
Management fee	(15)	102.418		136.555	
Other personnel expenses	(16)	39.532		47.639	
Depreciation/Amortization	(17)	76.337		32.972	
Accommodation expenses	(18)	143.668		159.072	
Operating costs	(19)	22.867		17.901	
Office expenses	(20)	42.023		39.117	
Car expenses	(21)	27.734		31.380	
Selling expenses	(22)	84.909		40.154	
General expenses	(23)	133.190		123.496	
			1.533.533		1.506.368
Operating result			689.341		932.058
Interest and similar income	(24)	165.837		5.474	
Interest and similar expenses	(25)	-9.982		-24.486	
Financial income and expenses			155.855		-19.012
Result from ordinary activities before tax			845.196		913.046
Taxation on result from ordinary activities	(26)		-201.298		-218.261
Result after tax			643.898		694.785

 Grant Thornton

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants and Adviseurs B.V.

13 MAY 2015

NOTES TO THE 2014/2015 FINANCIAL STATEMENTS

Activities

The activities of Pharmacin B.V., having its legal seat in Zwijndrecht, primarily consist of wholesale trade, import and export of pharmaceutical and chemical products and raw materials as well as services in the field of pharmaceutical industry.

Head of the group

The company is part of the (sub)group with Agile Pharma B.V. as (sub)group head.

GENERAL ACCOUNTING PRINCIPLES FOR THE PREPARATION OF THE FINANCIAL STATEMENTS

The financial statements in accordance with Part 9 of Book 2 of the Dutch Civil Code.

Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise at the relevant principle for the specific balance sheet item, assets and liabilities are presented at nominal value.

The financial statements of the company are presented in euros, which is the company's functional currency.

Translation of foreign currency

The financial statements of the company are presented in euros, which is the company's functional currency.

Receivables, liabilities and obligations denominated in foreign currency are translated at the exchange rates at balance sheet date. Transactions in foreign currency during the financial year are recognised in the financial statements at the exchange rates at transaction date. The exchange differences are recognised in the profit and loss account as financial income or expenditure respectively.

PRINCIPLES OF VALUATION OF ASSETS AND LIABILITIES

Intangible fixed assets

Intangible fixed assets are presented at cost less accumulated amortisation and, if applicable, less impairments in value. Amortisation is charged as a fixed percentage of cost, as specified in more detail in the notes to the balance sheet. The useful life and the amortisation method are reassessed at the end of each financial year.

Tangible fixed assets

Tangible fixed assets are presented at cost less accumulated depreciation and, if applicable, less impairments in value. Depreciation is based on the estimated useful life and calculated as a fixed percentage of cost, taking into account any residual value. Depreciation is provided from the date an asset comes into use.



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants in Advies BV

13 MAY 2015

Inventories

Raw materials, consumables and goods for resale are stated at the lower of cost and net realizable value. This lower net realizable value is based on basis of individual assessment of the recoverability of the inventories.

Trade and other receivables

The receivables are initially valued at its fair value, and subsequently valued at amortised cost, which is similar to the face value, after deduction of any provisions if necessary.

Cash and cash equivalents

Cash and cash equivalents are valued at nominal value.

PRINCIPLES FOR THE DETERMINATION OF THE RESULT

Net turnover

The net turnover consists of revenue from the sale of goods during the reporting period net of discounts, rebates and value added taxes.

Revenues ensuing from the sale of goods are accounted for when all major entitlements to economic benefits as well as all major risks have transferred to the buyer. The cost price of these goods is allocated to the same period.

Cost of sales

Cost of sales comprise costs that relate directly to the goods sold and services rendered. A write-down of inventories because of obsolete stock is reported as cost of sales.

Amortization/depreciation

Amortization on intangible fixed assets is calculated by using a fixed rate on the acquisition costs or costs of conversion.

The depreciation on tangible fixed assets is calculated by using a fixed rate on the acquisition cost or cost of conversion.

Gains and losses on disposal of (in)tangible fixed assets are recorded under amortization/depreciation, gains only to the extent that the gain is not capitalised for replacement investments.

Operating costs

These categories are attributed to the period to which they relate, respectively known for the first time.

Financial result

Financial income and expenses comprise interest income and expenses on loans as accounted for in the current reporting period.

Taxation

The taxation on the result of ordinary activities is calculated taking into account the facilities for tax purposes. As far as the calculated taxation relates to valuation differences between the commercial and the fiscal profit determination, the relevant part is added or charged to the provision for deferred tax. Deferred tax assets (if applicable) are only valued insofar as their realization is likely.

NOTES TO THE BALANCE SHEET AS AT 31 MARCH 2015

1. Intangible fixed assets

	Intellectual property rights
	€
<i>Book value as at 1 April 2014</i>	
Acquisition costs	407.847
Accumulated amortization	-352.455
	<u>55.392</u>
<i>Changes</i>	
Investments	156.689
Amortization	-35.076
	<u>121.613</u>
<i>Book value as at 31 March 2015</i>	
Acquisition costs	564.536
Accumulated amortization	-387.531
	<u>177.005</u>
<i>Rate of amortization</i>	%
Intellectual property rights	20

2. Tangible fixed assets

	Leasehold improvements	Equipments	Total
	€	€	€
<i>Book value as at 1 April 2014</i>			
Acquisition costs	33.037	346.290	379.327
Accumulated depreciation	-33.037	-281.502	-314.539
	-	64.788	64.788
<i>Changes</i>			
Investments	-	12.243	12.243
Disposals	-33.037	-293.476	-326.513
Accumulated depreciation desinvestment	33.037	293.476	326.513
Depreciation/Amortization	-	-41.261	-41.261
	-	-29.018	29.018
<i>Book value as at 31 March 2015</i>			
Acquisition costs	-	65.057	65.057
Accumulated depreciation	-	-29.287	-29.287
	-	35.770	35.770
<i>Rate of depreciation</i>			%
Leasehold improvements			20
Equipments			20

3. Inventories

	31-03-2015	31-03-2014
	€	€
Finished products, raw and auxiliary materials		
Finished products, raw and auxiliary materials	666.527	362.327
Provision	-7.426	-1.824
	<u>659.101</u>	<u>360.503</u>

Inventories are stated at cost or lower net realizable value where the net realizable value is based on the individual assesment of the recoverability of the inventories

4. Trade and other receivables

Trade debtors

Accounts receivable from third parties	963.678	1.087.646
Provision for bad debts	-24.903	-
	<u>938.775</u>	<u>1.087.646</u>

Receivable from group companies

Accounts receivable from group companies	<u>441.997</u>	<u>1.801.881</u>
--	----------------	------------------

Taxes and social securities

VAT	20.686	12.990
Pension contributions	-	74.567
	<u>20.686</u>	<u>87.557</u>

Other receivables

Deposits	1.500	1.500
Other receivables	16.810	33.338
	<u>18.310</u>	<u>34.838</u>

	31-03-2015	31-03-2014
	€	€
Prepayments and accrued income		
Insurance	11.231	10.301
Interest banker	80	1.800
Others	3.374	6.999
	<u>14.685</u>	<u>19.100</u>

5. Cash and cash equivalents

Rabobank	-	83.367
ING Bank N.V.	611.810	537.065
Danske Bank	15.321	128.722
Cash	113	526
	<u>627.244</u>	<u>749.680</u>

6. Shareholders' equity

Issued capital

400 ordinary shares at a par value of € 45,00	<u>18.000</u>	<u>18.000</u>
---	---------------	---------------

The statutory share capital amounts to € 90,000.00, divided into 2,000 ordinary shares with a nominal value of € 45,00 per share. A total of 400 shares has been issued and fully paid.

The shares are held by Agile Pharma B.V.

	2014/2015	2013/2014
	€	€
Share premium reserve		
Balance as at 1 April	717.807	717.807
Dividend to be paid	-363.987	-
Balance as at 31 March	<u>353.820</u>	<u>717.807</u>

	2014/2015	2013/2014
	€	€
Other reserves		
Balance as at 1 April	1.636.015	941.230
Appropriation of the net result	643.898	694.785
Dividend to be paid	-1.636.015	-
Balance as at 31 March	<u>643.898</u>	<u>1.636.015</u>

7. Current liabilities

	31-03-2015	31-03-2014
	€	€
Trade creditors		
Trade creditors	<u>604.416</u>	<u>959.335</u>
Payable to group companies		
Accounts payable to group companies	<u>939.717</u>	<u>473.958</u>
Taxes and social securities		
Pay-roll tax	98.935	23.702
Post-employment benefit obligation	11.636	-
	<u>110.571</u>	<u>23.702</u>

	31-3-2015	31-3-2014
	€	€
Accrued liabilities		
Vacation accruals	-	53.993
Holiday allowances	19.382	41.659
Commission fee	158.075	268.097
Audit fee	10.189	6.201
Other liabilities	74.525	61.418
Interest and bank costs	980	1.200
	<u>263.151</u>	<u>432.568</u>

Off-balance sheet commitments

Contingent liabilities

Tax entity

The company constitutes a tax entity for corporate income tax with Helix Healthcare B.V.; consequently the company is severally liable for the resulting debts.

Long-term financial obligations

Lease

The company has entered into long-term financial obligation contracts concerning the lease of two business cars (EUR 21.503 a year).

Rental commitments buildings

The company has entered into long-term financial obligations concerning the rent of business accommodations (EUR 64.086 a year).

NOTES TO THE PROFIT & LOSS ACCOUNT FOR THE YEAR 2014/2015

8. Net turnover

The net turnover decreased in 2014/2015 compared to 2013/2014 with 12,0%.

	2014/2015	2013/2014
	€	€
9. Net turnover		
Turnover	9.039.624	10.275.558
10. Cost of sales		
Cost of sales	7.061.920	8.239.048
11. Management fees		
Management fee Pharmacin-Aurobindo Pharma B.V.	245.170	401.916
Employee expenses		
12. Wages and salaries		
Gross wages	737.701	727.598
Sick pay received	-4.210	-5.971
	733.491	721.627
13. Social security charges		
Social securities	89.221	100.107
14. Pension expenses		
Pension costs	38.143	56.348
15. Management fee		
Management fee - Milpharm Ltd.	102.418	136.555
16. Other personnel expenses		
Temporary workers	765	1.941
Travelling expenses	14.272	16.036
Canteen costs	3.018	3.837
Education allowance and training costs	1.584	4.208
Health care insurance	10.795	11.446
Absence counsel health and safety authority	2.522	1.664
Other personnel expenses	6.576	8.507
	39.532	47.639

 Grant Thornton

INITIALED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants en Adviseurs B.V.

Staff

During the 2014/2015 financial year, the average number of employees, converted into full-time equivalents, amounted to 14 (2013/2014: 14).

	2014/2015	2013/2014
	€	€
17. Depreciation/Amortization		
Intangible fixed assets	35.076	13.005
Tangible fixed assets	41.261	19.967
	<u>76.337</u>	<u>32.972</u>
Amortization intangible fixed assets		
Intellectual property rights	<u>35.076</u>	<u>13.005</u>
Depreciation tangible fixed assets		
Equipments	<u>41.261</u>	<u>19.967</u>
Other operating expenses		
18. Accommodation expenses		
Rent	98.721	113.395
Energy and water costs	14.798	21.500
Maintenance and services	27.379	21.934
Other	2.770	2.243
	<u>143.668</u>	<u>159.072</u>
19. Operating costs		
Rent equipment and furniture	<u>22.867</u>	<u>17.901</u>
20. Office expenses		
Office supplies	<u>42.023</u>	<u>39.117</u>
21. Car expenses		
Lease expenses	<u>27.734</u>	<u>31.380</u>

	2014/2015	2013/2014
	€	€
22. Selling expenses		
Advertising expenses	4.404	542
Representation costs	2.099	1.312
Promotional gifts	61	1.376
Travelling expenses	27.105	10.691
Addition to provision for doubtful debtors	24.903	-
Other	26.337	26.233
	<u>84.909</u>	<u>40.154</u>
23. General expenses		
Audit fee	17.256	14.310
Consultancy fee	88.647	80.251
Legal charges	5.660	3.684
Insurances	21.451	25.685
Other	176	-434
	<u>133.190</u>	<u>123.496</u>
Financial income and expenses		
24. Interest and similar income		
Bank interest income	14.935	5.474
Exchange rate differences	150.902	-
	<u>165.837</u>	<u>5.474</u>
25. Interest and similar expenses		
Bank interest expenses and costs	9.982	11.342
Interest to group companies	-	1.401
Exchange rate differences	-	11.743
	<u>9.982</u>	<u>24.486</u>
26. Taxation on result from ordinary activities		
Corporate income tax	<u>201.298</u>	<u>218.261</u>

OTHER INFORMATION

Statutory regulations concerning profit appropriation

In Article 14 of the company statutory regulations the following has been presented concerning the appropriation of result:

- the profit is available to the General Meeting of Shareholders.

Proposal for profit appropriation

The General Meeting will be asked to approve that the 2014/2015 result amounting to € 643.898 is added to the other reserves. The financial statements reflect this proposal.

Registered number
03354124

Milpharm Limited
Report and Accounts
31 March 2015

07 MAY 2015

THE CORPORATE PRACTICE LIMITED
T/as ARORA & Co
CHARTERED ACCOUNTANTS
5 Darnley Road, H... 004 00
Tel 020 5075750 Fax 020 8573 5...

Milpharm Limited
Report and accounts
Contents

	Page
Company information	1
Directors' report	2
Statement of directors' responsibilities	3
Strategic report	4 to 5
Independent auditors' report	6
Profit and loss account	7
Balance sheet	8
Notes to the accounts	9 to 17

07 MAY 2015

THE CORPORATE FRANCHISE
T/as AROU & CO.
CHARTERED ACCOUNTANTS
85 Deodar Road, London SW19 8JL
Tel: 020 8876 5200

Milpharm Limited
Company Information

Directors

Mr Christopher Paul Johnson
Mr Venugopalan Muralidharan
Mr Manoj Prakash - appointed on 20 March 2015
Mr Gorla Phaneendra Prasad - appointed on 01 September 2014
Mr Avinash Chandra Swain

Secretary

Mr Parminder Sobti - resigned on 20 May 2014

Auditors

The Corporate Practice Limited
Chartered Accountants and Registered Auditors
65 Delamere Road
Hayes
Middlesex
UB4 0NN

Bankers

ICICI Bank
21 Knightsbridge
London
SW1X 7LY

Barclays Bank PLC
Heathrow Barclays Corporate
Cardinal Point
Newall Road
Heathrow
TW6 2AH


Registered office

Ares Block
Odyssey Business Park
West End Road
South Ruislip
Middlesex
HA4 6QD

Registered number

03354124

07 MAY 2015


THE CORPORATE PRACTICE LIMITED
T/as ASHORA & Co
CHARTERED ACCOUNTANTS
65 Delamere Road, Hayes, Middlesex UB4 0NN
Tel: 0201 662750 Fax: 0201 673511

Milpharm Limited
Statement of Directors' Responsibilities

The directors are responsible for preparing the report and accounts in accordance with applicable law and regulations.

Company law requires the directors to prepare accounts for each financial year. Under that law the directors have elected to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these accounts, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the accounts;
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the accounts comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

07 MAY 2015

THE CORPORATE PRACTICE LIMITED
T/as ARORA & Co
CHARTERED ACCOUNTANTS
51 Fenchurch Street, London EC3A 6DF
Tel: 020 3601 6150 Fax: 020 3601 2900

Milpharm Limited Strategic Report

Review of the business

Milpharm turnover grew by 17% compared with last year. However, the gross profit margin dropped significantly due to a number of reasons including nonexistence of abnormally high prices of a number of molecules achieved in previous years. In addition, unlike previous years more cheaper substitute products were obtainable in the market, thereby suppressing the sale prices.

In January 2015 the BD team was further strengthened with the appointment of a new vice president and director, who has significant knowledge about UK pharma market.

Future developments

The company has now shifted its focus from high margin products with low market share to turnover oriented products during the coming year. Directors are confident that revenue and overall profitability will increase. It is now moving further up the value chain as the company has received most of the targeted approvals from the MHRA i.e. Topiramate, Clarithromycin, Efavirenz and Venlafaxine. The company has received MHRA approval for addition of new API manufacturers for some of its products; this will help to source products at more competitive prices. For the coming years the company has gained valuable contracts for supply of new lines products to major customers.

Key performance indicators

	Year ended 31 March 2015	Year ended 31 March 2014
Turnover	£21,650,559	£18,522,930
Profit before taxation	£124,635	£1,768,606

Our budget for 2015/16 is £28m turnover with a gross margin of 13% and net margin of 5%.

Principal risks and uncertainties:

The company's main areas of risk are as follows:

Price risk

The price of pharmaceutical products can fluctuate widely depending up on the supply and competition. The risk is managed by maintaining adequate level of stock.

Foreign exchange risk

The company purchases and sells some product in foreign currencies. The risk is managed by monitoring foreign exchange rates on periodic basis.

Credit risk

Credit checks are carried out on all customers. Outstanding amounts are regularly monitored.


Liquidity risk

The company manages its cash flow to ensure that sufficient liquid resources are available to meet its operating needs.

Interest rate and cash flow risk

The company maintain a positive cash balance and lend funds to group undertaking at variable rates of interest. The company does not use derivative financial instrument to manage interest rate costs and as such no hedge accounting is applied.

07 MAY 2015


Mr V Muralidharan
Director

Mr V Muralidharan
Director

THE CORPORATE PRACTICE LIMITED
T/as ARORA & Co
CHARTERED ACCOUNTANTS
15 B. 40, 1st Floor, H. V. S. Road, DE 40, N.
Tel: 020 606 7501, ex. 020 606 9151

Milpharm Limited
Independent auditors' report
to the members of Milpharm Limited

We have audited the accounts of Milpharm Limited for the year ended 31 March 2015 which comprise the Profit and Loss Account, the Balance Sheet and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

As explained more fully in the Statement of Directors' Responsibilities, the directors are responsible for the preparation of the accounts and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the accounts in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the accounts

A description of the scope of an audit of financial statements is provided on the APB's website at www.frc.org.uk/auditscopeukprivate

Opinion on the accounts

In our opinion the accounts:

- give a true and fair view of the state of the company's affairs as at 31 March 2015 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion the information given in the Directors' Report and the Strategic Report for the financial year for which the accounts are prepared is consistent with the accounts.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the accounts are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.



Devender Arora

(Senior Statutory Auditor)

for and on behalf of

The Corporate Practice Limited
Accountants and Statutory Auditors

7 May 2015

Chartered Accountants and Registered Auditors
65 Delamere Road
Hayes
Middlesex
UB4 0NN

07 MAY 2015

THE CORPORATE PRACTICE LIMITED
T/as ARORA & Co
CHARTERED ACCOUNTANTS
65 Delamere Road Hayes Middlesex UB4 0NN
Tel: 020 8306 6755 Fax: 020 8306 6757

Milpharm Limited
Profit and Loss Account
for the year ended 31 March 2015

	Notes	2015 £	2014 £
Turnover	2	21,650,559	18,522,930
Cost of sales		(19,280,762)	(13,988,485)
Gross profit		2,369,797	4,534,445
Administrative expenses		(4,470,896)	(3,596,295)
Other operating income		2,219,866	839,136
Operating profit	3	118,767	1,777,286
Interest receivable		5,978	400
Interest payable	6	(110)	(9,080)
Profit on ordinary activities before taxation		124,635	1,768,606
Tax on profit on ordinary activities	7	(29,232)	(438,345)
Profit for the financial year		<u>95,403</u>	<u>1,330,261</u>

Continuing operations

None of the company's activities were acquired or discontinued during the above two financial years.

Statement of total recognised gains and losses

The company has no recognised gains or losses other than the profit for the above two financial years.

07 MAY 2015

THE CORPORATE PRACTICE LIMITED
T/as ARORA & Co
CHARTERED ACCOUNTANTS
55 Darnley Road, London, W14 9NA
Tel: 020 6603 6700 Fax: 020 6573 5557

Milpharm Limited
Registered number: 03354124
Balance Sheet
as at 31 March 2015

	Notes	2015 £	2014 £
Fixed assets			
Intangible assets	8	3,186,973	3,262,233
Tangible assets	9	<u>180,455</u>	<u>170,966</u>
		3,367,428	3,433,199
Current assets			
Stocks	10	5,941,420	6,221,395
Debtors	11	6,023,041	5,147,835
Cash at bank and in hand		<u>422,659</u>	<u>264,937</u>
		12,387,120	11,634,167
Creditors: amounts falling due within one year	12	(8,158,140)	(7,565,625)
Net current assets		4,228,980	4,068,542
Total assets less current liabilities		7,596,408	7,501,741
Provisions for liabilities			
Deferred taxation	13	(18,858)	(15,154)
Other provisions	14	<u>-</u>	<u>(4,440)</u>
		(18,858)	(19,594)
Net assets		<u>7,577,550</u>	<u>7,482,147</u>
Capital and reserves			
Called up share capital	15	3,598,311	3,598,311
Share premium	16	198,463	198,463
Profit and loss account	17	3,780,776	3,685,373
Shareholders' funds	18	<u>7,577,550</u>	<u>7,482,147</u>

Mr A Swain
Director

Approved by the board on 7 May 2015

Mr V Muralidharan
Director

07 MAY 2015

THE CORPORATE PRACTICE LIMITED
T/As ARORA & Co
CHARTERED ACCOUNTANTS
65 Delamater Road, 14th Floor, 14th Floor
Tel: 020 3 000 0000 Fax: 020 3 000 0001

Milpharm Limited
Notes to the Accounts
for the year ended 31 March 2015

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with applicable United Kingdom Accounting Standards.

Turnover

Turnover represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Product registrations

Product registrations are valued at cost less accumulated amortisation. Amortisation is calculated to write off the cost in equal instalments over their estimated useful lives of 10 years, from the date on which products, for which Medicines and Health Regulatory Agency marketing authorisation are held, are commercialised.

Where registrations previously capitalised are no longer considered by the directors to be commercially viable the amortisation charge for the year is increased to bring the net book value of each registration to nil. The cost and accumulated amortisation of each registration is then written off to profit and loss account.

Intangible work in progress

Capital work in progress represents costs incurred for which the marketing authorisation is yet to be obtained. Once the marketing authorisation is obtained, the accumulated cost is transferred to intangible assets. In circumstances where marketing authorisations are not granted or the applications are withdrawn, the accumulated costs are charged to the profit and loss account.

Cash flow statement

The company has this year taken advantage of the exemption provided by Financial Reporting Standard 1 not to disclose cash flow statement, as the ultimate holding company will be preparing consolidated financial statements which will be publicly available.

Depreciation

Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:

Fixture, fittings & equipment	15% straight line
-------------------------------	-------------------

Stocks

Stock is valued at the lower of cost and net realisable value.

Deferred taxation

Full provision is made for deferred taxation resulting from timing differences between the recognition of gains and losses in the accounts and their recognition for tax purposes. Deferred tax is calculated at the tax rates which are expected to apply in the periods when the timing differences will reverse.

Foreign currencies

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the profit and loss account.

07 MAY 2015

Milpharm Limited
Notes to the Accounts
for the year ended 31 March 2015

Average number of employees during the year	Number	Number
Business development	7	7
Distribution	2	2
Regulatory, QA & Pharmacovigilance	13	6
Finance and administration	6	3
Sales	6	4
Human Resource	2	-
	<u>36</u>	<u>22</u>

6 Interest payable	2015 £	2014 £
Bank loans and overdrafts	110	-
Group companies	-	9,080
	<u>110</u>	<u>9,080</u>

7 Taxation	2015 £	2014 £
Analysis of charge in period		
Current tax:		
UK corporation tax on profits of the period	25,528	427,793
Deferred tax:		
Origination and reversal of timing differences	3,704	10,552
	<u>29,232</u>	<u>438,345</u>
Tax on profit on ordinary activities		

Factors affecting tax charge for period

The differences between the tax assessed for the period and the standard rate of corporation tax are explained as follows:

	2015 £	2014 £
Profit on ordinary activities before tax	<u>124,635</u>	<u>1,768,606</u>
Standard rate of corporation tax in the UK	20%	23%
	£	£
Profit on ordinary activities multiplied by the standard rate of corporation tax	24,927	406,779
Effects of:		
Expenses not deductible for tax purposes	601	21,014
Current tax charge for period	<u>25,528</u>	<u>427,793</u>

07 MAY 2015

Milpharm Limited
Notes to the Accounts
for the year ended 31 March 2015

8 Intangible fixed assets and work in progress
Product registrations:

	Intangible fixed assets £	Intangible work in progress £	Total £
Cost			
At 1 April 2014	5,638,783	94,172	5,732,955
Additions	73,284	365,046	438,330
Cost - Reallocation from intangible work in progress	55,468	(55,468)	-
Disposals	(21,809)	(29,941)	(51,750)
At 31 March 2015	<u>5,745,726</u>	<u>373,809</u>	<u>6,119,535</u>
Amortisation			
At 1 April 2014	2,470,722	-	2,470,722
Provided during the year	473,017	-	473,017
On disposals	(11,177)	-	(11,177)
At 31 March 2015	<u>2,932,562</u>	<u>-</u>	<u>2,932,562</u>
Net book value			
At 31 March 2015	<u>2,813,164</u>	<u>373,809</u>	<u>3,186,973</u>
At 31 March 2014	<u>3,168,061</u>	<u>94,172</u>	<u>3,262,233</u>

9 Tangible fixed assets

	Fixtures, fittings, tools and equipment £
Cost	
At 1 April 2014	294,831
Additions	55,852
Disposals	(11,144)
At 31 March 2015	<u>339,539</u>
Depreciation	
At 1 April 2014	123,865
Charge for the year	42,704
On disposals	(7,485)
At 31 March 2015	<u>159,084</u>
Net book value	
At 31 March 2015	<u>180,455</u>
At 31 March 2014	<u>170,966</u>

07 MAY 2015

Milpharm Limited
Notes to the Accounts
for the year ended 31 March 2015

10 Stocks	2015 £	2014 £
Finished goods and goods for resale	<u>5,941,420</u>	<u>6,221,395</u>

The difference between purchase price or production cost of stocks and their replacement cost is not material.

11 Debtors	2015 £	2014 £
Trade debtors	4,524,780	3,832,679
Amounts owed by group undertakings and undertakings in which the company has a participating interest	1,300,800	1,261,813
Director's loan account	-	13,941
Other debtors	81,669	9,873
Prepayments and accrued income	<u>115,792</u>	<u>29,529</u>
	<u>6,023,041</u>	<u>5,147,835</u>

12 Creditors: amounts falling due within one year	2015 £	2014 £
Trade creditors	636,654	473,750
Amounts owed to group undertakings and undertakings in which the company has a participating interest	6,358,088	5,875,887
Corporation tax	-	429,481
Other taxes and social security costs	566,832	349,530
Other creditors	2,019	5,932
Accruals and deferred income	<u>594,547</u>	<u>431,045</u>
	<u>8,158,140</u>	<u>7,565,625</u>

13 Deferred taxation	2015 £	2014 £
Accelerated capital allowances	<u>18,858</u>	<u>15,154</u>
Undiscounted provision for deferred tax	18,858	15,154

	2015 £	2014 £
At 1 April	15,154	4,602
Deferred tax charge in profit and loss account	3,704	10,552
At 31 March	<u>18,858</u>	<u>15,154</u>

07 MAY 2015

Milpharm Limited
Notes to the Accounts
for the year ended 31 March 2015

14 Provisions for liabilities

	Dilapidation
	£
At 1 April 2014	4,440
Reallocation of opening provision to accruals	(4,440)
	<u> </u>
At 31 March 2015	<u> </u>

15 Share capital	Nominal value	2015 Number	2015 £	2014 £
Alotted, called up and fully paid:				
Ordinary shares	£1 each	3,598,311	<u>3,598,311</u>	<u>3,598,311</u>

16 Share premium	2015 £
At 1 April 2014	198,463
	<u> </u>
At 31 March 2015	<u>198,463</u>

17 Profit and loss account	2015 £
At 1 April 2014	3,685,373
Profit for the financial year	95,403
	<u> </u>
At 31 March 2015	<u>3,780,776</u>

18 Reconciliation of movement in shareholders' funds	2015 £	2014 £
At 1 April	7,482,147	6,151,886
Profit for the financial year	95,403	1,330,261
	<u> </u>	<u> </u>
At 31 March	<u>7,577,550</u>	<u>7,482,147</u>

07 MAY 2015

THE CORPORATE PRACTICE LIMITED
 T/as ARORA & Co
 CHARTERED ACCOUNTANTS
 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000

Milpharm Limited
Notes to the Accounts
for the year ended 31 March 2015

19 Other financial commitments

At the year end the company had annual commitments under non-cancellable operating leases as set out below:

	Land and buildings 2015 £	Land and buildings 2014 £	Other 2015 £	Other 2014 £
Operating leases which expire: within two to five years	-	249,854	-	-

20 Loans to directors

Description and conditions	B/fwd £	Paid £	Repaid £	C/fwd £
Mr Venugopalan Muralidharan Loan	4,248	-	(4,248)	-
Mr Avinash Chandra Swain Loan	6,143	-	(6,143)	-
	10,391	-	(10,391)	-

21 Related party transactions

The company has this year taken advantage of the exemption provided by Financial Reporting Standard 8 not to disclose transactions with other members of the Aurobindo Pharma Group, balances at the year end are as follows:

	2015 £	2014 £
Actavis BV		
Amount due from the related party	41,732	-
Actavis Deutschland GmbH & Co		
Amount due from the related party	152,934	-
Agile Pharma BV		
Amount due from the related party	182,125	495,583
APL Swift Services (Malta) Ltd		
Amount due from the related party	61,403	100,145
Arrow Generiques		
Amount due from the related party	19,756	-
Aurobindo Lab SLU		
Amount due from the related party	19,028	208,970

07 MAY 2015

THE CORPORATE PRACTICE LIMITED
T/As ARORA & Co
CHARTERED ACCOUNTANTS
65 Delamere Road, Harefield, Bucks HP84 0JN
Tel 020 6 675 9000 Fax 020 6 675 9057

Milpharm Limited
Notes to the Accounts
for the year ended 31 March 2015

Aurobindo Pharma (Australia) (Pty) Ltd		
Amount due from the related party	-	6,981
Aurobindo Pharma (Malta) Ltd		
Amount due from the related party	-	13,539
Aurobindo Pharma (Portugal) Unipessoal Limitada		
Amount due from the related party	150,135	13,369
Aurobindo Pharma GmbH		
Amount due from the related party	20,795	19,934
Aurobindo Pharma (Italia) SRL		
Amount due from the related party	155,351	44,324
Aurobindo Pharma Ltd		
Amount due from the related party	55,001	225,170
Aurobindo Pharma (Romania) SRL		
Amount due from the related party	194,272	46,762
Aurovitas Spain SA		
Amount due from the related party	21,931	-
Aurovitas Unipessoal, Lda		
Amount due from the related party	154,498	-
Pharmacin BV		
Amount due from the related party	71,839	87,036
Total	<u>1,300,800</u>	<u>1,261,813</u>
Aurobindo Lab SLU		
Amount due to the related party	-	517
APL Swift Services (Malta) Ltd		
Amount due to the related party	5,836,354	3,341,705
Aurobindo Pharma Italia		
Amount due to the related party	-	207
Aurobindo Pharma Limited		
Amount due to the related party	371,479	2,258,192
Aurobindo Pharma (Malta) Ltd		
Amount due to the related party	150,255	269,306
Helix Healthcare BV		
Amount due to the related party	-	5,960
Total	<u>6,358,088</u>	<u>5,875,887</u>

THE CORPORATE PRACTICE LIMITED
T/As ARO'RA & CO
CHARTERED ACCOUNTANTS
65 Delamare Road, Haywards, Singapore
Tel: 020 8606 5750 Fax: 020 8606 5751

07 MAY 2015

Milpharm Limited
Notes to the Accounts
for the year ended 31 March 2015

22 Ultimate holding company

The directors consider the immediate and ultimate parent company to be Helix Healthcare BV, a company registered in Netherland and Aurobindo Pharma Limited a company incorporated in India respectively.

The published consolidation accounts of the Ultimate Holding Company can be obtained from Plot No. 2, Maitrivihar, Ameerpet, Hyderabad 500038 India.

07 May 2015

THE CORPORATE SECRETARY
T/AS / FCO
CHARTERED ACCOUNTANTS
5 Delamater Street
Hyderabad 500038

Milpharm Limited
Detailed profit and loss account
for the year ended 31 March 2015

	2015 £	2014 £
Sales	21,650,559	18,522,930
Cost of sales	(19,280,762)	(13,988,485)
Gross profit	2,369,797	4,534,445
Administrative expenses	(4,470,896)	(3,596,295)
Other operating income	2,219,866	839,136
Operating profit	118,767	1,777,286
Interest receivable	5,978	400
Interest payable	(110)	(9,080)
Profit before tax	<u>124,635</u>	<u>1,768,606</u>

07 MAY 2015

THE CORPORATE TRUSTEES
T/A S. ARCTIC
CHARTERED ACCOUNTANTS
65 De'Ani St. (2015)
Tel: 020 3006 5000

Milpharm Limited
Detailed profit and loss account
for the year ended 31 March 2015

	2015 £	2014 £
Sales		
Sales	21,650,559	18,522,930
Cost of sales		
Opening stock	6,221,395	4,742,798
Purchases	16,545,433	13,629,014
Closing stock	(5,941,420)	(6,221,395)
Consumption for the year	16,825,408	12,150,417
Product testing	834,059	708,060
Transport & packaging	1,095,785	780,577
Commissions payable	471,829	305,980
Other direct costs	53,681	43,451
	19,280,762	13,988,485
Administrative expenses		
Employee costs:		
Wages and salaries	1,084,170	828,275
Directors' salaries	517,502	330,782
Bonuses	105,908	104,415
Employer's NI	188,819	149,468
Temporary staff and recruitment	70,800	7,078
Staff training and welfare	19,453	17,613
Travel and subsistence	193,287	169,053
Entertaining	35,065	28,351
	2,215,004	1,635,035
Premises costs:		
Rent	93,648	94,721
Rates	43,530	39,359
Service charges	60,003	34,712
Light and heat	2,859	1,984
Cleaning	6,470	6,533
	206,510	177,309
General administrative expenses:		
Telephone and fax	81,348	27,352
Postage	13,154	16,067
Stationery and printing	21,211	10,497
Computer expenses	157,325	16,389
Subscriptions	2,499	7,292
Bank charges	2,594	1,435
Insurance	12,078	12,805
(Profit)/loss on foreign currency	98,860	20,398
Loss on disposal of intangible assets	10,632	85,796
Loss on disposal of tangible assets	3,659	-
Licence maintenance	600,534	603,216
Repairs and maintenance	2,518	5,373
Depreciation	42,705	36,315
Amortisation of product registrations	473,017	564,025
Intangible work in progress written off	29,941	82,691
Bad debts	(17,220)	62,822
Charitable donations		(60)

07 MAY 2015

07 MAY 2015

THE CORPORATE PRACTICE LIMITED
T/As ARORA & Co
CHARTERED ACCOUNTANTS
65 Dulan Road, Hagen, P.O. Box 1
Tel: 020 4409 6700 Fax: 020 4409 6701

Milpharm Limited
Detailed profit and loss account
for the year ended 31 March 2015

	2015	2014
	£	£
Sundry expenses	1,892	343
	<u>1,536,847</u>	<u>1,552,756</u>
Legal and professional costs:		
Audit fees	13,050	11,850
Accountancy fees	6,650	3,650
Consultancy fees	476,197	192,230
Advertising and PR	233	9,051
Other legal and professional	16,405	14,414
	<u>512,535</u>	<u>231,195</u>
	<u>4,470,896</u>	<u>3,596,295</u>
Other operating income		
Management fees receivable	1,806,148	539,160
Other operating income	413,718	299,976
	<u>2,219,866</u>	<u>839,136</u>

07 MAY 2015

THE CORPORATE PRACTICE LIMITED
T/As ARORA & Co
CHARTERED ACCOUNTANTS
65 Dolan Road Hayes, Essex
Tel: 0201 226750 Fax: 0201 226751

AUROBINDO PHARMA (MALTA) LIMITED

**Annual Report
and
Financial Statements
31 March 2015**

C 42439

General Information

Company registration

Aurobindo Pharma (Malta) Limited is a limited liability company registered in Malta in terms of the Companies Act of 1995. The company's registration number is C42439. The company was registered on 26 September 2007.

Directors

Phaneendra Prasad Gorla
Frederick Schembri
Venugopalan Muralidharan

Company secretary

Dr. Louise Ellul Cachia Caruana

Auditor

John Zammit
Certified Public Accountant and Registered Auditor,
Suite 6, Isola Mare,
Bouverie Street,
Gzira GZR 1220
Malta

Registered office

Vault 14, Level 2,
Valletta Waterfront
Floriana FRN 1913
Malta

Bankers

HSBC Malta Plc.

Index

Page

1 - 2	Directors' Report
3 - 4	Independent Auditor's Report
5	Statement of Comprehensive Income
6	Statement of Financial Position
7	Statement of Changes in Equity
8	Statement of Cash Flows
9 - 21	Notes to the Financial Statements

Directors' Report

31 March 2015

The directors present the annual report together with the audited financial statements of the company for the year ended 31 March 2015.

Principal Activities

The company's principal activity is to trade in pharmaceutical licenses.

Review of Business Development

During the year under review, the company generated income amounting to €680,840 (2014: €327,472). The directors expect the level of turnover to be sustained and increase in the foreseeable future. On 1st January 2015, the company merged with its parent company Agile Malta Holdings Limited and all the assets, liabilities, capital and reserves that were held by Agile Malta Holdings Limited as at 31st December 2014 were transferred to Aurobindo Pharma (Malta) Limited.

Results and Dividends

The company incurred a loss for the year before taxation amounting to €136,488 (2014: loss of €42,079). After accounting for taxation the loss amounted to €140,938 (2014: loss of €102,512). The directors do not recommend the distribution of a dividend.

Directors

The directors of the company who held office during the year were:

Phaneendra Prasad Gorla
Frederick Schembri
Venugopalan Muralidharan

In terms of the company's Articles of Association the present directors will continue in office.

Events After the End Of the Reporting Period

No significant events, having effect on the financial results and position of the company, have taken place since the end of the reporting period.

Going Concern

After making enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operating existence for the foreseeable future. For this reason the going concern basis in preparing financial statements continues to be adopted.

AUROBINDO PHARMA (MALTA) LIMITED
Annual Report and Financial Statements – 31 March 2015

Directors' Report – continued
31 March 2015

Statement of Directors' Responsibilities

The Companies Act, 1995 require the directors to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the company at the end of the financial period and of the profit or loss of the company for that period.

In preparing the financial statements, the directors are required to:-


- adopt the going concern basis, unless it is inappropriate to presume that the company will continue in business;
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- account for income and charges relative to the accounting period on the accruals basis;
- value separately the components of asset and liability items; and
- report comparative figures corresponding to those of the preceding accounting period.


The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy, at any time, the financial position of the company and to enable the directors to ensure that the financial statements have been properly prepared in accordance with International Financial Reporting Standards, as adopted by the I.U. and the requirements of the Companies Act, 1995. The directors are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Auditor

The auditor, John Zammit, has expressed his willingness to remain in office and a resolution proposing his reappointment will be put before the members at the annual general meeting.

Approved and signed by the directors:


Phaneendra Prasad Gorla
Director


Frederick Schembri
Director

Registered Address:
Vault 14, Level 2,
Valletta Waterfront,
Floriana FRN 1913
Malta

Date: 11 May 2015

JOHN ZAMMIT
B.A. (HONS.) Accty, M.I.A., C.P.A.
Certified Public Accountant and Registered Auditor

"Isolamare" Suite 6,
Bouverie Street,
Gzira, GZR 1220 Malta
Tel: 21332970/6/7
Fax: 21332991
Mobile: 9949 0357

Independent Auditor's Report

To the Shareholders of Aurobindo Pharma (Malta) Limited

I have audited the financial statements of Aurobindo Pharma (Malta) Limited which comprise the company's statement of financial position as at 31 March 2015 and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended and a summary of significant accounting policies and other explanatory notes.

Directors' Responsibility for the Financial Statements

The directors are responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards, as adopted by the EU, and the requirements of the Maltese Companies Act, 1995. As described in the statement of directors' responsibilities on page 2, this responsibility includes designing, implementing and maintaining internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error, selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

My responsibility is to express an opinion on these financial statements based on my audit. I conducted my audit in accordance with International Standards on Auditing. Those standards require that I comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial statements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.

JOHN ZAMMIT

B.A. (HONS.) Accty, M.I.A., C.P.A.

Independent Auditor's Report - continued

To the Shareholders of Aurobindo Pharma (Malta) Limited

The Company is a private limited liability company incorporated under the laws of the Malta. The ultimate holding company is Aurobindo Pharma Limited, India and whose shares are traded on the Stock Exchanges of India.

Opinion


In my opinion, the financial statements give a true and fair view of the financial position of the company as at 31 March 2015, and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards, as adopted by the EU, and have been properly prepared in accordance with the requirements of the Maltese Companies Act, 1995 which exempts the company from preparing consolidated financial statements as required by IFRS 10 Consolidated Financial Statements.

Report on Other Legal and Regulatory Requirements

I also have responsibilities under the Maltese Companies Act, 1995 to report to you if, in my opinion:

- The information given in the directors' report is not consistent with the financial statements.
- Adequate accounting records have not been kept, or that returns adequate for my audit have not been received from branches not visited by me.
- The financial statements are not in agreement with the accounting records and returns.
- I have not received all the information and explanations I require for my audit.
- Certain disclosures of directors' remuneration specified by law are not made in the financial statements.

I have nothing to report to you in respect of these responsibilities.


John Zammit
Certified Public Accountant and Registered Auditor

Date: 11 May 2015

Statement of Comprehensive Income
For the year ended 31 March 2015

	Notes	2015 €	2014 €
Revenue	4	680,840	327,472
Cost of sales		<u>(526,256)</u>	<u>(7,400)</u>
Gross Profit		154,584	320,072
Administrative expenses		<u>(207,179)</u>	<u>(337,301)</u>
Operating Loss	5	(52,595)	(17,229)
Finance income		-	2
Interest payable and similar charges	7	<u>(83,893)</u>	<u>(24,852)</u>
Loss before Taxation		(136,488)	(42,079)
Taxation	8	<u>(4,450)</u>	<u>(60,433)</u>
Loss for the Year		<u>(140,938)</u>	<u>(102,512)</u>


AUROBINDO PHARMA (MALTA) LIMITED
Annual Report and Financial Statements - 31 March 2015


Statement of Financial Position
31 March 2015

	Notes	2015 €	2014 €
ASSETS			
Non-Current Assets			
Investment in subsidiary undertaking	9	<u>2,914,209</u>	-
Current Assets			
Trade and other receivables	11	7,959,506	12,319,516
Cash and cash equivalents		259,646	13,670
Taxation receivable		<u>17,500</u>	-
		<u>8,236,652</u>	<u>12,333,186</u>
Total Assets		<u>11,150,861</u>	<u>12,333,186</u>
EQUITY AND LIABILITIES			
Capital and Reserves			
Share capital	12	5,075,000	5,650,000
Retained earnings		<u>4,143,895</u>	<u>60,930</u>
		<u>9,218,895</u>	<u>5,710,930</u>
Non-Current Liabilities			
Deferred taxation	13	<u>2,824</u>	<u>2,824</u>
Current Liabilities			
Interest bearing borrowings	14	1,850,000	1,980,000
Trade and other payables	15	79,142	4,291,299
Taxation		-	348,133
		<u>1,929,142</u>	<u>6,619,432</u>
Total Equity and Liabilities		<u>11,150,861</u>	<u>12,333,186</u>

The financial statements on pages 5 to 21 were approved and signed by the directors on

11 May 2015


Phaneendra Prasad Gorla
Director


Frederick Schembri
Director

Statement of Changes in Equity

31 March 2015

	Share Capital €	Retained Earnings €	Total €
Balance at 1 April 2013	5,650,000	219,669	5,869,669
Loss for the year	-	(102,512)	(102,512)
Dividends paid	-	(56,227)	(56,227)
Balance at 31 March 2014	<u>5,650,000</u>	<u>60,930</u>	<u>5,710,930</u>
Balance at 1 April 2014	5,650,000	60,930	5,710,930
Changes in share capital upon merger	(575,000)	-	(575,000)
Loss for the year	-	(140,938)	(140,938)
Profits acquired upon merger	-	4,223,903	4,223,903
Balance at 31 March 2015	<u>5,075,000</u>	<u>4,143,895</u>	<u>9,218,895</u>

AUROBINDO PHARMA (MALTA) LIMITED
Annual Report and Financial Statements - 31 March 2015

Statement of Cash Flows

For the year ended 31 March 2015

	2015 €	2014 €
	Note	
Operating Activities		
Loss for the year before taxation	(136,488)	(42,079)
<i>Adjustment for:</i>		
Unrealised difference on exchange	59,853	158,740
Assets and liabilities taken over upon merger net of bank balances	103,147	-
	26,512	116,661
<i>Working capital changes:</i>		
Decrease in trade and other receivables	944,496	467,915
Decrease in trade and other payables	(23,000)	(125,547)
	948,008	459,029
Tax paid	(365,633)	(708,172)
Net Cash generated from /(used in) Operating Activities	582,375	(249,143)
Investing Activities		
Payments to acquire investments	(2,914,209)	-
Net Cash absorbed by Investing Activities	(2,914,209)	-
Financing Activities		
Advances from related and parent company	1,300,000	1,030,000
Advances from related companies	1,277,810	(1,290,412)
Dividends paid	-	(56,227)
Net Cash generated from/(used in) Financing Activities	2,577,810	(316,639)
Movement in Cash and Cash Equivalents	245,976	(565,782)
Cash and Cash Equivalents at Beginning of Year	13,670	579,452
Cash and Cash Equivalents at End of Year	16 259,646	13,670

Notes to the Financial Statements

31 March 2015

1. Basis of Preparation

The financial statements have been prepared in accordance with the provisions of the Companies Act, 1995 enacted in Malta, which require adherence to International Financial Reporting Standards (IFRSs) and their interpretations adopted by the International Accounting Standards Board (IASB). The financial statements are prepared under the historical cost convention.

The preparation of financial statements in conformity with IFRSs requires the use of certain accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies (refer to Note 3 – Critical accounting estimates and judgements).

On 1st January 2015, following a group re-organisation, Aurobindo Pharma (Malta) Limited acquired the total assets (amounting to €9,875,334), liabilities and capital and reserves (amounting to €580,583 and €9,294,751 respectively) of its parent company, Agile Malta Holdings Limited, through merger.

In accordance with Section 174 of the Companies Act, 1995 the company has taken advantage of the exemption from consolidation due to the fact that the company forms part of a larger group and is itself a wholly-owned subsidiary company of an immediate parent, Agile Pharma B.V., formed and registered under the laws of a Member State with the consolidation being prepared by Aurobindo Pharma Limited. Due to this statutory exemption the company has departed from the requirement for consolidation under IFRS10 and prepared separate financial statements.

Standards, interpretations and amendments to published standards effective in 2014

In the financial year ending 31 March 2015, the company adopted new standards, amendments and interpretations to existing standards that are mandatory for the company's accounting period beginning on 1 April 2014. The adoption of these revisions to the requirements of IFRSs, as adopted by the EU, did not result in substantial changes to the company's accounting policies.

Standards, interpretations and amendments to published standards not yet effective

Certain new standards, amendments and interpretations to existing standards have been published by the date of authorisation for issue of these financial statements that are mandatory for the company's accounting periods beginning on 1 April 2015. The company has not early-adopted these revisions to the requirements of IFRSs, as adopted by the EU, and the company's directors are of the opinion that there are no requirements that will have a possible significant material impact on the company's financial statements in the period of initial application.

2. Principal Accounting Policies

The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

Notes to the Financial Statements

31 March 2015

2. Principal Accounting Policies – continued

Reporting currency

The reporting currency used for the preparation of the financial statements is the Euro, which is the currency in which the company's share capital is denominated.

Revenue recognition

Revenue comprises the fair value of the consideration received or receivable for the sale of goods and services in the ordinary course of the company's activities. Revenue is shown net of value-added tax or other sales taxes, returns, rebates and discounts.

Sales of goods

Sales of goods are recognised when a company has delivered products to its customer the customer has accepted the products and collectability of the related debts is reasonably assured. It is the company's policy to sell its products with a right of return. Accumulated experience is used to estimate and provide for such returns at the time of sale.

Investments in group and associated undertakings

Subsidiary undertakings are all entities over which the company has the power to govern the financial and operating policies generally accompanying a shareholding of more than one half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the company controls another entity.

Associated undertakings are all entities over which the company has significant influence but not control, generally accompanying a shareholding of between 20% and 50% of the voting rights.

In the company's financial statements, investments in company and associated undertakings are accounted for by the cost method of accounting. The dividend income from such investments is included in the statement of comprehensive income in the accounting year in which the company's rights to receive payment of any dividend is established. The company gathers objective evidence that an investment is impaired using the same process disclosed in accounting policy *Impairment of Financial Assets*. On disposal of an investment, the difference between the net disposal proceeds and the carrying amount is charged or credited to the statement of comprehensive income.

Notes to the Financial Statements

31 March 2015

2. Principal Accounting Policies – continued

Impairment of financial assets

A financial asset is considered to be impaired if objective evidence indicates that one or more events have had a negative effect on the estimated future cash flows of that asset.

An impairment loss in respect of a financial asset measured at amortised cost is calculated as the difference between its carrying amount, and the present value of the estimated future cash flows discounted at the original effective interest rate. An impairment loss in respect of an available-for sale financial asset is calculated by reference to its current fair value.

The company assesses at the end of the reporting period whether there is objective evidence that a financial asset or a company of financial assets is impaired. If there is objective evidence that an impairment loss has been incurred on loans and receivables carried at amortised cost, the amount of the loss is recognized in the statement of comprehensive income and measured as the difference between the asset's carrying amount and the present value of estimated future cash flows discounted at the financial asset's original effective interest rate.

In the case of equity securities classified as available-for-sale, a significant or prolonged decline in the fair value of the security below its cost is considered in determining whether the securities are impaired. If any such evidence exists for available-for-sale financial assets, the cumulative loss – measured as the difference between the acquisition cost and the current fair value, less any impairment loss on that financial asset previously recognized in profit or loss – is reclassified from equity to profit or loss as a reclassification adjustment.

An impairment loss is reversed if the reversal can be related objectively to an event occurring after the impairment loss was recognised. For financial assets measured at amortised cost and available for sale financial assets that are debt securities, the reversal is recognised in profit or loss. For available-for-sale financial assets that are equity securities, the reversal is recognised directly in equity.

Trade and Other Receivables

Trade and other receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for impairment of trade receivables is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of debts.

Notes to the Financial Statements

31 March 2015

2. Principal Accounting Policies – continued

Trade and Other Receivables - continued

The amount of the provision is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the effective interest rate. The amount of the provision is recognized in the statement of comprehensive income.

Cash and cash equivalents

Cash and cash equivalents are carried in the statement of financial position at face value. For the purposes of the cash flow statement, cash and cash equivalents comprise cash in hand and deposits held at call with banks.

Income taxation

Income tax on the profit or loss for the period comprises current and deferred tax. Income tax is recognised in the statement of comprehensive income except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity.

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantially enacted at the end of the reporting period, and any adjustment to tax payable in respect of previous periods.

Deferred taxation is provided using the liability method, for all temporary differences arising between the tax bases of assets and liabilities and their carrying values for financial reporting purposes. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

Deferred tax assets are recognised only to the extent that it is probable that future taxable profits will be available against which the unutilised deferred tax credits can be utilised.

Share capital

Ordinary shares are classified as equity. Dividend distribution to the company's shareholders is recognised as a liability in the company's financial statements in the period in which the dividends are approved by the company's shareholders.

Trade Payables

Trade payables are carried at cost which is the fair value of the consideration to be paid in the future for goods and services received, billed to the company.

Notes to the Financial Statements

31 March 2015

2. Principal Accounting Policies - continued

Borrowings

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the statement of comprehensive income over the period of the borrowings using the effective interest method. Borrowings are classified as current liabilities unless the group has an unconditional right to defer settlement of the liability for at least twelve months after the statement of financial position date.

3. Critical Accounting Estimates and Judgements

Estimates and judgements are continually evaluated and based on historical experience and other factors including expectations of future events that are believed to be reasonable under the circumstances.

In the opinion of the directors, the accounting estimates and judgements made in the course of preparing these financial statements are not difficult, subjective or complex to a degree which would warrant their description as critical in terms of the requirements of IAS 1 (revised).

4. Revenue

Revenue during the year comprised the following:

	2015 €	2014 €
Sale of dossiers	680,840	300,963
Commission received	-	26,509
	<u>680,840</u>	<u>327,472</u>

5. Operating Loss

	2015 €	2014 €
<i>This is stated after charging:</i>		
Audit fee	4,200	7,200
Filing fees waived off	513,687	-
Realised loss on difference on exchange	1,173	742
Unrealised loss on difference on exchange	59,853	158,740
Penalties	1,944	-

Notes to the Financial Statements
31 March 2015

6. Staff Costs	2015	2014
	€	€
Wages and salaries	32,825	28,882
Social security costs	2,151	2,149
	<u>34,976</u>	<u>31,031</u>

The average number of persons employed during the year, was made up as follows:

	No.	No.
Administration	<u>1</u>	<u>1</u>

7. Interest Payable and Similar Charges	2015	2014
	€	€
Other interests	2,083	-
Interest on loans	75,245	17,385
Bank charges	4,645	7,467
Foreign taxes written off	1,920	-
	<u>83,893</u>	<u>24,852</u>

8. Taxation

The taxation charge for the year is made up as follows:

	2015	2014
	€	€
Foreign tax paid	4,450	22,395
Malta tax charge	-	38,038
	<u>4,450</u>	<u>60,433</u>

Notes to the Financial Statements
31 March 2015

8. Taxation - continued

The tax on the company's results before tax differs from the theoretical amount that would arise using the statutory tax rate of 35% as follows:

	2015 €	2014 €
Loss for the year before taxation	<u>(136,488)</u>	<u>(42,079)</u>
Tax income at the statutory tax rate	47,771	14,728
<i>Tax effect:</i>		
Disallowed expenses	<u>(52,221)</u>	<u>(75,161)</u>
Tax expense	<u>(4,450)</u>	<u>(60,433)</u>

9. Investments in Group Undertakings

	2015 €	2014 €
Opening net book amount at 1 April	-	-
Additions	<u>2,914,209</u>	-
Closing net book amount at 31 March	<u>2,914,209</u>	-
Cost at 1 January	-	-
Additions	2,914,209	-
Impairment provisions for investments	-	-
Net book amount at 31 December	<u>2,914,209</u>	-

The principal undertaking which is unlisted at 31 March 2015 is shown below:

	Registered office	Principal activities	Percentages of shares held	
			2015	2014
APL Swift Services (Malta) Limited	Vault 14, Level 2 Valletta Waterfront, Floriana FRN1914	Operate laboratories and testing facilities	99.99	-

Notes to the Financial Statements
31 March 2015

10. Property, Plant and Equipment

	Electronic Equipment €	Total €
Cost		
As at 01.04.14	4,507	4,507
Additions	-	-
	<u>4,507</u>	<u>4,507</u>
As at 31.03.15	<u>4,507</u>	<u>4,507</u>
Depreciation		
As at 01.04.14	4,507	4,507
Charge for the year	-	-
	<u>4,507</u>	<u>4,507</u>
As at 31.03.15	<u>4,507</u>	<u>4,507</u>
Net Book Value		
As at 31.03.15	<u>-</u>	<u>-</u>
Cost		
As at 01.04.13	4,507	4,507
Additions	-	-
	<u>4,507</u>	<u>4,507</u>
As at 31.03.14	<u>4,507</u>	<u>4,507</u>
Depreciation		
As at 01.04.13	4,507	4,507
Charge for the year	-	-
	<u>4,507</u>	<u>4,507</u>
As at 31.03.14	<u>4,507</u>	<u>4,507</u>
Net Book Value		
As at 31.03.14	<u>-</u>	<u>-</u>

Notes to the Financial Statements
31 March 2015

11. Trade and Other Receivables

	2015	2014
	€	€
Trade receivables	673,063	591,573
Advance deposits	1,907,037	2,933,024
Amounts due from related companies	5,368,569	8,784,083
Other receivables	40	4,947
Indirect taxation	10,797	5,889
	<u>7,959,506</u>	<u>12,319,516</u>

Amounts due from related companies are unsecured, interest free and repayable on demand.

12. Share Capital

	2015	2014
	€	€
<i>Authorised share capital</i>		
7,000,000 Ordinary shares of €1 each	<u>7,000,000</u>	<u>7,000,000</u>
<i>Issued and fully paid share capital</i>		
5,074,999 (2014: 5,649,999) Ordinary 'A' shares of € 1 each	<u>5,074,999</u>	<u>5,649,999</u>
1 Ordinary 'B' share of €1	<u>1</u>	<u>1</u>
	<u>5,075,000</u>	<u>5,650,000</u>

The holders of both classes of shares shall rank equally in all respects saving that the holder of the ordinary B share not be entitled to exercise any voting rights and shall not be entitled to participate in any profit sharing in respect of such shareholding.

Notes to the Financial Statements
31 March 2015

13. Deferred Taxation

	2015 €	2014 €
At beginning of year	2,824	2,824
Statement of Comprehensive Income	-	-
At end of year	<u>2,824</u>	<u>2,824</u>

Deferred income taxes are calculated on all temporary differences under the liability method using a principal tax rate of 35%.

The balance at 31 March represents:

	2015 €	2014 €
Provision for foreign exchange differences	<u>2,824</u>	<u>2,824</u>

14. Interest-Bearing Borrowings

	2015 €	2014 €
Amounts due to parent company	<u>1,850,000</u>	<u>1,980,000</u>

Amounts due to parent company are subjected to an interest rate of 1.3% above LIBOR rate per annum. These amounts are expected to be re-paid within 5 years.

Notes to the Financial Statements
31 March 2015

15. Trade and Other Payables

	2015 €	2014 €
Trade payables	3,182	36,344
Amounts due to parent company	63,958	1,672,443
Amounts due to related companies	-	2,518,899
Accruals	12,002	7,200
Other creditors	-	56,413
	<u>79,142</u>	<u>4,291,299</u>

Amounts due to parent company are unsecured, interest free and have no fixed date for repayment.

16. Dividends

	2015 €	2014 €
<i>Ordinary shares</i>		
Final dividend	-	56,227
Total net dividend	<u>-</u>	<u>56,227</u>
Cents per share	<u>-</u>	<u>0.010</u>

17. Cash and Cash Equivalents

For the purpose of the cash flow statements, the cash and cash equivalents at the end of the year comprise the following:

	2015 €	2014 €
Cash at bank	<u>259,646</u>	<u>13,670</u>

Notes to the Financial Statements
31 March 2015

18. Related Party Transactions

Aurobindo Pharma (Malta) Limited is fully owned by Agile Pharma B.V. Transactions with parent company and its shareholders and associated companies are related party transactions.

	Percentage of shares held	
	2015	2014
Agile Pharma B.V	99.99	-
Phaneendra Prasad Gorla	0.01	0.01
Agile Malta Holdings Limited	-	99.99

The following transactions were carried out with related parties:

	2015	2014
	€	€
<i>Loans and advances</i>		
Advances to related companies	1,277,810	(1,307,395)
Advances from parent company	1,300,000	1,030,000
Dividends paid	-	(56,227)
	<u>2,577,810</u>	<u>(333,622)</u>

19. Financial Instruments

At the year end, the company's main financial assets on the statement of financial position comprised of investments, trade and other receivables and cash at bank and in hand. At the year end there were no unreported financial assets in the statement of financial position.

At the year end, the company's main financial liabilities on the statement of financial position consisted of amounts due to parent and related companies, trade payables and accruals. The company had no unreported financial liabilities in the statement of financial position.

Timing of cash flows

The presentation of the financial assets and liabilities listed above under the current and non-current headings within the statement of financial position is intended to indicate the timing in which cash flows will arise.

Notes to the Financial Statements
31 March 2015

19. Financial Instruments - continued

Credit risk

Financial assets which potentially subject the company to concentrations of credit risk consist principally of cash at bank. The company's cash is placed with prime financial institutions. Trade receivables are presented net of impairment provision.

Fair values of non-derivative financial instruments

At 31 March 2015 the carrying amounts of cash at bank and in hand, receivables and payables approximated their fair values. The fair values of long-term borrowings are not materially different from their carrying amounts.

20. Ultimate Parent Company

The ultimate parent company of Aurobindo Pharma (Malta) Limited is Aurobindo Pharma Limited, India.

21. General Information

Aurobindo Pharma (Malta) Limited is a limited liability company domiciled and incorporated in Malta.

APL SWIFT SERVICES (MALTA) LIMITED

**Annual Report
and
Financial Statements
31 March 2015**

C 43079

General Information

Company registration

APL Swift Services (Malta) Limited is a limited liability company registered in Malta in terms of the Companies Act of 1995. The company's registration number is C43079. The company was registered on 12 December 2007.

Directors

Phaneendra Prasad Gorla
Frederick Schembri
Venugopalan Muralidharan

Company secretary

Louise Ellul Cachia Caruana

Auditor

John Zammit
Certified Public Accountant and Registered Auditor
Suite 6, Isola Mare,
Bouverie Street,
Gzira GZR 1220
Malta

Registered office

Vault 14, Level 2,
Valletta Waterfront
Floriana FRN 1913
Malta

Bankers

HSBC Malta Plc.

Index

Page

1 - 2	Directors' Report
3 - 4	Independent Auditor's Report
5	Statement of Comprehensive Income
6	Statement of Financial Position
7	Statement of Changes in Equity
8	Statement of Cash Flows
9 - 20	Notes to the Financial Statements

Directors' Report

31 March 2015

The directors present the annual report together with the audited financial statements of the company for the year ended 31 March 2015.

Principal Activities

The company's principal activities are to operate laboratories and other testing facilities and to provide warehousing related to the pharmaceutical industry. The company also traded in pharmaceutical products.

Review of Business Development

During the year under review, the company achieved a profit of €154,272. The company's performance has decreased significantly compared to prior year, however the management is of the opinion that the company's performance will improve in the future. The company continued to operate in its laboratories and testing facilities together with the provision of warehousing services.

Results and Dividends

The company achieved a profit for the year after taxation amounting to €154,272 (2014: profit of €1,101,792). The accumulated losses for the year amounted to €531,518 (2014: losses of €685,790).

The directors do not recommend the distribution of a dividend.

Directors

The directors of the company who held office during the year were:

Phaneendra Prasad Gorla
Frederick Schembri
Venugopalan Muralidharan

In terms of the company's Articles of Association the present directors will continue in office.

Events After the End of the Reporting Period

No significant events, having effect on the financial results and position of the company, have taken place since the end of the reporting period.

Going Concern

After making enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operating existence for the foreseeable future. For this reason the going concern basis in preparing financial statements continues to be adopted.

APL SWIFT SERVICES (MALTA) LIMITED
Annual Report and Financial Statements - 31 March 2015

Directors' Report - continued
31 March 2015

Statement of Directors' Responsibilities

The Companies Act, 1995 requires the directors to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the company at the end of the financial period and of the profit or loss of the company for that period.

In preparing the financial statements, the directors are required to:


- adopt the going concern basis, unless it is inappropriate to presume that the company will continue in business;
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- account for income and charges relative to the accounting period on the accruals basis;
- value separately the components of asset and liability items; and
- report comparative figures corresponding to those of the preceding accounting period.


The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy, at any time, the financial position of the company and to enable the directors to ensure that the financial statements have been properly prepared in accordance with International Reporting Standards, as adopted by the EU, and the requirements of the Companies Act, 1995. The directors are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Auditor

The auditor, John Zammit, has expressed his willingness to remain in office and a resolution proposing his reappointment will be put before the members at the annual general meeting.

Approved by the Board of Directors and signed on its behalf by:


Phaneendra Prasad Gorla
Director


Frederick Schembri
Director

Registered Address:
Vault 14, Level 2,
Valletta Waterfront,
Floriana FRN 1913
Malta

Date: 11 May 2015

JOHN ZAMMIT**B.A. (HONS.) Accty, M.I.A., C.P.A.****Certified Public Accountant and****Registered Auditor**

"Isolamare" Suite 6

Bouverie Street

Gzira, GZR 1220, Malta

Tel: 21332970/6/7

Fax: 21332991

Mobile: 9949 0357

Independent Auditor's Report**To the Shareholders of APL Swift Services (Malta) Limited**

I have audited the financial statements of APL Swift Services (Malta) Limited which comprise the company's statement of financial position as at 31 March 2015 and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended and a summary of significant accounting policies and other explanatory notes.

Directors' Responsibility for the Financial Statements

The directors are responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards, as adopted by the EU, and the requirements of the Maltese Companies Act, 1995. As described in the statement of directors' responsibilities on page 2, this responsibility includes designing, implementing and maintaining internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error, selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

My responsibility is to express an opinion on these financial statements based on my audit. I conducted my audit in accordance with International Standards on Auditing. Those standards require that I comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial statements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.

JOHN ZAMMIT

B.A. (HONS.) Accty, M.I.A., C.P.A.

Independent Auditor's Report - continued

To the Shareholders of APL Swift Services (Malta) Limited

The Company is a private limited liability company incorporated under the laws of the Malta. The ultimate holding company is Aurobindo Pharma Limited, India and whose shares are traded on the Stock Exchanges of India

Opinion

In my opinion, the financial statements give a true and fair view of the financial position of the company as at 31 March 2015, and of its financial performance and its cash flows for the year then ended in accordance with international Financial Reporting Standards, as adopted by the EU, and have been properly prepared in accordance with the requirements of the Maltese Companies Act, 1995

Report on Other Legal and Regulatory Requirements

I also have responsibilities under the Maltese Companies Act, 1995 to report to you if, in my opinion:

- The information given in the directors' report is not consistent with the financial statements.
- Adequate accounting records have not been kept, or that returns adequate for my audit have not been received from branches not visited by me.
- The financial statements are not in agreement with the accounting records and returns.
- I have not received all the information and explanations I require for my audit.
- Certain disclosures of directors' remuneration specified by law are not made in the financial statements.

I have nothing to report to you in respect of these responsibilities.



John Zammit
Certified Public Accountant and Registered Auditor

Date: **11 May 2015**

Statement of Comprehensive Income
For the year ended 31 March 2015


	Notes	31 Mar 15 €	31 Mar 14 €
Revenue	4	124,828,069	26,131,588
Cost of sales		<u>(120,987,555)</u>	<u>(22,337,195)</u>
Gross Profit		3,840,514	3,794,393
Administrative expenses		<u>(3,679,889)</u>	<u>(2,689,573)</u>
Operating Profit	5	160,625	1,104,820
Finance cost	7	(6,536)	(3,076)
Investment income	8	<u>183</u>	<u>48</u>
Profit for the Year before Taxation		154,272	1,101,792
Taxation	9	<u>-</u>	<u>-</u>
Profit for the Year		<u>154,272</u>	<u>1,101,792</u>


APL SWIFT SERVICES (MALTA) LIMITED
Annual Report and Financial Statements – 31 March 2015

Statement of Financial Position
31 March 2015

	Notes	2015 €	2014 €
ASSETS			
Non-Current Assets			
Property, plant and equipment	10	1,720,510	1,376,218
Current Assets			
Inventories	11	2,609,150	2,372,425
Trade and other receivables	12	36,328,170	15,287,522
Cash and cash equivalents		4,053,002	407,062
		42,990,322	18,067,009
Total Assets		44,710,832	19,443,227
EQUITY AND LIABILITIES			
Capital and Reserves			
Share capital	13	3,600,000	3,600,000
Retained earnings		(531,518)	(685,790)
		3,068,482	2,914,210
Current Liabilities			
Trade and other payables	14	41,642,350	16,529,017
Total Equity and Liabilities		44,710,832	19,443,227

The financial statements on pages 5 to 20 were approved by the Board of Directors on 11 May 2015 and signed on its behalf by:


Phaneendra Prasad Gorla
Director


Frederick Schembri
Director

Statement of Changes in Equity
31 March 2015

	Share Capital €	Retained Earnings €	Total €
Balance at 1 April 2013	3,600,000	(1,787,582)	1,812,418
Profit for the year	-	1,101,792	1,101,792
Balance at 31 March 2014	<u>3,600,000</u>	<u>(685,790)</u>	<u>2,914,210</u>
Balance at 1 April 2014	3,600,000	(685,790)	2,914,210
Profit for the year	-	154,272	154,272
Balance at 31 March 2015	<u>3,600,000</u>	<u>(531,518)</u>	<u>3,068,482</u>

Statement of Cash Flows

For the year ended 31 March 2015

	Note	31 Mar 15 €	31 Mar 14 €
Operating Activities			
Profit for the year before taxation		154,272	1,101,792
<i>Adjustment for:</i>			
Depreciation charge		310,280	341,642
Unrealised loss on exchange		422,397	103,505
		<u>886,949</u>	<u>1,546,939</u>
<i>Working capital changes:</i>			
Increase in inventories		(236,726)	(291,729)
Increase in trade and other receivables		(22,603,152)	(11,104,350)
Increase in trade and other payables		16,004,461	379,028
Net Cash (absorbed by)/ generated from Operating Activities		<u>(5,948,468)</u>	<u>(9,470,112)</u>
Investing Activities			
Payments to acquire property, plant and equipment		(654,572)	(191,600)
Net Cash used in Investing Activities		<u>(654,572)</u>	<u>(191,600)</u>
Financing Activities			
Advances from related companies		8,323,980	6,751,363
Receipts from related companies		1,925,000	3,041,644
Net Cash used in Financing Activities		<u>10,248,980</u>	<u>9,793,007</u>
Movement in Cash and Cash Equivalents		<u>3,645,940</u>	<u>131,295</u>
Cash and Cash Equivalents at Beginning of Year		<u>407,062</u>	<u>275,767</u>
Cash and Cash Equivalents at End of Year	15	<u>4,053,002</u>	<u>407,062</u>

Notes to the Financial Statements

31 March 2015

1. Basis of Preparation

The financial statements have been prepared in accordance with the provisions of the Companies Act, 1995 enacted in Malta, which require adherence to International Financial Reporting Standards (IFRSs) and their interpretations adopted by the International Accounting Standards Board (IASB). The financial statements are prepared under the historical cost convention.

The preparation of financial statements in conformity with IFRSs requires the use of certain accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies (refer to Note 3 – Critical accounting estimates and judgements).

Standards, interpretations and amendments to published standards effective in 2014

In the financial year ending 31 March 2015, the company adopted new standards, amendments and interpretations to existing standards that are mandatory for the company's accounting period beginning on 1 April 2014. The adoption of these revisions to the requirements of IFRSs, as adopted by the EU, did not result in substantial changes to the company's accounting policies.

Standards, interpretations and amendments to published standards not yet effective

Certain new standards, amendments and interpretations to existing standards have been published by the date of authorisation for issue of these financial statements that are mandatory for the company's accounting periods beginning on 1 April 2015. The company has not early-adopted these revisions to the requirements of IFRSs, as adopted by the EU, and the company's directors are of the opinion that there are no requirements that will have a possible significant material impact on the company's financial statements in the period of initial application.

2. Principal Accounting Policies

The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

Reporting currency

The reporting currency used for the preparation of the financial statements is the Euro, which is the currency in which the company's share capital is denominated.

Notes to the Financial Statements

31 March 2015

2. Principal Accounting Policies – continued

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the statement of comprehensive income.

Revenue recognition

Revenue comprises the fair value of the consideration received or receivable for the sale of goods and services in the ordinary course of the company's activities. Revenue is shown net of value-added tax or other sales taxes, returns, rebates and discounts. Revenue is recognised as follows:

Sales of services

Sales of services are recognised in the accounting period in which the services are rendered, by reference to completion of the specific transaction assessed on the basis of the actual service provided as a proportion of the total services to be provided.

Sales of goods – wholesale

Sales of goods are recognised when a company has delivered products to its customer, the customer has accepted the products and collectability of the related debts is reasonably assured. It is the company's policy to sell its products with a right of return. Accumulated experience is used to estimate and provide for such returns at the time of sale.

Property, plant and equipment

Property, plant and equipment are stated at historical cost less accumulated depreciation and impairment losses.

Depreciation is calculated to write down the cost of all tangible assets, by equal annual installments over their expected useful economic lives. A charge equivalent to a full year's depreciation is provided during the year the asset is first brought into use, while no depreciation is charged during the year the asset is disposed of or scrapped.

At the end of reporting period date, the carrying amounts of tangible assets are reviewed for indications of impairment. Impairment losses are recognised as an expense in the statement of comprehensive income.

Notes to the Financial Statements
31 March 2015

2. Principal Accounting Policies – continued

Property, plant and equipment – continued

The depreciation rates are as follows:

	%
Factory buildings	2
Laboratory equipment	17
Office equipment	20
Furniture and fittings	10
Warehouse equipment	20
Motor vehicles	20
Electrical installation	20

Expenditure incurred to replace a component of an item of property, plant and equipment including major inspection and overhaul expenditure, is capitalized. Other subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the item of property, plant and equipment. All other expenditure is recognized in the statement of comprehensive income as an expense as incurred.

Impairment of assets

The carrying amounts of the company's non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If such indication exists then the asset's recoverable amount is estimated. An impairment loss is recognized if the carrying amount of an asset or its cash-generating unit exceeds its recoverable amount. A cash-generating unit is the smallest identifiable asset group that generates cash flows that largely are independent from other assets and groups. Impairment losses are recognized in statement of comprehensive income.

The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

Notes to the Financial Statements

31 March 2015

2. Principal Accounting Policies - continued

Inventories

Inventories are stated at the lower of cost and net realisable value. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and selling expenses. The cost of inventories is based on the weighted average principle and includes expenditure incurred in acquiring the inventories and bringing them to their existing location and condition.

Trade and other receivables

Trade and other receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for impairment of trade receivables is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of debts.

Cash and cash equivalents

Cash and cash equivalents are carried in the statement of financial position at face value. For the purposes of the cash flow statement, cash and cash equivalents comprise cash in hand and deposits held at call with banks.

Income taxation

Income tax on the profit or loss for the period comprises current and deferred tax. Income tax is recognised in the statement of comprehensive income account except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity.

Current tax is the expected tax payable on the taxable income for the period, using tax rates enacted or substantially enacted at the statement of financial position date, and any adjustment to tax payable in respect of previous periods.

Deferred taxation is provided using the liability method, for all temporary differences arising between the tax bases of assets and liabilities and their carrying values for financial reporting purposes. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the statement of financial position date and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

Deferred tax assets are recognised only to the extent that it is probable that future taxable profits will be available against which the unutilised deferred tax credits can be utilised.

Notes to the Financial Statements

31 March 2015

2. Principal Accounting Policies - continued

Share capital

Ordinary shares are classified as equity. Dividend distribution to the company's shareholders is recognised as a liability in the company's financial statements in the period in which the dividends are approved by the company's shareholders.

Trade Payables

Trade payables are carried at cost which is the fair value of the consideration to be paid in the future for goods and services received, billed to the company.

Borrowings

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the statement of comprehensive income account over the period of the borrowings using the effective interest method.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the statement of financial position date.

3. Critical Accounting Estimates and Judgements

Estimates and judgements are continually evaluated and based on historical experience and other factors including expectations of future events that are believed to be reasonable under the circumstances.

In the opinion of the directors, the accounting estimates and judgements made in the course of preparing these financial statements are not difficult, subjective or complex to a degree which would warrant their description as critical in terms of the requirements of IAS 1 (revised).

Notes to the Financial Statements

31 March 2015

4. Revenue

The company's revenue during the year under review consisted mainly of quality control testing, and batch release of pharmaceutical products and rental of warehouse spacing.

	31 Mar 15	31 Mar 14
	€	€
Pharmaceutical products	118,029,136	22,741,445
QP & QC Services	460,905	2,994,769
Analytical charges	2,856,862	90,205
Artwork charges	77,732	-
Miscellaneous income	106,846	188,895
Recharge of carriage	3,296,588	121,402
Cash discounts	-	(5,128)
	<u>124,828,069</u>	<u>26,131,588</u>

5. Profit for the Year before Taxation

	31 Mar 15	31 Mar 14
	€	€
<i>This is stated after charging:</i>		
Audit fee	8,000	8,000
Depreciation	310,279	341,642
Unrealised loss on difference on exchange	422,397	103,504
Realised (gain)/loss on difference on exchange	(242,865)	34,643

6. Staff Costs

	31 Mar 15	31 Mar 14
	€	€
Wages and salaries	1,701,070	1,233,429
Social security costs	101,852	70,466
	<u>1,802,922</u>	<u>1,303,895</u>

Notes to the Financial Statements

31 March 2015

6. Staff Costs - continued

The average number of persons employed during the period, including directors was made up as follows:

	No.	No.
Management	1	1
Administration	11	12
Operations	48	27
	<u>60</u>	<u>40</u>

7. Finance Cost

	31 Mar 15 €	31 Mar 14 €
Bank and similar charges	6,387	3,076
Other interest	149	-
	<u>6,536</u>	<u>3,076</u>

8. Investment Income

	31 Mar 15 €	31 Mar 14 €
Bank interest	183	48

9. Taxation

No tax charge has been provided for in these financial statements in view of the tax losses brought forward from previous years.

Deferred income taxes are calculated on all temporary differences under the liability method using a principal tax rate of 35%.

Notes to the Financial Statements

31 March 2015

9. Taxation - continued

At 31 March 2015, the company had deductible temporary differences amounting to €538,013 (2014: €868,253). The related deferred tax asset has not been recognized in these financial statements. The tax on the company's results before tax differs from the theoretical amount that would arise using the statutory tax rate of 35% as follows:

	31 Mar 15 €	31 Mar 14 €
Profit for the year before taxation	<u>154,272</u>	<u>1,101,792</u>
Tax charge at the statutory tax rate	53,995	(385,627)
<i>Tax effect:</i>		
Temporary differences not recognised	<u>(53,995)</u>	<u>385,627</u>
Tax expense	<u>-</u>	<u>-</u>

10. Property, Plant and Equipment

	Factory Buildings	Laboratory Equipment	Office Equipment	Furniture & Fixtures	Warehouse Equipment	Motor Vehicle	Electrical installation	Total
	€	€	€	€	€	€	€	€
Cost								
As at 01.04.14	910,765	1,575,444	136,591	92,770	219,393	1,876	6,137	2,942,976
Additions	111,062	216,663	3,245	17,071	56,531	-	250,000	654,572
Disposals	-	-	-	-	-	-	-	-
As at 31.03.15	<u>1,021,827</u>	<u>1,792,107</u>	<u>139,836</u>	<u>109,841</u>	<u>275,924</u>	<u>1,876</u>	<u>256,137</u>	<u>3,597,548</u>
Depreciation								
As at 01.04.14	98,242	1,130,349	120,152	33,843	179,649	1,500	3,023	1,566,758
Charge for the year	<u>20,437</u>	<u>192,250</u>	<u>7,400</u>	<u>10,984</u>	<u>27,606</u>	<u>376</u>	<u>51,227</u>	<u>310,280</u>
As at 31.03.15	<u>118,679</u>	<u>1,322,599</u>	<u>127,552</u>	<u>44,827</u>	<u>207,255</u>	<u>1,876</u>	<u>54,250</u>	<u>1,877,038</u>
As at 31.03.15	<u>903,148</u>	<u>469,508</u>	<u>12,284</u>	<u>65,014</u>	<u>68,669</u>	<u>-</u>	<u>201,887</u>	<u>1,720,510</u>

As at 31 March 2015, the company has fully depreciated assets amounting to €994,301.

APL SWIFT SERVICES (MALTA) LIMITED
Annual Report and Financial Statements - 31 March 2015

Notes to the Financial Statements
31 March 2015

10. Property, Plant and Equipment - continued

	Factory Buildings	Laboratory Equipment	Office Equipment	Furniture & Fixtures	Warehouse Equipment	Motor Vehicle	Electrical installation	Total
	€	€	€	€	€	€	€	€
Cost								
As at 01.04.13	910,765	1,425,793	136,591	74,934	196,083	1,876	5,334	2,751,376
Additions	-	149,651	-	17,836	23,310	-	803	191,600
Disposals	-	-	-	-	-	-	-	-
As at 31.03.14	<u>910,765</u>	<u>1,575,444</u>	<u>136,591</u>	<u>92,770</u>	<u>219,393</u>	<u>1,876</u>	<u>6,137</u>	<u>2,942,976</u>
Depreciation								
As at 01.04.13	80,027	875,568	106,264	24,566	135,770	1,125	1,796	1,225,116
Charge for the year	<u>18,215</u>	<u>254,781</u>	<u>13,888</u>	<u>9,277</u>	<u>43,879</u>	<u>375</u>	<u>1,227</u>	<u>341,642</u>
As at 31.03.14	<u>98,242</u>	<u>1,130,349</u>	<u>120,152</u>	<u>33,843</u>	<u>179,649</u>	<u>1,500</u>	<u>3,023</u>	<u>1,566,758</u>
As at 31.03.14	<u>812,523</u>	<u>445,095</u>	<u>16,439</u>	<u>58,927</u>	<u>39,744</u>	<u>376</u>	<u>3,114</u>	<u>1,376,218</u>

As at 31 March 2014, the company has fully depreciated assets amounting to €895,676.

11. Inventories

	2015	2014
	€	€
Chemicals and related materials	<u>2,609,150</u>	<u>2,372,425</u>

Notes to the Financial Statements
31 March 2015

12. Trade and Other Receivables

	2015	2014
	€	€
Trade debtors	35,981,728	13,104,121
Indirect taxation	273,590	198,924
Prepayments	21,231	7,856
Advance deposits	16,315	16,315
Amounts due from related companies	-	1,925,000
Other debtors	35,306	35,306
	<u>36,328,170</u>	<u>15,287,522</u>

Amounts due from related companies are unsecured, interest free and repayable on demand.

13. Share Capital

	2015	2014
	€	€
<i>Authorised share capital</i>		
3,000,000 Ordinary shares of €1 each	3,000,000	3,000,000
1,000,000 Ordinary shares of €1 each	<u>1,000,000</u>	<u>1,000,000</u>
	<u>4,000,000</u>	<u>4,000,000</u>
<i>Issued and fully paid share capital</i>		
3,599,999 Ordinary 'A' shares of €1 each	3,599,999	3,599,999
1 Ordinary 'B' share of €1 each	<u>1</u>	<u>1</u>
	<u>3,600,000</u>	<u>3,600,000</u>

Notes to the Financial Statements

31 March 2015

14. Trade and Other Payables

	2015	2014
	€	€
Trade creditors	40,564,970	16,222,629
Accruals	677,380	306,388
Advances from related party	400,000	-
	<u>41,642,350</u>	<u>16,529,017</u>

Advances from related party are unsecured, subject to an interest rate of 1.6% above the LIBOR rates and re-payable on demand.

15. Cash and Cash Equivalents

For the purpose of the cash flow statements, the cash and cash equivalents at the end of the year comprise the following:

	2015	2014
	€	€
Cash at bank	4,045,683	397,795
Cash in hand	<u>7,319</u>	<u>9,267</u>
	<u>4,053,002</u>	<u>407,062</u>

16. Related Party Transactions

During the year under review the shares of APL Swift Services (Malta) Limited were transferred from APL Holdings (Jersey) Limited to Aurobindo Pharma (Malta) Limited. This latter company is ultimately fully owned by Aurobindo Pharma Limited, India and whose shares are traded on the Stock Exchanges of India. Transactions with parent company and its shareholders and associated companies are related party transactions.

	2015	2014
	€	€
<i>Loans and advances</i>		
Advances from related companies	8,323,980	6,751,363
Repayments from related companies	<u>1,925,000</u>	<u>3,041,644</u>
	<u>10,248,980</u>	<u>9,793,007</u>

Notes to the Financial Statements

31 March 2015

17. Financial Instruments

At the year end, the company's main financial assets on the statement of financial position comprised receivables and cash at bank. At the year end there were no unreported financial assets in the statement of financial position.

At the year end, the company's main financial liabilities on the statement of financial position consisted of amounts due to related companies, trade payables and accruals. At year end the company had no unreported financial liabilities in the statement of financial position.

Timing of cash flows

The presentation of the financial assets and liabilities listed above under the current and non-current headings within the statement of financial position is intended to indicate the timing in which cash flows will arise.

Credit risk

Financial assets which potentially subject the company to concentrations of credit risk consist principally of trade receivables and cash at bank. The company's cash is placed with prime financial institutions. Trade receivables are presented net of impairment provision.

Fair values of non-derivative financial instruments

At 31 March 2015 the carrying amounts of cash at bank and in hand, receivables and payables approximated their fair values. The fair values of long-term borrowings are not materially different from their carrying amounts.

18. Contingent Liabilities

At 31 March 2015, guarantees amounting to €500 (2014: €500) were given by the company with regards to bank facilities of company. As at that date, the company had no contingent liabilities which affect the financial position of the company.

19. General Information

APL Swift Services (Malta) Limited is a limited liability company domiciled and incorporated in Malta.

Registered number
98776

APL IP Company Limited

Report and Accounts

31 March 2015

**APL IP Company Limited
Report and accounts
Contents**

	Page
Company information	1
Directors' report	2
Statement of directors' responsibilities	3
Strategic report	4
Independent auditors' report	5
Profit and loss account	6
Balance sheet	7
Cash flow statement	8
Notes to the accounts	9 to 11

APL IP Company Limited
Company Information

Directors

Mr Frederick Schembri
Mr Venugopalan Muralidharan

Secretary

Verite Secretaries Limited

Auditors

The Corporate Practice Limited
Chartered Accountants and Registered Auditors
65 Delamere Road
Hayes
Middlesex
UB4 0NN

Bankers

HSBC Bank PLC
8 Library Place
St Helier
Jersey
JE4 8NU

Registered office

1st Floor
37 Broad Street
St Helier
Jersey
JE2 3RR

Registered number

98776

APL IP Company Limited

Registered number:

98776

Directors' Report

The directors present their report and accounts for the year ended 31 March 2015.

Principal activities

The company's principal activity during the year continued to be procuring marketing authorisations and granting licences for pharmaceutical products. The company's performance during the year is set out on page 4.

Dividends

The directors do not recommend any dividends for the period.

Directors

The following persons served as directors during the year:

Mr Frederick Schembri


Mr Venugopalan Muralidharan

Disclosure of information to auditors

Each person who was a director at the time this report was approved confirms that:

- so far as he is aware, there is no relevant audit information of which the company's auditor is unaware; and
- he has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditor is aware of that information.

This report was approved by the board on ^{19th} May 2015 and signed on its behalf.


Mr Frederick Schembri
Director

APL IP Company Limited
Statement of Directors' Responsibilities

The directors are responsible for preparing the report and accounts in accordance with applicable law and regulations.

Company law requires the directors to prepare accounts for each financial year. Under that law the directors have elected to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these accounts, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the accounts;
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the accounts comply with the applicable law. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

APL IP Company Limited Strategic Report

Review of the business

The management has decided to cease development activity for APL IP products and as such, the profit and loss charge in the period is substantially high.

Future developments

The directors feel that the company will strive to wind down its activity in near future.

Key performance indicators

	Year ended 31 March 2015	Year ended 31 March 2014
Turnover	€0	€0
(Loss)/Profit for the year	€(3,577,650)	€(6,821,173)

Principal risks and uncertainties:

The company's main areas of risk are as follows:

Financial instrument risk

The company's major financial instruments comprise bank balance. The main objective of these instruments is to raise funds and finance company's operations. The objective of the management framework of the company is to shelter the company from events which may hinder the company's performance targets and to ensure that sufficient funds exist for working capital.

Regulatory risk

The company relies on other group companies' regulatory teams to insure that the company adheres to all the applicable pharmaceutical regulations.

Price risk

The price of pharmaceutical intellectual properties can fluctuate widely depending up on the supply and competition. The risk is managed by reviewing the carrying value at the year end.

Foreign exchange risk

The company transacts in foreign currencies. The risk is managed by monitoring foreign exchange rates on periodic basis.

Credit risk

The company mainly deals with group companies. Outstanding amounts are regularly monitored.


Liquidity risk

The company manages its cash flow to ensure that sufficient liquid resources are available to meet its obligations.

Interest rate and cash flow risk

The company maintain a positive cash balance. It does not have borrowing from group undertaking or from external entities. The company does not use derivative financial instrument to manage interest rate costs and as such no hedge accounting is applied.

This report was approved by the board on 19th May 2015 and signed on its behalf.


Mr. Frederick Schembri
Director

APL IP Company Limited
Independent auditors' report
to the members of APL IP Company Limited

We have audited the accounts of APL IP Company Limited for the year ended 31 March 2015 which comprise the Profit and Loss Account, the Balance Sheet, the Cash Flow Statement and the related notes. The financial reporting framework that has been applied in their preparation is applicable law, the International Standard on Auditing (UK and Ireland) and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the company's directors. Our audit work has been undertaken so that we might state to the company's directors those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's directors, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

As explained more fully in the Statement of Directors' Responsibilities, the directors are responsible for the preparation of the accounts and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the accounts in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the accounts

A description of the scope of an audit of financial statements is provided on the APB's website at www.frc.org.uk/auditscopeukprivate

Opinion on the accounts

In our opinion the accounts:

- give a true and fair view of the state of the company's affairs as at 31 March 2015 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the applicable law.


Opinion on other matters

In our opinion the information given in the Directors' Report and the Strategic Report for the financial year for which the accounts are prepared is consistent with the accounts.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the applicable law requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the accounts are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.



Mr Devender Arora
(Senior Statutory Auditor)
for and on behalf of
The Corporate Practice Limited
Accountants and Statutory Auditors

19 May 2015

65 Delamere Road
Hayes

Middlesex
UB4 0NN

APL IP Company Limited
Profit and Loss Account
for the year ended 31 March 2015

	Notes	2015 €	2014 €
Administrative expenses		(3,577,650)	(6,821,173)
Operating loss	2	<u>(3,577,650)</u>	<u>(6,821,173)</u>
Loss on ordinary activities before taxation		<u>(3,577,650)</u>	<u>(6,821,173)</u>
Tax on loss on ordinary activities		-	-
Loss for the financial year		<u>(3,577,650)</u>	<u>(6,821,173)</u>

Continuing operations

The company's product licencing activities were discontinued during the above two financial years.

Statement of total recognised gains and losses

The company has no recognised gains or losses other than the loss for the above two financial years.

APL IP Company Limited
Balance Sheet
as at 31 March 2015

	Notes	2015 €	2014 €
Fixed assets			
Intangible assets	3	-	3,602,078
Current assets			
Debtors	4	1,798	1,880,652
Cash at bank and in hand		113,099	19,744
		<u>114,897</u>	<u>1,900,396</u>
Creditors: amounts falling due within one year	5	(7,087)	(1,817,014)
Net current assets		<u>107,810</u>	<u>83,382</u>
Net assets		<u>107,810</u>	<u>3,685,460</u>
Capital and reserves			
Called up share capital	6	105,383	105,383
Profit and loss account	7	2,427	3,580,077
Shareholders' funds	8	<u>107,810</u>	<u>3,685,460</u>


 Mr. Frederick Schembri
 Director

Approved by the board on 19th May 2015

APL IP Company Limited
Cash Flow Statement
for the year ended 31 March 2015

	Notes	2015 €	2014 €
Reconciliation of operating profit to net cash inflow from operating activities			
Operating loss		(3,577,650)	(6,821,173)
Depreciation and amortisation		3,602,078	6,767,506
Decrease in debtors		1,878,854	5,125,148
Decrease in creditors		(1,809,927)	(5,072,551)
Net cash inflow/(outflow) from operating activities		<u>93,355</u>	<u>(1,070)</u>
CASH FLOW STATEMENT			
Net cash Inflow/(outflow) from operating activities		93,355	(1,070)
Increase/(decrease) in cash		<u>93,355</u>	<u>(1,070)</u>
Reconciliation of net cash flow to movement in net debt			
Increase/(decrease) in cash in the period		93,355	(1,070)
Change in net debt	9	<u>93,355</u>	<u>(1,070)</u>
Net funds at 1 April		<u>19,744</u>	<u>20,814</u>
Net funds at 31 March		<u>113,099</u>	<u>19,744</u>

APL IP Company Limited
Notes to the Accounts
for the year ended 31 March 2015

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with applicable United Kingdom Accounting Standards.

Amortisation of product registrations

Product registrations are valued at cost less accumulated amortisation. Amortisation is calculated to write off the the cost in equal annual instalments over their estimated useful lives of five years, from the date on which products, for which marketing authorisation are held, are commercialised.

Foreign currencies

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the profit and loss account.

Taxation

The company does not provide for any tax liability on the profits in view of the zero rate tax status of the company.

2 Operating profit	2015	2014
	€	€
This is stated after charging:		
Amortisation of goodwill	3,602,078	6,767,506
Auditors' remuneration for audit services	<u>3,750</u>	<u>5,825</u>
3 Intangible fixed assets		€
Product registrations:		
Cost		
At 1 April 2014		<u>24,309,789</u>
At 31 March 2015		<u>24,309,789</u>
Amortisation		
At 1 April 2014		20,707,711
Provided during the year		<u>3,602,078</u>
At 31 March 2015		<u>24,309,789</u>
Net book value		
At 31 March 2015		-
At 31 March 2014		<u>3,602,078</u>

Product registrations are being written off in equal annual instalments over its estimated economic life of 5 years.

There is no activity of sub-licensing of the products for Europe to Aurobindo Pharma (Malta) Ltd (only customer of the company) for the two financial years 2013/14 and 2014/15 and no further business activity has been anticipated for these products. Hence the development cost which has been left over in the books of account has been amortized fully during the current financial year.

APL IP Company Limited
Notes to the Accounts
for the year ended 31 March 2015

4 Debtors			2015	2014
			€	€
Amounts owed by group undertakings and undertakings in which the company has a participating interest			-	1,878,990
Prepayments and accrued income			1,798	1,662
			<u>1,798</u>	<u>1,880,652</u>
5 Creditors: amounts falling due within one year			2015	2014
			€	€
Amounts owed to group undertakings and undertakings in which the company has a participating interest			-	1,812,514
Other creditors			3,337	-
Accruals and deferred income			3,750	4,500
			<u>7,087</u>	<u>1,817,014</u>
6 Share capital	Nominal value	2015 Number	2015	2014
			€	€
Allotted, called up and fully paid:				
Ordinary shares	€1 each	105,383	<u>105,383</u>	<u>105,383</u>
7 Profit and loss account			2015	
			€	
At 1 April 2014			3,580,077	
Loss for the financial year			(3,577,650)	
At 31 March 2015			<u>2,427</u>	
8 Reconciliation of movement in shareholders' funds			2015	2014
			€	€
At 1 April			3,685,460	10,506,633
Loss for the financial year			(3,577,650)	(6,821,173)
At 31 March			<u>107,810</u>	<u>3,685,460</u>
9 Analysis of changes in net debt				
	At 1 Apr 2014	Cash flows	Non-cash changes	At 31 Mar 2015
	€	€	€	€
Cash at bank and in hand	19,744	93,355		113,099
Total	<u>19,744</u>	<u>93,355</u>	<u>-</u>	<u>113,099</u>

10 Related party transactions

The company has this year taken advantage of the exemption provided by Financial Reporting Standard 8 not to disclose transaction with other members of the Aurobindo Pharma Group.

APL IP Company Limited
Notes to the Accounts
for the year ended 31 March 2015

11 Ultimate holding company

The directors consider the immediate and ultimate parent companies to be APL Holdings (Jersey) Limited, a company registered in Jersey and Aurobindo Pharma Limited a company incorporated in India respectively.

The published consolidated accounts of the Ultimate Holding Company can be obtained from Plot No. 2 Maltrivihar, Ameerpet, Hyderabad 500038 India.



Aurobindo Pharma GmbH, Munich

Directors Report as of 31.03.15

1. Bases and framework conditions

Aurobindo Pharma GmbH (in short: Aurobindo) is a provider of generic products. The focus is mainly on the prescription segment and on tender participation.

Fundamentally speaking, the German market for generics is one of the most difficult in the world, since, on the one hand, gross prices are regularly (mainly at annual intervals) adjusted downwards through reductions in reference prices and, on the other hand, the tender system has been established since 2007 to the market. These two regulators are turning a growing gross market into a shrinking net market.

Aurobindo has been affected by the measures that are reducing the costs of the German healthcare system. In 2014/2015, the market for generic products for the distribution channels wholesale and pharmacies was again characterised to a major extent by discount contracts as defined in Sections 129 and 130 of the SGB (Code of Social Law). These contracts are causing a redistribution of existing market shares. Volume growth is typically accompanied by a drastic reduction in product margins.

Additionally, "open house" discount contracts ensure savings for the health insurance funds after patent expiry period and tender calls.

The German pharmaceuticals market (retail)

The overall German pharmaceuticals market – valued at manufacturer's selling prices – totalled approx. EUR 22.7 billion current year; this equates to an increase of 7% compared to prior year (EUR 21.3 billion). This increase is driven mainly by an increase in sales (+13%) of patent-protected pharmaceuticals from EUR 8.3 billion (PY) to EUR 9.4 billion (CY). The background to this growth is new drugs and price increases.

The German generics market (retail)

The pure generics market – valued at manufacturer's selling prices – totalled EUR 4.9 billion (CY) (PY: EUR 4.8 billion); this equates to an increase of 2%. Nevertheless, according to estimations of the IGES Institute, the statutory health insurance funds received discounts totalling EUR 3.15 billion. The discounts granted to the statutory health insurance funds have risen by a further 0.25 billion or 9% compared to PY. Following deduction of the discounts as per

Section 130a, Subsection 8, SGB V, this results in a purely net generics market of EUR 1.75 billion compared to EUR 1.92 billion PY.

If one considers the generics market as the sum of the "pure" generics market and of the patent-expired original products without generics competition, one arrives at a gross market of EUR 7.6 billion. To obtain a net picture, the discounts as per Section 130a, Subsection 8, SGB V as well as the discounts as per Section 130a, Subsection 1, SGB V must be reduced. As these are not available in fully transparent form, we assume a net market of approx. EUR 4.45 billion.

In summary, it can be stated that, in 2014/2015, generics covered 76% of the pharmaceuticals requirement of the statutory health insurance funds, while the real costs of the statutory health insurance funds for these declined compared to the previous year.

The discount contracts (as per Section 130a, Subsection 8, SGB V)

Since 2013, several fundamental changes in the field of discount contracts have been observed.

Health insurance funds are increasingly offering the contracts for tender on a semi-exclusive basis, that means mostly 3 competitors are awarded for the contracts. This increases the security of supply for the health insurance funds but makes planning of volumes more difficult, particularly for small and medium-sized providers. This approach mainly helps the established large players who obtain the main share of the volumes offered in the semi-exclusive tenders.

A majority of the health insurance funds are now concluding what are known as "open-house contracts" with all interested companies immediately after the patent expiry of an active ingredient. The parameters of these contracts are fixed by the health insurance funds.

Currently, the ECJ is reviewing whether these open-house contracts comply with procurement law. A ruling is expected in late 2015 or early 2016.

Changes to reference prices

As in recent years, the reference prices were again adjusted in 2014/2015. In this respect, there were several rounds on individual active ingredients groups.

Group incorporation

Aurobindo is hold by its shareholder Agile Pharma B.V., seated in The Netherlands. Agile Pharma B.V. belongs to Aurobindo Pharma Ltd. This company is listed on the New Delhi and Mumbai Stock Exchange.

2. Economic report (business developments, trading result, net-worth, financial and earnings position)

It must first of all be stated that business has developed positively:

1. Aurobindo has again increased market shares. Compared to prior year, the market share in the retail market could be increased from 0.72% to 0.93% in 2014/2015.
2. Net Sales increased by 36% compare to prior year. In terms of absolute figures, sales showed a increase from EUR 6.77 million (PY) to EUR 10.69 million in 2014/2015. The main reasons are portfolio growth, new tender awards and good sales (Finasterid, Levetiracetam, Sumatriptan and ARV products).

Key performance indicators/management ratios

- a. Market share
Market share is an important management factor for Aurobindo and is mainly evaluated on an INN or molecule basis.
- b. Since 2012, market share is consistently increasing due to portfolio growth and successful tender participation.
As in previous years, top molecules are Finasterid and Sumatriptan.
- c. Sales
The central management factor for Aurobindo is net sales. A strong focus is placed here on deductions (above all discounts as per Section 130a, Subsection 8, SGB V). Given the massive discounts in the tender business, gross sales is an auxiliary factor only.
- d. Result on ordinary activities
The result on ordinary activities is the third central management factor. The main driving forces are the gross margin as well as the function costs.

There are no key non-financial management factors

Earnings position

Net sales revenues in the tender business increased from EUR 6.77 million in 2013/2014 to EUR 10.69 million in 2014/2015.

The gross profit stays stabile in comparison with the previous year on 12.2%.

Personnel costs have increased from EUR K 433 in 2013/2014 to EUR K 631 in 2014/2015. This increase is mainly related to higher staff number.

Depreciation has increased from EUR K 183 in 2013/2014 to EUR K 519 in 2014/2015.

Other operating expenses include a provision for contractual penalties due to short supply of EUR K 440.

The profit of the year in 2014/2015 is 1.3 million EUR.

Cash position

Cash Balance increased from EUR K 640 in 2013/2014 to EUR 5.6 million in 2014/2015. Short term loans to Agile B.V. have been granted in amount of EUR 6.39 million.

3. Forecast report

The following comments refer to the future and are thus uncertain by their nature. Actual events can deviate significantly from expectations.

The future profitability of the Company (in particular in the medium and long term) will depend above all on the developments in the German healthcare system and the resulting effects on the pharmaceuticals sector. However, it is difficult to predict these from today's perspective.

The trend towards market concentration in recent years, driven by the discount model for generics products, will continue.

In 2015/2016, we expect net sales to fall by 10–20% in comparison to 2014/2015, the reason for this is expiry of huge AOK tender and prediction of new AOK tender awards is not possible. However, as far as the gross margin is concerned, we are expecting an increase as spill over effects of expired AOK tender products will impact earnings positively.

Based on these planning assumptions, we reckon with a profitable result on ordinary activities in 2015/2016.

4. Report on opportunities and risks

The future development of the Company will be determined to a fundamental extent by developments in the German pharmaceuticals and generics market. We do not currently expect any far-reaching changes for the year 2015/2016.

New opportunities are arising in the generics market as a result of expiring patents and the launch of new products. In 2015/2016, only a few products will lose their patent protection.

In the field of health insurance fund tenders, there will be opportunities in the new tender rounds. However, we are expecting declining sales for the 2015/2016 financial year due to reduced discount contracts with health insurance funds. Nevertheless, the gross margin will increase slightly due to spill over effects to that of 2014/2015.

There were no significant new opportunities in the financial year compared to the previous year.

As a result of the incorporation of local risk management into the group's risk management strategy, we are able to ensure that risks are recognized in good time and that we are able to respond to these risks in an appropriate manner.

We have identified the following risks in particular:

Market risks

Changes in health policy, such as reductions in reference prices, new compulsory discounts, price moratoriums, are politically driven. Our involvement in associations means that we become aware of these developments at an early stage.

Product and approval risks

In the main, the risks are comparable for all manufacturers of a specific generics product. For this reason we see no particular risk.

Quality risks


All pharmaceuticals companies are faced by a risk of quality problems. In addition to the local quality assurance, concern offers support in order to minimise these risks.

We have also identified legal risks (e.g. risks of patent infringements) and supply chain risks (supply from parent company shows consistently delays and deviations in dispatch dates) as well as IT, tax and employee risks.

No significant new risks have become known compared to the previous year.

Munich, 11 May 2015

For Aurobindo Pharma GmbH


Alexander Fiedel



PricewaterhouseCoopers Aktiengesellschaft Wirtschaftsprüfungsgesellschaft
Bernhard-Wicki-Straße 8 80636 München

S.R. Batliboi & Associates LLP
Oval Office 18
1 Labs Center
Hitec City
Madhapur
Hyderabad 500 081
India

PricewaterhouseCoopers
Aktiengesellschaft
Wirtschaftsprüfungsgesellschaft

Bernhard-Wicki-Straße 8
80636 München
Postfach 21 02 63
80672 München
www.pwc.de

Tel.: +49 89 5790-50
Fax: +49 89 5790-5999

May 19, 2015

Auditor's Report – Aurobindo Pharma GmbH, Munich

As requested in your instructions dated April 4, 2015, we have audited for purposes of your audit of the consolidated financial statements of Aurobindo Pharma Limited, India, the accompanying balance sheet as of March 31, 2015, and the income statement for the 12 months ended March 31, 2015 of Aurobindo Pharma GmbH, Munich (the "financial information").

Management's Responsibility

The Management of Aurobindo Pharma GmbH, Munich, is responsible for the preparation of the financial information in accordance with German Commercial Law ("Handelsgesetzbuch": "German Commercial Law"). Management is also responsible for such internal control as management determines is necessary to enable the preparation of the financial information that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial information based on our audit. We conducted our audit of the financial information in accordance with German generally accepted standards for the audit of financial statements promulgated by the Institut der Wirtschaftsprüfer ("IDW") (Institute of Public Auditors in Germany). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial information is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and related disclosures in the financial information. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial information, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the financial information in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial information.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Vorsitzender des Aufsichtsrats, WP StB Dr. Norbert Vogelpoth
Vorstand, WP StB Prof. Dr. Norbert Winkeljohann, WP StB Dr. Peter Bartels, WP StB CPA Markus Burghardt, StB Prof. Dr. Dieter Endres, WP StB Petra Justenhoven,
WP StB Prof. Dr. Georg Kämpfer, WP StB Harald Kayser, WP RA StB Dr. Jan Konecny, StB Marius Möller, WP StB Martin Scholich
Sitz der Gesellschaft Frankfurt am Main, Amtsgericht Frankfurt am Main HRB 44845
PricewaterhouseCoopers Aktiengesellschaft Wirtschaftsprüfungsgesellschaft is member of PricewaterhouseCoopers International, a Company limited by guarantee registered in England and Wales

Audit Opinion

In our opinion based on the findings of our audit, the financial information has been prepared, in all material respects, in accordance with German Commercial Law ("Handelsgesetzbuch": "German Commercial Code").

Restriction on purpose, use and distribution

The financial information has been prepared solely for purposes of providing information to Aurobindo Pharma Limited, India, to enable it to prepare the consolidated financial statements of the group. As a result, the financial information is not a complete set of financial statements of Aurobindo Pharma GmbH, Munich, in accordance with the requirements of German Commercial Law and may, therefore, not be suitable for another purpose.


This report is intended solely for S.R. Batliboi & Associates LLP, Hyderabad, India, and shall not be used by or distributed to other parties. This report is confidential and shall not be published or referred to in a public document or any other public media.

Terms of Engagement

We issue this report on the basis of the engagement agreed with Aurobindo Pharma GmbH, Munich, which comprises the attached General Terms of Engagement for Wirtschaftsprüfer and Wirtschaftsprüfungsgesellschaften as of January 1, 2002, which are also applicable to third parties.

This report shall be exclusively governed by and construed in accordance with German law without giving effect to the provisions relating to private international law (Internationales Privatrecht). Exclusive place of jurisdiction for any action or other legal proceedings arising out of or in connection with this report shall be Frankfurt am Main, Germany.

**PricewaterhouseCoopers
Aktiengesellschaft
Wirtschaftsprüfungsgesellschaft**



Stefano Mulas
Wirtschaftsprüfer
(German Public Auditor)



Dietmar Eglauer
Wirtschaftsprüfer
(German Public Auditor)

Aurobindo Pharma GmbH
Balance Sheet as at March 15, 2015

(All amounts are in € except share data and unless otherwise stated)

	Note	31 March, 2015 (Euro)	31 March, 2014 (Euro)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	25.000	25.000
Share application money			
Reserves and surplus	3	3.443.604	2.129.780
		3.468.604	2.154.780
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	13.351.986
Other long-term liabilities	6	-	518.275
Long-term provisions	7	-	-
		-	13.870.261
Current liabilities			
Short-term borrowings	8	-	151.771
Trade payables	9	1.748.383	3.479.182
Other current liabilities	9	27.235.912	-
Short-term provisions	7	-	-
		28.984.295	3.630.953
TOTAL		32.452.899	19.655.994
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	21.923	15.659
Intangible assets	11	2.177.683	1.971.055
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	-	-
Trade receivables	14,1	-	-
Other non-current assets	14,2	-	-
		2.199.606	1.986.714
Current assets			
Current investments	15	-	-
Inventories	16	2.946.352	2.461.805
Trade receivables	14,1	15.221.396	9.510.148
Cash and bank balances	17	5.686.082	640.600
Short-term loans and advances	13	6.399.465	5.056.728
Other current assets	14,2	-	-
		30.253.294	17.669.281
TOTAL		32.452.900	19.655.995
Summary of significant accounting policies			
	1		

The accompanying notes are an integral part of the financial statements.

 PricewaterhouseCoopers AG, München
 Initialed for Identification Purposes Only
 Initial: MDI 7.5.2015

Aurobindo Pharma GmbH

Statement of profit and loss for 12 Months Period ended March 31, 2015

(All amounts are in € except share data and unless otherwise stated)

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	12 Months Period ended March 31, 2015 (Euro)	Year ended March 31, 2014 (Euro)
Income															
Revenue from operations (gross)	18	3,512,540	4,030,353	3,351,007	4,424,754	3,446,285	3,400,153	3,645,498	3,931,080	4,807,007	3,687,788	4,765,158	4,372,167	47,373,789	32,754,799
Less: Excise duty/Rebates		2,845,157	3,264,583	2,714,316	3,583,900	2,722,565	2,686,120	2,879,944	3,105,553	3,797,535	2,913,988	3,764,475	2,622,373	36,900,509	26,989,378
Revenue from operations (net)		667,383	765,770	636,691	840,854	723,720	714,033	765,554	825,527	1,009,472	773,800	1,000,683	1,749,794	10,473,280	5,765,421
Other income	19	1,976	11	30,787	73,867	1,239	18	3	5,341	5,140	3,917	7,058	90,852	220,208	1,009,832
Total revenue (I)		669,359	765,781	667,478	914,721	724,958	714,051	765,558	830,868	1,014,612	777,717	1,007,741	1,840,646	10,693,489	6,775,253
Expenses															
Cost of raw material and components consumed	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods	21	331,118	688,446	454,521	313,311	452,171	495,071	338,029	651,383	477,090	625,098	429,988	913,701	6,169,927	5,019,300
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	(254,602)	(12,321)	45,407	124,263	(239,110)	181,569	178,921	(258,447)	(33,596)	(203,852)	255,147	(267,926)	(484,547)	(1,438,070)
Employee benefit expense	22	38,095	39,071	33,111	36,219	28,868	86,442	41,488	40,994	39,670	39,907	39,207	167,957	631,028	433,043
Other expenses	23	70,297	159,440	103,494	160,823	216,528	174,136	115,833	133,679	389,853	180,387	212,844	623,791	2,541,103	1,729,618
Exceptional items	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total (II)		184,907	874,636	636,532	634,615	458,457	937,218	674,271	567,609	873,016	641,540	937,186	1,437,523	8,857,511	5,743,891
Earnings before interest, tax, depreciaton and amortization (EBITDA) (I)-(II)		484,452	(108,855)	30,946	280,105	266,502	(223,168)	91,287	263,258	141,595	136,177	70,555	403,124	1,835,978	1,031,362
Depreciation and amortization expense	25	20,006	21,410	39,916	28,635	30,942	32,803	32,548	32,982	30,610	30,611	37,724	181,272	519,459	188,336
Finance costs	26	245	-	1,146	45	100	432	248	2	348	81	-	48	2,695	7,600
Profit/(loss) before tax		464,201	(130,265)	(10,117)	251,425	235,460	(256,402)	58,492	230,275	110,637	105,485	32,831	221,804	1,313,824	835,426
Tax expenses															
Current tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: MAT credit entitlement		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fringe benefit tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax relating to previous years		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total tax expense		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Profit/(loss) for the Current Period/year		464,201	(130,265)	(10,117)	251,425	235,460	(256,402)	58,492	230,275	110,637	105,485	32,831	221,804	1,313,824	835,426

Summary of significant accounting policies

1

The accompanying notes are an integral part of the financial statements.

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MPI 7 S. 2015

12 Months column only

Note 1 : Summary of significant accounting policies (Refer General Instructions Note No.11)

The annual financial statements have been prepared in accordance with the regulations of the Income Tax Act and, where Assets are valued on the assumption that the business will continue.

Accounting and valuation were carried out taking account of the general rules of valuation and at the same time observing the In so far as they were purchased, intangible assets were valued at initial costs and were reduced as necessary by scheduled Tangible assets were valued at initial or manufacturing costs less scheduled depreciation. Material and manufacturing Depreciation is provided on straight-line.

In the case of goods purchased for resale, the stocks are valued at weighted average or manufacturing costs at the lower fair Receivables and other assets are valued at nominal value taking into account all acknowledged risks.

Liabilities were valued at the repayment amount.

Foreign currencies were valued at the current rate.

Provisions for tax and other provisions take account of all recognisable risks and uncertain obligations and are fixed at full value

Note 2 : Share capital (Refer General Instructions Note No.2)

	Mar 31, 2015	March 31, 2014
Authorised shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of XXXX each		
XXXXXXXX (31 March, 2014: XXXXXXXX) preference shares of XXX each		
Issued, Subscribed and Fully Paid-up shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of XXXX each fully paid-up	25.000	25.000

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 7.5.2015

Aurobindo Pharma GmbH
Notes to the Balance Sheet
 (All amounts are in € except share data and unless otherwise stated)

Note 3 : Reserves and surplus (Refer General Instructions Note No.3)

	Mar 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	3.666.000	3.666.000
	3.666.000	3.666.000
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet	-	-
General Reserve		
As per last Balance Sheet	-	-
Add: Transferred from statement of profit and loss	-	-
	-	-
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	(1.536.220)	(2.371.646)
Profit for the year	1.313.824	835.426
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)		
Tax on proposed equity dividend		
Interim dividend paid (amount per share XX (31 March, 2014 XX)		
Transfer to general reserve		
Total appropriations	-	-
Net surplus in the statement of profit and loss	(222.396)	(1.536.220)
Total reserves and surplus	3.443.604	2.129.780

Note 4 : Long-term borrowings (Refer General Instructions Note No.4)

	Non-current Portion	Current maturities	
	March 31, 2014	Mar 31, 2015	March 31, 2014
Term Loans			
From banks (Secured)			
Other Loans from banks			
Current account credit balance			
Loans and advances from related parties			
Other Loans and advances			
Sales tax deferment loan (Un Secured)			
	-	-	-
The above amount includes			
Secured borrowings			
Unsecured borrowings			
Amount disclosed under the head			
"Other current liabilities"			
Net Amount	-	-	-

PricewaterhouseCoopers AG, München
 Initialed for Identification Purposes Only
 Initial: MDI 7.5.2015

Note 5 : Deferred tax liability (net)		Mar 31, 2015	March 31, 2014
Deferred tax liability			
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis			
Provision for diminution in the value of investments			
Provision for doubtful debts and advances			
Fixed Assets (Depreciation)			
Retirement Benefits			
Others			
Gross deferred tax liability		-	-
Deferred tax asset			
Carried Forward Business Losses			
Others			
Gross deferred tax asset		-	-
Net deferred tax liability		-	-

Note 6 : Other long-term liabilities (Refer General Instructions Note No.5)		Mar 31, 2015	March 31, 2014
Trade payables (including acceptances)			13,351,986
Others			
Advances from customers			
Unclaimed dividends			
Other liabilities			518,275
Interest accrued but not due on loans			
Advances from related parties			
		-	518,275
		-	13,870,261

Note 7 : Provisions (Refer General Instructions Note No.6 & 10)		Non-current		Current	
		Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Provision for employee benefits					
- Gratuity					
- Leave encashment					
		-	-	-	-
Other Provisions					
For Taxation (net of advance payments)					
For Proposed dividend					
For Tax on proposed dividend					
		-	-	-	-
		-	-	-	-

Provision for warranties		Mar 31, 2015	March 31, 2014
At the beginning of the year			
Arising during the period			
Utilised during the period			
Unused amounts reversed			
At the end of the Quarter		-	-
Current portion			
Non-current portion			

Note 8 : Short-term borrowings (Refer General Instructions Note No.7)		Mar 31, 2015	March 31, 2014
Bank overdraft			
Loans and advances from related parties			151,771
Working capital loans (Secured)			
Short term loans (Un Secured)			
Working capital loans			
		-	151,771
The above amount includes			
Secured borrowings		-	-
Unsecured borrowings		-	-

Note 9 : Other current liabilities (Refer General Instructions Note No.9)		Mar 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)		1,748,383	3,479,182
Other liabilities			
Current maturities of long-term borrowings			
Trade deposits		27,235,912	
		27,235,912	-
		28,984,295	3,479,182

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
initial: MDI 7.5.2015

Aurobindo Pharma GmbH

Notes to the Balance Sheet

(All amounts are in € except share data and unless otherwise stated)

Note 10 : Tangible assets (Refer General Instructions Note No.11)

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment (including Computers & Software)	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation									
At 1 April 2013					4.954	22.374			27.328
Additions					7.953	4.239			12.192
Disposals									-
Other adjustments									
- Exchange differences									-
- Borrowing costs									-
At 31 March 2014		-	-	-	12.907	26.614	-	-	39.520
Additions					9.374	4.580			13.954
Acquisitions through amalgamation									-
Disposals									-
Other adjustments									
- Exchange differences									-
- Borrowing costs									-
At 31 March 2015	-	-	-	-	22.281	31.194	-	-	53.474
Depreciation									
At 1 April 2013					1.795	17.444			19.239
Charge for the year					575	4.047			4.622
Disposals									-
Other adjustments									
- Exchange differences									-
At 31 March 2014	-	-	-	-	2.370	21.491	-	-	23.861
Charge for the period					2.350	5.340			7.690
Disposals									-
Other adjustments									
- Exchange differences									-
At 31 March 2015	-	-	-	-	4.720	26.831	-	-	31.551
Impairment loss									
At 1 April 2013									
At 31 March 2014									
Charge for the period									
At 31 March 2015									

Aurobindo Pharma GmbH

Notes to the Balance Sheet

(All amounts are in C except share data and unless otherwise stated)

Net Block

At 31 March 2014	-	-	-	-	10.537	5.122	-	-	15.659
At 31 March 2015	-	-	-	-	17.561	4.362	-	-	21.923

Note 11 : Intangible assets (Refer General Instructions Note No.12)

	software	Product Development cost	Licences and patents	Total
Gross block				
At 1 April 2013	2.017		1.587.834	1.589.851
Purchase	8.000		826.171	834.171
Internal development				-
Disposals			65.328	65.328
Other adjustments				-
- Exchange differences				-
At 31 March 2014	10.017	-	2.348.677	2.358.694
Purchase	11593		662.713	674.306
Acquisitions through amalgamation				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At 31 March 2015	21.610	-	3.011.390	3.033.000
Amortization				
At 1 April 2013	2.412		201.913	204.325
Charge for the year			183.314	183.314
Disposals				-
Other adjustments				-
- Exchange differences				-
At 31 March 2014	2.412	-	385.227	387.639
Charge for the period	2617		509.152	511.769
Disposals				-
Other adjustments			44.090	44.090
- Exchange differences				-
At 31 March 2015	5.029	-	850.289	855.318
Net Block				
At 31 March 2014	7.605	-	1.963.450	1.971.055
At 31 March 2015	16.581	-	2.161.102	2.177.683

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 7.5.2015

Note 12: Non-current investments (Refer General Instructions Note No.13)

	Mar 31, 2015	March 31, 2014
Unquoted equity instruments		
Investment in subsidiaries		
Investment in joint ventures		
Investment in associates		
	-	-

Note 13: Loans and advances (Refer General Instructions Note No.14 & 21)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Capital advances				
Secured, considered good				
Unsecured, considered good				
(A)	-	-	-	-
Security deposit				
Secured, considered good			28.000	28.000
Unsecured, considered good				
Doubtful				
	-	-	28.000	28.000
Provision for doubtful security deposit				
(B)	-	-	28.000	28.000
Loan and advances to related parties				
Unsecured, considered good			5.500.000	4.750.000
(C)	-	-	5.500.000	4.750.000
Advances recoverable in cash or kind				
Secured, considered good				277.052
Unsecured, considered good			863.068	
Doubtful				
	-	-	863.068	277.052
Provision for doubtful advances				
(D)	-	-	863.068	277.052
Other loans and advances				
Advance income-tax (net of provision for taxation)				
Prepaid expenses			8.397	1.676
Loans to employees				
Loans to others				
Export incentives receivable				
Export incentives licenses				
Balances with Statutory/government authorities				
(E)	-	-	8.397	1.676
Total (A+B+C+D+E)	-	-	6.399.465	5.056.728

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors				
Dues from officers				
Dues from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner				
Dues from in which the company's managing director is a member				
Dues from the partnership firm in which the company's non-executive director is a partner				

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
initial: MDI 7.5.2015

Note 14 : Trade receivables and other assets

14.1 Trade receivable (Refer General Instructions Note No. 1 to 19)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others			60.670	24.665
Doubtful	-	-	60.670	24.665
Provision for doubtful receivables	-	-	-	-
(A)	-	-	60.670	24.665
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies			59.686	
Due from others			15.101.040	9.485.483
Doubtful	-	-	15.160.726	9.485.483
Provision for doubtful receivables	-	-	-	-
(B)	-	-	15.160.726	9.485.483
Total (A+B)	-	-	15.221.396	9.510.148

Trade receivables include:

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				

14.2 Other assets (Refer General Instructions Note No. 10 to 22)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)	-	-	-	-
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)	-	-	-	-
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on investments in subsidiaries - long term				
Others				
(C)	-	-	-	-
Total (A+B+C)	-	-	-	-

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 7.5.2015

Note 15 : Current investments (Refer General Instructions Note No.17)

	Mar 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any (Please specify)		

Note 16 : Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)

	Mar 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)		
Work - in - Progress		
Finished goods		
Traded goods (including stock -in-transit XXXX (31 March, 2014 XXX)	2.946.352	2.461.805
Stores, spares, consumables and packing materials		
Loose tools		
	2.946.352	2.461.805

Note 17 : Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			5.685.632	640.094
Deposits with original maturity of less than 3 months				
Cash credit accounts				
On unpaid dividend account				
Cheques/drafts on hand				
Unpaid matured deposits				
Cash on hand			450	506
			5.686.082	640.600
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
Amount disclosed under non-current assets			5.686.082	640.600

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 7.5.2015

12 Months column only

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 25.2.15

Aurobindo Pharma GmbH
Notes to the statement of profit and loss
(All amounts are in € except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-16	Mar-15	12 Months Period ended March 31, 2015 (Euro)	Year ended March 31, 2014 (Euro)
Note 18 : Revenue from operations (Refer General Instructions Note No.25)														
Revenue from operations														
Sale of products														
Finished goods													-	-
Traded goods	3,512,540	4,030,353	3,351,007	4,424,754	3,446,285	3,400,153	3,645,498	3,931,080	4,807,007	3,687,788	4,765,158	4,372,167	47,373,789	32,754,799
Sale of services													-	-
Sale of dossiers/licenses													-	-
Other operating revenue													-	-
Scrap sales													-	-
Other													-	-
Revenue from operations (gross)	3,512,540	4,030,353	3,351,007	4,424,754	3,446,285	3,400,153	3,645,498	3,931,080	4,807,007	3,687,788	4,765,158	4,372,167	47,373,789	32,754,799
Less: VAT/Excise duty/Rebates	2,845,157	3,264,583	2,714,316	3,583,900	2,722,565	2,686,120	2,879,944	3,105,553	3,797,535	2,913,988	3,764,475	2,622,373	36,900,509	26,989,378
Revenue from operations (net)	667,383	765,770	636,691	840,854	723,720	714,033	765,554	825,527	1,009,472	773,800	1,000,683	1,749,794	10,473,280	5,765,421

Note 19 : Other income (Refer General Instructions Note No.26)														
Interest income on														
Bank deposits	137		444	557	869	18	3	5,321	4,807	3,893	7,033	12,909	35,992	5,268
Long-term investments													-	-
Current investments													-	-
Loans to joint venture entities													-	-
Others													-	-
Dividend income on													-	-
Investment in subsidiaries													-	-
Current investments													-	-
Long-term investments													-	-
Net gain on sale of current investments													-	-
Profit on sale of fixed assets (net)													-	-
Foreign exchange gain (net)								20	233	-	-	-	253	20
Balances no longer required written back													-	-
Government grant													-	-
Commission income													-	-
Processing charges													-	-
Other non-operating income (net of expenses directly attributable to such income of Rs.XXXXX (31 March, 2014:XXXX))	1,839	11	30,343	73,309	370				100	23	25	77,943	183,963	1,004,544
	1,976	11	30,787	73,867	1,239	18	3	5,341	5,140	3,917	7,058	90,852	220,208	1,009,832

Note 20 : Cost of raw material and components consumed														
Inventory at the beginning of the period	-												-	-
Add: Purchases	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: inventory at the end of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-

221

Aurobindo Pharma GmbH

Notes to the statement of profit and loss

(All amounts are in € except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-16	Mar-15	12 Months Period ended March 31, 2015 (Euro)	Year ended March 31, 2014 (Euro)
Add:Packing material consumed														
Cost of raw material and components consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 21 : (Increase)/decrease in inventories														
Inventories at the end of the period														
Traded goods	2.716.407	2.728.728	2.683.321	2.559.058	2.798.168	2.616.599	2.437.678	2.696.125	2.729.721	2.933.573	2.678.425	2.946.352	2.946.352	2.461.805
GIT														-
Finished goods														-
	2.716.407	2.728.728	2.683.321	2.559.058	2.798.168	2.616.599	2.437.678	2.696.125	2.729.721	2.933.573	2.678.425	2.946.352	2.946.352	2.461.805
Inventories at the beginning of the period														
Traded goods	2.461.805	2.716.407	2.728.728	2.683.321	2.559.058	2.798.168	2.616.599	2.437.678	2.696.125	2.729.721	2.933.573	2.678.425	2.461.805	1.023.735
GIT														
Finished goods														
	2.461.805	2.716.407	2.728.728	2.683.321	2.559.058	2.798.168	2.616.599	2.437.678	2.696.125	2.729.721	2.933.573	2.678.425	2.461.805	1.023.735
	(254.602)	(12.321)	45.407	124.263	(239.110)	181.569	178.921	(258.447)	(33.596)	(203.852)	255.147	(267.926)	(484.547)	(1.438.070)
Details of purchase of traded goods														
Goods in stock	331.118	688.446	454.521	313.311	452.171	495.071	338.029	651.383	477.090	625.098	429.988	553.122	5.809.348	5.019.300
GIT												360.579	360.579	
Product C													-	
	331.118	688.446	454.521	313.311	452.171	495.071	338.029	651.383	477.090	625.098	429.988	913.701	6.169.927	5.019.300
Note 22 : Employee benefit expense														
Salaries, wages and bonus	31.521	33.572	28.260	30.948	24.606	79.683	35.425	34.714	33.690	33.754	33.572	161.447	561.191	369.042
Contribution to provident and other fund	6.573	5.499	4.851	5.271	4.855	6.758	6.063	6.280	5.980	6.153	5.635	6.510	70.428	63.949
Employee stock option scheme													-	
Gratuity expense													-	
Other employee benefits													-	
Post employment medical benefits													-	
Staff welfare expenses	1	-			(593)								(592)	52
	38.095	39.071	33.111	36.219	28.868	86.442	41.488	40.994	39.670	39.907	39.207	167.957	631.028	433.043
Note 23 : Other expenses														
Consumption of stores and spares													-	
Conversion charges													-	
Chemicals consumed													-	
Increase in VAT on finished goods													-	
Customer service expenditure									66.286			(66.286)	0	
Power and fuel													-	
Water charges													-	
Storage expenses	29.577	32.528	28.635	41.075	45.842	46.174	(9.042)	34.441	38.666	39.414	44.156	37.217	408.684	465.265
Freight and other services	2.674	1.502	2.708	4.486	1.516	1.671	1.013	3.607	1.544	2.443	2.164	2.950	28.277	
Carriage inward													-	
Carriage outwards													-	

Aurobindo Pharma GmbH

Notes to the statement of profit and loss

(All amounts are in € except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-16	Mar-15	12 Months Period ended March 31, 2015 (Euro)	Year ended March 31, 2014 (Euro)
Rent	3,257	3,257	3,257	3,257	3,461	5,081	4,865	4,865	3,489	4,865	5,065	5,065	49,780	37,334
Rates and taxes	36			147			1		11	68	-	0	262	
Insurance	49	49	12,866	6,064	73,104	9,028	14,245	9,170	18,198	992	10,304	89,688	243,756	174,276
Repairs and maintenance														
i) Plant and machinery													-	
ii) Buildings													-	
iii) Others													-	
Advertising and sales promotion													-	
Brokerage and discounts													-	
Remuneration to Auditors													-	
Sales commission													-	
Travelling and conveyance	1,906	698	1,666	3,564	53	70	2,759	2,863	2,107	2,024	1,849	5,539	25,098	22,020
Communication costs	1,206	305	312	650	228	1,267	807	386	899	741	266	4,844	11,911	7,353
Printing and stationery	258	416	563	1,106	1,457	316	1,165	1,295	995	974	590	534	9,669	12,887
Legal and professional fees	250	2,030	2,317	3,680	530	250	460	355	3,480	685	13,260	7,486	34,784	61,588
Directors sitting fees													-	
Payment to auditor (Refer details below)	700	700	700	700	700	700	700	700	700	733	700	13,768	21,501	19,800
Provision for diminution in value of investment in subsidiary company													-	
Provision for other than temporary decline in the carrying amount of other long-term investments													-	
Adjustment to the carrying amount of current investments													-	
Provision for warranties (net of reversals)													-	
Provision for litigations (net of reversals)													-	
Exchange differences (net)													-	
Loss on derivative contracts (including provisions mark-to-market loss)													-	
Bad debts/advances written off													-	93
Impairment loss on fixed assets													-	
Provision for doubtful debts and advances													-	
Loss on sale of fixed assets (net)													-	
Premium on forward exchange contract amortized													-	
Selling expenses						200	189	337			-	-	725	8,817
Factory maintenance													-	
Effluent treatment expenses													-	
Vehicle maintenance expenses													-	
Analytical charges													-	
Product development expenses (QC,QP,UQC)	22,733	44,600	28,350	33,700	33,700	45,533	32,533	29,500	44,700	36,933	38,000	41,049	431,332	451,675
Registration and filing charges	-	33,992	7,420	39,680	36,891	46,218	37,018	23,020	29,707	42,483	59,423	1,405	357,256	226,887
Safety and security													-	
Office expenses	952	952	822	948	948	948	948	948	948	948	948	948	11,253	11,163
Repairs and maintenance - others	215	214	100	373	966	100	2,717	352	121	1,074	876	1,119	8,227	4,517
Management fees	-	-	-	-	-	-	-	-	140,197	18,004	13,360	21,050	192,611	110,665
further education	1,640	648	1,062	950	3,802	950	530	3,770		1,990	621	-	15,963	5,633
Liquidated damages													-	

Aurobindo Pharma GmbH
Notes to the statement of profit and loss
(All amounts are in € except share data and unless otherwise stated)

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 2.5.2015

12. for the
column only

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-16	Mar-15	12 Months Period ended March 31, 2015 (Euro)	Year ended March 31, 2014 (Euro)
Donations													-	-
Software license and implementation expenses	3.598	3.598	4.371	6.247	4.327	4.327	4.327	4.327	4.327	4.327	4.327	4.327	52.429	56.448
Capital work-in-progress written off													-	-
Miscellaneous expenses	1.246	33.952	8.346	14.198	9.004	11.304	20.599	13.744	33.480	21.690	16.934	453.089	637.585	53.197
	70.297	159.440	103.494	160.823	216.528	174.136	115.833	133.679	389.853	180.387	212.844	623.791	2.541.103	1.729.618
Payment to Auditor														
As auditor:														
Audit fee												15.000	15.000	
Tax audit fee												10.000	10.000	
Limited review													-	
In other capacity:														
Taxation matters													-	
Company law matters													-	
Management services													-	
Other services (certification fees)													-	
Reimbursement of expenses												25.000	25.000	-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 24 : Exceptional items														
German GAP Differences													-	-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 25 : Depreciation and amortization expense														
Depreciation of tangible assets	698	109	142	120	316	2.969	813	403	403	403	906	409	7.690	4.622
Amortization of intangible assets	19.308	21.301	39.774	28.516	30.626	29.834	31.735	32.579	30.207	30.208	36.818	180.863	511.769	183.714
Depreciation of investment property													-	-
	20.006	21.410	39.916	28.635	30.942	32.803	32.548	32.982	30.610	30.611	37.724	181.272	519.459	188.336
Note 26 : Finance costs (Refer General Instructions Note No.27)														
Interest	-	-	807	-	-	-	-	-	-	-	-	(404)	403	5.867
Bank charges	245	-	339	45	100	432	248	2	348	81	-	452	2.292	1.733
Amortization of ancillary borrowing costs													-	-
Exchange difference to the extent considered as an adjustment to borrowing costs													-	-
	245	-	1.146	45	100	432	248	2	348	81	-	48	2.695	7.600

Aurobindo Pharma B.V.

ANNUAL REPORT

APRIL 2014 – MARCH 2015

 Grant Thornton
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants en Adviseurs B.V.


13 MAY 2015

Aurobindo Pharma B.V. – May 2015, page 1

DIRECTORS' REPORT

REPORT OF THE DIRECTORS

The management herewith presents to the shareholders, the annual accounts of **AUROBINDO PHARMA B.V.** for the year ended 31st March, 2015

GENERAL

The company is a limited liability company incorporated under the laws of The Netherlands and acts as a trading company. The principle object of the company is to trade and deal in pharmaceutical products and other allied products & services.

RESULTS

The directors of company have reviewed companies operations. During the financial year, the company has recorded Revenue from Operations of €2,111,284 and incurred a Loss of €403,870.

DIRECTORS

The Directors at the date of the report are

1. Mr. Muralidharan Venugopalan
2. Mr. G.P.Prasad
3. Mr. Kalman Petro
4. Mr. Avinash Swain
5. Mr. Ronald David Steentjes


UNUSUAL ITEMS AFTER THE FINANCIAL YEAR

No item, transaction or event of material nature has arisen during the period between the end of the year and date to this report, which would affect substantially the operation of the company during the current year.

STATEMENT BY DIRECTORS

In the opinion of the Directors, the accompanying financial statements were drawn up so as to give true and fair view of the statement of affairs of the company as at 31st March, 2015 and of the results of the business of the year. Directors have taken all the reasonable steps to prepare these financial statements on a going concern basis and that suitable accounting policies have been adopted consistently. Further directors are confident that with the support and guidance of the holding company your company can achieve better results in the future.

By Order of the Board on 19th May, 2015



Ronald David Steentjes
Director

Aurobindo Pharma BV

Molenvliet 103 - 3335 LH Zwijndrecht - The Netherlands - Tel: +31 (0)78 610 18 36 - Fax: +31 (0)78 610 28 82 - ING Bank No.: 65.37.06.146
IBAN: NL84 INGB 0653 7061 46 - BIC: INGBNL2A - VAT. No. NL 8230.07.078.B.01 - C.o.C. 50939351 -

To: the group auditors of Aurobindo Pharma Ltd

Grant Thornton
Accountants en Adviseurs B.V.
Gedempte Zalmhaven 4a
P.O. Box 23278
3001 KG Rotterdam
The Netherlands

INDEPENDENT AUDITOR'S REPORT

T +31 88 676 90 00
F +31 88 676 90 10
www.gt.nl

Report on the financial statements

As requested in your instructions, we have audited, for purposes of your audit of the consolidated financial statements of Aurobindo Pharma Limited, the special purpose financial information, signed for identification purposes, of Aurobindo Pharma B.V. as of 31 March 2015 and for the year then ended.

Management's responsibility

Management is responsible for the preparation of this special purpose financial information in accordance with policies and instructions contained in Aurobindo Pharma Limited's accounting manual. Furthermore management is responsible for such internal control as it determines is necessary to enable the preparation of special purpose financial information that is free from material misstatement, whether due to fraud or error. This special purpose financial information is prepared solely to enable Aurobindo Pharma Limited to prepare its consolidated financial statements.

Auditor's responsibility

Our responsibility is to express an opinion on this special purpose financial information based on our audit. We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing and your instructions. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the special purpose financial information is free from material misstatement. As requested, our audit procedures also included the additional procedures identified in your instructions. In accordance with your instructions we planned and performed our audit using the materiality level specified in your instructions, which is different than the materiality level to express an opinion on the special purpose financial information of the component alone.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the special purpose financial information. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the special purpose financial information, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and presentation of the special purpose financial information in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates, made by management, as well as evaluating the overall presentation of the special purpose financial information.

Grant Thornton Accountants en Adviseurs B.V. is a member firm within Grant Thornton International Ltd (Grant Thornton International).

Grant Thornton Accountants en Adviseurs B.V. is registered with the Chamber of Commerce of The Hague trade register under number 28105565. To all our services our general conditions, as registered with the Registry of the District Court in The Hague, apply. A copy of these conditions will be sent to you on request. Any liability shall be limited to the amount which is mentioned in the general conditions.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. The conclusions reached in forming our opinion are based on the component materiality level specified by you in the context of the audit of the consolidated financial statements of the group.

Opinion with respect to the financial statements

In our opinion, the special purpose financial information of Aurobindo Pharma B.V. as of 31 March 2015 and for the year then ended is prepared, in all material respects, in accordance with the policies and instructions contained in Aurobindo Pharma Limited's accounting manual.


Report on other legal and regulatory requirements

Without qualifying our opinion, we note that this special purpose financial information is prepared for purposes of providing information to Aurobindo Pharma Limited to enable it to prepare the consolidated financial statements of the group. As a result, the special purpose financial information is not a complete set of financial statements of Aurobindo Pharma B.V. in accordance with the group's accounting policies and is not intended to give a true and fair view of, in all material respects, the financial position of Aurobindo Pharma B.V. as of 31 March 2015, and of its result and its cash flows for the year then ended in accordance with the group's accounting policies. The special purpose financial information may, therefore, not be suitable for another purpose.

This report is intended solely for the group auditor and should not be distributed to or used by parties other than the group auditor.

Rotterdam, 19 May 2015

Grant Thornton Accountants en Adviseurs B.V.



drs. C. Holewijn RA

 Grant Thornton
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountants en Adviseurs B.V.




19 MAY 2015

Annual Report April 2014 – March 2015

Annual Accounts

• Balance Sheet	3
• Statement of profit and loss	5
• Notes	6
• Accounting principles	6
• Notes to the balance sheet	9

<i>Other information</i>	13
--------------------------	----

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountants en Adviseurs B.V.
13 MAY 2015

BALANCE SHEET
(after appropriation of result)

ASSETS	Note	31-03-2015 €'000	31-03-2014 €'000
NON-CURRENT ASSETS			
Intangible fixed assets	1	2,392	2,651
Deferred tax assets		346	245
		<u>2,392</u>	<u>2,651</u>
CURRENT ASSETS			
<i>Inventories and work in progress</i>	2		
Inventories		0	520
Work in progress		0	0
		<u>0</u>	<u>520</u>
<i>Receivables</i>	3		
Trade accounts receivable		12	328
Group companies		0	0
Taxes and social security		0	0
Other receivables and accrued income		0	0
		<u>12</u>	<u>328</u>
<i>Cash and cash equivalents</i>	4	18	92
		<u>2,768</u>	<u>3,836</u>







 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountants and Adviseurs B.V.

13 MAY 2015

EQUITY, PROVISIONS AND LIABILITIES**Note****31-03-2015****31-03-2014****€'000****€'000****EQUITY**

Issued share capital	5	18	18
Share premium reserve	6	2,500	2,500
Other reserves	7	-1,383	-979
		<u>1,135</u>	<u>1,539</u>

SHORT-TERM LIABILITIES

Trade accounts payable	0	13
Payables to group companies	772	1,969
Taxes and social securities	0	0
Other accounts payable and accrued liabilities	861	314
	<u>1,633</u>	<u>2,297</u>

2,7683,836

[Handwritten signatures]

 **Grant Thornton****INITIALLED FOR IDENTIFICATION
PURPOSES ONLY****Grant Thornton
Accountants and Advisers B.V.****13 MAY 2015**

Aurobindo Pharma B.V. – May 2015, page 4


STATEMENT OF PROFIT AND LOSS

	Apr. 2014- Mar. 2015	Apr. 2013- Mar. 2014
	€'000	€'000
NET TURNOVER	2,111	1,346
Cost of sales	1,849	1,125
Amortisation of intangible fixed assets	347	336
Office expenses	165	207
General expenses	10	7
Management fee	245	402
TOTAL OPERATING EXPENSES	2,616	2,077
OPERATING RESULT	-505	-731
FINANCIAL RESULT	-0	-0
RESULT FROM ORDINARY OPERATIONS BEFORE TAXATION	-505	-731
Corporate income tax (Deferred tax)	101	146
RESULT FROM ORDINARY OPERATIONS AFTER TAXATION	-404	-585

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountants & Adviseurs B.V.
13 MAY 2015

NOTES

General

The company is part of the (sub)group with Agile Pharma B.V. as (sub)group head.

ACCOUNTING PRINCIPLES



The annual accounts are prepared on basis of the principles of Title 9 of Book 2 of the Netherlands Civil Code.

Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise at the relevant principle for the specific balance sheet item, assets and liabilities are presented at nominal value.

The reporting currency of the annual accounts of the company is euro (€).

ACTIVITIES

Management has decided that the activities of the company will be merged into Actavis B.V. as of 1 July 2015. In anticipation on the merge the inventories have been sold to Actavis B.V. at cost.

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
 **Grant Thornton**
Accountants en Adviseurs B.V.
13 MAY 2015

Aurobindo Pharma B.V. – May 2015, page 6

VALUATION PRINCIPLES FOR ASSETS AND LIABILITIES

FIXED ASSETS

Intangible fixed assets

Intangible fixed assets are presented at cost less accumulated amortisation and, if applicable, less impairments in value. Amortisation charged as a fixed percentage of cost, as specified in more detail in the notes to the balance sheet. The useful life and amortisation method are reassessed at the end of each financial year

Amortisation rates

Asset	%
Intellectual property rights	10

CURRENT ASSETS

Inventories

Inventories are valued at the lower of cost and net realizable value. The cost is based on the first-in-first-out principle. This lower net realizable value is based on basis of individual assessment of the recoverability of the inventories.

Receivables

Receivables will be valued at nominal value at first and subsequently valued at amortised cost price, which is equal to the nominal value, if necessary diminished with a provision for bad debts.

Cash and cash equivalents

The cash is valued at face value. If cash equivalents are not freely disposable, then this has been taken into account in the valuation.

SHORT TERM LIABILITIES

Short term liabilities and accrued liabilities

Short term liabilities will be valued at nominal value at first and subsequently valued at amortised cost price, which is equal to the nominal value.
Accrued liabilities will be valued at nominal value.

PRINCIPLES FOR DETERMINATION OF RESULT

NET TURNOVER

Turnover is formed by revenue from deliveries of goods and services to third parties, net of discounts, rebates and value added taxes.

 Grant Thornton

INITIALLED FOR IDENTIFICATION

Aurobindo Pharma B.V. – May 2015, page 7
Grant Thornton

The revenue from deliveries of goods are recognised in the profit and loss account at the moment of economic delivery.

EXPENSES

Expenses are allocated to the period to which they refer, using accrual items if necessary.

AMORTISATION/ DEPRECIATION

The amortization/ depreciation on (in)tangible fixed assets is calculated by using a fixed rate on the acquisition cost or cost of conversion.

Gains and losses on disposal of (in)tangible fixed assets are recorded under amortisation/depreciation, gains only to the extent that the gain is not capitalised for replacement investments.


FINANCIAL RESULT

Financial income and expenses comprise interest income and expenses on loans as accounted for in the current reporting period.

CORPORATE INCOME TAX

Corporate income tax expense comprises current and deferred tax. Corporate income tax expense is recognised in profit or loss except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity.

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is provided for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountants & Adviseurs B.V.

13 MAY 2015

Aurobindo Pharma B.V. – May 2015, page 8

NOTES TO THE BALANCE SHEET

(Amounts in thousands of euro)

ASSETS

NON-CURRENT ASSETS

1) *Intangible fixed assets*

	Software
Book value as at 1 April 2014	2,651
Capital expenditure	88
	<u>2,739</u>
Amortisation	347
Book value as at 31 March 2015	<u>2,392</u>
Accumulated amortisation as at 31 March 2015	<u>1,109</u>
Amortisation percentage	<u>10%</u>

2) *Intangible fixed assets*

At the balance sheet date, the company has unused tax losses of € 345,766 available for offset against future profits. A deferred tax asset has been recognized of € 345,766 of such losses

CURRENT ASSETS

2) *Inventories*

	31-03-2015	31-03-2014
Finished products	0	536
Provision	0	-16
Book value as at period end	<u>0</u>	<u>520</u>

The company has sold the inventories to Actavis B.V. in anticipation of the merge with Actavis B.V.

3) *Receivables*


	31-03-2015	31-03-2014
Trade accounts receivable	12	328
Group companies		245
Book value as at period end	<u>12</u>	<u>573</u>

4) *Cash and cash equivalents*

	31-03-2015	31-03-2014
ING Bank N.V., current account	18	92

 Grant Thornton

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

 Grant Thornton
Accountants & Tax Advisors B.V.

Aurobindo Pharma B.V. – May 2015, page 9

EQUITY, PROVISIONS AND LIABILITIES

EQUITY

5) <i>Issued share capital</i>	31-03-2015	31-03-2014
180 ordinary share with par value of nominal € 100.00 per share	18	18

The statutory share capital amount to € 90,000.00, divided into 2,000 ordinary shares with a nominal value of € 45,00 per share. A total of 400 shares have been issued and fully paid.

The shares are held by Agile Pharma B.V.

6) <i>Legal reserve</i>	31-03-2015	31-03-2014
Share premium reserve	2,500	2,500

7) <i>Other reserves</i>	31-03-2015	31-03-2014
Book value as t 1 April	-979	-394
Allocation of financial year nett result	-404	-585
Book value as at 31 March	-1,383	-979

4) SHORT-TERM LIABILITIES

8) <i>Trade accounts payable</i>	31-03-2015	31-03-2014
Accounts payable to third parties	0	13

9) <i>Payables to group companies</i>	31-03-2015	31-03-2014
Accounts payable to group companies	772	1,969


 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountants en Adviseurs B.V.
13 MAY 2015

10) *Other accounts payable and accrued liabilities*

	31-03-2015	31-03-2014
Audit services	3	5
Contributions and subscriptions	0	50
Loan from group companies	650	
Other liabilities	208	259
	<u>861</u>	<u>314</u>

CONTINGENT LIABILITIES

The company constitutes a tax entity for corporate income tax with Helix Healthcare B.V.; consequently the company is severally liable for the resulting debts.

 **Grant Thornton**
 INITIALLED FOR IDENTIFICATION
 PURPOSES ONLY
 Grant Thornton
 Accountants en Adviseurs B.V.
13 MAY 2015

Aurobindo Pharma B.V. – May 2015, page 11

NOTES TO THE STATEMENT OF PROFIT AND LOSS

(Amounts in thousands of euro)

NUMBER OF EMPLOYEES


The number of employees employed by the company during the reporting period was 0 (2013/2014: 0). The employees are legally contracted by another party and are recharged on a monthly basis.

TAXATION

A provision for deferred taxation is formed for differences in commercial and fiscal valuation.

SIGNATURES TO THE ANNUAL ACCOUNTS

Baarn, 13 May 2015.



V. Muralidharan
Director



A. Swain
Director



G.P. Prasad
Director

K.W.P. Petro
Director

 Grant Thornton

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

 Grant Thornton
Accountants en Adviseurs B.V.

13 MAY 2015

Aurobindo Pharma B.V. – May 2015, page 12

OTHER INFORMATION

Statutory profit allocation

Article 19 reads:

19.1 The allocation of profits accrued in a financial year shall be determined by the Shareholders' Body. If the Shareholders' Body does not adopt a resolution regarding the allocation of the profits prior to or at latest immediately after the adoption of the annual accounts, the profits will be reserved.

19.2 Distribution of profits shall be made after adoption of the annual accounts if permissible under the law given the contents of the annual accounts.

19.3 The Shareholders' Body may resolve to make interim distributions on Shares and/or to make distributions on Shares at the expense of any reserve of the Company. In addition, the Management Board may decide to make interim distributions on Shares.

19.4 Distributions on Shares shall be made payable immediately after the resolution to make the distribution, unless another date of payment has been determined in the resolution.

19.5 Distributions on Shares may be made only up to an amount which does not exceed the amount of the Distributable Equity.

19.6 In calculating the amount of any distribution on Shares, Shares held by the Company shall be disregarded.

Result allocation proposal

The General Meeting of Shareholders proposes to allocate the negative result for the book year 2014-2015 of € 404,000 to the other reserves.

This proposal has been reflected in the annual accounts.



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants en Adviseurs B.V.

Aurobindo Pharma B.V. – May 2015, page 13 MAY 2015

Aurobindo Pharma Romania S.R.L.

Sediul/Registered office: Bucuresti, Sos. Bucuresti-Ploiesti nr. 42-44, Complex "Baneasa Business & Technology Park", Cladirea B, Aripa B2, etaj 2, sector 1, Romania
Nr. Registrul Comertului/Trade Registry no.: J40/9618/2010
Cod de identificare fiscala/Fiscal Identification Code: 27481011

Directors' report

Management of the company hereby presents its financial statements for the financial book year from 1 April 2014 to 31 March 2015.

General information

During the financial year, Aurobindo Pharma Romania SRL was engaged in the distribution and sales of pharmaceutical products. The company's activities include sales of generic medicines and pharmacies and drugstores in Romania. The mission of the company is to sell and market pharmaceuticals of the highest quality to our customers delivering best-in-class service and superior value.

Aurobindo Pharma Romania SRL is a subsidiary of Agile Pharma B.V., seated in Amsterdam, The Netherlands. The office of Aurobindo Pharma Romania SRL is located in Romania, Bucharest, 1st District, 42-44 Bucuresti-Ploiesti Road, Baneasa Business & Technology park, Building B, Wing B2, 2nd floor and it is registered at the Bucharest Trade Registry under the no. J40/9618/2010, having the tax identification number (CUI) 27481011. About 17 employees are working in the departments Pharmaceutical Affairs, Sales & Marketing, Finance, and Customer Service.

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, the Ultimate Holding Company, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 125 countries.

Financial information

- The company's activities resulted in a turnover for the year of RON8.100.289 (2013: RON416.774). The company just started the sales activity in 2013, and in 2014 the sales went very well.



Aurobindo Pharma Romania S.R.L.

Sediul/Registered office: Bucuresti, Sos. Bucuresti-Ploiesti nr. 42-44, Complex "Baneasa Business & Technology Park", Cladirea B, Aripa B2, etaj 2, sector 1, Romania
Nr. Registrul Comertului/Trade Registry no.: J40/9618/2010
Cod de identificare fiscala/Fiscal Identification Code: 27481011

- Aurobindo Pharma Romania SRL has an intercompany loan facility and it is also financed by way of equity funds, several share capital increase operations being done during the relevant period.

Financial performance indicators

	2013-2014	2014-2015
Net turnover (RON)	416.774	8.100.289
Gross margin (RON)	262.358	5.064.193
Net result (RON)	(3.328.090)	(1.141.462)

Personnel-related information

All staff is employed based on individual employment agreements.

Research and development information

The company does not perform research and development activities locally.

Other information

- AurobindoPharma Romania SRL is marketing its products in Romania from its head office in Bucharest. Distribution takes place through wholesalers to pharmacies, drugstores and hospitals in Romania.
- The pharmaceutical is a heavily regulated industry. Quality assurance & control is key to AurobindoPharma Romania SRL. A (financial) control framework is in place in order to adequately manage risks.

Information concerning application of code of conduct

AurobindoPharma Romania SRL is subject to both the internal code of conduct and Romanian Labour Code regulations. Information on male/female partitioning of board members

The board consists of three male members: a local director – Mr Hugh Richard Watkins, an English citizen, born on 01.03.1953 in London, identified with passport GBR 761217235, issued



Aurobindo Pharma Romania S.R.L.

Sediul/Registered office: Bucuresti, Sos. Bucuresti-Ploiesti nr. 42-44, Complex "Baneasa Business & Technology Park", Cladirea B, Aripa B2, etaj 2, sector 1, Romania
Nr. Registrul Comertului/Trade Registry no.: J4Q/9618/2010
Cod de identificare fiscala/Fiscal Identification Code: 27481011

by the English authorities on 30.01.2009 valid until 30.01.2019, having his domicile in Bucharest, 6th Prof. N. Moise street, 3rd District, CNP 7530301400011, having full powers of representation, and two non-resident directors: Mr. Gorla Phaneendra Prasad, an Indian citizen, born on Machilipatnam, Republic of India at 03.08.1957, identified with Passport no. G5491488, issued by the authorities of Republic of India on 10.10.2007, valid until 09.10.2017, having his domicile at Plot no. 53, Eswar Villas, Nijampet Road, Kukatpalli, Hyderabad – 72, Republic of India, having full powers of representation and Mr. Venugopalan Muralidharan, a British citizen, born on 07.12.1955, in Trichy, identified with Passport no. 099219293, issued by the British authorities on 29.11.2010, valid until 29.11.2020, having his domicile at 13 Rosepark Close, Hayes, Middlesex, London England, UB49AT, having full powers of representation. As much as the Board of Directors values diversity, the Board currently has no female Board members. As per this moment there is no policy on the desirable male/female split in the Board. The company will focus in the future on the competences of new Board members bearing in mind the added value from diversity in the Board.

Outlook

- No significant investments are expected to take place in the near future.
- No R&D activities will take place on local level.

Bucharest, 30 April, 2015

Hugh Richard Watkins
Director



Interoffice conclusion

To the primary team of S.C. AUROBINDO PHARMA ROMANIA SRL

- 1 As requested in your instructions we have performed a full scope engagement, for the purpose of your audit of the group financial statements of Aurobindo Pharma Limited, India on the Reporting Package forms of S.C. Aurobindo Pharma Romania SRL ("the Company") as of March 31, 2015 and for the year then ended (the specified forms).

Management's responsibility for the financial statements

- 2 Management is responsible for the preparation of the Group Reporting Package in accordance with the Accounting Guidelines. This responsibility includes: designing, implementing and maintaining internal control relevant to the preparation of the group Reporting Package that is free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditors' responsibility

- 3 Our responsibility is to express an opinion on the group Reporting Package based on our audit. We conducted our audit in accordance with International Standards on Auditing, issued by the International Auditing and Assurance Standards Board (IAASB) of the International Federation of Accountants (IFAC). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the group Reporting Package is free from material misstatement.
- 4 An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.
- 5 We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Audit opinion

- 6 In our opinion, the Group Reporting Package give a true and fair view of the financial position of the Company as of March 31, 2015, and of its financial performance for the year then ended in accordance with the Accounting Guidelines.



Limitation on Use

- 7 The specified forms have been prepared for purposes of providing information to Aurobindo Pharma Limited, India to enable it to prepare the group financial statements. As a result, the specified forms are not a complete set of financial statements of Aurobindo Pharma Romania S.R.L. The specified forms may, therefore, not be suitable for another purpose.
- 8 This full scope conclusion is solely for your information and use in conjunction with the audit of the group financial statements of Aurobindo Pharma Limited, India and should not be used by anyone for any other purpose.

Bucharest, 30 April 2015

Grant Thornton Audit SRL

Adriana Gheorghiu - Audit Partner

Grant Thornton



Aurobindo Pharma Romania Srl
Balance Sheet as at March 31, 2015


(All amounts are in Local RON except share data and unless otherwise stated)

	Note	31 March, 2015 (RON)	31 March, 2014 (RON)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	9,172,000	3,760,000
Share application money			1,263,036
Reserves and surplus	3	(5,090,173)	(3,948,711)
		<u>4,081,827</u>	<u>1,074,325</u>
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	(338,847)	(210,226)
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		<u>(338,847)</u>	<u>(210,226)</u>
Current liabilities			
Short-term borrowings	8	440,980	-
Trade payables	9	6,716,547	2,344,622
Other current liabilities	9	343,865	148,554
Short-term provisions	7	63,492	56,145
		<u>7,564,884</u>	<u>2,549,322</u>
TOTAL		<u>11,307,864</u>	<u>3,413,421</u>
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	42,407	52,417
Intangible assets	11	1,957,293	1,540,120
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	-	-
Trade receivables	14.1	-	-
Other non-current assets	14.2	-	-
		<u>1,999,700</u>	<u>1,592,537</u>
Current assets			
Current investments	15	-	-
Inventories	16	587,467	677,991
Trade receivables	14.1	7,764,466	315,592
Cash and bank balances	17	257,073	308,818
Short-term loans and advances	13	75,837	75,837
Other current assets	14.2	623,321	442,646
		<u>9,308,164</u>	<u>1,820,883</u>
TOTAL		<u>11,307,864</u>	<u>3,413,421</u>

Summary of significant accounting policies

1

The accompanying notes are an integral part of the financial statements.



Aurobindo Pharma Romania Srl

Statement of profit and loss for the year ended March 31, 2015

(All amounts are in Local RON except share data and unless otherwise stated)

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	March-15	Year ended March 31, 2015 (RON)	Year ended March 31, 2014 (RON)
Income															
Revenue from operations (gross)	18	21,522	142,859	473,562	252,287	237,140	384,528	1,165,204	640,694	872,959	1,148,129	949,953	1,811,452	8,100,289	416,774
Less: Excise duty/Rebates															
Revenue from operations (net)		21,522	142,859	473,562	252,287	237,140	384,528	1,165,204	640,694	872,959	1,148,129	949,953	1,811,452	8,100,289	416,774
Other income	19														
Total revenue (I)		21,522	142,859	473,562	252,287	237,140	384,528	1,165,204	640,694	872,959	1,148,129	949,953	1,811,452	8,100,289	416,774
Expenses															
Cost of raw material and components consumed	20														
Purchase of trading goods	21		91,824	110,676	28,591	154,504	178,541	97,760	256,165	235,279	307,383	689,822	795,023	2,915,572	832,407
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	66,345	(29,823)	138,143	83,945	(81,511)	(90,988)	141,444	123,595	(15,780)	(72,526)	(247,798)	72,477	90,524	(677,991)
Employee benefit expense	22	206,548	211,009	214,337	225,676	185,815	190,581	181,276	202,970	179,852	224,505	167,210	167,171	2,355,953	1,908,179
Other expenses	23	115,710	123,223	344,233	177,265	167,212	203,007	278,863	492,814	906,128	331,403	426,866	388,518	3,955,241	1,879,840
Exceptional items	24														
Total (II)		388,603	396,233	807,388	515,477	426,020	481,147	702,343	1,075,545	1,305,479	789,765	1,036,100	1,423,189	9,347,290	3,942,435
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		(367,082)	(253,374)	(333,826)	(263,190)	(188,880)	(96,619)	462,861	(434,851)	(432,520)	358,364	(86,147)	388,263	(1,247,002)	(3,525,661)
Depreciation and amortization expense	25	1,194	1,194	1,194	1,193	1,194	1,194	1,194	1,194	1,191	1,194	1,261	1,261	14,463	4,007
Finance costs	26	537	494	469	557	414	424	461	596	837	467	596	2,749	8,599	8,056
Profit/(loss) before tax		(368,812)	(255,061)	(335,488)	(264,940)	(190,488)	(98,237)	461,206	(436,641)	(434,551)	356,703	(88,007)	384,254	(1,270,063)	(3,537,724)
Tax expenses															
Current tax															592
Less: MAT credit entitlement															
Deferred tax		(48,018)	(34,645)	(34,514)	(47,852)	(24,799)	(6,447)	78,077	61,366	11,270	(60,447)	(18,958)	(3,634)	(128,601)	(210,226)
Fringe benefit tax															
Tax relating to previous years															
Total tax expense		(48,018)	(34,645)	(34,514)	(47,852)	(24,799)	(6,447)	78,077	61,366	11,270	(60,447)	(18,958)	(3,634)	(128,601)	(209,634)
Profit/(loss) for the year		(320,794)	(220,416)	(300,975)	(217,088)	(165,689)	(91,790)	383,129	(498,007)	(445,821)	417,150	(69,049)	387,888	(1,441,462)	(3,328,090)

Summary of significant accounting policies

The accompanying notes are an integral part of the financial statements.

FOR THE
DATE 30/05/2015
SIGNATURE BOA

Note 1 : Summary of significant accounting policies (Refer General Instructions Note No.1)

- 1.1
- 1.2
- 1.3
- 1.4
- 1.5

Note 2 : Share capital (Refer General Instructions Note No.2)

	March 31, 2015	March 31, 2014
Authorised shares:		
Agile Pharma BV 807,199 (31 March, 2014: 375,999) equity shares of 10 each	9,171,990	3,759,990
Corla Phaneendra Prasad 1 share (31 March, 2014: 1) preference shares of 10 RON each	10	10
	<u>9,172,000</u>	<u>3,760,000</u>
Issued, Subscribed and Fully Paid-up shares:		
807200 (31 March, 2014: 376000) equity shares of 10 RON per each fully paid-up	<u>9,172,000</u>	<u>3,760,000</u>

FOR THE DIRECTOR
 GRANT THOMAS
 DATE 30/04/2015
 SIGNATURE Bot

Aurobindo Pharma Romania Srl

Notes to the Balance Sheet

(All amounts are in Local RON except share data and unless otherwise stated)

Note 3 : Reserves and surplus (Refer General Instructions Note No.3)

	March 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	-	-
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet	-	-
General Reserve		
As per last Balance Sheet		
Add: Transferred from statement of profit and loss	-	-
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	(3,948,711)	(620,621)
Profit for the quarter	(1,141,462)	(3,328,090)
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)		
Tax on proposed equity dividend		
Interim dividend paid (amount per share XX (31 March, 2014 XX)		
Transfer to general reserve		
Total appropriations	-	-
Net surplus in the statement of profit and loss	(5,090,173)	(3,948,711)
Total reserves and surplus	(5,090,173)	(3,948,711)

Note 4 : Long -term borrowings (Refer General Instructions Note No.4)

	Non-current Portion		Current maturities	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)				
Other Loans from banks				
Current account credit balance				
Loans and advances from related parties				
Other Loans and advances				
Sales tax deferment loan (Un Secured)				
	-	-	-	-
The above amount includes				
Secured borrowings				
Unsecured borrowings				
Amount disclosed under the head				
"Other current liabilities"				
Net Amount	-	-	-	-

FOR THE BOARD
 CHAIRMAN
 DATE: 30/06/2015
 SIGNATURE: BOA

Aurobindo Pharma Romania Srl
Notes to the Balance Sheet

All amounts are in Local RON except share data and unless otherwise stated)

Note 5 : Deferred tax liability (net)

	March 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis		
Provision for diminution in the value of investments		
Provision for doubtful debts and advances		
Fixed Assets (Depreciation)		
Retirement benefits		
Others		
Gross deferred tax liability	-	-
Deferred tax asset		
Carried Forward Business Losses	338,847	210,226
Others		
Gross deferred tax asset	338,847	210,226
Net deferred tax liability	(338,847)	(210,226)

Note 6 : Other long-term liabilities (Refer General Instructions Note No.5)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances)		
Other liabilities		
Advances from related parties		
	-	-
	-	-

Note 7 : Provisions (Refer General Instructions Note No.6 & 10)


	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Provision for employee benefits				
- Gratuity				
- Leave encashment				
	-	-	-	-
Other Provisions				
For Taxation (net of advance payments)				
For Proposed dividend				
Provision for law life stock			63,492	56,145
	-	-	63,492	56,145
	-	-	63,492	56,145

Provision for warranties

	March 31, 2015	March 31, 2014
At the beginning of the year		
Arising during the period		
Utilised during the period		
Unused amounts reversed		
At the end of the year	-	-
Current portion		
Non-current portion		

Note 8 : Short-term borrowings (Refer General Instructions Note No.7)

	March 31, 2015	March 31, 2014
Bank overdraft		
Loans and advances from related parties	440,980	
Working capital loans (Secured)		
Short term loans (Un Secured)		
Working capital loans		
	440,980	-
The above amount includes		
Secured borrowings		
Unsecured borrowings	440,980	-



Note 9: Other current liabilities (Refer General Instructions Note No.9)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)	6,716,547	2,344,622
Other liabilities		
Other liabilities	341,506	118,554
Advances from customers		
Unclaimed dividends		
Interest accrued and due on loans taken from Agile Pharma BV, NL	2,359	
Trade deposits		
	343,865	148,554
	7,060,412	2,493,177

FOR DIRECTOR'S SIGNATURE
 30/01/2015
 BOA

Note 10: Tangible assets (i.e., x_1, \dots, x_n) are assumed to be sold at their book value.

[illegible]

Note 11 : Intangible assets (Refer General Instructions Note No.12)

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At 1 April 2013			541,859	541,859
Purchase			709,286	709,286
Internal development			289,126	289,126
Disposals				-
Other adjustments				
- Exchange differences				-
At 31 March 2014	-	-	1,540,271	1,540,271
Purchase			418072.5	418,073
Acquisitions through amalgamation				-
Disposals				-
Other adjustments				
- Exchange differences				-
At 31 March 2015	-	-	1,958,344	1,958,344
Amortization				
At 1 April 2013				-
Charge for the year			151	151
Disposals				-
Other adjustments				
- Exchange differences				-
At 31 March 2014	-	-	151	151
Charge for the period			900	900
Disposals				-
Other adjustments				
- Exchange differences				-
At 31 March 2015	-	-	1,051	1,051
Net Block				
At 31 March 2014	-	-	1,540,120	1,540,120
At 31 March 2015	-	-	1,957,293	1,957,293

FOR IDENTIFICATION
GRANT RECEIVED
DATE 30/04/2015
SIGNATURE BoA

Note 12: Non-current investments (Refer General Instructions Note No.17)

	March 31, 2015	March 31, 2014
Unquoted equity instruments		
Investment in subsidiaries		
Investment in joint ventures		
Investment in associates		

Note 13: Loans and advances (Refer General Instructions Note No.14 & 21)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Capital advances				
Secured, considered good				
Unsecured, considered good				
(A)	-	-	-	-
Security deposit				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful security deposit				
(B)	-	-	-	-
Loan and advances to related parties				
Unsecured, considered good				
(C)	-	-	-	-
Advances recoverable in cash or kind				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful advances				
(D)	-	-	-	-
Other loans and advances				
Advance income-tax (net of provision for taxation)				
Prepaid expenses			75,837	75,837
Loans to employees				
Loans to others				
Export incentives receivable				
Export incentives licenses				
Balances with Statutory / government authorities				
(E)	-	-	75,837	75,837
Total (A+B+C+D+E)	-	-	75,837	75,837

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors				
Dues from officers				
Dues from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner				
Dues from in which the company's managing director is a member				
Dues from the partnership firm in which the company's non-executive director is a partner				

30/01/2015
204

Note 14 : Trade receivables and other assets

14.1 Trade receivable (Refer General Instructions Note No.12 & 13)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others			7,764,466	315,592
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful				
Provision for doubtful receivables	-	-	7,764,466	315,592
(A)	-	-	7,764,466	315,592
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful				
Provision for doubtful receivables	-	-	-	-
(B)	-	-	-	-
Total (A+B)	-	-	7,764,466	315,592

Trade receivables include:

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				
14.2 Other assets (Refer General Instructions Note No.16 & 22)				
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)	-	-	-	-
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)	-	-	-	-
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on investments in subsidiaries - long term				
Others			623,321	442,646
(C)	-	-	623,321	442,646
Total (A+B+C)	-	-	623,321	442,646

30/04/2015
BOA

Note 15: Current investments (Refer General instructions Note No.17)

	March 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
equity shares (fully paid-up)		
If any (Please specify)		

Note 16: Inventories (valued at lower of cost and net realizable value) (Refer General instructions Note No.18)

	March 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)		
Work - in - Progress		
Finished goods		
Traded goods (including stock -in-transit XXXX (31 March, 2014 XXX)	587,467	677,991
Stores, spares, consumables and packing materials		
Loose tools		
	<u>587,467</u>	<u>677,991</u>

Note 17: Cash and bank balances (Refer General instructions Note No. 20)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			257,073	308,818
Deposits with original maturity of less than 3 months				
Cash credit accounts				
On unpaid dividend account				
Cheques/drafts on hand				
Unpaid matured deposits				
Cash on hand				
			<u>257,073</u>	<u>308,818</u>
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
Amount disclosed under non-current assets			<u>257,073</u>	<u>308,818</u>

FOR THE
GRAND
DATE 30/01/2015
SIGNATURE BOA

Aurobindo Pharma Romania Srl

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (RON)	Year ended March 31, 2014 (RON)
Note 18 : Revenue from operations (Refer General Instructions Note No. 23)														
Revenue from operations														
Sale of products														
Finished goods														
Traded goods	21,522	142,859	473,562	252,287	237,140	384,528	1,165,204	640,694	872,959	1,148,129	949,953	1,811,452	8,100,289	382,538
Sale of services														
Sale of dossiers/licenses														
Other operating revenue														
Scrap sales														
Other														34,247
Revenue from operations (gross)	21,522	142,859	473,562	252,287	237,140	384,528	1,165,204	640,694	872,959	1,148,129	949,953	1,811,452	8,100,289	416,774
Less: VAT/Excise duty/Rebates														
Revenue from operations (net)	21,522	142,859	473,562	252,287	237,140	384,528	1,165,204	640,694	872,959	1,148,129	949,953	1,811,452	8,100,289	416,774

Note 19 : Other income (Refer General Instructions Note No. 24)

Interest income on														
Bank deposits														
Long-term investments														
Current investments														
Loans to joint venture entities														
Others														
Dividend income on														
Investment in subsidiaries														
Current investments														
Long-term investments														
Net gain on sale of current investments														
Profit on sale of fixed assets (net)														
Foreign exchange gain (net)														
Balances no longer required written back														
Government grant														
Commission income														
Processing charges														
Other non-operating income (net of expenses directly attributable to such income of Rs.XXXXX (31 March, 2014:XXXX)														

Note 20 : Cost of raw material and components consumed

Inventory at the beginning of the period														
Add: Purchases														
Less: inventory at the end of the period														

DATE: 30/04/2015
804

Aurobindo Pharma Romania Srl

Notes to the statement of profit and loss

(All amounts are in local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (RON)	Year ended March 31, 2014 (RON)
Add Packing material consumed														
Cost of raw material and components consumed														

30/03/2015
BOA

Aurobindo Pharma Romania Srl
Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (RON)	Year ended March 31, 2014 (RON)
Note 21 : (Increase)/decrease in inventories														
Inventories at the end of the period														
Traded goods	611,646	641,469	503,327	419,382	500,892	591,880	447,436	323,841	339,620	412,146	659,944	587,467	587,467	677,991
Work-in-progress														
Finished goods	611,646	641,469	503,327	419,382	500,892	591,880	447,436	323,841	339,620	412,146	659,944	587,467	587,467	677,991
Inventories at the beginning of the period														
Traded goods	677,991	611,646	641,469	503,327	419,382	500,892	591,880	447,436	323,841	339,620	412,146	659,944	677,991	
Work-in-progress														
Finished goods	677,991	611,646	641,469	503,327	419,382	500,892	591,880	447,436	323,841	339,620	412,146	659,944	677,991	
	66,345	(29,823)	138,143	83,945	(81,511)	(90,988)	144,444	123,595	(15,780)	(72,526)	(247,798)	72,477	90,524	(677,991)
Details of purchase of traded goods														
Product A		91,824	110,676	28,591	154,504	178,544	97,760	256,165	235,279	307,383	689,822	795,023	2,945,572	832,407
Product B														
Product C														
	-	91,824	110,676	28,591	154,504	178,544	97,760	256,165	235,279	307,383	689,822	795,023	2,945,572	832,407
Note 22 : Employee benefit expense														
Salaries, wages and bonus	161,646	165,599	167,741	176,616	145,631	149,152	147,632	165,369	146,382	182,088	136,079	136,132	1,880,067	1,501,289
Contribution to provident and other fund	44,902	45,410	46,596	49,060	40,184	41,432	33,644	37,601	33,470	41,417	31,131	31,039	475,886	406,890
Employee stock option scheme													-	
Gratuity expense													-	
Other employee benefits													-	
Post employment medical benefits													-	
Staff welfare expenses													-	
	206,548	211,009	214,337	225,676	185,815	190,584	181,276	202,970	179,852	223,505	167,210	167,171	2,355,953	1,908,179

30/03/2015
BdA

Aurobindo Pharma Romania Srl
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (RON)	Year ended March 31, 2014 (RON)
Note 23 : Other expenses														
Consumption of stores and spares													-	-
Conversion charges													-	-
Chemicals consumed													-	-
Increase in VAT on finished goods													-	-
Customer service expenditure													-	-
Power and fuel													-	-
Water charges													-	-
Freight and forwarding charges													-	-
Carriage inward													-	-
Carriage outwards													-	-
Rent	11,021	11,137	12,648	11,103	11,103	12,602	12,672	12,672	12,672	12,875	12,875	2,267	135,645	112,293
Rates and taxes	585	92	92	92	3,100	181	1,742	3,306	534	158	158	3,446	13,488	3,770
Insurance	1,386	1,386	1,386	2,683	82	1,380	1,380	1,363	1,363	1,363	1,408	1,363	16,544	10,841
Repairs and maintenance													-	-
i) Plant and machinery													-	-
ii) Buildings	2,035	2,035	4,251	2,035	1,919	2,035	2,035	2,035	2,035	2,035	2,035	2,035	26,520	12,210
iii) Others	-	-	942	-	262	-	42,863	-	-	315	-	-	44,382	35,182
Advertising and sales promotion	3,220	21,429	67,497	2,153	12,263	11,966	(29,901)	75,104	41,983	21,802	55,488	112,322	395,275	57,381
Brokerage and discounts	(8,555)	8,567	5,481	1,881	1,827	1,836	1,845	1,875	2,059	1,702	1,831	1,709	22,061	
Remuneration to Auditors	2,152	14,286	47,356	25,229	23,714	38,453	116,520	64,069	87,296	114,813	94,996	47,755	676,639	18,778
Sales commission	25,301	27,270	19,236	23,149	21,664	25,539	31,587	19,282	20,213	20,431	22,789	30,626	287,087	240,676
Travelling and conveyance	1,974	2,533	2,557	3,052	1,989	2,202	3,340	2,270	2,541	2,865	3,080	2,573	30,927	16,206
Communication costs	71	522	326	260	403	319	365	333	641	451	250	111	4,056	5,183
Printing and stationery	21,247	18,816	15,361	19,829	20,153	21,482	31,891	33,013	30,046	22,670	25,055	26,759	285,722	252,093
Legal and professional fees													-	-
Directors sitting fees													-	-
Payment to auditor (Refer details below)													-	21,875
Provision for diminution in value of investment in subsidiary company													-	-
Provision for other than temporary decline in the carrying amount of other long-term investments													-	-
Adjustment to the carrying amount of current investments													-	-
Provision for warranties (net of reversals)													-	-
Provision for litigations (net of reversals)													-	-
Exchange differences (net)	2,449	(49,005)	(5,405)	21,290	6,185	5,909	(3,000)	12,179	50,302	(42,127)	5,443	(45,936)	(41,717)	23,607
Loss on derivative contracts (including provisions mark-to-market loss)													-	-
Bad debts/advances written off	(1,130)	(538)	(13,282)	(8,404)	(1,643)	13,437	(577)	146,160	(36,208)	(17,444)	25,115	(98,139)	7,347	56,145
Impairment loss on fixed assets													-	-
Provision for doubtful debts and advances													-	-
Loss on sale of fixed assets (net)													-	-
Premium on forward exchange contract amortized													-	-
Factory maintenance													-	-
Effluent treatment expenses													-	-

30/04/2015
BCA

Aurobindo Pharma Romania Srl

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (RON)	Year ended March 31, 2014 (RON)
Vehicle maintenance expenses	23,381	24,165	22,849	23,195	24,181	23,187	23,226	23,334	23,541	21,094	23,161	21,465	279,778	171,835
Analytical charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product development expenses	11,253	5,714	17,027	34,305	3,688	15,610	15,157	25,836	25,508	62,397	56,684	76,720	379,999	177,949
Registration and filing charges	12,337	12,337	129,370	36,994	28,605	20,472	20,409	20,409	20,409	12,337	28,620	20,254	362,563	262,078
Safety and security	300	300	300	300	300	300	300	300	300	300	300	300	3,600	3,600
Office expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	34,342
Repairs and maintenance - others	3,802	3,821	3,800	3,722	3,718	3,734	5,498	3,782	3,858	3,684	3,600	16,801	60,021	42,354
Management fees	1,843	1,843	1,843	3,259	3,348	3,294	1,807	2,511	642,325	86,260	60,886	146,959	956,178	252,149
Liquidated damages	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Donations	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Software license and implementation expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital work-in-progress written off	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Miscellaneous expenses	1,039	16,512	10,594	(28,862)	451	(931)	(296)	12,980	(25,294)	922	2,983	19,126	9,125	47,293
	115,710	123,223	344,233	177,265	167,212	203,007	278,863	492,814	906,128	331,403	426,866	388,518	3,955,241	1,879,840

30/03/2015
DCA

Aurobindo Pharma Romania Srl
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (RON)	Year ended March 31, 2014 (RON)
Payment to Auditor														
As auditor:														
Audit fee													-	-
Tax audit fee	(8,555)	8,567	5,484	1,881	1,827	1,836	1,845	1,875	2,059	1,702	1,831	1,709	22,061	23,875
Limited review													-	-
In other capacity:													-	-
Taxation matters													-	-
Company law matters													-	-
Management services													-	-
Other services (certification fees)													-	-
Reimbursement of expenses	(8,555)	8,567	5,484	1,881	1,827	1,836	1,845	1,875	2,059	1,702	1,831	1,709	22,061	23,875

Note 24 : Exceptional items

Others (Specify if any)

Note 25 : Depreciation and amortization expense

Depreciation of tangible assets	1,118	1,118	1,118	1,118	1,119	1,119	1,119	1,119	1,119	1,119	1,189	1,186	13,562	3,631
Amortization of intangible assets	75	75	75	75	75	75	75	75	75	75	75	75	901	376
Depreciation of investment property	1,194	1,194	1,194	1,193	1,194	1,194	1,194	1,194	1,194	1,194	1,264	1,261	14,463	4,007

Note 26 : Finance costs (Refer General Instructions Note No.22)

Interest												2,359	2,359	
Bank charges	537	494	469	557	414	424	461	596	837	467	596	389	6,240	8,056
Amortization of ancillary borrowing costs													-	-
Exchange difference to the extent considered as an adjustment to borrowing costs	537	494	469	557	414	424	461	596	837	467	596	2,748	8,599	8,056

DATE 30/04/2015
3004

Notes to the 2014-2015 financial statements

General

Relationship with parent company and principal activities

AUROBINDO PHARMA ROMANIA SRL, hereafter the company, having its legal address in Bucharest: Sos Bucuresti-Ploiesti 42-44, District 1, is a private limited liability company under Romanian law, with 99,9998% of its shares held by Agile Pharma B.V and 0.0002% of its shares held by Gorla Phaneendra Prasad. The ultimate parent company is Aurobindo Pharma Limited, seated in Hyderabad, India.

The activities of the company concern the distribution and sales of pharmaceutical products.

Going concern


These financial statements have been prepared on the basis of the going concern assumption. However, because of the financial position of the Company, there is significant doubt on the entity's ability to continue as a going concern without support of the Parent Company.

Comparative figures

The accounting policies have been consistently applied to all years presented. The comparative figures are 12 months.

Use of estimates

The preparation of the financial statements requires the management to form opinions and to make estimates and assumptions that influence the application of principles and the reported values of assets and liabilities and of income and expenditure. Actual results may differ from these estimates. The estimates and the underlying assumptions are constantly assessed. Revisions of estimates are recognised in the period in which the estimate is revised and in future periods for which the revision has consequences.



Basis of preparation

The financial statements have been prepared in accordance with the statutory provisions of Accounting Laws in Romania.

In general, assets and liabilities are stated at the amounts at which they were acquired or incurred, or current value. If not specifically stated otherwise, they are recognised at the amounts at which they were acquired or incurred. The balance sheet and profit and loss account include references to the notes.

An asset is disclosed in the balance sheet when it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the cost of the asset can be measured reliably. A liability is recognised in the balance sheet when it is expected to result in an outflow from the entity of resources embodying economic benefits and the amount of the obligation can be measured with sufficient reliability.

Income is recognised in the profit and loss account when an increase in future economic potential related to an increase in an asset or a decrease of a liability has arisen, the size of which can be measured reliably. Expenses are recognised when a decrease in the economic potential related to a decrease in an asset or an increase of a liability has arisen, the size of which can be measured with sufficient reliability.

If a transaction results in a transfer of future economic benefits and or when all risks relating to assets or liabilities transfer to a third party, the asset or liability is no longer included in the balance sheet. Assets and liabilities are not included in the balance sheet if economic benefits are not probable and/or cannot be measured with sufficient reliability.

The revenue and expenses are allocated to the period to which they relate. Revenues are recognized when the company has transferred the significant risks and rewards of ownership of the goods to the buyer.

Foreign currencies

The financial statements are presented in RON, the Romanian functional and presentation currency.

Transactions in foreign currencies

Transactions denominated in foreign currency are translated into the relevant functional currency of the company AUROBINDO PHARMA ROMANIA SRL at the exchange rate applying on the transaction date. Monetary assets and liabilities denominated in foreign currency are translated at the balance sheet date into the functional currency at the exchange rate applying on that date. Non-monetary assets and liabilities in foreign currency that are stated at historical cost are translated into euros at the applicable exchange rates applying on the transaction date. Translation gains and losses are taken to the profit and loss account as expenditure.


Financial assets and liabilities

Receivables

Receivables are carried at amortised cost on the basis of the effective interest method, less impairment losses.

Financial liabilities

Financial commitments that are not held for trading are carried at amortised cost on the basis of the effective interest rate method.



Impairment of financial assets

Objective evidence that financial assets are impaired includes default or delinquency by a debtor, indications that a debtor or issuer will enter bankruptcy, adverse changes in the payment status of borrowers or issuers, economic conditions that correlate with defaults or the disappearance of an active market for a security.

The entity considers evidence of impairment for financial assets measured at amortised cost (receivables) at both a specific asset and collective level. All individually significant assets are assessed for specific impairment. Those found not to be specifically impaired are then collectively assessed for any impairment that has been incurred but not yet identified. Assets that are not individually significant are collectively assessed for impairment by grouping together assets with similar risk characteristics.

In assessing collective impairment, the company uses historical trends of the probability of default, the timing of recoveries and the amount of loss incurred, adjusted for management's judgement as to whether current economic and credit conditions are such that the actual losses are likely to be greater or lesser than suggested by historical trends.

An impairment loss in respect of a financial asset measured at amortised cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognised in profit or loss and reflected in an allowance account against receivables. Interest on the impaired asset continues to be recognised. When an event occurring after the impairment was recognised causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss.

Tangible fixed assets

Land and buildings, prepayments on tangible fixed assets and other fixed operating assets are stated at cost of acquisition or manufacture, less accumulated depreciation.

Depreciation is recognised in profit or loss on a straight-line basis over the estimated useful lives of each item of the tangible fixed assets. Land, tangible fixed assets in production and prepayments on tangible fixed assets are not depreciated.


The following rates of depreciation are applied:

- other fixed operating assets: 1-10 years

Impairment

Assets with a long life should be tested for impairment in the case of changes or circumstances arising that lead to an indication that the carrying amount of the asset will not be recovered. The recoverability of assets in use is determined by comparing the carrying amount of an asset with the estimated present value of the future net cash flows which the asset is expected to generate.

If the carrying amount of an asset exceeds the estimated present value of the future cash flows, impairment is charged to the difference between the carrying amount and the recoverable amount.



Impairment of fixed assets

As at each balance sheet date, the Company tests whether there are any indications of assets being subject to impairment. If any such indications exist, the recoverable amount of the asset is determined. If this proves to be impossible, the recoverable amount of the cash-generating unit to which the asset belongs is identified. An asset is subject to impairment if its carrying amount exceeds its recoverable amount; the recoverable amount is the higher of an asset's fair value less costs to sell and value in use.

An impairment loss is directly expensed in the income statement.

If it is established that a previously recognised impairment loss no longer applies or has declined, the increased carrying amount of the assets in question is not set any higher than the carrying amount that would have been determined had no asset impairment been recognised.

Inventories

Merchandises and consumables are stated at the lower of cost and net realisable value. Cost is determined using the first in, first out (FIFO) method.

Acquisition price comprises all purchase costs and other costs incurred in bringing the inventories to their present location and conditions

Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. Net realisable value is determined making allowance for obsolescence of inventories.

Receivables

The accounting policies applied for the valuation of trade and other receivables are described under the heading 'Financial instruments'.

Cash and cash equivalents

Cash and cash equivalents include cash in hand and bank balances with maturities of less than 12 months. Bank overdrafts are shown within borrowings in current liabilities on the balance sheet. Cash and cash equivalents are stated at face value.

Provisions

A provision is recognised if the following applies:

- the company has a legal or constructive obligation, arising from a past event; and
- the amount can be estimated reliably; and
- it is probable that an outflow of economic benefits will be required to settle the obligation.

Revenue recognition

Sale of goods

Revenue from the sale of goods is measured at the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates. Revenue is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of consideration is



probable, the associated costs and possible return of goods can be estimated reliably, and there is no continuing management involvement with the goods.

The transfer of risks and benefits varies according to the conditions of the relevant sales contract.

Cost of sales

This concerns costs that are directly attributable to net turnover.

Selling expenses and general and administrative expenses

Selling expenses and general and administrative expenses comprise costs chargeable to the year that are not directly attributable to the cost of the goods and services sold.

Operating leases

Lease contracts for which a large part of the risks and rewards incidental to ownership of the assets does not lie with the Company, are recognised as operating leases. Obligations under operating leases are recognised on a straight-line basis in the income statement over the term of the contract, taking into account reimbursements received from the lessor.

Interest paid and received

Interest paid and received is recognised on a time-weighted basis, taking account of the effective interest rate of the assets and liabilities concerned. When recognising interest paid, allowance is made for transaction costs on loans received as part of the calculation of effective interest.

Corporate income tax

Corporate income tax comprises the current and deferred corporate income tax payable and deductible for the reporting period.

Corporate income tax is recognised in the profit and loss account except to the extent that it relates to items recognised directly to equity, in which case it is recognised in equity.


Current tax comprises the expected tax payable or receivable on the taxable profit or loss for the financial year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to the tax payable in respect of previous years.

Deferred tax is provided for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilised. Deferred tax assets are reviewed at each reporting date and reduced to the extent that it is no longer probable that the related tax benefit will be realised.



HUGH RICHARD WATKINS



Directors' Report

The management herewith presents the annual accounts of Aurobindo İlaç Sanayi ve Ticaret Ltd. Şti. for the year ended 31st March, 2015

PRINCIPAL ACTIVITY

The principle object of the company is to have marketing authorizations pharmaceutical products to be ready for trading. There is no active marketing operation in Turkey subsidiary.

REVIEW OF OPERATIONS

The directors of company have reviewed and discussed about the operations of the company. During the year, company received 28 Marketing Authorizations on strength basis belong to 11 molecules. The company has no revenue yet and the company made a loss TRY 528,813 during FY-15 after taking depreciation into consideration.

DIRECTORS

The Directors at the date of the report are

Mr. G. P. Prasad

Mr. Muralidharan V

Mrs. N. Tugba Kiymaz

AUDITORS

The auditors, Ertugrul Ozdemir, CPA have expressed their willingness to accept the financial statement to meet the legal requirements in line with generally accepted standards in Turkey.

THE DIRECTORS OF THE COMPANY DECLARS THAT:


The financial statements and notes comply with Accounting Standards as detailed in Notes to the financial statements, and present fairly the company's financial position as at March 31, 2015.

Disclosure of information to Auditors

So far as each director at the date of approval of this report is aware

- There is no relevant audit information of which the company's auditors are unaware; and
- The directors have taken all steps that they ought to have taken to make them aware of any relevant audit information and to establish that the auditors are aware of that information.

Board approved this report on 16th April, 2015



Muralidharan V
Director

ERTUĞRUL ÖZDEMİR**SERBEST MUHASEBECİ MALİ MÜŞAVİR**

Ahmet Kutsi Tecer Sok. No 22/1 81570 Kuşlukyali - Maltepe - İstanbul Tel: 0216 489 56 46 - Faks 489 56 49
e-mail ertugrul_ozdemir@ismmmo.org.tr ISMMMO Sicil No 11532 Kuşlukyali V D T.C. Kimlik No. 139 554 395 04

AUDITOR'S REPORT

As external auditors, we have audited the accounting records and the financial statements (balance sheet and income statement) of Aurobindo İlaç Sanayi ve Ticaret Limited Şirketi for the period from April 01, 2014 to March 31, 2015.


These financial statements are the responsibility of the manager. Our responsibility is to express an opinion on these financial statements based on our audit. We confirm that we meet the legal requirements concerning professional qualification and independence.

We conducted our audits in accordance with auditing standards generally accepted in Turkey. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit includes examining, on test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the accounting records and the financial statements gives a true and fair view and comply with Turkish law and the company's articles of incorporation.

İstanbul April 16,2015


ERTUĞRUL ÖZDEMİR
Certified Public Accountant
TÜRKİYE
M
SERBEST
MUHASEBECİ
MALİ MÜŞAVİR
03711

AUROBINDO ILAC SANAYI VE TICARET LTD, SRL, TURKEY**Balance Sheet as at March 31, 2015**

(All amounts are in TRY Currency except share data and unless otherwise stated)

	Note	31 March, 2015 (TRY)	31 March, 2014 (TRY)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	4.500.000	2.000.000
Share application money		2.175.763	2.620.265
Reserves and surplus	3	(2.393.515)	(1.864.702)
		4.282.248	2.755.563
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		-	-
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	-	-
Other current liabilities	9	41.980	40.987
Short-term provisions	7	-	-
		41.980	40.987
TOTAL		4.324.227	2.796.550
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	3.569	288
Intangible assets	11	16.421	-
Capital work-in-progress			
Intangible assets under development		3.293.773	2.533.199
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	-	-
Trade receivables	14,1	-	-
Other non-current assets	14,2	-	-
		3.313.763	2.533.487
Current assets			
Current investments	15	-	-
Inventories	16	-	-
Trade receivables	14,1	-	-
Cash and bank balances	17	721.267	25.804
Short-term loans and advances	13	289.196	237.259
Other current assets	14,2	-	-
		1.010.464	263.063
TOTAL		4.324.227	2.796.550
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.

AUROBINDO ILAC SANAYI VE TICARET LTD, SRL, TURKEY
Statement of profit and loss for the Year ended 31st March 2015
(All amounts are in TRY except share data and unless otherwise stated)

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (TRY)	Year ended March 31, 2014 (TRY)
Income															
Revenue from operations (gross)	18	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Excise duty/Rebates		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from operations (net)		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income	19	-	-	(2.523)	16.788	700	6.936	6.790	35.151	6.774	-	6.658	1.427	78.702	16.249
Total revenue (I)		-	-	(2.523)	16.788	700	6.936	6.790	35.151	6.774	-	6.658	1.427	78.702	16.249
Expenses															
Cost of raw material and components consumed	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods	21	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Employee benefit expense	22	20.401	21.206	20.447	20.506	27.042	21.767	20.319	22.023	22.021	21.731	21.822	21.822	261.107	242.033
Other expenses	23	18.481	20.682	29.162	14.737	26.784	65.794	46.649	36.864	19.172	24.933	17.585	17.152	337.995	204.709
Exceptional items	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total (II)		38.883	41.887	49.609	35.243	53.827	87.562	66.968	58.887	41.193	46.663	39.407	38.974	599.101	446.742
Earnings before interest, tax, depreciaton and amortization (EBITDA)		(38.883)	(41.887)	(52.131)	(18.455)	(53.127)	(80.626)	(60.178)	(23.735)	(34.418)	(46.663)	(32.749)	(37.547)	(520.399)	(430.493)
Depreciation and amortization expense	25	149	149	149	149	149	149	813	226	226	226	226	226	2.841	6.128
Finance costs	26	237	543	447	2.200	635	304	286	267	257	115	157	126	5.573	4.449
Profit/(loss) before tax		(39.269)	(42.580)	(52.728)	(20.804)	(53.911)	(81.079)	(61.276)	(24.229)	(34.901)	(47.005)	(33.133)	(37.898)	(528.813)	(441.070)
Tax expenses															
Current tax														-	-
Less: MAT credit entitlement														-	-
Deferred tax														-	-
Fringe benefit tax														-	-
Tax relating to previous years														-	-
Total tax expense		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Profit/(loss) for the Current Period/year		(39.269)	(42.580)	(52.728)	(20.804)	(53.911)	(81.079)	(61.276)	(24.229)	(34.901)	(47.005)	(33.133)	(37.898)	(528.813,48)	(441.070)

Summary of significant accounting policies

1

The accompanying notes are an integral part of the financial statements.

271

AUROBINDO ILAC SANAYI VE TICARET LTD, SRL, TURKEY**Notes to the Balance Sheet**

(All amounts are in TRY Currency except share data and unless otherwise stated)

Note 1 : Summary of significant accounting policies (Refer General Instructions Note No.1)

- 1,1
- 1,2
- 1,3
- 1,4
- 1,5

Note 2 : Share capital (Refer General Instructions Note No 2)

	MAR 31, 2015	March 31, 2014
Authorised shares:		
80,000 (31 March, 2014: 80,000) equity shares of TL 25/- each	4.500.000	2.000.000
	<u>4.500.000</u>	<u>2.000.000</u>
Issued, Subscribed and Fully Paid-up shares:		
180,000 (31 March, 2014: 80000) equity shares of 25 TL each fully paid-up	4.500.000	2.000.000
Share Application money (in process)	2.175.763	2.620.265



AUROBINDO ILAC SANAYI VE TICARET LTD, SRL, TURKEY

Notes to the Balance Sheet

(All amounts are in TRY Currency except share data and unless otherwise stated)

Note 3 : Reserves and surplus (Refer General Instructions Note No.3)

	MAR 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	-	-
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet	-	-
General Reserve		
As per last Balance Sheet		
Add: Transferred from statement of profit and loss	-	-
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	(1.864.702)	(1.423.632)
Profit for the quarter	(528.813)	(441.070)
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)		
Tax on proposed equity dividend		
Interim dividend paid (amount per share XX (31 March, 2014 XX)		
Transfer to general reserve		
Total appropriations	-	-
Net surplus in the statement of profit and loss	(2.393.515)	(1.864.702)
Total reserves and surplus	(2.393.515)	(1.864.702)

Note 4 : Long-term borrowings (Refer General Instructions Note No.4)

	Non-current Portion		Current maturities	
	MAR 31, 2015	March 31, 2014	MAR 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)				
Other Loans from banks				
Current account credit balance				
Loans and advances from related parties				
Other Loans and advances				
Sales tax deferment loan (Un Secured)				
The above amount includes				
Secured borrowings				
Unsecured borrowings				
Amount disclosed under the head				
"Other current liabilities"				
Net Amount				

AUROBINDO ILAC SANAYI VE TICARET LTD, SRL, TURKEY

Notes to the Balance Sheet

(All amounts are in TRY Currency except share data and unless otherwise stated)

Note 5 : Deferred tax liability (net)

	MAR 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis		
Provision for diminution in the value of investments		
Provision for doubtful debts and advances		
Fixed Assets (Depreciation)		
Retirement Benefits		
Others		
Gross deferred tax liability	-	-
Deferred tax asset		
Carried Forward Business Losses		
Others		
Gross deferred tax asset	-	-
Net deferred tax liability	-	-

Note 6 : Other long-term liabilities (Refer General Instructions Note No.5)

	MAR 31, 2015	March 31, 2014
Trade payables (including acceptances)		
Others		
Advances from customers		
Unclaimed dividends		
Other liabilities		
Interest accrued but not due on loans		
Advances from related parties	-	-
	-	-

Note 7 : Provisions (Refer General Instructions Note No.6 & 10)

	Non-current		Current	
	MAR 31, 2015	March 31, 2014	MAR 31, 2015	March 31, 2014
Provision for employee benefits				
- Gratuity				
- Leave encashment				
	-	-	-	-
Other Provisions				
For Taxation (net of advance payments)				
For Proposed dividend				
For Tax on proposed dividend				
	-	-	-	-
	-	-	-	-

Provision for warranties

	MAR 31, 2015	March 31, 2014
At the beginning of the year		
Arising during the period		
Utilised during the period		
Unused amounts reversed		
At the end of the Quarter	-	-
Current portion		
Non-current portion		

Note 8 : Short-term borrowings (Refer General Instructions Note No.7)

	MAR 31, 2015	March 31, 2014
Bank overdraft		
Loans and advances from related parties		
Working capital loans (Secured)		
Short term loans (Un Secured)		
Working capital loans	-	-
The above amount includes		
Secured borrowings	-	-
Unsecured borrowings	-	-

Note 9 : Other current liabilities (Refer General Instructions Note No.9)

	MAR 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)		
Other liabilities	9.721	
Other liabilities (Salaries + sal tax Payable)	24.875	23.365
Other Liabilities (Rent stoppage+note of exps+CPA Stopage)	2.267	1.198
Other Liabilities (Social security employer+unemployment)	4.159	3.278
Other liabilities (Incl Intertrust)	957	13.745
Current maturities of long-term borrowings		

AUROBINDO ILAC SANAYI VE TICARET LTD. SRL, TURKEY


Notes to the Balance Sheet

(All amounts are in TRY Currency except share data and unless otherwise stated)

Trade deposits

41.980 40.987

41.980 40.987



Note 10 : Tangible assets (Refer General Instructions Note No.11)

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment (including Computers & Software)	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation									
At 1 April 2013						27.678			27.678
Additions						359			359
Disposals									-
Other adjustments						1.444			1.444
- Exchange differences									-
- Borrowing costs									-
At 31 March 2014	-	-	-	-	-	26.593	-	-	26.593
Additions						4.617			4.617
Acquisitions through amalgamation									-
Disposals									-
Other adjustments									-
- Exchange differences									-
- Borrowing costs									-
At 31 Mar 2015	-	-	-	-	-	31.210	-	-	31.210
Depreciation									
At 1 April 2013						24.611			24.611
Charge for the year						1.694			1.694
Disposals									-
Other adjustments									-
- Exchange differences									-
At 31 March 2014	-	-	-	-	-	26.305	-	-	26.305
Charge for the period						1.336			1.336
Disposals									-
Other adjustments									-
- Exchange differences									-
At 31 Mar 2015	-	-	-	-	-	27.641	-	-	27.641
Impairment loss									
At 1 April 2013									
At 31 March 2014									
Charge for the period									
At 31 Mar 2015									
Net Block									
At 31 March 2014	-	-	-	-	-	288	-	-	288

AUROBINDO ILAC SANAYI VE TICARET LTD, SRI., TURKEY

Notes to the Balance Sheet

(All amounts are in TRY Currency except share data and unless otherwise stated)

At 31 Mar 2015	-	-	-	-	-	3.569	-	-	3.569
----------------	---	---	---	---	---	-------	---	---	-------

Note 11 : Intangible assets (Refer General Instructions Note No.12)

	Goodwill	Filings and registrations under process	Licences and patents	Total
Gross block				
At 1 April 2013		1.985.303		1.985.303
Purchase		551.480		551.480
Internal development				-
Disposals				-
Other adjustments		1.085		1.085
- Exchange differences				-
At 31 March 2014	-	2.537.867	-	2.537.867
Purchase		1.328.329	22.595	1.350.924
Acquisitions through amalgamation				-
Disposals				-
Other adjustments (withdrawals)		572.423		572.423
- Exchange differences				-
At 31 Mar 2015	-	3.293.773	22.595	3.316.368
Amortization				
At 1 April 2013				-
Charge for the year			4.668	4.668
Disposals				-
Other adjustments				-
- Exchange differences				-
At 31 March 2014	-	-	4.668	4.668
Charge for the period			1.506	1.506
Disposals				-
Other adjustments				-
- Exchange differences				-
At 31 Mar 2015	-	-	6.174	6.174
Net Block				
At 31 March 2014	-	2.537.867	(4.668)	2.533.199
At 31 Mar 2015	-	3.293.773	16.421	3.310.194

AUROBINDO ILAC SANAYI VE TICARET LTD, SRL, TURKEY

Notes to the Balance Sheet

(All amounts are in TRY Currency except share data and unless otherwise stated)

Note 12 : Non-current investments (Refer General Instructions Note No.13)

MAR 31, 2015 March 31, 2014

Unquoted equity instruments
Investment in subsidiaries
Investment in joint ventures
Investment in associates

- -

Note 13 : Loans and advances (Refer General Instructions Note No.14 & 21)

		Non-current		Current	
		MAR 31, 2015	March 31, 2014	MAR 31, 2015	March 31, 2014
Capital advances					
Secured, considered good					
Unsecured, considered good	(A)	-	-	-	-
Security deposit					
Secured, considered good				1.450	1.450
Unsecured, considered good					
Doubtful					
		-	-	1.450	1.450
Provision for doubtful security deposit	(B)	-	-	1.450	1.450
Loan and advances to related parties					
Unsecured, considered good	(C)	-	-	-	-
Advances recoverable in cash or kind					
Secured, considered good					
Unsecured, considered good					
Doubtful					
		-	-	-	-
Provision for doubtful advances	(D)	-	-	-	-
Other loans and advances					
Prepaid expenses (private health insurance)				300	674
Loans to employees (work advances Tugba)				6.892	3.757
Work advance to intertrust				461	1.884
Superonline communication services advance				-	
Office Insurance				89	
Rent Advance to Reba Akan Co Ltd				11.817	
Loans to others (Minimum Living Allowence)				541	482
				-	
Solomon Selim Aktas					
License Taxes 2014 (Tax Office)				-	-
Balances with Statutory/government authorities (def VAT)	(E)			267.646	229.012
		-	-	287.746	235.809
Total (A+B+C+D+E)		-	-	289.196	237.259

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	MAR 31, 2015	March 31, 2014	MAR 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors				
Dues from officers				
Dues from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner				
Dues from in which the company's managing director is a member				
Dues from the partnership firm in which the company's non-executive director is a partner				

AUROBINDO ILAC SANAYI VE TICARET LTD, SRL, TURKEY

Notes to the Balance Sheet

(All amounts are in TRY Currency except share data and unless otherwise stated)

Note 14 : Trade receivables and other assets

14.1 Trade receivable (Refer General Instructions Note No.15 & 19)

	Non-current		Current	
	MAR 31, 2015	March 31, 2014	MAR 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful				
Provision for doubtful receivables				
(A)				
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful				
Provision for doubtful receivables				
(B)				
Total (A+B)				

Trade receivables include:

	Non-current		Current	
	MAR 31, 2015	March 31, 2014	MAR 31, 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				

14.2 Other assets (Refer General Instructions Note No.16 & 22)

	Non-current		Current	
	MAR 31, 2015	March 31, 2014	MAR 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)				
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)				
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on investments in subsidiaries - long term				
Others				
(C)				
Total (A+B+C)				

AUROBINDO ILAC SANAYI VE TICARET LTD, SRL, TURKEY

Notes to the Balance Sheet

(All amounts are in TRY Currency except share data and unless otherwise stated)

Note 15 : Current Investments (Refer General Instructions Note No.17)

	MAR 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any (Please specify)		

Note 16 : Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No 18)

	MAR 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)		
Work - in - Progress		
Finished goods		
Traded goods (including stock -in-transit XXXX (31 March, 2014 XXX)		
Stores, spares, consumables and packing materials		
Loose tools		

Note 17 : Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	MAR 31, 2015	March 31, 2014	MAR 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts				
On current accounts - YKB Merkez 85143656 TL			0.22	25.804
On current accounts - HSBC BANK 666-1000437-282-00-TL			470.297	
On current accounts - HSBC BANK 666-1000437-773-99-EURO			250.970	
On unpaid dividend account				
Unpaid matured deposits				
Cash on hand				
			721.267	25.804
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
Amount disclosed under non-current assets			721.267	25.804

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (TRY)	Year ended March 31, 2014 (TRY)
Note 18: Revenue from operations (Refer General Instructions Note No.25)														
Revenue from operations														
Sale of products														
Finished goods													-	-
Traded goods													-	-
Sale of services													-	-
Sale of dossiers/licenses													-	-
Other operating revenue													-	-
Scrap sales													-	-
Other													-	-
Revenue from operations (gross)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: VAT/Excise duty/Rebates													-	-
Revenue from operations (net)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 19: Other income (Refer General Instructions Note No.26)														
Interest income on														
Bank deposits													-	-
Long-term investments													-	-
Current investments													-	-
Loans to joint venture entities													-	-
Others													-	-
Dividend income on													-	-
Investment in subsidiaries													-	-
Current investments													-	-
Long-term investments													-	-
Net gain on sale of current investmentss													-	-
Profit on sale of fixed assets (net)													-	-
Foreign exchange gain (net)			3.801	10.464	700	6.936	6.790	35.151	6.774	-	6.658	1.427	78.702	21.794
Balances no longer required written back													-	(235)
Prior Period Expenses and Losses (-)													-	(5.310)
Commission income			(6.324)	6.324									-	-
Processing charges													-	-
Other non-operating income (net of expenses directly attributable to such income of Rs.XXXXX (31 March, 2014:XXXX)													-	-
	-	-	(2.523)	16.788	700	6.936	6.790	35.151	6.774	-	6.658	1.427	78.702	16.249
Note 20: Cost of raw material and components consumed														
Inventory at the beginning of the period	-												-	-
Add: Purchases	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: inventory at the end of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-

AUROBINDO ILAC SANAYI VE TICARET LTD, SRL, TURKEY

Notes to the statement of profit and loss

(All amounts are in TRY Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (TRY)	Year ended March 31, 2014 (TRY)
Add:Packing material consumed														
Cost of raw material and components consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 21 : (Increase)/decrease in inventories														
Inventories at the end of the period														
Traded goods														-
Work-in-progress														-
Finished goods														-
Inventories at the beginning of the period														
Traded goods														-
Work-in-progress														-
Finished goods														-
Details of purchase of traded goods														
Product A													-	-
Product B													-	-
Product C													-	-
Note 22 : Employee benefit expense														
Salaries, wages and bonus	17.171	17.171	17.171	17.171	23.020	18.029	16.473	18.029	18.029	18.029	18.029	18.029	216.353	205.456
Social Security Fee Employer Contribution	1.568	2.068	1.564	1.647	1.991	1.632	1.661	1.669	1.667	1.736	1.719	1.719	20.642	18.417
Unemployment Security Fee	202	202	202	210		214	214	215	215	222	222	222	2.339	2.323
Transportation	210	210	210	210	210	223	244	245	245	210	210	210	2.635	2.635
Other employee benefits													-	-
Post employment medical benefits (Private Health insurance)	416	749	494	461	519	461	519	519	519	420	461	461	5.998	3.980
Staff welfare expenses (Lunch Aid)	835	807	807	807	1.302	1.207	1.207	1.346	1.346	1.114	1.181	1.181	13.140	9.222
	20.401	21.206	20.447	20.506	27.042	21.767	20.319	22.023	22.021	21.731	21.822	21.822	261.107	242.033
Note 23 : Other expenses														
Consumption of stores and spares													-	-
Conversion charges													-	-
Chemicals consumed													-	-
Increase in VAT on finished goods													-	-
Customer service expenditure													-	-
Power and fuel	63	48		56	100	87	52	112	101	101	83	128	932	765
Water charges	24	34	51	42	33	43	17	43	27	35	36	36	422	370
Freight and forwarding charges													-	-
Carriage inward													-	-
Carriage outwards													-	-
Rent	3.424	2.250	2.250	2.250	2.250	2.250	2.250	2.250	2.250	2.438	2.438	2.438	28.737	37.090

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (TRY)	Year ended March 31, 2014 (TRY)
Rates and taxes	48	90	48	75	48	90	75	90	48	82	99	52	843	1.348
Insurance	20		41	12	36	24	25	24	25	25	25	23	283	294
Repairs and maintenance													-	
i) Plant and machinery													-	
ii) Buildings													-	
iii) Others													-	
Advertising and sales promotion	384		146	839									1.368	
Brokerage and discounts													-	
Remuneration to Auditors													-	
Sales commission													-	
Travelling and conveyance (petrol, carparking, car rentals, foreign travel)	1.461		3.035	652	5.796	5.969	3.000	1.623	2.079	2.302	2.299	1.606	29.822	30.154
Communication costs	321	320	287	440	328	132	643	320	341	188	421	336	4.077	3.113
Printing and stationery	35	482				536		24	55			48	1.180	638
Translation fee						7.416			52		91	300	7.859	4.500
Postage/courier expenses	202	542	176	116	146	59	36	15	64	289	28	65	1.739	2.663
Payment to auditor (Refer details below)													-	
Provision for diminution in value of investment in subsidiary company													-	
Provision for other than temporary decline in the carrying amount of other long-term investments													-	
Adjustment to the carrying amount of current investments													-	
Provision for warranties (net of reversals)													-	
Provision for litigations (net of reversals)													-	
Exchange differences (net)	533	1.865	5.844			33.666	13.914	13.201		7.181			76.204	
Loss on derivative contracts (including provisions mark-to-market loss)													-	
Bad debts/advances written off													-	
Impairment loss on fixed assets													-	
Provision for doubtful debts and advances													-	
Loss on sale of fixed assets (net)													-	
Premium on forward exchange contract amortized													-	
Factory maintenance													-	
Effluent treatment expenses													-	
Vehicle maintenance expenses													-	
Analytical charges													-	
Product development expenses (seminor)						2.704							2.704	4.996
Registration and filing charges (notary, chamber dues, customs)	1.472	3.265	6.311	(6.311)					1.212	29	200	32	6.209	5.352
Safety and security													-	
Office expenses (monthly office dues)	156	156	156	156	156	156	156	260	224	156	351	156	2.235	4.379
Repairs and maintenance - Fixed Assets		483			156	156	156	156	156	156	156	156	1.733	1.634
Legal and professional fees (consultancy, and accounting service fee)	10.172	10.765	10.585	16.225	17.311	12.277	25.020	18.514	12.205	11.738	11.049	11.563	167.424	107.068
Liquidated damages													-	
Donations													-	
Software license and implementation expenses													-	
Capital work-in-progress written off													-	

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (TRY)	Year ended March 31, 2014 (TRY)
Miscellaneous expenses	168	381	232	186	425	229	1.305	231	333	213	309	213	4.224	345
	18.481	20.682	29.162	14.737	26.784	65.794	46.649	36.864	19.172	24.933	17.585	17.152	337.995	204.709
Payment to Auditor														
As auditor:														
Audit fee													-	
Tax audit fee													-	
Limited review													-	
In other capacity:														
Taxation matters													-	
Company law matters													-	
Management services													-	
Other services (certification fees)													-	
Reimbursement of expenses													-	
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 24 : Exceptional items														
Others (Specify if any)													-	-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 25 : Depreciation and amortization expense														
Depreciation of tangible assets	24	24	24	24	24	24	687	101	101	101	101	101	1.335	4.260
Amortization of intangible assets	126	126	126	126	126	126	126	126	126	126	126	126	1.506	1.868
Depreciation of investment property													-	
	149	149	149	149	149	149	813	226	226	226	226	226	2.841	6.128
Note 26 : Finance costs (Refer General Instructions Note No.27)														
Interest													-	
Bank charges	237	543	447	2.200	635	304	286	267	257	115	157	126	5.573	4.449
Amortization of ancillary borrowing costs													-	
Exchange difference to the extent considered as an adjustment to borrowing costs													-	
	237	543	447	2.200	635	304	286	267	257	115	157	126	5.573	4.449

Aurobindo Ilac Sanayi Ve Ticaret Limited Sirketi

Notes to the Financial Statements for the Year ended 31st March, 2015

1. Activity of the Company

Aurobindo Ilac Sanayi Ve Ticaret Limited Sirketi referred to as "Aurobindo Turkey" was incorporated in Madrid on 25th November, 2009. The Registered Office of the Company is located in Floor 28, Suit No. 172, Çeçen Sokak Ankara Asfaltı Yolu 4.Km, Acıbadem Mahallesi, Üsküdar, Turkey.

Pursuant to the Articles of its by-laws, the corporate purpose of the company is as follows:

- To buy, sell, import, export or store any pharmaceutical products
- To acquire, hold, develop, dispose or exploit industrial property rights.
- To provide all types of marketing support

The Sole Shareholder of the company as at 31st March, 2015 is Helix Healthcare B.V., legally seated in Amsterdam (Prins Bernhardplein 200, 1097 JB Amsterdam, The Netherlands) and registered with the Registry of Chamber of Commerce of Amsterdam under number 34187780.

2. Basis of Preparation and Presentation of Annual Accounts

True and fair view

The financial statements have been prepared by the Company's Board of Directors using all the Company's accounting registries upto 31st March, 2015. These annual accounts show the true and fair view of the equity, financial position and results of the company.

There are no reasons why, in representing the true and fair view, any legal accounting regulations have not been applied.

The attached annual accounts will be subject to examination by the Only Shareholder, with the expectation that they will be approved without any changes needing to be made.

3. Accounting Policies

The main accounting criteria applied are as follows:

a. Intangible Assets

"Concessions, patents, licenses and trade mark" are capitalized including registration fees for the industrial property. Subsequently, measured at cost less accumulated depreciation and impairment losses they experienced. Amortization is carried out systematically in ten years.

b. Property, Plant and Equipment

Items included in "Property, Plant and Equipment" are represented on the balance sheet by way of their purchase cost or production cost minus their accumulative amortization and loss of value through deterioration.

The company depreciates its fixed assets by distributing the cost of assets depending on its estimated economic life according to the following:

	Depreciation Rate
Building	20%
Furniture	10%
Information Processing Equipment	.25%

The Company uses a straight line method when calculating depreciation for all its fixed assets.

c. Classification of assets and liabilities

In the balance sheet, assets and liabilities with maturity of less than twelve months from the end of the reporting period are classified as current, while those maturing more than twelve months are classified as non-current.

d. Inventories

Goods for resale are valued downwards to their purchase price or their net realizable value. The purchase price is the amount billed by the provider less the discounts and interests incorporated into the nominal value of the debits, plus any additional costs so that stocks are ready for sale.

The cost of goods to the various units of inventories is assigned by applying the weighted average method.

e. Income and expenditure

Income and expenditure are accounted depending on the payment criteria, irrespective of the moment in which the monetary or financial effects derived from them occur.

The company only includes the profits yielded on the date of the periods close but, any foreseen risks and losses are accounted for as soon as they are known.

Income through the sale of goods or services is only recognized by the fair value received or to be received. Discounts by way of early payment, volume or other discount types, as well as interests incorporated into the nominal value of the credits are recorded as deductions.

f. Provisions and contingencies

In the preparation of the annual accounts the management differentiates between:

Provisions: Liabilities that cover present obligations at the balance sheet date which result from past events which could give rise to a loss of probable realization for the entity, which amount and time of cancellation are indeterminate. The balances are recognized at the present value of the most probable estimated amount that the company will have to pay to settle the obligation.

Contingent Liabilities: Possible obligations as a result from past events and whose existence depends on the occurrence or not one or more future events beyond the control of the entity.

The annual accounts include all the material provisions with respect to which it is estimated that the probability of having to meet the obligation is greater than the opposite. Contingent liabilities, if any, are the subject of information.

Provisions, which are quantified on the best information available on the consequence of the event giving rise to them and are re-estimated at each balance sheet date are used to meet the specific obligations for which they were originally recognized. Provisions are reversed in full or in part when such obligations cease to exist or are reduced.

g. Financial instruments

Financial assets and liabilities are categorized according to the instrument's characteristics and the reason behind its purchase. Financial assets held by the company are classified as:

Loans and receivables are trade and non-trade credits which come from the sale of goods or from services rendered, whose payments are of a determined or determinable value and are not negotiated on any active markets. The company records the corresponding impairments by the difference between the value to be reclaimed from the pending accounts and the book value for which they were recorded whether there is objective evidence of impairment.

Held to maturity investments are those debt values which have fixed maturity date, determined or determinable payments, are negotiated on an asset market and ones which the company has the intention and capacity to maintain up until their maturity. The assessment criteria for these investments are the same as those used for loans and receivables.

3. Reporting currency

The reporting currency used for the preparation of the financial statements is TRY, which is the currency in which the Company's share capital is denominated


4. Share capital

Ordinary shares are classified as equity.


5. Performance

During the Period, the company incurred a net loss of TRY 528,813. These financial statements have been prepared on a basis in view of the fact that the company's shareholders have decided and liquidated the company.

By Order of the Board on 30th April, 2015



Gorla Phaneendra Prasad
Director



Muralidharan Venugopalan
Director

Directors' Report

The management herewith presents to the shareholders the annual accounts of Aurobindo Pharma (Portugal) Unipessoal Lda for the year ended 31st March, 2015.

Principal Activity

The principle object of the company is to trade, deal in pharmaceutical products and other allied products and services.

Review of Operations

The directors of the company have discussed and reviewed company's operations. During the year, your company has registered a turnover of €3,101,476 (YoY growth of 12.9%) and made a loss of €2,239,325 after considering appropriate Depreciation/Amortizations.

Directors

The Directors at the date of the report are:

Mr.G.P.Prasad

Mr.Manoj Prakash

Mr.Muralidharan V

Auditors

The Auditors, Grant Thornton & Associados - SROC, Lda. have accepted to be the Auditors of the Company.

The Directors of the Company declares that:


The Financial Statements and notes comply with Accounting Standards as detailed in Notes to the Financial Statements and present fairly the company's financial position as at 31st March, 2015.

Disclosure of Information to Auditors

So far as each director at the date of approval of this report is aware:

- There is no relevant audit information of which the company's auditors are unaware; and
- The Directors have taken all steps that they ought to have taken to make them aware of any relevant audit information and to establish that the auditors are aware of that information.

Board approved this report on 15th May, 2015.


Manoj Prakash
Director



Grant Thornton

Statutory Auditors' Report

(CERTIFICAÇÃO DAS CONTAS)

FREE TRANSLATION OF THE ORIGINAL IN PORTUGUESE

Grant Thornton & Associados – SROC, Lda.

Edifício Amadeo Souza Cardoso
Alameda António Sérgio, 22, 11.º Miraflores –
1495-132 Algés – Portugal

T +351 214 123 520

F +351 214 123 539

Avenida Arriaga, 30 – 1.º B – 9000-064
Funchal – Portugal

T +351 291 200 540

F +351 291 200 549

E-mail: gt.lisboa@pt.gt.com

Introduction

1. We have audited the financial statements of Aurobindo Pharma (Portugal) Unipessoal, Lda., which comprise the balance sheet as at March 31, 2015, the income statement by nature, the statement of changes in equity and the cash flow statement for the year then ended and the related notes. The financial statements show net assets of 4.568.948 euro and a negative equity of 2.490.828 euro, including a loss for the year of 2.239.325 euro.

Responsibilities

2. The Company's Management is responsible for the preparation of financial statements that present fairly the Company's financial position and the result of its operations, as well as for the utilisation of adequate accounting methods and principles. Company's Management is also responsible for establishing and maintaining a proper system of internal accounting control.
3. Our responsibility is to express an opinion on the financial statements based on our audit.

Audit Scope

4. Our audit was carried out in accordance with the auditing standards (Normas Técnicas e Directrizes de Revisão / Auditoria) approved by the Portuguese Institute of Statutory Auditors (Ordem dos Revisores Oficiais de Contas). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. To achieve those objectives, an audit includes:

- examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, as well as assessing significant estimates made by Management;
 - assessing the adequacy of the accounting principles used as well as their disclosure in the financial statements, taking into consideration the circumstances and applicability, or not, of the going concern concept;
 - evaluating the overall presentation of the financial statements.
5. Our examination also included the analysis of the consistency between the financial data of the management report and the financial statements.
6. We believe that our audit provides a reasonable basis for our opinion.

Opinion

7. In our opinion, the financial statements mentioned in the first paragraph present fairly, in all material respects, the financial position of Aurobindo Pharma (Portugal) Unipessoal, Lda. as at March 31, 2015 and the results of its operations and the cash flow statement for the year then ended, in conformity with generally accepted accounting principles in Portugal.

Emphasis


8. Without affecting the opinion expressed above, we call the attention for the shareholders' equity being negative for the amount of 2.490.828 euro, essentially as a result of accumulated losses, including current year. In these circumstances, the Company is required to replace shareholders' equity to a minimum of a half of the share capital as per article 35º. of the company's act, being the maintenance of its going concern dependent on the continuity of shareholders support.



Report on other legal requirements

9. In our opinion the information included in the management's report agrees with the financial statements of the year then ended.

May 20, 2015



Grant Thornton & Associados – SROC, Lda.
Represented by C. Lisboa Nunes

Aurobindo Pharma Portugal
Balance Sheet as at March 31, 2015

(All amounts are in EURO Currency except share data and unless otherwise stated)

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

GRANT THORNTON & ASS., SPC, LDA

ESF *March 15, 2015*

	Note	31 March, 2015 (EURO)	31 March, 2014 (EURO)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	3.688.000	3.688.000
Share application money		3.775.000	3.675.000
Reserves and surplus	3	(9.953.828)	(7.714.503)
		<u>(2.490.828)</u>	<u>(351.503)</u>
Non-current liabilities			
Long-term borrowings	4	-	550.000
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		<u>-</u>	<u>550.000</u>
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	5.781.945	2.431.540
Other current liabilities	9	1.276.403	1.280.914
Short-term provisions	7	-	-
		<u>7.058.348</u>	<u>3.712.454</u>
TOTAL		<u><u>4.567.520</u></u>	<u><u>3.910.951</u></u>
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	70.136	77.487
Intangible assets	11	1.520.348	1.477.562
Capital work-in-progress		-	-
Intangible assets under development		-	-
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	-	-
Trade receivables	14,1	-	-
Other non-current assets	14,2	-	-
		<u>1.590.484</u>	<u>1.555.049</u>
Current assets			
Current investments	15	-	-
Inventories	16	1.874.213	1.237.754
Trade receivables	14,1	534.384	687.120
Cash and bank balances	17	482.044	382.374
Short-term loans and advances	13	86.395	48.653
Other current assets	14,2	-	-
		<u>2.977.036</u>	<u>2.355.901</u>
TOTAL		<u><u>4.567.520</u></u>	<u><u>3.910.950</u></u>
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.

Aurobindo Pharma Portugal
Statement of profit and loss for Year ended March 31, 2015
 (All amounts are in EURO Currency except share data and unless otherwise stated)

INITIALLED FOR IDENTIFICATION
 PURPOSES ONLY
 GRANT THORNTON & ASS., SROG, LDA.
 EJP 18.05.2015

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (EURO)	Year ended March 31, 2014 (EURO)
Income															
Revenue from operations (gross)	18	397.280	332.789	328.042	355.083	277.138	351.050	329.945	259.508	248.864	392.614	271.217	342.860	3.886.390	2.747.326
Less: Excise duty/Rebates		(78.939)	(66.292)	(66.535)	(69.104)	(55.674)	(72.184)	(71.638)	(51.671)	(49.678)	(78.232)	(56.453)	(68.514)	(784.914)	-
Revenue from operations (net)		318.341	266.497	261.507	285.979	221.464	278.866	258.307	207.837	199.186	314.382	214.764	274.346	3.101.476	2.747.326
Other income	19	78	173	78	164	176	81	84	178	84	87	143	87	1.413	1.020
Total revenue (I)		318.419	266.670	261.585	286.143	221.640	278.947	258.391	208.015	199.270	314.469	214.908	274.433	3.102.889	2.748.346
Expenses															
Cost of raw material and components consumed	20	17.275	21.498	14.892	19.586	13.350	12.005	19.814	12.334	12.713	9.611	17.538	15.093	185.709	145.078
Purchase of trading goods	21	174.252	255.365	256.741	190.438	281.794	312.202	(461.199)	140.664	163.405	134.193	(2.691)	224.551	1.669.715	1.335.302
(Increase)/decrease in inventories of finished goods, work-in-progress	21	(35.546)	(145.028)	(139.802)	(73.426)	(187.833)	(190.454)	563.626	(48.424)	(75.556)	9.102	89.111	(87.588)	(321.819)	(160.711)
Employee benefit expense	22	144.936	140.231	138.849	145.483	138.983	142.314	149.822	137.325	137.400	191.204	132.571	266.250	1.865.368	1.610.738
Other expenses	23	150.807	118.415	244.414	115.716	105.174	126.314	126.099	103.144	153.538	99.787	137.148	164.327	1.644.884	1.520.454
Exceptional items	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total (II)		451.724	390.481	515.094	397.797	351.469	402.381	398.162	345.043	391.500	443.896	373.676	582.634	5.043.856	4.450.861
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		(133.304)	(123.811)	(253.509)	(111.654)	(129.829)	(123.434)	(139.771)	(137.028)	(192.230)	(129.428)	(158.769)	(308.201)	(1.940.967)	(1.702.515)
Depreciation and amortization expense	25	16.113	16.618	16.837	16.891	17.987	17.987	17.987	17.987	17.987	17.987	17.987	19.472	211.840	174.291
Finance costs	26	177	(23)	173	2.088	77	2.975	1.453	30	2.808	1.888	1.269	1.462	14.381	5.295
Profit/(loss) before tax		(149.595)	(140.406)	(270.520)	(130.634)	(147.893)	(144.396)	(159.211)	(155.045)	(213.025)	(149.303)	(178.025)	(329.135)	(2.167.189)	(1.882.101)
Tax expenses															
Current tax														72.136	64.906
Less: MAT credit entitlement														-	-
Deferred tax														-	-
Fringe benefit tax														-	-
Tax relating to previous years														-	-
Total tax expense		-	-	-	-	-	-	-	-	-	-	-	72.136	72.136	64.906
Profit/(loss) for the year		(149.595)	(140.406)	(270.520)	(130.634)	(147.893)	(144.396)	(159.211)	(155.045)	(213.025)	(149.303)	(178.025)	(401.271)	(2.239.325)	(1.947.007)

Summary of significant accounting policies

1

The accompanying notes are an integral part of the financial statements.

ESF 10/15, 2015

Note 1 : Summary of significant accounting policies (Refer General Instructions Note No.1)

- 1,1
- 1,2
- 1,3
- 1,4
- 1,5

Note 2 : Share capital (Refer General Instructions Note No.2)

Authorised shares:

Mar 31, 2015 March 31, 2014

Issued, Subscribed and Fully Paid-up shares:

Equity shares of 3,688,000 of Euro 1/-fully paid-up
SHARE APPLICATION MONEY

-	-
3.688.000	3.688.000
3.775.000	3.675.000
7.463.000	7.363.000

Aurobindo Pharma Portugal
Notes to the Balance Sheet
(All amounts are in EURO Currency except share data and unless otherwise stated)

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROC, Lda.

ESS Proj W, 2015

Note 3 : Reserves and surplus (Refer General Instructions Note No.3)

	Mar 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	-	-
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet	-	-
General Reserve		
As per last Balance Sheet		
Add: Transferred from statement of profit and loss	-	-
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	(7.714.503)	(5.767.496)
Profit for the quarter	(2.239.325)	(1.947.007)
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)		
Tax on proposed equity dividend		
Interim dividend paid (amount per share XX (31 March, 2014 XX)		
Transfer to general reserve		
Total appropriations	-	-
Net surplus in the statement of profit and loss	(9.953.828)	(7.714.503)
Total reserves and surplus	(9.953.828)	(7.714.503)

Note 4 : Long-term borrowings (Refer General Instructions Note No.4)

	Non-current Portion		Current maturities	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)				
Other Loans from banks				
Current account credit balance				
Loans and advances from related parties				550.000
Other Loans and advances				
Sales tax deferment loan (Un Secured)				
	-	-	-	550.000
The above amount includes				
Secured borrowings				
Unsecured borrowings				550.000
Amount disclosed under the head				
"Other current liabilities"				
Net Amount	-	-	-	550.000

Note 5 : Deferred tax liability (net)

Deferred tax liability

Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis

Provision for diminution in the value of investments

Provision for doubtful debts and advances

Fixed Assets (Depreciation)

Retirement Benefits

Others

Gross deferred tax liability

Deferred tax asset

Carried Forward Business Losses

Others

Gross deferred tax asset

Net deferred tax liability

Note 6 : Other long-term liabilities (Refer General Instructions Note No.5)

Trade payables (including acceptances)

Others

Advances from customers

Unclaimed dividends

Other liabilities

Interest accrued but not due on loans

Advances from related parties

Note 7 : Provisions (Refer General Instructions Note No.6 & 10)

Provision for employee benefits

- Gratuity

- Leave encashment

Other Provisions

For Taxation (net of advance payments)

For Proposed dividend

For Tax on proposed dividend

Provision for warranties

At the beginning of the year

Arising during the period

Utilised during the period

Unused amounts reversed

At the end of the Quarter

Current portion

Non-current portion

Note 8 : Short-term borrowings (Refer General Instructions Note No.7)

Bank overdraft

Loans and advances from related parties

Working capital loans (Secured)

Short term loans (Un Secured)

Working capital loans

The above amount includes

Secured borrowings

Unsecured borrowings

Note 9 : Other current liabilities (Refer General Instructions Note No.9)

Trade payables (including acceptances) (Refer General Instructions Note No.8)

Other liabilities

Loan From Agile Pharma BV

Interest on Loans from Agile Pharma BV

Non-current		Current	
Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014

Mar 31, 2015 March 31, 2014

Mar 31, 2015 March 31, 2014

Mar 31, 2015 March 31, 2014

5,781.945 2,431.540

1,275.000 1,280.914

1,403

1,276.403 1,280.914

7,058.348 3,712.454

Aurobindo Pharma Portugal

Notes to the statement of profit and loss

(All amounts are in Euro Currency except share data and unless otherwise stated)

Note 10 : Tangible assets

	Leasehold Land	Buildings Works	Furniture & fixtures	Office Equipment	Total
Cost or valuation					
At April 1, 2013		66.729,0	23.022,0	33.921,0	123.672,0
Additions during the nine months			-	1.803,0	1.803,0
Disposals during the nine months				1.515,0	1.515,0
Transfer to assets held for sale					-
Other adjustments					
- Exchange differences					-
At December 31, 2013	-	66.729,0	23.022,0	34.209,0	123.960,0
Additions during the three months				3.271,0	3.271,0
Disposals during the three months					-
Other adjustments					
- Exchange differences					-
At March 31, 2014	-	66.729,0	23.022,0	37.480,0	127.231,0
Additions during the nine months					-
Disposals during the nine months					-
Additions on acquisition					-
Other adjustments					
- Exchange differences					-
At March 31, 2015	-	66.729,0	23.022,0	37.480,0	127.231,0
Depreciation					
At April 1, 2013		2.642,0	10.967,0	21.478,0	35.087,0
Charge for the period		1.001,0	2.158,0	7.792,0	10.951,0
Disposals					-
Transfer to assets held for sale					-
Other adjustments					
- Exchange differences					-
At December 31, 2013	-	3.643,0	13.125,0	29.270,0	46.038,0
Charge for the period		334,0	720,0	2.652,0	3.706,0
Disposals					-
Other adjustments					
- Exchange differences					-
At March 31, 2014	-	3.977,0	13.845,0	31.922,0	49.744,0
Charge for the period		1.334,6	2.877,7	3.138,6	7.350,9
Disposals					-
Additions on acquisition					-
Other adjustments					
- Exchange differences					-
At March 31, 2015	-	5.311,6	16.722,7	35.060,6	57.094,9
Net Block					
At December 31, 2013	-	63.086,0	9.897,0	4.939,0	77.922,0
At March 31, 2014	-	62.752,0	9.177,0	5.558,0	77.487,0
At March 31, 2015	-	61.417,4	6.299,3	2.419,4	70.136,1

Aurobindo Pharma Portugal
Notes to the statement of profit and loss

(All amounts are in Euro Currency except share data and unless otherwise stated)

PREPARED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROG, LDA.

ESG 900 10/2010

Note 11 : Intangible assets

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At April 1, 2013			1.524.481,0	1.524.481,0
Additions during the nine months			237.502,0	237.502,0
Internal development during the nine months				-
Disposals during the nine months				-
Other adjustments				-
- Exchange differences				-
At December 31, 2013	-	-	1.761.983,0	1.761.983,0
Additions during the three months			90.127,0	90.127,0
Internal development during the three months				-
Disposals during the three months				-
Other adjustments				-
- Exchange differences				-
At March 31, 2014	-	-	1.852.110,0	1.852.110,0
Additions during the nine months			247.275,0	247.275,0
Disposals during the nine months				-
Additions on acquisition				-
Other adjustments				-
- Exchange differences				-
At March 31, 2015	-	-	2.099.385,0	2.099.385,0
Amortization				
At April 1, 2013			214.917,0	214.917,0
Charge for the period			114.336,0	114.336,0
Disposals				-
Other adjustments				-
- Exchange differences				-
At December 31, 2013	-	-	329.253,0	329.253,0
Charge for the period			45.295,0	45.295,0
Disposals				-
Other adjustments				-
- Exchange differences				-
At March 31, 2014	-	-	374.548,0	374.548,0
Charge for the period			204.489,08	204.489,1
Disposals				-
Other adjustments				-
- Exchange differences				-
At March 31, 2015	-	-	579.037,1	579.037,1
Net Block				
At December 31, 2013	-	-	1.432.730,0	1.432.730,0
At March 31, 2014	-	-	1.477.562,0	1.477.562,0
At March 31, 2015	-	-	1.520.347,9	1.520.347,9

Note 12 : Non-current investments (Refer General Instructions Note No.13)

Mar 31, 2015 March 31, 2014

Unquoted equity instruments

Investment in subsidiaries
Investment in joint ventures
Investment in associates

Note 13 : Loans and advances (Refer General Instructions Note No.14 & 21)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Capital advances				
Secured, considered good				
Unsecured, considered good				
(A)	-	-	-	-
Security deposit				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful security deposit				
(B)	-	-	-	-
Loan and advances to related parties				
Unsecured, considered good				
(C)	-	-	-	-
Advances recoverable in cash or kind				
Secured, considered good			5.300	5.300
Unsecured, considered good				
Doubtful				
Provision for doubtful advances			5.300	5.300
(D)	-	-	5.300	5.300
Other loans and advances				
Advance income-tax (net of provision for taxation)			10.476	4.062
Prepaid expenses			70.619	39.291
Loans to employees				
Loans to others				
Export incentives receivable				
Export incentives licenses				
Balances with Statutory/government authorities				
(E)	-	-	81.095	43.353
Total (A+B+C+D+E)	-	-	86.395	48.653

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors				
Dues from officers				
Dues from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner				
Dues from in which the company's managing director is a member				
Dues from the partnership firm in which the company's non-executive director is a partner				

ESF Qcy 15, 2015

ESF Qcey 15, 2015

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Investment				
				11.925
				54.448
			534.384	
	-	-	534.384	66.373
	-	-		-
	-	-	534.384	66.373
Money are due for payment				
				9.293
				611.454
	-	-	-	620.747
	-	-		-
	-	-	-	620.747
	-	-	534.384	687.120

Non-current		Current	
Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014

Non-current		Current	
Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014

• • • •

Aurobindo Pharma Portugal
Notes to the Balance Sheet
(All amounts are in EURO Currency except share data and unless otherwise stated)

ENTIALED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROG, LDA.
EST 9/29/2015

Note 15 : Current investments (Refer General Instructions Note No.17)

	Mar 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any (Please specify)		

Note 16 : Inventories (valued at lower of cost and net relizable value) (Refer General Instructions Note No.18)

	Mar 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)		
Work - in - Progress		
Finished goods		
Traded goods (including stock -in-transit XXXX (31 March, 2014 XXX)	2.193.038	1.871.219
Stock adjustments	(318.825)	(633.465)
Provision stock to be destroid		
	<u>1.874.213</u>	<u>1.237.754</u>

Note 17 : Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			424.943	325.273
Deposits with original maturity of less than 3 months				
Cash credit accounts				
On unpaid dividend account				
Cheques/ drafts on hand				
Unpaid matured deposits				
Cash on hand				
			<u>424.943</u>	<u>325.273</u>
Other bank balances				
Deposits with original maturity for more than 12 months			57.101	57.101
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
	-	-	<u>57.101</u>	<u>57.101</u>
Amount disclosed under non-current assets	-	-	<u>482.044</u>	<u>382.374</u>

Aurobindo Pharma Portugal

Notes to the statement of profit and loss

(All amounts are in Euro Currency except share data and unless otherwise stated)

INITIALLED FOR IDENTIFICATION

PURPOSES ONLY

GRANT THORNTON & ASS., SROG, LDA.

ESF Gcey 15 2 15

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Euro)	Year ended March 31, 2014 (Euro)
Note 18 : Revenue from operations (Refer General Instructions Note No.25)														
Revenue from operations														
Sale of products														
Finished goods														
Traded goods	397.280	332.789	328.042	355.083	277.138	351.050	329.945	259.508	248.864	392.614	271.217	342.860	3.886.390	2.747.326
Sale of services													-	-
Sale of dossiers/licenses													-	-
Other operating revenue													-	-
Scrap sales													-	-
Other													-	-
Revenue from operations (gross)	397.280	332.789	328.042	355.083	277.138	351.050	329.945	259.508	248.864	392.614	271.217	342.860	3.886.390	2.747.326
Less: Rebates/Discounts	78.939	66.292	66.535	69.104	55.674	72.184	71.638	51.671	49.678	78.232	56.453	68.514	784.914	-
Revenue from operations (net)	318.341	266.497	261.507	285.979	221.464	278.866	258.307	207.837	199.186	314.382	214.764	274.346	3.101.476	2.747.326
Note 19 : Other income (Refer General Instructions Note No.26)														
Interest income on														
Bank deposits	78	173	78	164	176	81	84	178	84	87	143	87	1.413	1.020
Long-term investments													-	-
Current investments													-	-
Loans to joint venture entities													-	-
Others													-	-
Dividend income on														
Investment in subsidiaries													-	-
Current investments													-	-
Long-term investments													-	-
Net gain on sale of current investments													-	-
Profit on sale of fixed assets (net)													-	-
Foreign exchange gain (net)													-	-
Balances no longer required written back													-	-
Government grant													-	-
Commission income													-	-
Processing charges													-	-
Other non-operating income (net of expenses directly attributable to such income of Rs. XXXXX (31 March, 2014: XXXX)													-	-
	78	173	78	164	176	81	84	178	84	87	143	87	1.413	1.020
Note 20 : Cost of raw material and components consumed														
Inventory at the beginning of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add: Purchases	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: inventory at the end of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add: Packing material consumed	17.275	21.498	14.892	19.586	13.350	12.005	19.814	12.334	12.713	9.611	17.538	15.093	185.709	145.078
Cost of raw material and components consumed	17.275	21.498	14.892	19.586	13.350	12.005	19.814	12.334	12.713	9.611	17.538	15.093	185.709	145.078

Aurobindo Pharma Portugal
Notes to the statement of profit and loss
(All amounts are in Euro Currency except share data and unless otherwise stated)

PREPARED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROC, LPA.
355 Gey 12/2013

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Euro)	Year ended March 31, 2014 (Euro)
Note 21 : (Increase)/decrease in inventories														
Inventories at the end of the period														
Traded goods	1.906.765	2.051.794	2.191.596	2.265.022	2.452.854	2.643.308	2.079.682	2.128.106	2.203.663	2.194.561	2.105.450	2.193.038	2.193.038	19.757.306
Work-in-progress														
Finished goods														
	1.906.765	2.051.794	2.191.596	2.265.022	2.452.854	2.643.308	2.079.682	2.128.106	2.203.663	2.194.561	2.105.450	2.193.038	2.193.038	19.757.306
Inventories at the beginning of the period														
Traded goods	1.871.219	1.906.765	2.051.794	2.191.596	2.265.022	2.452.854	2.643.308	2.079.682	2.128.106	2.203.663	2.194.561	2.105.450	1.871.219	19.596.595
Work-in-progress														
Finished goods														
	1.871.219	1.906.765	2.051.794	2.191.596	2.265.022	2.452.854	2.643.308	2.079.682	2.128.106	2.203.663	2.194.561	2.105.450	1.871.219	19.596.595
	(35.546)	(145.028)	(139.802)	(73.426)	(187.833)	(190.454)	563.626	(48.424)	(75.556)	9.102	89.111	(87.588)	(321.819)	(160.711)
Purchase of traded goods	250.185	229.022	186.084	227.423	188.485	332.280	168.906	343.875	101.535	184.885	64.333	148.633	2.425.647	1.335.302
Stocks adjustments	(75.933)	26.343	70.658	(36.986)	93.309	(20.079)	(630.105)	(203.211)	61.870	(50.692)	(67.024)	75.918	(755.932)	
	174.252	255.365	256.741	190.438	281.794	312.202	(461.199)	140.664	163.405	134.193	(2.691)	224.551	1.669.715	1.335.302
Note 22 : Employee benefit expense														
Salaries, wages and bonus	112.882	112.678	105.164	113.038	111.602	113.365	118.226	110.244	108.612	156.295	106.697	240.971	1.509.774	1.272.229
Contribution to provident and other fund	25.916	25.890	31.872	25.965	25.717	25.892	26.774	25.418	24.525	26.848	24.232	24.758	313.807	299.704
Employee stock option scheme													-	
Gratuity expense													-	
Other employee benefits													-	
Post employment medical benefits													-	
Staff welfare expenses	6.138	1.663	1.813	6.480	1.663	3.057	4.822	1.663	4.263	8.062	1.642	521	41.787	38.805
	144.936	140.231	138.849	145.483	138.983	142.314	149.822	137.325	137.400	191.204	132.571	266.250	1.865.368	1.610.738

ENTRAGED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS. SROC LDA.
EST- (C) 13/12/13

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Euro)	Year ended March 31, 2014 (Euro)
Note 23 : Other expenses														
Consumption of stores and spares													-	325
Conversion charges													-	-
Chemicals consumed													-	-
Increase in VAT on finished goods													-	-
Customer service expenditure													-	-
Power and fuel	132	135	65	132	-	127	140	261	84	145	138	222	1.581	1.597
Water charges													-	-
Freight and forwarding charges	53	215	273	138	144	67	41	48	38	277	259	91	1.644	5.091
Carriage inward													-	-
Carriage outwards													-	-
Rent	7.466	7.466	7.466	7.466	7.466	7.466	7.466	7.466	7.462	(16.478)	6.444	6.444	63.600	89.159
Rates and taxes													-	-
Insurance	1.198	1.708	1.456	1.291	1.397	1.397	2.915	2.915	2.915	2.915	3.172	1.456	24.736	15.685
Repairs and maintenance													-	-
i) Plant and machinery													-	-
ii) Buildings													-	-
iii) Others	411	327				241	859	241	-				2.079	1.407
Advertising and sales promotion	62.461	41.745	(17.867)	24.080	13.590	20.428	24.312	24.338	18.427	26.856	38.837	29.978	307.186	378.016
Brokerage and discounts													-	-
Remuneration to Auditors	251	251	251	251	251	251	251	251	251	914	914	914	5.000	4.000
Sales commission													-	-
Travelling and conveyance	1.387	1.014	775				75	242		10	-	359	3.862	8.307
Communication costs	1.684	1.459	1.588	1.524	1.610	1.446	1.583	1.669	1.217	1.953	1.575	2.057	19.365	18.399
Printing and stationery	67	132	194	262	93	228	125	106	54	606	20	605	2.492	3.113
Legal and professional fees	5.800	5.800	2.300	4.750	5.550	5.500	5.700	5.500	12.025	5.500	5.500	5.549	69.474	69.600
Directors sitting fees													-	-
Payment to auditor (Refer details below)													-	-
Provision for diminution in value of investment in subsidiary company												33.725	33.725	-
Provision for other than temporary - Stocks	34.255	22.619	28.459	40.203	39.434	54.587	32.022	26.004	26.068	29.263	41.944	12.841	387.699	511.897
Provision for other than temporary - Bad debt			187.256				481						187.737	
Adjustment to the carrying amount of current investments													-	-
Provision for warranties (net of reversals)													-	-
Provision for litigations (net of reversals)													-	-
Exchange differences (net)													-	-
Loss on derivative contracts (including provisions mark-to-market loss)													-	-
Bad debts/advances written off													-	-
Impairment loss on fixed assets													-	-
Provision for doubtful debts and advances													-	-
Loss on sale of fixed assets (net)													-	-
Premium on forward exchange contract amortized													-	-
Factory maintenance													-	-
Effluent treatment expenses													-	-
Vehicle maintenance expenses	25.292	25.338	23.369	23.254	23.487	22.739	22.277	22.915	19.651	23.366	19.032	29.157	279.876	300.173
Analytical charges													-	-

Aurobindo Pharma Portugal

Notes to the statement of profit and loss

(All amounts are in Euro Currency except share data and unless otherwise stated)

ENTRAGED FOR IDENTIFICATION

PURPOSES ONLY

GRANT THORNTON & ASS., SROC, LPA

ESF 2014 10/2014

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Euro)	Year ended March 31, 2014 (Euro)
Product development expenses													-	-
Registration and filing charges	-	61	2,566	2,044	1,924	1,507	5,475	958	2,726	2,247	5,444	413	25,365	(1,932)
Safety and security													-	-
Office expenses													-	-
Repairs and maintenance - others	242	19	131	131	131	131	130	130	130	131	19	242	1,567	1,557
Management fees	10,000	10,000	6,110	10,000	10,000	10,000	10,000	10,000	62,403	22,002	13,360	37,606	211,481	111,825
Liquidated damages-Stock destruction costs							11,917						11,917	
Donations													-	-
Software license and implementation expenses													-	-
Capital work-in-progress written off													-	-
Miscellaneous expenses	108	126	23	191	98	199	329	100	86	80	490	2,668	4,498	2,235
	150,807	118,415	244,414	115,716	105,174	126,314	126,099	103,144	153,538	99,787	137,148	164,327	1,644,884	1,520,454

Aurobindo Pharma Portugal
Notes to the statement of profit and loss
(All amounts are in Euro Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Euro)	Year ended March 31, 2014 (Euro)
Remuneration to Auditor														
As auditor:														
Audit fee	251	251	251	251	251	251	251	251	251	914	914	914	5.000	4.000
Tax audit fee													-	-
Limited review													-	-
In other capacity:														
Taxation matters													-	-
Company law matters													-	-
Management services													-	-
Other services (certification fees)													-	-
Reimbursement of expenses														
	251	251	251	251	251	251	251	251	251	914	914	914	5.000	4.000
Note 24 : Exceptional items														
Others (Specify if any)													-	-
Note 25 : Depreciation and amortization expense														
Depreciation of tangible assets	1.217	1.044	633	521	492	492	492	492	492	492	492	492	7.351	14.660
Amortization of intangible assets	14.896	15.574	16.204	16.370	17.495	17.495	17.495	17.495	17.495	17.495	17.495	18.980	204.489	159.631
Depreciation of investment property													-	-
	16.113	16.618	16.837	16.891	17.987	17.987	17.987	17.987	17.987	17.987	17.987	19.472	211.840	174.291
Note 26 : Finance costs (Refer General Instructions Note No.27)														
Interest				2.011		2.898	1.376		2.726	1.376	1.192	1.403	12.982	3.795
Bank charges	177	(23)	173	77	77	77	77	30	82	512	77	59	1.399	1.500
Amortization of ancillary borrowing costs													-	-
Exchange difference to the extent considered as an adjustment to borrowing costs	177	(23)	173	2.088	77	2.975	1.453	30	2.808	1.888	1.269	1.462	14.381	5.295



AUROBINDO

Committed to healthier life!

MANAGEMENT REPORT AND ACCOUNTS


PORTUGAL

2014

(1 Abril 2014 until the 31st March 2015)

Índex

1. Management Report.....	3
2. Balance.....	6
3. Report Results.....	7
4. Notes to the Financial statements.....	8



MANAGEMENT REPORT

According to Articles 65 and 66 of the Commercial Companies Code (Código das Sociedades Comerciais), therefore the Management of the Company Aurobindo Pharma (Portugal) Unipessoal, Lda., Submitted to the General Assembly, the Management Report and Accounts for the year 2014.

EVOLUTION OF THE COMPANY'S ACTIVITY

During the reporting period, which occurred from the 1st of April 2014 to the 31st of March 31 2015, the Company conducted its business in accordance with its objectives.

The business itself grew by 13% over the previous year, as the growth occurred was still below the budgeted which was at 48%. The result to this was due much in to the rupture in the stocks as well as the late start-up of the computer system of the prescription regarding the active ingredient.


FINANCIAL RESULTS

The Company recorded the following amounts in 2014:

a. Billing:	€ 3 125 430,32
b. Income before the taxes:	€ - 2 167 188,82
c. Net income :	€ - 2 239 325,09

RELEVANT INFORMATION

- During the year there was no business between the Manager and the Company itself.
- From the date of exercise of the term and so far, there have been no material events, which in any way influencing the situation presented.
- There are no overdue debts to the State.
- There are no debts to banks.
- The business development expectations remain within the scope of the object of the Company.



ARTICLE 35 OF THE CODE OF COMMERCIAL COMPANIES

According to article 35 of the Commercial Companies Code, and as the capital of the company is negative at 2,490,827.69 euros, the partners at the General Meeting must decide to adopt one of the three possible measures to be applied according to the law.


1. Dissolution;
2. Reduction of the capital (which in this case specifically is not possible)
3. Inputs to cover the capital or choose the recovery, which will equally level the issue at hand.

This situation must be discussed and voted on at the next General Assembly of the Corporation, and must appear in the actual notice as well as the agenda.

PROPOSAL OF PROFITS

The Management proposes to the General Meeting that the net loss of the year 2014 in the amount of € 2,239,325.09, be transferred to the retained earnings account.

Manager


Manoj Prakash



Directors' Report

The management herewith presents to the shareholders the annual accounts of Aurobindo Pharma (Portugal) Unipessoal Lda for the year ended 31st March, 2015.

Principal Activity

The principle object of the company is to trade, deal in pharmaceutical products and other allied products and services.

Review of Operations

The directors of the company have discussed and reviewed company's operations. During the year, your company has registered a turnover of €3,101,476 (YoY growth of 12.9%) and made a loss of €2,239,325 after considering appropriate Depreciation/Amortizations.

Directors

The Directors at the date of the report are:

Mr.G.P.Prasad

Mr.Manoj Prakash

Mr.Muralidharan V

Auditors

The Auditors, Grant Thornton & Associados - SROC, Lda. have accepted to be the Auditors of the Company.

The Directors of the Company declares that:

The Financial Statements and notes comply with Accounting Standards as detailed in Notes to the Financial Statements and present fairly the company's financial position as at 31st March, 2015.


Disclosure of Information to Auditors


So far as each director at the date of approval of this report is aware:

- There is no relevant audit information of which the company's auditors are unaware; and
- The Directors have taken all steps that they ought to have taken to make them aware of any relevant audit information and to establish that the auditors are aware of that information.

Board approved this report on 15th May, 2015.

Director


Manoj Prakash



**NOTES TO THE FINANCIAL DEMONSTRATION PERIOD
AT THE END OF THE 31ST OF MARCH 2015**

(Amounts expressed in euros)

1 - IDENTIFICATION OF THE COMPANY:

Aurobindo Pharma (Portugal) Unipessoal, Lda., Headquarteres at Av. Do Forte nº3, Parque Suécia Edifício IV, 2º 2794-038 Carnaxide with share capital in the amount of 3.688.000.00 euros and held 100% by Agile Pharma BV

The company was incorporated on May 16, 2008, having as their object the trade, sale and distribution of drugs and marketing services.

2 -REFERENCIAL PREPARATION OF ACCOUNTING OF FINANCIAL STATEMENTS

The accompanying financial statements have been prepared in accordance with the provisions in force in Portugal, poured in Decree-Law No. 158/2009, of 13 July, and according to the conceptual framework, accounting standards and financial reporting standards and interpretations contained respectively in regulamentation nº 15652/2009, 15655/2009 and 15653/2009 of the 27th of August 2009. The financial statements are comparable with previous years.

3 - SIGNIFICANT ACCOUNTING POLICIES, ESTIMATES AND JUDGMENTS RELEVANT

The principal accounting policies adopted in preparing the accompanying financial statements are as follows:

3.1- Basis of presentation


The accompanying financial statements have been prepared on a going concern basis, from the accounting records of the Company.

3.2 Revenue

Revenue is measured at the fair value of the consideration received or receivable. The revenue to be recognized is deducted from the estimated amount of returns, discounts and other rebates. The recognized revenue does not include VAT and other taxes paid related to the sale or provision of services. All other income and expenses are recorded in accordance with the addition of the assumption that they are recognized as they are generated independently of when they are received or paid. Differences between the amounts received and paid and the corresponding income and expenses are recorded under "deferred income" or "Other accounts payable or receivable".

Revenue from the sale of goods is recognized when all the following conditions are met:

- All the risks and rewards of ownership of the assets have been transferred to the buyer;
- The Company does not maintain any control over the goods sold



- The amount of revenue can be measured reliably;
- It is probable that future economic benefits associated with the transaction will flow to the Company;
- The costs incurred or to be incurred with the transaction can be measured reliably.

Interest revenue is recognized using the effective interest method, it is probable that economic benefits will flow to the Company and its cost can be measured reliably.

Leases in which the Company is the lessee

Payments for operating leases are recognized as expense on a straight-line basis over the lease period.

3.3- Income tax

Current tax:

Current tax payable is based on taxable income of the company. Taxable income differs from accounting income as it excludes various costs and income that will only be taxable or deductible in other years.

Taxable income also excludes costs and income that are never taxable or deductible.

3.4- Tangible assets

Tangible fixed assets are initially recorded at cost of acquisition or production, which includes the purchase cost, any costs directly attributable to the necessary activities to put the asset in the location and condition necessary to operate in the manner intended and, where applicable, initial estimate of decommissioning costs and removal of assets and restoration of their local location that the Company expects to incur.

Depreciation is calculated after the time the goods are in a position to be used, according to the straight line method or straight line.

The depreciation rates used correspond to the following estimated useful lives:

Goods Years


Buildings and other constructions 5-50

Office equipment 3-8

The useful lives and methods of amortization of several properties are reviewed annually. The effect of any changes to these estimates is recognized in the income statement prospectively.

The maintenance and repair expenses (subsequent expenditure) that are unlikely to generate future economic benefits are recorded as expenses in the period they are incurred.

The gain (or loss) resulting from the sale or disposal of a tangible asset is determined as the difference between the amount received in the transaction and the carrying amount of the asset and is recognized in the period in which the sale occurs.



3.5- Intangible Assets

Intangible assets are comprised of Ownership AIM and expense log, recorded at cost and amortized on a straight-line basis over a period of ten years.

3.6 - Spending on goods

The goods acquired during the year are recognized as an expense period.

3.7 - Inventories

Inventories are stated at the lower of cost and net realizable value. Net realizable value represents the estimated selling price less all estimated costs necessary to complete the inventory and to make the sale. The inventory costing method adopted by the Company consists of:
Goods - are valued at cost, which includes all expenses until the entry into storage.

3.8 - Impairment of assets

At each reporting date, and whenever identified events or changes in circumstances indicate that the carrying amount of an asset is carried may not be recoverable, an impairment is performed valuation of tangible and intangible fixed assets.

Whenever the carrying amount of an asset is carried is greater than its recoverable amount, an impairment loss is recognized in the income statement under "Impairment of depreciable investments / amortized (losses / reversals)" or under the heading "Impairment of receivables (losses / reversals)" if the same respect to non-depreciable assets.

In the case of inventories is the amount recorded in the caption "Impairment of inventories (losses / reversals)".


3.9 - Accounts receivable

Customers

At the end of each reporting period are analyzed customer accounts in order to assess whether there is any objective evidence that they are non-returnable. If so is immediately recognized its impairment loss. Impairment losses are recorded as occurring sequence of events indicating, objectively and in a quantifiable manner, that all or part of the outstanding balance is not received. To this end, the entity takes into consideration market information which demonstrates that the customer is in breach of its responsibilities as well as historic information about due and not received balances.

3.10- Loans and non-current payables

Loans and accounts payable Non-current liabilities are recorded at cost.



3:11 - Trade and other payables

Debts to suppliers or other third parties are recorded at their nominal value as they do not bear interest and the discount effect is immaterial.

3:12 - Judgments and Estimates

In preparing the financial statements, the entity adopted certain assumptions and estimates that affect the assets and liabilities, reported income and expenses. All estimates and assumptions made by the management body were made based on the best knowledge at the time of approval of the financial statements of events and transactions in progress.

The most significant accounting estimates reflected in the financial statements include: lives

Useful of tangible and intangible fixed assets and impairment analyzes.

Estimates used are based on the best information available during the preparation of the financial statements and based on the best knowledge and experience of past and / or current. However, situations may occur in subsequent periods that, not being predictable at this time, were not considered in these estimates. Changes to these estimates, which occur after the date of the financial statements, will be recognized in the income statement prospectively.

3:13 - Subsequent Events

There are no events after the balance sheet date which are necessary to reflect in the financial statements. Also there are no events after the balance sheet date that require to be disclosed in the financial statements.

4 - RELATED PARTIES


Holders of capital

The share capital is represented by a share with a nominal value of 3,688,000.00 euros, belonging to the partner Agile Pharma BV.

Related party transactions

During the year ended March 31, 2015, the following transactions were made with related parties:

Related party	Transacctions	Income	Expenses
Agile Pharma BV	Capital remittances	100.000,00	
Agile Pharma BV	Loan and interests	725.000,00	12.982,00
APL Swift Malta	Products-sales and purchases	14.940,00	2.317.603,38
Milpharm UK	Services		211.481,89
Aurobindo Pharma Malta	Services		247.275,00
APL india	Services	92,08	



Balances with related parties


31st of March 2015, the Company presented the following balances regarding the related parties:

Related parties (Partners)	Balances	Actives	Liabilities/Equity
Agile Pharma BV	Participation of the Capital		3.688.000,00
Agile Pharma BV	Other inst. Equity		3.775.000,00
Agile Pharma BV	Outros Debitores/ Creditores		1.276.403,00
APL Swift Malta	Customer/ Supplier		3.802.574,24
Milpharm UK	Customer/ Supplier		207.483,89
Aurobindo Pharma Malta	Customer/ Supplier		1.064.868,07

5 - INTANGIBLE ASSETS

During the year ended March 31, 2015, changes in the carrying amount of intangible assets and corresponding accumulated amortization and impairment losses, was as follows:

	Goodwill	Proj. Developments.	Prog. Computeres	Industrial property	Investments in course	Total
Assets						
Opening balance	0,00	0,00	0,00	1.852.109,65		1.852.109,65
Acquisitions				247.275,00		247.275,00
Disposals						
Transferes and reductions						
Revaluations						
Final balance	0,00	0,00	0,00	2.099.384,65	0,00	2.099.384,65
Accumulated depreciation and impairment losses						
Opening balance				374.547,09		374.547,09
Amortizações do exercício				204.489,08		204.489,08
Disposals						
Revaluations						
Final balance				579.036,17		579.036,17
Net assets	0,00	0,00	0,00	1.520.348,48	0,00	1.520.348,48



6 - TANGIBLE FIXED ASSETS


During the year ended March 31, 2015, the changes in the carrying amount of tangible fixed assets and corresponding accumulated amortization and impairment losses, was as follows:

	Building Constructions	Basic equipment	Transport equipment	Administrative equipment	Investments in course	Total
Assets						
Opening balance	66.729,00	0,00	0,00	60.502,24	0,00	127.231,24
Acquisitopms						
Disposals						
Transfers and reductions						
Revaluations						
Final balance	66.729,00	0,00	0,00	60.502,24	0,00	127.231,24
Accumulated depreciation: impairment losses						
Opening balance	3.976,99	0,00	0,00	45.767,50	0,00	49.744,49
Depreciation	1.334,58			6.016,33		7.350,91
Disposals						
Revaluations						
Transfers and reductions						
Final balance	5.311,57	0,00	0,00	51.783,83	0,00	57.095,40
Net Assets	61.417,43	0,00	0,00	8.718,41	0,00	70.135,84

7 - LEASES

At the end of the period, the entity has commitments for operating leases under non-cancelable vehicles with the following maturities:

Less than one year 44,548.68 euros.



8 - INVENTORIES AND COST OF GOODS SOLD COSTS

During the year ended March 31, 2015 the movement in cost of goods sold headings are as follows:


	<u>31.03.15</u>	<u>31.03.14</u>
Opening balance	1.871.219,46	1.710.507,74
Shopping	2.566.444,28	1.467.480,07
Regularization of stocks	-723.223,09	
Final balance	2.193.037,77	1.871.219,46
CMVMC	1.521.402,88	1.306.768,35

Impairment losses	<u>31.03.15</u>	<u>31.03.14</u>
Opening balance	633.465,25	121.569,25
Reinforcement per year	408.582,52	511.896,00
Utilization	723.223,09	0,00
Final balance	318.824,68	633.465,25

9 - ACCOUNTS RECEIVABLE AND ACCOUNTS PAYABLE

Client's and other accounts to receive

	<u>31.03.15</u>	<u>31.03.14</u>
Current account customers		
0 – 30 days	4.158,42	315.513,74
31 – 60 days	291.205,57	142.869,00
61 – 90 days	69.487,68	36.811,00
91 – 120 days	2.729,11	191.926,00
+ 121 days	166.802,93	0,00
Total	534.383,71	687.119,74



	<u>31.03.15</u>	<u>31.03.14</u>
Other accounts to receive		
Advance for the staff regarding – Working capital	5.300,00	5.300,00
Advance for the staff regarding – Family insurances	1.222,15	
Payment to Aurovitas	0,00	5.921,09
Advance in the Montelukast case	37.104,00	0,00
Total	43.626,15	11.221,09

Suppliers and other accounts to pay

	<u>31.03.15</u>	<u>31.03.14</u>
Fornecedores conta corrente		
0 – 30 days	514.340,12	332.661,86
31 – 60 days	162.498,64	319.732,93
61 – 90 days	86.719,22	76.865,58
91 – 120 days	101.535,01	64.734,90
+ 121 days	3.340.475,43	1.637.543,54
Total	4.205.568,42	2.431.538,81

	<u>31.03.15</u>	<u>31.03.14</u>
Other accounts to pay		
Other operations with staff	4.733,10	5.518,21
Other Creditors	2.686.640,01	1.696.576,41
Total	2.691.373,11	1.702.094,62

10 - PREPAID EXPENSES

On 31/03/2015 and 03/31/2014 the items of current assets and current liabilities "Deferrals" were as follows:

	<u>31.03.15</u>	<u>31.03.14</u>
Deferrals assets		
Insurances	14.375,82	13.698,40
Others	19.344,51	19.671,90
Total	33.720,33	33.370,30



11 – STATE AND OTHER PUBLIC ENTITIES:

	31.03.15		31.03.14	
	Active	Liabilities	Active	Liabilities
Imposto sobre o rendimento das pessoas colectivas				
Payments on account	10.143,90		3.806,72	
Withholding tax	332,38		255,02	
Tax Estimate		72.136,27		64.906,29
Individual tax (individuals)		59.914,77		29.276,00
Value added tax		759,75	1.719,64	3.462,12
Contributions to the social security		30.023,23		32.894,92
Other taxes				
	10.476,28	162.834,02	5.781,38	130.539,33

According to current legislation, tax returns are subject to review and correction by the tax authorities for a period of four years (five years for Social Security), except when there are tax losses, tax benefits have been granted, or when inspections, complaints or disputes, in which case, depending on the circumstances, the deadlines are extended or suspended. Thus, the Company's tax returns for the years 2011 to 2014 may still be subject to review.

The company's management believes that any corrections resulting from reviews / inspections by the tax authorities of these tax returns will not have a significant effect on the financial statements at 31/03/15.


12 - CAPITAL

Legal reserve: In accordance with commercial law, at least 5% of annual net profit is positive, should be appropriated to the legal reserve until it represents 20% of the capital. This reserve is not available for distribution except upon liquidation of the company, but can be used to absorb losses after other reserves are exhausted, or to increase capital.

Other equity instruments:

Supplementary payments are not paid, can only be returned by resolution of the shareholders, if after your refund the net worth of the company is not less than the sum of capital and legal reserve.

In this exercise the additional benefits were added in the amount of 100 000.00 as movement of the frame 18.



13- REVENUE

The revenue recognized by the Company on 03.31.2014 and 31.03.2013 is detailed as follows:

	<u>31.03.15</u>	<u>31.03.14</u>
Merchandise sales	3.125.430,32	2.768.593,50

<u>Geographical distribution</u>	<u>Nacional market</u>	<u>External Market</u>
Merchandise sales	3.110.398,24	15.032,08

14 - SUPPLIES AND EXTERNAL SERVICES

The caption "External supplies and services" for the years ended 31/03/15 and 03/31/14 is detailed as follows:

	<u>Item</u>	<u>31.03.15</u>	<u>31.03.14</u>
621	Subcontracts	211.481,89	111.825,28
	Subcontracts Community Market	211.481,89	111.825,28
622	Especialized Services	395.949,60	457.951,50
	Especialized Jobs	303.000,37	306.075,11
	Publicity and propaganda	72.858,17	99.095,22
	Fees	11.042,09	46.335,30
	Reparation and Conservation	9.048,97	6.445,87
623	Materials	10.720,75	12.920,14
	Instruments, utensils of easy wear	299,00	325,36
	Book and techical documents	60,00	34,00
	Office materials	2.432,01	3.078,96
	Articles/items which we offer	7.929,74	9.481,82
624	Energy	61.010,17	67.617,21
	Electricity	1.581,34	1.595,87
	Fuels	59.428,83	66.021,34
625	Traveling expenses,	63.548,73	62.699,26
	Stays	63.348,73	62.699,26
	Transport of Merchandise	200,00	0,00
626	Serveral services	277.398,92	310.527,74
	Loan and rent	223.562,66	265.044,12
	Comunications	21.008,52	23.489,40
	Insurances	24.737,06	15.685,47
	Litigation and Notary	759,35	615,30
	Expenses with representation	6.266,05	4.292,59
	Cleaning, hygiene and comfort	1.065,28	1.400,86
	TOTAL	1.020.110,06	1.023.541,13

15 - EXPENSES WITH THE STAFF

The item "Expenses with the staff" for the years ended 03/31/15 and 03/31/14 is detailed as follows:

<u>Items</u>	<u>31.03.15</u>	<u>31.03.14</u>
Remuneration of the staff	1.341.290,88	1.272.229,31
Damages	168.483,25	0,00
Charges with the remuneration	313.807,12	299.703,72
Work injury insurance & Prof disease.	6.386,24	6.275,71
Other personnel costs (1)	35.400,83	32.530,17
TOTAL	1.865.368,32	1.610.738,91

(1) Other personnel expenses include in particular the Health Insurance Group, training and others.

Average number of people working for the company for the period ended March 31, 2015

Technical staff	29
-----------------	----

16 - OTHER EXPENSES AND LOSSES

The breakdown of the item "Other costs and losses" in the years ended 03/31/2015 and 03/31/2014 is as follows:

	<u>31.03.15</u>	<u>31.03.14</u>
Taxes (1)	49.099,39	18.168,05
Other expenses	2.720,27	1.043,58
Bank expenses	1.399,76	1.475,88
	53.219,42	20.687,51

(1) This amount is due mainly to fees paid to Infarmed in% on sales and registrations.

17 - TAXES ON INCOME

The profit for the year of 72,136.27 originated the tax amount only concerning autonomous taxation.


18 - MOVEMENTS IN EQUITY

	2013	Increases	Decreases	Transfers	2014
Capital	3.688.000,00				3.688.000,00
Other instruments of equity	3.675.000,00	100.000,00			3.775.000,00
Reserves					
Transited results	-5.767.495,45			-1.947.007,15	-7.714.502,60
Other changes in equity					
Net income for the year	-1.947.007,15		-2.239.325,09	1.947.007,15	-2.239.325,09
Total	-351.502,60	100.000,00	-2.239.325,09	0,00	-2.490.827,69

After the balance sheet date, there were no material events which need to be adjusted or disclosed in the financial statements.

20 - AUTHORIZATION TO ISSUE DATE OF THE FINANCIAL STATEMENTS

The financial statements for the year ended March 31, 2015 were approved by the governing body and authorized for issue on 15 May 2015.


Manoj Prakash
Director

DIRECTORS' REPORT

REPORT OF THE DIRECTORS

The management herewith presents to the shareholders, the annual accounts of **AUROVITAS S.L.** for the period ended 6th November, 2014.

GENERAL

The company is a limited liability company incorporated under the laws of Spain and acts as a trading company. The principle object of the company is to trade and deal in pharmaceutical products and other allied products & services.

RESULTS

During the period (1st April, 2014 to 6th November, 2014), the company had no Revenue and incurred a Loss of €5,749.

DIRECTORS

The Directors at the date of the report are

1. Mr. G.P.Prasad
2. Mr. Avinash Swain
3. Mr. Rodriguez Díaz Gabriel

STATEMENT BY DIRECTORS

In the opinion of the Directors, the accompanying financial statements were drawn up so as to give true and fair view of the statement of affairs of the company as at 6th November, 2014 and of the results of the business of the period. The Directors have decided to wind up the company.

By Order of the Board on 6th November, 2014



Rodriguez Díaz Gabriel
Director

INDEPENDENT AUDIT REPORT ON THE REPORTING PACKAGE

To the Shareholders of AUROVITAS, S.L.:

Report on the Reporting package

In accordance with your instructions we have audited the financial information included in the accompanying Reporting Package of the year 2014 of AUROVITAS, S.L., which comprise the Liquidation Balance at November 6, 2014, the P&L Account for the period of 6 months and 6 days then ended, the Sub-schedules to Balance Sheet and P&L and the Checklist providing Inter-company transactions.

Directors' responsibility for the Reporting Package

The Directors are responsible for the preparation of the accompanying Reporting Package in accordance with the Group General Instructions for preparing Balance Sheet and Statement of Profit and Loss, and for such internal control as they determine is necessary to enable the preparation of Reporting Package that are free from material misstatement, whether due to fraud or error.

The Reporting Package has been prepared for the sole purpose of carrying out the consolidation process of the Group Aurobindo Pharma Limited and the preparation of the group's consolidated financial statements for the yearly period ended March 31, 2015.

Auditor's responsibility

Our responsibility is to express an opinion on the accompanying Reporting Package based on our audit. We conducted our audit in accordance with prevailing audit regulations in Spain. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Reporting Package. The procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the Reporting Package, whether due to fraud or error. In making those risk assessments, the auditor consider internal control relevant to the preparation of Reporting Package by the Directors of the Company in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.



RUSSELL BEDFORD ESPAÑA
Audidores Consultores

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the accompanying Reporting Package give a true and fair view, in all material respects, of the equity and financial position of AUROVITAS, S.L. at November 06, 2014 and the results for the period of 6 months and 6 days then ended, in accordance with the Group General Instructions for preparing Balance Sheet and Statement of Profit and Loss and with the applicable regulatory framework for financial information in Spain, and specifically the accounting principles and criteria contained therein.

This Audit Report has been issued for the sole purpose of informing you and should not be distributed to third parties or used for any other purpose.

Madrid, May 14, 2015

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
(ROAC nº S-1357)

Jaime Salvador
Socio

RUSSELL BEDFORD ESPAÑA, AUDITORES Y CONSULTORES, S.L. CIF: B-96996079 – Tomo 6.727, Libro 4.031, Folio 218, Sección 8, Hoja V-73.978, Inscripción 4ª

Oficinas en España:

C/ Tránsito, 2 – 1º B
Plaza de Carlos Trias Bertrán, 4

46002 Valencia
28020 Madrid

Tel: 963 106 046 recepcion@russellbedford.es
Tel: 914 184 537 recepcion@russellbedford.es

Russell Bedford España es miembro de Russell Bedford International

Aurovitas S.L, Spain**Balance Sheet as at Nov 06, 2014**

(All amounts are in € except share data and unless otherwise stated)

	Note	06 Nov, 2014 (€)	31 March, 2014 (€)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	3.000	-
Contributions		2.749	
Share application money			
Reserves and surplus	3	(5.749)	-
		-	-
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		-	-
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	-	-
Other current liabilities	9	-	-
Short-term provisions	7	-	-
		-	-
TOTAL		-	-
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10		
Intangible assets	11		
Capital work-in-progress			
Intangible assets under development		-	-
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	-	-
Trade receivables	14,1	-	-
Other non-current assets	14,2	-	-
		-	-
Current assets			
Current investments	15	-	-
Inventories	16	-	-
Trade receivables	14,1	-	-
Cash and bank balances	17	-	-
Short-term loans and advances	13	-	-
Other current assets	14,2	-	-
		-	-
TOTAL		-	-
Summary of significant accounting policies		1	

The accompanying notes are an integral part of the financial statements.

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. 6-96096079
Plaza. de Carlos Trias Bertrán, nº 4
28020 MADRID

Aurovitas S.L, Spain

Statement of profit and loss for the Period 14th Apr 2014 to 06th Nov, 2014

(All amounts are in € except share data and unless otherwise stated)

	Note	Apr-14	May-14	June-14	July-14	Aug-14	Sep-14	Oct-14	Nov-14	Period of 14th Apr 2014 to 06 Nov 2014 (Euro)	Year ended March 31, 2014 (Euro)
Income											
Revenue from operations (gross)	18	-	-	-	-	-	-	-	-	-	-
Less: Excise duty		-	-	-	-	-	-	-	-	-	-
Revenue from operations (net)		-	-	-	-	-	-	-	-	-	-
Other income	19	-	-	-	-	-	-	-	-	-	-
Total revenue (I)		-	-	-	-	-	-	-	-	-	-
Expenses											
Cost of raw material and components consumed	20	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods	21	-	-	-	-	-	-	-	-	-	-
(Increase)/ decrease in inventories of finished goods, work-in-progress and traded goods	21	-	-	-	-	-	-	-	-	-	-
Employee benefit expense	22	-	-	-	-	-	-	-	-	-	-
Other expenses	23	-	-	-	-	-	-	5,721	-	5,721	-
Exceptional items	24	-	-	-	-	-	-	-	-	-	-
Total (II)		-	-	-	-	-	-	5,721	-	5,721	-
Earnings before interest, tax, depreciaton and amortization (EBITDA) (I)-(II)		-	-	-	-	-	-	(5,721)	-	(5,721)	-
Depreciation and amortization expense	25	-	-	-	-	-	-	-	-	-	-
Finance costs	26	18	-	-	9	-	-	-	-	27	-
Profit/(loss) before tax		(18)	-	-	(9)	-	-	(5,721)	-	(5,749)	-
Tax expenses											
Current tax		-	-	-	-	-	-	-	-	-	-
Less: MAT credit entitlement		-	-	-	-	-	-	-	-	-	-
Deferred tax		-	-	-	-	-	-	-	-	-	-
Fringe benefit tax		-	-	-	-	-	-	-	-	-	-
Tax relating to previous years		-	-	-	-	-	-	-	-	-	-
Total tax expense		-	-	-	-	-	-	-	-	-	-
Profit/(loss) for the year		(18)	-	-	(9)	-	-	(5,721)	-	(5,749)	-

Summary of significant accounting policies

1

The accompanying notes are an integral part of the financial statements.

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-56906079
Plaza. de Carlos III de Borbón, nº 4
28020 MADRID

Note 1: Summary of significant accounting policies (Refer General Instructions Note No 1)

1,1
1,2
1,3
1,4
1,5

Note 2: Share capital (Refer General Instructions Note No. 2)

	Nov 06, 2014	March 31, 2014
Authorised shares:		
Shares 3000 (xxxxx) equity shares of 1€ each	3.000	
XXXXXXXX (31 March, 2014: XXXXXXXX) preference shares of XXX each	3.000	
Issued, Subscribed and Fully Paid-up shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of XXXX each fully paid-up	3.000	

a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Equity Shares

	Nov 06, 2014		March 31, 2014	
	No.	Rs.	No.	Rs.
At the beginning of the period	-	-	-	-
Issued during the period	-	-	-	-
Outstanding at the end of the period	-	-	-	-

b. Shares held by holding/ultimate holding company and/or their subsidiaries/associates

Out of equity and preference shares issued by the company, shares held by its holding company, ultimate holding company and their subsidiaries/associates are as below:

	Nov 06, 2014	March 31, 2014
Agile Pharma B.V	3.000	

c. Details of shareholders holding more than 5% shares in the company

	Nov 06, 2014		March 31, 2014	
	No.	% of holding in the class	No.	% of holding in the class
Agile Pharma B.V	3.000	100%		

d. Details of Contributions

	Nov 06, 2014	March 31, 2014
Agile Pharma B.V	2.749	

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B06686079
Plaza de Carlos Trias Bertrán, nº 4
28020 MADRID

Aurovitas S.L, Spain

Notes to the Balance Sheet

(All amounts are in € except share data and unless otherwise stated)

Note 3 : Reserves and surplus (Refer General Instructions Note No.3)

	Nov 06, 2014	March 31, 2014
Capital Reserve		
As per last Balance Sheet	-	-
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet	-	-
General Reserve		
As per last Balance Sheet		
Add: Transferred from statement of profit and loss	-	-
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements		
Profit for the quarter	(5.749)	-
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)		
Tax on proposed equity dividend		
Interim dividend paid (amount per share XX (31 March, 2014 XX)		
Transfer to general reserve		
Total appropriations	-	-
Net surplus in the statement of profit and loss	(5.749)	-
Total reserves and surplus	(5.749)	-

Note 4 : Long -term borrowings (Refer General Instructions Note No.4)

	Non-current Portion		Current maturities	
	Nov 06, 2014	March 31, 2014	Nov 06, 2014	March 31, 2014
Term Loans				
From banks (Secured)				
Other Loans from banks				
Current account credit balance				
Loans and advances from related parties				
Other Loans and advances				
Sales tax deferment loan (Un Secured)				
The above amount includes				
Secured borrowings				
Unsecured borrowings				
Amount disclosed under the head				
"Other current liabilities"				
Net Amount	-	-	-	-

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B26696079
Plaza. de Carlos Trias Bertrán, nº 4
28020 MADRID

Note 5 : Deferred tax liability (net)

	Nov 06, 2014	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis		
Provision for diminution in the value of investments		
Provision for doubtful debts and advances		
Fixed Assets (Depreciation)		
Retirement Benefits		
Others		
Gross deferred tax liability	-	-
Deferred tax asset		
Carried Forward Business Losses		
Others		
Gross deferred tax asset	-	-
Net deferred tax liability	-	-

Note 6 : Other long-term liabilities (Refer General Instructions Note No.5)

	Nov 06, 2014	March 31, 2014
Trade payables (including acceptances)		
Others		
Advances from customers		
Unclaimed dividends		
Other liabilities		
Interest accrued but not due on loans		
Advances from related parties		
	-	-
	-	-

Note 7 : Provisions (Refer General Instructions Note No.6 & 10)

	Non-current		Current	
	Nov 06, 2014	March 31, 2014	Nov 06, 2014	March 31, 2014
Provision for employee benefits				
- Gratuity				
- Leave encashment				
Other Provisions				
For Taxation (net of advance payments)				
For Proposed dividend				
For Tax on proposed dividend				
	-	-	-	-
	-	-	-	-

Provision for warranties

	Nov 06, 2014	March 31, 2014
At the beginning of the year		
Arising during the period		
Utilised during the period		
Unused amounts reversed		
At the end of the Quarter		
Current portion		
Non-current portion		

Note 8 : Short-term borrowings (Refer General Instructions Note No.7)

	Nov 06, 2014	March 31, 2014
Book overdraft		
Loans and advances from related parties		
Working capital loans (Secured)		
Short term loans (Un Secured)		
Working capital loans		
	-	-
The above amount includes		
Secured borrowings		
Unsecured borrowings		

Note 9 : Other current liabilities (Refer General Instructions Note No.9)

	Nov 06, 2014	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)		
Other liabilities		
Current maturities of long-term borrowings		
Trade deposits		

Name of the company

Notes to the Balance Sheet

(All amounts are in € except share data and unless otherwise stated)

Note 10: Tangible assets (in accordance with IAS 16)

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment (including Computers & Software)	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation									
At 1 April 2013									-
Additions									-
Disposals									-
Other adjustments									-
- Exchange differences									-
- Borrowing costs									-
At 31 March 2014	-	-	-	-	-	-	-	-	-
Additions									-
Acquisitions through amalgamation									-
Disposals									-
Other adjustments									-
- Exchange differences									-
- Borrowing costs									-
At 06 Nov 2014	-	-	-	-	-	-	-	-	-
Depreciation									
At 1 April 2013									-
Charge for the year									-
Disposals									-
Other adjustments									-
- Exchange differences									-
At 31 March 2014	-	-	-	-	-	-	-	-	-
Charge for the period									-
Disposals									-
Other adjustments									-
- Exchange differences									-
At 06 Nov 2014	-	-	-	-	-	-	-	-	-
Impairment loss									
At 1 April 2013									-
At 31 March 2014									-
Charge for the period									-
At 06 Nov 2014	-	-	-	-	-	-	-	-	-
Net Block									
At 31 March 2014	-	-	-	-	-	-	-	-	-
At 06 Nov 2014	-	-	-	-	-	-	-	-	-

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-95986079
Plaza. de Carlos Trias Bertrán, nº 4
28020 MADRID

Name of the company

Notes to the Balance Sheet

(All amounts are in € except share data and unless otherwise stated)

Note 11: Intangible assets (see General Instructions Note No.12)

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At 1 April 2013				-
Purchase				-
Internal development				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At 31 March 2014	-	-	-	-
Purchase				-
Acquisitions through amalgamation				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At 06 Nov 2014	-	-	-	-
Amortization				
At 1 April 2013				-
Charge for the year				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At 31 March 2014	-	-	-	-
Charge for the period				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At 06 Nov 2014	-	-	-	-
Net Block				
At 31 March 2014	-	-	-	-
At 06 Nov 2014	-	-	-	-

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-95996079
Plaza. de Carlos Trias Bertrán, nº 4
28020 MADRID

Note 12: Non-current investments (Refer General Instructions Note No.13)

	Nov 06, 2014	March 31, 2014
Unquoted equity instruments		
Investment in subsidiaries		
Investment in joint ventures		
Investment in associates		
	-	-

Note 13: Loans and advances (Refer General Instructions Note Nos 11 & 21)

		Non-current		Current	
		Nov 06, 2014	March 31, 2014	Nov 06, 2014	March 31, 2014
Capital advances					
Secured, considered good					
Unsecured, considered good	(A)	-	-	-	-
Security deposit					
Secured, considered good					
Unsecured, considered good					
Doubtful		-	-	-	-
Provision for doubtful security deposit	(B)	-	-	-	-
Loan and advances to related parties					
Unsecured, considered good	(C)	-	-	-	-
Advances recoverable in cash or kind					
Secured, considered good					
Unsecured, considered good					
Doubtful		-	-	-	-
Provision for doubtful advances	(D)	-	-	-	-
Other loans and advances					
Advance income-tax (net of provision for taxation)					
Prepaid expenses					
Loans to employees					
Loans to others					
Export incentives receivable					
Export incentives licenses					
Balances with Statutory/government authorities	(E)	-	-	-	-
Total (A+B+C+D+E)		-	-	-	-

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	Nov 06, 2014	March 31, 2014	Nov 06, 2014	March 31, 2014
Loans to employees include				
Dues from non-executive directors				
Dues from officers				
Dues from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner				
Dues from in which the company's managing director is a member				
Dues from the partnership firm in which the company's non-executive director is a partner				

Note 14 : Trade receivables and other assets

14.1 Trade receivable (Refer to general instructions Note No.15 & 19)

	Non-current		Current	
	Nov 06, 2014	March 31, 2014	Nov 06, 2014	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful				
Provision for doubtful receivables	-	-	-	-
(A)	-	-	-	-
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful				
Provision for doubtful receivables	-	-	-	-
(B)	-	-	-	-
Total (A+B)	-	-	-	-

Trade receivables include:

	Non-current		Current	
	Nov 06, 2014	March 31, 2014	Nov 06, 2014	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				
14.2 Other assets (Refer to general instructions Note No.16 & 22)				
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)	-	-	-	-
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)	-	-	-	-
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on investments in subsidiaries - long term				
Others				
(C)	-	-	-	-
Total (A+B+C)	-	-	-	-

Aurovitas S.L, Spain

Notes to the Balance Sheet

(All amounts are in € except share data and unless otherwise stated)

Note 15: Current investments (Refer General Instructions Note No. 17)

	Nov 06, 2014	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any (Please specify)		

Note 16: Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No. 18)

	Nov 06, 2014	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)		
Work - in - Progress		
Finished goods		
Traded goods (including stock -in-transit XXXX (31 March, 2014 XXX)		
Stores, spares, consumables and packing materials		
Loose tools		

Note 17: Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	Nov 06, 2014	March 31, 2014	Nov 06, 2014	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts				
Deposits with original maturity of less than 3 months				
Cash credit accounts				
On unpaid dividend account				
Cheques/drafts on hand				
Unpaid matured deposits				
Cash on hand				
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
Amount disclosed under non-current assets				

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-58990079
Plaza. de Carlos Trias Bertrán, nº 4
28020 MADRID

Aurovitas S.L., Spain

Notes to the statement of profit and loss

(All amounts are in € except share data and unless otherwise stated)

	Apr-14	May-14	June-14	July-14	Aug-14	Sep-14	Oct-14	Nov-14	Period of 14th Apr 2014 to 06 Nov 2014 (Euro)	Year ended March 31, 2014 (Currency)
Note 18 : Revenue from operations (Refer General Instructions Note No.25)										
Revenue from operations										
Sale of products										
Finished goods										-
Traded goods										-
Sale of services										-
Sale of dossiers/licenses										-
Other operating revenue										-
Scrap sales										-
Other										-
Revenue from operations (gross)	-	-	-	-	-	-	-	-	-	-
Less: VAT/Excise duty										-
Revenue from operations (net)	-	-	-	-	-	-	-	-	-	-
Note 19 : Other income (Refer General Instructions Note No.26)										
Interest income on										
Bank deposits										-
Long-term investments										-
Current investments										-
Loans to joint venture entities										-
Others										-
Dividend income on										
Investment in subsidiaries										-
Current investments										-
Long-term investments										-
Net gain on sale of current investments										-
Profit on sale of fixed assets (net)										-
Foreign exchange gain (net)										-
Balances no longer required written back										-
Government grant										-
Commission income										-
Processing charges										-
Other non-operating income (net of expenses directly attributable to such income of Rs.XXXXX (31 March, 2014:XXXX)										-
	-	-	-	-	-	-	-	-	-	-
Note 20 : Cost of raw material and components consumed										
Inventory at the beginning of the period										-
Add: Purchases										-
	-	-	-	-	-	-	-	-	-	-
Less: inventory at the end of the period										-
	-	-	-	-	-	-	-	-	-	-
Add:Packing material consumed										-
Cost of raw material and components consumed	-	-	-	-	-	-	-	-	-	-
Note 21 : (Increase)/decrease in inventories										
Inventories at the end of the quarter										
Traded goods										-
Work-in-progress										-
Finished goods										-
	-	-	-	-	-	-	-	-	-	-
Inventories at the beginning of the quarter										
Traded goods										-
Work-in-progress										-
Finished goods										-
	-	-	-	-	-	-	-	-	-	-
Details of purchase of traded goods										
Product A										-
Product B										-
Product C										-
	-	-	-	-	-	-	-	-	-	-
Note 22 : Employee benefit expense										
Salaries, wages and bonus										-
Contribution to provident and other fund										-
Employee stock option scheme										-
Gratuity expense										-
Other employee benefits										-

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-96946079
Plaza. de Carlos Trias Bertrán, nº 4
28020 MADRID

Aurovitas S.L., Spain

Notes to the statement of profit and loss

(All amounts are in € except share data and unless otherwise stated)

	Apr-14	May-14	June-14	July-14	Aug-14	Sep-14	Oct-14	Nov-14	Period of 14th Apr 2014 to 06 Nov 2014 (Euro)	Year ended March 31, 2014 (Currency)
Post employment medical benefits									-	-
Staff welfare expenses									-	-
Note 23 : Other expenses										
Consumption of stores and spares									-	-
Conversion charges									-	-
Chemicals consumed									-	-
Increase in VAT on finished goods									-	-
Customer service expenditure									-	-
Power and fuel									-	-
Water charges									-	-
Freight and forwarding charges									-	-
Carriage inward									-	-
Carriage outwards									-	-
Rent									-	-
Rates and taxes									-	-
Insurance									-	-
Repairs and maintenance:									-	-
i) Plant and machinery									-	-
ii) Buildings									-	-
iii) Others									-	-
Advertising and sales promotion									-	-
Brokerage and discounts									-	-
Remuneration to Auditors									-	-
Sales commission									-	-
Travelling and conveyance									-	-
Communication costs									-	-
Printing and stationery									-	-
Legal and professional fees								5721	5.721	-
Directors sitting fees									-	-
Payment to auditor (Refer details below)									-	-
Provision for diminution in value of investment in subsidiary company									-	-
Provision for other than temporary decline in the carrying amount of other long-term investments									-	-
Adjustment to the carrying amount of current investments									-	-
Provision for warranties (net of reversals)									-	-
Provision for litigations (net of reversals)									-	-
Exchange differences (net)									-	-
Loss on derivative contracts (including provisions mark-to-market loss)									-	-
Bad debts/advances written off									-	-
Impairment loss on fixed assets									-	-
Provision for doubtful debts and advances									-	-
Loss on sale of fixed assets (net)									-	-
Premium on forward exchange contract amortized									-	-
Factory maintenance									-	-
Effluent treatment expenses									-	-
Vehicle maintenance expenses									-	-
Analytical charges									-	-
Product development expenses									-	-
Registration and filing charges									-	-
Safety and security									-	-
Office expenses									-	-
Repairs and maintenance - others									-	-
Management fees									-	-
Liquidated damages									-	-
Donations									-	-
Software license and implementation expenses									-	-
Capital work-in-progress written off									-	-
Miscellaneous expenses									-	-
								5.721	5.721	-
Payment to Auditor										
As auditor:										
Audit fee									-	-
Tax audit fee									-	-
Limited review									-	-
In other capacity:										
Taxation matters									-	-
Company law matters									-	-
Management services									-	-

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-66969078
Plaza de Carlos III/Tras Bertrán, nº 4
28020 MADRID

Aurovitas S.L., Spain

Notes to the statement of profit and loss

(All amounts are in € except share data and unless otherwise stated)

	Apr-14	May-14	June-14	July-14	Aug-14	Sep-14	Oct-14	Nov-14	Period of 14th Apr 2014 to 06 Nov 2014 (Euro)	Year ended March 31, 2014 (Currency)
Other services (certification fees)									-	-
Reimbursement of expenses									-	-
Note 24 : Exceptional items										
Others (Specify if any)									-	-
Note 25 : Depreciation and amortization expense										
Depreciation of tangible assets									-	-
Amortization of intangible assets									-	-
Depreciation of investment property									-	-
Note 26 : Finance costs (Refer to general instructions, Note No. 26)										
Interest									-	-
Bank charges	18,15			9,2					27	-
Amortization of auxiliary borrowing costs									-	-
Exchange difference to the extent considered as an adjustment to borrowing costs									-	-
	18	-	-	9	-	-	-	-	27	-

RUSSELL BEDFORD ESPAÑA
AUDITORES Y CONSULTORES, S.L.
C.I.F. B-66896078
Plaza. de Carlos Trias Bertrán, nº 4
28020 MADRID

Aurovitas S.L,

Notes to the Financial Statements for the Period from April 14, 2014 to November 06, 2014

1. Activity of the Company

Aurovitas S.L. was incorporated in Madrid on 14th April, 2014. The Registered Office of the Company is located in CL/Hermosilla, 11, 4^o, Madrid 28001, Spain.

Pursuant to the Articles of its by-laws, the corporate purpose of the company is as follows:

- To buy, sell, import, export or store any pharmaceutical products
- To acquire, hold, develop, dispose or exploit industrial property rights.
- To provide all types of marketing support

The Sole Shareholder of the company as at November 6, 2014 is Agile Pharma B.V., legally seated in Amsterdam (Prins Bernhardplein 200, 1097 JB Amsterdam, The Netherlands) and registered with the Registry of Chamber of Commerce of Amsterdam under number 34255461.

2. Basis of Preparation and Presentation of Annual Accounts

True and fair view

The financial statements have been prepared by the Company's Board of Directors using all the Company's accounting registries upto 6nd November, 2014. In this report all the accounting principles and assessment criteria compiled in the General Accounting Plan (GAP), which was approved in Royal Decree 1514/2007, have been applied. These annual accounts show the true and fair view of the equity, financial position and results of the company.

There are no reasons why, in representing the true and fair view, any legal accounting regulations have not been applied.

The attached annual accounts will be subject to examination by the Only Shareholder, with the expectation that they will be approved without any changes needing to be made.

3. Accounting Policies

The main accounting criteria applied are as follows:

a. Intangible Assets

"Concessions, patents, licenses and trade mark" are capitalized including registration fees for the industrial property. Subsequently, measured at cost less accumulated depreciation and impairment losses they experienced. Amortization is carried out systematically in ten years.

b. Property, Plant and Equipment

Items included in "Property, Plant and Equipment" are represented on the balance sheet by way of their purchase cost or production cost minus their accumulative amortization and loss of value through deterioration.

The company depreciates its fixed assets by distributing the cost of assets depending on its estimated economic life according to the following:

	Depreciation Rate
Building	20%
Furniture	10%
Information Processing Equipment	25%

The Company uses a straight line method when calculating depreciation for all its fixed assets.

c. Classification of assets and liabilities

In the balance sheet, assets and liabilities with maturity of less than twelve months from the end of the reporting period are classified as current, while those maturing more than twelve months are classified as non-current.

d. Inventories

Goods for resale are valued downwards to their purchase price or their net realizable value. The purchase price is the amount billed by the provider less the discounts and interests incorporated into the nominal value of the debits, plus any additional costs so that stocks are ready for sale.

The cost of goods to the various units of inventories is assigned by applying the weighted average method.

e. Income and expenditure

Income and expenditure are accounted depending on the payment criteria, irrespective of the moment in which the monetary or financial effects derived from them occur.

The company only includes the profits yielded on the date of the periods close but, any foreseen risks and losses are accounted for as soon as they are known.

Income through the sale of goods or services is only recognized by the fair value received or to be received. Discounts by way of early payment, volume or other discount types, as well as interests incorporated into the nominal value of the credits are recorded as deductions.

f. Provisions and contingencies

In the preparation of the annual accounts the management differentiates between:

Provisions: Liabilities that cover present obligations at the balance sheet date which result from past events which could give rise to a loss of probable realization for the entity, which amount and time of cancellation are indeterminate. The balances are recognized at the present value of the most probable estimated amount that the company will have to pay to settle the obligation.

Contingent Liabilities: Possible obligations as a result from past events and whose existence depends on the occurrence or not one or more future events beyond the control of the entity.

The annual accounts include all the material provisions with respect to which it is estimated that the probability of having to meet the obligation is greater than the opposite. Contingent liabilities, if any, are the subject of information.

Provisions, which are quantified on the best information available on the consequence of the event giving rise to them and are re-estimated at each balance sheet date are used to meet the specific obligations for which they were originally recognized. Provisions are reversed in full or in part when such obligations cease to exist or are reduced.

g. Financial instruments

Financial assets and liabilities are categorized according to the instrument's characteristics and the reason behind its purchase. Financial assets held by the company are classified as:

Loans and receivables are trade and non-trade credits which come from the sale of goods or from services rendered, whose payments are of a determined or determinable value and are not negotiated on any active markets. The company records the corresponding impairments by the difference between the value to be reclaimed from the pending accounts and the book value for which they were recorded whether there is objective evidence of impairment.

Held to maturity investments are those debt values which have fixed maturity date, determined or determinable payments, are negotiated on an asset market and ones which the company has the intention and capacity to maintain up until their maturity. The assessment criteria for these investments are the same as those used for loans and receivables.

3. Reporting currency

The reporting currency used for the preparation of the financial statements is Euro, which is the currency in which the Company's share capital is denominated

4. Share capital

Ordinary shares are classified as equity.

5. Performance

During the Period, the company incurred a net loss of €5,749. These financial statements have been prepared on a basis in view of the fact that the company's shareholders have decided and liquidated the company.

By Order of the Board on 6nd November, 2014



Gabriel Diaz Rodriguez
Director

Aurex B.V.

ANNUAL REPORT

OCTOBER 2014 – MARCH 2015



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants-Adviseurs B.V.

13 MAY 2015
345

Aurex B.V. – May 2015, page 1



AUROBINDO

DIRECTORS' REPORT

REPORT OF THE DIRECTORS

The management herewith presents to the shareholders, the annual accounts of **Aurex B.V.** for the six months ended 31st March, 2015 (period).

GENERAL

The company is a limited liability company incorporated under the laws of The Netherlands and act as a trading company. The principle object of the company is to trade and deal in pharmaceutical products and other allied products & services.

REVIEW OF OPERATIONS

Company has been incorporated on 1st October, 2014 and directors decided to close their first financial year on 31st March, 2015. The company has not started its operations in this period ended 31st March, 2015. Directors reviewed the business opportunities in Europe and across the world and decided to start the Operations from 1st April, 2015 onwards.

DIRECTORS

The Directors at the date of the report are:

1. Mr. G.P.Prasad
2. Mr. Ronald David Steentjes

SHARE CAPITAL

The shares of the company have been fully allotted to its shareholder, Agile Pharma B.V.; these shares are fully paid up as at March 31, 2015. Total paid up capital of company as at 31st March 2015 was Euro 90,000.


UNUSUAL ITEMS AFTER THE FINANCIAL PERIOD

No item, transaction or event of material nature has arisen during the period between the end of the period and date to this report, which would affect substantially the operation of the company during the current period.

STATEMENT BY DIRECTORS,

In the opinion of the directors, the accompanying financial statements were drawn up to give true and fair view of the statement of affairs of the company as at March 31, 2015. Company directors have taken all the reasonable steps to prepare financial statements on a going concern basis and that suitable accounting policies have been adopted consistently. Further, Directors are confident that with the support and guidance of the holding company, company can achieve better results in the future.

By Order of the Board on 19th May, 2015


Ronald David Steentjes
Director

Aurex B.V.
an Aurebindo Pharma Company

Baarnsche Dijk 1 – 3741 LN Baarn – The Netherlands – Tel: +31 (0)35 5429933 – Fax: +31(0)35 5429932
C.o.C. 61580481

Annual Report OCTOBER 2014 – March 2015

Annual Accounts

• Balance Sheet	3
• Statement of profit and loss	5
• Notes	6
• Accounting principles	6
• Notes to the balance sheet	8
• Notes to the statement of profit and loss	9

<i>Other information</i>	11
--------------------------	----



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants & Adviseurs B.V.

13 MAY 2015

347

BALANCE SHEET
(after appropriation of result)

ASSETS	<u>Note</u>	<u>31-03-2015</u> €'000	<u>01-10-2014</u> €'000
CURRENT ASSETS			
<i>Cash and cash equivalents</i>	1	90	0
		<u>90</u>	<u>0</u>



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants & Adviseurs B.V.

13 MAY 2015

Aurex B.V. – May 2015, page 3

EQUITY, PROVISIONS AND LIABILITIES	<u>Note</u>	<u>31-03-2015</u> €'000	<u>01-10-2014</u> €'000
EQUITY			
Issued share capital	2	<u>90</u> <u>90</u>	<u>0</u> <u>0</u>
		<u>90</u>	<u>90</u>

13 MAY 2015

STATEMENT OF PROFIT AND LOSS

	Oct. 2014- Mar. 2015 <u>€'000</u>
NET TURNOVER	0
TOTAL OPERATING EXPENSES	<u>0</u>
OPERATING RESULT	0
FINANCIAL RESULT	0
RESULT FROM ORDINARY OPERATIONS BEFORE TAXATION	<u>0</u>
Corporate income tax	0
RESULT FROM ORDINARY OPERATIONS AFTER TAXATION	<u>0</u>



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants en Adviseurs B.V.

13 MAY 2015

350

NOTES

General

The company is part of the (sub)group with Agile Pharma B.V. as (sub)group head.

ACCOUNTING PRINCIPLES

The annual accounts are prepared on basis of the principles of Title 9 of Book 2 of the Netherlands Civil Code.

Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise at the relevant principle for the specific balance sheet item, assets and liabilities are presented at nominal value.

The reporting currency of the annual accounts of the company is euro (€).

VALUATION PRINCIPLES FOR ASSETS AND LIABILITIES

CURRENT ASSETS

Cash and cash equivalents

The cash is valued at face value. If cash equivalents are not freely disposable, then this has been taken into account in the valuation.

SHORT TERM LIABILITIES

Short term liabilities and accrued liabilities

Short term liabilities will be valued at nominal value at first and subsequently valued at amortised cost price, which is equal to the nominal value.

Accrued liabilities will be valued at nominal value.

PRINCIPLES FOR DETERMINATION OF RESULT

NET TURNOVER

Turnover is formed by revenue from deliveries of goods and services to third parties, net of discounts, rebates and value added taxes.

The revenue from deliveries of goods are recognised in the profit and loss account at the moment of economic delivery.

EXPENSES

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants and Adviseurs B.V.

13 MAY 2015

Aurex B.V. – May 2015, page 6

Expenses are allocated to the period to which they refer, using accrual items if necessary.

AMORTISATION/ DEPRECIATION

The amortization/ depreciation on (in)tangible fixed assets is calculated by using a fixed rate on the acquisition cost or cost of conversion.

Gains and losses on disposal of (in)tangible fixed assets are recorded under amortisation/depreciation, gains only to the extent that the gain is not capitalised for replacement investments.

FINANCIAL RESULT

Financial income and expenses comprise interest income and expenses on loans as accounted for in the current reporting period.

CORPORATE INCOME TAX

Corporate income tax expense comprises current and deferred tax. Corporate income tax expense is recognised in profit or loss except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity.

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is provided for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants & Adviseurs B.V.

13 MAY 2015

Aurex B.V. – May 2015, page 7

NOTES TO THE BALANCE SHEET

(Amounts in thousands of euro)

ASSETS

CURRENT ASSETS

	31-03-2015	31-03-2014
1) <i>Cash and cash equivalents</i>		
ING Bank N.V., current account	90	0

EQUITY, PROVISIONS AND LIABILITIES

EQUITY

2) <i>Issued share capital</i>	31-03-2015	01-10-2014
900 ordinary share with par value of nominal € 100.00 per share	90	0

The statutory share capital amount to € 90,000.00, divided into 1,000 ordinary shares with a nominal value of € 100,00 per share. A total of 900 shares have been issued and fully paid.

The shares are held by Agile Pharma B.V.



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants en Adviseurs B.V.

13 MAY 2015

Aurex B.V. – May 2015, page 8

NOTES TO THE STATEMENT OF PROFIT AND LOSS

(Amounts in thousands of euro)

NUMBER OF EMPLOYEES

The number of employees employed by the company during the reporting period was 0.

TAXATION

A provision for deferred taxation is formed for differences in commercial and fiscal valuation.

CONTINGENT LIABILITIES

The company constitutes a tax entity for corporate income tax with Helix Healthcare B.V.; consequently the company is severally liable for the resulting debts



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants en Adviseurs B.V.

13 MAY 2015

Aurex B.V. – May 2015, page 9

SIGNATURES TO THE ANNUAL ACCOUNTS

Baarn, 13 May 2015.

The Board of Directors:

R.D.A. Steentjes

V. Muralidharan

G.P. Prasad



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants & Adviseurs B.V.

13 MAY 2015

Aurex B.V. – May 2015, page 10

OTHER INFORMATION

Statutory profit allocation

Article 19 reads:

19.1 The allocation of profits accrued in a financial year shall be determined by the Shareholders' Body. If the Shareholders' Body does not adopt a resolution regarding the allocation of the profits prior to or at latest immediately after the adoption of the annual accounts, the profits will be reserved.

19.2 Distribution of profits shall be made after adoption of the annual accounts if permissible under the law given the contents of the annual accounts.

19.3 The Shareholders' Body may resolve to make interim distributions on Shares and/or to make distributions on Shares at the expense of any reserve of the Company. In addition, the Management Board may decide to make interim distributions on Shares.

19.4 Distributions on Shares shall be made payable immediately after the resolution to make the distribution, unless another date of payment has been determined in the resolution.

19.5 Distributions on Shares may be made only up to an amount which does not exceed the amount of the Distributable Equity.

19.6 In calculating the amount of any distribution on Shares, Shares held by the Company shall be disregarded.

Result allocation proposal

The General Meeting of Shareholders proposes to allocate the result for the book year 2014-2015 of € 0 to the other reserves.

This proposal has been reflected in the annual accounts.



Grant Thornton
Accountants en Adviseurs B.V.
Gedempte Zalmhaven 4a
P.O. Box 23278
3001 KG Rotterdam
The Netherlands

T +31 88 676 90 00
F +31 88 676 90 10
www.gt.nl

To: the shareholder of Aurex B.V.

INDEPENDENT AUDITOR'S REPORT

Report on the financial statements

We have audited the accompanying financial statements for the year ended 31 March 2015 of Aurex B.V., Zwijndrecht, which comprise the company balance sheet as at 31 March 2015, the company profit and loss account for the period 1 October 2014 until 31 March 2015 and the notes, comprising a summary of the accounting policies and other explanatory information.

Management's responsibility

Management is responsible for the preparation and fair presentation of these financial statements and for the preparation of the management board report, both in accordance with Part 9 of Book 2 of the Dutch Civil Code. Furthermore management is responsible for such internal control as it determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

Grant Thornton Accountants en Adviseurs B.V. is a member firm within Grant Thornton International Ltd. (Grant Thornton International)

Grant Thornton Accountants en Adviseurs B.V. is registered with the Chamber of Commerce of The Hague trade register under number 28105565. To all our services our general conditions, as registered with the Registry of the District Court in The Hague, apply. A copy of these conditions will be sent to you on request. Any liability shall be limited to the amount which is mentioned in the general conditions.


We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion with respect to the financial statements

In our opinion, the financial statements give a true and fair view of the financial position of Aurex B.V. as at 31 March 2015 and of its result for the period then ended in accordance with Part 9 of Book 2 of the Dutch Civil Code.

Rotterdam, 13 May 2015

Grant Thornton Accountants en Adviseurs B.V.



drs. G. Houtewijn RA

Initialed for identification purposes only:



Directors' Report

The management herewith presents to the shareholders the annual accounts of Aurobindo Pharma Italia S.r.l, Italy for the year ended 31st March, 2015

PRINCIPAL ACTIVITY

The principle object of the company is to trade, deal in pharmaceutical products and other allied products and services.

REVIEW OF OPERATIONS

The directors of company have reviewed companies operations and discussed about the operations of the company. During the year, your company has registered a turnover of Euro 19.3 million and made a loss of Euro 6.9 mil after taking Depreciation into consideration.

DIRECTORS

The directors at the date of the report are

Mr. Muralidharan .Venugopalan	Chairmain
Mr. Kalman Petro	Managing Director and Legal Representative
Mr. G. P. Prasad	Board Member
Mr. Massimo Micheli	Board Member and Legal Representative

AUDITORS

The auditors, Analisi SPA, Chartered Accountants have expressed their willingness to accept re-appointment.

THE DIRECTORS OF THE COMPANY DECLARS THAT:

The financial statements and notes comply with Accounting Standards as detailed in Notes to the financial statements, and present fairly the company's financial position as at March 31, 2015.

Disclosure of information to Auditors

So far as each director at the date of approval of this report is aware

- There is no relevant audit information of which the company's auditors are unaware; and
- The directors have taken all steps that they ought to have taken to make them aware of any relevant audit information and to establish that the auditors are aware of that information.

Aurobindo Pharma (Italia) S.r.l. (in forma abbreviata **Aurobindo S.r.l.**)
Via San Giuseppe 102 - 21047 Saronno (Va) - Tel. +39 02 96392601 - Fax: +39 02 96193260

Capitale Sociale € 2.000.000 i.v. - Registro delle Imprese di Varese/Codice Fiscale/Partita IVA: 06058020964 - R.E.A. VA- 349297



Board approved this report on 8th May 2015

Murlidharan V

Chairman

Aurobindo Pharma (Italia) S.r.l. (in forma abbreviata **Aurobindo S.r.l.**)
Via San Giuseppe 102 - 21047 Saronno (Va) - Tel. +39 02 96392601 - Fax: +39 02 96193260

Capitale Sociale € 2.000.000 i.v. – Registro delle Imprese di Varese/Codice Fiscale/Partita IVA: 06058020964 – R.E.A. VA- 349297

AUROBINDO GROUP
AUDITORS' OPINION ON THE REPORTING PACKAGE
AT MARCH 31, 2015

1. Scope of the audit work:

We audited the reporting package of AUROBINDO PHARMA (ITALIA) Srl, comprising the balance sheet at March 31, 2015, the related income statement and the detail of the notes to the financial statements for the year then ended, prepared in accordance with Italian standard accounting policies. Our examination was performed in accordance with Italian Auditing Standards.

2. Special purpose of the report:

This reporting package was prepared for use in the preparation of the consolidated financial statements of the Aurobindo Pharma Group and, accordingly, shows the assets, liabilities and investments of the shareholders and the income and expense of AUROBINDO PHARMA (ITALIA) Srl, for this purpose. The reporting packages were not prepared for use for other purposes and are not appropriate for such end.


3. Auditors' opinion:

In our opinion, the aforementioned reporting package present fairly, in all material respects, for the purpose described in paragraph 2 above, the net worth and financial position of AUROBINDO PHARMA (ITALIA) Srl, as of March 31, 2015 and the results of its operations at the date, in conformity with Group Auditing Policies and accounting principles and standards applied on a basis consistent with that of the previous year.

Reggio Emilia, May 20, 2015

Analisi S.p.A.

Francesco Notari
Partner



Aurobindo Pharma Italia Srl**Balance Sheet as at March 31, 2015**

(All amounts are in Eur except share data and unless otherwise stated)

	Note	March 31, 2015 (Eur)	31 March, 2014 (Eur)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	2.000.000	2.000.000
Share application money		-	10.748.000
Reserves and surplus	3	(377.069)	(11.415.671)
		1.622.931	1.332.329
Non-current liabilities			
Long-term borrowings	4	6.262.245	-
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	5.274.509
Other long-term liabilities	6	382.365	371.356
Long-term provisions	7	-	-
		6.644.610	5.645.865
Current liabilities			
Short-term borrowings	8	-	645.241
Trade payables	9	8.016.450	-
Other current liabilities	9	5.258.195	-
Short-term provisions	7	-	16.251
		13.274.644	661.492
TOTAL		21.542.186	7.639.686
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	210.531	12.922
Intangible assets	11	3.891.434	4.145.825
Capital work-in-progress		345.746	741.565
Intangible assets under development		-	-
Non-current investments	12	-	-
Deferred tax assets (net)	5	642.232	640.313
Long-term loans and advances	13	14.500	-
Trade receivables	14,1	-	-
Other non-current assets	14,2	-	-
		5.104.442	5.540.625
Current assets			
Current investments	15	-	-
Inventories	16	5.193.396	1.070.592
Trade receivables	14,1	10.065.988	779.567
Cash and bank balances	17	799.783	25.676
Short-term loans and advances	13	337.049	223.226
Other current assets	14,2	41.527	-
		16.437.744	2.099.061
TOTAL		21.542.186	7.639.686
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.

**Anafisi S.p.A.**

Aurobindo Pharma Italia Srl

Statement of profit and loss for the year ended March 31, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	12Months Period ended Mar 31, 2015 (Eur)	Year ended March 31, 2014 (Eur)
Income															
Revenue from operations (gross)	18	322.080	2.388.923	2.195.149	2.136.904	441.813	1.774.711	1.570.733	1.728.438	1.470.389	1.520.975	1.548.687	1.804.512	18.903.315	253.054
Less: Excise duty/Rebates		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from operations (net)		322.080	2.388.923	2.195.149	2.136.904	441.813	1.774.711	1.570.733	1.728.438	1.470.389	1.520.975	1.548.687	1.804.512	18.903.315	253.054
Other income	19	22.844	11.424	312.793	6.021	6.652	23.659	9.474	8.967	24.146	(56.086)	15.932	7.907	393.732	23.686
Total revenue (I)		344.924	2.400.346	2.507.942	2.142.925	448.465	1.798.371	1.580.207	1.737.405	1.494.535	1.464.888	1.564.619	1.812.419	19.297.047	276.740
Expenses															
Cost of raw material and components consumed	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods	21	3.812.790	13.162	2.343.494	690.680	683.029	663.101	1.836.900	754.196	504.202	689.553	824.732	1.382.810	14.198.649	522.416
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	(3.563.868)	442.590	(50.254)	222.407	(373.739)	441.342	(731.303)	81.273	(13.034)	117.851	176.710	(872.781)	(4.122.804)	(445.471)
Employee benefit expense	22	397.402	476.045	253.783	313.014	248.223	120.732	561.680	315.777	337.644	278.220	311.385	320.583	3.934.487	709.745
Other expenses	23	489.666	2.056.155	(230.891)	827.056	468.392	1.626.655	957.216	821.289	1.295.089	701.901	565.096	1.902.173	11.479.797	2.041.533
Exceptional items	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total (II)		1.135.990	2.987.953	2.316.133	2.053.157	1.025.906	2.851.830	2.624.493	1.972.535	2.123.900	1.787.525	1.877.922	2.732.785	25.490.129	2.828.223
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		(791.065)	(587.607)	191.809	89.768	(577.441)	(1.053.459)	(1.044.286)	(235.130)	(629.365)	(322.636)	(313.304)	(920.366)	(6.193.082)	(2.551.483)
Depreciation and amortization expense	25	44.686	45.060	59.680	50.841	50.705	50.492	50.918	50.622	50.840	50.907	50.119	(7.181)	547.689	823.333
Finance costs	26	528	823	57.236	(335)	3.808	56.991	7.204	20.231	24.495	(566)	9.069	14.142	193.626	14.982
Profit/(loss) before tax		(836.279)	(633.490)	74.893	39.263	(631.954)	(1.160.942)	(1.102.408)	(305.983)	(704.700)	(372.977)	(372.492)	(927.328)	(6.934.398)	(3.389.798)
Tax expenses		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: MAT credit entitlement		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fringe benefit tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax relating to previous years		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total tax expense		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Profit/(loss) for the Current Period/year		(836.279)	(633.490)	74.893	39.263	(631.954)	(1.160.942)	(1.102.408)	(305.983)	(704.700)	(372.977)	(372.492)	(927.328)	(6.934.398)	(3.389.798)

Summary of significant accounting policies

1

The accompanying notes are an integral part of the financial statements.

363

Analisi S.p.A.



Note 1 : Summary of significant accounting policies (Refer General Instructions Note No.1)

Accounting Policies	Note
1.1. Basis of preparation	The financial statements have been prepared under the historical cost convention on accrual basis to comply in all material respects with the mandatory Accounting Standards issued by the Institute of Chartered Accountants of India and the relevant provisions of the Indian Companies Act, 2013. Only in case Italian GAAP was requesting a deviation, we applied the Italian GAAP (reference to Goodwill)
1.2. Revenue recognition	Domestic Sales: Revenue from sale of goods is recognized on goods delivery at the customer desk. VAT is recognized according to Italian specific rules and exclusive of trade discounts, sales returns and sales tax, where applicable.
	Interest :Interest is recognized on a quarterly basis as per bank statement.
1.3. Tangible Fixed Assets	Tangible Fixed assets are stated at cost less accumulated depreciation. Cost includes purchase price, freight, duties, and taxes (net of VAT) and any attributable cost of bringing the asset to its working condition and location for its intended use. Any trade discounts and rebates are deducted in arriving at the purchase price.
1.4. Depreciation	Depreciation is provided on the straight-line method, based on the useful life of the assets as estimated by the Management which generally coincides with useful lives accepted as per local and Indian GAAP
1.5. Borrowing Cost	Borrowing is in line with terms and conditions signed with the mother company, regarding the funds.
1.7. Inventories	Raw materials, packing materials, stores, spares and consumables are valued at lower of cost, calculated on "Weighted average" basis, and net realisable value.
	Trading goods are valued at lower of cost and net realisable value. Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on a "Weighted average" basis.
	Net realisable value is the estimated selling price in the ordinary course of business, reduced by the estimated costs of completion and costs to effect the sale.
1.8. Retirement Benefits	Retirement benefits calculated in line with Italian civil code.
1.11. Foreign Currency Transactions	Foreign currency transactions (other than those relating to foreign branches) arising during the year are recorded at the exchange rates prevailing at the transaction dates.
1.13. Leases	Leases where the lessor effectively retains substantially all the risks and rewards incidental to ownership are classified as operating leases. Operating lease payments are recognized as an expense in the Statement of Profit and Loss on a straight-line basis over the lease term.
1.14. Intangible assets	Definition: An intangible asset is an identifiable non-monetary asset (other than money held and assets to be received in fixed or determinable amounts of money), without physical substance, held for use in the production or supply of goods or services, for rental to others, or for administrative purposes.



Analisi S.p.A.

	Amortisation period: The depreciable amount of an intangible asset should be allocated on a systematic basis over the best estimate of its useful life.
	Amortisation should commence when the asset is available for use.
	Amortisation method: The amortisation method used should reflect the pattern in which the asset's economic benefits are consumed by the enterprise. If the same cannot be determined reliably, the straight-line method should be used. The amortisation charge should be recognized as an expense.
	Review: The amortisation period and method should be reviewed at least at each financial year-end. If there is significant change in the useful life from previously estimated or in the expected pattern of economic benefits, the amortisation period and method should be changed accordingly.
	Disclosure: The financial statement should disclose for each class of Intangible assets (internally generated and other intangible assets), the useful life/amortisation rates used, amortisation method, gross carrying amount and accumulated amortisation at the beginning and end of the period, amortisation recognized during the period and other changes in the carrying amount during the period.
1.15. Impairment of Assets	Definition: An asset is said to have been impaired if the carrying value of the asset exceeds the amount to be recovered through use or sale of the asset.
	Assessment of impairment: The recoverable amount of an asset should be estimated whenever there is an indication that the asset may be impaired.
	In the case of an annual financial statement, impairment assessment should be made atleast once on the assets at the balance sheet date.
	How to calculate value in use for the asset impaired: Estimating the value in use of an asset involves the following steps:
	(i) Estimating the future cash inflows and outflows to be derived from continuing use of the asset and its ultimate disposal; and
	(ii) Applying the appropriate discount rate to these future cash flows.
	After impairment, depreciation is provided on the revised carrying value over the remaining life of the asset.
	During the year we wrote off several intangible because the marketing authorization was not available any longer or the annual amortization was in excess of the profit generated by the product.
1.16. Provisions, Contingent liabilities and Contingent	Objective: The objective is to ensure that appropriate recognition criteria and measurement bases are applied to provisions and contingent liabilities and that sufficient information is disclosed in the notes to financial statements to enable users to understand their nature, timing and amount.
	The objective of this is also to lay down appropriate accounting for contingent assets.



Analisi S.p.A.

Note 1 : Summary of significant accounting policies (Refer General Instructions Note No.1)

- 1,1 We have confirmed the Aurobindo accounting policy except for what reported below
- 1,2 we have adopted amortization of goodwill as per local GAAP
- 1,3
- 1,4
- 1,5

Note 2 : Share capital (Refer General Instructions Note No.2)

	Mar 31, 2015	March 31, 2014
Authorised shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of XXXX each		
XXXXXXXX (31 March, 2014: XXXXXXXX) preference shares of XXX each		
Issued, Subscribed and Fully Paid-up shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of XXXX each fully paid-up	2.000.000	2.000.000

Note 3 : Reserves and surplus (Refer General Instructions Note No.3)

	Mar 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	17.973.000	-
	17.973.000	-
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet	-	-
	-	-
General Reserve		
As per last Balance Sheet	-	-
Add: Transferred from statement of profit and loss	-	-
	-	-
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	(11.415.671)	(8.025.873)
Profit for the quarter	(6.934.398)	(3.389.798)
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)		
Tax on proposed equity dividend		
Interim dividend paid (amount per share XX (31 March, 2014 XX)		
Transfer to general reserve		
Total appropriations	-	-
Net surplus in the statement of profit and loss	(18.350.069)	(11.415.671)
Total reserves and surplus	(377.069)	(11.415.671)

Note 4 : Long-term borrowings (Refer General Instructions Note No.4)

	Non-current Portion		Current maturities	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)	-	-	-	-
Other Loans from banks	-	-	-	-
Current account credit balance	-	-	-	-
Loans and advances from related parties	6.262.245	-	-	-
Other Loans and advances	-	-	-	-
Sales tax deferment loan (Un Secured)	-	-	-	-
	6.262.245	-	-	-
The above amount includes				
Secured borrowings	-	-	-	-
Unsecured borrowings	-	-	-	-
Amount disclosed under the head	-	-	-	-
"Other current liabilities"	-	-	-	-
Net Amount	-	-	-	-



Note 5 : Deferred tax liability (net)

	Mar 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis	-	-
Provision for diminution in the value of investments	-	-
Provision for doubtful debts and advances	-	-
Fixed Assets (Depreciation)	-	-
Retirement Benefits	-	-
Others	-	-
Gross deferred tax liability	-	-
Deferred tax asset	-	-
Carried Forward Business Losses	-	-
Others	1.919	-
Gross deferred tax asset	1.919	-
Net deferred tax liability	(1.919)	-

Note 6 : Other long-term liabilities (Refer General Instructions Note No.5)

	Mar 31, 2015	March 31, 2014
Trade payables (including acceptances)	-	5.274.509
Others	-	-
Advances from customers	127.713	127.713
Unclaimed dividends	-	-
Other liabilities	254.652	243.643
Interest accrued but not due on loans	-	-
Advances from related parties	-	-
	382.365	371.356
	382.365	5.645.865

Note 7 : Provisions (Refer General Instructions Note No.6 & 10)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Provision for employee benefits				
- Gratuity	-	-	-	16.251
- Leave encasement	-	-	-	-
	-	-	-	16.251
Other Provisions				
For Taxation (net of advance payments)	-	-	-	-
For Proposed dividend	-	-	-	-
For Tax on proposed dividend	-	-	-	-
	-	-	-	16.251

Provision for warranties

	Mar 31, 2015	March 31, 2014
At the beginning of the year	-	-
Arising during the period	-	-
Utilised during the period	-	-
Unused amounts reversed	-	-
At the end of the Quarter	-	-
Current portion	-	-
Non-current portion	-	-

Note 8 : Short-term borrowings (Refer General Instructions Note No.7)

	Mar 31, 2015	March 31, 2014
Bank overdraft	-	-
Loans and advances from related parties	-	645.241
Working capital loans (Secured)	-	-
Short term loans (Un Secured)	-	-
Working capital loans	-	-
	-	645.241
The above amount includes		
Secured borrowings	-	-
Unsecured borrowings	-	-

Note 9 : Other current liabilities (Refer General Instructions Note No.9)

	Mar 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)	8.016.450	-
Other liabilities	4.783.608	-
Current maturities of long-term borrowings	174.438	-
Trade deposits	300.149	-
	5.258.195	-
	13.274.644	-



Aurobindo Pharma Italia Srl

Notes to the Balance Sheet

(All amounts are in Eur except share data and unless otherwise stated)

Note 10 : Tangible assets (Refer General Instructions Note No.11)

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment	Computers	Computer Software	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation											
At 1 April 2013	-	-	-	-	-	-	-	33.613	-	-	33.613
Additions	-	-	-	-	-	-	-	1.524	-	-	1.524
Disposals	-	-	-	-	-	-	-	6.000	-	-	6.000
Other adjustments	-	-	-	-	-	-	-	-	-	-	-
- Exchange differences	-	-	-	-	-	-	-	-	-	-	-
- Borrowing costs	-	-	-	-	-	-	-	-	-	-	-
At 31 March 2014	-	-	-	-	-	-	-	29.137	-	-	29.137
Additions	-	-	137.686	-	-	43.075	16.564	15.970	-	-	213.295
Acquisitions through amalgamation	-	-	-	-	-	-	-	-	-	-	-
Disposals	-	-	-	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	-	-	-	-	-	-	-
- Exchange differences	-	-	-	-	-	-	-	-	-	-	-
- Borrowing costs	-	-	-	-	-	-	5.867	-	-	-	5.867
At 31 March 2015	-	-	137.686	-	-	43.075	22.431	45.107	-	-	248.300
Depreciation											
At 1 April 2013	-	-	-	-	-	-	-	14.574	-	-	14.574
Charge for the year	-	-	-	-	-	-	-	3.412	-	-	3.412
Disposals	-	-	-	-	-	-	-	1.771	-	-	1.771
Other adjustments	-	-	-	-	-	-	-	-	-	-	-
- Exchange differences	-	-	-	-	-	-	-	-	-	-	-
At 31 March 2014	-	-	-	-	-	-	-	16.215	-	-	16.215
Charge for the period	-	-	6.854	-	-	2.747	4.066	4.633	-	-	18.300
Disposals	-	-	-	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	-	-	-	-	-	-	-
- Exchange differences	-	-	-	-	-	-	3.864	(610)	-	-	3.254
At 31 March 2015	-	-	6.854	-	-	2.747	7.930	20.238	-	-	37.769
Impairment loss											
At 1 April 2013	-	-	-	-	-	-	-	-	-	-	-
At 31 March 2014	-	-	-	-	-	-	-	-	-	-	-
Charge for the period	-	-	-	-	-	-	-	-	-	-	-
At 31 March 2015	-	-	-	-	-	-	-	-	-	-	-
Net Block											
At 31 March 2014	-	-	-	-	-	-	-	12.922	-	-	12.922
At 31 March 2015	-	-	130.833	-	-	40.328	14.501	24.869	-	-	210.531



Aurobindo Pharma Italia Srl

Notes to the Balance Sheet

(All amounts are in Eur except share data and unless otherwise stated)

Note 11 : Intangible assets (Refer General Instructions Note No.12)

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At 1 April 2013	-	309.131	6.523.748	6.832.878
Purchase	-	-	-	-
Internal development	-	-	-	-
Disposals	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At 31 March 2014	-	309.131	6.523.748	6.832.878
Purchase	41.146	-	345.574	386.720
Acquisitions through amalgamation	-	320.937	146.781	467.719
Disposals	-	7.531	1.239.500	1.247.031
Other adjustments	-	-	-	-
- Exchange differences	-	-	(5.867)	(5.867)
At 31 March 2015	41.146	622.537	5.770.735	6.434.418
Amortization				
At 1 April 2013	-	-	-	-
Charge for the year	-	30.913	2.656.140	2.687.053
Disposals	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At 31 March 2014	-	30.913	2.656.140	2.687.053
Charge for the period	2.285	59.193	467.913	529.390
Disposals	-	(76)	669.522	669.447
Other adjustments	-	-	-	-
- Exchange differences	-	-	(4.013)	(4.013)
At 31 March 2015	2.285	90.181	2.450.519	2.542.984
Net Block				
At 31 March 2014	-	278.218	3.867.608	4.145.825
At 31 March 2015	38.862	532.356	3.320.217	3.891.434

370

Anafisi S.p.A.



Note 12 : Non-current investments (Refer General Instructions Note No.13)

	Mar 31, 2015	March 31, 2014
Unquoted equity instruments	-	-
Investment in subsidiaries	-	-
Investment in joint ventures	-	-
Investment in associates	-	-
	-	-

Note 13 : Loans and advances (Refer General Instructions Note No.14 & 21)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Capital advances				
Secured, considered good	-	-	-	-
Unsecured, considered good	-	-	-	-
(A)	-	-	-	-
Security deposit	-	-	-	-
Secured, considered good	-	-	-	-
Unsecured, considered good	-	-	-	-
Doubtful	-	-	-	-
Provision for doubtful security deposit	-	-	-	-
(B)	-	-	-	-
Loan and advances to related parties	-	-	-	-
Unsecured, considered good	-	-	-	-
(C)	-	-	-	-
Advances recoverable in cash or kind	-	-	-	-
Secured, considered good	-	-	-	-
Unsecured, considered good	-	-	-	-
Doubtful	-	-	-	-
Provision for doubtful advances	-	-	-	-
(D)	-	-	-	-
Other loans and advances				
Advance income-tax (net of provision for taxation)	-	-	-	-
Prepaid expenses	-	-	239.490	8.054
Loans to employees	14.500	-	-	500
Loans to others	-	-	-	60.140
Export incentives receivable	-	-	-	-
Export incentives licenses	-	-	-	-
Balances with Statutory/government authorities	-	-	97.559	154.532
(E)	14.500	-	337.049	223.226
Total (A+B+C+D+E)	14.500	-	337.049	223.226

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors	-	-	-	-
Dues from officers	-	-	-	-
Dues from non-executive and officers jointly with other persons	-	-	-	-
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner	-	-	-	-
Dues from in which the company's managing director is a member	-	-	-	-
Dues from the partnership firm in which the company's non-executive director is a partner	-	-	-	-



Note 14: Trade receivables and other assets

14.1 Trade receivable (Refer General Instructions Note No.15 & 19)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment	-	-	-	-
Secured, considered good	-	-	-	-
Due from group companies	-	-	-	-
Due from others	-	-	-	-
Unsecured, considered good	-	-	-	-
Due from group companies	-	-	-	-
Due from others	-	-	424.744	779.567
Doubtful	-	-	2.749.105	1.064.425
	-	-	3.173.848	1.843.992
Provision for doubtful receivables	-	-	2.749.105	1.064.425
(A)	-	-	424.744	779.567
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies	-	-	-	-
Due from others	-	-	-	-
Unsecured, considered good	-	-	-	-
Due from group companies	-	-	-	-
Due from others	-	-	9.641.245	-
Doubtful	-	-	370.747	-
	-	-	10.011.992	-
Provision for doubtful receivables	-	-	370.747	-
(B)	-	-	9.641.245	-
Total (A+B)	-	-	10.065.988	779.567

Trade receivables include:

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Due from non-executive directors	-	-	-	-
Due from officers	-	-	-	-
Due from non-executive directors and officers jointly with other persons	-	-	-	-
Dues from partnership firm in which the company's non-executive director is a partner	-	-	-	-
Dues from in which the company's non-executive director is a director	-	-	-	-

14.2 Other assets (Refer General Instructions Note No.16 & 22)

	Non-current		Current	
	Feb 28, 2015	March 31, 2014	Feb 28, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances	-	-	-	-
(A)	-	-	-	-
Unamortized expenditure				
Unamortized premium on forward contract	-	-	-	-
Ancillary cost of arranging the borrowings	-	-	-	-
(B)	-	-	-	-
Others				
Interest accrued on fixed deposits	-	-	-	-
Interest accrued on investments	-	-	-	-
Dividend receivable on investments in subsidiaries - long term	-	-	-	-
Others	-	-	41.527	-
(C)	-	-	41.527	-
Total (A+B+C)	-	-	41.527	-



Note 15 : Current investments (Refer General Instructions Note No.17)

	Mar 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)	-	-
Quoted equity instruments - Non-trade	-	-
Equity shares (fully paid-up)	-	-
If any (Please specify)	-	-

Note 16 : Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)

	Mar 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)	394	-
Work - in - Progress	187.609	-
Finished goods	4.866.338	1.070.592
Traded goods (including stock -in-transit XXXX (31 March, 2014 XXX)	-	-
Stores, spares, consumables and packing materials	139.055	-
Loose tools	-	-
	5.193.396	1.070.592

Note 17 : Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			870.929	25.555
Deposits with original maturity of less than 3 months			-	-
Cash credit accounts			(71.313)	-
On unpaid dividend account			-	-
Cheques/drafts on hand			-	-
Unpaid matured deposits			-	-
Cash on hand			168	120
			799.783	25.676
Other bank balances				
Deposits with original maturity for more than 12 months			-	-
Deposits with original maturity for more than 3 months but less than 12 months			-	-
Margin money deposit			-	-
			-	-
Amount disclosed under non-current assets			799.783	25.676



Analisi S.p.A.

Aurobindo Pharma Italia Srl
Notes to the statement of profit and loss
(All amounts are in Eur Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	12 Months Period ended Mar 31, 2015 (Eur)	Year ended March 31, 2014 (Eur)
Note 18 : Revenue from operations (Refer General Instructions Note No.25)														
Revenue from operations														
Sale of products														
Finished goods	33.421	4.742	154.444	14.877	-	-	172.000	-	-	(40.472)	-	-	339.011	-
Traded goods	288.660	2.384.181	2.040.705	2.122.028	441.813	1.774.711	1.398.733	1.728.438	1.470.389	1.561.447	1.548.687	1.804.512	18.564.303	253.054
Sale of services													-	-
Sale of dossiers/licenses													-	-
Other operating revenue													-	-
Scrap sales													-	-
Other													-	-
Revenue from operations (gross)	322.080	2.388.923	2.195.149	2.136.904	441.813	1.774.711	1.570.733	1.728.438	1.470.389	1.520.975	1.548.687	1.804.512	18.903.315	253.054
Less: VAT/ Excise duty/ Rebates													-	-
Revenue from operations (net)	322.080	2.388.923	2.195.149	2.136.904	441.813	1.774.711	1.570.733	1.728.438	1.470.389	1.520.975	1.548.687	1.804.512	18.903.315	253.054
Note 19 : Other income (Refer General Instructions Note No.26)														
Interest income on														
Bank deposits	-	-	-	-	-	-	-	-	-	1.860	-	6.515	8.375	-
Long-term investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loans to joint venture entities	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Others	-	-	1	416	2	-	54	-	-	-	-	-	473	-
Dividend income on														12
Investment in subsidiaries	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net gain on sale of current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Profit on sale of fixed assets (net)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Foreign exchange gain (net)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balances no longer required written back	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Government grant	-	-	-	-	-	-	-	-	-	-	-	-	-	20.203
Commission income	18.000	49	26.947	14.893	4.231	9.885	2.854	6.740	7.804	13.309	4.621	9.165	112.692	-
Processing charges	-	-	100	28.757	1.487	-	8.659	3.422	-	74.849	-	21.439	(138.713)	-
Other non-operating income (net of expenses directly attributable to such income of Rs.XXXXX (31 March, 2014:XXXX))	4.844	11.473	285.944	19.469	3.906	13.775	20.933	5.649	16.342	3.593	11.310	13.666	410.904	3.265
	-	-	-	-	-	-	-	-	-	-	-	0	0	206
	22.844	11.424	312.793	6.021	6.652	23.659	9.474	8.967	24.146	(56.086)	15.932	7.907	393.732	23.686
Note 20 : Cost of raw material and components consumed														
Inventory at the beginning of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add: Purchases	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: inventory at the end of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add: Packing material consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of raw material and components consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-

374

Anapoi S.p.A.



	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	12 Months Period ended Mar 31, 2015 (Eur)	Year ended March 31, 2014 (Eur)
Note 21 : (Increase)/decrease in inventories														
Inventories at the end of the period														
Traded goods	3,622,842	3,337,602	3,406,221	3,426,262	3,821,194	3,733,108	4,518,783	4,464,250	4,513,262	4,482,707	4,320,616	5,193,396	5,193,396	-
Work-in-progress	-	-	162,337	-	-	-	-	-	-	-	-	-	-	-
Finished goods	1,011,618	854,268	673,566	593,454	572,261	219,005	164,633	137,892	101,914	14,618	-	-	-	1,070,592
	4,634,460	4,191,870	4,242,124	4,019,716	4,393,455	3,952,113	4,683,416	4,602,142	4,615,176	4,497,325	4,320,616	5,193,396	5,193,396	1,070,592
Inventories at the beginning of the period														
Traded goods	-	3,622,842	3,337,602	3,406,221	3,426,262	3,821,194	3,733,108	4,518,783	4,464,250	4,513,262	4,482,707	4,320,616	-	-
Work-in-progress	-	-	-	162,337	-	-	-	-	-	-	-	-	-	-
Finished goods	1,070,592	1,011,618	854,268	673,566	593,454	572,261	219,005	164,633	137,892	101,914	14,618	-	1,070,592	1,516,063
	1,070,592	4,634,460	4,191,870	4,242,124	4,019,716	4,393,455	3,952,113	4,683,416	4,602,142	4,615,176	4,497,325	4,320,616	1,070,592	1,516,063
	(3,563,868)	442,590	(50,254)	222,407	(373,739)	441,342	(731,303)	81,273	(13,034)	117,851	176,710	(872,781)	(4,122,804)	(445,471)
Details of purchase of traded goods														
Product A	3,812,790	13,422	2,343,234	918,738	638,145	663,468	1,871,035	764,355	290,575	687,263	803,911	1,516,348	14,323,284	-
Product B	-	(260)	280	(228,059)	44,885	(368)	(34,134)	(10,159)	213,627	2,290	20,821	(1,33,538)	(124,636)	522,416
Product C	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	3,812,790	13,162	2,343,494	690,680	683,029	663,101	1,836,900	754,196	504,202	689,553	824,732	1,382,810	14,198,649	522,416
Note 22 : Employee benefit expense														
Salaries, wages and bonus	297,827	373,022	183,325	223,129	239,527	146,513	507,553	255,265	270,073	208,156	239,600	240,334	3,184,325	355,170
Contribution to provident and other fund	99,259	101,575	56,656	78,578	83,467	57,069	48,027	58,257	65,745	62,758	69,113	74,629	855,131	139,223
Employee stock option scheme	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gratuity expense	-	-	-	-	-	-	-	-	-	-	-	-	-	9,664
Other employee benefits	-	-	3,900	9,000	(78,372)	(94,140)	3,708	-	168	-	500	5,620	(149,615)	199,871
Post employment medical benefits	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Staff welfare expenses	316	1,448	9,901	2,308	3,601	11,291	2,392	2,256	1,658	7,306	2,171	-	44,647	5,816
	397,402	476,045	253,783	313,014	248,223	120,732	561,680	315,777	337,644	278,220	311,385	320,583	3,934,487	709,745



	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	12 Months Period ended Mar 31, 2015 (Eur)	Year ended March 31, 2014 (Eur)
Note 23 : Other expenses														
Consumption of stores and spares	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Chemicals consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in VAT on finished goods	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Customer service expenditure	100	198	-	123	-	-	-	-	-	-	-	-	421	7.741
Power and fuel	-	3.700	2.816	2.246	1.997	(7.059)	624	183	1.719	2.846	1.377	1.577	12.026	929
Water charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Freight and forwarding charges	4.779	8.347	6.727	8.113	4.923	2.680	-	-	-	-	-	-	35.569	157.330
Carriage inward	30.000	66.837	45.708	49.546	40.000	60.000	38.824	32.424	43.812	39.689	74.805	18.202	539.847	200
Carriage outwards	780	8.956	21.544	24.649	13.905	16.990	20.282	19.393	21.612	19.051	15.901	26.604	209.666	-
Rent	9.826	9.705	9.700	17.260	3.040	10.129	7.400	7.089	7.089	7.406	7.089	7.166	102.897	36.567
Rates and taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	516
Insurance	16.017	7.054	5.939	6.982	3.607	5.730	6.678	4.948	7.084	5.390	13.280	(6.985)	75.722	1.500
Repairs and maintenance	-	-	-	-	-	-	-	-	-	-	-	-	-	-
i) Plant and machinery	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ii) Buildings	-	593	-	232	-	-	144	3.258	1.873	175	(1.133)	1.435	6.577	-
iii) Others	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Advertising and sales promotion	54.667	400.738	487.750	7.200	133.214	279.234	377.649	474.913	374.801	118.090	175.158	939.260	3.822.674	78.747
Brokerage and discounts	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Remuneration to Auditors	1.489	6.169	1.489	1.489	13.914	1.963	9.928	8.822	156	(3.844)	8.156	3.645	53.374	93.116
Sales commission	-	12.201	9.532	8.533	(16.564)	70.546	46.919	30.053	44.982	7.084	77.590	77.756	368.633	20.735
Travelling and conveyance	36.432	37.612	29.386	19.934	16.804	53.130	29.952	37.333	22.411	33.771	19.186	40.462	376.414	51.741
Communication costs	791	14.073	4.501	3.627	8.133	(2.481)	(377)	2.667	9.440	4.484	4.319	(3.441)	45.735	28.016
Printing and stationery	15.244	8.594	8.912	10.257	3.002	11.064	12.997	4.655	15.046	813	11.083	14.554	116.222	5.170
Legal and professional fees	40.774	229.686	34.781	170.265	64.917	140.695	432.496	51.726	346.499	207.500	161.496	(277.768)	1.603.069	112.172
Directors sitting fees	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment to auditor (Refer details below)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for diminution in value of investment in subsidiary company	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for other than temporary decline in the carrying amount of other long-term investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adjustment to the carrying amount of current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for warranties (net of reversals)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for litigations (net of reversals)	-	-	-	-	-	140.000	(140.000)	-	-	-	-	-	-	-
Exchange differences (net)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on derivative contracts (including provisions mark-to-market loss)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bad debts/advances written off	-	-	-	-	-	56.332	-	-	3.050	-	-	-	59.382	652.231
Impairment loss on fixed assets	-	-	-	-	-	-	-	-	-	-	-	689.797	689.797	-
Provision for doubtful debts and advances	50.000	50.000	149.239	180.850	15.582	688.151	88.016	(44.419)	(39.925)	24.857	(66.990)	86.347	1.181.707	600.000
Loss on sale of fixed assets (net)	-	-	-	-	-	-	-	-	-	-	-	-	-	3.780
Premium on forward exchange contract amortized	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Factory maintenance	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effluent treatment expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Vehicle maintenance expenses	41.035	40.019	38.631	42.378	37.894	(22.330)	29.793	27.017	37.233	28.134	31.949	26.617	358.371	70.892
Analytical charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product development expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Registration and filing charges	33.896	105.036	33.878	291.996	103.386	85.313	70.232	31.141	66.334	66.508	107.926	112.242	1.107.890	94.506
Safety and security	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Office expenses	287	500	950	3.900	585	500	-	-	-	-	-	-	6.722	8.999
Repairs and maintenance - others	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Management fees	-	-	-	-	-	-	-	-	278.716	29.789	41.365	37.913	387.783	12.684
Liquidated damages	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Donations	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Software license and implementation expenses	2.689	4.039	5.344	1.989	2.689	3.789	1.289	3.389	11.055	9.179	(4.884)	9.773	50.342	1.625
Capital work-in-progress written off	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Miscellaneous expenses	150.859	1.042.100	(1.127.715)	(24.513)	17.364	32.278	(75.628)	126.694	42.104	100.979	(112.575)	97.016	268.960	2.336
	489.666	2.056.155	(230.891)	827.056	468.392	1.626.655	957.216	821.289	1.295.089	701.901	565.096	1.902.173	11.479.797	2.041.533



Aurobindo Pharma Italia Srl
Notes to the statement of profit and loss
(All amounts are in Eur Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sept-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	12 Months Period ended Mar 31, 2015 (Eur)	Year ended March 31, 2014 (Eur)
Payment to Auditor														
As auditor:														
Audit fee	1.489	1.489	1.489	1.489	1.489	1.489	1.489	8.048	(618)	(4.618)	7.382	2.097	22.713	-
Tax audit fee	-	-	-	-	-	-	-	-	-	-	-	-	-	17.868
Limited review	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In other capacity:														
Taxation matters	-	-	-	-	4.000	-	-	-	-	-	-	-	4.000	-
Company law matters	-	4.680	-	-	8.425	474	8.439	-	-	-	-	-	22.017	-
Management services	-	-	-	-	-	-	-	-	-	-	-	-	-	75.248
Other services (certification fees)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reimbursement of expenses	-	-	-	-	-	-	-	774	774	774	774	1.548	4.644	-
	1.489	6.169	1.489	1.489	13.914	1.963	9.928	8.822	156	(3.844)	8.156	3.645	53.374	93.116
Note 24 : Exceptional items														
Others (Specify if any)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 25 : Depreciation and amortization expense														
Depreciation of tangible assets	1.165	1.192	1.181	1.207	1.207	1.179	1.212	1.190	1.218	882	1.251	5.415	18.300	4.579
Amortization of intangible assets	43.521	43.967	58.500	49.633	49.498	49.312	49.706	49.432	49.622	50.025	48.848	(12.596)	529.390	818.754
Depreciation of investment property	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	44.686	45.060	59.680	50.841	50.705	50.492	50.918	50.622	50.840	50.907	50.119	(7.181)	547.689	823.333
Note 26 : Finance costs (Refer General Instructions Note No.27)														
Interest	-	(261)	55.505	(1.829)	3.487	55.395	5.793	16.213	16.390	8.451	7.633	15.281	182.059	-
Bank charges	528	1.084	1.731	1.494	320	1.596	1.410	883	1.393	858	1.510	1.164	13.971	11.855
Amortization of ancillary borrowing costs	-	-	-	-	-	-	-	-	-	-	-	-	-	3.127
Exchange difference to the extent considered as an adjustment to borrowing cos	-	-	-	-	-	-	-	3.135	6.712	(9.875)	(73)	(2.303)	(2.403)	-
	528	823	57.236	(335)	3.808	56.991	7.204	20.231	24.495	(566)	9.069	14.142	193.626	14.982






AUDIT REPORT 2014-15

Management report

According to articles 65 and 66 of the commercial company code (código das sociedades comerciais), we present with the respective references regarding the financial year 2014, the management report of Aurovitas Unipessoal, Lda., Headquarteres at Av. Do Forte nº 3, Parque Suécia, Edifício IV piso 2, Carnaxide, Concelho de Oeiras, VAT No. 513 053 239, registered at the Commercial Registry of Cascais under the single number 513 053 239, with a share capital fully paid amounting to € 5,000.

Index

1. Message from the management body.....	Error! Bookmark not defined.
2. Main Events	Error! Bookmark not defined.
3. Market analysis.....	Error! Bookmark not defined.
4. Prospects for 2015-2016.....	Error! Bookmark not defined.
5. Economic and financial function.....	Error! Bookmark not defined.
6. Human Resources	Error! Bookmark not defined.
7. Relevant factors occurring after the financial term year	Error! Bookmark not defined.
8. Proposal for appropriation.....	Error! Bookmark not defined.
9. State public sector.....	Error! Bookmark not defined.
10. Acknowledgments.....	Error! Bookmark not defined.



1. Management from the management body

Aurovitas Unipessoal Lda in Portugal's main activities with the respective reference to the business year of 2014-15, was focused on its two main market channels - Retail (85%) and hospital (15%) - and was based on four areas of business: Generic Drugs Manufacturers, Hospital and OTC products.

The Aurovitas business was driven by sales of generic drugs, having benefited from a positive market development in this segment. According Sell-Out market data, sales of generic drugs accounted for about 60% of total company revenue, reaching a significant growth above market growth figures for this segment both in value and in units.

Overcoming the adverse economic conditions in Portugal, Aurovitas made an ambitious and aggressive management of their assets and resources in order to expand the business and consolidate results and at the same time carried out the transition from the old organization for integration into Aurobindo Group and reached the main financial objectives, namely the achievement of the Budget and an exceptionally higher than originally expected EBIT.

Based on an approach focused on the customer, the business model of Aurovitas is centered on pharmacy and hospital business, targeting the oncology centers. With this approach it is possible to promote and sell a balanced portfolio, backed by an adjusted organization and served by a team of competent employees, enthusiastic and very professional at all levels of the organization.

2. Main Events:


March 2014 – Constitution of a company which main social objective lies on the Trade, sale and distribution of medicines and Marketing Services

Abril 2014 – Initial activity

June 2014 – Obtaining the Permit for Human Medicinal Products Trading

July 2014 – The First issue invoiced by Aurovitas

September 2014 – Obtaining the License for Medical Device Commercialization



3. Market analysis:

• In Medicines Market Value

Regarding the pharmaceutical market, in 2014 the value showed a slight decrease over the previous year, away from the strong negative growth recorded in recent years (PYG -0.5% in 2014, -4% in 2013 and -11.2% in 2012). This decrease was primarily the result of the trend observed in Brand MSRM (PYG -2.5%), as both the market for generic drugs (MG's) or the MNSRM (OTC's) recorded growth in value (of PYG + 5.7% and + 0.9% respectively).

• Units

The consumption of drugs in units decreased slightly in 2014 (-0.9%), a result of the trend in MSRM (PYG -2.5%) and OTC's (PYG -4.1%), to have the MG's was an increase of packaging sold at + 4.1% over the previous year. Of about 264 million drug packages sold in 2014, 79 million were MG's (29.9%) and close to 42 million were OTC's (15.9%).

• In PVP East for Packaging

In 2014 the average PVP for packaging of medicines showed a slight increase, bucking the negative trend consecutively over the past few years. The average price of a drug was € 9.89 in 2014, + 0.3% on the previous year (PYG to -4.2% in 2013 and -11.9% in 2012). In MG's, the average PVP per pack stood at € 6.74, an increase of 1.6% over the previous year (PYG to -6.9% in 2013 and -32.2% in 2012). In OTC's average price increase was 5.2% (PYG to 6.3% in 2013 and + 4% in 2012), passing the cost on average (weighted by units) € 7.


• The market for generic drugs

The market for generic drugs (MG's) in 2014 again showed volume growth of 4.1% (+ about 3 million packages) and in value by 5.7% (+28.7 million € than in 2013).

The trend value was the result of the market performance units, together with the variation of the average PVP per package. On average, a pack of MG in 2014 cost € 6.74, 1.6% more than in 2013.

The pace of market growth of MG's resulted in market share gains for medicinal products, reaching in 2014 about 29.9% by volume (1.4 pp more than in 2013), 38% share in counting units and 20.4% share in value (1.2 pp more than in the previous year).

Source: Dados HMR



4. Prospects for 2015-2016:

The strategic objectives for the financial year 2015-2016 based on the following pillars:

- Sales volume growth over the previous year
- Consolidation of position in the Ranking of Generic Market
- Rebranding Brand Aurovitas.

5. Economic and Financial function:

2014-15 was the first year of Aurovitas Unipessoal, Lda., So that the analysis of financial performance is made exclusively with year indicators without being able to call on comparative.

In terms of cash the company has the determination to maintain a balanced management.

After the start of activity that was required additional operational effort, since the funds were channeled to pay the Asset Deal with Actavis. The Aurovitas throughout the year succeeded in reducing short-term debt in order to reach the balance.

The Aurovitas does not register at the closing date of bank debt accounts.

• Principal indicators:


	2014-15
Sales and Services	15.785.863
EBITDA	1.192.837
Margin of EBITDA	7,6%
EBIT	1.132.541
Margin of EBIT	7,17%
Taxes	(470.483)
Exercise net profit	662.057

6. Human Resources:

The company's Human Resources Policy is based mainly on the development of its employees, providing them with an effective involvement in the operational and decision-making activities.

The average number of employees working for the company for the year ended March 31, 2015 can be detailed as follows:

	2014-15
Management, administrative and financial department	5
Department of R&D and Logistic's	6
Department of Marketing and sales	24




7. Relevant factors occurring after the financial term:

After the end of the year there were no material events affecting the financial position and the financial stability of the Company, and consequently should be subject to reference.

8. Proposals for appropriation:

The Management of Aurovitas Unipessoal, Lda., Under and for the purposes of paragraph b) of paragraph 1 of article 376 of the Companies Code and in accordance with the Management Report, proposed that the net result the Society for the year 2014-15 in the amount of 662,057.49 Euros, is allocated as follows:

- 2,500 Euros - Legal Reserves;
- 659,557.49 euros - Retained Earnings from Previous Years.



9. State Public Sector:

According to the Decree Law No. 411/91, it should be noted that there are situations of delay in relation to the state public sector entities and there are no other situations involving obligatory reference in this report.


10. Acknowledgements

After a year of dedication, we must thank our employees and partners along the way of dedicated exercise all made in the company's defense for the results to be achieved.


Financial institutions also appreciate the support and trust, in the day to day operations.

To managers and auditors and consultants we want to thank the availability waived, being recognized and important contribution to the achievement of results.

Lisbon, April 27, 2015



Mr. Manoj Prakash



Aurovitas Unipessoal, Lda.

Attachment of the financial demonstrations on the 31st of March 2015

(Amount expressed in euros)

1 INTRODUCTION NOTES

Aurovitas Unipessoal, Lda. started its business in April the 1st of 2014, following the international operation Asset purchase by Actavis A / S Branch.

In Portugal, the transaction coated figure of Asset Deal.

The Aurovitas is a subsidiary of the international group, Aurobindo and has its registered office at Avenida do Forte nº3, Parque Suécia, Edifício IV Piso 2, Carnaxide.

The Company has as its object the marketing, including import, export and commercial representation of chemical and pharmaceutical products, medicinal products and products for preventing and treating diseases.

The Board of Directors believes that these financial statements reflect a true and fair view of the financial position of the Company, the results of its operations, changes in equity and its cash flows.

2 ACCOUNTING REFERENCES IN RELATION TO THE PREPARATION OF THE FINANCIAL DEMONSTRATIONS

2.1 Base de Preparação

The financial statements were prepared in accordance with the provisions of the CNS and the Accounting Standards and Financial Reporting (IFRS) issued and the date of March 31, 2015.

The preparation of financial statements in accordance with SNC requires the use of estimates, assumptions and critical judgments in the process of determining the accounting policies to be adopted by the Company, with significant impact on the carrying values of assets and liabilities and the income and expenses of reporting period.



Although these estimates are based on the best experience of the Board and their best expectations in relation to the events and current and future operations, current and future results may differ from these estimates. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are presented in Note 3.8.

2.2 Notwithstanding dispositions of the SNC

There were, during the year to which they relate these financial statements, any exceptional cases which directly Notwithstanding any provision in the SNC.

2.3 Comparability of the financial demonstrations

The information contained in these financial statements has not comparable period, since it is the first year of the company's business.

3 THE PRINCIPAL POLITICS FR THE ACCOUNTING

The principal accounting policies adopted in preparing the accompanying financial statements are as follows:

3.1 Bases for the presentation:

The accompanying financial statements have been prepared on a going concern basis, from the accounting records of the Company, in accordance with the Accounting Standards and Financial Reporting.

3.2 Tangible assets:

Tangible fixed assets are recorded at cost, which includes the purchase cost, any costs directly attributable to the necessary activities to put the asset in the location and condition necessary to operate in the manner intended less accumulated depreciation and impairment losses accumulated.

Depreciation is calculated after the time the goods are in a position to be used, according to the straight-line basis in accordance with the useful life for each class of assets.



✓ The depreciation rates used correspond to the following estimated useful lives:

Class of goods	Years
Buildings and other constructions	10 a 50
Basic equipment	3 a 10
Administrative equipment	4 a 8

The useful lives and methods of amortization of several properties are reviewed annually. The effect of any changes to these estimates is recognized prospectively in the income statement.

Maintenance and repair expenses that are unlikely to generate additional future economic benefits are recorded as expenses in the period they are incurred.


The gain (or loss) resulting from the sale or disposal of a tangible asset is determined as the difference between the fair value of the amount received in the transaction or receivable and the net amount of accumulated depreciation of the asset and is recognized in earnings the period in which the slaughter or sale.

3.3 Locations:

Leases are classified as financial whenever their terms substantially transfer all the risks and rewards of ownership to the lessee. The remaining leases are classified as operating leases. The classification of leases depends on the substance and not form of the contract.

Payments for operating leases are recognized as expense on a straight-line basis over the lease period. Assets under operating leases relate to the light vehicles allocated for the Company.

Contingent rents are recognized as expenses in the period they are incurred.



3.4 Impairment of tangible fixed assets

At each reporting date the Company reviews the carrying amounts of tangible fixed assets of the Company to determine whether there is any indication that they may be impaired. If there is any indicator, the recoverable amount of its assets (or cash generating unit) is estimated in order to determine the extent of the impairment loss (if any).

The recoverable amount of the asset (or cash-generating unit) is the greater of (i) the fair value less costs to sell and (ii) the value in use. In determining the value in use, the estimated future cash flows are discounted using a discount rate that reflects the market expectations for the time value of money and the risks specific to the asset (or cash-generating unit) for which estimates of future cash flows have not been adjusted.

Whenever the carrying amount of the asset (or cash-generating unit) exceeds its recoverable amount, an impairment loss is recognized. The impairment loss is recorded immediately in the income statement under "Impairment losses" unless such loss offset a revaluation surplus recorded in equity. In the latter case, such a loss is treated as a revaluation decrease of that.

3.5 Inventories

Inventories are stated at the lower of cost and net realizable value. The cost includes the purchase price. Net realizable value represents the estimated selling price less all estimated costs necessary to complete the inventory and to process your sale. In situations where the cost value is higher than the net realizable value adjustment (impairment loss) is recorded by their difference. Variations of the year in impairment losses of inventories are recognized in the income under "Impairment losses on inventories" and "Reversal of adjustments in inventories".

The inventory costing method adopted by the Company is the acquisition cost, which does not differ significantly from the average cost, due to inventory acquired are at fixed rates and are reviewed on an annual basis. Additionally, the Company has inventories organized by lot, always looking for there is an inventory output it corresponds to the lot whose expiration date expires earlier.

The value per lot is recorded at average cost price (Weighted Average Method of Valuation).



3.6 Financial assets and liabilities

Assets and liabilities are recognized in the balance sheet when the Company becomes party to the relevant contractual provisions, being used for this purpose the provisions of IAS 27 - Financial instruments.

Assets and liabilities are thus measured according to its cost.

a) Trade and other receivables

The balances of customers and other receivables are carried at amortized cost less any impairment losses. Usually, the amortized cost of these financial assets does not differ from its nominal value.

b) Cash and cash equivalents

The amounts included under "Cash and cash equivalents" correspond to cash, bank deposits and term deposits and other treasury applications which mature in less than three months and for which the risk of change in value is negligible.

These assets are measured at amortized cost. Usually, the amortized cost of these financial assets does not differ from its nominal value.

c) Trade and other payables

The balances of suppliers and other payables are carried at amortized cost. Usually, the amortized cost of these financial liabilities does not differ from face value

d) Loans obtained



The financing obtained are recorded as liabilities at amortized cost.

(i) Impairment of financial assets

Financial assets included in the category "at cost or amortized cost" are subject to impairment testing at each reporting date. Such financial assets are impaired when there is objective evidence that as a result of one or more events that occurred after the initial recognition, their estimated future cash flows are affected.

For financial assets measured at amortized cost, the impairment loss to be recognized corresponds to the difference between the asset's carrying amount and the present value at the reporting date of the new estimated future cash flows discounted at the original effective interest rate.


For financial assets measured at cost, the impairment loss to be recognized corresponds to the difference between the asset's carrying amount and the best estimate of the fair value of the asset at the reporting date.

Impairment losses are recognized in profit and loss caption "Impairment losses" in the period they are determined.

Subsequently, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, it must be reversed by results. The reversal must be made up to the amount recognized (amortized cost) if the loss had not been initially registered. The reversal of impairment losses is recorded in the income statement under "Reversals of impairment losses". It is not allowed to reversal of impairment losses recorded on investments in equity instruments (measured at cost).

(ii) De-recognition of financial assets and liabilities

Derecognition of financial assets and liabilities



The Company derecognises financial assets only when the contractual rights to cash flows expire for collection, or when it transfers to another entity controlling those financial assets and all the significant risks and rewards of ownership of the property.

The Company derecognises financial liabilities only when the corresponding obligation is settled, canceled or expires.


According to the described, assets and liabilities were classified as follows:

Financial actives		
	Notes	2014-15
Active corrents		
Clients	11	3.015.446
Advance to suppliers	11	53
Other accounts to receive	11	7.808
Other accounts to receive- group	11 e 19	41.623
Cash and bank deposits	5	336.123
		<u>3.401.052</u>
Financial liabilities		
	Notas	2014-15
Corrent liabilities		
Suppliers	15	909.461
Suppliers - group	15 e 19	2.424.733
Other accounts to pay	15	1.445.237
Financing obtained - group	16	-
		<u>4.779.432</u>

3.7 Revenue

Revenue is measured at the fair value of the consideration received or receivable. The recognized revenue is deducted from the amount of returns, discounts and other rebates and does not include VAT and other taxes paid related to the sale.

Revenue from the sale of goods is recognized when all the following conditions are met:



- All the risks and rewards associated with ownership of the assets have been transferred to the buyer;
- The Company does not maintain any control over the goods sold;
- The amount of revenue can be measured reliably;
- It is probable that future economic benefits associated with the transaction will flow to the Company;
- The costs incurred or to be incurred with the transaction can be measured reliably.

3.8 Critical value judgments and key sources of uncertainty associated with estimates

In preparing the accompanying financial statements have been made judgments and estimates and use various assumptions that affect the reported amounts of assets and liabilities and the reported amounts of income and expenses for the period.

Estimates and underlying assumptions are determined by reference to the reporting date based on the best information available at the date of approval of the financial statements of events and transactions in progress, as well as the past and / or current events experience. However, situations may occur in subsequent periods that are not foreseeable at the time of approval of the financial statements, were not considered in these estimates.

Changes to the estimates that occur after the date of the financial statements will be corrected prospectively. For this reason and given the degree of associated uncertainty, actual results of the transactions in question may differ from corresponding estimates, it is not expected that any differences may significantly affect the financial statements.

The main judgments and estimates made in preparing the accompanying financial statements are as follows:

- a) Useful lives of tangible fixed assets;
- b) Impairment analysis of tangible fixed assets;
- c) Recognition of adjustments on assets and provisions;
- d) Impairment of deferred tax assets;
- e) Estimate for product returns - expiration date.

The main assumptions used in the estimates made by the Company are disclosed in the notes of the corresponding notes.



3.9 Income tax

The tax income for the year recorded in the income statement is the sum of current taxes and deferred taxes.

Current tax payable is calculated based on taxable income of the company. Taxable income differs from accounting income as it excludes many expenses and income that will only be taxable or deductible in other years as well as expenses and income that are never taxable or deductible.

Deferred taxes refer to temporary differences between the amounts of assets and liabilities for accounting reporting and the respective amounts for tax purposes. Assets and deferred tax liabilities are measured using tax rates expected to be in force at the date of reversal of temporary differences based on tax rates (and tax laws) that have formally issued at the reporting date.

The deferred tax liabilities are recognized for all taxable temporary differences and deferred tax assets are recognized for deductible temporary differences for which there is reasonable expectation of sufficient future taxable income to utilize these deferred tax assets, or taxable temporary differences. They are reversed in the same period of reversal of deductible temporary differences. At each reporting date the Company reviews the deferred tax assets, and they are adjusted for expectations as to its future use.


In the fiscal year regarding 2014-15 deferred tax liabilities were not recognized, because there are no situations to justify its accounting.

3.10 Transaction and balances for foreign currency

Foreign currency transactions are essentially carried out with the group and are recorded at the exchange rates at the dates of the transactions. At each reporting date, the carrying amounts of monetary items denominated in foreign currencies are updated to that date exchange rates.

Exchange differences arising on the date of receipt or payment of foreign currency transactions and those resulting from the above-mentioned updates are recorded in the income statement for the period to which they relate.

As at March 31, 2015 the Company has no amounts recorded in foreign currency item.



3.11 Provisions

Provisions are recognized when the Company has a present obligation (legal or constructive) resulting from a past event, it is likely to settle the obligation occurs a resource output and the amount can be reasonably estimated.

The amount of recorded provisions is the best estimate at the reporting date, the resources required to settle the obligation. This estimate, revised at each reporting date is determined taking into account the risks and uncertainties associated with each obligation.

Taking into account the status of the product defined in Decree Law 176/2006, the company recorded a provision to deal with product returns. According to the number 3 of the same article, the license holders are financially responsible for the collected drugs (regardless of the reason for the collection, including term expired) and must credit the packaging returned by distributors, pharmacies and hospitals.


Contingent liabilities are not recognized in the financial statements but disclosed when the possibility of a cash outflow embodying economic benefits is remote. Contingent assets are not recognized in the financial statements but disclosed when it is probable that there is a future economic inflow of resources.

3.12 Borrowing costs and loans

Financial charges related to loans obtained are recognized as expenses as they are incurred.

3.13 Increase in the regime

The Company records its income and expenses in accordance with the principle of increase, by which income and expenses are recognized as they are generated, regardless of the time of their receipt or payment. Differences between the amounts received and paid and the corresponding generated revenues and expenses are recorded as assets or liabilities.



3.14 Subsequent events

Events after the balance sheet date that provide additional information about conditions that existed at the balance sheet date are reflected in the financial statements.

Events after the balance sheet date that provide information on conditions occurring after the balance sheet date are disclosed in the financial statements, if materials are considered.

4 NUMBER OF COLABORADORES IN SERVICES FOR THE COMPANY

The average number of employees working for the company for the year ended March 31, 2015 can be detailed as follows:

	2014-15
Management and Administrative and Financial Department	5
Department of R&D and Logistics	6
Department of Marketing and Sales	24
	35


5 CASH FLOW

In the consolidated statement of cash flows, cash and cash equivalents includes cash and immediately available bank deposits (of a maturity not exceeding three months). The caption Cash and cash equivalents at March 31, 2015 is detailed as follows:

	2014-15
Cash	1.074
Bank deposits mobilized immediately	335.049
	336.123

6 ACTIVOS FIXOS

6.1 Fixed tangible assets



During the year ended March 31, 2015, the changes in the carrying amount of tangible fixed assets, and in the related accumulated depreciation and amortization were as follows:

	2014-15				Total
	Buildings And other Constructions	Basic equipment	Administrative Equipment	Other actives Tangible assets	
Active					
Opening balance	-	-	-	-	-
Acquisitions - Asset Deal	81.779	83.720	49.461	-	214.960
Acquisitions	-	-	62.933	-	62.933
Abates / alienações	-	(1.599)	-	-	(1.599)
Saldo final	81.779	82.121	112.393	-	276.293
Amortizações acumuladas e perdas por Imparidade					
Saldo Inicial	-	-	-	-	-
Asset Deal	69.046	83.720	42.056	-	194.822
Amortizations	7.200	-	13.394	-	20.594
Disposals	-	(1.599)	-	-	(1.599)
Final balance	76.246	82.121	55.450	-	213.817
Liquid assets	5.533	-	56.944	-	62.477

6.2 Other financial assets

During 2014-15 were recorded in this account of the monthly payments values supported by the company for employees who are covered by labor compensation fund regime. The discounted value for the labor compensation fund corresponds to 0.925%, based on the pay and seniority bonuses payable to the employee and 0.075% for the clearing guarantee fund for employees covered by the compensation fund or similar mechanism.


7 LEASES

On March 31, 2015 the Company is the lessee in operating lease contracts related to the vehicle fleet, which are denominated in euros.

The minimum payments for operating leases at March 31, 2015 are detailed as follows:

Tenant	Minimum payments
	Non-cancelable
	2014-15
Until 1 year	39.868
between 1 - 5 years	47.254
	87.123

The related expense to operating leases recorded under "Supplies and services" recognized in the year ended March 31, 2015 is detailed as follows:



Tenants	Expenses during the period
	2014-15
Minimum payments	
Cars	260.432
Other rents	4.907
	<u>265.339</u>

8 DEFERRED TAXES

The movement in the balance assets deferred tax during the year ended March 31, 2015 was as follows:

	Actives for deferred taxes 2014-15
Opening balances	-
Impact of results:	
Constitution of the actives for deferred taxes	<u>289.725</u>
Total effect on results (Note 9)	<u>289.725</u>
	<u>289.725</u>

9 INCOME TAX


According to current legislation, tax returns are subject to review and correction by the tax authorities for a period of four years (five years for Social Security), except when there are tax losses, tax benefits have been granted, or when inspections, complaints or disputes, in which case, depending on the circumstances, the deadlines are extended or suspended.

Spending on income tax on March 31, 2015 is detailed as follows:

	2014-15
Current tax	(760.208)
Deferred tax (Note 8)	<u>289.725</u>
	<u>(470.483)</u>

The tax rate used for the valuation of taxable temporary differences at the balance sheet date for the year ended March 31, 2015 was 23%.

A reconciliation of the tax amount for the year is as follows:



	<u>2014-15</u>
Results after the tax	1.132.541
Rate of taxes	23,00%
Pour	1,50%
	<u>277.473</u>
Nondeductible expenses	1.446.201
Non-taxable income	(2.818)
Deduction tax losses	-
Autonomous taxation	96.829
Tax income current	760.208
Tax income deferred	<u>(289.725)</u>
No income tax	<u>470.483</u>
Effective tax rate	42%

The tax rate used in determining the tax amount in the financial statements is as follows:

	<u>2014-15</u>
Tax rate	23%
Pour	1,5%
Pour state	3,0%

10 INVENTORIES

On March 31, 2015, the Company's inventories are detailed as follows:

	<u>2014-15</u>		
	Gross amount	Impairment losses	Net amount
Merchandise	4.335.099	(1.136.986)	3.198.113
Merchandise and transit	141.870	-	141.870
	<u>4.476.968</u>	<u>(1.136.986)</u>	<u>3.339.983</u>

Cost of goods sold and materials consumed

The cost of goods sold and materials consumed recognized in the year ended March 31, 2015 is detailed as follows:



	2014-15
Opening balance	3.533.857,91
Shopping	8.433.113
Regularizations	263.737
Final balance	(4.476.968)
	<u>7.753.739</u>

Impairment losses

The evolution of impairment losses accumulated inventories for the year ended March 31, 2015 is detailed as follows:

	2014-15				
	Initial balance	Increases	Uses	Reductions	Final Balance
Merchandise	872.623	280.388	-	(16.025)	1.136.986
	<u>872.623</u>	<u>280.388</u>	<u>-</u>	<u>(16.025)</u>	<u>1.136.986</u>


Impairment losses in the inventories result from the analysis of products whose expiration date is nearing its end. Additionally impairment losses were also recorded to adjust the value of the assets to their net realizable value:

11 CLIENTS AND OTHER ACCOUNTS TO RECEIVE

On the 31st of March 2015, the accounts to receive from the company presented the following composition:

	2014-15		
	Montante bruto	Imparidade acumulada	Montante líquido
Correntes:			
Clients	3.015.446	-	3.015.446
Other accounts to receive	7.808	-	7.808
Other accounts to receive - group (Note 19)	41.623	-	41.623
	<u>3.064.877</u>	<u>-</u>	<u>3.064.877</u>

The Company's exposure to credit risk is attributed to accounts receivable arising from its operational activity, understanding the direction of the Company that there is no



significant concentration of credit risk as the risk is spread over a wide range of customers.

The aging of accounts receivable is detailed as follows:

	2014-15
Unexpired	1.547.426
< 90 days	812.181
> 90 < 120 days	56.710
120 < 365 days	369.517
> 365 days	279.044
	<u>3.064.877</u>

12 DEFERRED ASSETS

On March 31, 2015 the items of current assets "Deferrals" are as follows:

	2014-15
Expenditures to recognize	
Rents	7.340
Insurance premiums	30.485
Assistance contracts	90
Marketing expenses	44.000
Other expenses to recognize	32.474
	<u>114.389</u>
	<u>114.389</u>

The amount of 7,340 Euros recorded under "Income" is the income of the Company's facilities for the month of April 2015.


Insurance premiums and deferred service contracts relate to insurance and assistance contracts whose validity period includes the year 2015.

13 EQUITY INSTRUMENTS

Capital

The capital of the company is 100% owned by the company Agile Pharma BV

The company Agile Pharma BV is a subsidiary company of Aurobindo International Group and has its registered office in Amsterdam, the Netherlands.



14 PROVISIONS, CONTINGENT ASSETS AND LIABILITIES

The evolution of provisions in the year ended March 31, 2015 is detailed as follows:

	2014-15			
	Opening balance	Increases	Utilization	Final balance
Legal proceeding	-	-	-	-
Product return	877.271	263.004	(366.476)	773.798
	877.271	263.004	(366.476)	773.798

The provision for product returns was set up to deal with any Returns inventories for a period of validity expired or to expire within six months. This provision was calculated based on historical information occurred returns.

15. SUPPLIERS AND OTHER ACCOUNTS TO PAY

On March 31, 2015 accounts payable of the Company are as follows:

	2014-15
Corrent:	
Advances to suppliers	(53)
Suppliers corrent account	909.461
Suppliers - group (Note 19)	2.424.733
Other accounts to pay	1.445.237
	4.779.379

On March 31, 2015 accounts payable of the Company resulting from purchases in the normal course of the Company's activity. On March 31, 2015, the Company believes that the carrying value of these debt corresponds to their fair value.

The value of other payables at March 31, 2015 includes the following items:



	2014-15
Several creditores	95
Consultantes	14.643
Actavis Transacctions	76.587
Staff - visa cards	748
	<u>92.073</u>
Creditores by accrued expenses:	
Vacation and vacation allowances	290.192
Awards and incentives	229.158
Discounts to give	585.278
Marketing	55.401
Supplies and services	79.241
Other increases	113.896
	<u>1.353.165</u>
	<u>1.445.237</u>

16.FINANCING OBTAINED BY THE GROUP

During 2014-15 the company obtained the Agile Pharma BV funding of 3,423,581 Euros for operational management, which was also paid in fiscal year 2014-15.

As at 31.03.2015 the company has no amounts due before the Agile Pharma BV

17 STATE AND OTHER PUBLIC ENTITIES

On March 31, 2015 the caption "State and other public entities" are as follows:

	2014-15	
	Active	Liabilities
IRC tax to pay	-	760.027
Withholding tax	-	33.363
Value added tax	3.271	68.350
Social security	-	37.336
Infarmed – Monthly taxes- medications	-	8.358
	<u>3.271</u>	<u>907.433</u>

18 DEFERRED LIABILITIES

On March 31, 2015 the items of current liabilities "Deferrals" are as follows:

	2014-15
Income to recognize :	
Sales deferral	83.369
	83.369
	83.369

19 PARTS RELATED

Balances and transactions with related parties during the year ended March 31, 2015, in addition to the overdraft of the group, mentioned in Note 16, are detailed as follows:

	Balances	
	Other accounts to receive (Note 11)	Suppliers (Note 15)
	2014-15	2014-15
APL Swift Services (Malta) Ltd	41.043	2.211.219
Aurobindo Pharma Ltd	579	-
Milpharma Limited	-	213.514
	41.623	2.424.733


The amounts recorded under suppliers, respect to acquisitions of stocks within the normal Company's operations.

The amount payable to APL Swift Services (Malta) Ltd corresponds essentially to purchases of the months of November to March 2015, including goods in transit (Note 10) and incidental expenses related to the purchase of stocks, including transport and temperature controllers.

The amount described in the Milpharma Limited item corresponds to amounts of shared management services.

The amount receivable from 41,043 Euros APL Swift Services (Malta) Ltd corresponds to the re-invoicing of regulatory costs for licensing of products that have been supported at national level and should be supported internationally by the group.

The amount receivable of 579 Euros of Aurobindo Pharma Ltd corresponds to the re-invoicing of costs associated with the acquisition of drug samples requested by the group, for regulatory testing.



	Transactions		
	Services obtained	Interest	Purchases
	2014-15	2014-15	2014-15
APL Swift Services (Malta) Ltd	344.540	-	4.685.739
Aurobindo Pharma Ltd India	(579)	-	-
Milpharma Limited	217.327	-	-
Aurobindo Pharma Portugal	(244)	-	-
Agile Pharma B.V.	-	40.427	-
	<u>561.043</u>	<u>40.427</u>	<u>4.685.739</u>

Transactions with the group boil down essentially to inventory purchases (purchases), interest arising from financing obtained (interest expense) and shared management services (services obtained).

20 REVENUE

The revenue recognized by the Company on March 31, 2015 is detailed as follows:

	2014-15
Sales and Merchandise	21.533.586
Devolutions of sales	(61.238)
Discounts and rebates on sales	(5.686.485)
	<u>15.785.863</u>

The total sales for the year ended March 31, 2015 were made in the domestic market.

21 SUPPLIES AND EXTERNAL SERVICES

The caption "External supplies and services" for the year ended March 31, 2015 is detailed as follows:



	2014-15
Specialized Services	1.906.785
Rents and loans	353.458
Expenses with representation	273.738
Publicity and propaganda	105.384
Travels and stays	105.555
Communications	70.304
Fees	24.863
Fuel	87.714
Conservation and repairs	61.210
Awards to offer	13.349
Insurances	8.558
Office materials	16.570
Banking Services	5.386
Transport of merchandise	171.276
Litigation and notary	8.647
Electricity, water, cleaning	24.667
Other supplies and services	16.922
	<u>3.254.388</u>

The amounts recorded under "specialized work" correspond essentially to expenses with sales promoters in Pharmacy, training expenditures, spending on market analysis, costs arising from trade agreements and shared services invoiced by the group.

The item "Rents" includes amounts related to the lease of the Company's facilities, as well as the incomes of cars hired on operating leases.

The amount recorded under "representation expenses" related mainly to expenses with courses and conferences as well as costs of such conferences as hotels and meals.

The caption "Advertising" believes figures for the promotion and dissemination activities of the products sold by the Company.

22 EXPENSES WITH THE PERSONAL

The item "Expenses with staff" in the year ended March 31, 2015 is detailed as follows:



	2014-15
Remuneration of the Directors	195.723
Remuneration of the Staff	1.557.805
Indemnities	11.302
Charges regarding to remunerations	404.429
Work insurances	13.030
Health insurance	17.435
Life insurance	3.711
Expenses with recruiting staff	-
Other expenses with the staff	2.822
	<u>2.206.258</u>

Staff remuneration include the amounts of 198,035 Euros and 32,357 Euros related to awards made by sales and productivity bonuses, respectively.

23 OTHER INCOME AND GAINS

The caption "Other operating income" for the year ended March 31, 2015 is detailed as follows:


	2014-15
Differences in favorable exchanges	51
Other income and gains	85.916
	<u>85.967</u>

24 OTHER EXPENSES AND LOSSES

The item "Other costs and losses" in the year ended March 31, 2015 is detailed as follows:

	2014-15
Taxes	838.526
Investments gain and losses	73.536
Liabilities in inventory	-
Tax estimation failure	-
Differences in desfavorable exchanges	40
Other gains and losses	25.139
	<u>937.242</u>

The amount of 838,526 Euros recorded under "Taxes" refers primarily to fees paid to INFARMED on units sold, as well as fees for product registration and the contribution rate of the pharmaceutical industry (CIF).



25 INTEREST AND OTHER INCOME AND SIMILAR EXPENSES

Os gastos e perdas de financiamento reconhecidos no decurso do exercício findo em 31 de Março de 2015 são detalhados conforme se segue:

	2014-15
Supported interests	40.427
	40.427
	2014-15
Interests obtained and other similar incomes	726
	726

The amount of 40,427 Euros recorded under "Interest expense" relates to interest expenses resulting from financing obtained described in Note 16.

26 LEGALLY REQUIRED DISCLOSURES

The Company is inserted into the marketing activity sector of pharmaceutical products, which is regulated by the national authority INFARMED - National Authority of Medicines and Health Products, IP (Under the Ministry of Health) that evaluates, authorizes, regulates and controls the human medicines and health products, including medical devices and cosmetics and personal hygiene products, and its main task of ensuring the quality, safety and efficacy of medicines and health products, preventing the risks arising from their use, ensuring the highest standards of public health and protection of consumers' interests.

They have been transposed into national law (Decree-Law No. 176/2006 of 30 August), EU Directive No. 2001/83 / EC (6 November), 2004/24 / EC (31 March), 2004/27 / EC (March 31), 2003/94 / EC (8 October) and 2003/63 / EC (25 June), the European Parliament and Council.

The Drug Statute, approved by Decree-Law No. 176/2006, of 30 August referred to above, establishes the legal framework that govern the introduction of the marketing authorization as amended, manufacture, import, export, marketing, labeling and information, advertising, pharmacy vigilance and use of medicines for human use and their inspection, including, in particular, homeopathic medicines, pharmacists radio medicines and traditional herbal medicinal products to.

On the other hand, this Decree defines what are the criteria / general principles to be followed by pharmaceutical companies in the collection system of medicine, wrappings or drug residues, for whatever reason, must be withdrawn. It also defines the authorization holders in the market, the parallel import license or equivalent



authorizations are responsible for the removal, collection and disposal of drugs and packaging that, for whatever reason, must be withdrawn from the market, without prejudice to the possibility the withdrawal be triggered in the case of medicinal products whose validity there is expired, the distributor, the pharmacy or other natural or legal person lawfully in possession of drugs for supply, on any account, to the public.

Market medicines collected are credited to distributors, to pharmacies, drug sales from non-prescription and units to provide health care, taking the pharmaceutical companies or holders of authorizations described above, the corresponding financial liabilities unless intent or gross negligence.

In addition, Article 103 of Decree-Law No. 176/2006, of 30 August, also states that the price system of medicinal products subject to medical prescription and medicines obtained without a prescription reimbursed is fixed by decree-law, and to this effect was approved by Decree-Law No. 65/2007, of March 14, added later, by Decree-law No. 184/2008, of 5 September.

Based on those decrees, the price cap regime was established (being the starting price of the drug made by comparing the average price of benchmark countries) for medicines for human use subject to medical prescription with the exception of medicinal products subject to medical prescription, which is exclusively for hospital use as well as medicines obtained without a prescription reimbursed.

In 2010, Decree-Law No. 48-A / 2010 of 13 May, approving the general system of state reimbursement the price of medicines change the rules that govern the prior evaluation of medicinal products for purchase by hospitals NHS (National Health Service), proceeding to the first amendment to Decree No. 195/2006 of 3 October, and modifies the price formation system of medicinal products subject to medical prescription and medicines obtained without a prescription reimbursed, proceeding to second amendment to Decree No. 65/2007 of 14 March.


In addition, Decree No. 1041-A / 2010, of October 07, establishes a deduction to practice on the selling prices to maximum authorized public of medicines reimbursed human use.

In 2012 it was published Ordinance No. 3/2012 of January 2 which regulates the review exceptionally price for reasons of public interest or on the initiative of the marketing authorization holder. Ordinance No. 137-A / 2012 of 11 May embodied by Order No. 15700/2012 of the Health Secretary of State's Office instituted a new medication use paradigm in our country, implementing the obligation of prescribing and dispensing by DCI "Denomination International common "privileging the decoupling trademarks and treatments for the active ingredient.



27 SUBSEQUENT EVENTS

After the end of the year there were no material events affecting the financial position and the financial stability of the Company, and consequently should be subject to reference.



MANAGER

Manoj Prakash



Grant Thornton

Statutory Auditors' Report

(CERTIFICAÇÃO DAS CONTAS)

FREE TRANSLATION OF THE ORIGINAL IN PORTUGUESE

Grant Thornton & Associados – SROC, Lda.

Edifício Amadeo Souza Cardoso
Alameda António Sérgio, 22, 11.º Miraflores –
1495-132 Alges – Portugal

T +351 214 123 520

F +351 214 123 539

Avenida Arraga, 30 – 1.º B – 9000-064
Funchal – Portugal

T +351 291 200 540

F +351 291 200 549

E-mail: gt.lisboa@ptgt.com

Introduction

1. We have audited the financial statements of Aurovitas Unipessoal, Lda., which comprise the balance sheet as at March 31, 2015, the income statement by nature, the statement of changes in equity and the cash flow statement for the year then ended and the related notes. The financial statements show net assets of 7.211.090 euro and equity of 667.057 euro, including a profit for the year of 662.057 euro.

Responsibilities

2. The Company's Management is responsible for the preparation of financial statements that present fairly the Company's financial position and the result of its operations, as well as for the utilisation of adequate accounting methods and principles. Company's Management is also responsible for establishing and maintaining a proper system of internal accounting control.
3. Our responsibility is to express an opinion on the financial statements based on our audit.

Audit Scope

4. Our audit was carried out in accordance with the auditing standards (Normas Técnicas e Directrizes de Revisão / Auditoria) approved by the Portuguese Institute of Statutory Auditors (Ordem dos Revisores Oficiais de Contas). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. To achieve those objectives, an audit includes:

- examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, as well as assessing significant estimates made by Management;
 - assessing the adequacy of the accounting principles used as well as their disclosure in the financial statements, taking into consideration the circumstances and applicability, or not, of the going concern concept;
 - evaluating the overall presentation of the financial statements.
5. Our examination also included the analysis of the consistency between the financial data of the management report and the financial statements.
6. We believe that our audit provides a reasonable basis for our opinion.


Opinion

7. In our opinion, the financial statements mentioned in the first paragraph present fairly, in all material respects, the financial position of Aurovitas Unipessoal, Lda. as at March 31, 2015 and the results of its operations and the cash flow statement for the year then ended, in conformity with generally accepted accounting principles in Portugal.

Report on other legal requirements

8. In our opinion the information included in the management's report agrees with the financial statements of the year then ended.

May 13, 2015



Grant Thornton & Associados – SROC, Lda.
Represented by C. Lisboa Nunes

Aurovitas Unipessoal Lda - Portugal

Balance Sheet as at March 31, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

INITIALLED FOR IDENTIFICATION

PURPOSES ONLY

GRANT THORNTON & ASS. SROG LDA.

Not 13, 2015 68F

	Note	31 March, 2015 (€)	31 March, 2014 (€)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	5.000	-
Share application money			
Reserves and surplus	3	662.057	-
		667.057	-
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	3.384.433	-
Other current liabilities	9	1.862.770	-
Short-term provisions	7	2.219.876	-
		7.467.078	-
TOTAL		8.134.136	-
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	62.477	-
Intangible assets	11	193	-
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5	289.725	-
Long-term loans and advances	13	-	-
Trade receivables	14,1	-	-
Other non-current assets	14,2	-	-
		352.395	-
Current assets			
Current investments	15	-	-
Inventories	16	4.266.710,68	-
Trade receivables	14,1	3.057.068	-
Cash and bank balances	17	336.123	-
Short-term loans and advances	13	121.260	-
Other current assets	14,2	580	-
		7.781.741	-
TOTAL		8.134.136	-
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.

INITIALED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROC, LMA
HGT 13, 20 15 EYF

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	March-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Income															
Revenue from operations (gross)	18	1,959,050	2,059,545	1,895,943	1,865,669	1,244,750	1,906,847	1,903,225	1,805,012	1,434,448	1,912,354	1,871,639	1,613,866	21,472,348	-
Less: Excise duty/Rebates		(611,537)	(588,394)	(585,491)	(565,705)	(506,059)	(586,639)	(513,461)	(474,048)	(367,488)	(487,095)	(521,481)	(142,091)	(5,949,489)	-
Revenue from operations (net)		1,347,513	1,471,151	1,310,452	1,299,964	738,691	1,320,208	1,389,764	1,330,964	1,066,959	1,425,259	1,350,158	1,471,775	15,522,859	-
Other income	19	-	26	121	139	108	79	71	97	85	-	-	-	726	-
Total revenue (I)		1,347,513	1,471,177	1,310,573	1,300,102	738,799	1,320,287	1,389,836	1,331,062	1,067,044	1,425,259	1,350,158	1,471,775	15,523,585	-
Expenses															
Cost of raw material and components consumed	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods	21	572,439	710,952	622,440	932,779	832,319	695,657	1,025,379	746,345	734,704	513,608	579,214	660,898	8,626,735	-
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	98,122	(5,455)	38,209	(299,376)	(398,854)	(9,805)	(286,333)	(137,656)	(197,873)	187,346	68,911	(104,448)	(1,047,210)	-
Employee benefit expense	22	199,347	179,201	191,841	190,327	198,450	174,765	191,037	182,617	186,793	150,526	208,071	136,541	2,189,516	-
Other expenses	23	422,018	206,635	248,312	361,237	138,176	385,758	431,835	164,198	368,903	516,725	429,231	700,406	4,373,433	-
Exceptional items	24	-	-	180,000	-	-	-	-	-	-	-	-	-	180,000	-
Total (II)		1,291,926	1,091,334	1,280,802	1,184,967	770,091	1,246,375	1,361,920	955,503	1,092,527	1,368,204	1,285,428	1,393,397	14,322,474	-
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		55,586	379,843	29,771	115,136	(31,292)	73,912	27,916	375,558	(25,483)	57,055	64,730	78,378	1,201,111	-
Depreciation and amortization expense	25	877	974	974	974	974	974	1,890	2,625	2,625	2,625	2,625	2,461	20,595	-
Finance costs	26	(139)	4,902	16,279	(0)	-	11,706	3,959	(2)	2,663	7,334	1,128	145	47,975	-
Profit/(loss) before tax		54,849	373,967	12,518	114,162	(32,266)	61,232	22,068	372,935	(30,771)	47,097	60,978	75,773	1,132,541	-
Tax expenses															
Current tax		0 €	0 €	148,195 €	56,397 €	-8,473 €	61,773 €	58,962 €	107,728 €	-20,540 €	11,072 €	36,271 €	308,823 €	760,208	0 €
Less: MAT credit entitlement		0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	-	0 €
Deferred tax		2,757 €	0 €	0 €	-2,757 €	0 €	-6,608 €	6,608 €	0 €	0 €	0 €	0 €	-289,725 €	(289,725)	0 €
Fringe benefit tax		0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	-	0 €
Tax relating to previous years		0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	0 €	-	0 €
Total tax expense		2,757	-	148,195	53,640	(8,473)	55,166	65,569	107,728	(20,540)	11,072	36,271	19,099	470,484	-
Profit/(loss) for the year		52,092	373,967	(135,677)	60,522	(23,793)	6,066	(43,502)	265,207	(10,231)	36,025	24,707	56,674	662,057	-
Summary of significant accounting policies															
	1														

Note 1 : Summary of significant accounting policies (Refer General Instructions Note No.1)

- 1,1
- 1,2
- 1,3
- 1,4
- 1,5

Note 2 : Share capital (Refer General Instructions Note No.2)

	March 31, 2015	March 31, 2014
Authorised shares:		
XXXXXXXXXX (31 March, 2014: XXXXXXXXXX) equity shares of XXXX each	- €	- €
XXXXXXXXXX (31 March, 2014: XXXXXXXXXX) preference shares of XXX each	- €	- €
	-	-
Issued, Subscribed and Fully Paid-up shares:		
XXXXXXXXXX (31 March, 2014: XXXXXXXXXX) equity shares of XXXX each fully paid-up	5.000 €	- €

Aurovitas Unipessoal Lda - Portugal
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROG, LDA.
ESF May 13, 2015

Note 3: Reserves and surplus (Refer General Instructions Note No.3)

	March 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	- €	- €
	- €	- €
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet	- €	- €
	- €	- €
General Reserve		
As per last Balance Sheet	- €	- €
Add: Transferred from statement of profit and loss	- €	- €
	- €	- €
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements		
Profit for the quarter	662.057	-
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)	- €	- €
Tax on proposed equity dividend	- €	- €
Interim dividend paid (amount per share XX (31 March, 2014 XX)	- €	- €
Transfer to general reserve	- €	- €
Total appropriations	- €	- €
Net surplus in the statement of profit and loss	662.057 €	- €
Total reserves and surplus	662.057 €	- €

Note 4: Long-term borrowings (Refer General Instructions Note No.4)

	Non-current Portion		Current maturities	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)	- €	- €	- €	- €
Other Loans from banks				
Current account credit balance	- €	- €	- €	- €
Loans and advances from related parties	- €	- €	- €	- €
Other Loans and advances				
Sales tax deferment loan (Un Secured)	- €	- €	- €	- €
	- €	- €	- €	- €
The above amount includes				
Secured borrowings	- €	- €	- €	- €
Unsecured borrowings	- €	- €	- €	- €
Amount disclosed under the head	- €	- €	- €	- €
"Other current liabilities"	- €	- €	- €	- €
Net Amount	- €	- €	- €	- €

Note 5: Deferred tax liability (net)

	March 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis	- €	- €
Provision for diminution in the value of investments	- €	- €
Provision for doubtful debts and advances	- €	- €
Fixed Assets (Depreciation)	- €	- €
Retirement Benefits	- €	- €
Others	- €	- €
Gross deferred tax liability	- €	- €
Deferred tax asset		
Carried Forward Business Losses	- €	- €
Others	289.725 €	- €
Gross deferred tax asset	289.725 €	- €
Net deferred tax liability	- 289.725 €	- €

Note 6: Other long-term liabilities (Refer General Instructions Note No.5)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances)	- €	- €
Other liabilities	- €	- €
Advances from related parties	- €	- €
	- €	- €
	289.725 €	- €

Note 7: Provisions (Refer General Instructions Note No.6 & 10)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Provision for employee benefits				
- Gratuity	- €	- €	- €	- €
- Bonus/13 Month Salaries and Others	- €	- €	519.349 €	- €
	- €	- €	519.349 €	- €
Other Provisions				
For Taxation (net of advance payments)	- €	- €	- €	- €
For Proposed dividend	- €	- €	- €	- €
For Tax on proposed dividend	- €	- €	- €	- €
	- €	- €	- €	- €
	- €	- €	519.349 €	- €

Provision for warranties

	March 31, 2015	March 31, 2014
At the beginning of the year	1.666.483 €	- €
Arising during the period	1.150.367 €	- €
Utilised during the period	- €	- €
Unused amounts reversed	- 1.116.324 €	- €
At the end of the year	1.700.526 €	- €
Current portion		
Non-current portion		

Note 8: Short-term borrowings (Refer General Instructions Note No.7)

	March 31, 2015	March 31, 2014
Bank overdraft	- €	- €
Loans and advances from related parties	- €	- €
Working capital loans (Secured)	- €	- €
Short term loans (Un Secured)		
Working capital loans	- €	- €
	- €	- €
The above amount includes		
Secured borrowings	- €	- €
Unsecured borrowings	- €	- €

Note 9: Other current liabilities (Refer General Instructions Note No.9)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)	3.384.433 €	- €
Other liabilities		
Current maturities of long-term borrowings	- €	- €
Advances from customers	- €	- €
Unclaimed dividends	- €	- €
Interest accrued but not due on loans	- €	- €
Trade deposits	- €	- €
Accrued expenses	274.689 €	- €
Accrued discounts	585.278 €	- €
Deferred revenue	83.369 €	- €
Other Short Term Liabilities	919.290 €	- €
Accrued interest	144 €	- €
	1.862.770 €	- €
	5.247.203 €	- €

Aurovitas Unipessoal Lda - Portugal

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 10: Tangible assets (Refer General Instructions Note No.11)

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROG, LDA
ESF 9cey 13 2015

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment	Computers	Computer Software	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation											
At 1 April 2013	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	-
Additions	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	-
Disposals	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	-
Other adjustments	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	-
- Exchange differences	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	-
- Borrowing costs	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	-
At 31 March 2014	-	-	-	-	-	-	-	-	-	-	-
Additions	0€	0€	0€	0€	0€	59.426 €	3.507 €	0€	0€	0€	62.933 €
Acquisitions through amalgamation	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
Disposals	0€	0€	0€	0€	0€	1.599 €	0€	0€	0€	0€	1.599 €
Additions on acquisition (Gross Block)	0€	0€	0€	0€	0€	0€	0€	214.960 €	0€	0€	214.960 €
Other adjustments	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
- Exchange differences	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
- Borrowing costs	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	-
At 31 March 2015	-	-	-	-	-	57.827	3.507	214.960	-	-	276.293
Depreciation											
At 1 April 2013	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
Charge for the year	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
Disposals	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
Other adjustments	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
- Exchange differences	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
At 31 March 2014	-	-	-	-	-	-	-	-	-	-	-
Charge for the period	0€	0€	0€	0€	0€	9.168 €	1.071 €	10.355 €	0€	0€	20.595 €
Disposals	0€	0€	0€	0€	0€	1.599 €	0€	0€	0€	0€	1.599 €
Other adjustments (Depreciation adj of	0€	0€	0€	0€	0€	0€	0€	194.820 €	0€	0€	194.820 €
- Exchange differences	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
At 31 March 2015	-	-	-	-	-	7.570	1.071	205.176	-	-	213.817
Impairment loss											
At 1 April 2013	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
At 31 March 2014	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
Charge for the period	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€	0€
At 31 March 2015	-	-	-	-	-	-	-	-	-	-	-
Net Block											
At 31 March 2014	-	-	-	-	-	-	-	-	-	-	-
At 31 March 2015	-	-	-	-	-	50.257	2.435	9.784	-	-	62.477

Aurovitas Unipessoal Lda - Portugal

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 11 : Intangible assets (Refer General Instructions Note No.72)

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At 1 April 2013	0 €	0 €	0 €	-
Purchase	0 €	0 €	0 €	-
Internal development	0 €	0 €	0 €	-
Disposals	0 €	0 €	0 €	-
Other adjustments	0 €	0 €	0 €	-
- Exchange differences	0 €	0 €	0 €	-
At 31 March 2014	-	-	-	-
Purchase	0 €	193 €	0 €	193
Acquisitions through amalgamation	0 €	0 €	0 €	-
Disposals	0 €	0 €	0 €	-
Other adjustments	0 €	0 €	0 €	-
- Exchange differences	0 €	0 €	0 €	-
At 31 March 2015	-	193	-	193
Amortization				
At 1 April 2013	0 €	0 €	0 €	-
Charge for the year	0 €	0 €	0 €	-
Disposals	0 €	0 €	0 €	-
Other adjustments	0 €	0 €	0 €	-
- Exchange differences	0 €	0 €	0 €	-
At 31 March 2014	-	-	-	-
Charge for the period	0 €	0 €	0 €	-
Disposals	0 €	0 €	0 €	-
Other adjustments	0 €	0 €	0 €	-
- Exchange differences	0 €	0 €	0 €	-
At 31 March 2015	-	-	-	-
Net Block				
At 31 March 2014	-	-	-	-
At 31 March 2015	-	193	-	193

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROG, LDA
ESF July 13, 2015

Note 12: Non-current investments (Refer General Instructions Note No.13)

Off 9/23/15
March 31, 2015 March 31, 2014

Unquoted equity instruments

Investment in subsidiaries	- €	- €
Investment in joint ventures	- €	- €
Investment in associates	- €	- €
	- €	- €

Note 13: Loans and advances (Refer General Instructions Note No.14 & 21)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Capital advances				
Secured, considered good	- €	- €	- €	- €
Unsecured, considered good	- €	- €	- €	- €
(A)	- €	- €	- €	- €
Security deposit				
Secured, considered good	- €	- €	- €	- €
Unsecured, considered good	- €	- €	- €	- €
Doubtful	- €	- €	- €	- €
Provision for doubtful security deposit	- €	- €	- €	- €
(B)	- €	- €	- €	- €
Loan and advances to related parties				
Unsecured, considered good	- €	- €	- €	- €
(C)	- €	- €	- €	- €
Advances recoverable in cash or kind				
Secured, considered good	- €	- €	- €	- €
Unsecured, considered good	- €	- €	- €	- €
Doubtful	- €	- €	- €	- €
Provision for doubtful advances	- €	- €	- €	- €
(D)	- €	- €	- €	- €
Other loans and advances				
Advance income-tax (net of provision for taxation)	- €	- €	- €	- €
Prepaid expenses	- €	- €	114,389 €	- €
Loans to employees	- €	- €	1,862 €	- €
Loans to others	- €	- €	- €	- €
Export incentives receivable	- €	- €	- €	- €
Export incentives licenses	- €	- €	- €	- €
Balances with Statutory/government authorities	- €	- €	5,009 €	- €
(E)	- €	- €	121,260 €	- €
Total (A+B+C+D+E)	- €	- €	121,260 €	- €

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors	- €	- €	- €	- €
Dues from officers	- €	- €	- €	- €
Dues from non-executive and officers jointly with other persons	- €	- €	- €	- €
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner	- €	- €	- €	- €
Dues from in which the company's managing director is a member	- €	- €	- €	- €
Dues from the partnership firm in which the company's non-executive director is a partner	- €	- €	- €	- €

EST 909 10, 2015

Note 14: Trade receivables and other assets

14.1 Trade receivable (Refer General Instructions Note No.15 & 19)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for pa	- €	- €	- €	- €
Secured, considered good				
Due from group companies	- €	- €	- €	- €
Due from others	- €	- €	- €	- €
Unsecured, considered good				
Due from group companies	- €	- €	- €	- €
Due from others	- €	- €	- €	- €
Doubtful	- €	- €	- €	- €
Provision for doubtful receivables	- €	- €	- €	- €
(A)	- €	- €	- €	- €
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies	- €	- €	- €	- €
Due from others	- €	- €	- €	- €
Unsecured, considered good				
Due from group companies	- €	- €	41.623 €	- €
Due from others	- €	- €	3.015.446 €	- €
Doubtful	- €	- €	- €	- €
Provision for doubtful receivables	- €	- €	3.057.068 €	- €
(B)	- €	- €	- €	- €
Total (A+B)	- €	- €	3.057.068 €	- €

Trade receivables include:

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Due from non-executive directors	- €	- €	- €	- €
Due from officers	- €	- €	- €	- €
Due from non-executive directors and officers jointly with other persons	- €	- €	- €	- €
Dues from partnership firm in which the company's non-executive director is a partner	- €	- €	- €	- €
Dues from in which the company's non-executive director is a director	- €	- €	- €	- €

14.2 Other assets (Refer General Instructions Note No.16 & 22)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances	- €	- €	- €	- €
(A)	- €	- €	- €	- €
Unamortized expenditure				
Unamortized premium on forward contract	- €	- €	- €	- €
Ancillary cost of arranging the borrowings	- €	- €	- €	- €
(B)	- €	- €	- €	- €
Others				
Interest accrued on fixed deposits	- €	- €	- €	- €
Interest accrued on investments	- €	- €	- €	- €
Dividend receivable on investments in subsidiaries - long term	- €	- €	- €	- €
Others	- €	- €	580 €	- €
(C)	- €	- €	580 €	- €
Total (A+B+C)	- €	- €	580 €	- €

Note 15: Current investments (Refer General Instructions Note No.17)

658 903 13, 2015
March 31, 2015 March 31, 2014

Current investments (valued at lower of cost and fair value, unless stated otherwise)

Quoted equity instruments - Non-trade

Equity shares (fully paid-up)

If any (Please specify)

- €	- €
- €	- €
- €	- €

Note 16: Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)

March 31, 2015	March 31, 2014
- €	- €
4.124.841	- €
141.870	- €
- €	- €
- €	- €
4.266.711	-

Raw materials and components (includes in transit XXX (31 March, 2014 XXX)

Work - in - Progress

Finished goods

Traded goods (including stock -in-transit XXXX (31 March, 2014 XXX)

Stores, spares, consumables and packing materials

Loose tools

Note 17: Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts	- €	- €	335.049 €	- €
Deposits with original maturity of less than 3 months	- €	- €	- €	- €
Cash credit accounts	- €	- €	- €	- €
On unpaid dividend account	- €	- €	- €	- €
Cheques/drafts on hand	- €	- €	- €	- €
Unpaid matured deposits	- €	- €	- €	- €
Cash on hand	- €	- €	1.074 €	- €
			336.123 €	- €
Other bank balances				
Deposits with original maturity for more than 12 months	- €	- €	- €	- €
Deposits with original maturity for more than 3 months but less than 12 months	- €	- €	- €	- €
Margin money deposit	- €	- €	- €	- €
	- €	- €	- €	- €
Amount disclosed under non-current assets	- €	- €	- €	- €
	- €	- €	336.123 €	- €

Aurovitas Unipessoal Lda - Portugal
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROG, LDA.
EST 9/24/13 2013

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 18 : Revenue from operations (Refer General Instructions Note No.25)														
Revenue from operations														
Sale of products														
Finished goods	1.959.050 €	2.059.545 €	1.895.943 €	1.865.669 €	1.244.750 €	1.906.847 €	1.903.225 €	1.805.012 €	1.434.448 €	1.912.354 €	1.871.639 €	1.613.866 €	21.472.348 €	- €
Traded goods													- €	- €
Sale of services													- €	- €
Sale of dossiers/licenses													- €	- €
Other operating revenue													- €	- €
Scrap sales													- €	- €
Other													- €	- €
Revenue from operations (gross)	1.959.050	2.059.545	1.895.943	1.865.669	1.244.750	1.906.847	1.903.225	1.805.012	1.434.448	1.912.354	1.871.639	1.613.866	21.472.348	-
Less: VAT/Excise duty/Rebates	611.537 €	588.394 €	585.491 €	565.705 €	506.059 €	586.639 €	513.461 €	474.048 €	367.488 €	487.095 €	521.481 €	142.091 €	5.949.489 €	-
Revenue from operations (net)	1.347.513	1.471.151	1.310.452	1.299.964	738.691	1.320.208	1.389.764	1.330.964	1.066.959	1.425.259	1.350.158	1.471.775	15.522.859	-

Note 19 : Other income (Refer General Instructions Note No.26)

Interest income on														
Bank deposits	- €	26 €	121 €	139 €	108 €	79 €	71 €	97 €	85 €	- €	- €	- €	726 €	- €
Long-term investments	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Current investments	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Loans to joint venture entities	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Others	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Dividend income on														
Investment in subsidiaries	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Current investments	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Long-term investments	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Net gain on sale of current investments	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Profit on sale of fixed assets (net)	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Foreign exchange gain (net)	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Balances no longer required written back	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Government grant	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Commission income	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Processing charges	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Other non-operating income (net of expenses direct)	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
to such income of Rs.XXXXX (31 March, 2014:XXX)	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
	- €	26 €	121 €	139 €	108 €	79 €	71 €	97 €	85 €	- €	- €	- €	726 €	- €

Note 20 : Cost of raw material and components consumed

Inventory at the beginning of the period	-													
Add: Purchases	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Less: inventory at the end of the period	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Add:Packing material consumed	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Cost of raw material and components consumed	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €

Aurovitas Unipessoal Lda - Portugal
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROG, LDA.
ESG 10215

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 21 : (Increase)/decrease in inventories														
Inventories at the end of the period														
Traded goods														-
Work-in-progress														-
Finished goods	#####	2.984.963 €	2.946.754 €	3.246.130 €	3.644.984 €	3.654.789 €	3.941.121 €	4.078.777 €	4.276.650 €	4.089.304 €	4.020.393 €	4.124.841 €	4.124.841 €	-
	2.979.509	2.984.963	2.946.754	3.246.130	3.644.984	3.654.789	3.941.121	4.078.777	4.276.650	4.089.304	4.020.393	4.124.841	4.124.841	-
Inventories at the beginning of the period														
Traded goods														- €
Work-in-progress														-
Finished goods	#####	2.979.509 €	2.984.963 €	2.946.754 €	3.246.130 €	3.644.984 €	3.654.789 €	3.941.121 €	4.078.777 €	4.276.650 €	4.089.304 €	4.020.393 €	3.077.631 €	- €
	3.077.631	2.979.509	2.984.963	2.946.754	3.246.130	3.644.984	3.654.789	3.941.121	4.078.777	4.276.650	4.089.304	4.020.393	3.077.631	-
	98.122	(5.455)	38.209	(299.376)	(398.854)	(9.805)	(286.333)	(137.656)	(197.873)	187.346	68.911	(104.448)	(1.047.210)	-
Details of purchase of traded goods														
Product A	572.439 €	710.952 €	622.440 €	932.779 €	832.319 €	695.657 €	1.025.379 €	746.345 €	734.704 €	513.608 €	579.214 €	697.806 €	8.663.643 €	- €
Product B													-	- €
Adjustments/Deferred Revenue COGs												36.908 €	36.908 €	- €
	572.439 €	710.952 €	622.440 €	932.779 €	832.319 €	695.657 €	1.025.379 €	746.345 €	734.704 €	513.608 €	579.214 €	660.898 €	8.626.735 €	- €
Note 22 : Employee benefit expense														
Salaries, wages and bonus	160.257 €	144.044 €	154.192 €	152.808 €	159.060 €	143.070 €	153.616 €	148.939 €	149.441 €	121.728 €	157.005 €	109.368 €	1.753.529 €	- €
Contribution to provident and other fund	37.061 €	33.128 €	35.620 €	35.246 €	37.233 €	32.383 €	35.426 €	34.366 €	34.713 €	27.893 €	36.581 €	24.778 €	404.429 €	- €
Employee stock option scheme	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Gratuity expense	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Other employee benefits	2.029 €	2.029 €	2.029 €	2.272 €	2.157 €	688 €	1.995 €	688 €	2.639 €	905 €	14.486 €	2.395 €	31.559 €	- €
Post employment medical benefits	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Staff welfare expenses	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
	199.347 €	179.201 €	191.841 €	190.327 €	198.450 €	174.765 €	191.037 €	182.617 €	186.793 €	150.526 €	208.071 €	136.541 €	2.189.516 €	- €

Aurovitas Unipessoal Lda - Portugal
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROG, Lda.
ESF. 907.13.20.13

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 23 : Other expenses														
Consumption of stores and spares	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Conversion charges	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Chemicals consumed	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Increase in VAT on finished goods	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Customer service expenditure	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Power and fuel	571 €	138 €	1.504 €	962 €	651 €	415 €	2.224 €	724 €	1.046 €	600 €	1.254 €	1.390 €	10.176 €	- €
Water charges	120 €	293 €	226 €	367 €	47 €	165 €	340 €	73 €	111 €	216 €	388 €	235 €	2.581 €	- €
Freight and forwarding charges	3.800 €	28.051 €	39.287 €	50.233 €	3.897 €	3.870 €	7.481 €	4.309 €	4.305 €	2.599 €	8.575 €	14.870 €	171.276 €	- €
Carriage inward	42.525 €	51.100 €	41.313 €	40.764 €	29.583 €	44.823 €	44.416 €	38.495 €	38.191 €	45.181 €	24.503 €	35.521 €	476.414 €	- €
Carriage outwards	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Rent	7.340 €	7.340 €	7.340 €	7.340 €	7.340 €	7.340 €	7.340 €	7.340 €	7.340 €	7.340 €	7.379 €	7.340 €	88.119 €	- €
Rates and taxes	21.353 €	21.191 €	21.041 €	18.013 €	17.914 €	17.778 €	19.271 €	18.508 €	14.295 €	27.587 €	130.884 €	155.882 €	483.717 €	- €
Insurance	2.099 €	1.841 €	2.442 €	2.945 €	2.656 €	2.425 €	2.653 €	2.597 €	2.597 €	1.233 €	1.366 €	3.178 €	25.300 €	- €
Repairs and maintenance													- €	- €
i) Plant and machinery	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
ii) Buildings	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
iii) Others	5.123 €	1.699 €	1.137 €	2.569 €	2.800 €	1.561 €	1.660 €	2.345 €	1.260 €	1.247 €	1.986 €	1.469 €	24.856 €	- €
Advertising and sales promotion	26.563 €	24.337 €	183.293 €	30.113 €	32.802 €	34.054 €	37.118 €	43.680 €	88.443 €	15.625 €	20.248 €	187.181 €	723.456 €	- €
Brokerage and discounts	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Remuneration to Auditors	1.688 €	1.688 €	1.688 €	1.688 €	1.688 €	6.188 €	1.688 €	4.688 €	1.688 €	8.788 €	650 €	3.850 €	18.400 €	- €
Sales commission	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Travelling and conveyance	1.901 €	2.002 €	6.800 €	5.359 €	2.569 €	8.702 €	4.239 €	8.592 €	10.725 €	7.787 €	3.843 €	6.419 €	65.135 €	- €
Communication costs	5.935 €	5.916 €	6.445 €	5.966 €	6.179 €	13.658 €	318 €	4.788 €	5.373 €	5.441 €	4.943 €	5.342 €	70.304 €	- €
Printing and stationery	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Legal and professional fees	1.500 €	- €	1.500 €	- €	1.500 €	- €	- €	- €	- €	- €	- €	700 €	2.200 €	- €
Directors sitting fees	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Payment to auditor (Refer details below)	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Provision for diminution in value of investment in s	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Provision for other than temporary decline in the	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
carrying amount of other long-term investments	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Adjustment to the carrying amount of current invest	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Provision for warranties (net of reversals)	100.381 €	96.072 €	192.793 €	60.242 €	55.159 €	61.331 €	239.595 €	89.275 €	111.517 €	248.589 €	51.569 €	111.021 €	438.230 €	- €
Provision for litigations (net of reversals)	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Exchange differences (net)	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Loss on derivative contracts (including provisions m	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Bad debts/advances written off	95.837 €	20.307 €	8.203 €	- €	126.763 €	69.263 €	70.510 €	8.789 €	290 €	301 €	353 €	1.763 €	11.031 €	- €
Impairment loss on fixed assets	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Provision for doubtful debts and advances	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Loss on sale of fixed assets (net)	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Preimum on forward exchange contract amortized	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Factory maintenance	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Effluent treatment expenses	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Vehicle maintenance expenses	32.530 €	38.484 €	32.602 €	31.811 €	29.235 €	30.285 €	40.567 €	32.942 €	31.869 €	30.655 €	56.792 €	32.544 €	420.316 €	- €
Analytical charges	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Product development expenses	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €

Aurovitas Unipessoal Lda - Portugal
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROC, LDA.
ESF 904 13, 2014

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Registration and filing charges	23.605 €	44.896 €	39.492 €	43.550 €	21.451 €	27.983 €	54.718 €	38.734 €	31.951 €	70.959 €	48.217 €	27.081 €	472.634 €	- €
Other Services	46.727 €	46.242 €	41.934 €	42.173 €	43.770 €	48.444 €	33.876 €	50.326 €	42.010 €	36.925 €	43.907 €	59.823 €	536.158 €	- €
Safety and security	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Office expenses	1.928 €	1.297 €	2.426 €	12.764 €	4.990 €	4.952 €	2.411 €	1.732 €	6.004 €	1.128 €	2.448 €	2.902 €	44.983 €	- €
Repairs and maintenance - others	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Management fees	- €	- €	- €	- €	- €	- €	- €	- €	188.708 €	18.004 €	20.605 €	34.469 €	261.785 €	- €
Liquidated damages	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Donations	- €	- €	- €	- €	- €	- €	- €	- €	158 €	- €	- €	4.640 €	4.798 €	- €
Software license and implementation expenses	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Capital work-in-progress written off	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Miscellaneous expenses	4.294 €	5.887 €	2.434 €	4.379 €	5.012 €	2.519 €	2.432 €	2.389 €	4.639 €	4.094 €	2.759 €	2.787 €	43.626 €	- €
	422.018 €	206.635 €	248.312 €	361.237 €	138.176 €	385.758 €	431.835 €	164.198 €	368.903 €	516.725 €	429.231 €	700.406 €	4.373.433 €	- €

Aurovitas Unipessoal Lda - Portugal
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
GRANT THORNTON & ASS., SROG, LDA.
EWF 9 Oct 13 Jo 13

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Payment to Auditor														
As auditor:														
Audit fee	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Tax audit fee	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Limited review	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
In other capacity:														
Taxation matters	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Company law matters	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Management services	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Other services (certification fees)	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Reimbursement of expenses	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Note 24 : Exceptional items														
Others (Specify if any)	- €	- €	180.000 €	- €	- €	- €	- €	- €	- €	- €	- €	- €	180.000 €	- €
	- €	- €	180.000 €	- €	- €	- €	- €	- €	- €	- €	- €	- €	180.000 €	- €
Note 25 : Depreciation and amortization expense														
Depreciation of tangible assets	877 €	877 €	877 €	877 €	877 €	877 €	1.792 €	2.527 €	2.527 €	2.527 €	3.501 €	2.461 €	20.595 €	- €
Amortization of intangible assets	- €	97 €	97 €	97 €	97 €	97 €	97 €	97 €	97 €	97 €	877 €	- €	0 €	- €
Depreciation of investment property	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
	877 €	974 €	974 €	974 €	974 €	974 €	1.890 €	2.625 €	2.625 €	2.625 €	2.625 €	2.461 €	20.595 €	- €
Note 26 : Finance costs (Refer General Instructions Note No.27)														
Interest	- €	- €	16.280 €	- €	- €	11.661 €	3.958 €	- €	- €	7.333 €	1.051 €	144 €	40.427 €	- €
Bank charges	- 139 €	4.902 €	1 €	0 €	- €	45 €	1 €	2 €	2.663 €	1 €	77 €	1 €	7.548 €	- €
Amortization of ancillary borrowing costs	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
Exchange difference to the extent considered as an ac	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €	- €
	- 139 €	4.902 €	16.279 €	0 €	- €	11.706 €	3.959 €	2 €	2.663 €	7.334 €	1.128 €	145 €	47.975 €	- €

427

Director Report
Actavis Management GmbH
For the Period 01.04.14 – 31.03.15

Bases and framework conditions:

Actavis Management GmbH is for the above mentioned Period a non-operating company without Sales and without any Employees.

The company was a subsidiary of Actavis Inc. (NYSE: ACT) until 31.03.2014;

As of 1 April 2014, Aurobindo Group has taken over the Actavis companies in several Western European countries. This applies also to Actavis Management GmbH, which is now wholly owned by the ultimate parent Aurobindo Pharma Ltd., India. The latter is listed on BSE & NSE in India.

Financial position:

The company made a profit of 3k€ during the above mentioned period. Mainly effected by recharges to Actavis Deutschland GmbH & Co. KG

Cash Position:

The cash position of the company is 67k€ which is comparable to prior year.

Risks and Opportunities:

As the company has currently no sales and no employees the Management don't foresee any risks and opportunities.


Managing Directors:

Herr Kalman Petro, NL – 3972 JN Dreibergern-Rijsenburg,
Herr Dr. Martin Schwarz, AT – 6341 Ebbs,

München, 17. Juli 2015
1980 Puren Pharma GmbH
(former Actavis Management GmbH)



Dr. Martin Schwarz



PricewaterhouseCoopers Aktiengesellschaft Wirtschaftsprüfungsgesellschaft
Bernhard-Wicki-Straße 8, 80636 München

S.R. Batliboi & Associates LLP
Oval Office 18
1 Labs Center
HITEC City
Madhapur
Hyderabad 500 081
India

PricewaterhouseCoopers
Aktiengesellschaft
Wirtschaftsprüfungsgesellschaft

Bernhard-Wicki-Straße 8
80636 München
Postfach 21 02 63
80672 München
www.pwc.de

Tel.: +49 89 5790-50
Fax: +49 89 5790-5999

May 19, 2015

Auditor's Report - Actavis Management GmbH, Munich

As requested in your instructions dated April 4, 2015, we have audited for purposes of your audit of the consolidated financial statements of Aurobindo Pharma Limited, India, the accompanying balance sheet as of March 31, 2015, and the income statement for the 12 months ended March 31, 2015 of Actavis Management GmbH, Munich (the "financial information").

Management's Responsibility

The Management of Actavis Management GmbH, Munich, is responsible for the preparation of the financial information in accordance with German Commercial Law ("Handelsgesetzbuch": "German Commercial Law"). Management is also responsible for such internal control as management determines is necessary to enable the preparation of the financial information that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial information based on our audit. We conducted our audit of the financial information in accordance with German generally accepted standards for the audit of financial statements promulgated by the Institut der Wirtschaftsprüfer ("IDW") (Institute of Public Auditors in Germany). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial information is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and related disclosures in the financial information. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial information, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the financial information in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial information.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Vorsitzender des Aufsichtsrats WP StB Dr. Norbert Vogelpoth
Vorstand WP StB Prof. Dr. Norbert Winkeljohann, WP StB Dr. Peter Bartels, WP StB CPA Markus Burghardt, StB Prof. Dr. Dieter Endres, WP StB Petra Justenhoven
WP StB Prof. Dr. Georg Kampfer, WP StB Harald Keyser, WP RA StB Dr. Jan Koneiding, StB Manus Möller, WP StB Martin Scholich
Sitz der Gesellschaft: Frankfurt am Main, Amtsgericht Frankfurt am Main HRB 44845
PricewaterhouseCoopers Aktiengesellschaft Wirtschaftsprüfungsgesellschaft is member of PricewaterhouseCoopers International, a Company limited by guarantee registered in England and Wales

Audit Opinion

In our opinion based on the findings of our audit, the financial information has been prepared, in all material respects, in accordance with German Commercial Law ("Handelsgesetzbuch": "German Commercial Code").

Restriction on purpose, use and distribution

The financial information has been prepared solely for purposes of providing information to Aurobindo Pharma Limited, India, to enable it to prepare the consolidated financial statements of the group. As a result, the financial information is not a complete set of financial statements of Actavis Management GmbH, Munich, in accordance with the requirements of German Commercial Law and may, therefore, not be suitable for another purpose.


This report is intended solely for S.R. Batliboi & Associates LLP, Hyderabad, India, and shall not be used by or distributed to other parties. This report is confidential and shall not be published or referred to in a public document or any other public media.

Terms of Engagement

We issue this report on the basis of the engagement agreed with Actavis Management GmbH, Munich, which comprises the attached General Terms of Engagement for Wirtschaftsprüfer and Wirtschaftsprüfungsgesellschaften as of January 1, 2002, which are also applicable to third parties.

This report shall be exclusively governed by and construed in accordance with German law without giving effect to the provisions relating to private international law (Internationales Privatrecht). Exclusive place of jurisdiction for any action or other legal proceedings arising out of or in connection with this report shall be Frankfurt am Main, Germany.

PricewaterhouseCoopers
Aktiengesellschaft
Wirtschaftsprüfungsgesellschaft



Stefan Mulas
Wirtschaftsprüfer
(German Public Auditor)



Dietmar Eglauer
Wirtschaftsprüfer
(German Public Auditor)

Actavis Management GmbH, Germany

Balance Sheet as at March 31, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	31 Mar, 2015 (EUR)	31 March, 2014 (EUR)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	25.000	25.000
Share application money			
Reserves and surplus	3	37.399	34.467
		<u>62.399</u>	<u>59.467</u>
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		<u>-</u>	<u>-</u>
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	5.500	5.156
Other current liabilities	9	-	-
Short-term provisions	7	231	2.004
		<u>5.731</u>	<u>7.160</u>
TOTAL		<u>68.129</u>	<u>66.626</u>
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	-	-
Intangible assets	11	-	-
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	-	-
Trade receivables	14,1	-	-
Other non-current assets	14,2	-	-
		<u>-</u>	<u>-</u>
Current assets			
Current investments	15	-	-
Inventories	16	-	-
Trade receivables	14,1	984	-
Cash and bank balances	17	67.146	66.626
Short-term loans and advances	13	-	-
Other current assets	14,2	-	-
		<u>68.129</u>	<u>66.626</u>
TOTAL		<u>68.129</u>	<u>66.626</u>
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDC 8.5.2.15

Actavis Management GmbH, Germany

Statement of profit and loss for the twelve months period ended March 31, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	12 Months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Income			
Revenue from operations (gross)	18	-	-
Less: Excise duty/ Rebates		-	-
Revenue from operations (net)		-	-
Other income	19	4.851	11.622
Total revenue (I)		4.851	11.622
Expenses			
Cost of raw material and components consumed	20	-	-
Purchase of trading goods	21	-	-
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	-	-
Employer benefit expense	22	-	-
Other expenses	23	1.689	3.559
Exceptional items	24	-	-
Total (II)		1.689	3.559
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		3.162	8.063
Depreciation and amortization expense	25	-	-
Finance costs	26	1.200	1.200
Profit/(loss) before tax		1.962	6.863
Tax expenses		-	-
Corporate Income Tax for the Current Period		-	1.259
Deferred tax		-	-
Corporate Income Tax relating to previous years (shortfall/ (refunds) only)		(969)	650
Total tax expense		(969)	1.909
Profit/(loss) for the year		2.932	4.954
Summary of significant accounting policies	1		
The accompanying notes are an integral part of the financial statements.			

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDE 18 05 2015

Note 1: Summary of significant accounting policies (Note 1 General instructions, 2 de 10, 11)

- 1,1
- 1,2
- 1,3
- 1,4
- 1,5

Note 2: Share Capital (Note 2 General instructions, 2 de 10, 11)

	Mar 31, 2015	March 31, 2014
Authorised shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of XXXX each	25.000	25.000
XXXXXXXX (31 March, 2014: XXXXXXXX) preference shares of XXX each	25.000	25.000
Issued, Subscribed and Fully Paid-up shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of XXXX each fully paid-up	25.000	25.000

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
initial: MDI 8.5.2015

Note 3: Reserves and surplus (in thousands of Euros)

	Mar 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet		
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet		
General Reserve		
As per last Balance Sheet	34,467	29,513
Add: Transferred from statement of profit and loss	34,467	29,513
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements		
Profit for the quarter	2,932	4,954
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)		
Tax on proposed equity dividend		
Interim dividend paid (amount per share XX (31 March, 2014 XX)		
Transfer to general reserve		
Total appropriations		
Net surplus in the statement of profit and loss	2,932	4,954
Total reserves and surplus	37,399	34,467

Note 4: Long-term borrowings (in thousands of Euros)

	Non-current Portion		Current maturities	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)				
Other Loans from banks				
Current account credit balance				
Loans and advances from related parties				
Other Loans and advances				
Sales tax deferment loan (Un Secured)				
The above amount includes				
Secured borrowings				
Unsecured borrowings				
Amount disclosed under the head				
"Other current liabilities"				
Net Amount				

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: 8.5.15 MDL

Note 5: Deferred tax liability (net)

	Mar 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis		
Provision for diminution in the value of investments		
Provision for doubtful debts and advances		
Fixed Assets (Depreciation)		
Retirement Benefits		
Others		
Gross deferred tax liability		
Deferred tax asset		
Carried Forward Business Losses		
Others		
Gross deferred tax asset		
Net deferred tax liability		

Note 6: Other long-term liabilities (Refer General Instructions Note No. 5)

	Mar 31, 2015	March 31, 2014
Trade payables (including acceptances)		
Others		
Advances from customers		
Unclaimed dividends		
Other liabilities		
Interest accrued but not due on loans		
Advances from related parties		

Note 7: Provisions (Refer General Instructions Note No. 5)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Provision for employee benefits				
- Gratuity				
- Leave encashment				
Other Provisions				
For Taxation (net of advance payments)			231	2,004
For Proposed dividend				
For Tax on proposed dividend			231	2,004

Provision for warranties

	Mar 31, 2015	March 31, 2014
At the beginning of the year		
Arising during the period		
Utilised during the period		
Unused amounts reversed		
At the end of the Quarter		
Current portion		
Non-current portion		

Note 8: Short-term borrowings (Refer General Instructions Note No. 5)

	Mar 31, 2015	March 31, 2014
Bank overdraft		
Loans and advances from related parties		
Working capital loans (Secured)		
Short term loans (Un Secured)		
Working capital loans		
The above amount includes		
Secured borrowings		
Unsecured borrowings		

Note 9: Other current liabilities (Refer General Instructions Note No. 9)

	Mar 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No. 8)	5,500	5,156
Other liabilities		
Current maturities of long-term borrowings		
Trade deposits		

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only

Initial: 11.11.15 11.11.15

Actavis Management GmbH, Germany
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

Note 10: Tangible assets

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation									
At April 1, 2013									-
Additions during the nine months									-
Disposals during the nine months									-
Transfer to assets held for sale									-
Other adjustments									-
- Exchange differences									-
At December 31, 2013	-	-	-	-	-	-	-	-	-
Additions during the three months									-
Disposals during the three months									-
Other adjustments									-
- Exchange differences									-
At March 31, 2014	-	-	-	-	-	-	-	-	-
Additions during the nine months									-
Disposals during the nine months									-
Additions on acquisition									-
Other adjustments									-
- Exchange differences									-
At December 31, 2014	-	-	-	-	-	-	-	-	-
Depreciation									
At April 1, 2013									-
Charge for the period									-
Disposals									-
Transfer to assets held for sale									-
Other adjustments									-
- Exchange differences									-
At December 31, 2013	-	-	-	-	-	-	-	-	-
Charge for the period									-
Disposals									-
Other adjustments									-
- Exchange differences									-
At March 31, 2014	-	-	-	-	-	-	-	-	-
Charge for the period									-
Disposals									-
Additions on acquisition									-
Other adjustments									-
- Exchange differences									-
At December 31, 2014	-	-	-	-	-	-	-	-	-
Net Book									
At December 31, 2013	-	-	-	-	-	-	-	-	-
At March 31, 2014	-	-	-	-	-	-	-	-	-
At December 31, 2014	-	-	-	-	-	-	-	-	-

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: RST 7.5 2015

Actavis Management GmbH, Germany

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 11 : Intangible assets

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At April 1, 2013				-
Additions during the nine months				-
Internal development during the nine months				-
Disposals during the nine months				-
Other adjustments				-
- Exchange differences				-
At December 31, 2013				-
Additions during the three months				-
Internal development during the three months				-
Disposals during the three months				-
Other adjustments				-
- Exchange differences				-
At March 31, 2014				-
Additions during the nine months				-
Disposals during the nine months				-
Additions on acquisition				-
Other adjustments				-
- Exchange differences				-
At December 31, 2014				-
Amortization				
At April 1, 2013				-
Charge for the period				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At December 31, 2013				-
Charge for the period				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At March 31, 2014				-
Charge for the period				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At December 31, 2014				-
Net Block				
At December 31, 2013				-
At March 31, 2014				-
At December 31, 2014				-

PricewaterhouseCoopers AG, München
 Initialed for Identification Purposes Only
 Initial: RST 7.5.2015

Note 12: Non-current investments (in thousands of Euros)

	Mar 31, 2015	Mar 31, 2014
Unquoted equity instruments		
Investment in subsidiaries		
Investment in joint ventures		
Investment in associates		

Note 13: Loans and advances (in thousands of Euros)

		Non-current		Current	
		Mar 31, 2015	Mar 31, 2014	Mar 31, 2015	Mar 31, 2014
Capital advances					
Secured, considered good					
Unsecured, considered good					
	(A)				
Security deposit					
Secured, considered good					
Unsecured, considered good					
Doubtful					
Provision for doubtful security deposit					
	(B)				
Loan and advances to related parties					
Unsecured, considered good					
	(C)				
Advances recoverable in cash or kind					
Secured, considered good					
Unsecured, considered good					
Doubtful					
Provision for doubtful advances					
	(D)				
Other loans and advances					
Advance income-tax (net of provision for taxation)					
Prepaid expenses					
Loans to employees					
Loans to others					
Export incentives receivable					
Export incentives licenses					
Balances with Statutory/government authorities					
	(E)				
Total (A+B+C+D+E)					
Loans and advances due by directors or other officers, etc.					
		Non-current		Current	
		Mar 31, 2015	Mar 31, 2014	Mar 31, 2015	Mar 31, 2014
Loans to employees include					
Dues from non-executive directors					
Dues from officers					
Dues from non-executive and officers jointly with other persons					
Loans and advances to related parties include					
Dues from the partnership firm in which the company's executive director is a partner					
Dues from in which the company's managing director is a member					
Dues from the partnership firm in which the company's non-executive director is a partner					

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDT 8.5.2015

Note 14: Trade receivables and other assets

14.1 Trade receivable *(Refer to General Instructions Note No. 14.1.1)*

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful				
Provision for doubtful receivables	-	-	-	-
(A)				
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies			984	-
Due from others				
Doubtful				
Provision for doubtful receivables	-	-	984	-
(B)				
Total (A+B)	-	-	984	-

Trade receivables include:

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				
14.2 Other assets <i>(Refer to General Instructions Note No. 14.2)</i>				
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)				
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)				
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on investments in subsidiaries - long term				
Others				
(C)				
Total (A+B+C)	-	-	-	-

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDL 85 24.5

Note 15: Current investments (cf. Accounting Instructions No. 3, 14, 15)

	Mar 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any: (Please specify)		

Note 16: Inventories (valued at lower of cost and net realizable value) (cf. Accounting Instructions No. 14, 15)

	Mar 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)		
Work - in - Progress		
Finished goods		
Traded goods (including stock-in-transit XXX (31 March, 2014 XXX)		
Stores, spares, consumables and packing materials		
Loose tools		

Note 17: Cash and bank balances (cf. Accounting Instructions No. 14, 15, 16)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			67.146	66.626
Deposits with original maturity of less than 3 months				
Cash credit accounts				
On unpaid dividend account				
Cheques/drafts on hand				
Unpaid matured deposits				
Cash on hand			67.146	66.626
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
Amount disclosed under non-current assets			67.146	66.626

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 8.5.2015

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: PWC

Actavis Management GmbH, Germany
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	12 months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Note 21 : (Increase)/decrease in inventories		
Inventories at the end of the period		
Traded goods	-	-
Work-in-progress		
Finished goods		
	-	-
Inventories at the beginning of the period		
Traded goods		
Work-in-progress		
Finished goods		
	-	-
	-	-
Purchase of traded goods		
Purchase of Stores, spares, consumables and packing materials		
	-	-
Note 22 : Employee benefit expense		
Salaries, wages and bonus		
Contribution to provident and other fund		
Employee stock option scheme		
Gratuity expense		
Other employee benefits		
Post employment medical benefits		
Staff welfare expenses		
	-	-

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDi 85 2015

	12 months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Note 23 : Other expenses		
Consumption of stores and spares		
Conversion charges		
Chemicals consumed		
Increase in VAT on finished goods		
Customer service expenditure		
Power and fuel		
Water charges		
Freight and forwarding charges		
Carriage inward		
Carriage outwards		
Rent		
Rates and taxes		
Insurance		
Repairs and maintenance		
i) Plant and machinery		
ii) Buildings		
iii) Others		
Advertising and sales promotion		
Brokerage and discounts		
Remuneration to Auditors	1.475	2.799
Sales commission		
Travelling and conveyance		
Communication costs		
Printing and stationery		
Legal and professional fees		
Directors sitting fees		
Payment to auditor (Refer details below)		
Provision for diminution in value of investment in subsidiary company		
Provision for other than temporary decline in the carrying amount of other long-term investments		
Adjustment to the carrying amount of current investments		
Provision for warranties (net of reversals)		
Provision for litigations (net of reversals)		
Exchange differences (net)		
Loss on derivative contracts (including provisions mark-to-market loss)		
Bad debts/advances written off		
Impairment loss on fixed assets		
Provision for doubtful debts and advances		
Loss on sale of fixed assets (net)		
Premium on forward exchange contract amortized		
Factory maintenance		
Effluent treatment expenses		
Vehicle maintenance expenses		
Analytical charges		
Product development expenses		
Registration and filing charges		
Safety and security		
Office expenses		
Repairs and maintenance - others		

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: *W.D. D. S. H.*

Actavis Management GmbH, Germany

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

	12 months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Management fees		
Liquidated damages		
Donations		
Software license and implementation expenses		
Capital work-in-progress written off		
Miscellaneous expenses	214	760
	1.689	3.559

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 8 5 2015

Actavis Management GmbH, Germany

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

	12 months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Remuneration to Auditor		
As auditor:		
Audit fee		
Tax audit fee		
Limited review		
In other capacity:		
Taxation matters	1.475	2.013
Company law matters		433
Management services		
Other services (certification fees)		353
Reimbursement of expenses		
	<u>1.475</u>	<u>2.799</u>
Note 24 : Exceptional items		
Others (Specify if any)		
	<u>-</u>	<u>-</u>
Note 25 : Depreciation and amortization expense		
Depreciation of tangible assets		
Amortization of intangible assets		
Depreciation of investment property		
	<u>-</u>	<u>-</u>
Note 26 : Finance costs (Refer General Instructions Note No.27)		
Interest		
Bank charges	1.200	1.200
Amortization of ancillary borrowing costs		
Exchange difference to the extent considered as an adjustment to borrowing costs		
	<u>1.200</u>	<u>1.200</u>

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: PDI 3.3.2015

Actavis Management GmbH, Munich
Notes to accounts for the Year ended 31st March, 2015

I. General Information

The annual financial statements for the financial year from April 1, 2015 to March 31, 2015, have been prepared in accordance with the accounting provisions of German Commercial Code. In addition, the provisions of the Companies Act have been complied with.

For the income statement, the total cost method was chosen. The accounting policies are unchanged from the previous year.

II. Notes to Financial Statements

Receivables from affiliated companies relate to receivables from supplies and services amounting to TEUR 1 against Actavis Deutschland GmbH & Co. KG, Munich and have a remaining maturity of less than one year.

Cash and cash equivalents are stated at nominal amounts and have a remaining maturity of less than one year.

The provisions cover all identifiable risks at an appropriate level.

III. Notes to the Income Statement

Other operating income consists, inter alia, the liability compensation in the amount of TEUR 2 and the expense allowance in the amount of TEUR 3 on the part of Actavis Germany GmbH & Co. KG. The item "Other operating expenses" are included primarily expenses for legal and tax advice.

IV. Other Notes and Information

The Actavis Management GmbH, Munich, is the fully liable partner of Actavis Germany GmbH & Co. KG, Munich.

Employee

The Company has no employees.

Managing

Directors of the Company are:

Mr. Kalman Petro

Dr. Martin Schwarz

1980 Pura Pharma GmbH
Willy-Brandt-Allee 2
81629 München
Postfach 82 01 65, 81801 München

! (089) 558909-0
! (089) 558909-240

Amtsgericht München, HRB 160036
Geschäftsführer: Kalman Petro
Martin Schwarz

DnB Bank ASA
Konto-Nr. 503 520 07
Bankleitzahl: 202 201 00
IBAN: DE62262201000050352007
BIC/SWIFT: DNBAD333

The Board did not receive remuneration in the 2014-15 financial year.

Contingent liabilities / Other financial commitments

At the balance sheet date, no contingent liabilities or other financial obligations exists.

Scope of Consolidation

The company was until 31.03.2014 a subsidiary of Actavis Inc.; (NYSE: ACT)

As of April 1, 2014, Aurobindo Pharma Ltd., India, acquired the Actavis companies in several West European countries. This applies also to Actavis Management GmbH, which is now wholly owned by the ultimate parent Aurobindo Pharma Ltd., India. The latter is listed on BSE & NSE in India.

Appropriation

The management proposes, to carry forward the net profit of EUR 2,932 for the year to the new account.

**For 1980 Puren Pharma GmbH
(former Actavis Management GmbH)**



**Dr. Martin Schwarz
Director**

Actavis Deutschland GmbH & Co. KG, Munich
Management Report for Financial Year ended 31st March 2015

1. Background and General Setting

Actavis Deutschland GmbH und Co. KG (briefly: Actavis Deutschland) is a provider of generic drugs, originators, OTC products, medical devices, and dietary supplements. Focus is on the prescription drugs segment.

Basically, the German generic pharmaceuticals market belongs to the most difficult markets on the globe because, on the one hand, gross prices are consistently (mostly at annual intervals) subject to downward adjustments by reference price cuts and, on the other hand, the bidding system known from the Nordic countries has come. These two regulatory mechanisms are turning an increasing gross market into a shrinking net market.

Actavis Deutschland has for years been affected by these measures which reduce the cost of the German healthcare system. Also in 2015, the generic products market for the wholesale and pharmacy distribution channels was largely characterized by discount agreements within the meaning of Sections 129 and 130 SGB [Social Security Code]. These agreements cause a redistribution of existing market shares. Typically, volume growth is accompanied by a strong decline in product margins.

As regards newly launched products, the period of generic competition continued to decrease; after six to nine months, these products, too, come within the ambit of invitations for bids. In addition, "Open House" discount agreements secure cost savings for the health insurance funds during such product launch period.

The German pharmaceuticals market (retail)

The total German pharmaceuticals market - measured at manufacturer's prices - amounted to about EUR22.7 billion in 2014, which corresponds to a 7% rise as compared with 2013 (EUR21.3 billion). This growth is mainly driven by an increase in sales (+13%) with on-patent drugs from EUR8.3 billion (2013) to EUR9.4 billion (2014) against the background of new preparations and rising prices. In the period from January to March 2015, too, pharmaceuticals sales rose by approx. 5%.

The German generic drugs market (retail)

The pure generic drugs market - measured at manufacturer's prices - amounted to EUR4.9 billion in 2014 (2013: EUR4.8 billion), corresponding to a 2% increase. In the period from January to March 2015, growth in the total generic drugs market is 2.8%. However, according to assessments by IGES, statutory health insurance (SHI) funds received discounts of EUR 3.15 billion for generic drugs. Compared with the year of 2013, the discounts granted to the SHI funds increased by a further 0.25 billion or 9%. Reduced by the discounts under Section 130a (8) SGB V, there is consequently a pure net generic drugs market of EUR1.75 billion compared with EUR1.92 billion in 2013. The burden due to discounts granted to social health insurance funds decreased slightly in the period from January to March 2015. Looking at the generic drugs market as the sum of the "pure" generic drugs market and the offpatent originator products without competition by generic products, one arrives at a gross market of EUR7.6 billion. In order to get a net value, the discounts under Section 130a (8) SGB V and the discounts under Section 130a (1) SGB V have to be deducted. Since the discounts are not available in a fully transparent way, we assume a net market of about EUR4.45 billion.

Discount agreements (under Section 130a (8) SGB V)

Since 2013, some fundamental changes have been observed in respect of discount agreements: Health insurance funds are increasingly inviting for bids in respect of the agreements semi exclusively, i.e. typically, 3 competitors are awarded a contract. This strengthens the reliability of supply for the health insurance funds, but makes volume planning more difficult for medium and small vendors. This practice helps primarily established major players who pocket the largest portion of the proposed quantities in the semi-exclusive invitations for bids. Most of the health insurance funds now enter into so-called "Open House" agreements with all interested pharmaceutical companies immediately after expiration of patent for an active substance. The cornerstones of these agreements are specified by the health insurance funds. The EuHG currently checks whether the "Open House" agreements are in compliance with legal regulations for awarding contracts. A decision is expected at the end of 2015/beginning of 2016.

Reference price changes

As in the past years, reference prices were adjusted also in 2014 and 2015. There were several negotiating sessions with regard to individual active substance groups.

Group affiliation

Until March 31, 2014, Actavis Deutschland was incorporated in the Actavis Inc. Group. As of April 1, 2014, the Aurobindo Group acquired the Actavis companies in several West European countries. This applies also to Actavis Deutschland GmbH & Co. KG, which is now wholly owned by Aurobindo

Pharma Ltd., India, through its direct parent, Agile Pharma B.V., Amsterdam, The Netherlands. This company is listed on the Indian stock exchanges.

As of April 1, 2015, Actavis Deutschland GmbH & Co. KG aligned its financial year with that of the Aurobindo Group. In future, the Company's financial year will run from April 1 of any year until March 31 of the following year.

2. Economic Report (Business Performance, Net Assets, Financial Position and Results of Operations)

At first, it has to be noted that the Company's business performance developed favorably:

1. Compared with 2013, the Company's share of the retail market improved from 4.2% to 4.8% in 2014. As of March 31, 2015, the Company's market share rules at 4.3% and is thus slightly on the decrease.

2. Sales continued to develop favorably also in the year, showing an improvement compared to the budget. In absolute figures, net sales increased from EUR85.6 million to EUR86.8 million.

Major financial performance indicators/control variables

Major financial performance indicators are sales and income from ordinary activities. As regards their development and analysis, reference is made to the "Results of Operations" section".

a. Sales

The central control variable for Actavis is net sales. Special attention is in this respect turned on reductions of sales (primarily discounts under Section 130a (8) SGB V). In view of the extreme discounts in the bidding business, gross sales are only an auxiliary parameter.

b. Income from ordinary activities

The income from ordinary activities is the third central control variable. Its main drivers are the gross margin and selling and general administrative expenses.

Major non-financial performance indicators/control variables

Market share: Market share is a key control variable for Actavis Deutschland. Evaluation is mainly on INN or molecular basis.

Since the end of 2013, the Company's market share has stabilized at above 4%, reaching 4.8% at the end of 2014. As of March 31, 2015, it is 4.3%, with Pantoprazol being the main driver as had been the case in the preceding years. For 2015, a market share of 4.4% has been budgeted.

Results of operations

Profit for the year was EUR4.17 million as against EUR 10.59 million in FY-15. However, the result for the previous year had been adversely affected by a provision for contractual penalties/damages in the amount of EUR5.2 million.

Net assets

The balance sheet total increased from EUR104.1 million in the preceding year to EUR108.0 million.

Financial position

As of March 31, 2015, the Company's reported equity is EUR14.9 million. A loan for EUR53.5 million has been extended to Agile Pharma B.V. by the Company. According to the loan agreement, the loan has to be repaid by August 2016.

3. Forecast

The following statements refer to the future and are thus uncertain by their nature. Actual events may materially differ from expectations. The Company's future profitability (especially medium- and long-term) will depend in particular from the developments in the German health care system and the resulting effects on the pharmaceutical industry. However, from a present-day perspective, such effects are difficult to assess.

The shown market concentration trend of the last years, driven by discount models for generic products, will continue. Due to the Company's acquisition by the Aurobindo Group, Actavis Deutschland GmbH & Co. KG can in future additionally fall back on the cost-effective manufacturing units of the Group and will thus be able to further reduce its cost of production. However, the changeover will take some time, and so no major impacts from this are to be expected for 2015-16.

Compared with 2014-15, net sales will go back by 10% to 20% in financial year 2015/2016. The reason for this is a decline in the bid-based business due to higher cost of materials. However, as regards the gross margin, we expect only a slight decrease owing to a systematic improvement of the product mix.

On the basis of the aforesaid planning assumptions, we anticipate a profitable result from ordinary activities in financial year 2015/2016. In aggregate, we expect a slight decrease in result. We anticipate a market share of 4.4% in 2015-16.

4. Opportunities and Risks

The following opportunities and risks are classified below in descending order according to probability of occurrence.

a) Opportunities

☐ **Market opportunities**

The Company's future development will in essence be subject to the development of the German pharmaceuticals and generic drugs market. We are currently not expecting any wide ranging changes for 2015-16.

☐ **Product and market authorization opportunities**

New opportunities will open up in the generic drugs market due to patent expiration and the launch of new products. In 2015/2016, only a few products will drop out of patent protection. In the field of invitations for bids by health insurance funds, future opportunities will arise in the new bidding sessions due to cost-optimized manufacturing processes implemented by Actavis and the Aurobindo Group respectively. However, as regards financial year 2015/2016, we expect a drop in sales as a result of reduced discount agreements with the health insurance funds. Nevertheless, the gross margin will be on a level similar to that of 2014-15.

The relocation of the manufacture of some key products to company-owned production sites in India may well create opportunities through lower cost of production.

b) Risks

Our local risk management as part of the Group's risk management makes sure that risks are recognized early enough to enable us to respond adequately to such risks. Particularly the following risks have been identified:

☐ **Market risks**

Changes with regard to health policy, such as reference price reductions, new compulsory discounts and price moratoria, are politically intended. We inform ourselves promptly of such developments by membership in appropriate associations.


☐ **Product and market authorization risks**

Mostly, the risks for all manufacturers of a certain generic product are comparable. Therefore, we do not see any special risk. In addition, our local units are supported by their integration into global structures.


☐ **Quality risks**

The risk of quality problems exists for all pharmaceutical companies. Global functions provide additional support to our local quality department in order to minimize such risks. Furthermore, we identified legal risks (e.g. the risk of patent violations) inherent in the generic business model, which risks are in our view currently of minor importance, as well as supply chain risks (mainly risks due to problems with suppliers). Although we cannot exclude IT, tax and employee risks, we are currently not aware of any specific critical situation. No risks endangering the Company's continued existence as a going concern are known and we have not become aware of any new major risks as compared with the preceding year.

For Actavis Deutschland GmbH & Co. KG
The Management of Actavis Management GmbH



Dr. Martin Schwarz



PricewaterhouseCoopers Aktiengesellschaft Wirtschaftsprüfungsgesellschaft
Bernhard-Wicki-Straße 8 80636 München

S.R. Batliboi & Associates LLP
Oval Office 18
1 Labs Center
HITEC City
Madhapur
Hyderabad 500 081
India

PricewaterhouseCoopers
Aktiengesellschaft
Wirtschaftsprüfungsgesellschaft

Bernhard-Wicki-Straße 8
80636 München
Postfach 21 02 63
80672 München
www.pwc.de

Tel.: +49 89 5790-50
Fax: 5999

21 May 2015

Auditor's Report - Actavis Deutschland GmbH & Co. KG, Munich

As requested in your instructions dated April 4, 2015, we have audited for purposes of your audit of the consolidated financial statements of Aurobindo Pharma Limited, India, the accompanying balance sheet as of March 31, 2015, and the income statement for the 12 months ended March 31, 2015 of Actavis Deutschland GmbH & Co. KG, Munich (the "financial information").

Management's Responsibility

The Management of Actavis Deutschland GmbH & Co. KG, Munich, is responsible for the preparation of the financial information in accordance with German Commercial Law ("Handelsgesetzbuch": "German Commercial Law"). Management is also responsible for such internal control as management determines is necessary to enable the preparation of the financial information that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial information based on our audit. We conducted our audit of the financial information in accordance with German generally accepted standards for the audit of financial statements promulgated by the Institut der Wirtschaftsprüfer ("IDW") (Institute of Public Auditors in Germany). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial information is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and related disclosures in the financial information. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial information, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the financial information in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial information.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Vorsitzender des Aufsichtsrats: WP StB Dr. Norbert Vogelthoß
Vorstand: WP StB Prof. Dr. Norbert Winkeljohann, WP StB Dr. Peter Bartels, WP StB CPA Markus Burghardt, StB Prof. Dr. Dieter Endres, WP StB Petra Justenhoven,
WP StB Prof. Dr. Georg Kampfer, WP StB Harald Kayser, WP RA StB Dr. Jan Konerding, StB Marius Möller, WP StB Martin Scholich
Sitz der Gesellschaft: Frankfurt am Main, Amtsgericht Frankfurt am Main HRB 44845
PricewaterhouseCoopers Aktiengesellschaft Wirtschaftsprüfungsgesellschaft is a member of PricewaterhouseCoopers International, a Company limited by guarantee registered in England and Wales

Audit Opinion

In our opinion based on the findings of our audit, the financial information has been prepared, in all material respects, in accordance with German Commercial Law ("Handelsgesetzbuch": "German Commercial Code").

Restriction on purpose, use and distribution

The financial information has been prepared solely for purposes of providing information to Aurobindo Pharma Limited, India, to enable it to prepare the consolidated financial statements of the group. As a result, the financial information is not a complete set of financial statements of Actavis Deutschland GmbH & Co. KG, Munich, in accordance with the requirements of German Commercial Law and may, therefore, not be suitable for another purpose.


This report is intended solely for S.R. Batliboi & Associates LLP, Hyderabad, India, and shall not be used by or distributed to other parties. This report is confidential and shall not be published or referred to in a public document or any other public media.

Terms of Engagement

We issue this report on the basis of the engagement agreed with Actavis Deutschland GmbH & Co. KG, Munich, which comprises the attached General Terms of Engagement for Wirtschaftsprüfer and Wirtschaftsprüfungsgesellschaften as of January 1, 2002, which are also applicable to third parties.

This report shall be exclusively governed by and construed in accordance with German law without giving effect to the provisions relating to private international law (Internationales Privatrecht). Exclusive place of jurisdiction for any action or other legal proceedings arising out of or in connection with this report shall be Frankfurt am Main, Germany.

**PricewaterhouseCoopers
Aktiengesellschaft
Wirtschaftsprüfungsgesellschaft**

A handwritten signature in black ink, appearing to read 'Stefan Mulas'.

Stefan Mulas
Wirtschaftsprüfer
(German Public Auditor)

A handwritten signature in black ink, appearing to read 'Dietmar Eglauer'.

Dietmar Eglauer
Wirtschaftsprüfer
(German Public Auditor)

Actavis Deutschland GmbH & Co KG

Balance Sheet as at March 31, 2015

(All amounts are in € except share data and unless otherwise stated)

	Note	Mar 31, 2015 (EUR)	31 March, 2014 (EUR)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	25.565	25.565
Share application money			
Reserves and surplus	3	14.884.755	10.714.475
		14.910.320	10.740.040
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	-	45.407
Trade payables	6	-	-
Other long-term liabilities	6	2.176.687	1.901.385
Long-term provisions	7	-	-
		2.176.687	1.946.792
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	15.422.368	3.692.847
Other current liabilities	9	72.717.925	86.332.675
Short-term provisions	7	2.829.525	1.391.410
		90.969.818	91.416.932
TOTAL		108.056.825	104.103.764
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	112.615	142.022
Intangible assets	11	1.123.710	2.227.338
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5		
Long-term loans and advances	13	53.500.000	35.988.801
Trade receivables	14,1	-	-
Other non-current assets	14,2	-	-
		54.736.325	38.358.161
Current assets			
Current investments	15	-	-
Inventories	16	20.430.509	19.497.769
Trade receivables	14,1	13.389.276	12.790.130
Cash and bank balances	17	18.878.428	33.198.640
Short-term loans and advances	13	-	-
Other current assets	14,2	622.287	259.064
		53.320.500	65.745.603
TOTAL		108.056.825	104.103.764

Summary of significant accounting policies

The accompanying notes are an integral part of the financial statements.

1
PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
initial. MDI 18.05.2015

Actavis Deutschland GmbH & Co KG
Statement of profit and loss for year Ended March 31, 2015

(All amounts are in € except share data and unless otherwise stated)

	Note	12 Months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Income			
Revenue from operations (gross)	18	239.648.783	256.489.085
Less: Excise duty/Rebates		152.824.774	170.869.497
Revenue from operations (net)		86.824.009	85.619.588
Other income	19	1.016.224	318.839
Total revenue (I)		87.840.233	85.938.427
Expenses			
Cost of raw material and components consumed	20	(98.176)	920.345
Purchase of trading goods	21	56.709.153	39.500.755
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	(834.564)	4.027.249
Employee benefit expense	22	6.567.836	7.525.113
Other expenses	23	19.041.170	12.749.558
Exceptional items	24	-	31.380
Total (II)		81.385.419	64.754.400
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		6.454.814	21.184.027
Depreciation and amortization expense	25	1.176.707	8.809.095
Finance costs	26	367.265	220.000
Profit/(loss) before tax		4.910.842	12.154.932
Tax expenses			
Corporate Income Tax for the Current Period		615.358	255.806
Deferred tax		(45.407)	1.307.151
Corporate Income Tax relating to previous years [shortfall/(refunds) only]		170.611	
Total tax expense		740.562	1.562.957
Profit/(loss) for the year		4.170.280	10.591.975
Profit/(loss) for the year incl. Local GAAP adjustment		4.170.280	
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.

Local GAAP Adjustment. Closing Stock is valued at the lowest of the Purchase price as per German G **1.135.601**
 Euro 1135601 is the variance in Closing Stock valuation between German GAAP and Weighted Average Method of Inventory Valuation

Profit excluding Local GAAP Inventory adjustment for year-end revaluation **5.305.881,00**

PricewaterhouseCoopers AG, München
 Initialed for Identification Purposes Only
 Initial: MDI 18.05.2015

Note 1 : Summary of significant accounting policies :

- 1.1
- 1.2
- 1.3
- 1.4
- 1.5

Note 2 : Share capital :

	Mar 31, 2015	March 31, 2014
Authorized shares:		
XXXXXXXXXX (31 March, 2014: XXXXXXXXX) equity shares of XXXX each		
XXXXXXXXXX (31 March, 2014: XXXXXXXXX) preference shares of XXX each		
Issued, Subscribed and Fully Paid-up shares:		
XXXXXXXXXX (31 March, 2014: XXXXXXXXX) equity shares of XXXX each fully paid-up	25.565	25.565

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 13.05.2015

Note 3 : Reserves and surplus (

	Mar 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	156.471.524	156.471.524
	156.471.524	156.471.524
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet		
	-	-
General Reserve		
As per last Balance Sheet	(145.757.049)	(156.349.024)
Add: Transferred from statement of profit and loss	(145.757.049)	(156.349.024)
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements		
Profit for the quarter	4.170.280	10.591.975
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)		
Tax on proposed equity dividend		
Interim dividend paid (amount per share XX (31 March, 2014 XX)		
Transfer to general reserve		
Total appropriations	-	-
Net surplus in the statement of profit and loss	4.170.280	10.591.975
Total reserves and surplus	14.884.755	10.714.475

Note 4 : Long-term borrowings (Note 10 : Current liabilities, Note 11 : Off-balance sheet)

	Non-current Portion		Current maturities	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)				
Other Loans from banks				
Current account credit balance				
Loans and advances from related parties				
Other Loans and advances				
Sales tax deferment loan (Un Secured)				
The above amount includes				
Secured borrowings				
Unsecured borrowings				
Amount disclosed under the head				
Other current liabilities				
Net Amount				

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 18.05.2015

Note 5: Deferred tax liability (net)

	Mar 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis		
Provision for diminution in the value of investments		
Provision for doubtful debts and advances		
Fixed Assets (Depreciation)		
Retirement Benefits		
Others	-	231.434
Gross deferred tax liability	-	231.434
Deferred tax asset		
Carried Forward Business Losses		
Others	-	186.027
Gross deferred tax asset	-	186.027
Net deferred tax liability	-	45.407

Note 6: Other long-term liabilities (including provisions)

	Mar 31, 2015	March 31, 2014
Trade payables (including acceptances)		
Others		
Advances from customers		
Unclaimed dividends		
Other liabilities	2.176.687	1.901.385
Interest accrued but not due on loans		
Advances from related parties		
	2.176.687	1.901.385
	2.176.687	1.901.385

Note 7: Provisions (including provisions)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Provision for employee benefits				
employee salary provisions			713.506	487.923
Provision for Bonus			777.596	372.300
	-	-	1.491.102	860.223
Other Provisions				
For Taxation (net of advance payments)			1.338.423	531.187
For Proposed dividend				
For Tax on proposed dividend				
	-	-	1.338.423	531.187
	-	-	2.829.525	1.391.410

Provision for warranties

	Mar 31, 2015	March 31, 2014
At the beginning of the year		
Arising during the period		
Utilised during the period		
Unused amounts reversed		
At the end of the Quarter	-	-
Current portion		
Non-current portion		

Note 8: Short-term borrowings (including provisions)

	Mar 31, 2015	March 31, 2014
Bank overdraft		
Loans and advances from related parties		
Working capital loans (Secured)		
Short term loans (Un Secured)		
Working capital loans		
	-	-
The above amount includes		
Secured borrowings		
Unsecured borrowings		

Note 9: Other current liabilities (including provisions)

	Mar 31, 2015	March 31, 2014
Trade payables (including acceptances)	15.422.368	3.692.847
Finished Goods Intercompany invoice not received	(76.722)	-
Other Current liabilities- (Rabates & Discounts and other Sales deductions)	72.794.647	86.332.675
Current maturities of long-term borrowings		
Trade deposits		
	72.717.925	86.332.675
	88.063.571	90.025.522

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only

initial: MDI 19.05.2015

Actavis Deutschland GmbH & Co KG
Notes to the statement of profit and loss
(All amounts are in € except share data and unless otherwise stated)

Note 10: Tangible assets

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation									
At April 1, 2013					1.809.550,8				1.809.550,8
Additions during the nine months					63.525,4				63.525,4
Disposals during the nine months									
Transfer to assets held for sale									
Other adjustments									
- Exchange differences									
At December 31, 2013	-	-	-	-	1.873.076,1	-	-	-	1.873.076,1
Additions during the three months									
Disposals during the three months									
Other adjustments									
- Exchange differences									
At March 31, 2014	-	-	-	-	1.873.076,1	-	-	-	1.873.076,1
Additions during the nine months					34.522,8				34.522,8
Disposals during the nine months					309.584,1				309.584,1
Additions on acquisition									
Other adjustments									
- Exchange differences									
At December 31, 2014	-	-	-	-	1.598.014,9	-	-	-	1.598.014,9
Depreciation									
At April 1, 2013					1.668.588,8				1.668.588,8
Charge for the period					50.838,4				50.838,4
Disposals									
Transfer to assets held for sale									
Other adjustments									
- Exchange differences									
At December 31, 2013	-	-	-	-	1.719.427,1	-	-	-	1.719.427,1
Charge for the period					11.627,0				11.627,0
Disposals									
Other adjustments									
- Exchange differences									
At March 31, 2014	-	-	-	-	1.731.054,1	-	-	-	1.731.054,1
Charge for the period					63.630,8				63.630,8
Disposals					309.285,1				309.285,1
Additions on acquisition									
Other adjustments									
- Exchange differences									
At March 31, 2015	-	-	-	-	1.485.399,9	-	-	-	1.485.399,9
Net Block									
At December 31, 2013	-	-	-	-	153.649,0	-	-	-	153.649,0
At March 31, 2014	-	-	-	-	142.022,0	-	-	-	142.022,0
At March 31, 2015	-	-	-	-	112.615,0	-	-	-	112.615,0

PricewaterhouseCoopers AG, München
at aled for Identification Purposes Only
MDI 18.05.2015

Note 11 : Intangible assets

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At 1.1.2013	15.166.259,8	-	161.110.833,9	176.277.093,7
Increases during the nine months	-	-	55.253,1	55.253,1
Decreases during the nine months	-	-	-	-
Other adjustments	-	-	-	-
At December 31, 2013	15.166.259,8	-	161.166.087,0	176.332.346,8
Additions during the three months	-	-	-	-
Internal development during the three months	-	-	-	-
Disposals during the three months	-	-	16.585.704,0	16.585.704,0
Other adjustments	-	-	-	-
At March 31, 2014	15.166.259,8	-	144.580.383,0	159.746.642,8
Additions during the nine months	-	-	8.591,2	8.591,2
Disposals during the nine months	-	-	-	-
Additions on acquisition	-	-	-	-
Other adjustments	-	-	-	-
At December 31, 2014	15.166.259,8	-	144.588.974,2	159.755.234,0
Amortization				
At 1.1.2013	13.396.863,8	-	145.115.634,9	158.512.498,7
Charge for the period	758.312,0	-	186.140,1	944.452,1
Disposals	-	-	(- 046.522,0)	(- 046.522,0)
Other adjustments	-	-	-	-
At December 31, 2013	14.155.176,8	-	152.348.297,0	166.503.473,8
Charge for the period	252.771,0	-	502.854,0	755.625,0
Disposals	-	-	9.739.794,0	9.739.794,0
Other adjustments	-	-	-	-
At March 31, 2014	14.407.947,8	-	143.111.357,0	157.519.304,8
Charge for the period	758.312,0	-	354.764,2	1.113.076,2
Disposals	-	-	857,0	857,0
Other adjustments	-	-	-	-
At March 31, 2015	15.166.259,8	-	143.465.264,2	158.631.524,0
Net Block				
At December 31, 2013	1.011.083,0	-	8.817.790,0	9.828.873,0
At March 31, 2014	758.312,0	-	1.469.026,0	2.227.338,0
At March 31, 2015	-	-	1.123.710,0	1.123.710,0

PricewaterhouseCoopers AG, München
 Initialed for Identification Purposes Only
 initial: MDI 18.05.2015

Note 12 : Non-current investments

	Mar 31, 2015	March 31, 2014
Unquoted equity instruments		
Investment in subsidiaries		
Investment in joint ventures		
Investment in associates		
	-	-

Note 13 : Loans and advances

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Capital advances				
Secured, considered good				
Unsecured, considered good				
(A)	-	-	-	-
Security deposit				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful security deposit				
(B)	-	-	-	-
Loan and advances to related parties				
Unsecured, considered good	53.500.000	35.988.801		
(C)	53.500.000	35.988.801	-	-
Advances recoverable in cash or kind				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful advances				
(D)	-	-	-	-
Other loans and advances				
Advance income-tax (net of provision for taxation)				
Prepaid expenses				
Loans to employees				
Loans to others				
Export incentives receivable				
Export incentives licenses				
Balances with Statutory / government authorities				
(E)	-	-	-	-
Total (A+B+C+D+E)	53.500.000	35.988.801	-	-

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors				
Dues from officers				
Dues from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner				
Dues from in which the company's managing director is a member				
Dues from the partnership firm in which the company's non-executive director is a partner				

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 18.05.2015

Note 14 : Trade receivables and other assets

14.1 Trade receivable

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others			13 267 585	6 717 792
Unsecured, considered good				
Due from group companies			-	316 554
Due from others			-	5 267 082
Doubtful			730 332	451 687
	-	-	13 997 917	12 753 115
Provision for doubtful receivables	-	-	730 332	451 687
(A)	-	-	13 267 585	12 301 428
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies			475	1 100
Due from others			121 216	487 602
Doubtful				
	-	-	121 691	488 702
Provision for doubtful receivables	-	-	-	-
(B)	-	-	121 691	488 702
Total (A+B)	-	-	13 389 276	12 790 130

Trade receivables include:

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons			18 423	20 503
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				

14.2 Other assets

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)	-	-	-	-
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)	-	-	-	-
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on investments in subsidiaries - long term				
Interests accrued on loans given to group companies			421 397	
Others			200 890	259 064
(C)	-	-	622 287	259 064
Total (A+B+C)	-	-	622 287	259 064

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
initial MDI 18.05.2015

Note 15: Current investments

	Mar 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any (Please specify)		

Note 16: Inventories (valued at lower of cost and net realizable value) (in million of Euro)

	Mar 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)	420.459	322.283
Work-in-Progress		
Finished goods	994.706	1.701.987
Finished Goods Intercompany invoice not received	(76.722)	
Traded goods (including stock-in-transit XXXX (31 March, 2014 XXX)	19.092.066	17.473.499
Stores, spares, consumables and packing materials		
Loose tools		
Inventories adjustment due to local GAAP 12/2014		
	20.430.509	19.497.769

Note 17: Cash and bank balances

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			18.878.428	33.198.640
Deposits with original maturity of less than 3 months				
Cash credit accounts				
On unpaid dividend account				
Cheques/drafts on hand				
Unpaid matured deposits				
Cash on hand				
			18.878.428	33.198.640
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
Amount disclosed under non-current assets			18.878.428	33.198.640

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 18.05.2015

	12 months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Note 18 : Revenue from operations (Refer General Instructions Note No.25)		
Revenue from operations		
Sale of products		
Finished goods		
Traded goods	237.287.046	255.098.842
Sale of services		
Sale of dossiers/licenses		
Other operating revenue	2.361.737	672.556
Scrap sales		
Other	-	717.687
Revenue from operations (gross)	239.648.783	256.489.085
Less: Rebates/Discounts	152.824.774	170.869.497
Revenue from operations (net)	86.824.009	85.619.588

Note 19 : Other income (Refer General Instructions Note No.26)

Interest income on		
Bank deposits	30.360	334
Long-term investments		
Current investments		
interest on Loans to entities		
Others	985.864	318.505
Dividend income on		
Investment in subsidiaries		
Current investments		
Long-term investments		
Net gain on sale of current investmentss		
Profit on sale of fixed assets (net)		
Foreign exchange gain (net)		
Balances no longer required written back		
Government grant		
Commission income		
Processing charges		
Other non-operating income (net of expenses directly attributable to such income of Rs.XXXXX (31 March, 2014:XXXX)		
	1.016.224	318.839

Note 20 : Cost of raw material and components consumed

Inventory at the beginning of the period	322.283	1.242.628
Add: Purchases		
	322.283	1.242.628
Less: inventory at the end of the period	420.459	322.283
	(98.176)	920.345

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 18.05.2015

Actavis Deutschland GmbH & Co KG

Notes to the statement of profit and loss

(All amounts are in € except share data and unless otherwise stated)

	12 months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Add: Packing material consumed		
Cost of raw material and components consumed	(98.176)	920.345

PricewaterhouseCoopers AG, München
initialed for Identification Purposes Only
Initial: _____

Actavis Deutschland GmbH & Co KG
Notes to the statement of profit and loss
(All amounts are in € except share data and unless otherwise stated)

	12 months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Note 21 : (Increase)/decrease in inventories		
Inventories at the end of the period		
Traded goods	19.092.066	17.473.499
Work-in-progress	-	-
Finished goods	994.706	1.701.987
Finished Goods Intercompany invoice not received	(76.722)	
	20.010.050	19.175.486
Inventories at the beginning of the period		
Traded goods	17.473.499	21.809.683
Work-in-progress	-	-
Finished goods	1.701.987	1.393.052
	19.175.486	23.202.735
	(834.564)	4.027.249
Purchase of traded goods	56.785.875	39.500.755
Finished Goods Intercompany invoice not received	(76.722)	
Purchase of Stores, spares, consumables and packing materials		
	56.709.153	39.500.755
Note 22 : Employee benefit expense		
Salaries, wages and bonus	6.494.800	7.491.555
Contribution to provident and other fund	73.036	33.558
Employee stock option scheme		
Gratuity expense		
Other employee benefits		
Post employment medical benefits		
Staff welfare expenses		
	6.567.836	7.525.113

PricewaterhouseCoopers AG, München
Initiated for Identification Purposes Only
initial: MDI 18.06.2019

Actavis Deutschland GmbH & Co KG
Notes to the statement of profit and loss
(All amounts are in € except share data and unless otherwise stated)

	12 months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Note 23 : Other expenses		
Consumption of stores and spares		
Conversion charges		
Chemicals consumed		
Increase in VAT on finished goods		
Customer service expenditure		
Power and fuel	14.535	15.395
Water charges		
Freight and forwarding charges	4.211.562	4.550.211
Carriage inward		
Carriage outwards		
Rent	593.060	574.621
Rates and taxes		
Insurance	363.955	339.824
Repairs and maintenance		
i) Plant and machinery		
ii) Buildings	9.388	5.473
iii) Others	18.391	17.340
Advertising and sales promotion	1.481.304	1.845.459
Brokerage and discounts		
Remuneration to Auditors	-	-
Sales commission		
Travelling and conveyance	240.091	269.765
Communication costs		
Printing and stationery	36.605	21.746
Legal and professional fees	2.762.820	2.166.307
Directors sitting fees		
Payment to auditor (Refer details below)	239.498	270.882
Provision for diminution in value of investment in subsidiary company		
Provision for other than temporary decline in the carrying amount of other long-term investments		
Adjustment to the carrying amount of current investments		
Provision for warranties (net of reversals)		
Provision for litigations (net of reversals)		
Exchange differences (net)	-	125
Loss on derivative contracts (including provisions mark-to-market loss)		
Bad debts/advances written off		
Impairment loss on fixed assets		
Provision for doubtful debts and advances	281.379	(46.152)
Loss on sale of fixed assets (net)		
Premium on forward exchange contract amortized		
Factory maintenance		
Effluent treatment expenses		
Vehicle maintenance expenses	350.253	345.654

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
Initial: MDI 18.05.2015

Actavis Deutschland GmbH & Co KG

Notes to the statement of profit and loss

(All amounts are in € except share data and unless otherwise stated)

	12 months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Analytical charges	318.540	271.095
Product development expenses		
Registration and filing charges	222.108	264.019
Safety and security		
Office expenses	157.516	161.399
Repairs and maintenance - others		
Management fees		
Liquidated damages		
Donations	5.250	3.000
Software license and implementation expenses	90.377	213.860
Capital work-in-progress written off		
Penalty for Short Supplies	5.173.500	
Miscellaneous expenses	2.471.038	1.459.535
	<u>19.041.170</u>	<u>12.749.558</u>

PricewaterhouseCoopers AG, München
Initialed for Identification Purposes Only
--- initial: MDI 18.05.2015

Actavis Deutschland GmbH & Co KG

Notes to the statement of profit and loss

(All amounts are in € except share data and unless otherwise stated)

	12 months Period ended Mar 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Remuneration to Auditor		
As auditor:		
Audit fee		
Tax audit fee		
Limited review		
In other capacity:		
Taxation matters		
Company law matters		
Management services		
Other services (certification fees)		
Reimbursement of expenses	-	-
Note 24 : Exceptional items		
Others (Specify if any)		31.380
	-	31.380
Note 25 : Depreciation and amortization expense		
Depreciation of tangible assets	63.631	62.495
Amortization of intangible assets	1.113.076	8.746.600
Depreciation of investment property	1.176.707	8.809.095
Note 26 : Finance costs (Refer General Instructions Note No.27)		
Interest	367.265	220.000
Bank charges		
Amortization of ancillary borrowing costs		
Exchange difference to the extent considered as an adjustment to borrowing costs	367.265	220.000

Handwritten note: MDI 18.05.2015

Actavis Deutschland GmbH & Co. KG, Munich
Notes to accounts for the Year ended 31st March, 2015

I. General Information

The annual financial statements for the financial year from April 1, 2015 to March 31, 2015, have been prepared with due regard to the special provisions for limited partnerships within the meaning of Section 264a HGB in accordance with the accounting and valuation rules for corporations of the German Commercial Code. The provisions for large corporations within the meaning of Section 267 (3) HGB apply.

The cost-categories oriented format has been chosen for the income statement.

Until December 31, 2014, the Company's financial year was the calendar year. As from April 1, 2015, the financial year will begin on April 1 of each year and end on March 31 of the following year.

II. Accounting and Valuation Principles

The following accounting and valuation methods have been applied unchanged as against the preceding year.

Intangible assets and tangible assets are reported at acquisition cost, reduced by regular amortization and depreciation. Purchased intangible assets are carried at acquisition cost and are reported at the lower attributable value pursuant to Section 253 (3) Clause 3 HGB.

Amortization and depreciation is determined pro rata temporis according to the straight-line method on the basis of their useful lives.

Since January 1, 2010, low-value assets the acquisition cost of which does not exceed EUR410.00 have completely been written off and are disclosed as disposal in the fixed asset movement schedule.

Inventories (raw materials, supplies, merchandise) are reported at original cost with due regard to the lower-of-cost-or-market principle. Inventory risks arising from a lengthy duration of storage and reduced marketability are allowed for by appropriate write-downs.

Receivables and other assets have been reported at nominal value. Risks with regard to trade receivables are taken into account by itemized valuation allowances and a general valuation allowance for the general credit risk.

Liquid funds are equivalent to their nominal values. The partners' equity is carried at nominal value.

Other provisions are reported at the settlement amount necessary according to sound business judgment. Liabilities are reported at settlement amount.

Receivables and payables in foreign currency are entered in the books at the exchange rate of the transaction date and measured at the lower or higher exchange rate of the balance sheet date. Receivables and payables in foreign currency falling due within one year have been measured at the mean spot rate of exchange.

Exercising the option according to Section 274 (1) Clause 2 HGB, no deferred tax assets on different tax-based and HGB-based values for tangible assets and provisions have been capitalized.

Actavis Deutschland GmbH & Co. KG
Member of Aurobindo Pharma Ltd.
Willy-Brandt-Allee 2
81829 München
Postfach 82 01 65, 81801 München

t (089) 558909-0
F (089) 556909-240
@ info-de@aurobindo.com
w www.de.aurobindo.com

Amtsgericht München, HRA 96731
Komplementär: 1980 Puren Pharma GmbH
Amtsgericht München, HRB 190038
Geschäftsführer: Dr. Martin Schwarz, Kalman Petro

DnB Bank ASA
Konto-Nr.: 500 990 09
Bankleitzahl: 202 201 00
IBAN: DE74202201000050099009
BIC/SWIFT: DNBDE333
UST-ID: DE 813 035 864

Sales are generally recognized after service provision and delivery with due regard to the time of passage of risk.

III. Notes to the Balance Sheet

Receivables and other assets

Trade receivables are falling due within one year.

Receivables from affiliated companies relate to a loan extended to the partner Agile Pharma B.V., Amsterdam, The Netherlands, in the amount of TEUR53,500 plus interest of TEUR421. According to the loan agreement, the loan has to be repaid by August 31, 2016. The loan agreement stipulates that TEUR31,500 are falling due within one year, whereas the remaining TEUR22,000 have a residual term of more than one year.

Other provisions

The high discount credits are owed to the changes in the Company's business model towards a classical generics player and mostly driven by provisions in favor of health insurance funds (primarily AOK).

Liabilities

All liabilities have a residual term of up to one year. No collateral has been provided.

Employees

On an annual average, 66 (previous year: 65) employees worked for the Company, there of 18 in sales and 48 in administration.

General partner/Management

The general partner of Actavis Deutschland GmbH & Co. KG, Munich, is 1980 Puren Pharma GmbH (former Actavis Management GmbH) domiciled in Munich. The subscribed capital of Actavis Management GmbH as of March 31, 2015, is TEUR25.

The managing directors of 1980 Puren Pharma GmbH are:

Mr. Kalman Petro, NL – 3972 JN Driebergen-Rijsenburg, Commercial Managing Director

Dr. Martin Schwarz, AT – 6341 Ebbs, Commercial Managing Director

In accordance with Section 286 (4) HGB, disclosure of the amount of management remuneration is dispensed with.

Group


The capital interests of the limited partner amount to EUR25,564.59. Until March 31, 2014, Actavis Holding Germany GmbH was the Company's limited partner. Until March 31, 2014, the ultimate parent company was Actavis plc, Ireland.

As of April 1, 2014, Aurobindo Pharma Ltd., India, acquired the Actavis companies in several West European countries. This applies also to Actavis Deutschland GmbH & CO KG, which is now wholly owned by the ultimate parent Aurobindo Pharma Ltd., India. The latter is listed on BSE & NSE in India.


Since April 1, 2014, Agile Pharma BV, The Netherlands, is the Company's direct limited partner. The general partner, Actavis Management GmbH, Munich, does not hold any capital interests.

For Actavis Deutschland GmbH & Co. KG

The Management of 1980 Puren Pharma GmbH (former Actavis Management GmbH)



Dr. Martin Schwarz



AUROVITAS SPAIN, S.A.U.

Independent auditor's report on special purpose
financial information prepared for consolidation purposes

March 31, 2015



AUROVITAS SPAIN S.A.

MANAGEMENT REPORT AS AT 31 MARCH 2015

The Company's Board of Directors has prepared this management report in which it intends to provide a clear view of the evolution of the business and of the Company's equity situation, in reference to the fiscal year closed on 31 March 2015, according to the application precepts and the Corporate Bylaws.

Evolution of the Company's activity and situation

The net turnover of the year reached the figure of 27,181 thousand Euros, which signifies a decrease in sales of 6% in relation to the previous year.

The average staff for the fiscal year 2014/15 has been of 85 persons (99 in 2013).

The year 2014/15 has been the year of consolidation for Aurovitas Spain S.A. in the Spanish pharmaceutical market, with a stable portfolio of clients, sales over that budgeted and a positive EBITDA, being an intense year both internally and externally.

As regards the market, the year 2014/15 has been marked principally by the implementation of the fourth and fifth auction of medicines in the Region of Andalusia. These auctions, which will have a duration of two years, have meant the impossibility of selling part of our product catalogue in that Autonomous Region. Nonetheless, the growth of Aurovitas Spain S.A. in 2014 with respect to the same period the previous year, according to IMS (Sell-out) data, has been in keeping with the growth of the market of generics if we do not take into account the impact of the auctions (6% vs. 5%).

In 2014 one new auction has again been announced (renewal of the 2nd and with a duration of two years). All of them are appealed by the different agents of the sector as well as by the central Government before the Constitutional Court, although it has not yet pronounced on this matter.

Internally, 2014 has been marked by the purchase of seven subsidiaries of Actavis Group by Aurobindo Pharma Limited, by which the first six months of 2014 were characterized by the great effort aimed at adapting Actavis Spain with its name changed to Aurovitas Spain to the standards of the new company. In Spain, the synergies in terms of portfolio and strategy allow us to face this next year with a diversified structure in all the channels of the sector (Hospitals, Retail and Auctions) and focus on increasing the market share of each of the channels and being prepared for the evolution of the autonomous management referred to. This year the change of the name of all our products from Actavis to Aurovitas and the change of the manufacturer of many of our specialities, from the Actavis plants to the Aurobindo plants in India will also be a challenge, and we hope it will minimize all the negative impacts of the re-branding and will add synergies to the vertical integration and economy of scales that Aurobindo contributes as a world power in the development and production of medicines and that positions us in the European Top Ten in the sale of generic medicines.

Due to the difficulty created by confronting such complex situations in the same year, we value even more positively the sales figure and the EBITDA obtained by Aurovitas Spain S.A. in 2014

The Company is completely healthy and with the financial equilibrium necessary for the development of its businesses. The Company's Directors consider, therefore, that based on the plans and the development of the operations in progress, the signed projects and those in negotiations will allow the future results to continue being positive.

For the year 2015 we expect that the market will continue being stable, but with less growth than in previous years since the new Royal Decree of Reference Prices will be implemented in the middle of the year which will lower the current prices of medicines. In addition, no launchings of generics of important volumes (blockbusters) are predicted due to the fact that increasingly fewer patents are expiring. Furthermore, we expect that the synergies in costs and the new products of the portfolio of the group Aurobindo will allow us to be increasingly more competitive in the Spanish pharmaceutical market.

Financial instruments and risks

The management of the financial risk is controlled by the Company's Treasury Department that identifies, evaluates and hedges the financial risks according to the policies approved by the Financial Management.

The Company is not exposed to significant risks regarding the interest rate. With respect to the exchange rate risk, the Company carries out practically all its transactions in Euros, for which reason the exchange rate risk for operations in other currencies is minimal.

Activities in R&D&i

The Company does not carry out activities of R&D&i.

Environmental activities


The Company complies with the regulatory requirements on the subject of the environment.

Treasury shares

No operations have been carried out with its own shares.

Events subsequent to the closing

No significant subsequent events have taken place other than those reflected in Note 15 of the attached Annual Report.



Director
Gabriel Díaz



**INDEPENDENT AUDITOR'S REPORT ON SPECIAL PURPOSE FINANCIAL
INFORMATION PREPARED FOR CONSOLIDATION PURPOSES**

To the Local Management of Aurovitas Spain, S.A.U:

As requested in our engagement letter dated April 16, 2015, we have audited, for purposes of your audit of the consolidated financial statements of Aurobindo Pharma India, the accompanying special purpose financial information of Aurovitas Spain, S.A.U. as of March 31, 2015 and for the year then ended on pages 1 to 5 of the accompanying financial reporting package of Aurobindo Pharma India. This special purpose financial information has been prepared solely to enable Aurobindo Pharma India to prepare its consolidated financial statements.

Management's responsibility for the special purpose financial information

Management is responsible for the preparation of this special purpose financial information in accordance with policies and instructions contained in our engagement letter dated April 16, 2015 and for such internal control as management determines is necessary to enable the preparation of special purpose financial information that is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on this special purpose financial information based on our audit. We conducted our audit in accordance with International Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the special purpose financial information is free from material misstatement. As requested by you, we planned and performed our audit using the materiality level specified in your instructions, which is different than the materiality level that we would have used had we been designing the audit to express an opinion on the special purpose financial information of the component alone.


An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial information. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the special purpose financial information, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the special purpose financial information in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates, made by management, as well as evaluating the overall presentation of the special purpose financial information.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. The conclusions reached in forming our opinion are based on the component materiality level specified by you in the engagement letter dated April 16, 2015.

PricewaterhouseCoopers Auditores, S.L., Torre PwC, Pº de la Castellana 259 B, 28046 Madrid, España
Tel.: +34 915 684 400 / +34 902 021 111, Fax: +34 913 083 566, www.pwc.com/es

1

R. M. Madrid, hoja 87.250-1, folio 75, tomo 9.267, libro 8.054, sección 3ª
Inscrita en el R.O.A.C. con el número S0242 - CIF: B-79 031290



Opinion


In our opinion, the accompanying special purpose financial information for Aurovitas Spain S.A.U. as of March 31, 2015 and for the year then ended has been prepared, in all material respects in accordance with the policies and instructions contained in our engagement letter dated April 16, 2015.

Restriction on use and distribution

This special purpose financial information has been prepared for purposes of providing information to Aurobindo Pharma India to enable it to prepare the consolidated financial statements of the group. As a result, the special purpose financial information is not a complete set of financial statements of Aurovitas Spain S.A.U. in accordance with applicable financial reporting framework of Spain and is not intended to present fairly, in all material respects, the financial position of Aurovitas Spain S.A.U. as of March 31, 2015, and its financial performance, and its cash flows for the year then ended in accordance with applicable financial reporting framework underlying the policies and instructions detailed in our engagement letter dated April 16, 2015. The financial information may, therefore, not be suitable for another purpose.

This report is intended solely for Board of Directors of Aurovitas Spain, S.A.U and should not be used by or distributed to other parties.

PricewaterhouseCoopers Auditores, S.L.



Nerea Urrea Pérez

May 14, 2015


Name of the company: Aurovitas Spain SAU			
Balance Sheet as at March 31, 2015			
(All amounts are in Local Currency except share data and unless otherwise stated)			
	Note	31 March, 2015 (Currency)	31 March, 2014 (Currency)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	124,103	124,103
Share application money			
Reserves and surplus	3	9,082,494	9,026,591
		9,206,597	9,150,694
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5		
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		-	-
Current liabilities			
Short-term borrowings	8	185	1,341,120
Trade payables	9	3,038,358	739,772
Other current liabilities	9	-	-
Short-term provisions	7	4,719,645	5,733,943
		7,758,188	7,814,835
TOTAL		16,964,784	16,965,528
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	166,028	210,149
Intangible assets	11	256,102	300,525
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5	608,110	701,656
Long-term loans and advances	13	-	-
Trade receivables	14.1	-	-
Other non-current assets	14.2	-	-
		1,030,240	1,212,330
Current assets			
Current investments	15	-	-
Inventories	16	6,235,364	5,039,459
Trade receivables	14.1	7,599,872	7,489,672
Cash and bank balances	17	976,477	1,985,297
Short-term loans and advances	13	816,107	865,850
Other current assets	14.2	306,724	372,921
		15,934,544	15,753,199
TOTAL		16,964,784	16,965,529
Summary of significant accounting policies	1		
The accompanying notes are an integral part of the financial statements.			

AUROVITAS

Aurovitas Spain S.A.
Avda. de Burgos, 16-D, 5º
Edificio Euremor, 28036 Madrid, España
CIF A89104875

PRICEWATERHOUSECOOPERS AUDITORES, S.L.

Name of the company: Aurovitas Spain SAU			
Statement of profit and loss for 12 Months Period ended March 31, 2015			
(All amounts are in Local Currency except share data and unless otherwise stated)			
	Note	12 Months Period ended Mar 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Income			
Revenue from operations (gross)	18	56,951,257	56,418,238
Less: Excise duty / VAT/ Rebates		29,943,064	27,398,205
Revenue from operations (net)		27,008,193	29,020,033
Other income	19	5,236	5,984
Total revenue (I)		27,013,429	29,026,018
Expenses			
Cost of raw material and components consumed	20	-	-
Purchase of trading goods	21	12,756,939	7,574,252
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	(1,195,905)	2,639,044
Employee benefit expense	22	5,851,270	6,663,501
Other expenses	23	9,305,435	9,072,228
Exceptional items	24	-	-
Total (II)		26,717,739	25,949,024
Earnings before interest, tax, depreciaton and amortization (EBITDA) (I)-(II)		295,690	3,076,993
Depreciation and amortization expense	25	107,129	266,157
Finance costs	26	41,499	191,533
Profit/(loss) before tax		147,062	2,619,303
Tax expenses			
Current tax		(2,387)	-
Less: MAT credit entitlement		-	-
Deferred tax		93,546	800,048
Fringe benefit tax		-	-
Tax relating to previous years		-	-
Total tax expense		91,159	800,048
Profit/(loss) for the year		55,903	1,819,255
		0.02	-
Summary of significant accounting policies	1		
The accompanying notes are an integral part of the financial statements.			


AUROVITAS
 Aurovitas Spain S.A.
 Avda. de Burgos, 16-D, 5ª
 Edificio Euromon 28036 Madrid, España
 CIF: A85104875

PRICEWATERHOUSECOOPERS AUDITORES, S.L.

Name of the company: Aurovitas Spain SAU			
Notes to the Balance Sheet			
(All amounts are in Local Currency except share data and unless otherwise stated)			
Note 1 : Summary of significant accounting policies (Refer General Instructions Note No.1)			
1.1			
1.2			
1.3			
1.4			
1.5			
Note 2 : Share capital (Refer General Instructions Note No.2)			
		Mar 31, 2015	March 31, 2014
Authorised shares:			
124103 (31 March, 2014: 124103) shares of Euro 1/- each			
Issued, Subscribed and Fully Paid-up shares:			
124103 (31 March, 2014: 124103) equity shares of 1 € each fully paid-up		124,103	124,103

PRICEWATERHOUSECOOPERS AUDITORES, S.L.

AUROVITAS
Aurovitas Spain S.A.
Avda. de Europa, 16-D, 5º
Edificio Euromor 28036 Madrid, España
CIF A85104875

Name of the company: Aurovitas Spain SAU			
Notes to the Balance Sheet			
(All amounts are in Local Currency except share data and unless otherwise stated)			
Note 3 : Reserves and surplus (Refer General Instructions Note No.3)			
		Mar 31, 2015	March 31, 2014
Capital Reserve			
As per last Balance Sheet		9,936,155	9,936,155
		9,936,155	9,936,155
Capital Redemption Reserve			
Securities Premium Account			
As per last Balance Sheet			
General Reserve			
As per last Balance Sheet		24,820	24,820
Add: Transferred from statement of profit and loss		24,820	24,820
Surplus/(deficit) in the statement of profit and loss			
Balance as per last financial statements		(934,385)	(2,753,640)
Profit for the quarter		55,903	1,819,255
Less: Appropriations			
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)			
Tax on proposed equity dividend			
Interim dividend paid (amount per share XX (31 March, 2014 XX)			
Transfer to general reserve			
Total appropriations			
Net surplus in the statement of profit and loss		(878,482)	(934,385)
Total reserves and surplus		9,082,494	9,026,591
Note 4 : Long-term borrowings (Refer General Instructions Note No.4)			
		Non-current Portion	
		Current maturities	
		Mar 31, 2015	March 31, 2014
Term Loans			
From banks (Secured)			
Other Loans from banks			
Current account credit balance			
Loans and advances from related parties			
Other Loans and advances			
Sales tax deferment loan (Un Secured)			
The above amount includes			
Secured borrowings			
Unsecured borrowings			
Amount disclosed under the head			
"Other current liabilities"			
Net Amount			

PRICEWATERHOUSECOOPERS AUDITORES, S.L.

AUROVITAS
Aurovitas Spain S.A.
Avda. de Burgos, 16-D, 5^a
Edificio Euromor, 28036 Madrid, España
CIF A65104876

Name of the company: Aurovitas Spain SAU			
Notes to the Balance Sheet			
(All amounts are in Local Currency except share data and unless otherwise stated)			
Note 5 : Deferred tax liability (net)		Mar 31, 2015	March 31, 2014
Deferred tax liability			
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis			
Provision for diminution in the value of investments			
Provision for doubtful debts and advances			
Fixed Assets (Depreciation)			
Retirement Benefits			
Others			
Gross deferred tax liability			
Deferred tax asset			
Carried Forward Business Losses			22,174
Others		608,110	679,483
Gross deferred tax asset		608,110	701,656
Net deferred tax liability		(608,110)	(701,656)
Note 6 : Other long-term liabilities (Refer General Instructions Note No.5)		Mar 31, 2015	March 31, 2014
Trade payables (including acceptances)			
Others			
Advances from customers			
Unclaimed dividends			
Other liabilities			
Interest accrued but not due on loans			
Advances from related parties			
Note 7 : Provisions (Refer General Instructions Note No.6 & 10)			
		Non-current	Current
		Mar 31, 2015	March 31, 2014
		Mar 31, 2015	March 31, 2014
Provision for employee benefits			
- Gratuity			
- Leave encashment			
Other Provisions			
Provision For Expenses		4,719,645	5,733,943
For Taxation (net of advance payments)			
For Proposed dividend			
For Tax on proposed dividend		4,719,645	5,733,943
		4,719,645	5,733,943
Provision for warranties			
At the beginning of the year			
Arising during the quarter			
Utilised during the quarter			
Unused amounts reversed			
At the end of the Quarter			
Current portion			
Non-current portion			
Note 8 : Short-term borrowings (Refer General Instructions Note No.7)		Mar 31, 2015	March 31, 2014
Bank overdraft			
Loans and advances from related parties			1,341,120
Interest on Loans Payables to related parties Agile Pharma BV		185	
Working capital loans (Secured)			
Short term loans (Un Secured)			
Working capital loans		185	1,341,120
The above amount includes			
Secured borrowings			
Unsecured borrowings			
Note 9 : Other current liabilities (Refer General Instructions Note No.9)		Mar 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)		3,038,358	739,772
Other liabilities			
Current maturities of long-term borrowings			
Trade deposits			

AUROVITAS

Aurovitas Spain S.A.
Avda. de Burgos, 16 D. 5^a
Edificio Euromor, 28036 Madrid, España
CIF A85064875

PRICEWATERHOUSECOOPERS AUDITORES S.L.

Name of the company: Aurovitas Spain SAU				
Notes to the Balance Sheet				
(All amounts are in Local Currency except share data and unless otherwise stated)				
			3,038,358	739,772

PRICEWATERHOUSECOOPERS AUDITORES, S.L.


AUROVITAS
Aurovitas Spain S.A.
Avda. de Europa, 16-D, 5º
Edificio Euromat, 28036 Madrid, España
CIF: A85104875

Name of the company: Aurovitas Spain SAU									
Notes to the Balance Sheet									
(All amounts are in Local Currency except share data and unless otherwise stated)									
Note 10: Tangible assets (Refer General Instructions Note No.11)									
	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment (including Computers & Software)	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation									
At 1 April 2013					173,979	141,018	-	98,948	413,945
Additions					12,673	1,502		4,142	18,317
Disposals									
Other adjustments									
- Exchange differences									
- Borrowing costs									
At 31 March 2014					186,652	142,520	-	103,090	432,262
Additions					3,176	6,990		4,158	14,324
Acquisitions through amalgamation									
Disposals									
Other adjustments									
- Exchange differences									
- Borrowing costs									
At 31 January 2015					189,828	149,510	-	107,248	446,586
Depreciation									
At 1 April 2013					100,025	43,193	-	16,080	159,298
Charge for the year					38,572	14,214	-	10,029	62,815
Disposals									
Other adjustments									
- Exchange differences									
At 31 March 2014					138,597	57,407	-	26,109	222,113
Charge for the period					33,160	14,866		10,419	58,445
Disposals									
Other adjustments									
- Exchange differences									
At 31 March 2015					171,757	72,273	-	36,528	280,558
Impairment loss									
At 1 April 2013									
At 31 March 2014									
Charge for the period									
At 31 March 2015									
Net Block									
At 31 March 2014					48,055	85,113	-	76,981	210,149
At 31 March 2015					18,071	77,237	-	70,720	166,028

PRICEWATERHOUSECOOPERS AUDITORES, S.L.

AUROVITAS
Aurovitas Spain S.A.
Avda. de Burgos, 16-D, 5^a
Edificio Euromer, 28036 Madrid, España
CIF: A65104878

Name of the company: Aurovitas Spain SAU				
Notes to the Balance Sheet				
(All amounts are in Local Currency except share data and unless otherwise stated)				
Note 11 : Intangible assets (Refer General Instructions Note No.12)				
	Goodwill	Software	Licences and patents	Total
Gross block				
At 1 April 2013		63,209	606,782	669,991
Purchase		2,166		2,166
Internal development				
Disposals				
Other adjustments				
- Exchange differences				
At 31 March 2014	-	65,375	606,782	672,157
Purchase		4,261		4,261
Acquisitions through amalgamation				
Disposals				
Other adjustments				
- Exchange differences				
At 31 January 2015	-	69,636	606,782	676,418
Amortization				
At 1 April 2013		37,333	130,957	168,290
Charge for the year		20,369	182,973	203,342
Disposals				
Other adjustments				
- Exchange differences				
At 31 March 2014	-	57,702	313,930	371,632
Charge for the period		7213	41471	48,684
Disposals				
Other adjustments				
- Exchange differences				
At 31 January 2015	-	64,915	355,401	420,316
Net Block				
At 31 March 2014	-	7,673	292,852	300,525
At 31 January 2015	-	4,721	251,381	256,102

AUROVITAS
Aurovitas Spain S.A.
Avda. de Burgos, 16-D, 5º
Edificio Euromor, 28016 Madrid, España
CIF: A85104875

PRICEWATERHOUSECOOPERS AUDITORES, S.L.

Name of the company: Aurovitas Spain SAU			
Notes to the Balance Sheet			
(All amounts are in Local Currency except share data and unless otherwise stated)			
Note 12: Non-current investments (Refer General Instructions Note No.13)			
		Mar 31, 2015	March 31, 2014
Unquoted equity instruments			
Investment in subsidiaries			
Investment in joint ventures			
Investment in associates			
Note 13: Loans and advances (Refer General Instructions Note No.14 & 21)			
	Non-current		Current
	Mar 31, 2015	March 31, 2014	Mar 31, 2015
Capital advances			March 31, 2014
Secured, considered good			
Unsecured, considered good			
(A)			
Security deposit			
Secured, considered good			
Unsecured, considered good			
Doubtful			
Provision for doubtful security deposit			
(B)			
Loan and advances to related parties			
Unsecured, considered good			
(C)			
Advances recoverable in cash or kind			
Secured, considered good			
Unsecured, considered good			
Doubtful			
Provision for doubtful advances			
(D)			
Other loans and advances			
Advance income-tax (net of provision for taxation)			
Prepaid expenses			6,213
Loans to employees			21,302
Loans to others			-
Export incentives receivable			-
Export incentives licenses			-
Balances with Statutory/government authorities			788,592
(E)			822,660
Total (A+B+C+D+E)			816,107
			865,850
Loans and advances due by directors or other officers, etc.			
	Non-current		Current
	Mar 31, 2015	March 31, 2014	Mar 31, 2015
Loans to employees include			March 31, 2014
Dues from non-executive directors			
Dues from officers			
Dues from non-executive and officers jointly with other persons			
Loans and advances to related parties include			
Dues from the partnership firm in which the company's executive director is a partner			
Dues from in which the company's managing director is a member			
Dues from the partnership firm in which the company's non-executive director is a partner			

PRICEWATERHOUSECOOPERS AUDITORES S.L.

AUROVITAS
Aurovitas Spain S.A.
Avda. de Europa, 16-D, 5º
Edificio Euromor, 28036 Madrid, España
CIF A88164875

Name of the company: Aurovitas Spain SAU				
Notes to the Balance Sheet				
(All amounts are in Local Currency except share data and unless otherwise stated)				
Note 14 : Trade receivables and other assets				
14.1 Trade receivable (Refer General Instructions Note No.15 & 19)				
	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Secured, considered good				
Due from group companies			15,238	
Due from others			458,721	288,416
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful			758,718	627,675
	-	-	1,232,677	916,091
Provision for doubtful receivables	-	-	758,718	627,675
(A)	-	-	473,959	288,416
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others			7,125,913	7,201,257
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful			232,135	215,950
	-	-	7,358,048	7,417,207
Provision for doubtful receivables	-	-	232,135	215,950
(B)	-	-	7,125,913	7,201,257
Total (A+B)	-	-	7,599,872	7,489,672
Trade receivables include:				
	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				
14.2 Other assets (Refer General Instructions Note No.16 & 22)				
	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)	-	-	-	-
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)	-	-	-	-
Others				
Interest accrued on fixed deposits				
Interest Receivables on Loans to Subsidiaries Agile Pharma BV				
Dividend receivable on investments in subsidiaries - long term				
Others			306,724	372,921
(C)	-	-	306,724	372,921
Total (A+B+C)	-	-	306,724	372,921

PRICEWATERHOUSECOOPERS AUDITORES S.L.

AUROVITAS
Aurovitas Spain S.A.
Avda. de Burgos, 15 0.S.
Edificio Euromor, 28036 Madrid, España
CIF A83104875

Name of the company: Aurovitas Spain SAU			
Notes to the Balance Sheet			
(All amounts are in Local Currency except share data and unless otherwise stated)			
Note 15 : Current investments (Refer General Instructions Note No.17)			
		Mar 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)			
Quoted equity instruments - Non-trade			
Equity shares (fully paid-up)			
If any (Please specify)			
Note 16 : Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)			
		Mar 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)			
Work - in - Progress			
Finished goods			
Traded goods (including stock -in-transit XXXX (31 March, 2014 XXX)		6,235,364	5,039,459
Stores, spares, consumables and packing materials			
Loose tools			
		6,235,364	5,039,459
Note 17 : Cash and bank balances (Refer General Instructions Note No. 20)			
		Non-current	
		Current	
		Mar 31, 2015	March 31, 2014
Cash and cash equivalents			
Balances with banks:			
On current accounts		539,611	1,854,696
Deposits with original maturity of less than 3 months			
Cash credit accounts			
On unpaid dividend account			
Cheques/drafts on hand			
Unpaid matured deposits		1,286	601
Cash on hand		540,897	1,855,297
Other bank balances			
Deposits with original maturity for more than 12 months		435,580	130,000
Deposits with original maturity for more than 3 months but less than 12 months			
Margin money deposit			
		435,580	130,000
Amount disclosed under non-current assets			
		976,477	1,985,297

PRICEWATERHOUSECOOPERS AUDITORES, S.L.

AUOVITAS
Aurovitas Spain S.A.
Avda. de Burgos, 19-D, 5º
Edificio Euromor, 28036 Madrid, España
CIF A85104875

Name of the company: Aurovitas Spain SAU		
Notes to the statement of profit and loss		
(All amounts are in Local Currency except share data and unless otherwise stated)		
	12 Months Period ended Mar 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 18 : Revenue from operations (Refer General Instructions Note No.25)		
Revenue from operations		
Sale of products		
Finished goods.		-
Traded goods	56,951,257	56,418,238
Sale of services		-
Sale of dossiers/licenses		-
Other operating revenue		-
Scrap sales		-
Other		-
Revenue from operations (gross)	56,951,257	56,418,238
Less: Rebates/Discounts	29,943,064	27,398,205
Revenue from operations (net)	27,008,193	29,020,033
Note 19 : Other income (Refer General Instructions Note No.26)		
Interest income on:		
Bank deposits	-	-
Long-term investments	-	-
Current investments	-	-
Loans to joint venture entities	3,338	-
Others	-	-
Dividend income on		
Investment in subsidiaries	-	-
Current investments	-	-
Long-term investments	-	-
Net gain on sale of current investments	-	-
Profit on sale of fixed assets (net)	-	-
Foreign exchange gain (net)	-	-
Balances no longer required written back	-	-
Government grant	-	-
Commission income	-	-
Processing charges	-	-
Other non-operating income (net of expenses directly attributable to such income of Rs.XXXXX (31 March, 2014:XXXX)	1,898	5,984
	5,236	5,984
Note 20 : Cost of raw material and components consumed		
Inventory at the beginning of the quarter		
Add: Purchases		
	-	-
Less: inventory at the end of the quarter		
	-	-
Add:Packing material consumed		
Cost of raw material and components consumed:		

PRICEWATERHOUSECOOPERS AUDITORES, S.L.

AUROVITAS
Aurovitas Spain S.A.
Avda. de Burgos 16-D, 5ª
Edificio Euromor, 28036 Madrid, España
CIF A85104875

Name of the company: Aurovitas Spain SAU			
Notes to the statement of profit and loss			
(All amounts are in Local Currency except share data and unless otherwise stated)			
		12 Months Period ended Mar 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 21 : (Increase)/decrease in inventories			
Inventories at the end of the quarter			
Traded goods		6,235,364	5,039,459
Work-in-progress		-	-
Finished goods		-	-
		6,235,364	5,039,459
Inventories at the beginning of the quarter			
Traded goods		5,039,459	7,678,503
Work-in-progress		-	-
Finished goods		-	-
		5,039,459	7,678,503
		1,195,905	(2,639,044)
Details of purchase of traded goods			
Product A		12,756,939	7,574,252
Product B		-	-
Product C		-	-
		12,756,939	7,574,252
Note 22 : Employee benefit expense			
Salaries, wages and bonus		5,782,594	6,588,554
Contribution to provident and other fund		-	-
Employee stock option scheme		-	-
Gratuity expense		-	-
Other employee benefits		68,676	74,947
Post employment medical benefits		-	-
Staff welfare expenses		-	-
		5,851,270	6,663,501
Note 23 : Other expenses			
Consumption of stores and spares		-	-
Conversion charges		-	-
Chemicals consumed		-	-
Increase in VAT on finished goods		-	-
Customer service expenditure		-	-
Power and fuel		-	-
Water charges		-	-
Relabeling and repackaging		46,250	89,382
Freight and forwarding charges		-	-
Provision for Expiry Products		(551,726)	(725,146)
Carriage inward		358,382	22,421
Carriage outwards		968,783	557,919
Rent		278,782	271,971
Rates and taxes		10,106	6,990
Insurance		29,006	21,569
Repairs and maintenance		-	-
i) Plant and machinery		-	-
ii) Buildings		760	4,413
iii) Others		-	-
Advertising and sales promotion		5,489,908	6,887,907
Brokerage and discounts		-	-
Remuneration to Auditors		43,589	28,976
Sales commission		-	-
Travelling and conveyance		1,021,063	1,178,798

AUROVITAS

Aurovitas Spain S.A.
Avda. de Burgos 14 D. 5.
Edificio Euromar, 28035 Madrid, España
CIF A85104675

PRICEWATERHOUSECOOPERS AUDITORS


Name of the company: Aurovitas Spain SAU				
Notes to the statement of profit and loss				
(All amounts are in Local Currency except share data and unless otherwise stated)				
			12 Months Period ended Mar 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Communication costs			96,079	102,362
Printing and stationery			39,361	29,901
Legal and professional fees			447,073	154,934
Directors sitting fees			-	-
Payment to auditor (Refer details below)			-	-
Provision for diminution in value of investment in subsidiary company			-	-
Provision for other than temporary decline in the carrying amount of other long-term investments			-	-
Adjustment to the carrying amount of current investments			-	-
Provision for warranties (net of reversals)			-	-
Provision for litigations (net of reversals)			-	-
Exchange differences (net)			-	-
Loss on derivative contracts (including provisions mark-to-market loss)			-	-
Bad debts/advances written off			17,609	18
Impairment loss on fixed assets			-	-
Provision for doubtful debts and advances			147,228	68,063
Loss on sale of fixed assets (net)			-	-
Premium on forward exchange contract amortized			-	-
Factory maintenance			-	-
Effluent treatment expenses			-	-
Vehicle maintenance expenses			-	-
Analytical charges			-	-
Product development expenses			-	-
Registration and filing charges			647,279	164,789
Safety and security			-	-
Office expenses			50,423	41,609
Repairs and maintenance - others			-	-
Management fees			33,638	-
Liquidated damages			-	-
Donations			-	-
Software license and implementation expenses			116,932	134,480
Capital work-in-progress written off			-	-
Miscellaneous expenses			14,910	30,871
			9,305,435	9,072,228
Payment to Auditor				
As auditor:				
Audit fee			43,589	28,976
Tax audit fee			-	-
Limited review			-	-
In other capacity:			-	-
Taxation matters			-	-
Company law matters			-	-
Management services			-	-
Other services (certification fees)			-	-
Reimbursement of expenses			-	-
			43,589	28,976

PRICEWATERHOUSECOOPERS AUDITORES, S.L.

AUROVITAS
Aurovitas Spain S.A.
Avda. de Burgos, 16-D, 5^a

Name of the company: Aurovitas Spain SAU				
Notes to the statement of profit and loss				
(All amounts are in Local Currency except share data and unless otherwise stated)				
			12 Months Period ended Mar 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 24 : Exceptional items				
Others (Specify if any)				-
			-	-
Note 25 : Depreciation and amortization expense				
Depreciation of tangible assets			58,445	62,815
Amortization of intangible assets			48,684	203,342
Depreciation of investment property				
			107,129	266,157
Note 26 : Finance costs (Refer General Instructions Note No.27)				
Interest			7,249	150,674
Bank charges			34,250	40,859
Amortization of ancillary borrowing costs			-	-
Exchange difference to the extent considered as an adjustment to borrowing costs			-	-
			41,499	191,533

PRICEWATERHOUSECOOPERS AUDITORES, S.L.


AUROVITAS
Aurovitas Spain S.A.
Avda. de Europa, 16-D, 5ª
Edificio Euromor, 28036 Madrid, España
CIF A85104275

**NOTES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31ST
MARCH 2015**

NOTE 1 ACTIVITY OF THE COMPANY

AUROVITAS SPAIN S.A. was incorporated in Madrid on 23th March 2007. The registered office of the company is located in Av. De Burgos, 16D, Madrid.

Pursuant the articles of its by-laws, the corporate purpose of the company is as follows:

- To buy, sell, import, export or store any pharmaceutical products.
- To acquire, hold, developed, dispose or exploit industrial property rights.
- To acquire, hold, exploit, management, hand over, lease and sell the property or the use of rights, and personal goods or real state.
- To provide all type of marketing support.
- To act as commercial agent or broker.

The Sole Shareholder of the company at 31 March 2015 is Agile Pharma, B.V., legally seated in Amsterdam (Prins Bernhardplein 200, 1097 JN, The Netherlands), and registered with the Registry of Chamber of Commerce of Amsterdam under number 34255461.

The ultimate parent company is Aurobindo Pharma Limited, with domicile in Plot, 2, Maitiri Vihar, Ameerpet, Hyderabad, 500 038, Telangana, India. The annual consolidated accounts settle in India.

NOTE 2 BASIS OF PRESENTATION OF THE ANNUAL ACCOUNTS.

a) True and fair view

The attached annual accounts for 2014/2015 have been prepared by the Company's Board of Directors using all the Company's accounting registries up to 31 March 2015. In this report all the accounting principles and assessment criteria compiled in the General Accounting Plan (GAP), which was approved in Royal Decree 1514/2007, have been applied. These annual accounts show the true and fair view of the equity, financial position and results of the company.

There are no reasons why, in representing the true and fair view, any legal accounting regulations have not been applied.

The attached annual accounts will be subject to examination by the Only Shareholder, with the expectation that they will be approved without any changes needing to be made.



b) Critical issues regarding the measurement and estimation of uncertainties

The Company have prepared its financial statements based on the principles of a running business, without there being any large risks that would affect the value of any assets or liabilities in the following year.

Despite these estimations being made according to the best information that was available on 31 March 2015 regarding the facts that were analysed and the progress up until the date the current annual accounts were formalised, it is also possible that certain future events which may take place could cause them to be modified (upwards or downwards) in the coming years.

c) Comparative information

In agreement with the Mercantile Legislation, the Company shows, to comparative effects, in addition to the current period figures of the balance, of the income statement and statement of changes in equity, the figures corresponding to the previous period.

As explained in the following section f) in the current period it has been considered more appropriate the adoption of certain accounting classification criteria in relation to the items mentioned therein.

The reporting year of the Company starts on April 1st and ends on March 31st of the following year.

d) Aggregation of items

No items have been aggregated with other items on the face of the balance sheet, income statement and statement of changes in equity that require details to be disclosed.

e) Items disclosed under several line items

No items of assets and liabilities are recognised under two or more balance sheet line items.


f) Changes in accounting policies and correction of errors

No adjustments have been made for changes in accounting policies or correction of errors during the reporting period.

However, during the current period it has been considered more appropriate the adoption of the following accounting criteria of classification of certain expenses and liabilities that in prior periods were registered in other items of the income statement and balance sheet.

In particular, the sales volume discounts consisting in deliveries of goods in kind, which were previously recorded under the heading of External services are now recorded as a Sales volume discounts decreasing the revenue of the period. Also, the subcontracted work of a third party relating to the storage and distribution of the goods of the company, which were previously recorded under the heading of External services are now recorded as Supplies under the heading of Subcontracted work.

In the same way, the contributions to the equity made by the Single Shareholder that in the previous year were recorded as a current liabilities with Group companies and associates, are now classified as Equity under the heading Other equity holder contributions.



NOTE 3 ACCOUNTING POLICIES

The main accounting criteria applied are as follows:

a) Intangible assets

“Concessions, patents, licenses and trade mark” are the capitalized expenses included the registration fees for the industrial property. Subsequently, measured at cost less accumulated depreciation and impairment losses they experienced. Amortization is carried out systematically in ten years.

The “Computer software” is calculated first by the price originally paid to purchase the property or the rights to use the computer software and, subsequently, valued by the accumulated profit stemming from its use or any losses through deterioration that it experienced.

Amortisation of computer software is charged on a straight-line basis over a maximum period of 3 years. Maintenance costs are attributed to the year's results in which they were incurred.

b) Property, plant and equipment

Items included in “Property, plant and equipment” are represented on the balance sheet by way of their purchase cost or production cost minus their accumulative amortisation and loss of value through deterioration.

For those fixed material assets which require more than one year in order to be ready for use, the financial expenditure that they have incurred up to that moment is included in the purchase price or production cost.

The Company is not committed to dismantling, removing or repairing its material assets. This is why figures or values for covering such obligations in the future, have not been included.

Expansion costs, modernising or improvements that represent an increase in economic capacity or an extension of the assets' economic life, are classified as a higher cost for the corresponding goods.

The Company amortises its fixed material assets by distributing the cost of the assets depending on its estimated economic life according to the following breakdown:

	Depreciation rates
Tecnical instalations	10%
Furniture	10 %
Information processing equipment	25 %
Other fixed assets	10%

The Company uses a straight-line method when calculating amortisation for all its fixed assets.

The Administrators consider that the accounting value of the assets is not higher than their recoverable value, causing this calculation to be based on the future cash flows that these assets generate.

c) Financial instruments

The Company includes in the financial instruments chapter, those contracts which lead to a financial asset in one company and, simultaneously, to a financial liability or a capital instrument in another company.

For assessment purposes, financial assets and liabilities are categorised according to the instrument's characteristics and the reason behind its purchase.

The assessment regulations applied by the Company to its financial instruments are as follows:

Financial assets:

Financial assets held by the Company are classified as:

- Loans and receivables: are trade and non-trade credits which come from the sale of goods or from services rendered, whose payments are of a determined or determinable value and are not negotiated on any active markets. Subsequently, they are recorded according to their repayment cost using the cash interest rate method. The Company records the corresponding impairments by the difference between the value to be reclaimed from the pending accounts and the book value for which they were recorded whether there is objective evidence of impairment
- Held-to-maturity investments: are those debt values which have a fixed maturity date, determined or determinable payments, are negotiated on an asset market and ones which the Company has the intention and capacity to maintain up until their maturity. The assessment criteria for these investments are the same as those used for loans and receivables.

Financial liabilities


Loans, obligations and similar operations are recorded by their received amount and their direct net issuing costs. The financial costs, including payable premiums for liquidation and reimbursement and direct issuing costs are accounted according to the payment criteria in the profit and loss account by using the cash interest rate method and adding the instrument's book value in such a way that they are not liquidated during the period in which they were created.

Debits in commercial operations that do not have a maturity of over a year and do not have a contractual interest rate are classified by their nominal value when the effect of not updating the cash flows is not that significant.

The Company suspends its financial instruments when the obligations they have generated expire.

d) Classification of assets and liabilities

In the balance sheet, assets and liabilities with maturity of less than twelve months from the end of the year are classified as current, while those maturing more than twelve months are classified as non-current.



e) Inventories

Goods for resale are valued downwards to their purchase price or their net realisable value. The purchase price is the amount billed by the provider less the discounts and interests incorporated into the nominal value of the debits, plus any additional costs so that stocks are ready for sale.

The cost of goods to the various units of inventories is assigned by applying the weighted average method.

The valuation of reversible losses due defective or slow-moving inventories are boils down to your realizable value, as well as those whose expiry date occurs before six months from the closing date of the period.

Advance payments on account of future supplies inventories are valued at cost.

f) Income taxes

The income tax due to be paid is worked out by determining the total of the deferred tax and the current tax cost which is then calculated by applying the current tax rate to the taxable amount and deducting the amount obtained from the general deductions and allowances total applied throughout the year.

Deferred tax assets include any temporary differences, which are identified as those amounts which are expected to be paid or to be recovered due to the differences between the asset and liability book values and their tax value, as well as any pending negative taxable amounts and any credits or tax deductions which have not been applied. These amounts are listed after having applied the corresponding encumbrance rate with which they are expected to be recovered or liquidated.

Deferred tax assets, identified as having temporary differences are only ones recognised in case where it is considered probable that the entity is going to have enough tax gains in the future. These assets should not come from (apart from in cases of combined business deals) other assets and liabilities in operations that do not affect either the accounting or tax result.


At the end of the accounting close, the deferred taxes registered are revised (assets as well as liabilities) with the aim of checking if they are still correct, and carrying out any opportune modifications needed according to the results of the analyses carried out. In addition the company perform a provision for the slow moving goods.

g) Income and expenditure

Income and expenditure are accounted depending on the payment criteria, irrespective of the moment in which the monetary or financial effects derived from them occur.

The Company only includes the profits yielded on the date of the year's close but, any foreseen risks and losses are accounted for as soon as they are known.

Income through the sale of goods or services is only recognised by the fair value received or to be received. Discounts by way of early payment, volume or other discount types, as well as interests incorporated into the nominal value of the credits are recorded as deductions.

Handwritten signature and initials in the bottom right corner of the page.

h) Provisions and contingencies

In the preparation of the annual accounts the Management difference between:

- Provisions: Liabilities that cover present obligations at the balance sheet date which result from past events which could give rise to a loss of probable realization for the entity, which amount and time of cancellation are indeterminate. These balances are recognized at the present value of the most probable estimated amount that the Company will have to pay to settle the obligation.
- Contingent liabilities: Possible obligations as a result from past events and whose existence depends on the occurrence or not one or more future events beyond of the entity.

The annual accounts include all the material provisions with respect to which it is estimated that the probability of having to meet the obligation is greater than the opposite. Contingent liabilities, if any, are the subject of information in memory.


Provisions, which are quantified on the best information available on the consequences of the event giving rise to them and are re-estimated at each balance sheet date are used to meet the specific obligations for which they were originally recognized. Provisions are reversed in full or in part when such obligations cease to exist or are reduced.


i) Related party transactions

In general, transactions are accounted for at the beginning for their fair value and, subsequently, they are valued in accordance with the corresponding general regulations. In the case where the agreed price for an operation differs from that of its fair value, the difference is recorded in accordance with the economic reality of the operation.

For the purposes of showing the annual accounts, it is understood that a company forms part of the Group when both sides are connected (directly or indirectly) by a controlling relationship similar to that set out in article 42 of the Trading Standards, or when the companies are controlled in some way or another by one or various legal persons acting together or grouped under one collective name by agreement or statutory clauses.

Shall be deemed that company is to associated when without in question of a group company, in the lines set out previously one or more of the companies that form, including the dominant entity or a natural person, over such exert significant influence. Is presumed significant influence when it holds at least 20% of the voting rights of another company.


Gabriel Diaz


Sue Rouero

Directors' report

Management of the company hereby presents its financial statements for the financial book year from 1 April 2014 to 31 March 2015.

General information

During the financial year, Actavis B.V. was engaged in the import, distribution and sales of pharmaceutical products. The company's activities include sales of generic medicines and OTC products to wholesalers, hospitals, pharmacies and drugstores in the Netherlands, Belgium and Luxembourg. The mission of the company is to sell and market pharmaceuticals of the highest quality to our customers delivering best-in-class service and superior value.

On 17 January 2014 it was announced that Aurobindo Pharma Limited would acquire generic commercial operations of Actavis plc in 7 countries. The transaction was completed on the 1st of April 2014. Aurobindo acquired Actavis' pharmaceutical commercial infrastructure in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands, including products, marketing authorizations and dossier license rights. The two companies also entered into a long-term strategic supply arrangement. Actavis B.V. is operating in the Dutch and Belgian markets and was part of the Aurobindo acquisition.

The market for generic medicines is heavily influenced by tenders organised by the Health Insurance companies, resulting in top-line growth, but also in lower gross margin percentages. As Aurobindo Pharma Limited is a vertically integrated company, significant cost price savings are expected. Next to this, new product launches expanding the current portfolio will contribute to the growth both in sales and operating income in the coming years.

Actavis B.V. is a subsidiary of Aurobindo Pharma Ltd, a Indian listed company. The office of Actavis B.V. is located in Baarn. About 65 employees are working in the departments Pharmaceutical Affairs, Sales & Marketing, Finance, Customer Service, Export, Portfolio Management and Warehouse. The statutory two-tier rules are not applicable to Actavis B.V.

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 125 countries.

Financial information

- The company's activities resulted in a turnover for the year of EUR 44,104,151 (2013: EUR 81,628,001). The decrease in revenue was caused by the fact that in 2013 Actavis B.V. was also servicing sales to Poland. Poland has not been sold to Aurobindo, so this activity was cut-off from Actavis B.V. as of 31 March 2014. The net loss for the year is EUR (1,978,678) (2013: EUR a profit of 2,887,150). The decrease in the result is mainly due to the fact that cost structure of Actavis changed being part of Aurobindo Pharma Ltd, integration activities and cut-off of Poland activities following the sale to Aurobindo.
- Financing activities take place on group level. Actavis B.V. has an intercompany loan facility.

Aurobindo

Baarnsche Dijk 1 - Postbus 313 - 3740 AH Baarn - Tel: +31 (0)35 542 99 33 - Fax: +31 (0)35 542 99 32 - Email: info@eurobindo.com
IBAN: NL72 ABNA 0430 0121 95 - BIC: ABNANL2A - BTW: NL 0027.24.352.B01 - K.v.K. Hilversum 32030582 - www.aurobindo.nl

- The management of the business and the execution of the Company's strategy are subject to a number of risks. Further details are disclosed in the Financial Notes (8).

Financial performance indicators

	2013-2014	2014-2015
Net turnover (EUR '000)	44,104	81,628
Net turnover growth	-44.4%	-46.0%
Gross margin (EUR '000)	9,119	13,063
Net result (EUR '000)	(1,979)	2,887
Current ratio	1.89	2.93

Personnel-related information

Remuneration of directors is currently based on market and benchmarking information.

Information regarding financial instruments

Most of the financial instruments are managed on group level by Corporate Treasury.

Receivables and payables are managed locally and reported to Corporate Treasury.

Research and development information

The company does not perform research and development activities locally.

Other information

- Actavis B.V. is marketing its products in the Benelux from its head office in Baarn. Distribution takes place through wholesalers to pharmacies, drugstores and hospitals in the Benelux.
- The pharmaceutical is a heavily regulated industry. Quality assurance & control is key to Actavis B.V. A (financial) control framework is in place in order to adequately manage risks.
- There is a strong focus on controlling costs of healthcare. Cost reductions have been effected by the Health Insurers by tendering generic pharmaceutical products. This has resulted in significant price decreases in generic medicines over the past years.



Information concerning application of code of conduct

Actavis B.V. is subject to both the internal code of conduct and the CGR (Code Geneesmiddelen Reclame) regulations.

It contains rules around marketing & promotion towards healthcare professionals.


Information on male/female partitioning of board members

The board consists of four male members: the managing director, the finance director, the Senior Vice President Europe Operations and the Senior Vice President Global Finance and Operations. As much as the Board of Directors values diversity, the Board currently has no female Board members. As per this moment there is no policy on the desirable male/female split in the Board. The company will focus in the future on the competences of new Board members bearing in mind the added value from diversity in the Board.

Outlook

- No significant investments are expected to take place in the near future.
- Financing will be facilitated by corporate treasury.
- No R&D activities will take place on local level.
- Subsequent events are disclosed in the Financial Notes (21).

Baarn, 18 May 2015



M.B. van Loenen

Director



To: the group auditors of Aurobindo Pharma Ltd

Grant Thornton
Accountants en Adviseurs B.V.
Gedempe Zalmhaven 4a
P.O. Box 23278
3001 KG Rotterdam
The Netherlands

T +31 88 676 90 00
F +31 88 676 90 10
www.gt.nl

INDEPENDENT AUDITOR'S REPORT

Report on the financial statements

As requested in your instructions, we have audited, for purposes of your audit of the consolidated financial statements of Aurobindo Pharma Limited, the special purpose financial information, signed for identification purposes, of Actavis B.V. as of 31 March 2015 and for the year then ended.

Management's responsibility

Management is responsible for the preparation of this special purpose financial information in accordance with policies and instructions contained in Aurobindo Pharma Limited's accounting manual. Furthermore management is responsible for such internal control as it determines is necessary to enable the preparation of special purpose financial information that is free from material misstatement, whether due to fraud or error. This special purpose financial information is prepared solely to enable Aurobindo Pharma Limited to prepare its consolidated financial statements.

Auditor's responsibility

Our responsibility is to express an opinion on this special purpose financial information based on our audit. We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing and your instructions. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the special purpose financial information is free from material misstatement. As requested, our audit procedures also included the additional procedures identified in your instructions. In accordance with your instructions we planned and performed our audit using the materiality level specified in your instructions, which is different than the materiality level to express an opinion on the special purpose financial information of the component alone.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the special purpose financial information. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the special purpose financial information, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and presentation of the special purpose financial information in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates, made by management, as well as evaluating the overall presentation of the special purpose financial information.

Grant Thornton Accountants en Adviseurs B.V. is a member firm within Grant Thornton International Ltd (Grant Thornton International).

Grant Thornton Accountants en Adviseurs B.V. is registered with the Chamber of Commerce of The Hague trade register under number 28105565. To all our services our general conditions, as registered with the Registry of the District Court in The Hague, apply. A copy of these conditions will be sent to you on request. Any liability shall be limited to the amount which is mentioned in the general conditions.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. The conclusions reached in forming our opinion are based on the component materiality level specified by you in the context of the audit of the consolidated financial statements of the group.

Opinion with respect to the financial statements

In our opinion, the special purpose financial information of Actavis B.V. as of 31 March 2015 and for the year then ended is prepared, in all material respects, in accordance with the policies and instructions contained in Aurobindo Pharma Limited's accounting manual.

Report on other legal and regulatory requirements

Without qualifying our opinion, we note that this special purpose financial information is prepared for purposes of providing information to Aurobindo Pharma Limited to enable it to prepare the consolidated financial statements of the group. As a result, the special purpose financial information is not a complete set of financial statements of Actavis B.V. in accordance with the group's accounting policies and is not intended to give a true and fair view of, in all material respects, the financial position of Actavis B.V. as of 31 March 2015, and of its result and its cash flows for the year then ended in accordance with the group's accounting policies. The special purpose financial information may, therefore, not be suitable for another purpose.


This report is intended solely for the group auditor and should not be distributed to or used by parties other than the group auditor.

Rotterdam, 19 May 2015

Grant Thornton Accountants en Adviseurs B.V.




drs. C. Holewijn RA

 Grant Thornton
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountants en Adviseurs B.V.
19 MAY 2015

Actavis BV
Balance Sheet as at March 31, 2015

(All amounts are in € except share data and unless otherwise stated)

	Note	31 March, 2015 (EUR)	31 March, 2014 (EUR)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	50.000	50.000
Share application money			
Reserves and surplus	3	60.111	2.038.789
		110.111	2.088.789
Non-current liabilities			
Long-term borrowings	4	13.000.000	14.444.502
Deferred Tax Liabilities (net)	5		
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	63.897	87.652
		13.063.897	14.532.155
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	6.258.612	2.181.099
Other current liabilities	9	8.363.549	6.365.892
Short-term provisions	7	-	8.748
		14.622.161	8.555.739
TOTAL		27.796.169	25.176.683
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	190.827	132.458
Intangible assets	11	-	-
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	10.278
Long-term loans and advances	13	-	-
Trade receivables	14,1	-	-
Other non-current assets	14,2	-	-
		190.827	142.736
Current assets			
Current investments	15	-	-
Inventories	16	16.028.359	13.280.850
Trade receivables	14,1	10.237.682	9.486.455
Cash and bank balances	17	789.587	1.565.519
Short-term loans and advances	13	(52.292)	(7.721)
Other current assets	14,2	602.006	708.844
		27.605.342	25.033.947
TOTAL		27.796.169	25.176.683
Summary of significant accounting policies	1		
The accompanying notes are an integral part of the financial statements.			

 **Grant Thornton**

 INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

 Grant Thornton
Accountants and Adviseurs B.V.

19 MAY 2015

Actavis BV**Statement of profit and loss for the year ended March 31, 2015**


(All amounts are in € except share data and unless otherwise stated)

	Note	Year ended March 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Income			
Revenue from operations (gross)	18	65.082.799	101.924.600
Less: Excise duty / VAT/ Rebates		20.996.893	20.296.599
Revenue from operations (net)		44.085.905,22	81.628.001
Other income	19	18.246	-
Total revenue (I)		44.104.151	81.628.001
Expenses			
Cost of raw material and components consumed	20	-	-
Purchase of trading goods	21	37.732.614	60.586.323
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	(2.747.509)	7.978.535
Employee benefit expense	22	5.218.025	5.013.213
Other expenses	23	5.576.066	4.319.972
Exceptional items	24	-	-
Total (II)		45.779.195	77.898.043
Earnings before interest, tax, depreciaton and amortization (EBITDA) (I)-(II)		(1.675.044)	3.729.959
Depreciation and amortization expense	25	55.607	77.675
Finance costs	26	237.749	543.741
Profit/(loss) before tax		(1.968.400)	3.108.542
Tax expenses			
Current tax			
Less: MAT credit entitlement			
Deferred tax		10.278	221.392
Fringe benefit tax			
Tax relating to previous years			
Total tax expense		10.278	221.392
Profit/(loss) for the year		(1.978.678)	2.887.150
Summary of significant accounting policies			
	1		
The accompanying notes are an integral part of the financial statements.			

 Grant Thornton
 INITIALLED FOR IDENTIFICATION
 PURPOSES ONLY
 Grant Thornton
 Accountants en Adviseurs B.V.

 19 MAY 2015

Actavis BV		
Notes to the Balance Sheet		
(All amounts are in € except share data and unless otherwise stated)		
Note 1 : Summary of significant accounting policies (Refer General Instructions Note No 1)		
<p>1.1 Change as opposed to June reporting: Discounts to customers were reported initially in Other current assets; after discussion we were instructed to report in Other current liabilities. We changed the March number (as also instructed) so that the March/Sept numbers are comparable.</p> <p>1.2 Pension Liability is not required under Dutch GAAP. In September: reversal of pension provision of 2014 in P&L and previous years in equity</p> <p>1.3</p> <p>1.4</p> <p>1.5</p>		
Note 2 : Share capital (Refer General Instructions Note No 2)		
	March 31, 2015	March 31, 2014
Authorised shares:		
5,000 (31 March, 2014: 5,000) equity shares of EUR 50 each	250.000	250.000
0 (31 March, 2014: 0) preference shares of 0 each	250.000	250.000
Issued, Subscribed and Fully Paid-up shares:		
1,000 (31 March, 2014: 1,000) equity shares of EUR 50 each fully paid-up	50.000	50.000

 Grant Thornton
 INITIALLED FOR IDENTIFICATION
 PURPOSES ONLY
 Grant Thornton
 Accountants en Adviseurs B.V.

EW

19 MAY 2015

Actavis BV			
Notes to the Balance Sheet			
(All amounts are in € except share data and unless otherwise stated)			
Note 3 : Reserves and surplus (Refer General Instructions Note No. 3)			
	March 31, 2015	March 31, 2014	
Capital Reserve			
As per last Balance Sheet			
Capital Redemption Reserve			
Securities Premium Account			
As per last Balance Sheet			
General Reserve			
As per last Balance Sheet			
Add: Transferred from statement of profit and loss			
Surplus/(deficit) in the statement of profit and loss			
Balance as per last financial statements	2,038,789	(1,686,111)	
Profit for the quarter	(1,978,678)	2,887,150	
Less: Appropriations			
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)			
Tax on proposed equity dividend			
Interim dividend paid (amount per share XX (31 March, 2014 XX)			
(Transfer to general reserve) Release of pension provision		(837,750)	
Total appropriations		(837,750)	
Net surplus in the statement of profit and loss	60,111	2,038,789	
Total reserves and surplus	60,111	2,038,789	
Note 4 : Long-term borrowings (Refer General Instructions Note No. 4)			
	Non-current Portion		Current maturities
	March 31, 2015	March 31, 2014	March 31, 2015
			March 31, 2014
Term Loans			
From banks (Secured)			
Other Loans from banks			
Current account credit balance			
Loans and advances from related parties	13,000,000		
Other Loans and advances		14,444,502	
Sales tax deferment loan (Un Secured)			
	13,000,000	14,444,502	
The above amount includes			
Secured borrowings			
Unsecured borrowings			
Amount disclosed under the head			
Other current liabilities			
Net Amount			

Grant Thornton
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY
Grant Thornton
Accountants en Adviseurs R.V.

19 MAY 2015

Actavis BV				
Notes to the Balance Sheet				
(All amounts are in € except share data and unless otherwise stated)				
Note 5 : Deferred tax liability (net)				
		March 31, 2015	March 31, 2014	
Deferred tax liability				
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis				
Provision for diminution in the value of investments				
Provision for doubtful debts and advances				
Fixed Assets (Depreciation)				
Retirement Benefits				
Others				
Gross deferred tax liability				
Deferred tax asset				
Carried Forward Business Losses				
Others: retirement benefits			10.278	
Gross deferred tax asset			10.278	
Net deferred tax liability			(10.278)	
Note 6 : Other long-term liabilities (Refer General Instructions Note No 3)				
		March 31, 2015	March 31, 2014	
Trade payables (including acceptances)				
Other liabilities				
Advances from related parties				
Note 7 : Provisions (Refer General Instructions Note No 5 & 10)				
		Non-current		Current
		March 31, 2015	March 31, 2014	March 31, 2015
				March 31, 2014
Provision for employee benefits				
- Gratuity				
- Leave encashment				
- Fringe benefits		63.897	46.540	8.748
- Pension provision			41.112	
		63.897	87.652	8.748
Other Provisions				
For Taxation (net of advance payments)				
For Proposed dividend				
For Tax on proposed dividend				
		63.897	87.652	8.748
Provision for warranties				
			March 31, 2015	March 31, 2014
At the beginning of the year				
Arising during the quarter				
Utilised during the quarter				
Unused amounts reversed				
At the end of the year				
Current portion				
Non-current portion				
Note 8 : Short-term borrowings (Refer General Instructions Note No 7)				
		March 31, 2015	March 31, 2014	
Bank overdraft				
Loans and advances from related parties				
Working capital loans (Secured)				
Short term loans (Un Secured)				
Working capital loans				
The above amount includes				
- Secured borrowings				
- Unsecured borrowings				
Note 9 : Other current liabilities (Refer General Instructions Note No 9)				
		March 31, 2015	March 31, 2014	
Trade payables (including acceptances) (Refer General Instructions Note No 8)		6.258.612	2.181.099	
Other liabilities		2.931.233	6.365.892	
Current maturities of long-term borrowings				
Trade Payables (Rebates & Discounts)		5.412.888		
Unclaimed dividends				
Interest accrued but not due on loans		19.428		
Trade deposits				
		8.363.549	6.365.892	
		14.622.161	8.546.991	

INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants en Revisors B.V.

19 MAY 2015

Actavis BV				
Notes to the Balance Sheet				
(All amounts are in € except share data and unless otherwise stated)				
Note 10 : Tangible assets (Refer General Instructions Note No 11)				
	Leasehold Buildings	Plant & Equipment	Computers	Total
Cost or valuation				
At 1 April 2013	201.163	321.655	514.746	1.037.564
Additions		50.274	18.646	68.921
Disposals		64.082	19.726	83.808
Other adjustments		-	-	-
- Exchange differences		-	-	-
- Borrowing costs		-	-	-
At 31 March 2014	201.163	307.847	513.666	1.022.676
Additions		51.177	62.879	114.056
Acquisitions through amalgamation		-	-	-
Disposals		30.562	9.130	39.692
Other adjustments		-	-	-
- Exchange differences		-	-	-
- Borrowing costs		-	-	-
At 31 March 2015	201.163	328.462	567.415	1.097.040
Depreciation				
At 1 April 2013	201.163	250.125	444.616	895.905
Charge for the year		36.396	41.279	77.675
Disposals		63.636	19.726	83.362
Other adjustments		-	-	-
- Exchange differences		-	-	-
At 31 March 2014	201.163	222.886	466.169	890.218
Charge for the period		32.910	22.697	55.607
Disposals		30.035	9.577	39.612
Other adjustments		-	-	-
- Exchange differences		-	-	-
At 31 March 2015	201.163	225.761	479.289	906.213
Impairment loss				
At 1 April 2013				
At 31 March 2014				
Charge for the period				
At 31 March 2015				
Net Block				
At 31 March 2014	-	84.961	47.497	132.458
At 31 March 2015	-	102.701	88.126	190.827





Grant Thornton

INITIALED FOR IDENTIFICATION
PURPOSES ONLYGrant Thornton
Accountants & Advisors s.r.l. s.p.a.


19 MAY 2015

Actavis BV				
Notes to the Balance Sheet				
(All amounts are in € except share data and unless otherwise stated)				
Note 12 : Non-current investments (Refer General Instructions Note No 13)				
	March 31, 2015		March 31, 2014	
Unquoted equity instruments				
Investment in subsidiaries				
Investment in joint ventures				
Investment in associates				
Note 13 : Loans and advances (Refer General Instructions Note No 14 & 21)				
	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Capital advances				
Secured, considered good				
Unsecured, considered good				
	(A)			
Security deposit				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful security deposit				
	(B)			
Loan and advances to related parties				
Unsecured, considered good				
	(C)			
Advances recoverable in cash or kind				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful advances				
	(D)			
Other loans and advances				
Advance income-tax (net of provision for taxation)				
Prepaid expenses				
Loans to employees				
Loans to others				
Export incentives receivable				
Export incentives licenses				
Balances with Statutory/government authorities				
	(E)		(52.292)	(7.721)
Total (A+B+C+D+E)				
			(52.292)	(7.721)
Loans and advances due by directors or other officers, etc.				
	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors				
Dues from officers				
Dues from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner				
Dues from in which the company's managing director is a member				
Dues from the partnership firm in which the company's non-executive director is a partner				

 Grant Thornton
 INITIALLED FOR IDENTIFICATION
 PURPOSES ONLY
 Grant Thornton
 Accountants en Adviseurs B.V.


 19 MAY 2015

Actavis BV				
Notes to the Balance Sheet				
(All amounts are in € except share data and unless otherwise stated)				
Note 14: Trade receivables and other assets				
14.1 Trade receivable (Refer General Instructions Note No.15 & 19)				
	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful			28.000	63.000
Provision for doubtful receivables			28.000	63.000
(A)				
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others			10.237.682	9.486.455
Doubtful				
Provision for doubtful receivables			10.237.682	9.486.455
(B)				
Total (A+B)			10.237.682	9.486.455
Trade receivables include:				
	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				
14.2 Other assets (Refer General Instructions Note No 16 & 22)				
	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)				
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)				
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on investments in subsidiaries - long term				
Others: prepayments			602.006	708.844
(C)			602.006	708.844
Total (A+B+C)			602.006	708.844

 Grant Thornton
 INITIALLED FOR IDENTIFICATION
 PURPOSES ONLY
 Grant Thornton
 Accountants & Adviseurs B.V.

19 MAY 2015

Aclavis BV				
Notes to the Balance Sheet				
(All amounts are in € except share data and unless otherwise stated)				
Note 15 : Current Investments (Refer General Instructions Note No.17)				
			March 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)				
Quoted equity instruments - Non-trade				
Equity shares (fully paid-up)				
If any (Please specify)				
Note 16 : Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)				
			March 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)				
Work in - Progress				
Finished goods				
			16,028,359	13,280,850
Traded goods (including stock in-transit XXXX (31 March, 2013 XXX)				
Stores, spares, consumables and packing materials				
Loose tools				
			16,028,359	13,280,850
Note 17 : Cash and bank balances (Refer General Instructions Note No. 20)				



INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants & Tax Advisors B.V.

19 MAY 2015

Actavis BV
Notes to the statement of profit and loss

(All amounts are in € except share data and unless otherwise stated)

	Year ended March 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Note 18 : Revenue from operations (Refer General Instructions Note No.25)		
Revenue from operations		
Sale of products		
Finished goods	65.034.287	101.927.224
Traded goods		
Sale of services		
Sale of dossiers/licenses		
Other operating revenue		
Scrap sales		
Other Revenue	(1.488)	(2.024)
Less: Sales returns	50.000	(600)
Revenue from operations (gross)	65.082.799	101.924.600
Less: Discounts	20.996.893	20.296.599
Revenue from operations (net)	44.085.905	81.628.001
	32%	20%

Note 19 : Other income (Refer General Instructions Note No.26)

Interest income on		
Bank deposits		
Long-term investments	18.246	
Current investments		
Loans to joint venture entities		
Others		
Dividend income on		
Investment in subsidiaries		
Current investments		
Long-term investments		
Net gain on sale of current investmentss		
Profit on sale of fixed assets (net)		
Foreign exchange gain (net)		
Balances no longer required written back		
Government grant		
Commission income		
Processing charges		
Other non-operating income (net of expenses directly attributable to such income of Rs.XXXXX (31 March, 2014:XXXX)	18.246	-



 **Grant Thornton**
 INITIALLED FOR IDENTIFICATION
 PURPOSES ONLY

Grant Thornton
 Accountants for Actavis B.V.

Note 20 : Cost of raw material and components consumed
19 MAY 2015

Inventory at the beginning of the quarter		
Add: Purchases		
	-	-
Less: inventory at the end of the quarter		-

Actavis BV						
Notes to the statement of profit and loss						
(All amounts are in € except share data and unless otherwise stated)						
					Year ended March 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
					-	-
Add:Packing material consumed						
Cost of raw material and components consumed					-	-

 Grant Thornton
 INT. FILED FOR IDENTIFICATION
 PURPOSES ONLY
 Grant Thornton
 6000 Lehigh Valley, PA 18002-1000

 19 MAY 2015


Actavis BV

Notes to the statement of profit and loss

(All amounts are in € except share data and unless otherwise stated)


	Year ended March 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Note 21 : (Increase)/decrease in inventories		
Inventories at the end of the quarter		
Traded goods	-	-
Work-in-progress	-	-
Finished goods	16.028.359	13.280.850
	16.028.359	13.280.850
Inventories at the beginning of the quarter		
Traded goods	-	-
Work-in-progress	-	-
Finished goods	13.280.850	21.259.384
	13.280.850	21.259.384
	2.747.509	(7.978.535)
Details of purchase of traded goods		
	37.732.614	60.586.323
	37.732.614	60.586.323
Note 22 : Employee benefit expense		
Salaries, wages and bonus	4.718.729	5.303.792
Pension	440.963	(337.523)
Contribution to provident and other fund	-	-
Employee stock option scheme	-	-
Gratuity expense	-	-
Other employee benefits	58.332	46.944
Post employment medical benefits	-	-
Staff welfare expenses	-	-
	5.218.025	5.013.213
Note 23 : Other expenses		
Consumption of stores and spares	-	-
Conversion charges	-	-
Royalty on sales	26.489	-
Rebranding	7.243	-
Temporary staff	288.274	463.135
Representation	18.925	7.656
Congress and Symposias	100.163	21.834
Cleaning	29.684	29.850
Warehouse	440.657	471.254
Operating supplies	11.774	11.871
Operational lease	344.760	404.052
Statistical material	149.779	169.729
IT costs	25.547	7.661

Actavis BV		
Notes to the statement of profit and loss		
(All amounts are in € except share data and unless otherwise stated)		
	Year ended March 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Subscription and postage	162.462	150.007
Vehicle miscellaneous expenses	93.056	113.476
Chemicals consumed	-	-
Increase in VAT on finished goods	-	-
Customer service expenditure	-	-
Power and fuel	57.474	38.528
Water charges	-	-
Freight and forwarding charges	-	-
Carriage inward	-	-
Carriage outwards	418.657	459.387
Rent	294.330	240.922
Rates and taxes	4.475	4.127
Insurance	97.104	85.709
Repairs and maintenance	-	-
i) Plant and machinery	-	-
ii) Buildings	28.355	25.317
iii) Others	16.556	20.584
Advertising and sales promotion	698.787	732.187
Brokerage and discounts	-	-
Remuneration to Auditors	-	-
Sales commission	-	-
Travelling and conveyance	282.746	298.558
Communication costs	77.137	67.106
Printing and stationery	68.061	24.620
Legal and professional fees	306.591	204.590
Directors sitting fees	-	-
Payment to auditor (Refer details below)	7.542	112.937
Provision for diminution in value of investment in subsidiary company	-	-
Provision for other than temporary decline in the carrying amount of other long-term investments	-	-
Adjustment to the carrying amount of current investments	-	-
Provision for warranties (net of reversals)	-	-
Provision for litigations (net of reversals)	-	-
Exchange differences (net)	10.675	(23.704)
Loss on derivative contracts (including provisions mark-to-market loss)	-	-
Bad debts/advances written off	-	-
Impairment loss on fixed assets	-	-
Provision for doubtful debts and advances	6.044	(36.816)
Loss on sale of fixed assets (net)	2.104	446
Premium on forward exchange contract amortized	-	-
Factory maintenance	-	-
Effluent treatment expenses	-	-
Vehicle maintenance expenses	-	-


 Grant Thornton
 INITIALLED FOR IDENTIFICATION
 PURPOSES ONLY
 Grant Thornton
 Accountants & Tax Advisers B.V.

19 MAY 2015

Actavis BV		
Notes to the statement of profit and loss		
(All amounts are in € except share data and unless otherwise stated)		
	Year ended March 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Analytical charges	-	-
Product development expenses	-	-
Registration and filing charges	934.963	341.274
Safety and security	-	-
Office expenses	-	-
Repairs and maintenance - others	-	-
Management fees	481.164	-
Liquidated damages	-	-
Donations	1.857	500
Software license and implementation expenses	54.211	38.905
Capital work-in-progress written off	-	-
Miscellaneous expenses	28.422	(165.732)
	5.576.066	4.319.972
Payment to Auditor		
As auditor:		
Audit fee	34.171	88.280
Tax audit fee		
Limited review		
In other capacity:		
Taxation matters		
Company law matters		22.398
Management services		
Other services (certification fees)		
Reimbursement of expenses		
Accruals	(26.629)	2.259
	7.542	112.937

 **Grant Thornton**
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants en Adviseurs B.V.


19 MAY 2015

Actavis BV					
Notes to the statement of profit and loss					
(All amounts are in € except share data and unless otherwise stated)					
				Year ended March 31, 2015 (EUR)	Year ended March 31, 2014 (EUR)
Note 24 : Exceptional items					
Others (Specify if any)					
					-
					-
Note 25 : Depreciation and amortization expense					
Depreciation of tangible assets				55.607	77.675
Amortization of intangible assets				-	-
Depreciation of investment property					
				55.607	77.675
Note 26 : Finance costs (Refer General Instructions Note No.27)					
Interest				231.934	536.419
Bank charges				5.815	7.322
Amortization of ancillary borrowing costs					
Exchange difference to the extent considered as an adjustment to borrowing costs					
				237.749	543.741

 Grant Thornton
INITIALLED FOR IDENTIFICATION
PURPOSES ONLY

Grant Thornton
Accountants and Tax Advisors B.V.


19 MAY 2015

Notes to the 2014-2015 financial statements

General

Relationship with parent company and principal activities

Actavis B.V., hereafter the company, having its legal address in Baarn: Baarnsche Dijk 1, 3741 LN Baarn, is a private limited liability company under Dutch law, with 100% of its shares held by Agile Pharma B.V. The ultimate parent company is Aurobindo Pharma Limited, seated in Hyderabad, India.

The activities of the company concern the import, distribution and sales of pharmaceutical products.

Going concern

These financial statements have been prepared on the basis of the going concern assumption. However, because of the financial position of the Company, there is significant doubt on the entity's ability to continue as a going concern without support of the Parent Company.

During the financial year being reported, the Company was acquired by Aurobindo Pharma Ltd in India. Aurobindo's forecast and projections, is to use the Company for the distribution of Aurobindo manufactured products in Europe. Thus benefiting both from an increased market share.

Considering the factors above, after making enquiries, the directors have reasonable expectation that, with Parent Company support, the Company has adequate resources to continue in operation.

Comparative figures


The accounting policies have been consistently applied to all years presented. The comparative figures are 12 months.

Use of estimates

The preparation of the financial statements requires the management to form opinions and to make estimates and assumptions that influence the application of principles and the reported values of assets and liabilities and of income and expenditure. Actual results may differ from these estimates. The estimates and the underlying assumptions are constantly assessed. Revisions of estimates are recognised in the period in which the estimate is revised and in future periods for which the revision has consequences.

Aurobindo

Baarnsche Dijk 1 - Postbus 313 - 3740 AH Baarn - Tel: +31 (0)35 542 99 33 - Fax: +31 (0)35 542 99 32 - Email: info@eurobindo.com
IBAN: NL72 ABNA 0430 0121 95 - BIC: ABNANL2A - BTW: NL 0027.24.352.B01 - K.v.K. Hilversum 32030582 - www.aurobindo.nl



General policies

Basis of preparation

The financial statements have been prepared in accordance with the statutory provisions of Part 9, Book 2 of the Dutch Civil Code and the firm pronouncements in the Guidelines for Annual Reporting in the Netherlands as issued by the Dutch Accounting Standards Board.

In general, assets and liabilities are stated at the amounts at which they were acquired or incurred, or current value. If not specifically stated otherwise, they are recognised at the amounts at which they were acquired or incurred. The balance sheet and profit and loss account include references to the notes.

An asset is disclosed in the balance sheet when it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the cost of the asset can be measured reliably. A liability is recognised in the balance sheet when it is expected to result in an outflow from the entity of resources embodying economic benefits and the amount of the obligation can be measured with sufficient reliability.

Income is recognised in the profit and loss account when an increase in future economic potential related to an increase in an asset or a decrease of a liability has arisen, the size of which can be measured reliably. Expenses are recognised when a decrease in the economic potential related to a decrease in an asset or an increase of a liability has arisen, the size of which can be measured with sufficient reliability.

If a transaction results in a transfer of future economic benefits and or when all risks relating to assets or liabilities transfer to a third party, the asset or liability is no longer included in the balance sheet. Assets and liabilities are not included in the balance sheet if economic benefits are not probable and/or cannot be measured with sufficient reliability.

The revenue and expenses are allocated to the period to which they relate. Revenues are recognized when the company has transferred the significant risks and rewards of ownership of the goods to the buyer.

Foreign currencies

The financial statements are presented in euros, the company's functional and presentation currency.

Transactions in foreign currencies

Transactions denominated in foreign currency are translated into the relevant functional currency of the former group company Actavis Group hf. at the exchange rate applying on the transaction date. Monetary assets and liabilities denominated in foreign currency are translated at the balance sheet date into to the functional currency at the exchange rate applying on that date. Non-monetary assets and liabilities in foreign currency that are stated at historical cost are translated into euros at the applicable exchange rates applying on the transaction date. Translation gains and losses are taken to the profit and loss account as expenditure.



Financial assets and liabilities

Receivables

Receivables are carried at amortised cost on the basis of the effective interest method, less impairment losses.

Financial liabilities

Financial commitments that are not held for trading are carried at amortised cost on the basis of the effective interest rate method.

Impairment of financial assets

Objective evidence that financial assets are impaired includes default or delinquency by a debtor, indications that a debtor or issuer will enter bankruptcy, adverse changes in the payment status of borrowers or issuers, economic conditions that correlate with defaults or the disappearance of an active market for a security.

The entity considers evidence of impairment for financial assets measured at amortised cost (receivables) at both a specific asset and collective level. All individually significant assets are assessed for specific impairment. Those found not to be specifically impaired are then collectively assessed for any impairment that has been incurred but not yet identified. Assets that are not individually significant are collectively assessed for impairment by grouping together assets with similar risk characteristics.

In assessing collective impairment, the company uses historical trends of the probability of default, the timing of recoveries and the amount of loss incurred, adjusted for management's judgement as to whether current economic and credit conditions are such that the actual losses are likely to be greater or lesser than suggested by historical trends.

An impairment loss in respect of a financial asset measured at amortised cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognised in profit or loss and reflected in an allowance account against receivables. Interest on the impaired asset continues to be recognised. When an event occurring after the impairment was recognised causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss.

Tangible fixed assets

Land and buildings, prepayments on tangible fixed assets and other fixed operating assets are stated at cost of acquisition or manufacture, less accumulated depreciation.

Depreciation is recognised in profit or loss on a straight-line basis over the estimated useful lives of each item of the tangible fixed assets. Land, tangible fixed assets in production and prepayments on tangible fixed assets are not depreciated.

The following rates of depreciation are applied:

- buildings: 10%;
- other fixed operating assets: 10-20%.



Impairment

Assets with a long life should be tested for impairment in the case of changes or circumstances arising that lead to an indication that the carrying amount of the asset will not be recovered. The recoverability of assets in use is determined by comparing the carrying amount of an asset with the estimated present value of the future net cash flows which the asset is expected to generate.

If the carrying amount of an asset exceeds the estimated present value of the future cash flows, impairment is charged to the difference between the carrying amount and the recoverable amount.

Impairment of fixed assets

As at each balance sheet date, the Company tests whether there are any indications of assets being subject to impairment. If any such indications exist, the recoverable amount of the asset is determined. If this proves to be impossible, the recoverable amount of the cash-generating unit to which the asset belongs is identified. An asset is subject to impairment if its carrying amount exceeds its recoverable amount; the recoverable amount is the higher of an asset's fair value less costs to sell and value in use.

An impairment loss is directly expensed in the income statement.

If it is established that a previously recognised impairment loss no longer applies or has declined, the increased carrying amount of the assets in question is not set any higher than the carrying amount that would have been determined had no asset impairment been recognised.

Inventories

Raw materials and consumables are stated at the lower of cost and net realisable value. Cost is determined using the first in, first out (FIFO) method.

Inventories of finished or partially finished goods are stated at the lower of manufacturing price and net realisable value. Manufacturing price comprises all purchase or conversion costs, and other costs incurred in bringing the inventories to their present location and condition. Conversion cost includes direct labour costs and mark-ups for fixed and variable production overheads, including costs of the production planning department, maintenance division and internal logistics.

Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. Net realisable value is determined making allowance for obsolescence of inventories.

Receivables

The accounting policies applied for the valuation of trade and other receivables are described under the heading 'Financial instruments'.

Cash and cash equivalents

Cash and cash equivalents include cash in hand and bank balances with maturities of less than 12 months. Bank overdrafts are shown within borrowings in current liabilities on the balance sheet. Cash and cash equivalents are stated at face value.



Provisions

A provision is recognised if the following applies:

- the company has a legal or constructive obligation, arising from a past event; and
- the amount can be estimated reliably; and
- it is probable that an outflow of economic benefits will be required to settle the obligation.

The fringe benefits provision is valued based on the number of years an employee is employed for Actavis B.V. and the expectation of staying until the jubileum benefit may be received, weighted against salary.

Revenue recognition

Sale of goods

Revenue from the sale of goods is measured at the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates. Revenue is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of consideration is probable, the associated costs and possible return of goods can be estimated reliably, and there is no continuing management involvement with the goods.

The transfer of risks and benefits varies according to the conditions of the relevant sales contract.

Cost of sales

This concerns costs that are directly attributable to net turnover.

Selling expenses and general and administrative expenses

Selling expenses and general and administrative expenses comprise costs chargeable to the year that are not directly attributable to the cost of the goods and services sold.

Operating leases

Lease contracts for which a large part of the risks and rewards incidental to ownership of the assets does not lie with the Company, are recognised as operating leases. Obligations under operating leases are recognised on a straight-line basis in the income statement over the term of the contract, taking into account reimbursements received from the lessor.

Employee benefits/pensions

Dutch pension plans

The main principle is that the pension charge to be recognised for the reporting period should be equal to the pension contributions payable to the insurance company over the period. Insofar as the payable contributions have not yet been paid as at balance sheet date, a liability is recognised. If the contributions already paid exceed the payable contributions as at balance sheet date, a receivable is recognised to account for any repayment by the insurance company or settlement with contributions payable in future.



In addition, a provision is included as at balance sheet date for existing additional commitments to the insurance company and the employees, provided that it is likely that there will be an outflow of funds for the settlement of the commitments and it is possible to reliably estimate the amount of the commitments. The existence or non-existence of additional commitments is assessed on the basis of the administration agreement concluded with the insurance company, the pension agreement with the staff and other (explicit or implicit) commitments to staff. The liability is stated at the best estimate of the present value of the anticipated costs of settling the commitments as at balance sheet date.

The employees of Actavis B.V. in the Netherlands have a pension scheme which is funded through a guaranteed insurance contract with Delta Lloyd. The scheme is a conditionally indexed average-salary scheme. Entitlements and rights that have been granted are only indexed (adjusted in line with rising prices) if and to the extent that the board has decided accordingly. The pension scheme is classified as a defined-benefit agreement under the Pensions Act.

Interest paid and received

Interest paid and received is recognised on a time-weighted basis, taking account of the effective interest rate of the assets and liabilities concerned. When recognising interest paid, allowance is made for transaction costs on loans received as part of the calculation of effective interest.

Corporate income tax

Corporate income tax comprises the current and deferred corporate income tax payable and deductible for the reporting period.


Corporate income tax is recognised in the profit and loss account except to the extent that it relates to items recognised directly to equity, in which case it is recognised in equity.

Current tax comprises the expected tax payable or receivable on the taxable profit or loss for the financial year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to the tax payable in respect of previous years.

Deferred tax is provided for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilised. Deferred tax assets are reviewed at each reporting date and reduced to the extent that it is no longer probable that the related tax benefit will be realised.

Baarn, 18 May 2015



M.B. van Loenen
Director

DIRECTORS' REPORT

The directors present their report and the audited financial statements for the year ended 31st March 2015.

PRINCIPAL ACTIVITY

The principle object of the company is to trade and deal in pharmaceutical products and other allied products and services.

Unusual Items after the Financial Year:

No item, transaction or event of a Material nature has arisen during the period between the end of the financial year and the date of this report, which would affect substantially the operations of the company during the current year.

REVIEW OF OPERATIONS

Your company had registered a loss of THB 6,079,875 against a Sale of THB 120,159,938 and in previous year it made a Loss of THB 14,889,730 against a Sale of THB 182,225,819. With the support and guidance of the holding company and with trading of new products which are at final stage of registration, your directors are confident that your company can achieve better results in the future.

Statement of Directors:


In the opinion of the Directors, the accompanying Financial statements were drawn up so as to give a true and fair view of the state of affairs of the Company as on 31st March 2015 and the results of the business for that period. Your Directors have taken all reasonable steps to prepare these financial statements on a going concern basis and suitable accounting policies have been adopted consistently. Further your Directors are confident that with the support and guidance of the Holding company, your Company can achieve better results in the future.

DIRECTORS

The Directors at the date of the report are:

1. Mr.Phaneendra Prasad Gorla
2. Mr. M.V Sastry

By Order of the Board



Mudigonda Veerabhadra Sastry.
Director
Thailand



Prime Management

APL PHARMA THAI LTD.

AUDIT CLEARANCE LETTER

For the attention of Group Company Auditors

Dear Sir,

We have audited the attached financial statements of APL Pharma Thai Ltd. as of and for the year ended 31 March 2015. The financial statements are the responsibility of the Company's management as to their correctness and completeness of the presentation. Our responsibility is to express an opinion on them based on our audit.

We conducted our audit of these financial statements in accordance with Generally Accepted Auditing Standards. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the statutory financial statements are free of material misstatement. An audit also includes examining on a test basis, evidence supporting the amounts and disclosures in the statutory financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the statutory financial statements' presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, a true and fair view of the financial position of APL Pharma Thai Ltd. as at 31 March 2015 and the results of its operation for the year from 1 April 2014 to 31 March 2015 in conformity with generally accepted accounting principles.

We draw attention to Annexure 16 to the financial statements which describe the management is aware in making its assessment of the uncertainties related to the experiencing losses.

Yours faithfully,

Prime Management.

PRIME MANAGEMENT

Bangkok
23 April 2015

APL Pharma Thai Ltd.
Balance Sheet as at March 31, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	31 March, 2015 (THB)	31 March, 2014 (THB)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	100,000,000.00	100,000,000.00
Share application money			
Reserves and surplus	3	(7,038,435.34)	(958,559.86)
		<u>92,961,564.66</u>	<u>99,041,440.14</u>
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	840,000.00	1,471,710.00
		<u>840,000.00</u>	<u>1,471,710.00</u>
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	42,223,013.65	24,798,283.62
Other current liabilities	9	1,432,489.23	1,712,599.91
Short-term provisions	7	-	-
		<u>43,655,502.88</u>	<u>26,510,883.53</u>
TOTAL		<u><u>137,457,067.54</u></u>	<u><u>127,024,033.67</u></u>
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	209,367.55	272,932.16
Intangible assets	11	-	-
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5		
Long-term loans and advances	13	-	-
Trade receivables	14.1	506,795.00	506,795.00
Other non-current assets	14.2	-	-
		<u>716,162.55</u>	<u>779,727.16</u>
Current assets			
Current investments	15	-	-
Inventories	16	25,107,599.18	8,284,815.84
Trade receivables	14.1	81,810,343.09	91,948,074.80
Cash and bank balances	17	23,437,859.89	21,100,174.91
Short-term loans and advances	13	95,810.01	46,192.61
Other current assets	14.2	6,289,292.82	4,865,048.35
		<u>136,740,904.99</u>	<u>126,244,306.51</u>
TOTAL		<u><u>137,457,067.54</u></u>	<u><u>127,024,033.67</u></u>
Summary of significant accounting policies		1	

The accompanying notes are an integral part of the financial statements.

Note 1: Summary of significant accounting policies (Refer General Instructions Note No.1)

The financial statements have been prepared in accordance with Generally Accepted Accounting Practice & on the historical cost basis, and incorporate the principal accounting policies set out below...

1.1 Fixed Assets

The cost of an item of fixed asset is recognised as an asset when:

- is probable that future economic benefits associated with the item will flow to the company; and
- cost of the item can be measured reliably.

The useful lives of items of property, plant and equipment have been assessed as follows:

Furniture and fixtures	- 5 years
Office equipment	- 5 years

1.2 Intangible assets

An Intangible asset is recognised when:

Intangible assets license granted by the FDA for import finished medicines from overseas which are stated at cost less accumulated amortization and impairment loss.

- Intangible asset of the company are indefinite life assets which are amortized on a straight-line basis over the estimated useful lives of 10 years as specific by the new accounting standard.

Amortisation is charged to the statement of income.

1.3 Inventories

Inventories are measured at the lower of cost and net realisable value.

1.4 Revenue

Revenue from the sale of goods is recognised when all the following conditions have been satisfied:

- the company has transferred to the buyer the significant risks and rewards of ownership of the goods;
- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the company; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.5 Cost of Sales


When inventories are sold, the carrying amount of those inventories is recognised as an expense in the period in which the related revenue is recognised.

The amount of any write-down of inventories to net realisable value and all losses of inventories are recognised as an expenses in the period the write-down or loss occurs.

The amount of any reversal of any write-down of inventories, arising from an increase in net realisable value, is recognised as a reduction in the amount of inventories recognised as an expenses in the period in which the reversal occurs.

Note 2: Share capital (Refer General Instructions Note No.2)

	March 31, 2015	March 31, 2014
Authorised shares:		
40,000 ordinary shares of baht 100 each	4,000,000.00	4,000,000.00
960,000 ordinary shares of baht 100 each	96,000,000.00	96,000,000.00
	<u>100,000,000.00</u>	<u>100,000,000.00</u>
Issued, Subscribed and Fully Paid-up shares:		
1,000,000 ordinary shares of baht 100 each, fully paid-up	<u>100,000,000.00</u>	<u>100,000,000.00</u>



Note 3 : Reserves and surplus (Refer General Instructions Note No.3)

	March 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	-	-
Capital Redemption Reserve	-	-
Securities Premium Account		
As per last Balance Sheet	-	-
General Reserve		
As per last Balance Sheet	400,000.00	400,000.00
Add: Transferred from statement of profit and loss	-	-
	400,000.00	400,000.00
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	(1,358,559.86)	13,531,170.31
Profit for the quarter	(6,079,875.48)	(14,889,730.17)
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)	-	-
Tax on proposed equity dividend	-	-
Interim dividend paid (amount per share XX (31 March, 2014 XX)	-	-
Transfer to general reserve	-	-
Total appropriations	-	-
Net surplus in the statement of profit and loss	(7,438,435.34)	(1,358,559.86)
Total reserves and surplus	(7,038,435.34)	(958,559.86)

Note 4 : Long -term borrowings (Refer General Instructions Note No.4)

	Non-current Portion		Current maturities	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)	-	-	-	-
Other Loans from banks	-	-	-	-
Current account credit balance	-	-	-	-
Loans and advances from related parties	-	-	-	-
Other Loans and advances	-	-	-	-
Sales tax deferment loan (Un Secured)	-	-	-	-
	-	-	-	-
The above amount includes				
Secured borrowings	-	-	-	-
Unsecured borrowings	-	-	-	-
Amount disclosed under the head	-	-	-	-
"Other current liabilities"	-	-	-	-
Net Amount	-	-	-	-

Stamped for the purpose of identification

Prime Management

23 APR 2015

Bangkok

Note 5: Deferred tax liability (net)

	March 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis	-	-
Provision for diminution in the value of investments	-	-
Provision for doubtful debts and advances	-	-
Fixed Assets (Depreciation)	-	-
Retirement Benefits	-	-
Others	-	-
Gross deferred tax liability	-	-
Deferred tax asset		
Carried Forward Business Losses	-	-
Others	-	-
Gross deferred tax asset	-	-
Net deferred tax liability	-	-

Note 6: Other long-term liabilities (Refer General Instructions Note No.5)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances)	-	-
Other liabilities	-	-
Advances from related parties	-	-

Note 7: Provisions (Refer General Instructions Note No.6 & 10)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Provision for employee benefits				
- Gratuity	840,000.00	1,471,710.00	-	-
- Leave encashment	-	-	-	-
	840,000.00	1,471,710.00	-	-
Other Provisions				
For Taxation (net of advance payments)	-	-	-	-
For Proposed dividend	-	-	-	-
For Tax on proposed dividend	-	-	-	-
	840,000.00	1,471,710.00	-	-

Provision for warranties


	March 31, 2015	March 31, 2014
At the beginning of the year	-	-
Arising during the period	-	-
Utilised during the period	-	-
Unused amounts reversed	-	-
At the end of the year	-	-
Current portion	-	-
Non-current portion	-	-

Note 8: Short-term borrowings (Refer General Instructions Note No.7)

	March 31, 2015	March 31, 2014
Bank overdraft	-	-
Loans and advances from related parties	-	-
Working capital loans (Secured)	-	-
Short term loans (Un Secured)	-	-
Working capital loans	-	-
The above amount includes		
Secured borrowings	-	-
Unsecured borrowings	-	-

Note 9: Other current liabilities (Refer General Instructions Note No.9)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)	42,223,013.65	24,798,283.62
Other liabilities	30,086.47	20,867.91
Current maturities of long-term borrowings	-	-
Advances from customers	1,402,402.76	1,691,732.00
Unclaimed dividends	-	-
Interest accrued but not due on loans	-	-
Trade deposits	1,432,489.23	1,712,599.91
	43,655,502.88	26,510,883.53



Name of the company
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

Note 10 : Tangible assets (Refer General Instructions Note No.12)

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment	Computers	Computer Software	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation											
At 1 April 2013	-	-	49,120.00	-	52,548.09	-	-	877,619.45	2,898,380.87	844,720.47	4,722,388.88
Additions	-	-	14,000.00	-	-	-	-	21,432.30	-	117,216.50	132,648.80
Disposals	-	-	-	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	-	-	-	-	-	1,281.78	1,281.78
- Exchange differences	-	-	-	-	-	-	-	-	-	-	-
- Borrowing costs	-	-	-	-	-	-	-	-	-	-	-
At 31 March 2014	-	-	63,120.00	-	52,548.09	-	-	899,051.75	2,898,380.87	960,655.19	4,873,755.90
Additions	-	-	-	-	-	-	-	17,146.28	-	6,323.13	23,469.41
Acquisitions through amalgamation	-	-	-	-	-	-	-	-	-	-	-
Disposals	-	-	-	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	-	-	-	-	-	-	-
- Exchange differences	-	-	-	-	-	-	-	-	-	-	-
- Borrowing costs	-	-	-	-	-	-	-	-	-	-	-
At 31 March 2015	-	-	63,120.00	-	52,548.09	-	-	916,198.03	2,898,380.87	966,978.32	4,897,225.31
Depreciation											
At 1 April 2013	-	-	49,119.00	-	39,447.33	-	-	745,097.23	2,898,374.87	785,691.48	4,517,729.91
Charge for the year	-	-	5,964.38	-	4,212.64	-	-	31,695.30	-	41,242.58	83,114.90
Disposals	-	-	-	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	-	-	-	-	-	21.07	21.07
- Exchange differences	-	-	-	-	-	-	-	-	-	-	-
At 31 March 2014	-	-	55,083.38	-	43,659.97	-	-	776,792.53	2,898,374.87	826,912.99	4,600,823.74
Charge for the period	-	-	6,999.99	-	3,759.18	-	-	34,239.11	-	42,035.74	87,034.02
Disposals	-	-	-	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	-	-	-	-	-	-	-
- Exchange differences	-	-	-	-	-	-	-	-	-	-	-
At 31 March 2015	-	-	62,083.37	-	47,419.15	-	-	811,031.64	2,898,374.87	868,948.73	4,687,857.76
Impairment loss											
At 1 April 2013	-	-	-	-	-	-	-	-	-	-	-
At 31 March 2014	-	-	-	-	-	-	-	-	-	-	-
Charge for the period	-	-	-	-	-	-	-	-	-	-	-
At 31 March 2015	-	-	-	-	-	-	-	-	-	-	-
Net Block											
At 31 March 2014	-	-	8,036.62	-	8,888.12	-	-	122,259.22	6.00	133,742.20	272,932.16
At 31 March 2015	-	-	1,036.63	-	5,128.94	-	-	105,166.39	6.00	96,029.59	209,367.55

Stamped for the purposes of identification

Primo Management

23 APR 2015

Bangkok

Name of the company
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

Note 11 : Intangible assets (Refer General Instructions Note No.12)

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At 1 April 2013	-	-	-	-
Purchase	-	-	-	-
Internal development	-	-	-	-
Disposals	-	-	-	-
Other adjustments				
- Exchange differences	-	-	-	-
At 31 March 2014	-	-	-	-
Purchase	-	-	-	-
Acquisitions through amalgamation	-	-	-	-
Disposals	-	-	-	-
Other adjustments				
- Exchange differences	-	-	-	-
At 31 March 2015	-	-	-	-
Amortization				
At 1 April 2013	-	-	-	-
Charge for the year	-	-	-	-
Disposals	-	-	-	-
Other adjustments				
- Exchange differences	-	-	-	-
At 31 March 2014	-	-	-	-
Charge for the period	-	-	-	-
Disposals	-	-	-	-
Other adjustments				
- Exchange differences	-	-	-	-
At 31 March 2015	-	-	-	-
Net Block				
At 31 March 2014	-	-	-	-
At 31 March 2015	-	-	-	-

Stamped for the purpose of identification

Prime Management

23 APR 2015

Signature

Note 12: Non-current investments (Refer General Instructions Note No.13)


	March 31, 2015	March 31, 2014
Unquoted equity instruments		
Investment in subsidiaries	-	-
Investment in joint ventures	-	-
Investment in associates	-	-

Note 13: Loans and advances (Refer General Instructions Note No.14 & 21)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Capital advances				
Secured, considered good	-	-	-	-
Unsecured, considered good	-	-	-	-
(A)	-	-	-	-
Security deposit				
Secured, considered good	-	-	-	-
Unsecured, considered good	-	-	-	-
Doubtful	-	-	-	-
Provision for doubtful security deposit	-	-	-	-
(B)	-	-	-	-
Loan and advances to related parties				
Unsecured, considered good	-	-	-	-
(C)	-	-	-	-
Advances recoverable in cash or kind				
Secured, considered good	-	-	-	-
Unsecured, considered good	-	-	-	-
Doubtful	-	-	-	-
Provision for doubtful advances	-	-	-	-
(D)	-	-	-	-
Other loans and advances				
Advance income-tax (net of provision for taxation)	-	-	-	-
Prepaid expenses	-	-	-	-
Loans to employees	-	-	49,500.00	20,880.00
Loans to others	-	-	46,310.01	25,312.61
Export incentives receivable	-	-	-	-
Export incentives licenses	-	-	-	-
Balances with Statutory/government authorities	-	-	-	-
(E)	-	-	95,810.01	46,192.61
Total (A+B+C+D+E)	-	-	95,810.01	46,192.61

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors	-	-	-	-
Dues from officers	-	-	-	-
Dues from non-executive and officers jointly with other persons	-	-	-	-
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner	-	-	-	-
Dues from in which the company's managing director is a member	-	-	-	-
Dues from the partnership firm in which the company's non-executive director is a partner	-	-	-	-



Note 14: Trade receivables and other assets

14.1 Trade receivable (Refer General Instructions Note No.15 & 19)


	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Secured, considered good				
Due from group companies	-	-	-	-
Due from others	-	-	-	-
Unsecured, considered good				
Due from group companies	-	-	-	-
Due from others	-	-	-	-
Doubtful	506,795.00	506,795.00	-	-
Provision for doubtful receivables	506,795.00	506,795.00	-	-
(A)	506,795.00	506,795.00	-	-
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies	-	-	-	-
Due from others	-	-	-	-
Unsecured, considered good				
Due from group companies	-	-	-	-
Due from others	-	-	81,810,343.09	91,948,074.80
Doubtful	-	-	81,810,343.09	91,948,074.80
Provision for doubtful receivables	-	-	81,810,343.09	91,948,074.80
(B)	-	-	81,810,343.09	91,948,074.80
Total (A+B)	506,795.00	506,795.00	81,810,343.09	91,948,074.80

Trade receivables include:

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Due from non-executive directors	-	-	-	-
Due from officers	-	-	-	-
Due from non-executive directors and officers jointly with other persons	-	-	-	-
Dues from partnership firm in which the company's non-executive director is a partner	-	-	-	-
Dues from in which the company's non-executive director is a director	-	-	-	-

14.2 Other assets (Refer General Instructions Note No.16 & 22)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances	-	-	-	-
(A)	-	-	-	-
Unamortized expenditure	-	-	-	-
Unamortized premium on forward contract	-	-	-	-
Ancillary cost of arranging the borrowings	-	-	-	-
(B)	-	-	-	-
Others				
Interest accrued on fixed deposits	-	-	-	-
Interest accrued on investments	-	-	-	-
Dividend receivable on investments in subsidiaries - long term	-	-	-	-
VAT Opening balance	-	-	5,621,694.27	3,940,502.59
Accrued income	-	-	119,096.79	137,580.08
Income tax - customer	-	-	-	209,605.89
Income tax - bank interest	-	-	1,001.21	7,164.59
Prepaid expenses	-	-	35,526.26	37,960.76
Undue input tax	-	-	7,466.97	4,941.40
FDA Licenses	-	-	463,840.00	389,840.00
Accumulated Amortization - FDA Licenses	-	-	(164,610.68)	(123,576.96)
Other deposit	-	-	23,700.00	35,700.00
Rental deposit	-	-	60,000.00	225,330.00
Professional fee line FDA Licenses	-	-	110,000.00	-
Bank Guarantee	-	-	11,578.00	-
Others	-	-	-	-
(C)	-	-	6,289,292.82	4,865,048.35
Total (A+B+C)	-	-	6,289,292.82	4,865,048.35



Note 15: Current Investments (Refer General Instructions Note No.17)


	March 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)	-	-
If any (Please specify)	-	-

Note 16: Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)

	March 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX))	-	-
Work - in - Progress	-	-
Finished goods	26,852,037.36	9,574,734.37
Traded goods (including stock -in-transit XXXX (31 March, 2014 XXXX))	-	-
Stores, spares, consumables and packing materials	-	-
Loose tools	(1,744,438.18)	(1,289,918.53)
	25,107,599.18	8,284,815.84

Note 17: Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts	-	-	1,726,505.69	833,080.28
On saving accounts	-	-	1,417,553.51	483,695.96
Deposits with original maturity of less than 3 months	-	-	-	-
Cash credit accounts	-	-	-	-
On unpaid dividend account	-	-	-	-
Cheques/drafts on hand	-	-	-	-
Unpaid matured deposits	-	-	-	-
Cash on hand	-	-	17,069.83	10,657.65
	-	-	3,161,129.03	1,327,433.89
Other bank balances				
Deposits with original maturity for more than 12 months	-	-	2,907,299.19	2,822,084.15
Deposits with original maturity for more than 3 months but less than 12 months	-	-	17,369,431.67	16,950,656.87
Margin money deposit	-	-	-	-
	-	-	20,276,730.86	19,772,741.02
Amount disclosed under non-current assets	-	-	-	-
	-	-	23,437,859.89	21,100,174.91



APL Pharma Thai Ltd.
Statement of profit and loss for the year ended March 31, 2015
(All amounts are in Local Currency except share data and unless otherwise stated)

	Now	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	March-15	Year ended March 31, 2015 (THB)	Year ended March 31, 2014 (THB)
Income															
Revenue from operations (gross)	18	1,988,211.20	254,200.00	3,881,450.00	6,634,188.75	10,241,918.00	5,172,482.50	2,873,150.00	8,413,300.00	12,521,817.50	12,744,700.00	16,974,108.56	38,460,411.20	120,159,937.71	182,223,819.47
Less: Excise duty/ Rebates		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from operations (net)		1,988,211.20	254,200.00	3,881,450.00	6,634,188.75	10,241,918.00	5,172,482.50	2,873,150.00	8,413,300.00	12,521,817.50	12,744,700.00	16,974,108.56	38,460,411.20	120,159,937.71	182,223,819.47
Other income	19	285,621.66	206,978.18	43,292.49	233,129.63	169,032.81	151,632.77	93,299.84	106,390.52	637,528.33	337,456.09	325,646.71	200,195.17	2,785,701.41	7,756,368.76
Total revenue (I)		2,273,832.86	461,178.18	3,924,742.49	6,867,318.38	10,410,950.81	5,324,115.27	2,966,449.84	8,519,690.52	13,159,345.83	13,077,156.09	17,299,755.28	38,660,606.37	122,945,639.12	189,980,188.23
Expenses															
Cost of raw material and components consumed	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods	21	234,136.57	-	3,732,036.87	10,766,917.19	9,103,352.14	8,870,480.35	4,132,408.12	24,672,755.46	20,914,254.31	11,342,407.81	23,986,239.58	20,565,655.92	138,326,346.12	172,621,549.00
(Increase)/ decrease in inventories of finished goods, work-in-progress and traded goods	21	1,536,260.73	267,657.86	473,026.06	(4,359,030.85)	1,618,671.34	(3,874,979.41)	(890,766.58)	(16,365,767.55)	(8,340,415.99)	2,942,172.15	(11,669,270.36)	21,218,529.34	(17,443,613.46)	13,482,769.81
Employee benefit expense	22	253,619.39	217,347.13	181,364.46	181,778.04	183,693.27	186,893.46	192,549.09	187,048.57	325,938.58	189,798.44	183,259.06	187,820.84	2,471,108.75	4,921,264.98
Other expenses	23	303,096.16	593,534.90	550,082.34	516,335.66	364,409.80	406,690.26	270,745.73	666,035.08	669,281.97	763,470.34	192,309.19	434,087.73	5,549,499.16	13,730,267.20
Exceptional items	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total (II)		2,777,112.85	1,073,539.91	4,936,509.53	7,105,998.04	11,075,126.35	5,588,043.06	3,705,136.36	8,960,071.56	13,569,028.87	15,239,986.74	12,492,537.47	42,426,093.83	228,903,338.57	204,255,850.99
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		(453,279.79)	(612,361.73)	(1,011,767.04)	(238,679.66)	(664,175.54)	(263,927.79)	(738,686.52)	(446,771.04)	(409,686.04)	(2,161,442.65)	4,807,217.81	(3,765,487.46)	(5,957,699.45)	(14,773,662.76)
Depreciation and amortization expense	25	7,259.98	7,502.00	7,249.33	7,451.90	7,469.90	7,293.12	7,559.30	7,423.36	7,213.28	7,853.83	6,373.94	6,984.06	87,034.02	83,093.83
Finance costs	26	2,085.00	1,085.00	833.00	10,674.63	2,385.00	1,325.00	585.00	1,882.50	1,545.00	10,851.88	995.00	795.00	35,142.01	32,973.58
Profit/(loss) before tax		(462,624.77)	(625,944.73)	(1,019,649.37)	(256,806.19)	(674,030.44)	(272,587.91)	(746,830.82)	(449,686.90)	(418,444.32)	(2,179,648.38)	4,799,848.87	(3,773,266.32)	(6,079,875.48)	(14,889,730.17)
Tax expenses															
Current tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: MAT credit entitlement		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fringe benefit tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax relating to previous years		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total tax expense		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Profit/(loss) for the year		(462,624.77)	(625,944.73)	(1,019,649.37)	(256,806.19)	(674,030.44)	(272,587.91)	(746,830.82)	(449,686.90)	(418,444.32)	(2,179,648.38)	4,799,848.87	(3,773,266.32)	(6,079,875.48)	(14,889,730.17)

Summary of significant accounting policies

The accompanying notes are an integral part of the financial statements.

1

Stamped for the purpose of identification

Prime Management

23 APR 2015

Signature

AFL Pharma Thai Ltd.
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (THB)	Year ended March 31, 2014 (THB)
Note 18: Revenue from operations (Refer General Instructions Note No.25)														
Revenue from operations														
Sale of products														
Finished goods	256,211.20	-	-	2,492,438.75	-	2,015,232.50	-	-	-	-	-	1,487,411.20	6,251,293.65	3,985,832.22
Traded goods	1,730,000.00	254,200.00	3,681,450.00	4,141,750.00	10,241,918.00	3,157,250.00	2,873,150.00	8,413,300.00	12,521,817.50	12,744,700.00	16,974,108.56	36,973,000.00	113,906,644.06	178,239,967.25
Sale of services	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of dosages/licenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other operating revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Scrap sales	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from operations (gross)	1,988,211.20	254,200.00	3,681,450.00	6,634,188.75	10,241,918.00	5,172,482.50	2,873,150.00	8,413,300.00	12,521,817.50	12,744,700.00	16,974,108.56	38,460,411.20	120,159,937.71	182,225,819.47
Less: VAT/Excise duty/Rebates	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from operations (net)	1,988,211.20	254,200.00	3,681,450.00	6,634,188.75	10,241,918.00	5,172,482.50	2,873,150.00	8,413,300.00	12,521,817.50	12,744,700.00	16,974,108.56	38,460,411.20	120,159,937.71	182,225,819.47
Note 19: Other Income (Refer General Instructions Note No.26)														
Interest Income on														
Bank deposits	45,425.11	47,163.40	43,292.49	43,097.40	36,378.59	38,929.95	40,227.74	39,123.32	43,680.48	40,415.09	36,705.89	40,638.66	495,278.12	581,477.12
Long-term investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loans to joint venture entities	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Others	-	-	-	2,546.96	15,175.59	2,514.65	-	-	579,600.00	(3,000.00)	23,110.00	46.92	619,994.12	8,092.85
Dividend Income on														
Investment in subsidiaries	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net gain on sale of current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Profit on sale of fixed assets (net)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Foreign exchange gain (net)	240,196.75	159,814.78	-	187,485.27	117,478.63	110,186.17	53,072.10	67,267.20	14,044.85	295,541.00	265,830.83	159,509.59	1,670,429.17	6,664,798.79
Balance no longer required written back	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Government grant	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Commission income	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Processing charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other non-operating income (net of expenses directly attributable to such income of Ba.XXXXX (31 March, 2014:XXXX))	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	285,621.86	206,978.18	43,292.49	233,129.63	169,032.61	151,632.77	93,299.84	106,390.52	637,525.33	332,956.09	325,646.72	200,195.17	2,785,701.41	7,250,368.76
Note 20: Cost of raw material and components consumed														
Inventory at the beginning of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add: Purchases	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Inventory at the end of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add: Packing material consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of raw material and components consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Stamped for the purpose of identification

Prime Management

23 APR 2015

English

APL Pharma Thai Ltd.
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (THB)	Year ended March 31, 2014 (THB)
Note 21 : (Increase)/decrease in inventories														
Inventories at the end of the period														
Traded goods	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Work-in-progress	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Finished goods	(7,637,335.43)	(7,369,677.57)	(6,875,131.26)	(11,234,162.11)	(9,747,469.26)	(13,622,448.67)	(14,513,215.25)	(30,878,982.80)	(39,166,898.79)	(34,406,780.37)	(48,070,566.70)	(26,852,037.36)	(26,852,037.36)	(9,574,734.37)
	(7,637,335.43)	(7,369,677.57)	(6,875,131.26)	(11,234,162.11)	(9,747,469.26)	(13,622,448.67)	(14,513,215.25)	(30,878,982.80)	(39,166,898.79)	(34,406,780.37)	(48,070,566.70)	(26,852,037.36)	(26,852,037.36)	(9,574,734.37)
Less: Other Adjustments														
	(1,138.21)	-	(21,820.25)	-	(68,021.71)	-	-	-	(32,500.00)	(1,817,646.27)	1,794,515.97	-	(166,310.47)	(862,056.92)
	(1,138.21)	-	(21,820.25)	-	(68,021.71)	-	-	-	(32,500.00)	(1,817,646.27)	1,794,515.97	-	(166,310.47)	(862,056.92)
Inventories at the beginning of the period														
Traded goods	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Work-in-progress	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Finished goods	9,574,734.37	7,637,335.43	7,369,677.57	6,875,131.26	11,234,162.11	9,747,469.26	13,622,448.67	14,513,215.25	30,878,982.80	39,166,898.79	34,406,780.37	48,070,566.70	9,574,734.37	23,919,561.10
	9,574,734.37	7,637,335.43	7,369,677.57	6,875,131.26	11,234,162.11	9,747,469.26	13,622,448.67	14,513,215.25	30,878,982.80	39,166,898.79	34,406,780.37	48,070,566.70	9,574,734.37	23,919,561.10
	1,936,260.73	267,637.86	473,026.06	(4,359,030.85)	1,418,671.16	(3,874,979.41)	(890,766.58)	(16,365,767.53)	(8,340,415.99)	2,942,472.13	(11,869,270.36)	21,218,529.34	(17,443,613.66)	13,482,769.81
Details of purchase of traded goods														
Product A	234,136.57	-	3,732,036.67	10,766,917.19	9,108,352.14	8,870,480.35	4,132,608.12	24,672,755.46	20,914,254.31	11,342,907.81	23,986,239.58	20,566,655.92	138,326,344.12	172,621,549.00
Product B	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product C	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	234,136.57	-	3,732,036.67	10,766,917.19	9,108,352.14	8,870,480.35	4,132,608.12	24,672,755.46	20,914,254.31	11,342,907.81	23,986,239.58	20,566,655.92	138,326,344.12	172,621,549.00
Note 22 : Employee benefit expense														
Salaries, wages and bonus	269,434.39	211,733.15	174,371.89	178,326.04	180,258.27	183,398.86	187,289.13	183,292.89	319,313.57	184,252.13	179,779.06	183,212.39	2,414,662.17	4,304,763.75
Contribution to provident and other fund	4,185.00	4,170.00	3,480.00	3,450.00	3,435.00	3,495.00	3,465.00	3,465.00	3,450.00	4,659.00	3,460.00	3,435.00	64,169.00	50,020.00
Employee stock option scheme	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gratuity expense	-	-	-	-	-	-	-	-	-	-	-	-	-	108,000.00
Other employee benefits	-	1,444.00	3,312.57	-	-	-	1,794.36	290.68	3,175.01	887.31	-	1,173.45	12,077.58	440,400.00
Post employment medical benefits	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Staff welfare expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	18,081.23
	253,619.39	217,347.15	181,364.46	181,776.04	183,693.27	186,893.86	192,549.89	187,048.57	325,938.58	189,796.44	183,259.06	187,820.84	2,471,108.75	4,921,264.98

Stamped for the purpose of identification

Prime Management

23 APR 2015

Bangkok

AFL Pharma Thai Ltd.
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (THB)	Year ended March 31, 2014 (THB)
Note 23 : Other expenses														
Consumption of stores and spares	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Chemicals consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in VAT on finished goods	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Customer service expenditure	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Power and fuel	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Water charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Freight and forwarding charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Carriage inward	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Carriage outwards	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rent	86,352.10	86,352.10	86,352.10	86,352.10	86,352.10	86,352.10	86,352.10	62,471.10	66,694.73	15,789.47	31,242.10	31,242.10	791,904.20	1,043,200.20
Rates and taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Insurance	9,189.11	10,665.91	9,757.70	9,479.92	10,684.82	9,310.63	9,579.34	9,270.34	9,579.35	9,579.35	8,652.30	9,579.35	114,666.12	129,535.16
Repairs and maintenance	-	-	-	-	-	-	-	-	-	-	-	-	-	-
i) Plant and machinery	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ii) Buildings	-	-	-	-	-	-	-	-	-	-	-	-	-	-
iii) Others	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Advertising and sales promotion	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Brokerage and discounts	-	-	-	-	-	-	-	-	-	-	-	-	-	151,167.68
Remuneration to Auditors	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales commission	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Travelling and conveyance	11,515.36	17,338.93	8,646.55	23,403.98	10,673.34	66,370.40	15,787.92	33,062.97	15,088.40	14,797.57	10,991.77	9,233.09	238,472.30	142,436.75
Communication costs	4,265.64	5,653.92	14,156.02	6,063.08	12,172.33	10,324.76	13,138.61	17,650.23	1,124.19	6,261.21	12,751.47	8,499.47	108,040.93	220,431.68
Printing and stationery	1,235.11	3,525.56	1,710.34	3,562.40	4,348.38	22,344.34	4,243.28	1,033.80	5,031.36	1,726.65	1,937.12	812.77	51,681.11	27,970.44
Legal and professional fees	26,455.41	25,421.79	104,593.67	151,638.29	75,975.66	22,042.80	36,475.68	57,372.22	35,835.67	119,561.74	36,154.99	35,738.47	727,277.61	329,619.58
Directors sitting fees	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment to auditor (Refer details below)	4,315.00	-	145,578.00	-	(12,756.00)	45,000.00	-	-	187,370.00	-	-	54,920.00	424,433.00	323,342.00
Provision for diminution in value of investment in subsidiary company	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for other than temporary decline in the carrying amount of other long-term investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adjustment to the carrying amount of current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for warranties (net of reversals)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for litigations (net of reversals)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exchange differences (net)	103,755.23	3,668.55	110,696.38	210,616.92	110,186.17	100,010.17	56,825.90	262,839.85	60,289.76	59,255.81	71,376.18	265,830.83	1,415,313.75	9,861,344.03
Loss on derivative contracts (including provisions mark-to-market loss)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bad debts/advances written off	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment loss on fixed assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for doubtful debt and advances	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on sale of fixed assets (net)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Premium on forward exchange contract amortized	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Factory maintenance	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effluent treatment expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Vehicle maintenance expenses	206.30	-	4,595.23	1,159.00	-	1,278.76	535.00	1,000.00	165.00	910.71	140.00	2,855.00	12,545.00	163,593.36
Analytical charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product development expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Registration and filing charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Safety and security	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Office expenses	20,025.93	18,490.72	16,104.73	11,795.48	13,594.31	12,066.48	12,023.73	11,646.97	7,846.99	4,710.31	6,054.64	7,717.50	141,678.01	193,101.89
Repairs and maintenance - others	446.53	2,609.90	4,203.91	32.58	472.58	5,412.28	14,515.13	408.53	32.58	254.31	254.3	2,923.17	31,340.93	37,711.58
Management fees	192.05	201.22	194.72	201.22	201.22	219.34	343.17	333.02	344.13	308.12	219.21	242.69	3,000.11	-
Liquidated damages	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Donations	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Software license and implementation expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital work-in-progress written off	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Miscellaneous expenses	35,142.37	419,656.30	43,532.79	12,010.69	52,894.87	22,958.20	20,955.85	8,975.05	299,549.81	530,745.09	13,159.78	28,963.29	1,488,844.09	606,812.65
	303,096.16	593,534.90	550,082.34	516,335.66	364,409.80	405,690.26	270,745.73	466,035.08	669,251.97	763,920.34	192,309.19	454,087.73	5,549,499.16	13,230,267.20

Stamped for the purpose of identification

Prima Management
23 APR 2015

Bangkok

APL Pharmacy Thai Ltd.
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (THB)	Year ended March 31, 2014 (THB)
Payment to Auditor														
As auditor:														
Audit fee	4,315.00	-	145,578.00	-	(12,798.00)	45,000.00	-	-	187,370.00	-	-	54,920.00	424,433.00	323,342.00
Tax audit fee	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Limited review	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In other capacity:														
Taxation matters	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Company law matters	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Management services	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other services (certification fees)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reimbursement of expenses	4,315.00	-	145,578.00	-	(12,798.00)	45,000.00	-	-	187,370.00	-	-	54,920.00	424,433.00	323,342.00
Note 24 : Exceptional Items														
Others (Specify if any)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 25 : Depreciation and amortization expense														
Depreciation of tangible assets	7,259.98	7,502.00	7,249.33	7,451.90	7,469.90	7,293.12	7,559.30	7,423.36	7,213.28	7,253.85	6,373.94	6,984.06	87,034.02	83,093.83
Amortization of intangible assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation of investment property	7,259.98	7,502.00	7,249.33	7,451.90	7,469.90	7,293.12	7,559.30	7,423.36	7,213.28	7,253.85	6,373.94	6,984.06	87,034.02	83,093.83
Note 26 : Finance costs (Refer General Instructions Note No.27)														
Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bank charges	2,065.00	1,065.00	833.00	10,674.63	2,365.00	1,325.00	583.00	1,882.50	1,545.00	10,951.88	995.00	795.00	35,142.01	32,973.58
Amortization of ancillary borrowing costs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exchange difference to the extent considered as an adjustment to borrowing costs	2,065.00	1,065.00	833.00	10,674.63	2,365.00	1,325.00	583.00	1,882.50	1,545.00	10,951.88	995.00	795.00	35,142.01	32,973.58

Stamped for the purpose of identification

Prime Management

23 APR 2015

Bangkok



Prime Management

23 April 2015

Mr. M.V. Sastry
APL Pharma Thai Ltd.
128/358, Payatai Plaza Building, 33rd Floor
Phayathai Road, Khwaeng Thung Phaya Thai
Khet Ratchathewee, Bangkok 10400

Dear Mr. Sastry,

APL PHARMA THAI LTD. 31 MARCH 2015 FINANCIAL STATEMENTS

As requested we have pleasure to attach herewith three copies of the following financial statements and details of accounts for the twelve-month period from 1 April 2014 to 31 March 2015 duly stamped by us for the purpose of identification.

<u>Financial statements and details</u>	<u>Period/date</u>
- Annexure	31 March 2015
- Financial Statement Format August Month (Integral)	31 March 2015
- Balance sheet	31 March 2015
- Profit and loss	1 April 2014 – 31 March 2015
- Detail of accounts:	
- Bank reconciliation	31 March 2015
- Accounts receivable	31 March 2015
- Accounts receivable (overseas)	31 March 2015
- Accounts payable (overseas)	31 March 2015
- Postdated cheques	31 March 2015
- Fixed assets register	31 March 2015
- Inventory	31 March 2015

In this regard, we would like to draw your attention for the accounting points in connection with income tax, fixed deposits, trade accounts receivable, inventory valuation, and others as listed below:

1. Income tax

The company had operated business with losses for the twelve-month period of Baht 6,079,875.48. As a result, provision for current tax for this period ended as at 31 March 2015 was not required.

Based on corporate income tax return form CIT50, the company has tax loss which could be utilized as taxable expenses not over than 5 years as shown as follows:

Fiscal year	Taxable		Tax losses utilised	Tax losses carried forward	Expiry year
	profit	(loss)			
2009	-	(2,533,274.55)	-	(2,533,274.55)	2014
2010	-	(3,409,290.15)	-	(3,409,290.15)	2015
2011	-	(7,804,513.48)	-	(7,804,513.48)	2016
2012	-	(8,450,011.66)	-	(8,450,011.66)	2017
2013	-	(8,281,704.83)	-	(8,281,704.83)	2018
		<u>(30,478,794.67)</u>	<u>-</u>	<u>(30,478,794.67)</u>	

2. Sundry Debtors

As at 31 March 2015, there were long outstanding debtors over than six months amount of Baht 506,795.00 and company management believed that it could be collectible and did not set up allowance for doubtful debt at period ended.

3. Inventories

Inventories of Baht 25,107,599.18 net from obsolescence valuation as presented in balance sheet at 31 March 2015 were stated at cost based on average basis. If these inventories were stated at the lower of cost or net realizable value, inventories would be decreased by Baht 452,775.33, whereas inventory value adjustment as presented in administrative and selling expenses in profit and loss account would be increased by Baht 452,775.33 as at 31 March 2015 respectively. Additionally, net loss would be increased by Baht 452,775.33 for the year ended 31 March 2015.

4. Trade Payables

As at 31 March 2015, the balance of trade accounts payable overseas denominated in foreign currency with Aurobindo Pharma Limited of US Dollars 1,274,601.20 (equivalent to Baht 41,683,028.12) were translated into Baht by using bank selling rate at 31 March 2015 and resulted in unrealizable gain on exchange rate of Baht 23,280.52. Consequently, exchange differences as presented in other income in profit and loss account were increased by Baht 23,280.52.

5. Operating Results

For the fiscal year ended 31 March 2015, the company had loss of Baht 6,079,875.48.

6. Fixed deposit (Baht 20,276,730.86)

As at 31 March 2015 there were outstanding bank guarantees of Baht 10,572.00 issued by the bank on behalf of for Aurobindo Pharma Limited in respect of certain performance bonds as required in the normal course of business of the company. The fixed deposit accounts amounting to Baht 10,572.00 have been pledged with the bank as collateral for the bank guarantee.

9. Emphasis of matter

The accompanying financial statement have been prepared on the basis of the company continuing in business as a going concern, which presumes the realisation of its assets and payment of its liabilities in the ordinary course of business. Subsequent to the financial reporting date, the company has been experiencing losses. The management is aware in making its assessment of the uncertainties related to the events.

Yours faithfully,



Attachai Boonchalaksi
Partner

AUROBINDO PHARMA INDÚSTRIA FARMACÊUTICA LTDA
Directors' Report

The directors present their Report and the Audited financial statements for the year ended 31st March, 2015.

PRINCIPAL ACTIVITY

The principal activity of the company during the year was trading of medicines.

REVIEW OF OPERATIONS

During the period under report, your company has registered a total turnover of R\$ 71.319.311,00 and earned a profit of R\$ 18.293.267,00

AUDITORS

During the year the accounts were audited by M/s. Denerson Rosa & Associados, Goiânia, Goiás (State), Brazil.

ISSUE OF SHARE CAPITAL

During the year under report no shares has been Issued.


UNUSUAL ITEMS AFTER THE FINANCIAL YEAR

No item, transaction or event of a material nature has arisen during the period between the end of the financial year and the date of this report, which would affect substantially the operations of the Company during the current year.

STATEMENT OF DIRECTORS

In the opinion of the Directors, the accompanying Financial statements were drawn up so as to give a true and fair view of the state of affairs of the Company as on 31st March, 2015 and the results of the business for that period. Your Directors have taken all reasonable steps to prepare these financial statements on a going concern basis and suitable accounting policies have been adopted consistently. Further Your Directors are confident that with the support and guidance of the Holding Company, your company can achieve better results in the future.

By Order of the board



Sd/ S.B.Reddy

Director

Anápolis, 06th May, 2015

AUROBINDO PHARMA INDÚSTRIA FARMACÊUTICA LTDA.

R. 36 E - Quad. 9 - Mod. 12-15 - DAIÁ - CEP. 75.132-135 - Anápolis, GO - Brasil

Tel. + 55 62 4015 3400 - Fax. + 55 62 4015 3401

www.aurobindo.com


AUDIT REPORT

To the board of Directors and Members
Aurobindo Pharma Indústria Farmacêutica Ltda.,
Anápolis, Goiás State, Brazil.

- 1 We have audited the accompanying Balance Sheet of Aurobindo Pharma Indústria Farmacêutica Ltda., as of March 31, 2015 and the related Profit and Loss Account for the year ended March 31, 2015. These Financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements.
- 2 We conducted our audit in accordance with approved Brazilian auditing standards which require that we perform the audit to obtain reasonable assurance about whether the financial statements are fairly presented in all material aspects. Accordingly, our work included, among other procedures; (a) planning our audit taking into consideration the significance of balances, the volume of transactions, and the accounting and internal control systems of the Company; (b) examining, on a test basis, evidence and records supporting the amounts and disclosures in the financial statements, and (c) assessing the accounting practices adopted in Brazil.
- 3 In our opinion, the financial statements audited by us present fairly, in all material aspects, the financial position of Aurobindo Pharma Indústria Farmacêutica Ltda., as of 31st March, 2015 and the results of its operations for the year then ended, in conformity with accounting practices adopted in Brazil.
- 4 Our audits were conducted for the purpose of issuing an opinion on the basic financial statements referred to in paragraph 1, taken as a whole.
- 5 The financial statements as of and for the year ended 31st March, 2015 have been prepared in accordance with accounting practices applicable to companies operating as a going concern.

Anápolis, 06th May, 2014

for Dênerson Rosa & Associates
CNPJ NO: 05.682.466/0001-38


Jaqueline Araújo de Santana
Responsavel Tecnico,
Contador CRC-GO 022.060/P
CPF: 019.738.291-69

Jaqueline Araújo de Santana
CRC GO 022.060/P
CPF 019.738.291-69

Av. República do Líbano, 1921
1º andar - Setor Oeste
Goiânia - Goiás - CEP 74125-125
Tel +55 (62) 3093-5100
www.drconsult.com.br

Aurobindo Pharma Industria Farmaceutia Ltda.,
Balance Sheet as at March 31, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	31 Mar, 2015 (Reais)	31 March, 2014 (Reais)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	10.127.795	10.127.795
Share application money			
Reserves and surplus	3	14.215.271	(4.081.587)
		24.343.066	6.046.208
Non-current liabilities			
Long-term borrowings	4	188.284	118.912
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		188.284	118.912
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	11.916.660	13.858.384
Other current liabilities	9	738.415	974.253
Short-term provisions	7	905.923	730.089
		13.560.998	15.562.727
TOTAL		38.092.348	21.727.847
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	5.399.886	5.621.521
Intangible assets	11	-	-
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	-	-
Trade receivables	14,1	-	-
Other non-current assets	14,2	27.739	27.739
		5.427.625	5.649.260
Current assets			
Current investments	15	-	-
Inventories	16	11.118.886	4.120.492
Trade receivables	14,1	14.220.495	10.266.672
Cash and bank balances	17	4.093.073	301.106
Short-term loans and advances	13	3.232.268	1.390.318
Other current assets	14,2	-	-
		32.664.723	16.078.588
TOTAL		38.092.348	21.727.848
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.

for Aurobindo Pharma Ind Farmaceutia Ltda

Jacqueline Araújo de Santana
 Contador, CRC GO 122060/P
 CPF: 019.738.391-69

S.B. Reddy
 Director
 CPF: 742.900.471-78

Aurobindo Pharma Industria Farmaceutica Ltda.,
Statement of profit and loss for the year ended March 31, 2015
(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended Mar 31, 2015 (Reais)	Year ended March 31, 2014 (Reais)
Income															
Revenue from operations (gross)	18	4,122,774	6,377,273	6,998,426	3,692,401	8,185,865	6,149,329	4,684,144	7,137,553	6,410,486	5,501,131	5,907,335	6,156,595	71,319,311	44,190,737
Less: Discounts, Rebates															
Revenue from operations (net)		4,122,774	6,377,273	6,998,426	3,692,401	8,185,865	6,149,329	4,684,144	7,137,553	6,410,486	5,501,131	5,907,335	6,156,595	71,319,311	44,190,737
Other income	19	20,124	28,089	30,033	4,732,505	25,432	525,682	29,770	64,711	120,866	34,528	24,191	41,097	4,675,832	785,200
Total revenue (I)		4,142,898	6,405,362	7,028,459	7,424,906	8,211,297	6,675,011	4,713,914	7,202,267	6,531,351	5,535,659	5,931,526	6,197,693	75,995,143	44,975,937
Expenses															
Cost of raw material and components consumed	20	505,395	561,993	253,599	162,460	774,532	108,540	55,313	173,536	61,403	(43,120)	321,611	781,949	3,429,210	3,204,184
Purchase of trading goods	21	1,411,580	3,320,403	1,284,699	1,730,307	2,856,131	1,658,784	1,954,619	2,999,358	4,373,375	1,842,116	2,181,666	5,168,203	30,981,111	21,607,865
(Increase)/ decrease in inventories of finished goods, work in progress and traded goods	21	227,586	(1,188,190)	877,194	(520,718)	(548,468)	479,493	(117,151)	(422,226)	410,957	266,672	(41,782)	(2,919,952)	(3,496,616)	495,318
ICMS on Sales		288,594	1,901,640	531,634	282,137	613,530	475,319	359,040	521,587	420,478	441,033	461,119	469,766	5,214,877	3,293,664
Employee benefit expense	22	397,073	372,540	386,325	444,662	408,906	434,241	395,872	434,180	287,450	884,821	437,925	422,657	4,806,633	4,205,472
Other expenses	23	135,526	494,249	212,675	1,926,414	347,719	2,130,577	324,471	976,317	1,063,138	806,631	845,422	1,426,916	10,680,055	6,531,473
Exceptional items	24	22,411	3,282	6,001	7,288	(3,315)	1,102	6,873	2,285	19,007	8,264	2,346	11,410	86,953	75,936
Total (II)		2,988,166	3,917,816	3,552,126	4,032,520	4,448,035	5,288,055	2,979,037	4,685,037	6,635,808	3,616,416	4,198,308	5,360,928	51,702,252	39,593,912
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		1,154,732	2,487,546	3,476,333	3,392,386	3,763,261	1,386,956	1,734,877	2,516,230	(104,657)	1,919,243	1,733,218	836,765	24,292,891	5,382,025
Depreciation and amortization expense	25	56,935	59,240	59,380	58,620	57,501	54,870	49,789	49,789	49,789	49,894	49,961	50,550	646,317	780,523
Finance costs	26	7,011	4,159	5,159	9,843	3,260	3,367	6,057	14,746	6,258	5,582	3,393	3,501	72,335	65,841
Profit/(loss) before tax		1,090,786	2,424,148	3,411,795	3,323,923	3,702,500	1,328,719	1,679,031	2,451,695	(160,703)	1,863,768	1,679,863	782,714	23,574,239	4,535,660
Tax expenses															
Current tax		209,651	688,644	495,602	721,128	1,058,912	538,806	687,737	880,491					5,280,972	
Less: MAT credit entitlement														-	
Deferred tax														-	157,717
Fringe benefit tax														-	
Tax relating to previous years														-	
Total tax expense		209,651	688,644	495,602	721,128	1,058,912	538,806	687,737	880,491	-	-	-	-	5,280,972	157,717
Profit/(loss) for the year		881,135	1,735,504	2,916,193	2,602,795	2,643,588	789,912	991,294	1,571,204	(160,703)	1,863,768	1,679,863	782,714	18,293,267	4,377,944

Summary of significant accounting policies

1

The accompanying notes are an integral part of the financial statements

547

Jagadeo Araújo de Santana
CPF: 019.738.016-68

for Aurobindo Pharma Ind Farmaceutica Ltda
S B Reddy
Director
CPF: 323.990.311-78

Note 1: Summary of significant accounting policies (Refer General Instructions Note No. 1)

- 1.1
- 1.2
- 1.3
- 1.4
- 1.5

Note 2: Share capital (Refer General Instructions Note No. 2)

	March 31, 2015	March 31, 2014
Authorised shares:		
10,127,795 (31 March, 2014: 10,127,795) equity shares of RS 1 each	10,127,795	
XXXXXXXX (31 March, 2014: XXXXXXXX), preference shares of XXX each	10,127,795	
Issued, Subscribed and Fully Paid-up shares:		
10,124,795 (31 March, 2014: 10,124,795) equity shares of RS 1 each fully paid-up (Aurobindo Pharma Ltd.)	10,124,795	10,124,795
3,000 (31 March, 2014: 3,000) equity shares of RS 1 each fully paid-up (Minority Share Holders)	3,000	3,000
	10,127,795	10,127,795

Note 3: Reserves and surplus (Refer General Instructions Note No. 3)

	March 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	-	-
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet	-	-
General Reserve		
As per last Balance Sheet	-	-
Add: Transferred from statement of profit and loss	-	-
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	(4,081,587)	(8,459,531)
Profit for the quarter	18,293,267	4,377,944
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014: XX)		
Transfer to proposed equity dividend		
Transfer to long term fund (amount per share XX (31 March, 2014: XX)		
Transfer to general reserve	(3,590)	-
Profit / Less: Prior period	(3,590)	-
Total appropriations	14,215,271	(4,081,587)
Net surplus in the statement of profit and loss		
	14,215,271	(4,081,587)
Total reserves and surplus		
	14,215,271	(4,081,587)

Note 4: Long-term borrowings (Refer General Instructions Note No. 4)

	Non-current Portion		Current maturities	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)				
Other Loans from banks				
Current account credit balance				
Loans and advances from related parties				
Other Loans and advances				
GNPS deferred loan (Un Secured)	188,284	118,912		
	188,284	118,912		
The above amount includes				
Secured borrowings				
Unsecured borrowings				
Amount disclosed under the head				
"Other current liabilities"				
Net Amount				

Jayalinda Arce de Santana
CNPJ 09.974.811/11-69

Aurobindo Pharma Ind. Farmaceutica Ltda
S.B. Reddy
Director
CNPJ 743.909.471-78

Note 5: Deferred tax liability (net)

	March 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis		
Provision for diminution in the value of investments		
Provision for doubtful debts and advances		
Fixed Assets (Depreciation)		
Retirement benefits		
Others		
Gross deferred tax liability		
Deferred tax asset		
Carried forward Business Losses		
Others		
Gross deferred tax asset		
Net deferred tax liability		

Note 6: Other long-term liabilities (Refer General Instructions Note No 6)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances)		
Others		
Advances from customers		
Unclaimed dividends		
Other liabilities		
Interest accrued but not due on loans		
Advances from related parties		

Note 7: Provisions (Refer General Instructions Note No 6)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Provision for employee benefits				
CGIS & INSS			184,484	175,591
Leave Encashment			260,732	262,091
Other Provisions				
ISS			705	784
PIS & COFINS				
PIS & COFINS Diferida				
IRRF			49,418	47,329
ICMS			402,935	237,214
Contribution to Assistência Social			7,650	7,028
			461,707	292,406
			905,923	730,089

Provision for warranties

	March 31, 2015	March 31, 2014
At the beginning of the year		
Arising during the period		
Utilised during the period		
Unused amounts reversed		
At the end of the Quarter		
Current portion		
Non-current portion		

Note 8: Short-term borrowings (Refer General Instructions Note No 8)

	March 31, 2015	March 31, 2014
Bank overdraft		
Loans and advances from related parties		
Working capital loans (Secured)		
Short term loans (Un Secured)		
Working capital loans		
The above amount includes		
Secured borrowings		
Unsecured borrowings		

Note 9: Other current liabilities (Refer General Instructions Note No 9)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No 8)	11,976,660	13,858,384
Other liabilities	738,415	974,253
Current maturities of long-term borrowings		
Trade deposits	738,415	974,253
	12,655,075	14,832,637

Note 12: Non-current investments (Refer General Instructions Note No 12)

	March 31, 2015	March 31, 2014
Unquoted equity instruments		
Investment in subsidiaries		
Investment in joint ventures		
Investment in associates		

José Maria de Sá
Diretor
CPF: 019.738.137-69

Aurobindo Pharma Ind. Farmaceutica Ltda.
S. B. Reddy
Diretor
CPF: 42.806.521-58

Note 13. Loans and advances (See *Accounting Instructions Note No. 15 & 21*)

		Non-current		Current	
		March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Capital advances					
Secured, considered good					
Unsecured, considered good	(A)	-	-	-	-
Security deposit					
Secured, considered good					
Unsecured, considered good					
Doubtful					
Provision for doubtful security deposit	(B)	-	-	-	-
Loan and advances to related parties	(C)	-	-	-	-
Advances recoverable in cash or kind					
Secured, considered good					
Unsecured, considered good					
Doubtful					
Provision for doubtful advances	(D)	-	-	-	-
Other loans and advances					
Advance for supplies				86,183	83,340
Advance for Expenses				12,408	417,858
Salary Advance				74,618	57,192
Prepaid Expenses				173,908	171,689
PPS & COFFINS Deducted at source				11,285	6,439
PPS & COFFINS Excess				5,807	5,807
Advance Income tax				2,498,610	327,743
Income Tax deducted at source				169,383	77,475
in MS Credit on Fixed Assets				175,230	137,544
IPF Credit to be recovered				48,509	70,825
Other Values to receive				32,297	32,208
	(E)	-	-	3,232,284	1,390,318
Total (A+B+C+D+E)		-	-	3,232,284	1,390,318

Loans and advances due by directors or other officers, etc.

		Non-current		Current	
		March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Loans to employees include					
Due to non-executive directors					
Due to executive directors					
Loans from non-executive and officers jointly with other persons					
Loans and advances to related parties include					
Due from the partnership firm in which the company's executive director is a partner					
Due from in which the company's managing director is a member					
Due from the partnership firm in which the company's non-executive director is a partner					

Jacqueline Araújo de Santana
CNPJ nº 06.904.220/0001-90
CPF: 019.738.291-69

Aurobindo Pharma Indústria Farmacêutica Ltda.
S.B. Reddy
Director
CPF: 142.890.421-78

Note 15 : Current investments (Refer General Instructions Note No.17)

	March 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any (Please specify)		

Note 16 : Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)

	March 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)	5,090,165	1,349,671
Work - in - Progress		
Finished goods		
Traded goods (including stock-in-transit XXXX (31 March, 2014 XXX)	5,895,414	2,630,074
Stores, spares, consumables and packing materials	103,307	141,747
Loose tools		
	<u>11,118,886</u>	<u>4,120,492</u>

Note 17 : Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			4,071,617	280,267
Short term deposits				
Fixed deposits				
On unpaid dividend account				
State Govt. Account (RMB)			19,154	12,014
Cheques/drafts on hand				
Unpaid matured deposits			2,302	2,820
Cash on hand			<u>4,093,073</u>	<u>301,106</u>
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
Amount disclosed under non-current assets			<u>4,093,073</u>	<u>301,106</u>

17
Jagjit Singh Arora de Santana
CPF 019.708.31.69

for Aurobindo Pharma Indústria Farmacêutica Ltda.
S.B. Reddy
Director
CPF 742.999.421-78

Notes to the statement of profit and loss
 (All amounts in Lakhs of Rupees, except share data and unless otherwise stated)

	Apr-11	May-11	Jun-11	Jul-11	Aug-11	Sep-11	Oct-11	Nov-11	Dec-11	Jan-12	Feb-12	Mar-12	12 months Period ended Mar 31, 2012 (Rupees)	Year ended Mar 31, 2011 (Rupees)
Note 18: Revenue from operations (Refer schedule 11, Part A, Schedule 11)														
Revenue from operations														
- sale of goods	1,122,771	8,371,273	8,998,126	3,692,401	8,183,865	6,149,329	1,681,111	7,137,553	8,150,186	5,501,131	5,902,335	6,156,595	71,318,311	44,198,732
- sale of services														
- sale of products, services														
- other operating revenue														
- scrap sales														
- other														
Revenue from operations (gross)	1,122,771	8,371,273	8,998,126	3,692,401	8,183,865	6,149,329	1,681,111	7,137,553	8,150,186	5,501,131	5,902,335	6,156,595	71,318,311	44,198,732
Less: cost of sales (deductions)														
Revenue from operations (net)	1,122,771	8,371,273	8,998,126	3,692,401	8,183,865	6,149,329	1,681,111	7,137,553	8,150,186	5,501,131	5,902,335	6,156,595	71,318,311	44,198,732
Note 19: Other income (Refer schedule 11, Part A, Schedule 11)														
Interest income on														
- Bank deposits														
- Fixed deposits														
- Current deposits														
- Other deposits														
Dividend income on														
- Equity shares														
- Debt securities														
- Other securities														
Net gain/loss on sale of investments														
Income from other sources														
Other income														
Other income (net)	20,121	28,068	30,033	3,732,505	25,432	525,662	29,770	63,714	120,000	34,826	24,191	41,097	4,875,632	8,533
Revenue from operations (net)	20,121	28,068	30,033	3,732,505	25,432	525,662	29,770	63,714	120,000	34,826	24,191	41,097	4,875,632	8,533
Note 20: Cost of raw material and components consumed														
- at the beginning of the period	1,348,871	964,214	800,314	2,233,103	2,177,583	1,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,363,136	1,348,871	1,348,871
- Add: Purchases	121,209	101,093	1,096,187	106,940	2,421,162	1,236,432	152,076	58,968	71,869	109,968	97,012	958,793	7,440,979	1,075,111
- Less: at the end of the period	1,469,876	1,065,307	2,496,701	2,340,043	4,598,745	3,061,645	5,125,181	5,128,836	5,026,307	5,074,898	5,204,941	5,362,113	8,469,641	4,493,219
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069,868	4,954,294	4,964,934	5,107,929	4,863,330	5,099,165	1,348,871	1,348,871
Cost of raw material and components consumed	964,214	800,314	2,233,103	2,177,583	3,825,213	4,973,106	5,069							

for Aurobindo Pharma Ind Pharmaceuticals Ltd
S.B. Reddy
Director
CPE: 747 999 421-78

Aurobindo Pharma Industria Farmaceutica Ltda.,

Notes to the statement of profit and loss

(All amounts are in Local currency except share data and unless otherwise stated)

Note 10 - Tangible assets

	Freehold Land	Freehold Buildings	Air Condition Plant	Furniture & fixtures	Labs Equipments	Alarm Equipments	Electrical Equipment	Ware House Equipment	Computers	Office Equipments	Software	Vehicles	Total
Cost or valuation													
At April 1, 2013	66,848	6,418,982	510,623	4,394	3,389,743	23,552	20,953	115,681	319,984	45,261	217,001	108,823	11,951,841
Additions during the nine months		8,789		6,311	11,426	1,104			29,038		2,200		61,868
Disposals during the nine months													
Transfer to assets held for sale													
Other adjustments													
- Exchange differences													
At December 31, 2013	66,848	6,427,771	510,623	680,705	3,404,169	24,655	20,953	115,681	349,022	45,261	219,201	148,823	12,013,712
Additions during the three months									3,875				3,875
Disposals during the three months													
Other adjustments													
- Exchange differences													
At March 31, 2014	66,848	6,427,771	510,623	680,705	3,404,169	24,655	20,953	115,681	352,897	45,261	219,201	148,823	12,017,587
Additions during the 12 months			5,278	13,657	351,383			390	18,070		3,581	32,323	424,682
Disposals during the 11 months													
Additions on acquisition													
Other adjustments													
- Exchange differences													
At March 31, 2015	66,848	6,427,771	515,902	694,362	3,755,552	24,655	20,953	116,071	370,967	45,261	222,782	181,145	12,442,269
Depreciation													
At April 1, 2013	4,263	1,741,676	448,437	523,615	2,152,935	11,855	20,953	106,119	251,467	43,859	214,732	95,333	5,615,542
Charge for the period	700	192,687	38,297	71,368	255,196	1,794		3,725	15,397	1,402	2,452	17,243	600,261
Disposals													
Transfer to assets held for sale													
Other adjustments													
- Exchange differences													
At December 31, 2013	4,963	1,934,362	486,734	594,983	2,408,131	13,649	20,953	110,144	266,864	45,261	217,184	112,575	6,215,803
Charge for the period	233	64,278	7,183	10,821	85,104	618		270	5,899		110	5,717	180,262
Disposals													
Other adjustments													
- Exchange differences													
At March 31, 2014	5,197	1,998,640	493,917	605,804	2,493,235	14,265	20,953	110,414	272,763	45,261	217,294	118,293	6,396,066
Charge for the period	934	257,111	4,029	27,076	314,564	2,466		1,090	25,573		736	17,739	646,317
Disposals													
Additions on acquisition													
Other adjustments													
- Exchange differences													
At March 31, 2015	6,130	2,255,751	497,946	632,879	2,807,799	16,731	20,953	111,504	298,336	45,261	218,030	131,061	7,042,383
Net Block													
At December 31, 2013	61,885	4,493,409	23,889	85,722	996,038	11,017		5,537	82,158		2,017	36,247	5,797,909
At March 31, 2014	61,651	4,429,131	16,706	74,901	910,933	10,390		5,267	80,131		1,907	30,500	5,621,521
At March 31, 2015	60,718	4,172,020	17,955	61,483	947,753	7,925		4,567	72,611		4,751	50,084	5,399,886

Jayashree Aravind de Santana

For Aurobindo Pharma Ind Farmaceutica Ltda

S.B. Reddy
Director

CPE 2012/000 150775

Aurobindo Pharma Indústria Farmacêutica Ltda.,

Notes to the statement of profit and loss

(All amounts are in Local Currency, except share data and unless otherwise stated)

Note 11 : Intangible assets

	Goodwill	Product Development cost	Licences and patents	Total
Gross Block				
At April 1, 2013	-	-	-	-
Additions during the nine months	-	-	-	-
Internal development during the nine months	-	-	-	-
Disposals during the nine months	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At December 31, 2013	-	-	-	-
Additions during the three months	-	-	-	-
Internal development during the three months	-	-	-	-
Disposals during the three months	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At March 31, 2014	-	-	-	-
Additions during the nine months	-	-	-	-
Disposals during the nine months	-	-	-	-
Additions on acquisition	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At December 31, 2014	-	-	-	-
Amortization				
At April 1, 2013	-	-	-	-
Charge for the period	-	-	-	-
Disposals	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At December 31, 2013	-	-	-	-
Charge for the period	-	-	-	-
Disposals	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At March 31, 2014	-	-	-	-
Charge for the period	-	-	-	-
Disposals	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At December 31, 2014	-	-	-	-
Net Block				
At December 31, 2013	-	-	-	-
At March 31, 2014	-	-	-	-
At December 31, 2014	-	-	-	-

Jacqueline Araújo de Santana
CPF 019.028.11-89

for Aurobindo Pharma Ind Farmacêutica Ltda

S.H. Rocha

Director

CPF 732.899.472-78

Annex 1 - Summary of significant accounting policies

a) Basis of preparation

The financial statements have been prepared under the historical cost convention on accrual basis.

b) Revenue Recognition

Revenue from sale of goods is recognized on dispatch and is exclusive of ICMS and net of discounts and sales returns.

c) Fixed Assets and Depreciation

Fixed Assets are stated at cost less accumulated depreciation. Cost includes freight, duties, taxes and any attributable costs in bringing the asset to its working condition for future use.
Depreciation is provided on straight line method as prescribed by the Income Tax Law.

d) Inventories

Raw materials, packaging materials, stores, spares and consumables are valued at lower of cost, calculated on Weighted Average basis and net realizable value.
Finished goods are valued at lower of cost or net realizable value, with cost being determined using Weighted Average method.

e) Retirement Benefits

The contributions to GPF and NPS are recognized on accrual basis.

f) Deferred Tax Liability

A deferred tax liability during the period under audit.

g) Foreign Exchange Transactions

Foreign currency transactions during the year are recorded at the exchange rates prevailing at the transaction dates. Gains and losses on foreign currency transactions are shown separately in the Profit & Loss Account.
Provision for profit/loss on foreign currency liabilities are provided at R\$ 1.21 per each US\$ on 31st Mar, 2015.


h) Leases

The firm has no finance leases. Operating leases are mainly in the nature of lease of office premises with no restrictions and are renewable at mutual consent.

i) Partners Share Capital

The partners liability is limited by subscription to capital. 99.97% of the paid up Share Capital is being held by Asubundo Pharma Ind. Farmacêutica Ltda. and the remaining 0.03% is being held by other Minority Share Holders.


Jacqueline Kratochvil de Santana
Contador CRC/GO 602860/P
CPF: 019.738.291-69


S. B. Reddy
Director
CPF: 742.899.471-74

AUROBINDO PHARMA PRODUTOS FARMACEUTICOS LTDA
Directors' Report

The directors present their Report and the Audited financial statements for the year ended 31st March, 2015.

PRINCIPAL ACTIVITY

The principal activity of the company during the year was trading of medicines.

REVIEW OF OPERATIONS

During the period under report, your company Has registered a total turn over of Reals 17.048.737,87 and incurred a loss of Reals (2.138.198,19)

AUDITORS

During the year the accounts were audited by M/s .Denerson Rosa & Associados, Goiânia, Goiás (state), Brazil.

ISSUE OF SHARE CAPITAL

During the year under report no shares has been issued.


UNUSUAL ITEMS AFTER THE FINANCIAL YEAR

No item, transaction or event of a material nature has arisen during the period between the end of the financial year and the date of this report, which would affect substantially the operations of the Company during the current year.

STATEMENT OF DIRECTORS

In the opinion of the Directors, the accompanying Financial statements were drawn up so as to give a true and fair view of the state of affairs of the Company as on 31st March, 2015 and the results of the business for that period. Your Directors have taken all reasonable steps to prepare these financial statements on a going concern basis and suitable accounting policies have been adopted consistently. Further Your Directors are confident that with the support and guidance of the Holding Company, your company can achieve better results in the future.

By Order of the board



Sd/ S.B.Reddy

Director

Anápolis, 06th May, 2015

AUROBINDO PHARMA PRODUTOS FARMACÊUTICOS LTDA.

www.aurobindo.com

AUDIT REPORT

To the board of Directors and Members
Aurobindo Pharma Produtos Farmaceuticos Ltda.,
Anápolis, Goiás State, Brazil.

- 1 We have audited the accompanying Balance Sheet of Aurobindo Pharma Produtos Farmaceuticos Ltda., as of 31st March, 2015 and the related Profit and Loss Account for the year ended 31st March, 2015. These Financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements.
- 2 We conducted our audit in accordance with approved Brazilian auditing standards which require that we perform the audit to obtain reasonable assurance about whether the financial statements are fairly presented in all material aspects. Accordingly, our work included, among other procedures; (a) planning our audit taking into consideration the significance of balances, the volume of transactions, and the accounting and internal control systems of the Company; (b) examining, on a test basis, evidence and records supporting the amounts and disclosures in the financial statements, and (c) assessing the accounting practices adopted in Brazil.
- 3 In our opinion, the financial statements audited by us present fairly, in all material aspects, the financial position of Aurobindo Pharma Produtos Farmaceuticos Ltda., as of 31st March, 2015 and the results of its operations for the year then ended, in conformity with accounting practices adopted in Brazil.
- 4 Our audits were conducted for the purpose of issuing an opinion on the basic financial statements referred to in paragraph 1, taken as a whole.
- 5 The financial statements as of and for the year ended 31st March, 2015 have been prepared in accordance with accounting practices applicable to companies operating as a going concern.

Anápolis, 06th May, 2014

for Dênerson Rosa & Associates
CNPJ NO: 05.682.466/0001-38

Jaqueline Araújo de Santana
Responsavel Técnico,
Contador CRC-GO 022.060/P
CPF: 019.738.291-69

Jaqueline Araújo de Santana
Contador CRC-GO 022.060/P
CPF: 019.738.291-69

Av. República do Líbano, 1921
1º andar - Setor Oeste
Goiânia - Goiás - CEP 74125-125
Tel +55 (62) 3093-5100
www.drconsult.com.br

AUROBINDO PHARMA PRODUTOS FARMACEUTICOS LTDA.,

Balance Sheet as at 31st March, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	31st March, 2015 (Reais)	31 March, 2014 (Reais)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	100,000	100,000
Share application money			
Reserves and surplus	3	(1,740,064)	398,134
		<u>(1,640,064)</u>	<u>498,134</u>
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		<u>-</u>	<u>-</u>
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	22,250,562	8,484,867
Other current liabilities	9	-	-
Short-term provisions	7	448,652	185,814
		<u>22,699,214</u>	<u>8,670,681</u>
TOTAL		<u><u>21,059,151</u></u>	<u><u>9,168,815</u></u>
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	231,630	172,027
Intangible assets	11	-	-
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	-	-
Trade receivables	14.1	-	-
Other non-current assets	14.2	-	-
		<u>231,630</u>	<u>172,027</u>
Current assets			
Current investments	15	-	-
Inventories	16	12,698,267	2,440,970
Trade receivables	14.1	5,981,395	6,119,495
Cash and bank balances	17	1,316,599	146,199
Short-term loans and advances	13	831,260	290,124
Other current assets	14.2	-	-
		<u>20,827,521</u>	<u>8,996,788</u>
TOTAL		<u><u>21,059,151</u></u>	<u><u>9,168,815</u></u>
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.

S.B.Reddy
Director
CPF: 742.899.421-72

Argemiro Araujo de Santana
Contador
CPF: 014.278.711-64

AUROBINDO PHARMA PRODUTOS FARMACÊUTICOS LTDA.,
Statement of profit and loss for the nine months period ended 31st March, 2015
(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Period Ending 31st March, 2015 (Reais)	Year ended March 31, 2014 (Reais)
Income															
Revenue from operations (gross)	18	1,634,919	1,469,680	1,224,844	642,168	1,804,080	380,513	432,842	540,833	424,111	1,858,997	2,032,927	4,602,825	17,048,738	12,611,361
Less: Excise duty/ Rebates															
Revenue from operations (net)		1,634,919	1,469,680	1,224,844	642,168	1,804,080	380,513	432,842	540,833	424,111	1,858,997	2,032,927	4,602,825	17,048,738	12,611,361
Other income	19	32,130	149,991	73,627	151,672	31,286	57,949	65,257	46,107	612,976	70,710	87,407	30,045	1,369,158	447,042
Total revenue (I)		1,667,049	1,619,671	1,298,471	793,840	1,835,366	438,462	498,099	586,939	1,037,087	1,889,707	2,120,334	4,632,871	18,417,896	13,058,403
Expenses															
Cost of raw material and components consumed	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods	21	9,748	1,136,672	2,618,864	120,808	4,172,965	198,234	2,699,920	2,523,220	1,235,917	2,122,517	2,941,842	3,126,023	22,906,730	10,218,795
(Increase)/ decrease in inventories of finished goods, work-in-progress and traded goods	21	1,433,136	(19,679)	(1,008,755)	360,473	(2,886,604)	111,325	(2,556,761)	(2,260,636)	(1,012,794)	(531,082)	(1,542,697)	256,777	(10,257,297)	(503,600)
Fis & Cofins		-	-	-	-	-	-	-	-	-	-	-	-	-	-
ICMS on sales		89,954	68,975	43,051	15,978	67,830	17,960	14,423	15,018	20,216	97,444	62,822	372,969	887,141	824,567
Employee benefit expense	22	58,376	94,460	77,987	89,131	79,250	103,891	56,559	79,367	67,762	76,239	72,422	80,393	935,835	879,114
Other expenses	23	(21,569)	42,220	(74,049)	178,955	12,366	666,351	25,046	647,895	472,983	45,935	1,253,556	2,168,394	5,418,083	1,489,899
Exceptional items	24	4	4	46	4	131	4	10,338	39	4	2	2,762	2,079	15,418	28,857
Total (II)		1,569,649	1,322,652	1,057,144	765,350	1,445,938	1,097,765	249,525	1,004,903	784,087	1,811,554	2,790,707	6,006,635	19,905,910	12,937,632
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		97,400	297,018	241,327	28,490	389,429	(689,303)	248,575	(417,964)	253,000	78,153	(670,373)	(1,373,764)	(1,488,014)	153,775
Depreciation and amortization expense	25	2,858	2,891	2,891	2,918	4,135	4,135	4,135	4,164	4,434	4,537	4,537	4,357	45,992	32,629
Finance costs	26	12,051	14,801	11,921	2,637	1,310	2,676	22,277	2,321	279	20,525	1,392	3,733	95,924	18,721
Profit/(loss) before tax		82,492	279,326	226,515	22,934	383,983	(666,115)	222,162	(424,450)	248,296	53,091	(676,302)	(1,381,854)	(1,629,930)	102,424
Tax expenses															
Current tax		-	-	103,100	73,365	33,603	33,698	79,239	95,232	90,031	-	-	-	508,268	-
Less: MAT credit entitlement		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fringe benefit tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax relating to previous years		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total tax expense		-	-	103,100	73,365	33,603	33,698	79,239	95,232	90,031	-	-	-	508,268	-
Profit/(loss) for the year		82,492	279,326	123,415	(50,430)	350,380	(699,813)	142,924	(519,682)	158,265	53,091	(676,302)	(1,381,854)	(2,138,198)	102,424

Summary of significant accounting policies

1

The accompanying notes are an integral part of the financial statements.

14/04/2015
S. B. Reddy
Director
CPF: 009.238.9169

for AurbindoPharma Prod. Farmacêuticos Ltda.

S. B. Reddy
Director
CPF: 742.899.421-72

AUROBINDO PHARMA PRODUTOS FARMACEUTICOS LTDA.,
Notes to the Balance Sheet

(All amounts are in local Currency, except share data and unless otherwise stated.)

Note 1: Summary of significant accounting policies (Refer General Instructions Note No.1)

 1.1
1.2
1.3
1.4
1.5

Note 2: Share Capital (Refer General Instructions Note No.2)

	Mar 31, 2015	March 31, 2014
Authorized shares:		
100,000 (31 March, 2014: 100,000) equity shares of R\$ 1 each	100,000	100,000
	100,000	100,000
Issued, Subscribed and Fully Paid-up shares:		
99,000 (31 March, 2014: 99,000) equity shares of R\$ 1 each fully paid-up (Aurobindo Pharma Ltd.)	99,000	99,000
1,000 (31st March, 2014: 1,000) equity share of R\$ 1 each fully paid-up (Others)	1,000	1,000
	100,000	100,000

Note 3: Reserves and surplus (Refer General Instructions Note No.3)

	Jan 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	-	-
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet	-	-
General Reserve		
As per last Balance Sheet	-	-
And: Transferred from statement of profit and loss	-	-
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	398,134	369,710
Profit for the quarter	(2,138,198)	102,424
Profit/(loss)/previous periods adjustments	-	(74,000)
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014: XX))	-	-
Proposed equity dividend	-	-
Interim dividend paid (amount per share XX (31 March, 2014: XX))	-	-
Transfer to general reserve	-	-
Total Appropriations	-	-
Net surplus in the statement of profit and loss	(1,740,064)	398,134
Total reserves and surplus	(1,740,064)	398,134

Note 4: Long-term borrowings (Refer General Instructions Note No.4)

	Non-current Portion			Current maturities	
	Mar 31, 2015	Dec 31, 2013	March 31, 2014	Mar 31, 2015	March 31, 2014
Term Loans					
From banks (Secured)					
Other Loans from banks					
Current account credit balance					
Loans and advances from related parties					
Other Loans and advances					
Sales tax deferment loan (Un Secured)					
	-	-	-	-	-
The above amount includes					
Secured borrowings					
Secured borrowings					
Amount disclosed under the head					
Other current liabilities					
Net Amount	-	-	-	-	-

Note 5: Deferred tax liability (net)

	Mar 31, 2015	March 31, 2014
Deferred tax liability		
Impact on expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis		
Provision for diminution in the value of investments		
Provision for doubtful debts and advances		
Fixed Assets (Depreciation)		
Retirement Benefits		
Others		
Gross deferred tax liability	-	-
Deferred tax asset		
Carried Forward Business Losses		
Others		
Gross deferred tax asset	-	-
Net deferred tax liability	-	-

for AurobindoPharma Prod. Farmaceuticos Ltda.

 S.B.Reddy
Director

CPF: 742.899.421-72

 Lag. Rinc. Aracy de Santana
CPF: 019.738.011-69

Note 6: Other long-term liabilities (Refer General Instructions Note No 5)

	Mar 31, 2015	March 31, 2014
Trade payables (including acceptances)		
Others		
Advances from customers		
Unclaimed dividends		
Other liabilities		
Interest accrued but not due on loans		
Advances from related parties		
	-	-
	-	-

Note 7: Provisions (Refer General Instructions Note No 6 & 7)

	Non-current			Current	
	Mar 31, 2015	Dec 31, 2013	March 31, 2014	Mar 31, 2015	March 31, 2014
Provision for employee benefits					
INSS & FGTS				36,239	41,142
Folau encashment				44,960	62,071
	-	-	-	81,199	103,212
Other Provisions					
For Taxation (net of advance payments)				367,453	82,602
For Proposed dividend					
For Tax on proposed dividend					
	-	-	-	367,453	82,602
	-	-	-	448,652	185,814

Provision for warranties

	Mar 31, 2015	March 31, 2014
At the beginning of the year		
Arising during the period		
Utilised during the period		
Crushed amounts reversed		
At the end of the Quarter	-	-
Current portion		
Non-current portion		

Note 8: Short-term borrowings (Refer General Instructions Note No 8)

	Mar 31, 2015	March 31, 2014
Bank overdraft		
Loans and advances from related parties		
Working capital loans (Secured)		
Short term loans (Un Secured)		
Working capital loans		
	-	-
The above amount includes		
Secured borrowings		
Unsecured borrowings		

Note 9: Other current liabilities (Refer General Instructions Note No 9)

	Mar 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)	22,952,077	7,973,480
for expenses & services	198,485	811,384
Other liabilities		
Current maturities of long-term borrowings		
Trade deposits		
	-	-
	22,250,562	8,484,867

Note 12: Non-current investments (Refer General Instructions Note No.13)

	Mar 31, 2015	March 31, 2014
Unquoted equity instruments		
Investment in subsidiaries		
Investment in joint ventures		
Investment in associates		
	-	-

For Auobindopharma Prod. Farmaceuticos Ltda.

S.B.Reddy
Director
CPF: 742.899.421-72


S.B.Reddy de Santana
CPF: 031.728.111-69

Note 13. Loans and advances (Refer General Instructions Note No.14 & 21)

		Non-current		Current	
		Mar 31, 2015	Dec 31, 2013	March 31, 2014	Mar 31, 2015
Capital advances					
Secured, considered good					
Unsecured, considered good	(A)	-	-	-	-
Security deposit					
Secured, considered good					
Unsecured, considered good					
Provision		-	-	-	-
Provision for doubtful security deposit	(B)	-	-	-	-
Loan and advances to related parties					
Unsecured, considered good	(C)	-	-	-	-
Advances recoverable in cash or kind					
Secured, considered good					
Unsecured, considered good					
Provision		-	-	-	-
Provision for doubtful advances	(D)	-	-	-	-
Other loans and advances					
Advance for Supplies					76,439
Advance for Expenses					14,538
Salary Advances					14,390
Prepaid expenses					-
Grant Advance					-
PP&E & Int. AS Deducted at source					-
PP&E & Cash & M. Excess					97,285
Advance income tax					70,820
Income Tax Deducted at source					64,113
ICMS credit on Fixed Assets					30
Other Receivables					493,646
(E)		-	-	-	831,260
Total (A+B+C+D+E)		-	-	-	831,260

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	Mar 31, 2015	Dec 31, 2013	March 31, 2014	Mar 31, 2015
Loans to employees include				
Loans from non-executive directors				
Loans from officers				
Loans from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Loans from the partnership firm in which the company's executive director is a partner				
Loans from in which the company's managing director is a member				
Loans from the partnership firm in which the company's non-executive director is a partner				

for AurobindoPharma Prod. Farmaceuticos Ltda.

S.B.Reddy
Director
CPF: 742.899-421-72

Dr. João Antônio de Santana
Diretor
CPF: 014.738-911-62

AUROBINDO PHARMA PRODUTOS FARMACUTICOS LTDA.

Notes to the Balance Sheet

(A) amounts are in local Currency except share data and unless otherwise stated)

Note 14 Trade receivables and other assets

14.1 Trade receivable (Refer General Instructions Item No. 12 & 19)

	Non-current			Current	
	Mar 31, 2015	Dec 31, 2013	March 31, 2014	Mar 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)					
Outstanding for a period exceeding six months from the date they are due for payment					
Secured, considered good					
Due from group companies					
Due from others					
Unsecured, considered good					
Due from group companies					
Due from others				46,151	46,151
Provision for doubtful receivables				46,151	46,151
(A)				46,151	46,151
Other receivables outstanding for a period less than six months from the date they are due for payment					
Secured, considered good					
Due from group companies					
Due from others					
Unsecured, considered good					
Due from group companies					
Due from others				5,935,245	6,073,345
Provision for doubtful receivables				5,935,245	6,073,345
(B)				5,935,245	6,073,345
Total (A+B)				5,981,395	6,119,495

Trade receivables include:

	Non-current			Current	
	Feb 28, 2015	Dec 31, 2013	March 31, 2014	Feb 28, 2015	March 31, 2014
Due from non-executive directors					
Due from officers					
Due from non-executive directors and officers jointly with other persons					
Due from partnership firm in which the company's non-executive director is a partner					
Due from in which the company's non-executive director is a director					

14.2 Other assets (Refer General Instructions Item No. 16 & 22)

	Non-current			Current	
	Mar 31, 2015	Dec 31, 2013	March 31, 2014	Mar 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)					
Non-current bank balances					
(A)					
Unamortized expenditure					
Unamortized premium on forward contract					
Amortized cost of arranging the borrowings					
(B)					
Others					
Interest accrued on fixed deposits					
Interest accrued on investments					
Dividend receivable on investments in subsidiaries - long term					
Others					
(C)					
Total (A+B+C)					

for AurbindoPharma Prod. Farmacêuticos Ltda.

S.B.Reddy
Director
CPF: 742.899.421-72

Luiz Antonio de Santana
CPF: 000.000.000-00

AURUBINDO PHARMA PRODUTOS FARMACEUTICOS LTDA.
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

Note 15: Current investments (Refer General Instructions Note No.17)

	Mar 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
equity shares fully paid-up		
(also, if these specifics)		

Note 16: Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)

	Mar 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)		
Work-in-progress		
Finished goods		
Traded goods (including stock-in-transit XXXX (31 March, 2014 XXX)	12,698,267	2,440,970
Stores, spares, consumables and packing materials		
Losses/losses		
	<u>12,698,267</u>	<u>2,440,970</u>

Note 17: Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current			Current	
	Mar 31, 2015	Dec 31, 2013	March 31, 2014	Mar 31, 2015	March 31, 2014
Cash and cash equivalents					
Balances with banks:					
On current accounts				1,315,863	145,335
Deposits with original maturity of less than 3 months					
Cash credit accounts					
On unpaid dividend account					
Cheques/drafts on hand					
Unpaid matured deposits					
Cash on hand				736	864
				<u>1,316,599</u>	<u>146,199</u>
Other bank balances					
Deposits with original maturity for more than 12 months					
Deposits with original maturity for more than 3 months but less than 12 months					
Margin money deposit					
Amount disclosed under non-current assets					
				<u>1,316,599</u>	<u>146,199</u>

for AurubindoPharma Prod. Farmaceuticos Ltda.

S.B.Reddy
Director
CPF: 742.899.421-72

Aracy de Santana
CPF: 738.201.68

Notes to the Statement of Profit and Loss
 For the year ended 31st March 2014

	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620	1619	1618	1617	1616	1615	1614	1613	1612	1611	1610	1609	1608	1607	1606	1605	1604	1603	1602	1601	1600	1599	1598	1597	1596	1595	1594	1593	1592	1591	1590	1589	1588	1587	1586	1585	1584	1583	1582	1581	1580	1579	1578	1577	1576	1575	1574	1573	1572	1571	1570	1569	1568	1567	1566	1565	1564	1563	1562	1561	1560	1559	1558	1557	1556	1555	1554	1553	1552	1551	1550	1549	1548	1547	1546	1545	1544	1543	1542	1541	1540	1539	1538	1537	1536	1535	1534	1533	1532	1531	1530	1529	1528	1527	1526	1525	1524	1523	1522	1521	1520	1519	1518	1517	1516	1515	1514	1513	1512	1511	1510	1509	1508	1507	1506	1505	1504	1503	1502	1501	1500	1499	1498	1497	1496	1495	1494	1493	1492	1491	1490	1489	1488	1487	1486	1485	1484	1483	1482	1481	1480	1479	1478	1477	1476	1475	1474	1473	1472	1471	1470	1469	1468	1467	1466	1465	1464	1463	1462	1461	1460	1459	1458	1457	1456	1455	1454	1453	1452	1451	1450	1449	1448	1447	1446	1445	1444	1443	1442	1441	1440	1439	1438	1437	1436	1435	1434	1433	1432	1431	1430	1429	1428	1427	1426	1425	1424	1423	1422	1421	1420	1419	1418	1417	1416	1415	1414	1413	1412	1411	1410	1409	1408	1407	1406	1405	1404	1403	1402	1401	1400	1399	1398	1397	1396	1395	1394	1393	1392	1391	1390	1389	1388	1387	1386	1385	1384	1383	1382	1381	1380	1379	1378	1377	1376	1375	1374	1373	1372	1371	1370	1369	1368	1367	1366	1365	1364	1363	1362	1361	1360	1359	1358	1357	1356	1355	1354	1353	1352	1351	1350	1349	1348	1347	1346	1345	1344	1343	1342	1341	1340	1339	1338	1337	1336	1335	1334	1333	1332	1331	1330	1329	1328	1327	1326	1325	1324	1323	1322	1321	1320	1319	1318	1317	1316	1315	1314	1313	1312	1311	1310	1309	1308	1307	1306	1305	1304	1303	1302	1301	1300	1299	1298	1297	1296	1295	1294	1293	1292	1291	1290	1289	1288	1287	1286	1285	1284	1283	1282	1281	1280	1279	1278	1277	1276	1275	1274	1273	1272	1271	1270	1269	1268	1267	1266	1265	1264	1263	1262	1261	1260	1259	1258	1257	1256	1255	1254	1253	1252	1251	1250	1249	1248	1247	1246	1245	1244	1243	1242	1241	1240	1239	1238	1237	1236	1235	1234	1233	1232	1231	1230	1229	1228	1227	1226	1225	1224	1223	1222	1221	1220	1219	1218	1217	1216	1215	1214	1213	1212	1211	1210	1209	1208	1207	1206	1205	1204	1203	1202	1201	1200	1199	1198	1197	1196	1195	1194	1193	1192	1191	1190	1189	1188	1187	1186	1185	1184	1183	1182	1181	1180	1179	1178	1177	1176	1175	1174	1173	1172	1171	1170	1169	1168	1167	1166	1165	1164	1163	1162	1161	1160	1159	1158	1157	1156	1155	1154	1153	1152	1151	1150	1149	1148	1147	1146	1145	1144	1143	1142	1141	1140	1139	1138	1137	1136	1135	1134	1133	1132	1131	1130	1129	1128	1127	1126	1125	1124	1123	1122	1121	1120	1119	1118	1117	1116	1115	1114	1113	1112	1111	1110	1109	1108	1107	1106	1105	1104	1103	1102	1101	1100	1099	1098	1097	1096	1095	1094	1093	1092	1091	1090	1089	1088	1087	1086	1085	1084	1083	1082	1081	1080	1079	1078	1077	1076	1075	1074	1073	1072	1071	1070	1069	1068	1067	1066	1065	1064	1063	1062	1061	1060	1059	1058	1057	1056	1055	1054	1053	1052	1051	1050	1049	1048	1047	1046	1045	1044	1043	1042	1041	1040	1039	1038	1037	1036	1035	1034	1033	1032	1031	1030	1029	1028	1027	1026	1025	1024	1023	1022	1021	1020	1019	1018	1017	1016	1015	1014	1013	1012	1011	1010	1009	1008	1007	1006	1005	1004	1003	1002	1001	1000	999	998	997	996	995	994	993	992	991	990	989	988	987	986	985	984	983	982	981	980	979	978	977	976	975	974	973	972	971	970	969	968	967	966	965	964	963	962	961	960	959	958	957	956	955	954	953	952	951	950	949	948	947	946	945	944	943	942	941	940	939	938	937	936	935	934	933	932	931	930	929	928	927	926	925	924	923	922	921	920	919	918	917	916	915	914	913	912	911	910	909	908	907	906	905	904	903	902	901	900	899	898	897	896	895	894	893	892	891	890	889	888	887	886	885	884	883	882	881	880	879	878	877	876	875	874	873	872	871	870	869	868	867	866	865	864	863	862	861	860	859	858	857	856	855	854	853	852	851	850	849	848	847	846	845	844	843	842	841	840	839	838	837	836	835	834	833	832	831	830	829	828	827	826	825	824	823	822	821	820	819	818	817	816	815	814	813	812	811	810	809	808	807	806	805	804	803	802	801	800	799	798	797	796	795	794	793	792	791	790	789	788	787	786	785	784	783	782	781	780	779	778	777	776	775	774	773	772	771	770	769	768	767	766	765	764	763	762	761	760	759	758	757	756	755	754	753	752	751	750	749	748	747	746	745	744	743	742	741	740	739	738	737	736	735	734	733	732	731	730	729	728	727	726	725	724	723	722	721	720	719	718	717	716	715	714	713	712	711	710	709	708	707	706	705	704	703	702	701	700	699	698	697	696	695	694	693	692	691	690	689	688	687	686	685	684	683	682	681	680	679	678	677	676	675	674	673	672	671	670	669	668	667	666	665	664	663	662	661	660	659	658	657	656	655	654	653	652	651	650	649	648	647	646	645	644	643	642	641	640	639	638	637	636	635	634	633	632	631	630	629	628	627	626	625	624	623	622	621	620	619	618	617	616	615	614	613	612	611	610	609</
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-------

	Apr 14	May 14	Jun 14	Jul 14	Aug 14	Sep 14	Oct 14	Nov 14	Dec 14	Jan 15	Feb 15	Mar 15	Apr 15	May 15	Jun 15	Jul 15	Aug 15	Sep 15	Oct 15	Nov 15	Dec 15	Jan 16	Feb 16	Mar 16	Apr 16	May 16	Jun 16	Jul 16	Aug 16	Sep 16	Oct 16	Nov 16	Dec 16	Jan 17	Feb 17	Mar 17	Apr 17	May 17	Jun 17	Jul 17	Aug 17	Sep 17	Oct 17	Nov 17	Dec 17	Jan 18	Feb 18	Mar 18	Apr 18	May 18	Jun 18	Jul 18	Aug 18	Sep 18	Oct 18	Nov 18	Dec 18	Jan 19	Feb 19	Mar 19	Apr 19	May 19	Jun 19	Jul 19	Aug 19	Sep 19	Oct 19	Nov 19	Dec 19	Jan 20	Feb 20	Mar 20	Apr 20	May 20	Jun 20	Jul 20	Aug 20	Sep 20	Oct 20	Nov 20	Dec 20	Jan 21	Feb 21	Mar 21	Apr 21	May 21	Jun 21	Jul 21	Aug 21	Sep 21	Oct 21	Nov 21	Dec 21	Jan 22	Feb 22	Mar 22	Apr 22	May 22	Jun 22	Jul 22	Aug 22	Sep 22	Oct 22	Nov 22	Dec 22	Jan 23	Feb 23	Mar 23	Apr 23	May 23	Jun 23	Jul 23	Aug 23	Sep 23	Oct 23	Nov 23	Dec 23	Jan 24	Feb 24	Mar 24	Apr 24	May 24	Jun 24	Jul 24	Aug 24	Sep 24	Oct 24	Nov 24	Dec 24	Jan 25	Feb 25	Mar 25	Apr 25	May 25	Jun 25	Jul 25	Aug 25	Sep 25	Oct 25	Nov 25	Dec 25	Jan 26	Feb 26	Mar 26	Apr 26	May 26	Jun 26	Jul 26	Aug 26	Sep 26	Oct 26	Nov 26	Dec 26	Jan 27	Feb 27	Mar 27	Apr 27	May 27	Jun 27	Jul 27	Aug 27	Sep 27	Oct 27	Nov 27	Dec 27	Jan 28	Feb 28	Mar 28	Apr 28	May 28	Jun 28	Jul 28	Aug 28	Sep 28	Oct 28	Nov 28	Dec 28	Jan 29	Feb 29	Mar 29	Apr 29	May 29	Jun 29	Jul 29	Aug 29	Sep 29	Oct 29	Nov 29	Dec 29	Jan 30	Feb 30	Mar 30	Apr 30	May 30	Jun 30	Jul 30	Aug 30	Sep 30	Oct 30	Nov 30	Dec 30	Jan 31	Feb 31	Mar 31	Apr 31	May 31	Jun 31	Jul 31	Aug 31	Sep 31	Oct 31	Nov 31	Dec 31	Jan 32	Feb 32	Mar 32	Apr 32	May 32	Jun 32	Jul 32	Aug 32	Sep 32	Oct 32	Nov 32	Dec 32	Jan 33	Feb 33	Mar 33	Apr 33	May 33	Jun 33	Jul 33	Aug 33	Sep 33	Oct 33	Nov 33	Dec 33	Jan 34	Feb 34	Mar 34	Apr 34	May 34	Jun 34	Jul 34	Aug 34	Sep 34	Oct 34	Nov 34	Dec 34	Jan 35	Feb 35	Mar 35	Apr 35	May 35	Jun 35	Jul 35	Aug 35	Sep 35	Oct 35	Nov 35	Dec 35	Jan 36	Feb 36	Mar 36	Apr 36	May 36	Jun 36	Jul 36	Aug 36	Sep 36	Oct 36	Nov 36	Dec 36	Jan 37	Feb 37	Mar 37	Apr 37	May 37	Jun 37	Jul 37	Aug 37	Sep 37	Oct 37	Nov 37	Dec 37	Jan 38	Feb 38	Mar 38	Apr 38	May 38	Jun 38	Jul 38	Aug 38	Sep 38	Oct 38	Nov 38	Dec 38	Jan 39	Feb 39	Mar 39	Apr 39	May 39	Jun 39	Jul 39	Aug 39	Sep 39	Oct 39	Nov 39	Dec 39	Jan 40	Feb 40	Mar 40	Apr 40	May 40	Jun 40	Jul 40	Aug 40	Sep 40	Oct 40	Nov 40	Dec 40	Jan 41	Feb 41	Mar 41	Apr 41	May 41	Jun 41	Jul 41	Aug 41	Sep 41	Oct 41	Nov 41	Dec 41	Jan 42	Feb 42	Mar 42	Apr 42	May 42	Jun 42	Jul 42	Aug 42	Sep 42	Oct 42	Nov 42	Dec 42	Jan 43	Feb 43	Mar 43	Apr 43	May 43	Jun 43	Jul 43	Aug 43	Sep 43	Oct 43	Nov 43	Dec 43	Jan 44	Feb 44	Mar 44	Apr 44	May 44	Jun 44	Jul 44	Aug 44	Sep 44	Oct 44	Nov 44	Dec 44	Jan 45	Feb 45	Mar 45	Apr 45	May 45	Jun 45	Jul 45	Aug 45	Sep 45	Oct 45	Nov 45	Dec 45	Jan 46	Feb 46	Mar 46	Apr 46	May 46	Jun 46	Jul 46	Aug 46	Sep 46	Oct 46	Nov 46	Dec 46	Jan 47	Feb 47	Mar 47	Apr 47	May 47	Jun 47	Jul 47	Aug 47	Sep 47	Oct 47	Nov 47	Dec 47	Jan 48	Feb 48	Mar 48	Apr 48	May 48	Jun 48	Jul 48	Aug 48	Sep 48	Oct 48	Nov 48	Dec 48	Jan 49	Feb 49	Mar 49	Apr 49	May 49	Jun 49	Jul 49	Aug 49	Sep 49	Oct 49	Nov 49	Dec 49	Jan 50	Feb 50	Mar 50	Apr 50	May 50	Jun 50	Jul 50	Aug 50	Sep 50	Oct 50	Nov 50	Dec 50	Jan 51	Feb 51	Mar 51	Apr 51	May 51	Jun 51	Jul 51	Aug 51	Sep 51	Oct 51	Nov 51	Dec 51	Jan 52	Feb 52	Mar 52	Apr 52	May 52	Jun 52	Jul 52	Aug 52	Sep 52	Oct 52	Nov 52	Dec 52	Jan 53	Feb 53	Mar 53	Apr 53	May 53	Jun 53	Jul 53	Aug 53	Sep 53	Oct 53	Nov 53	Dec 53	Jan 54	Feb 54	Mar 54	Apr 54	May 54	Jun 54	Jul 54	Aug 54	Sep 54	Oct 54	Nov 54	Dec 54	Jan 55	Feb 55	Mar 55	Apr 55	May 55	Jun 55	Jul 55	Aug 55	Sep 55	Oct 55	Nov 55	Dec 55	Jan 56	Feb 56	Mar 56	Apr 56	May 56	Jun 56	Jul 56	Aug 56	Sep 56	Oct 56	Nov 56	Dec 56	Jan 57	Feb 57	Mar 57	Apr 57	May 57	Jun 57	Jul 57	Aug 57	Sep 57	Oct 57	Nov 57	Dec 57	Jan 58	Feb 58	Mar 58	Apr 58	May 58	Jun 58	Jul 58	Aug 58	Sep 58	Oct 58	Nov 58	Dec 58	Jan 59	Feb 59	Mar 59	Apr 59	May 59	Jun 59	Jul 59	Aug 59	Sep 59	Oct 59	Nov 59	Dec 59	Jan 60	Feb 60	Mar 60	Apr 60	May 60	Jun 60	Jul 60	Aug 60	Sep 60	Oct 60	Nov 60	Dec 60	Jan 61	Feb 61	Mar 61	Apr 61	May 61	Jun 61	Jul 61	Aug 61	Sep 61	Oct 61	Nov 61	Dec 61	Jan 62	Feb 62	Mar 62	Apr 62	May 62	Jun 62	Jul 62	Aug 62	Sep 62	Oct 62	Nov 62	Dec 62	Jan 63	Feb 63	Mar 63	Apr 63	May 63	Jun 63	Jul 63	Aug 63	Sep 63	Oct 63	Nov 63	Dec 63	Jan 64	Feb 64	Mar 64	Apr 64	May 64	Jun 64	Jul 64	Aug 64	Sep 64	Oct 64	Nov 64	Dec 64	Jan 65	Feb 65	Mar 65	Apr 65	May 65	Jun 65	Jul 65	Aug 65	Sep 65	Oct 65	Nov 65	Dec 65	Jan 66	Feb 66	Mar 66	Apr 66	May 66	Jun 66	Jul 66	Aug 66	Sep 66	Oct 66	Nov 66	Dec 66	Jan 67	Feb 67	Mar 67	Apr 67	May 67	Jun 67	Jul 67	Aug 67	Sep 67	Oct 67	Nov 67	Dec 67	Jan 68	Feb 68	Mar 68	Apr 68	May 68	Jun 68	Jul 68	Aug 68	Sep 68	Oct 68	Nov 68	Dec 68	Jan 69	Feb 69	Mar 69	Apr 69	May 69	Jun 69	Jul 69	Aug 69	Sep 69	Oct 69	Nov 69	Dec 69	Jan 70	Feb 70	Mar 70	Apr 70	May 70	Jun 70	Jul 70	Aug 70	Sep 70	Oct 70	Nov 70	Dec 70	Jan 71	Feb 71	Mar 71	Apr 71	May 71	Jun 71	Jul 71	Aug 71	Sep 71	Oct 71	Nov 71	Dec 71	Jan 72	Feb 72	Mar 72	Apr 72	May 72	Jun 72	Jul 72	Aug 72	Sep 72	Oct 72	Nov 72	Dec 72	Jan 73	Feb 73	Mar 73	Apr 73	May 73	Jun 73	Jul 73	Aug 73	Sep 73	Oct 73	Nov 73	Dec 73	Jan 74	Feb 74	Mar 74	Apr 74	May 74	Jun 74	Jul 74	Aug 74	Sep 74	Oct 74	Nov 74	Dec 74	Jan 75	Feb 75	Mar 75	Apr 75	May 75	Jun 75	Jul 75	Aug 75	Sep 75	Oct 75	Nov 75	Dec 75	Jan 76	Feb 76	Mar 76	Apr 76	May 76	Jun 76	Jul 76	Aug 76	Sep 76	Oct 76	Nov 76	Dec 76	Jan 77	Feb 77	Mar 77	Apr 77	May 77	Jun 77	Jul 77	Aug 77	Sep 77	Oct 77	Nov 77	Dec 77	Jan 78	Feb 78	Mar 78	Apr 78	May 78	Jun 78	Jul 78	Aug 78	Sep 78	Oct 78	Nov 78	Dec 78	Jan 79	Feb 79	Mar 79	Apr 79	May 79	Jun 79	Jul 79	Aug 79	Sep 79	Oct 79	Nov 79	Dec 79	Jan 80	Feb 80	Mar 80	Apr 80	May 80	Jun 80	Jul 80	Aug 80	Sep 80	Oct 80	Nov 80	Dec 80	Jan 81	Feb 81	Mar 81	Apr 81	May 81	Jun 81	Jul 81	Aug 81	Sep 81	Oct 81	Nov 81	Dec 81	Jan 82	Feb 82	Mar 82	Apr 82	May 82	Jun 82	Jul 82	Aug 82	Sep 82	Oct 82	Nov 82	Dec 82	Jan 83	Feb 83	Mar 83	Apr 83	May 83	Jun 83	Jul 83	Aug 83	Sep 83	Oct 83	Nov 83	Dec 83	Jan 84	Feb 84	Mar 84	Apr 84	May 84	Jun 84	Jul 84	Aug 84	Sep 84	Oct 84	Nov 84	Dec 84	Jan 85	Feb 85	Mar 85	Apr 85	May 85	Jun 85	Jul 85	Aug 85	Sep 85	Oct 85	Nov 85	Dec 85	Jan 86	Feb 86	Mar 86	Apr 86	May 86	Jun 86	Jul 86	Aug 86	Sep 86	Oct 86	Nov 86	Dec 86	Jan 87	Feb 87	Mar 87	Apr 87	May 87	Jun 87	Jul 87	Aug 87	Sep 87	Oct 87	Nov 87	Dec 87	Jan 88	Feb 88	Mar 88	Apr 88	May 88	Jun 88	Jul 88	Aug 88	Sep 88	Oct 88	Nov 88	Dec 88	Jan 89	Feb 89	Mar 89	Apr 89	May 89	Jun 89	Jul 89	Aug 89	Sep 89	Oct 89	Nov 89	Dec 89	Jan 90	Feb 90	Mar 90	Apr 90	May 90	Jun 90	Jul 90	Aug 90	Sep 90	Oct 90	Nov 90	Dec 90	Jan 91	Feb 91	Mar 91	Apr 91	May 91	Jun 91	Jul 91	Aug 91	Sep 91	Oct 91	Nov 91	Dec 91	Jan 92	Feb 92	Mar 92	Apr 92	May 92	Jun 92	Jul 92	Aug 92	Sep 92	Oct 92	Nov 92	Dec 92	Jan 93	Feb 93	Mar 93	Apr 93	May 93	Jun 93	Jul 93	Aug 93	Sep 93	Oct 93	Nov 93	Dec 93	Jan 94	Feb 94	Mar 94	Apr 94	May 94	Jun 94	Jul 94	Aug 94	Sep 94	Oct 94	Nov 94	Dec 94	Jan 95	Feb 95	Mar 95	Apr 95	May 95	Jun 95	Jul 95	Aug 95	Sep 95	Oct 95	Nov 95	Dec 95	Jan 96	Feb 96	Mar 96	Apr 96	May 96	Jun 96	Jul 96	Aug 96	Sep 96	Oct 96	Nov 96	Dec 96	Jan 97	Feb 97	Mar 97	Apr 97	May 97	Jun 97	Jul 97	Aug 97	Sep 97	Oct 97	Nov 97	Dec 97	Jan 98	Feb 98	Mar 98	Apr 98	May 98	Jun 98	Jul 98	Aug 98	Sep 98	Oct 98	Nov 98	Dec 98	Jan 99	Feb 99	Mar 99	Apr 99	May 99	Jun 99	Jul 99	Aug 99	Sep 99	Oct 99	Nov 99	Dec 99	Jan 00	Feb 00	Mar 00	Apr 00	May 00	Jun 00	Jul 00	Aug 00	Sep 00	Oct 00	Nov 00	Dec 00	Jan 01	Feb 01	Mar 01	Apr 01	May 01	Jun 01	Jul 01	Aug 01	Sep 01	Oct 01	Nov 01	Dec 01	Jan 02	Feb 02	Mar 02	Apr 02	May 02	Jun 02	Jul 02	Aug 02	Sep 02	Oct 02	Nov 02	Dec 02	Jan 03	Feb 03	Mar 03	Apr 03	May 03	Jun 03	Jul 03	Aug 03	Sep 03	Oct 03	Nov 03	Dec 03	Jan 04	Feb 04	Mar 04	Apr 04	May 04	Jun 04	Jul 04	Aug 04	Sep 04	Oct 04	Nov 04	Dec 04	Jan 05	Feb 05	Mar 05	Apr 05	May 05	Jun 05	Jul 05	Aug 05	Sep 05	Oct 05	Nov 05	Dec 05	Jan 06	Feb 06	Mar 06	Apr 06	May 06	Jun 06	Jul 06	Aug 06	Sep 06	Oct 06	Nov 06	Dec 06	Jan 07	Feb 07	Mar 07	Apr 07	May 07	Jun 07	Jul 07	Aug 07	Sep 07	Oct 07	Nov 07	Dec 07	Jan 08	Feb 08	Mar 08	Apr 08	May 08	Jun 08	Jul 08	Aug 08	Sep 08	Oct 08	Nov 08	Dec 08	Jan 09	Feb 09	Mar 09	Apr 09	May 09	Jun 09	Jul 09	Aug 09	Sep 09	Oct 09	Nov 09	Dec 09	Jan 10	Feb 10	Mar 10	Apr 10	May 10	Jun 10	Jul 10	Aug 10	Sep 10	Oct 10	Nov 10	Dec 10	Jan 11	Feb 11	Mar 11	Apr 11	May 11	Jun 11	Jul 11	Aug 11	Sep 11	Oct 11	Nov 11	Dec 11	Jan 12	Feb 12	Mar 12	Apr 12	May 12	Jun 12	Jul 12	Aug 12	Sep 12	Oct 12	Nov 12	Dec 12	Jan 13	Feb 13	Mar 13	Apr 13	May 13	Jun 13	Jul 13	Aug 13	Sep 13	Oct 13	Nov 13	Dec 13	Jan 14	Feb 14	Mar 14	Apr 14	May 14	Jun 14	Jul 14	Aug 14	Sep 14	Oct 14	Nov 14	Dec 14	Jan 15	Feb 15	Mar 15	Apr 15	May 15	Jun 15	Jul 15	Aug 15	Sep 15	Oct 15	Nov 15	Dec 15	Jan 16	Feb 16	Mar 16	Apr 16	May 16	Jun 16	Jul 16	Aug 16	Sep 16	Oct 16	Nov 16	Dec 16	Jan 17	Feb 17	Mar 17	Apr 17	May 17	Jun 17	Jul 17	Aug 17	Sep 17	Oct 17	Nov 17	Dec 17	Jan 18	Feb 18	Mar 18	Apr 18	May 18	Jun 18	Jul 18	Aug 18	Sep 18	Oct 18	Nov 18	Dec 18	Jan 19	Feb 19	Mar 19	Apr 19	May 19	Jun 19	Jul 19	Aug 19	Sep 19	Oct 19	Nov 19	Dec 19	Jan 20	Feb 20	Mar 20	Apr 20	May 20	Jun 20	Jul 20	Aug 20	Sep 20	Oct 20	Nov 20	Dec 20	Jan 21	Feb 21	Mar 21	Apr 21	May 21	Jun 21	Jul 21	Aug 21	Sep 21	Oct 21	Nov 21	Dec 21	Jan 22	Feb 22	Mar 22	Apr 22	May 22	Jun 22	Jul 22	Aug 22	Sep 22	Oct 22	Nov 22	Dec 22	Jan 23	Feb 23	Mar 23	Apr 23	May 23	Jun 23	Jul 23	Aug 23	Sep 23	Oct 23	Nov 23	Dec 23	Jan 24	Feb 24	Mar 24	Apr 24	May 24	Jun 24	Jul 24	Aug 24	Sep 24	Oct 24	Nov 24	Dec 24	Jan 25	Feb 25	Mar 25	Apr 25	May 25	Jun 25	Jul 25	Aug 25	Sep 25	Oct 25	Nov 25	Dec 25	Jan 26	Feb 26	Mar 26	Apr 26	May 26	Jun 26	Jul 26	Aug 26	Sep 26	Oct 26	Nov 26	Dec 26	Jan 27	Feb 27	Mar 27	Apr 27	May 27	Jun 27	Jul 27	Aug 27	Sep 27	Oct 27	Nov 27	Dec 27	Jan 28	Feb 28	Mar 28	Apr 28	May 28	Jun 28	Jul 28	Aug 28	Sep 28	Oct 28
--	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------

100 Anotokish-Pharma Prod. Farmacéuticos Ltda.

S.B.Reddy
Director

PF 742.899 421-72

Agustino Arana de Santiano
Calle 3100 2 100
Tel. 019 738 0100

ALROBINDO PHARMA PRODUTOS FARMACÊUTICOS LTDA.

Notes to the statement of profit and loss

(All amounts are in US dollar Current except share data and unless otherwise stated)

Note 10: Tangible assets

	Air Condition Plant	Furniture & Fixtures	Computers	Office Equipments	Software	Plant & Equipment	Vehicles	Ware House Equipments	Total
Cost or valuation									
At April 1, 2013	6,308.86	246,197.95	21,959.61	2,326.48	13,101.80				289,894.75
Additions during the nine months			16,236.73		1,549.38				11,786.11
Disposals during the nine months									
Transfer to assets held for sale									
Other adjustments									
Exchange differences									
At December 31, 2013	6,308.86	246,197.95	32,196.34	2,326.48	14,651.23	-	-	-	301,680.86
Additions during the three months					743.54				743.54
Disposals during the three months									
Other adjustments									
Exchange differences									
At March 31, 2014	6,308.86	246,197.95	32,196.34	2,326.48	15,394.77	-	-	-	302,424.40
Additions during the nine months		2,000.01	16,378.41		1,396.12		86,000.00		105,774.54
Disposals during the nine months									
Additions on acquisition									
Other adjustments									
Exchange differences									
At March 31, 2015	6,308.86	248,197.96	48,574.75	2,326.48	16,790.89	-	86,000.00	-	408,198.94
Depreciation									
At April 1, 2013	2,461.65	70,327.30	15,172.21	1,110.28	8,696.74	-	-	-	97,768.18
Charge for the period	473.22	17,470.71	4,084.20	174.51	2,007.21	-	-	-	24,209.85
Disposals									
Transfer to assets held for sale									
Other adjustments									
Exchange differences									
At December 31, 2013	2,934.87	87,798.01	19,256.41	1,284.79	10,703.95	-	-	-	121,978.03
Charge for the period	157.71	5,823.57	1,645.32	58.17	734.25	-	-	-	8,419.02
Disposals									
Other adjustments									
Exchange differences									
At March 31, 2014	3,092.58	93,621.58	20,901.73	1,342.96	11,438.20	-	-	-	130,397.05
Charge for the period	632.76	23,342.37	8,470.07	232.68	3,002.32	-	10,491.96	-	46,172.16
Disposals									
Additions on acquisition									
Other adjustments									
Exchange differences									
At March 31, 2015	3,725.34	116,963.95	29,371.80	1,575.64	14,440.52	-	10,491.96	-	176,569.21
Net Block									
At December 31, 2013	3,373.99	158,399.94	12,939.93	1,041.69	3,947.28	-	-	-	179,702.83
At March 31, 2014	3,216.28	152,576.37	11,294.61	983.52	3,956.57	-	-	-	172,027.35
At March 31, 2015	2,583.52	131,234.01	19,202.95	750.84	2,350.37	-	75,508.04	-	231,629.73

Alrobindo Pharma Prod Farmacêuticos Ltda.

S.B Reddy
Director

041 742.899.421-72

Dr. V. S. Arjun de Santana
Diretor
041 742.899.421-72

AUROBINDO PHARMA PRODUTOS FARMACÉUTICOS LTDA.,

Notes to the statement of profit and loss

(All amounts are in Local currency except share data and unless otherwise stated)

Note 11 - Intangible assets

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At April 1, 2013	-	-	-	-
Additions during the nine months	-	-	-	-
Internal development during the nine months	-	-	-	-
Disposals during the nine months	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At December 31, 2013	-	-	-	-
Additions during the three months	-	-	-	-
Internal development during the three months	-	-	-	-
Disposals during the three months	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At March 31, 2014	-	-	-	-
Additions during the nine months	-	-	-	-
Disposals during the nine months	-	-	-	-
Additions on acquisition	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At December 31, 2014	-	-	-	-
Amortization				
At April 1, 2013	-	-	-	-
Charge for the period	-	-	-	-
Disposals	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At December 31, 2013	-	-	-	-
Charge for the period	-	-	-	-
Disposals	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At March 31, 2014	-	-	-	-
Charge for the period	-	-	-	-
Disposals	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At December 31, 2014	-	-	-	-
Net Block				
At December 31, 2013	-	-	-	-
At March 31, 2014	-	-	-	-
At December 31, 2014	-	-	-	-

Aurobindo Pharma Prod. Farmacéuticos Ltda.

S.B.Reddy
Director

742.899.421-72

Attestado de Saitang
Attestado de Saitang
Attestado de Saitang

CONDOMIO PHARMA PRODUITOS FARMACÊUTICOS LTDA
Balance Sheet as at March 31, 2015

As of March 31, 2015, the company's financial statements were prepared in accordance with the accounting principles of Brazil.

The financial statements have been prepared under the historical cost convention on accrual basis.

a) Basis of preparation

The financial statements have been prepared under the historical cost convention on accrual basis.

b) Revenue Recognition

Revenue from sale of goods is recognized at dispatch and is exclusive of IMS and net of discounts and sales return.

c) Fixed Assets and Depreciation

Fixed assets are stated at cost less accumulated depreciation. Cost include freight, duties, taxes, and any other related cost. Depreciation is calculated on straight line method as prescribed by the Income Tax Law.

d) Inventories

Inventories are valued at lower of cost or net realizable value, with cost being determined using Weighted Average Method.

e) Retirement Benefits

Retirement benefits are provided by the company and are recorded on accrual basis.

f) Deferred Tax Liability

Deferred tax liability is determined on temporary differences.

g) Foreign Exchange Transactions

Foreign currency transactions arising during the year are recorded at the exchange rates prevailing at the transaction date. Foreign currency transactions are shown separately in the Profit & Loss Account. Foreign exchange rates are provided at R\$ 1.01 per each USD on 31st Mar, 2015.


h) Leases

The company has entered into operating leases and mainly in the nature of lease of office premises with no restriction and are cancellable at mutual consent.

i) Authorized share capital

The authorized capital is limited by subscription to capital 99% of the paid up Share Capital is being held by Acondio Pharma Ltda. and the remaining 1% is being held by other minority Shareholders.


Jacqueline Araujo de Santana
 Contadora CRC/GO 022060/P
 CPF: 019.738.201-69


S.H. Reddy
 Director
 CNPJ: 14.289.942-72

DIRECTORS' REPORT

The directors present their report and the audited financial statements for the year ended March 31st 2015.

PRINCIPAL ACTIVITY

The principle object of the company is to trade and deal in pharmaceutical products and other allied products and services.

Unusual Items after the Financial Year:

No item, transaction or event of a Material nature has arisen during the period between the end of the financial year and the date of this report, which would affect substantially the operations of the company during the current year.

REVIEW OF OPERATIONS

During the year the company had registered a Profit of CNY 959,761.02 against a Total Revenue of CNY 273,402,845.56 and in previous year it made a Profit of CNY 1,128,361.76 against a Total Revenue of CNY 322,228,304.78.

Statement of Directors:


In the opinion of the Directors, the accompanying Financial statements were drawn up so as to give a true and fair view of the state of affairs of the Company as on 31st March 2015 and the results of the business for that period. Your Directors have taken all reasonable steps to prepare these financial statements on a going concern basis and suitable accounting policies have been adopted consistently. Further your Directors are confident that with the support and guidance of the Holding company, your Company can achieve better results in the future

DIRECTORS

The Directors at the date of the report are:

1. Mr.Aravind Chandak
2. Mr. Govind

By Order of the Board:



Mr.Aravind Chandak.
Director
China



上海高仁会计师事务所

Shanghai Gaoren Certified Public Accountants Partnership

地址：上海市张江高科技园区祖冲之路1559号创意大厦1001~1002室

电话：+86 21-50800718

传真：+86 21-50804049

E-mail: gr_cpa@163.com

邮政编码：201203

Auditors' Report

H.G.R (2015) W. Z. No: 021099

To the Board of Directors of All Pharma(Shanghai) Trading Co., Ltd.:

We have audited the financial statements of All Pharma(Shanghai) Trading Co.,Ltd. (hereinafter referred to as "All Pharma(Shanghai) Trading company") including its balance sheet as at March 31st, 2015, profit statement for the period of April 1st,2014 to March 31st,2015, and review the notes to the financial statements.

I . The Management's Responsibility for Financial Statement

The responsibility of All Pharma(Shanghai) Trading company's management is to prepare and fair report those financial statements, which includes (1) prepare those financial statements in accordance with the Accounting System for Business Enterprises and Accounting Standards for Business Enterprises and give a true and fair view of the financial position; (2)the design, implementation and maintenance of internal control over the preparation of financial statements so as to ensure these financial statements are free from material misstatement as a result of fraudulent practices or mistakes.

II . Responsibilities of Certified Public Accountants

Our responsibility is to express an audit opinion, based on our audit, on those financial statements. We conducted our audit in accordance with the Auditing Standards for CPAs of China. It is required in the Auditing Standards for CPAs of China that we must plan and conduct our audit in accordance with the The Chinese Institute of CPA occupation moral codes so as to provide us with sufficient evidence to give reasonable assurance as to whether the financial statements are free from material misstatement.

An audit includes the implementation of auditing procedures so as to obtain auditing evidence relevant to the amounts and disclosures in the financial statements. As to which auditing

- 1 -

procedure shall be chosen depends on the judgments made by the CPAs, which includes an assessment of the risk of material misstatement arising from the fraud practices and mistakes in the preparation of the financial statements. During the risk assessment, the CPAs take into account the internal control over the preparation of the financial statements in order to design an appropriate auditing procedure. However, the purpose is not to form an opinion on the effectiveness of internal control. Our audit also includes the assessment of the appropriateness of accounting policies applied by the management, the reasonableness of accounting estimate that was made and the evaluation of the overall financial statements presentation.

We believe that the audit evidences we obtained are sufficient and appropriate enough to provide a reasonable basis for our opinion.

III. Audit Opinion

In our opinion, All Pharma(Shanghai) Trading company's financial statements have been prepared in accordance with the Accounting Standards for Enterprises, in all material respects, which give a true and fair view of the financial position of All Pharma(Shanghai) Trading company as at March 31th, 2015 and of its business performance for the period from April 1st, 2014 to March 31th, 2015..

English Translation For Reference Only. Should there be any inconsistency between the Chinese and English version, then the Chinese version should prevail.

Shanghai GaoRen Certified Public Accountant Partnership.

China's Certified Public Accountant: Mao dongfeng

China's Certified Public Accountant: Liu shangyan

Shanghai, China

April 20th, 2015

All Pharma (Shanghai) Trading Co. Ltd.

Balance Sheet as at March 31, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	31 March, 2015 (CNY)	31 March, 2014 (CNY)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	5,001,815	5,001,815
Share application money			
Reserves and surplus	3	9,045,424	8,085,663
		<u>14,047,239</u>	<u>13,087,478</u>
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		<u>-</u>	<u>-</u>
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	43,712,679	23,820,216
Other current liabilities	9	2,688,810	913,085
Short-term provisions	7	(403,366)	(320,246)
		<u>45,998,122</u>	<u>24,413,054</u>
TOTAL		<u><u>60,045,361</u></u>	<u><u>37,500,532</u></u>
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	247,827	322,584
Intangible assets	11	-	-
Capital work-in-progress			
Intangible assets under development			
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	-	-
Trade receivables	14.1	-	-
Other non-current assets	14.2	-	-
		<u>247,827</u>	<u>322,584</u>
Current assets			
Current investments	15	-	-
Inventories	16	-	-
Trade receivables	14.1	25,953,463	15,018,342
Cash and bank balances	17	11,996,280	9,143,137
Short-term loans and advances	13	18,248,289	11,696,250
Other current assets	14.2	3,599,502	1,320,218
		<u>59,797,534</u>	<u>37,177,948</u>
TOTAL		<u><u>60,045,361</u></u>	<u><u>37,500,532</u></u>
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.

All Pharma (Shanghai) Trading Co. Ltd.

Statement of profit and loss for the Year ended March 31, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015	Year ended March 31, 2014
Income															
Revenue from operations (gross)	18	17,313,070	11,777,124	15,966,862	16,138,167	25,700,078	34,079,368	21,161,877	36,394,929	17,215,682	24,600,013	36,431,379	21,271,984	278,050,533	329,131,050
Less: Excise duty/Rebates		(1,006)	-	(312,907)	(772,102)	(1,263,303)	(1,431,836)	(985,219)	(678,993)	(504,247)	(440,230)	(5,052)	(134,131)	(6,529,027)	(8,882,455)
Revenue from operations (net)		17,312,064	11,777,124	15,653,955	15,366,065	24,436,775	32,647,532	20,176,658	35,715,936	16,711,435	24,159,784	36,426,327	21,137,852	271,521,506	320,248,596
Other income	19	199,950	28,305	149,659	280,729	169,154	99,253	193,491	195,793	239,626	(10,340)	219,084	-	1,764,704	1,869,120
Total revenue (I)		17,512,014	11,805,429	15,803,614	15,646,794	24,605,929	32,746,784	20,370,149	35,911,728	16,951,061	24,149,444	36,645,411	21,137,852	273,286,210	322,117,716
Expenses															
Cost of raw material and components consumed	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods	21	16,175,637	11,236,309	14,941,094	14,562,576	23,598,084	31,732,206	19,613,995	34,804,874	16,262,570	22,558,835	35,562,423	20,130,244	261,178,847	307,258,284
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Employee benefit expense	22	191,953	178,826	272,076	150,026	154,713	180,155	173,292	247,251	170,125	175,657	186,055	182,790	2,262,919	2,529,917
Other expenses	23	1,011,185	235,426	467,591	614,172	500,528	448,767	490,230	623,393	46,845	896,295	388,339	455,708	6,178,478	7,498,799
Exceptional items	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total (II)		17,378,775	11,650,560	15,680,761	15,326,774	24,253,325	32,361,127	20,277,516	35,675,519	16,479,540	23,630,787	36,136,817	20,768,742	269,620,243	317,287,000
Earnings before interest, tax, depreciaton and amortization		133,240	154,868	122,854	320,020	352,604	385,657	92,633	236,209	471,521	518,657	508,594	369,110	3,665,967	4,830,716
Depreciation and amortization expense	25	6,767	6,650	6,650	6,650	6,650	6,650	6,650	6,650	6,650	6,650	6,650	1,490.00	74,757	83,272
Finance costs	26	93,684	162,517	114,011	259,257	131,783	235,405	117,278	191,745	286,071	151,791	290,516	205,925	2,239,982	3,089,090
Profit/(loss) before tax		32,788	(14,298)	2,193	54,113	214,171	143,602	(31,295)	37,814	178,800	360,216	211,428	161,695	1,351,228	1,658,354
Tax expenses															
Current tax				5,171			102,972			101,771	53,645		127,909	391,467	529,992
Less: MAT credit entitlement														-	-
Deferred tax														-	-
Fringe benefit tax														-	-
Tax relating to previous years														-	-
Total tax expense		-	-	5,171	-	-	102,972	-	-	101,771	53,645	-	127,909	391,467	529,992
Profit/(loss) for the year		32,788	(14,298)	(2,978)	54,113	214,171	40,630	(31,295)	37,814	77,029	306,572	211,428	33,785	959,761	1,128,362

Summary of significant accounting policies

1

The accompanying notes are an integral part of the financial statements.

Note 1 : Summary of significant accounting policies (Refer General Instructions Note No.1)

1.1 Accounting basis and principle:

The Company's financials accounting is carried out on an accrual basis. The accounting records are maintained on a historical cost basis.

1.2 FIXED ASSETS

The cost of an item of Fixed asset is recognised as an asset when:

- is probable that future economic benefits associated with the item will flow to the company; and
- cost of the item can be measured reliably.

The useful lives of items of property, plant and equipment have been assessed as follows:

- Furniture and fixtures - 5 Years
- Office equipment - 5 Years
- Vehicle - 5 Years

1.3 Inventories

Inventories are measured at the lower of cost and net realisable value.

1.4 Revenue

Revenue from the sale of goods is recognised when all the following conditions have been satisfied:

- the company has transferred to the buyer the significant risks and rewards of ownership of the goods;
- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the company; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Note 2 : Share capital (Refer General Instructions Note No.2)

	March 31, 2015	March 31, 2014
Authorised shares:	5,001,815	5,001,815
	<u>5,001,815</u>	<u>5,001,815</u>
Issued, Subscribed and Fully Paid-up shares:	5,001,815	5,001,815

All Pharma (Shanghai) Trading Co. Ltd.
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

Note 3 : Reserves and surplus (Refer General Instructions Note No.3)		March 31, 2015	March 31, 2014
Capital Reserve			
As per last Balance Sheet		-	-
Capital Redemption Reserve			
Securities Premium Account			
As per last Balance Sheet		-	-
General Reserve			
As per last Balance Sheet			
Add: Transferred from: statement of profit and loss		-	-
Surplus/(deficit) in the statement of profit and loss			
Balance as per last financial statements		8,085,663	6,957,301
Profit for the quarter		959,761	1,128,362
Less: Appropriations			
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)			
Tax on proposed equity dividend			
Interim dividend paid (amount per share XX (31 March, 2014 XX)			
Transfer to general reserve			
Total appropriations		-	-
Net surplus in the statement of profit and loss		9,045,424	8,085,663
Total reserves and surplus		9,045,424	8,085,663

Note 4 : Long -term borrowings (Refer General Instructions Note No.4)			
	Non-current Portion		Current maturities
	March 31, 2015	March 31, 2014	March 31, 2015
Term Loans			
From banks (Secured)			
Other Loans from banks			
Current account credit balance			
Loans and advances from related parties			
Other Loans and advances			
Sales tax deferment loan (Un Secured)			
	-	-	-
The above amount includes			
Secured borrowings			
Unsecured borrowings			
Amount disclosed under the head			
"Other current liabilities"			
Net Amount	-	-	-

Note 5 : Deferred tax liability (net)

	March 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis		
Provision for diminution in the value of investments		
Provision for doubtful debts and advances		
Fixed Assets (Depreciation)		
Retirement Benefits		
Others		
Gross deferred tax liability	-	-
Deferred tax asset		
Carried Forward Business Losses		
Others		
Gross deferred tax asset	-	-
Net deferred tax liability	-	-

Note 6 : Other long-term liabilities (Refer General Instructions Note No.5)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances)		
Others		
Advances from customers		
Unclaimed dividends		
Other liabilities		
Interest accrued but not due on loans		
Advances from related parties		
	-	-
	-	-

Note 7 : Provisions (Refer General Instructions Note No.6 & 10)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Provision for employee benefits				
- Gratuity				
- Leave encashment				
	-	-	-	-
Other Provisions				
For Taxation (net of advance payments)			(403,366)	(320,246)
For Proposed dividend				
For Tax on proposed dividend				
	-	-	(403,366)	(320,246)
	-	-	(403,366)	(320,246)

Provision for warranties

	March 31, 2015	March 31, 2014
At the beginning of the year		
Arising during the period		
Utilised during the period		
Unused amounts reversed		
At the end of the Quarter	-	-
Current portion		
Non-current portion		

Note 8 : Short-term borrowings (Refer General Instructions Note No.7)

	March 31, 2015	March 31, 2014
Book overdraft		
Loans and advances from related parties		
Working capital loans (Secured)		
Short term loans (Un Secured)		
Working capital loans		
	-	-
The above amount includes		
Secured borrowings	-	-
Unsecured borrowings	-	-

Note 9 : Other current liabilities (Refer General Instructions Note No.9)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)	43,712,679	23,820,216
Other liabilities		
Current maturities of long-term borrowings	1,088,508	141,611
Trade deposits	1,600,301	771,474
	2,688,810	913,085
	46,401,488	24,733,301

All Pharma (Shanghai) Trading Co. Ltd.

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 10 : Tangible assets (Refer General Instructions Note No.11)

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment	Computers	Computer Software	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation											
At 1 April 2013									639,066	202,351	841,417
Additions											-
Disposals									299,600		299,600
Other adjustments											
- Exchange differences											-
- Borrowing costs											-
At 31 March 2014	-	-	-	-	-	-	-	-	339,466	202,351	541,817
Additions											-
Acquisitions through											-
Disposals											-
Other adjustments											
- Exchange differences											-
- Borrowing costs											-
At 31 March 2015	-	-	-	-	-	-	-	-	339,466	202,351	541,817
Depreciation											
At 1 April 2013									279,074	126,525	405,599
Charge for the year									42,130	19,095	61,225
Disposals									247,591		247,591
Other adjustments											
- Exchange differences											-
At 31 March 2014	-	-	-	-	-	-	-	-	73,613	145,620	219,233
Charge for the period									60,382	14,375	74,757
Disposals											-
Other adjustments											
- Exchange differences											-
At 31 March 2015	-	-	-	-	-	-	-	-	133,995	159,995	293,990
Impairment loss											
At 1 April 2013											
Charge for the period											
At 31 March 2015											
Net Block											
At 31 March 2014	-	-	-	-	-	-	-	-	265,853	56,731	322,584
At 31 March 2015	-	-	-	-	-	-	-	-	205,471	42,356	247,827

All Pharma (Shanghai) Trading Co. Ltd.

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 11 : Intangible assets

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At April 1, 2013				-
Additions during the nine months				-
Internal development during the nine months				-
Disposals during the nine months				-
Other adjustments				-
- Exchange differences				-
At December 31, 2013	-	-	-	-
Additions during the three months				-
Internal development during the three months				-
Disposals during the three months				-
Other adjustments				-
- Exchange differences				-
At March 31, 2014	-	-	-	-
Additions during the nine months				-
Disposals during the nine months				-
Additions on acquisition				-
Other adjustments				-
- Exchange differences				-
At December 31, 2014	-	-	-	-
Amortization				
At April 1, 2013				-
Charge for the period				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At December 31, 2013	-	-	-	-
Charge for the period				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At March 31, 2014	-	-	-	-
Charge for the period				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At December 31, 2014	-	-	-	-
Net Block				
At December 31, 2013	-	-	-	-
At March 31, 2014	-	-	-	-
At December 31, 2014	-	-	-	-

Note 12: Non-current investments (Refer General Instructions Note No.13)

	March 31, 2015	March 31, 2014
Unquoted equity instruments		
Investment in subsidiaries		
Investment in joint ventures		
Investment in associates		
	-	-

Note 13: Loans and advances (Refer General Instructions Note No.14 & 21)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Capital advances				
Secured, considered good				
Unsecured, considered good				
(A)	-	-	-	-
Security deposit				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful security deposit				
(B)	-	-	-	-
Loan and advances to related parties				
Unsecured, considered good				
(C)	-	-	-	-
Advances recoverable in cash or kind				
Secured, considered good				
Unsecured, considered good			7,447,955	4,215,083
Doubtful				
Provision for doubtful advances				
(D)	-	-	7,447,955	4,215,083
Other loans and advances				
Advance income-tax (net of provision for taxation)				
Prepaid expenses			465,909	645,969
Loans to employees				
Loans to others				
Export incentives receivable			10,334,424	6,835,198
Export incentives licenses				
Balances with Statutory/government authorities				
(E)	-	-	10,800,333	7,481,168
Total (A+B+C+D+E)	-	-	18,248,289	11,696,250

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors				
Dues from officers				
Dues from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner				
Dues from in which the company's managing director is a member				
Dues from the partnership firm in which the company's non-executive director is a partner				

Note 14: Trade receivables and other assets

14.1 Trade receivable (Refer General Instructions Note No.15 & 19)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Secured, considered good				
Due from related parties				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others				
Doubtful				
Provision for doubtful receivables	-	-	-	-
(A)	-	-	-	-
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies			25,112,031	14,897,216
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others			841,432	121,127
Doubtful				
Provision for doubtful receivables	-	-	25,953,463	15,018,342
(B)	-	-	25,953,463	15,018,342
Total (A+B)	-	-	25,953,463	15,018,342

Trade receivables include:

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				

14.2 Other assets (Refer General Instructions Note No.16 & 22)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)	-	-	-	-
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)	-	-	-	-
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on investments in subsidiaries - long term				
Others			3,599,502	1,320,218
(C)	-	-	3,599,502	1,320,218
Total (A+B+C)	-	-	3,599,502	1,320,218

All Pharma (Shanghai) Trading Co. Ltd.
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

Note 15 : Current investments (Refer General Instructions Note No.17)

	March 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any (Please specify)	-	-

Note 16 : Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)

	March 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)		
Work - in - Progress		
Finished goods		
Traded goods (including stock -in-transit XXXX (31 March, 2014 XXX)		
Stores, spares, consumables and packing materials		
Loose tools	-	-

Note 17 : Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			11,957,641	9,120,136
Deposits with original maturity of less than 3 months				
Cash credit accounts				
On unpaid dividend account				
Cheques/drafts on hand				
Unpaid matured deposits				
Cash on hand			38,640	23,001
			11,996,280	9,143,137
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
	-	-	-	-
Amount disclosed under non-current assets	-	-	11,996,280	9,143,137

All Pharnia (Shanghai) Trading Co. Ltd.
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (CNY)	Year ended March 31, 2014
Note 18 : Revenue from operations (Refer General Instructions Note No.25)														
Revenue from operations														
Sale of products														
Finished goods	17,313,070	11,777,124	15,966,862	16,138,167	25,700,078	34,079,368	21,161,877	36,394,929	17,215,682	24,600,013	36,431,379	21,271,984	278,050,532.97	329,131,050
Traded goods													-	-
Sale of services													-	-
Sale of dossiers/licenses													-	-
Other operating revenue													-	-
Scrap sales													-	-
Other													-	-
Revenue from operations (gross)	17,313,070	11,777,124	15,966,862	16,138,167	25,700,078	34,079,368	21,161,877	36,394,929	17,215,682	24,600,013	36,431,379	21,271,984	278,050,533	329,131,050
Less: VAT/Excise duty/Rebates	(1,006)		(312,907)	(772,102)	(1,263,303)	(1,431,836)	(985,219)	(678,993)	(504,247)	(440,230)	(5,052)	(134,131)	(6,529,027)	(8,882,455)
Revenue from operations (net)	17,312,064	11,777,124	15,653,955	15,366,065	24,436,775	32,647,532	20,176,658	35,715,936	16,711,435	24,159,784	36,426,327	21,406,115	271,521,506	320,248,596
Note 19 : Other income (Refer General Instructions Note No.26)														
Interest income on														
Bank deposits													-	-
Long-term investments													-	-
Current investments													-	-
Loans to joint venture entities													-	-
Others													-	-
Dividend income on													-	-
Investment in subsidiaries													-	-
Current investments													-	-
Long-term investments													-	-
Net gain on sale of current investments													-	-
Profit on sale of fixed assets (net)													-	-
Foreign exchange gain (net)													-	-
Balances no longer required written back													-	-
Government grant													-	-
Commission income	199,950	28,305	149,659	280,729	169,154	99,253	193,491	195,793	239,626	(10,340)	219,084		1,764,704	1,869,120
Processing charges													-	-
Other non-operating income (net of expenses-directly attributable to such income of Rs.XXXXX (31 March, 2014:XXXX)													-	-
	199,950	28,305	149,659	280,729	169,154	99,253	193,491	195,793	239,626	(10,340)	219,084	-	1,764,704	1,869,120
Note 20 : Cost of raw material and components consumed														
Inventory at the beginning of the period	-												-	-
Add: Purchases													-	-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: inventory at the end of the period													-	-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add:Packing material consumed													-	-
Cost of raw material and components consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All Pharma (Shanghai) Trading Co. Ltd.
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (CNY)	Year ended March 31, 2014
Note 21 : (Increase)/decrease in inventories														
Inventories at the end of the period														
Traded goods														-
Work-in-progress														-
Finished goods														-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventories at the beginning of the period														
Traded goods														-
Work-in-progress														-
Finished goods														-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Details of purchase of traded goods														
Product A	16,175,637	11,236,309	14,941,094	14,562,576	23,598,084	31,732,206	19,613,995	34,804,874	16,262,570	22,558,835	35,562,423.30	20,130,244	261,178,847	307,258,284
Product B													-	-
Product C													-	-
	16,175,637	11,236,309	14,941,094	14,562,576	23,598,084	31,732,206	19,613,995	34,804,874	16,262,570	22,558,835	35,562,423	20,130,244	261,178,847	307,258,284
Note 22 : Employee benefit expense														
Salaries, wages and bonus	120,317	114,230	114,769	109,569	107,987	137,795	120,299	156,399	87,249	126,747	130,261	126,220	1,451,841	1,403,340
Contribution to provident and other fund	44,091	39,156	33,023	40,458	46,726	30,554	32,803	32,803	33,127	32,803	32,803	32,803	431,146	441,455
Employee stock option scheme													-	-
Gratuity expense													-	-
Other employee benefits			70,000										70,000	-
Post employment medical benefits													-	-
Staff welfare expenses	27,546	25,440	54,284			11,806	20,190	58,049	49,749	16,108	22,991	23,768	309,931	685,122
	191,953	178,826	272,076	150,026	154,713	180,155	173,292	247,251	170,125	175,657	186,055	182,790	2,262,919	2,529,917
Note 23 : Other expenses														
Consumption of stores and spares													-	-
Conversion charges													-	-
Chemicals consumed													-	-
Increase in VAT on finished goods													-	-
Customer service expenditure													-	-
Power and fuel													-	-
Water charges													-	-
Freight and forwarding charges	164,167	354,334	158,166	292,641	172,432	273,764	248,062	342,985	124,405	352,625	424,575	191,571	3,099,726	4,241,727
Carriage inward													-	-
Carriage outwards													-	-
Rent	34,292	34,292	34,292	34,292	34,292	34,292	34,292	36,007	36,007	36,007	36,007	36,007	420,079	411,504
Rates and taxes		10,000	70,000						7,000	10,000	10,000	110,319	217,319	90,000
Insurance	2,333	1,737	4,655	3,892	5,981	5,124	5,430	10,472	5,231	10,394	4,999	7,148	67,396	156,071
Repairs and maintenance													-	-
i) Plant and machinery													-	-
ii) Buildings													-	-
iii) Others													-	-

All Pharma (Shanghai) Trading Co. Ltd.
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (CNY)	Year ended March 31, 2014
Advertising and sales promotion													-	-
Brokerage and discounts													-	-
Remuneration to Auditors													-	-
Sales commission								61,707					61,707	-
Travelling and conveyance	74,710	72,509	78,775	94,178	30,174	42,075	42,041	74,179	83,989	57,011	87,781	83,338	820,757	736,475
Communication costs	13,061	13,738	19,873	12,516	20,241	13,131	16,295	14,302	21,008	17,150	16,229	14,812	192,356	212,948
Printing and stationery	4,831	5,551	12,583	3,234	6,362	6,819	3,901	18,390	10,159	10,693	10,889	7,892	101,302	107,251
Legal and professional fees	9,142	9,142	13,642	84,142	9,142	38,142	11,142	40,142	64,772	9,142	7,142	9,622	305,310	259,694
Directors sitting fees													-	-
Payment to auditor (Refer details below)		20,000								14,000			34,000	34,000
Provision for diminution in value of investment in subsidiary company													-	-
Provision for other than temporary decline in the carrying amount of other long-term investments													-	-
Adjustment to the carrying amount of current investments													-	-
Provision for warranties (net of reversals)													-	-
Provision for litigations (net of reversals)													-	-
Exchange differences (net)	644,295	(342,862)	14,655	16,262	153,944	(35,162)	54,346	(59,081)	(377,352)	293,841.82	(270,200)	(172,065)	(79,378)	45,736
Loss on derivative contracts (including provisions mark-to-market loss)													-	-
Bad debts/advances written off													-	-
Impairment loss on fixed assets													-	-
Provision for doubtful debts and advances													-	-
Loss on sale of fixed assets (net)													-	-
Premium on forward exchange contract amortized													-	-
Factory maintenance													-	-
Effluent treatment expenses													-	-
Vehicle maintenance expenses	1,182	2,042	300	1,852		1,454	7,972	2,847	200		580	7,194	25,624	56,952
Analytical charges													-	-
Product development expenses													-	93,000
Registration and filing charges	26,684	26,684	26,684	26,684	26,684	26,684	26,684	26,684	26,684	26,684	10,999	10,999	288,839	311,094
Safety and security													-	-
Office expenses	837	630	1,350	4,028	1,520	840	210	7,705		6,840	3,000	1,510	28,470	47,766
Repairs and maintenance - others				6,140		1,900		3,300	700	8,000		1,500	21,540	11,960
Management fees	5,261	5,261	5,461	5,581	5,461	6,111	5,461	8,261	5,461	5,631	5,461	5,461	68,875	64,608
Liquidated damages													-	-
Quality evaluation fee	8,900	1,600	4,500	2,300	201	1,500	2,300	3,400	4,600	2,900	5,500	6,100	43,801	137,840
Drug registration fee	21,490	20,769	22,656	26,431	34,094	32,094	32,094	32,094	33,981	35,376	35,376	134,301	460,756	118,805
Capital work-in-progress written off													-	337,128
Miscellaneous expenses													-	24,242
	1,011,185	235,426	467,591	614,172	500,528	448,767	490,230	623,393	46,845	896,295	388,339	455,708	6,178,478	7,498,799
Payment to Auditor														
As auditor:														
Audit fee													-	-
Tax audit fee													-	-
Limited review													-	-
In other capacity:													-	-

All Pharma (Shanghai) Trading Co. Ltd.

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (CNY)	Year ended March 31, 2014
Taxation matters													-	-
Company law matters													-	-
Management services													-	-
Other services (certification fees)													-	-
Reimbursement of expenses													-	-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 24 : Exceptional items														
Others (Specify if any)													-	-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 25 : Depreciation and amortization expense														
Depreciation of tangible assets	6,767	6,650	6,650	6,650	6,650	6,650	6,650	6,650	6,650	6,650	6,650	1,490	74,757	83,272
Amortization of intangible assets													-	-
Depreciation of investment property													-	-
	6,767	6,650	6,650	6,650	6,650	6,650	6,650	6,650	6,650	6,650	6,650	1,490	74,757	83,272
Note 26 : Finance costs (Refer General Instructions Note No.27)														
Interest	47,150	86,714	47,168	173,739	67,833	132,910	53,105	102,025	153,797	77,020	166,815	104,774	1,213,051	2,101,158
Bank charges	46,535	75,802	66,842	85,517	63,950	102,495	64,173	89,720	132,274	74,771	123,700	101,151	1,026,931	987,932
Amortization of ancillary borrowing costs													-	-
Exchange difference to the extent considered as an adjustment to borrowing costs													-	-
	93,684	162,517	114,011	259,257	131,783	235,405	117,278	191,745	286,071	151,791	290,516	205,925	2,239,982	3,089,090

AURO PHARMA INC.
FINANCIAL STATEMENTS
MARCH 31, 2015

ANEAL R. THANSINGH, F.C.M.A., C.F.P.
CHARTERED PROFESSIONAL ACCOUNTANT

INDEX

	<u>Page</u>
Independent Auditor's Report	1
Balance Sheet	2
Statement of Deficit	3
Statement of Income - Loss	4
Statement of Cash Flows	5
Notes to Financial Statements	6



ANEAL R. THANSINGH,

Chartered Accountant

Independent Auditor's Report

To the Shareholders of
Auro Pharma Inc.

We have audited the accompanying financial statements of Auro Pharma Inc. which comprise the balance sheet as at March 31, 2015 and the statements of income (loss), deficit and cash flows for the year ended then, and a summary of significant accounting policies and other explanatory information.

Management's responsibility for the financial statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for private enterprises and for such internal controls as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance that the financial statements are free from material misstatement.

We performed our audit procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including an assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the fair preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Our audit also includes evaluating the appropriateness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Opinion

In our opinion, the financial statements present fairly, in all material respects, the financial position of Auro Pharma Inc. as at March 31, 2015 and its financial operations and its cash flows for the year ended then, in accordance with Canadian accounting standards for private enterprises.

Mississauga, Ontario
May 6, 2015

Aneal R. Thansingh
ANEAL R. THANSINGH, CPA, CA
Licensed Public Accountant

DIRECTORS' REPORT



The directors present their report and the audited financial statements for the year ended March 31st 2015.

PRINCIPAL ACTIVITY

The principle object of the company is to trade and deal in pharmaceutical products and other allied products and services.

Unusual Items after the Financial Year:

No item, transaction or event of a Material nature has arisen during the period between the end of the financial year and the date of this report, which would affect substantially the operations of the company during the current year.

REVIEW OF OPERATIONS

During the year the company had registered a Profit of CAD 18,670 against a Total Revenue of CAD 23,340,506 and in previous year it made a Loss of CAD (86,545) against a Total Revenue of CAD 18,251,053

Statement of Directors:

In the opinion of the Directors, the accompanying Financial statements were drawn up so as to give a true and fair view of the state of affairs of the Company as on 31st March 2015 and the results of the business for that period. Your Directors have taken all reasonable steps to prepare these financial statements on a going concern basis and suitable accounting policies have been adopted consistently. Further your Directors are confident that with the support and guidance of the Holding company, your Company can achieve better results in the future.

DIRECTORS

The Directors at the date of the report are:

1. Mr. Suresh Kalidoss
2. Mr. Vijay Sastry K
3. Mr. Phaneendra Prasad Gorla

By Order of the Board:

A handwritten signature in black ink, appearing to read 'Suresh', is written over a horizontal line.

Mr. Suresh Kalidoss.
Director
Canada

Auro Pharma Inc.

3700 Steeles Ave. West, Suite #402, Woodbridge, Ontario, Canada L4L 8K8


Tel : 905 856 8063 Fax : 905 856 8094


www.auropharma.ca

AURO PHARMA INC.
BALANCE SHEET
AS AT MARCH 31, 2015

	2015	2014
	\$	\$
ASSETS		
Current		
Cash	14,000	14,000
Accounts receivable	5,031,000	4,880,000
Inventory	429,800	429,800
Prepaid expenses	1,311,000	1,311,000
Deferred expenses	87,244	87,244
	<u>7,653,044</u>	<u>7,651,844</u>
Long-Term		
Patents to related party - note 2	100,000	100,000
Long-term prepaid registration fees - note 4	2,731,000	2,731,000
	<u>2,831,000</u>	<u>2,831,000</u>
Property, plant and equipment - notes 1 & 3	<u>83,728</u>	<u>83,728</u>
Total Assets	<u><u>10,567,772</u></u>	<u><u>10,566,572</u></u>
LIABILITIES		
Current		
Accounts payable and accrued liabilities	3,711,000	3,711,000
Accounts receivable from related parties - note 5	1,144,000	1,144,000
Accounts payable to shareholders - note 6	170,000	170,000
	<u>5,025,000</u>	<u>5,025,000</u>
Long-Term		
Long-term debt - note 7	<u>3,449,000</u>	<u>3,449,000</u>
Total Liabilities	<u><u>8,474,000</u></u>	<u><u>8,474,000</u></u>
SHAREHOLDERS' EQUITY		
Share Capital (note 7)	401,000	401,000
Reserves	<u>2,191,772</u>	<u>2,191,772</u>
	<u>2,592,772</u>	<u>2,592,772</u>
Total Liabilities & Shareholders' Equity	<u><u>10,566,772</u></u>	<u><u>10,566,772</u></u>

APPROVED ON BEHALF OF THE BOARD





Anil Kumar Thansingh

See Notes to Financial Statements

ANIL K. THANSINGH,

AURO PHARMA INC.
STATEMENT OF DEFICIT
FOR THE YEAR ENDED MARCH 31, 2015

	2015	2014
	\$	\$
Deficit - beginning of year	2,161,119	2,144,814
Net income (loss) for the year	18,670	(2,601)
Deficit - end of year	<u>2,179,789</u>	<u>2,142,213</u>

See Notes to Financial Statements-

ANIL K. BHANSINGH,

AURO PHARMA INC
STATEMENT OF INCOME (LOSS)
FOR THE YEAR ENDED MARCH 31, 2015

	2015	2014
	\$	\$
REVENUE		
Sales	23,340,606	16,211,121
COST OF GOOD SOLD		
Inventory, beginning of year	1,403,843	1,310,111
Purchases - note B	19,841,939	16,947,810
	21,250,787	18,257,921
Inventory, end of year	1,164,170	1,413,943
	20,086,617	16,843,978
GROSS PROFIT	3,253,989	2,367,143
Add: Gain on sale of assets		77,457
	3,253,989	2,444,600
EXPENSES		
Advertising	26,603	1,000
Auto and travel	313,976	244,112
Car charges and mileage	23,481	18,688
Exchange gain/loss	1,132	
Insurance	64,992	41,711
License fees and fees	33,192	14,800
Office and professional	66,221	11,111
Postage	27,457	13,221
Rent	33,415	14,000
Telephone and fees	23,000	11,000
Travel and meals		2,633
Rent	31,674	31,407
Materials and maintenance	6,706	6,000
Salaries and benefits	2,196,617	1,671,651
Depreciation	20,787	22,931
	2,197,961	1,813,773
NET INCOME (LOSS) BEFORE UNDERNOTED	15,572	630,827
Income tax	37,261	1,621,111
NET INCOME (LOSS) FOR THE YEAR	15,572	(990,284)

- See Notes to Financial Statements -

AURO PHARMA INC.
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED MARCH 31, 2015

	2015	2014
	\$	\$
CASH WAS PROVIDED (USED) BY		
Operating Activities		
Net income (loss) for the year	13,677	37,117
Adjustments not requiring cash outlay - amortization	37,232	5,111
	<u>50,909</u>	<u>42,228</u>
Net changes in non-cash working capital items		
Increase in accounts receivable	12,676,402	741,626
Increase in HST receivable	139,735	181,269
Decrease in inventory	244,678	401,191
Increase/decrease in deposits and prepaid expenses	65,159	40,374
Increase in accounts payable & accrued liabilities	1,276,414	1,523,181
	<u>13,362,388</u>	<u>2,487,641</u>
Cash provided (used) by operations	<u>13,413,297</u>	<u>2,529,869</u>
Investing Activities		
Acquisition of related company	13,641	1,114
Related product registration fees	366,507	6,111
Acquisition of related party - affiliated company	379,161	878,411
Acquisition/disposal of property, plant & equipment - Net	31,671	123,111
	<u>790,980</u>	<u>1,009,737</u>
Financing Activities		
Issuance of common shares for cash	1,300,000	11
	<u>1,300,000</u>	<u>11</u>
NET DECREASE IN CASH	<u>41,896</u>	<u>1,539,617</u>
CASH - beginning of year	<u>2,487,641</u>	<u>948,024</u>
CASH - end of year	<u>2,529,537</u>	<u>1,487,641</u>

See Notes to Financial Statements.

NOTE 1 THE COMPANY

Auro Pharma Inc. is a private company incorporated Federally under the Canada Business Corporations Act on August 24, 2004. Its main business activity is to sell pharmaceuticals.

These financial statements were prepared in accordance with Canadian accounting standards for private enterprises (ASPE) and include the following significant accounting policies:

SIGNIFICANT ACCOUNTING POLICIES

Income Taxes

The company applies the taxes payable method of accounting for income taxes under which the company records as an expense of the year only the cost of current income taxes for that year as determined in accordance with the rules established by the taxation authorities.

Revenue recognition

The company earns substantially all of its revenue from sale of pharmaceutical drugs and services. Revenue is recognized based on FOB destination, net of provision of returns, allowances and claims for defective processing.

Foreign currency translations

The company uses the temporal method to translate its foreign currency transactions.

Monetary assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Other assets and liabilities are translated at the exchange rate in effect at the transaction date, with a exception in the current year's income statement, except for the following:

• Depreciation and amortization translated at a historic rate are translated at average rate.
• Exchange gains and losses are included in the income statement.

Inventory

Inventory is recorded at the lower of cost and net realizable value. With cost being determined by the first-in, first-out method. The inventory is being supplied 85% by a single manufacturer and 15% by a related company.

Property, plant and equipment

Property, plant and equipment are recorded at cost. Amortization is provided at rates estimated to be sufficient to amortize cost of the assets over their estimated useful lives as follows:

	Rate	Basis
Buildings	20%	Declining balance
Equipment	30%	Declining balance
Leasehold	55%	Declining balance

Whichever stated rate of amortization is taken in the year of acquisition of the assets.

SIGNIFICANT ACCOUNTING POLICIES - CONTINUED

Use of Estimates

The preparation of financial statements in conformity with Canadian accounting standards for private enterprises requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are reviewed periodically and adjustments are made if the actual outcome in the year they become known. Major estimates include bad debt allowances and determining the estimated useful lives of property, plant and equipment.

Financial Instruments

The carrying values of cash, accounts receivable, inventory, HST receivable, prepaid product registration fees, accounts payable and accrued liabilities, approximate their fair values due to the relatively short period to maturity of these financial instruments.

Impairment of Long-Lived Assets

Property, plant and equipment is reviewed for impairment whenever an event or change in circumstances indicates that the carrying amount may not be recoverable. When the carrying amount exceeds the projected undiscounted cash flows, an impairment loss is recognized as the amount by which the carrying value exceeds the recoverable amount.

NOTES TO FINANCIAL STATEMENTS - CONTINUED

ADVANCES TO RELATED PARTY

These advances are due to APL, and a related party. They are un-secured, require no collateral and have no repayment terms. They are not expected to be repaid within the next 12 months and therefore, has been classified as long-term.

PROPERTY, PLANT AND EQUIPMENT

The carrying amounts of property, plant and equipment are shown in the balance sheet and the following table. The depreciation rates are as follows:

	2015	ACCUM AMORTN	NET BOOK VALUE 2015	2014
	\$	\$	\$	\$
Land	22,210	29,083	52,927	39,247
Buildings	23,617	17,896	11,101	11,302
Equipment	50,440	36,449	19,697	38,193
	<u>196,167</u>	<u>93,428</u>	<u>83,725</u>	<u>89,296</u>

DEFERRED PRODUCT REGISTRATION FEES

These fees are paid to Health Canada and are amortized over ten years commencing from the date of product registration for which the fees were incurred. This year 2015-16, \$2,000,000 has been amortized and is included in the cost of goods sold.

NOTE 11: ACCOUNTS PAYABLE - RELATED PARTIES

Accounts payable - related parties consist of the following:

	2015	2014
	\$	\$
Aurcopharma Pharma Ltd. India	1,756,562	2,141,435
APL Swift Services, Malta Limited	12,261	5,549
	<u>1,768,823</u>	<u>2,146,984</u>

NOTE 12: ADVANCES FROM SHAREHOLDERS

There are three (3) loans advanced from shareholder Helix Health Care E.V. to the Company, secured with interest at CAD LIBOR (London InterBank Offer Rate) plus 1% per annum. Details are as follows:

	Loan #1	Loan #2	Loan #3	Total 2015	Total 2014
	\$	\$	\$	\$	\$
Principal amount	996,870	1,000,000	1,000,000	2,996,870	980,996
Accrued interest	12,850	5,347	1,057	19,254	15,751
Payments made	(123,458)	-	-	(123,458)	-
	<u>986,062</u>	<u>1,005,347</u>	<u>1,001,057</u>	<u>2,992,466</u>	<u>996,751</u>

	2015	2014
	\$	\$
Current portion	986,062	996,751
Long-term portion	2,006,404	-
	<u>2,992,466</u>	<u>996,751</u>

As of March 31, 2015, the total principal payments were made by the Company in March of 2015, and the balance therefore, has been classified as current.

The loan payments are a maturity date of 5 years from date of the advance, and are secured with mutual agreement. Principal payments and dates due are as follows:

Payment date	Loan #2 Amount \$	Payment date	Loan #3 Amount \$
22-Aug-16	150,000	1-Apr-16	100,000
22-Feb-17	150,000	1-Oct-16	100,000
22-Aug-17	150,000	1-Apr-17	100,000
22-Feb-18	150,000	1-Oct-17	100,000
22-Aug-18	150,000	1-Apr-18	100,000
22-Feb-19	150,000	1-Oct-18	100,000
22-Aug-20	100,000	1-Apr-19	100,000
	<u>1,000,000</u>	1-Oct-19	100,000
		1-Apr-20	100,000
		1-Oct-20	100,000
			<u>1,000,000</u>

NOTE - SHARE CAPITAL

(In thousands)

Authorized number of Class 'A' voting shares

Authorized number of Class 'B' non-voting shares

	2015	2014
	\$	\$
Authorized Class 'A' shares	4,327,138	4,327,138

NOTE - RELATED PARTIES TRANSACTIONS

During the year sales \$2,953,629 (2014 - \$2,156,756) purchased from Aurora Health Limited, APL India and \$67,702 (2014 - \$14,013) paid for services to APL Swift Services, India and Mita.

These transactions are in the normal course of operations and are recorded at the fair value, which is the consideration agreed to by the related parties.

NOTE - ECONOMIC DEPENDENCE

The Company has a majority of its inventory of pharmaceutical goods from Aurora Health Limited, India. The Company has a large amount due to that company and is thus dependent on that company in order to carry on its business in Canada.

NOTE - INCOME TAX LOSSES CARRYFORWARD

The Company has a carryforward of 2011 reporting income tax losses of \$2,260,700. These losses can be utilized in the operations in year 2030. The losses are as follows:

Year	Amount	Expiry
	\$	
2014	105,438	2034
2010		2033
2011	230,510	2032
2011	507,340	2031
2010	509,088	2030
2009	378,572	2029
2008	375,400	2028
2007	39,030	2027
2006	62,314	2026
	<u>2,260,700</u>	

NOTE 16 COMMITMENTS

The Company has entered into a lease for the premises from October 1, 2012 to September 30, 2017 with an annual rent of \$44,022 for the first three years and \$47,286 for the last two years plus monthly payment for common area charges of \$2,650.

NOTE 17 COMPARATIVE FIGURES

Some of the comparative figures were audited by another accounting office. Certain comparative figures have been reclassified to conform to the current year's presentation.

Aurobindo Pharma (Australia) Pty Ltd

ABN: 45 118 452 369

DIRECTORS' REPORT

Your directors present their report on Aurobindo Pharma (Australia) Pty Ltd ("the Company") for the financial year ended 31 March 2015.

1. General Information

Directors

The names of the directors in office at any time during or since the end of the year are:

Names	Position	Appointed/Resigned
Phaneendra Prasad Gorla	Director	30/03/2007
Arvind Vasudeva	Director	22/02/2013
Anantha Rama Krishna Kishore Parimi	Director	13/01/2014

Directors have been in office since the start of the relevant financial year to the date of this report unless otherwise stated.

Principal Activities

The principal activity of the Company during the financial year was the import and distribution of bulk drugs, formulations and oral suspensions.

No significant change in the nature of these activities occurred during the year.

2. Business Review

Operating Results:

The Company incurred a loss before income tax of A\$ 2,027,222.

Dividends paid or declared

No dividends were paid or declared since the start of the financial year. No recommendation for payment of dividends has been made.

3. Other items

Significant Changes in state of affairs

No significant changes in the Company's state of affairs occurred during the financial year.

After the Balance Sheet Day Events

The shareholder Helix Healthcare B.V. (Helix) has decided to transfer 100% shareholding in the Company to Eris Pharmaceuticals (Australia) Pty Ltd ("Eris") with an effective date of 10-Apr-2015.

Apart from the events mentioned above, no other events, matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Company, the results of those operations or the state of affairs of the Company in future financial years.

3. Other items (Cont'd)

Future Developments

Likely developments in the operations of the Company and the expected results of those operations in future financial years have not been included in this report as the inclusion of such information may result in unreasonable prejudice to the Company.

Environmental Issues

The Company's operations are not regulated by any significant environmental regulation

Aurobindo Pharma (Australia) Pty Ltd

ABN:45 118 452 369

DIRECTORS' REPORT

under a law of the Commonwealth of Australia or of a state or territory of Australia.

Indemnifying Officers or Auditors

No indemnities have been given or insurance premiums paid, during or since the end of the financial year, for any person who is or has been an officer or auditor of the Company.

Options

No Options Granted or outstanding

No options over issued shares or interests in the company were granted during or since the end of the financial year and there were no options outstanding at the date of this report.

Proceedings on Behalf of or against the Company

No person has applied for leave of any relevant court to bring proceedings on behalf of the Company or intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or any part of those proceedings.

The Company was not a party to any such proceedings during the relevant financial year.

This directors' report is signed in accordance with a resolution of the Board of Directors.

DIRECTORS' DECLARATION

The Directors of the Company declare that:

1. The financial statements and notes;
 - a. comply with Australian Accounting Standards; and
 - b. give a true and fair view of the company's financial position as at 31 March 2015 and of its performance for the year ended on that date in accordance with the accounting policies described in Note 1 to the financial statements.
2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

Director.....

Phaneendra Prasad Gorla

Director.....

Arvind Vasudeva

Dated:09April 2015

Aurobindo Pharma (Australia) Pty Ltd
A.B.N 45 118 452 369
Independent Auditor Report

To the members of Aurobindo Pharma (Australia) Pty Ltd.
Scope

Report on the Financial Report

We have audited the accompanying financial report of Aurobindo Pharma (Australia) Pty Ltd, which comprises the Balance Sheet as at 31 March 2015, Profit and Loss, a summary of significant accounting policies and other explanatory notes.

Directors' Responsibility for the Financial Report

The directors of the company are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards (including the Australian Accounting Interpretations) and the *Corporations Act 2001*. This responsibility includes establishing and maintaining internal control relevant to the preparation and fair presentation of the financial report that is free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances. In Note 1, the directors also state, in accordance with Accounting Standard AASB 101: Presentation of Financial Statements, that compliance with the Australian equivalents to International Financial Reporting Standards (IFRS) ensures that the financial report, comprising the financial statements and notes, complies with IFRS.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. These Auditing Standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Independence

In conducting our audit, we have complied with the independence requirements of the Corporations Act 2001.

Auditor's Opinion

In our opinion:

- a. the financial report of Aurobindo Pharma (Australia) Pty Ltd is in accordance with the *Corporations Act 2001*, including:
 - i. giving a true and fair view of the company's financial position as at 31 March 2015 and of their performance for the year ended on that date; and
 - ii. complying with Australian Accounting Standards (including the Australian Accounting Interpretations) and the Corporations Regulations 2001;
- b. the financial report also complies with International Financial Reporting Standards as disclosed in Note 1; and.

MSI Taylor Audit Services Pty Ltd.



Raj Prabhu
Director -Audit
CPA, Registered Company Auditor

Brisbane, Australia
Signed on 7th day of May, 2015.

Name of the company

AUROBINDO PHARMA (AUSTRALIA) PTY LTD

Balance Sheet as at March 31, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	31 Mar, 2015 (Currency)	31 March, 2014 (Currency)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	10,803,743	7,429,184
Share application money			
Reserves and surplus	3	(8,137,730)	(6,110,508)
		2,666,013	1,318,676
Non-current liabilities			
Long-term borrowings	4	-	1,286,219
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		-	1,286,219
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	1,686,654	1,096,659
Other current liabilities	9	-	-
Short-term provisions	7	10,153	123,553
		1,696,808	1,220,212
TOTAL		4,362,820	3,825,107
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	14,087	29,356
Intangible assets	11	2,696,346	2,976,764
Capital work-in-progress			
Intangible assets under development			
Non-current Investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	-	-
Trade receivables	14.1	-	-
Other non-current assets	14.2	-	-
		2,710,432	3,006,120
Current assets			
Current Investments	15	-	-
Inventories	16	1,288,790	377,696
Trade receivables	14.1	189,355	270,782
Cash and bank balances	17	49,654	43,778
Short-term loans and advances	13	124,589	126,732
Other current assets	14.2	-	-
		1,652,388	818,988
TOTAL		4,362,821	3,825,108
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.

MSI Taylor Audit Service



Raj Prabhu
CPA, Registered Company Auditor # 297379
Date 07 May 2015- Brisbane, Australia


Name of the company AUROBINDO PHARMA (AUSTRALIA) PTY LTD
Statement of profit and loss for the year ended March 31, 2015
(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Period ended Mar 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Income															
Revenue from operations (gross)	19	827,150	698,436	503,401	400,007	280,648	295,016	254,629	290,213	179,813	312,004	280,288	256,568	4,578,173	9,047,793
Less: Excise duty/Rebates		(656,285)	(571,069)	(347,806)	(358,236)	(254,511)	(218,614)	(196,616)	(230,631)	(131,738)	(206,167)	(175,006)	(189,086)	(3,535,765)	(7,226,556)
Revenue from operations (net)		170,864	127,367	155,595	41,771	26,137	76,402	58,013	59,582	48,075	105,838	105,282	67,482	1,042,408	1,821,237
Other income	20	-	-	-	-	-	-	-	-	-	-	-	-	-	(522)
Total revenue (I)		170,864	127,367	155,595	41,771	26,137	76,402	58,013	59,582	48,075	105,838	105,282	67,482	1,042,408	1,820,715
Expenses															
Cost of raw material and components consumed	21	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods (increase)/decrease in inventories of finished goods, work-in-progress and traded goods	22	43,490	27,898	75,969	69,448	10,756	60,610	85,424	431,737	182,060	344,814	136,711	117,023	1,585,941	589,324
Employee benefit expense	23	39,781	31,520	16,032	(12,184)	43,605	3,463	(74,690)	(398,576)	(137,060)	(284,708)	(116,812)	(21,466)	(911,094)	(16,987)
Other expenses	24	92,159	81,046	76,117	82,394	77,777	81,526	66,434	74,380	75,380	78,760	78,866	90,887	955,824	1,407,056
Exceptional items	25	67,527	70,502	71,113	60,202	60,858	77,980	49,600	60,704	57,938	154,268	146,263	154,709	1,026,664	1,387,000
Total (II)		242,959	210,966	239,231	199,860	192,896	223,678	126,768	168,245	178,317	293,135	245,028	341,153	2,657,335	3,366,393
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		(72,094)	(83,599)	(83,636)	(158,088)	(166,859)	(147,276)	(68,755)	(108,662)	(130,243)	(187,297)	(139,746)	(273,671)	(1,614,927)	(1,545,678)
Depreciation and amortization expense	26	31,374	31,374	31,374	31,374	31,374	31,374	31,374	31,374	30,705	32,112	32,087	32,087	377,984	414,734
Finance costs	27	2,967	(14,519)	(10,014)	4,911	7,834	28,155	21,421	5,389	111,872	(14,939)	(83,187)	(25,579)	34,311	23,868
Profit/(loss) before tax		(106,435)	(100,454)	(104,996)	(194,374)	(206,067)	(206,805)	(121,550)	(145,425)	(272,819)	(204,470)	(88,646)	(280,179)	(2,027,222)	(1,984,280)
Tax expenses															
Current tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: MAT credit entitlement		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fringe benefit tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax relating to previous years		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total tax expense		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Profit/(loss) for the year		(106,435)	(100,454)	(104,996)	(194,374)	(206,067)	(206,805)	(121,550)	(145,425)	(272,819)	(204,470)	(88,646)	(280,179)	(2,027,222)	(1,984,280)

Summary of significant accounting policies

The accompanying notes are an integral part of the financial statements

MSI Taylor Audit Service



Raj Prabhu
CPA, Registered Company Auditor # 297379
Date 07 May 2015- Brisbane, Australia

Name of the company **AUROBINDO PHARMA (AUSTRALIA) PTY LTD**
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

Note 1 : Summary of significant accounting policies (Refer General Instructions Note No.1)

- 1.1
- 1.2
- 1.3
- 1.4
- 1.5

Note 2 : Share capital (Refer General Instructions Note No.2)

	Mar 31, 2015	March 31, 2014
Authorised shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of XXXX each		
XXXXXXXX (31 March, 2014: XXXXXXXX) preference shares of XXX each		
Issued, Subscribed and Fully Paid-up shares:		
7429184 (31 March, 2014: 7429184) equity shares of AUD 1 each fully paid-up	7,429,184	7,429,184
Addition of Capital during the year (3374559 shares of AUD 1 each)	3,374,559	
Total Capital	10,803,743	7,429,184

Note 3 : Reserves and surplus (Refer General Instructions Note No.3)

	Mar 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet		
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet		
General Reserve		
As per last Balance Sheet		
Add: Transferred from statement of profit and loss		
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	(6,110,508)	(4,126,228)
Profit for the period	(2,027,222)	(1,984,280)
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)		
Tax on proposed equity dividend		
Interim dividend paid (amount per share XX (31 March, 2014 XX)		
Transfer to general reserve		
Total appropriations		
Net surplus in the statement of profit and loss	(8,137,730)	(6,110,508)
Total reserves and surplus	(8,137,730)	(6,110,508)

MSI Taylor Audit Service



Raj Prabhu
CPA, Registered Company Auditor #297379
Date 07 May 2015- Brisbane, Australia

Note 4 : Long -term borrowings (Refer General Instructions Note No.4)

	Non-current Portion		Current maturities	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)				
Other Loans from banks				
Current account credit balance				
Loans and advances from related parties		1,286,219		
Other Loans and advances				
Sales tax deferment loan (Un Secured)				
		1,286,219		
The above amount includes				
Secured borrowings				
Unsecured borrowings				
Amount disclosed under the head				
"Other current liabilities"				
Net Amount				

Note 5 : Deferred tax liability (net)

	Mar 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis		
Provision for diminution in the value of Investments		
Provision for doubtful debts and advances		
Fixed Assets (Depreciation)		
Retirement Benefits		
Others		
Gross deferred tax liability		
Deferred tax asset		
Carried Forward Business Losses		
Others		
Gross deferred tax asset		
Net deferred tax liability		

Note 6 : Other long -term liabilities (Refer General Instructions Note No.5)

	Mar 31, 2015	March 31, 2014
Trade payables (including acceptances)		
Others		
Advances from customers		
Unclaimed dividends		
Other liabilities		
Interest accrued but not due on loans		
Advances from related parties		

MSI Taylor Audit Service



Raj Prabhu
CPA, Registered Company Auditor #297379
Date 07 May 2015- Brisbane, Australia

Name of the company
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

AUROBINDO PHARMA (AUSTRALIA) PTY LTD

Note 7 : Provisions (Refer General Instructions Note No.6 & 10)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Provision for employee benefits				
- PAYG				22,222
- Superannuation Provision			23,372	23,243
- Leave encashment			32,168	52,570
			55,540	98,035
Other Provisions				
For Taxation (net of advance payments)				
For GST			(45,387)	25,518
For Proposed dividend				
For Tax on proposed dividend				
			(45,387)	25,518
			10,153	123,553

Provision for warranties

	Mar 31, 2015	March 31, 2014
At the beginning of the year		
Arising during the period		
Utilised during the period		
Unused amounts reversed		
At the end of the Quarter		
Current portion		
Non-current portion		

Note 8 : Short-term borrowings (Refer General Instructions Note No.7)

	Mar 31, 2015	March 31, 2014
Book overdraft		
Loans and advances from related parties		
Working capital loans (Secured)		
Short term loans (Un Secured)		
Working capital loans		
The above amount includes		
Secured borrowings		
Unsecured borrowings		

Note 9 : Other current liabilities (Refer General Instructions Note No.9)

	Mar 31, 2015	March 31, 2014
Trade payables (Including acceptances) (Refer General Instructions Note No.8)	1,686,654	1,096,659
API(Purchases)	1,444,706	1,096,659
Mederich	24,869	
Others	217,079	
Other liabilities		
Current maturities of long-term borrowings		
Trade deposits		
	1,686,654	1,096,659

MSI Taylor Audit Service



Raj Prabhu
CPA, Registered Company Auditor #297379
Date 07 May 2015- Brisbane, Australia

Name of the company AUROBINDO PHARMA (AUSTRALIA) PTY LTD

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 10 : Tangible assets

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation									
At April 1, 2014						38,676		28,799	67,475.5
Additions during the nine months								1,245	1,245.5
Disposals during the nine months									-
Transfer to assets held for sale									-
Other adjustments									
- Exchange differences									-
At March 31, 2015	-	-	-	-	-	38,676	-	30,045	68,720.9
Depreciation									
At April 1, 2014						22,953		15,167	38,120.0
Charge for the period						7,734		8,780	16,514.2
Disposals									-
Transfer to assets held for sale									-
Other adjustments									
- Exchange differences									-
At March 31, 2015	-	-	-	-	-	30,687	-	23,947	54,634.2
Net Block									
At March 31, 2015	-	-	-	-	-	7,989	-	6,098	14,086.7
At March 31, 2014	-	-	-	-	-	15,723	-	13,632	29,355.5

MSI Taylor Audit Service



Raj Prabhu

CPA, Registered Company Auditor #297379

Date 07 May 2015- Brisbane, Australia

Name of the company

AUROBINDO PHARMA (AUSTRALIA) PTY LTD

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 11 : Intangible assets

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At April 1, 2014		3,806,576	17,900	3,824,476
Additions during the nine months		81,050		81,050
Internal development during the nine months				-
Disposals during the nine months				-
Other adjustments				
- Exchange differences				-
At March 31, 2015	-	3,887,626	17,900	3,905,526
Amortization				
At April 1, 2014		842,919	4,793	847,712
Charge for the period		356,994	4,474	361,469
Disposals				-
Other adjustments				
- Exchange differences				-
At March 31, 2015	-	1,199,913	9,267	1,209,180
Net Block				
At March 31, 2015	-	2,687,713	8,633	2,696,346
At March 31, 2014	-	2,963,657	13,107	2,976,764

MSI Taylor Audit Service



Raj Prabhu

CPA, Registered Company Auditor #297379

Date 07 May 2015- Brisbane, Australia

Note 12 : Non-current investments (Refer General Instructions Note No.13)

	Mar 31, 2015	March 31, 2014
Unquoted equity instruments		
Investment in subsidiaries		
Investment in joint ventures		
Investment in associates		

Note 13 : Loans and advances (Refer General Instructions Note No.14 & 21)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Capital advances				
Secured, considered good				
Unsecured, considered good				
(A)				
Security deposit				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful security deposit				
(B)				
Loan and advances to related parties				
Unsecured, considered good			66,951	111,781
(C)			66,951	111,781
Advances recoverable in cash or kind				
Secured, considered good				
Unsecured, considered good			57,638	
Doubtful				
Provision for doubtful advances			57,638	
(D)			57,638	
Other loans and advances				
Advance income-tax (net of provision for taxation)				
Prepaid expenses				
Loans to employees				
Loans to others				14,951
Export incentives receivable				
Export incentives licenses				
Balances with Statutory/government authorities				
(E)				14,951
Total (A+B+C+D+E)			124,589	126,732

MSI Taylor Audit Service



Raj Prabhu
CPA, Registered Company Auditor #297379
Date 07 May 2015- Brisbane, Australia

AUROBINDO PHARMA (AUSTRALIA) PTY LTD

Loans and advances due by directors or other officers, etc.

Note 14 : Trade receivables and other assets

Non-current		Current	
Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014

(A)

(B)

	189,355	270,782
--	---------	---------

Robert

Date 07 May 2015- Brisbane, Australia

Name of the company
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

AUROBINDO PHARMA (AUSTRALIA) PTY LTD

Trade receivables include:

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				

14.2 Other assets (Refer General Instructions Note No.16 & 22)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)				
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)				
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on Investments in subsidiaries - long term				
Others				
(C)				
Total (A+B+C)				


Note 15 : Current Investments (Refer General Instructions Note No.17)

	Mar 31, 2015	March 31, 2014
Current Investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any (Please specify)		

Note 16 : Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)

	Mar 31, 2015	March 31, 2014
Raw materials and components (includes In transit XXX (31 March, 2014 XXX)		
Work - In - Progress		
Finished goods		
Traded goods (including stock -In-transit XXXX (31 March, 2014 XXX)	1,288,790	377,696
Stores, spares, consumables and packing materials		
Loose tools		
	1,288,790	377,696

MSI Taylor Audit Service



Raj Prabhu
CPA, Registered Company Auditor #297379
Date 07 May 2015- Brisbane, Australia

Name of the company
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

AUROBINDO PHARMA (AUSTRALIA) PTY LTD

Note 17 : Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	Mar 31, 2015	March 31, 2014	Mar 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			49,654	43,778
Deposits with original maturity of less than 3 months				
Cash credit accounts				
On unpaid dividend account				
Cheques/drafts on hand				
Unpaid matured deposits				
Cash on hand				
			49,654	43,778
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
Amount disclosed under non-current assets			49,654	43,778

Note 18 : Events occurring after the Balance Sheet Date

On 10th April, Helix Healthcare has transferred its 100% shareholding in Aurobindo Pharma Australia Pty Ltd to Eris Pharmaceuticals (Australia) Pty Ltd.

MSI Taylor Audit Service



Raj Prabhu
CPA, Registered Company Auditor #297379
Date 07 May 2015- Brisbane, Australia

Name of the company AUROBINDO PHARMA (AUSTRALIA) PTY LTD
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Period ended Mar 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 19 : Revenue from operations (Refer General Instructions Note No 23)														
Revenue from operations														
Sale of products														
Finished goods	827,150	698,436	503,401	400,007	280,648	295,016	254,629	290,213	179,813	312,004	280,288	256,568	4,578,173	9,047,793
Traded goods													-	-
Sale of services													-	-
Sale of dossiers/licenses													-	-
Other operating revenue													-	-
Scrap sales													-	-
Other													-	-
Revenue from operations (gross)	827,150	698,436	503,401	400,007	280,648	295,016	254,629	290,213	179,813	312,004	280,288	256,568	4,578,173	9,047,793
Less: VAT/Excise duty/Rebates	656,285	571,069	347,806	358,236	254,511	218,614	196,616	230,631	131,738	206,167	175,006	189,086	3,535,765	7,226,556
Revenue from operations (net)	170,864	127,367	155,595	41,771	26,137	76,402	58,013	59,582	48,075	105,838	105,282	67,482	1,042,408	1,821,237

Note 20 : Other income (Refer General Instructions Note No 26)

Interest Income on														
Bank deposits													-	11
Long-term investments													-	-
Current investments													-	-
Loans to joint venture entities													-	-
Others													-	-
Dividend Income on													-	-
Investment in subsidiaries													-	-
Current investments													-	-
Long-term investments													-	-
Net gain on sale of current investments													-	-
Profit on sale of fixed assets (net)													-	(533)
Foreign exchange gain (net)													-	-
Balances no longer required written back													-	-
Government grant													-	-
Commission income													-	-
Processing charges													-	-
Other non-operating income (net of expenses directly attributable to such income of Rs XXXXX (31 March, 2014:XXXX))													-	-
													-	(522)

MSI Taylor Audit Service




Raj Prabhu
CPA, Registered Company Auditor #297379
Date 07 May 2015- Brisbane, Australia

Name of the company AUROBINDO PHARMA (AUSTRALIA) PTY LTD
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Period ended Mar 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 21 : Cost of raw material and components consumed														
Inventory at the beginning of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add: Purchases	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: inventory at the end of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add: Packing material consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of raw material and components consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note 22 : (Increase)/decrease in inventories														
Inventories at the end of the period														
Traded goods	337,915	306,394	290,362	302,547	258,942	255,479	330,169	728,745	865,805	1,150,513	1,267,324	1,288,790	7,382,985	377,696
Work-in-progress	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Finished goods	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	337,915	306,394	290,362	302,547	258,942	255,479	330,169	728,745	865,805	1,150,513	1,267,324	1,288,790	7,382,985	377,696
Inventories at the beginning of the period														
Traded goods	377,696	337,915	306,394	290,362	302,547	258,942	255,479	330,169	728,745	865,805	1,150,513	1,267,324	6,471,891	360,709
Work-in-progress	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Finished goods	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	377,696	337,915	306,394	290,362	302,547	258,942	255,479	330,169	728,745	865,805	1,150,513	1,267,324	6,471,891	360,709
	39,781	31,520	16,032	(12,184)	43,605	3,463	(74,690)	(398,576)	(137,060)	(284,708)	(116,812)	(21,466)	911,094	16,987
Details of purchase of traded goods														
Product A	43,490	27,898	75,969	69,448	10,756	60,610	85,424	431,737	182,060	344,814	136,711	117,023	1,585,941	589,324
Product B	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product C	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	43,490	27,898	75,969	69,448	10,756	60,610	85,424	431,737	182,060	344,814	136,711	117,023	1,585,941	589,324

MSI Taylor Audit Service




Raj Prabhu
CPA, Registered Company Auditor #297379
Date 07 May 2015- Brisbane, Australia

Name of the company AUROBINDO PHARMA (AUSTRALIA) PTY LTD
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Period ended Mar 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 23 : Employee benefit expense														
Salaries, wages and bonus	84,826	74,483	66,554	71,903	71,436	72,035	60,718	65,651	69,069	70,025	69,769	65,316	841,784	1,257,560
Contribution to provident and other fund	6,180	6,023	5,212	5,767	5,723	5,779	4,850	5,160	5,465	5,559	5,656	5,407	66,780	97,813
Employee stock option scheme													-	-
Gratuity expense													-	-
Other employee benefits	1,154	540	4,351	4,724	618	3,811	866	3,568	847	3,176	3,440	20,163	47,259	51,683
Post employment medical benefits													-	-
Staff welfare expenses													-	-
	92,159	81,046	76,117	82,394	77,777	81,626	66,434	74,380	75,380	78,760	78,866	90,887	955,824	1,407,056
Note 24 : Other expenses														
Consumption of stores and spares													-	-
Conversion charges													-	-
Chemicals consumed													-	-
Increase in VAT on finished goods													-	-
Customer service expenditure													-	-
Power and fuel	-	-	1,922		1,083	846			1,974			2,485	8,310	10,910
Water charges													-	-
Freight and forwarding charges													-	4,396
Carriage inward				645	4,823	1,562	373	232	2,193	593	395	395	11,212	-
Carriage outwards	47,145	47,419	49,990	42,152	32,164	38,959	28,981	37,548	30,617	37,008	39,132	41,287	472,401	697,376
Rent	8,646	8,646	8,646	-	-	4,733	8,098	8,098	8,098	8,098	8,098	8,098	79,257	88,205
Rates and taxes													-	-
Insurance	2,830	100	1,046	-	-				1,139				5,115	2,258
Repairs and maintenance													-	-
i) Plant and machinery	975	750	1,200										2,925	11,880
ii) Buildings													-	15,915
iii) Others							1,350		375	1,370	327	225	3,647	-
Advertising and sales promotion	1,112	2,703	491	76	226	3,500	220	125			1,110	1,040	10,601	62,913
Brokerage and discounts													-	-
Remuneration to Auditors													-	9,500
Sales commission													-	-
Travelling and conveyance	1,301	1,038	1,419	2,940	1,604	1,064	2,511	1,482	1,546	871	1,685	81	17,542	51,439
Communication costs	2,848	2,861	2,422	2,790	3,268	2,310	3,040	2,676	2,626	2,090	3,152	2,798	32,881	44,874
Printing and stationery	620	307	134	495	536	1,635	963	878	936	523	1,019	380	8,425	3,940
Legal and professional fees	-	312	-	7,000	-	927	1,124	1,900	100			400	11,763	118,730
Directors sitting fees													-	-
Payment to auditor (Refer details below)													-	-
Provision for diminution in value of investment in subsidiary company													-	-
Provision for other than temporary decline in the													-	-

MSI Taylor Audit Service



Raj Prabhu, CPA, Registered Company Auditor #297379
Date 07 May 2015- Brisbane, Australia


Name of the company AUROBINDO PHARMA (AUSTRALIA) PTY LTD

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Period ended Mar 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
carrying amount of other long-term investments													-	
Adjustment to the carrying amount of current investments													-	
Provision for warranties (net of reversals)													-	
Provision for litigations (net of reversals)													-	
Exchange differences (net)													-	42,939
Loss on derivative contracts (including provisions mark-to-market loss)													-	
Write off of New Zealand subsidiary expenses										14,951			14,951	
Bad Debts / Advances written off										90,591	88,216	60,499	239,306	1,261
Impairment loss on fixed assets													-	
Provision for doubtful debts and advances													-	33,726
Loss on sale of fixed assets (net)													-	
Premium on forward exchange contract amortized													-	
Factory maintenance													-	
Effluent treatment expenses													-	
Provision for Printer and Telephone equipment rentals												25,000	25,000	922
Analytical charges													-	
Product development expenses													-	
Registration and filing charges	65	4,492	2,000	3,097	15,500	20,994	0	5,877	6,662	(4,350)	337		54,674	155,150
Safety and security													-	
Office expenses	1,985	1,874	1,843	1,007	1,654	1,452	2,940	1,890	1,342	2,524	2,793	2,021	23,324	17,516
Repairs and maintenance - others													-	
Management fees													-	13,150
Liquidated damages													-	
Donations													-	
Software license and implementation expenses													-	
Capital work-in-progress written off													-	
Miscellaneous expenses									330				330	
	67,527	70,502	71,113	60,202	60,858	77,980	49,600	60,704	57,938	154,268	146,263	144,709	1,021,664	1,387,000
Payment to Auditor													-	
As auditor:													-	
Audit fee												5,000	5,000	9,500
Tax audit fee													-	
Limited review													-	
In other capacity:													-	
Taxation matters													-	
Company law matters													-	
Management services													-	
Other services (certification fees)													-	
Reimbursement of expenses													-	2,700
												5,000	5,000	12,200

MSI Taylor Audit Service



Raj Prabhu, CPA, Registered Company Auditor #297379, Date 07 May 2015- Brisbane, Australia


Name of the company AUROBINDO PHARMA (AUSTRALIA) PTY LTD

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Period ended Mar 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 25 : Exceptional items														
Others (Specify if any)														
Note 26 : Depreciation and amortization expense														
Depreciation of tangible assets	1,365	1,365	1,365	1,365	1,365	1,365	1,365	1,365	1,399	1,399	1,399	1,399	16,513	14,939
Amortization of intangible assets	30,009	30,009	30,009	30,009	30,009	30,009	30,009	30,009	29,306	30,713	30,688	30,688	361,471	399,795
Depreciation of investment property														
	31,374	31,374	31,374	31,374	31,374	31,374	31,374	31,374	30,705	32,112	32,087	32,087	377,984	414,734
Note 27 : Finance costs (Refer General Instructions Note No 27)														
Interest	1,508	1,972	2,635	2,758	2,800	3,787	1,262	5,272	8,719	2,345	2,422	1,935	37,416	11,854
Bank charges	134	354	171	103	104	298	102	117	185	57	113	76	1,813	2,190
Amortization of ancillary borrowing costs														
Exchange difference to the extent considered as an :	1,325	(16,845)	(12,820)	2,050	4,930	24,070	20,057		102,967	(17,342)	(85,721)	(27,590)	(4,919)	9,824
	2,967	(14,519)	(10,014)	4,911	7,834	28,155	21,421	5,389	111,872	(14,939)	(83,187)	(25,579)	34,311	23,868

MSI Taylor Audit Service



Raj Prabhu

CPA, Registered Company Auditor # 297379

Date 07 May 2015- Brisbane, Australia

Note 1 : Summary of significant accounting policies

a) **Basis of preparation**

The financial statements have been prepared under the historical cost convention on accrual basis.

b) **Revenue Recognition**

Revenue from sale of good is recognized on dispatch and is inclusive of local taxes and net of discounts and sales returns.

c) **Fixed Assets and Depreciation**

(i) Fixed assets are stated at cost less accumulated depreciation. Cost includes freight, duties, taxes and any attributable costs of bringing the asset to its working condition for future use.

(ii) Depreciation is provided on straight-line method as prescribed by the Income-Tax laws.

d) **Intangible Assets and Amortisation**

Cost relating to licenses, which are acquired, are capitalized and amortized on a straight-line basis over their useful life as per company policy. Development expenditure incurred in respect of internally generated Intangible assets such as product development is carried forward when the future recoverability can reasonably be regarded as assured.

e) **Inventories**

Trading Goods are valued at lower of cost or net realizable value, with cost being determined using Weighted Average method.

f) **Foreign Exchange Transactions**

Foreign currency transactions arising during the year are recorded at the exchange rates prevailing at the transaction dates.

Profits and losses on foreign currency transactions are shown separately in the Profit & Loss Account.

2. **Leases**

The firm has no finance leases. Operating leases are mainly in the nature of lease of office premises with no restrictions and are renewable at mutual consent.

3. **Partners Share Capital**

The partners liability is limited by subscription to Capital. 100% of the paid up Share Capital is being held by Helix Healthcare BV.,



AUROBINDO PHARMA (PTY) LTD

(Registration number 2005/002455/07)

Financial statements

for the year ended 31 March 2015

Published 20 April 2015



GR (SA) / CA (SA)

36 Lebombo Road
Ashlea Gardens
MENLO PARK
PRETORIA 0081

P.O. BOX / POSBUS 35780
MENLO PARK 0102

M
B
G *Gregory, Butt & Marx*

Chartered Accountants (SA)
Geokrooleerde Rekenmeesters (SA)

Registered Accountants and Auditors
Geregistreerde Rekenmeesters en
Ouditeurs



Tel: (012) 346-1703 / (012) 346 5826
Fax / Faks: (012) 460 7728

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

General Information

Country of incorporation and domicile	South Africa
Nature of business and principal activities	Pharmaceutical wholesale
Directors	V. Galal G.P. Prasad A. Vasudeva
Registered office	Woodhill Office Park, Building no 1 53 Phillip Engelbrecht Avenue Meyersdal Johannesburg, South Africa 1448
Business address	Woodhill Office Park, Building no 1 53 Phillip Engelbrecht Avenue Meyersdal Johannesburg, South Africa 1448
Postal address	Postnest suite #17 Privatebag x1569 Glenvista South Africa 2058
Bankers	ABSA Bank Citl Bank Nedbank Limited Standard Chartered
Auditors	Gregory, Butt and Marx Chartered Accountants (S.A.) Registered Auditor
Company registration number	2005/002455/07
Tax reference number	9298/660/15/1
Level of assurance	These financial statements have been audited in compliance with the applicable requirements of the Companies Act of South Africa, 71 of 2008.
Preparer	The financial statements were independently compiled by: S. Swarts
Published	20 April 2015

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Index

The reports and statements set out below comprise the financial statements presented to the shareholder:

Index	Page
Directors' Responsibilities and Approval	3
Independent Auditor's Report	4
Directors' Report	5
Statement of Financial Position	6
Statement of Comprehensive Income	7
Statement of Changes in Equity	8
Statement of Cash Flows	9
Accounting Policies	10 - 14
Notes to the Financial Statements	15 - 19

The following supplementary information does not form part of the financial statements and is unaudited:

Detailed Income Statement	20 - 21
Tax Computation	22

Preparer

S. Swarts

Published

20 April 2015

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Directors' Responsibilities and Approval

The directors are required in terms of the Companies Act of South Africa, 71 of 2008 to maintain adequate accounting records and are responsible for the content and integrity of the financial statements and related financial information included in this report. It is their responsibility to ensure that the financial statements fairly present the state of affairs of the company as at the end of the financial year and the results of its operations and cash flows for the period then ended, in conformity with International Financial Reporting Standards. The external auditors are engaged to express an independent opinion on the financial statements.

The financial statements are prepared in accordance with International Financial Reporting Standards and are based upon appropriate accounting policies consistently applied and supported by reasonable and prudent judgements and estimates.

The directors acknowledge that they are ultimately responsible for the system of internal financial control established by the company and place considerable importance on maintaining a strong control environment. To enable the directors to meet these responsibilities, the directors set standards for internal control aimed at reducing the risk of error or loss in a cost effective manner. The standards include the proper delegation of responsibilities within a clearly defined framework, effective accounting procedures and adequate segregation of duties to ensure an acceptable level of risk. These controls are monitored throughout the company and all employees are required to maintain the highest ethical standards in ensuring the company's business is conducted in a manner that in all reasonable circumstances is above reproach. The focus of risk management in the company is on identifying, assessing, managing and monitoring all known forms of risk across the company. While operating risk cannot be fully eliminated, the company endeavours to minimise it by ensuring that appropriate infrastructure, controls, systems and ethical behaviour are applied and managed within predetermined procedures and constraints.

The directors are of the opinion, based on the information and explanations given by management, that the system of internal control provides reasonable assurance that the financial records may be relied on for the preparation of the financial statements. However, any system of internal financial control can provide only reasonable, and not absolute, assurance against material misstatement or loss.

The directors have reviewed the company's cash flow forecast for the year to 31 March 2016 and, in the light of this review and the current financial position, they are satisfied that the company has or has access to adequate resources to continue in operational existence for the foreseeable future.

The external auditors are responsible for independently reviewing and reporting on the company's financial statements. The financial statements have been examined by the company's external auditors and their report is presented on page 4.

The financial statements set out on pages 5 to 22, which have been prepared on the going concern basis, were approved by the directors on 20 April 2015 and were signed on its behalf by:



V. Galal

Johannesburg

20 April 2015

Independent Auditor's Report

To the Shareholder of Aurobindo Pharma (Pty) Ltd

We have audited the financial statements of Aurobindo Pharma (Pty) Ltd; as set out on pages 6 to 19, which comprise the statement of financial position as at 31 March 2015, and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and the notes, comprising a summary of significant accounting policies and other explanatory information.

Directors' Responsibility for the Financial Statements

The company's directors are responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards, and requirements of the Companies Act of South Africa, 71 of 2008, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatements, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with International Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements present fairly, in all material respects, the financial position of Aurobindo Pharma (Pty) Ltd as at 31 March 2015, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards, and the requirements of the Companies Act of South Africa, 71 of 2008.

Gregory Butt & Marx
Gregory, Butt and Marx
Chartered Accountants CA (SA)
Registered Auditor
WJ Marx

20 April 2015

36 Lebombo Road
Ashlea Gardens
Pretoria
0081



Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Directors' Report

The directors submit their report for the year ended 31 March 2015.

1. Review of activities

Main business and operations

The company is engaged in pharmaceutical wholesale and operates principally in South Africa.

The operating results and state of affairs of the company are fully set out in the attached financial statements and do not in our opinion require any further comment.

2. Going concern

The financial statements have been prepared on the basis of accounting policies applicable to a going concern. This basis presumes that funds will be available to finance future operations and that the realisation of assets and settlement of liabilities, contingent obligations and commitments will occur in the ordinary course of business.

3. Events after the reporting period

The directors are not aware of any matter or circumstance arising since the end of the financial year.

4. Accounting policies

The International Financial Reporting Standards were applied prior to the commencement dates in the current year:

5. Authorised and Issued share capital

Ordinary shares were converted from par value to no par value.

6. Dividends

No dividends were declared or paid to shareholder during the year.

7. Directors

The directors of the company as on the date of this report are as follows:

Name	Nationality
V. Galal	South African
G.P. Prasad	Indian
A. Vasudeva	Indian

8. Secretary

The company had no secretary during the year.

9. Auditors

Gregory, Butl and Marx will continue in office in accordance with section 90 of the Companies Act of South Africa, 71 of 2008.

10. Liquidity and solvency

The directors have performed the required liquidity and solvency tests required by the Companies Act of South Africa, 71 of 2008.

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Statement of Financial Position as at 31 March 2015

Figures in Rand	Note(s)	2015	2014
Assets			
Intangible assets	3	6 923 216	7 402 958
Investments in associates	4	16 500 000	16 500 000
Non-Current Assets			
Property, plant and equipment	2	9 877 720	10 210 592
		33 300 936	34 113 550
Current Assets			
Other assets	5	4 579 850	8 832 091
Inventories	6	24 317 446	35 669 967
Current tax receivable		1 035 690	1 672 280
Trade and other receivables	7	27 359 646	20 457 964
Short-term loans and advances		160 864	60 000
Cash and cash equivalents	8	21 780 001	8 893 726
		79 233 497	75 586 028
Total Assets		112 534 433	109 699 578
Equity and Liabilities			
Equity			
Share capital	9	41 903 147	41 903 147
Retained income		35 620 112	11 213 428
		77 523 259	53 116 575
Liabilities			
Current Liabilities			
Provisions	10	6 534 401	-
Trade and other payables	11	28 476 773	56 583 003
		35 011 174	56 583 003
Total Equity and Liabilities		112 534 433	109 699 578

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Statement of Comprehensive Income

Figures in Rand	Note(s)	2015	2014
Revenue	12	124 763 301	186 066 641
Cost of sales	13	(80 247 273)	(149 706 060)
Gross profit		44 516 028	36 360 581
Other income		7 963 146	4 425 131
Operating expenses		(61 051 182)	(48 098 979)
Operating (loss) profit		(8 572 008)	(7 313 267)
Investment revenue	14	33 615 282	637 632
Profit (loss) before taxation		25 043 274	(6 675 635)
Taxation		(636 590)	-
Profit (loss) for the year		24 406 684	(6 675 635)
Other comprehensive Income		-	-
Total comprehensive income (loss) for the year		24 406 684	(6 675 635)

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Statement of Changes in Equity

Figures in Rand	Share capital	Retained income	Total equity
Balance at 01 April 2013	41 903 147	17 889 063	59 792 210
Loss for the year	-	(6 675 635)	(6 675 635)
Total comprehensive Loss for the year	-	(6 675 635)	(6 675 635)
Balance at 01 April 2014	41 903 147	11 213 428	53 116 575
Profit for the year	-	24 406 684	24 406 684
Total comprehensive income for the year	-	24 406 684	24 406 684
Balance at 31 March 2015	41 903 147	35 620 112	77 523 259
Note(s)	9		

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Statement of Cash Flows

Figures in Rand	Note(s)	2015	2014
Cash flows from operating activities			
Cash receipts from customers		101 284 323	191 273 662
Cash paid to suppliers and employees		(125 054 711)	(196 621 758)
Cash used in operations	16	(23 770 388)	(5 348 096)
Interest income		115 282	637 632
Dividends received		33 500 000	-
Tax paid	17	-	(528 723)
Net cash from operating activities		9 844 894	(5 239 187)
Cash flows from investing activities			
Purchase of property, plant and equipment	2	(84 685)	(107 764)
Increase in intangible assets	3	(1 025 313)	(1 833 450)
Decrease (increase) in other assets.		4 252 245	(6 165 842)
Purchase of other asset		(100 864)	(20 000)
Net cash from Investing activities		3 041 381	(8 127 056)
Cash flows from financing activities			
Total cash movement for the year		12 886 275	(13 366 243)
Cash at the beginning of the year		8 893 726	22 259 968
Total cash at end of the year	8	21 780 001	8 893 725

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Accounting Policies

1. Presentation of Financial Statements

The financial statements have been prepared in accordance with International Financial Reporting Standards, and the Companies Act of South Africa, 71 of 2008. The financial statements have been prepared on the historical cost basis, and incorporate the principal accounting policies set out below. They are presented in South African Rands.

These accounting policies are consistent with the previous period.

1.1 Property, plant and equipment

The cost of an item of property, plant and equipment is recognised as an asset when:

- it is probable that future economic benefits associated with the item will flow to the company; and
- the cost of the item can be measured reliably.

Property, plant and equipment is initially measured at cost.

Costs include costs incurred initially to acquire or construct an item of property, plant and equipment and costs incurred subsequently to add to, replace part of, or service it. If a replacement cost is recognised in the carrying amount of an item of property, plant and equipment, the carrying amount of the replaced part is derecognised.

Property, plant and equipment is carried at cost less accumulated depreciation and any impairment losses.

Property, plant and equipment is carried at revalued amount, being the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

When an item of property, plant and equipment is revalued, any accumulated depreciation at the date of the revaluation is restated proportionately with the change in the gross carrying amount of the asset so that the carrying amount of the asset after revaluation equals its revalued amount.

The revaluation surplus in equity related to a specific item of property, plant and equipment is transferred directly to retained earnings when the asset is derecognised.

Property, plant and equipment are depreciated on the straight line basis over their expected useful lives to their estimated residual value.

Property, plant and equipment is carried at cost less accumulated depreciation and any impairment losses.

The useful lives of items of property, plant and equipment have been assessed as follows:

Item	Average useful life
Furniture and fixtures	5 Years
Motor vehicles	5 Years
Office equipment	10 Years
IT equipment	3 Years
Library	5 Years

The residual value, useful life and depreciation method of each asset are reviewed at the end of each reporting period. If the expectations differ from previous estimates, the change is accounted for as a change in accounting estimate.

The depreciation charge for each period is recognised in profit or loss unless it is included in the carrying amount of another asset.

The gain or loss arising from the derecognition of an item of property, plant and equipment is included in profit or loss when the item is derecognised. The gain or loss arising from the derecognition of an item of property, plant and equipment is determined as the difference between the net disposal proceeds, if any, and the carrying amount of the item.

Assets which the (company/group) holds for rentals to others and subsequently routinely sell as part of the ordinary course of activities, are transferred to inventories when the rentals end and the assets are available-for-sale. These assets are not accounted for as non-current assets held for sale. Proceeds from sales of these assets are recognised as revenue. All cash flows on these assets are included in cash flows from operating activities in the cash flow statement.

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Accounting Policies

1.2 Intangible assets

An intangible asset is recognised when:

- it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity; and
- the cost of the asset can be measured reliably.

Intangible assets are initially recognised at cost.

Expenditure on research (or on the research phase of an internal project) is recognised as an expense when it is incurred.

An intangible asset arising from development (or from the development phase of an internal project) is recognised when:

- it is technically feasible to complete the asset so that it will be available for use or sale.
- there is an intention to complete and use or sell it.
- there is an ability to use or sell it.
- it will generate probable future economic benefits.
- there are available technical, financial and other resources to complete the development and to use or sell the asset.
- the expenditure attributable to the asset during its development can be measured reliably.

Intangible assets are carried at cost less any accumulated amortisation and any impairment losses.

An intangible asset is regarded as having an indefinite useful life when, based on all relevant factors, there is no foreseeable limit to the period over which the asset is expected to generate net cash inflows. Amortisation is not provided for these intangible assets, but they are tested for impairment annually and whenever there is an indication that the asset may be impaired. For all other intangible assets amortisation is provided on a straight line basis over their useful life.

The amortisation period and the amortisation method for intangible assets are reviewed every period-end.

Reassessing the useful life of an intangible asset with a finite useful life after it was classified as indefinite is an indicator that the asset may be impaired. As a result the asset is tested for impairment and the remaining carrying amount is amortised over its useful life.

Internally generated brands, mastheads, publishing titles, customer lists and items similar in substance are not recognised as intangible assets.

Amortisation is provided to write down the intangible assets, on a straight line basis, to their residual values as follows:

Item	Useful life
Licenses and franchises	
Intangible assets under development	

1.3 Investments in associates

An investment in an associate is carried at cost less any accumulated impairment.

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Accounting Policies

1.4 Tax

Current tax assets and liabilities

Current tax for current and prior periods is, to the extent unpaid, recognised as a liability. If the amount already paid in respect of current and prior periods exceeds the amount due for those periods, the excess is recognised as an asset.

Current tax liabilities (assets) for the current and prior periods are measured at the amount expected to be paid to (recovered from) the tax authorities, using the tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Tax expenses

Current and deferred taxes are recognised as income or an expense and included in profit or loss for the period, except to the extent that the tax arises from:

- a transaction or event which is recognised, in the same or a different period, to other comprehensive income, or
- a business combination.

Current tax and deferred taxes are charged or credited to other comprehensive income if the tax relates to items that are credited or charged, in the same or a different period, to other comprehensive income.

Current tax and deferred taxes are charged or credited directly to equity if the tax relates to items that are credited or charged, in the same or a different period, directly in equity.

1.5 Inventories

Inventories are measured at the lower of cost and net realisable value.

Inventories are measured at the lower of cost and net realisable value on the weighted average cost basis.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

The cost of inventories comprises of all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.

The cost of inventories of items that are not ordinarily interchangeable and goods or services produced and segregated for specific projects is assigned using specific identification of the individual costs.

The cost of inventories is assigned using the weighted average cost formula. The same cost formula is used for all inventories having a similar nature and use to the entity.

When inventories are sold, the carrying amount of those inventories are recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of inventories to net realisable value and all losses of inventories are recognised as an expense in the period the write-down or loss occurs. The amount of any reversal of any write-down of inventories, arising from an increase in net realisable value, are recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

1.6 Share capital and equity

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities.

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Accounting Policies

1.7 Revenue

Revenue from the sale of goods is recognised when all the following conditions have been satisfied:

- the company has transferred to the buyer the significant risks and rewards of ownership of the goods;
- the company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the company; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

When the outcome of a transaction involving the rendering of services can be estimated reliably, revenue associated with the transaction is recognised by reference to the stage of completion of the transaction at the end of the reporting period. The outcome of a transaction can be estimated reliably when all the following conditions are satisfied:

- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the company;
- the stage of completion of the transaction at the end of the reporting period can be measured reliably; and
- the costs incurred for the transaction and the costs to complete the transaction can be measured reliably.

When the outcome of the transaction involving the rendering of services cannot be estimated reliably, revenue shall be recognised only to the extent of the expenses recognised that are recoverable.

Contract revenue comprises:

- the initial amount of revenue agreed in the contract; and
- variations in contract work, claims and incentive payments:
 - to the extent that it is probable that they will result in revenue; and
 - they are capable of being reliably measured.

Revenue is measured at the fair value of the consideration received or receivable and represents the amounts receivable for goods and services provided in the normal course of business, net of trade discounts and volume rebates, and value added tax.

Interest is recognised, in profit or loss, using the effective interest rate method.

Royalties are recognised on the accrual basis in accordance with the substance of the relevant agreements.

Dividends are recognised, in profit or loss, when the company's right to receive payment has been established.

Service fees included in the price of the product are recognised as revenue over the period during which the service is performed.

1.8 Cost of sales

When inventories are sold, the carrying amount of those inventories is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of inventories to net realisable value and all losses of inventories are recognised as an expense in the period the write-down or loss occurs. The amount of any reversal of any write-down of inventories, arising from an increase in net realisable value, is recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

The related cost of providing services recognised as revenue in the current period is included in cost of sales.

Contract costs comprise:

- costs that relate directly to the specific contract;
- costs that are attributable to contract activity in general and can be allocated to the contract; and
- such other costs as are specifically chargeable to the customer under the terms of the contract.

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Accounting Policies

1.9 Borrowing costs

Borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised as part of the cost of that asset until such time as the asset is ready for its intended use. The amount of borrowing costs eligible for capitalisation is determined as follows:

- Actual borrowing costs on funds specifically borrowed for the purpose of obtaining a qualifying asset less any temporary investment of those borrowings.
- Weighted average of the borrowing costs applicable to the entity on funds generally borrowed for the purpose of obtaining a qualifying asset. The borrowing costs capitalised do not exceed the total borrowing costs incurred.

The capitalisation of borrowing costs commences when:

- expenditures for the asset have occurred;
- borrowing costs have been incurred, and
- activities that are necessary to prepare the asset for its intended use or sale are in progress.

Capitalisation is suspended during extended periods in which active development is interrupted.

Capitalisation ceases when substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are complete.

All other borrowing costs are recognised as an expense in the period in which they are incurred.

1.10 Translation of foreign currencies

Foreign currency transactions

A foreign currency transaction is recorded, on initial recognition in Rands, by applying to the foreign currency amount the spot exchange rate between the functional currency and the foreign currency at the date of the transaction.

At the end of the reporting period:

- non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction; and
- non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognised in profit or loss in the period in which they arise.

When a gain or loss on a non-monetary item is recognised to other comprehensive income and accumulated in equity, any exchange component of that gain or loss is recognised to other comprehensive income and accumulated in equity. When a gain or loss on a non-monetary item is recognised in profit or loss, any exchange component of that gain or loss is recognised in profit or loss.

Cash flows arising from transactions in a foreign currency are recorded in Rands by applying to the foreign currency amount the exchange rate between the Rand and the foreign currency at the date of the cash flow.

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Notes to the Financial Statements

Figures in Rand 2015 2014

2. Property, plant and equipment

	2015			2014		
	Cost / Valuation	Accumulated depreciation	Carrying value	Cost / Valuation	Accumulated depreciation	Carrying value
Buildings	10 740 164	(1 285 154)	9 455 010	10 740 164	(1 070 354)	9 669 810
Furniture and fixtures	838 385	(827 734)	10 651	838 385	(768 234)	70 151
Motor vehicles	128 098	(128 098)	-	128 098	(117 423)	10 675
Office equipment	511 973	(206 460)	305 513	511 973	(155 268)	356 705
IT equipment	637 134	(530 589)	106 545	552 449	(449 199)	103 250
Library	6 730	(6 729)	1	6 730	(6 729)	1
Total	12 862 484	(2 984 764)	9 877 720	12 777 799	(2 567 207)	10 210 592

Reconciliation of property, plant and equipment - 2015

	Opening balance	Additions	Depreciation	Total
Buildings	9 669 810	-	(214 800)	9 455 010
Furniture and fixtures	70 151	-	(59 500)	10 651
Motor vehicles	10 675	-	(10 675)	-
Office equipment	356 705	-	(51 192)	305 513
IT equipment	103 250	84 685	(81 390)	106 545
Library	1	-	-	1
	10 210 592	84 685	(417 557)	9 877 720

Reconciliation of property, plant and equipment - 2014

	Opening balance	Additions	Depreciation	Total
Buildings	9 884 613	-	(214 803)	9 669 810
Furniture and fixtures	220 078	17 750	(167 677)	70 151
Motor vehicles	36 294	-	(25 619)	10 675
Office equipment	404 648	3 227	(51 170)	356 705
IT equipment	66 491	86 787	(50 028)	103 250
Library	1	-	-	1
	10 612 125	107 764	(509 297)	10 210 592

A register containing the information required by Regulation 25(3) of the Companies Regulations, 2011 is available for inspection at the registered office of the company.

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Notes to the Financial Statements

3. Intangible assets

	2015			2014		
	Cost / Valuation	Accumulated amortisation	Carrying value	Cost / Valuation	Accumulated amortisation	Carrying value
Patents, trademarks and other rights	10 236 236	(9 995 689)	240 547	10 236 236	(8 490 634)	1 745 602
Capital work in progress	6 682 669	-	6 682 669	5 657 356	-	5 657 356
Total	16 918 905	(9 995 689)	6 923 216	15 893 592	(8 490 634)	7 402 958

Reconciliation of intangible assets - 2015

	Opening balance	Additions	Amortisation	Total
Patents, trademarks and other rights	1 745 602	-	(1 505 055)	240 547
Capital work in progress	5 657 356	1 025 313	-	6 682 669
	7 402 958	1 025 313	(1 505 055)	6 923 216

Reconciliation of intangible assets - 2014

	Opening balance	Additions	Amortisation	Total
Patents, trademarks and other rights	3 405 263	367 600	(2 027 261)	1 745 602
Capital work in progress	4 191 506	1 465 850	-	5 657 356
	7 596 769	1 833 450	(2 027 261)	7 402 958

4. Investments in associates

Name of company	Listed / Unlisted	% holding 2015	% holding 2014	Carrying amount 2015	Carrying amount 2014
Novagen Pharma (Pty) Ltd		50.00 %	50.00 %	16 500 000	16 500 000

The carrying amounts of Associates are shown net of impairment losses.

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Notes to the Financial Statements

5. Other assets

At fair value through profit or loss - held for trading
Vat refundable

5 033 563	8 473 780
-----------	-----------

Loans and receivables		
Provision for revaluation	(453 713)	358 311

Total other financial assets	4 579 850	8 832 091
------------------------------	-----------	-----------

Current assets		
Loans and receivables	5 033 563	8 473 780
	(453 713)	358 311
	4 579 850	8 832 091

The company has not reclassified any financial assets from cost or amortised cost to fair value, or from fair value to cost or amortised cost during the current or prior year.

The maximum exposure to credit risk at the reporting date is the fair value of each class of loan mentioned above. The company does not hold any collateral as security.

6. Inventories

Merchandise	24 317 446	35 669 967
-------------	------------	------------

7. Trade and other receivables

Trade receivables	27 359 646	20 457 964
-------------------	------------	------------

8. Cash and cash equivalents

Cash and cash equivalents consist of:

Bank balances	21 780 001	8 893 728
---------------	------------	-----------

9. Share capital

Authorised		
45 000 000 Ordinary shares	45 000 000	45 000 000

Reconciliation of number of shares issued:		
Reported as at 01 April 2014	41 903 147	41 903 147

Issued		
Ordinary	41 903 147	41 903 147

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Notes to the Financial Statements

10. Provisions

Reconciliation of provisions - 2015

	Opening balance	Additions	Total
Marketing and logistic fees	-	4 064 401	4 064 401
Stock awaiting write off	-	2 350 000	2 350 000
Provision for audit fees	-	120 000	120 000
	-	6 534 401	6 534 401

Reconciliation of provisions - 2014

	Opening balance	Reversed during the year	Total
Stock awaiting write off	1 353 234	(1 353 234)	-

11. Trade and other payables

Trade payables	27 879 444	56 019 190
Sundry payables	76 500	17 672
Outstanding salaries	520 829	546 141
	28 476 773	56 583 003

12. Revenue

Sale of goods	124 763 301	186 066 641
---------------	-------------	-------------

13. Cost of sales

Sale of goods		
Cost of goods sold	80 247 273	149 706 060

14. Investment revenue

Dividend revenue		
Joint venture	33 500 000	-
Interest revenue		
Interest received	115 282	637 588
Discount received	-	44
	115 282	637 632
	33 615 282	637 632

15. Auditors' remuneration

Fees	248 500	66 000
------	---------	--------

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Notes to the Financial Statements

Figures in Rand	2015	2014
16. Cash used in operations		
Profit before taxation	25 043 274	(6 675 635)
Adjustments for:		
Depreciation and amortisation	1 922 612	2 536 559
Dividends received	(33 500 000)	-
Interest received	(115 282)	(637 632)
Movements in provisions	6 534 401	(1 353 234)
Changes in working capital:		
Inventories	11 352 521	(22 333 750)
Trade and other receivables	(6 901 684)	15 099 227
Trade and other payables	(28 106 230)	8 016 369
	(23 770 388)	(5 348 096)
17. Tax refunded		
Balance at beginning of the year	1 672 280	1 669 969
Current tax for the year recognised in profit or loss	(636 590)	-
Adjustment in respect of businesses sold and acquired during the year including exchange rate movements	-	(526 412)
Balance at end of the year	(1 035 690)	(1 672 280)
	-	(528 723)

18. Related parties

Relationships

Ultimate holding company
Holding company
Members of key management
Joint ventures

Aurobindo Pharma Limited (APL), India
Helix Healthcare BV
V. Galal (Director)
Novagen Pharma (Pty) Ltd

19. Risk management

Liquidity risk

The company's risk to liquidity is a result of the funds available to cover future commitments. The company manages liquidity risk through an ongoing review of future commitments and credit facilities.

Credit risk

Credit risk consists mainly of cash deposits, cash equivalents, derivative financial instruments and trade debtors. The company only deposits cash with major banks with high quality credit standing and limits exposure to any one counter-party.

Trade receivables comprise a widespread customer base. Management evaluated credit risk relating to customers on an ongoing basis. If customers are independently rated, these ratings are used. Otherwise, if there is no independent rating, risk control assesses the credit quality of the customer, taking into account its financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the board. The utilisation of credit limits is regularly monitored. Sales to retail customers are settled in cash or using major credit cards. Credit guarantee insurance is purchased when deemed appropriate.

Foreign exchange risk

The company reviews its foreign currency exposure, including commitments on an ongoing basis. The company expects its foreign exchange contracts to hedge foreign exchange exposure.

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Detailed Income Statement

Figures in Rand	Note(s)	2015	2014
Revenue			
Sale of goods		124 763 301	186 066 641
Cost of sales			
Opening stock		(35 669 967)	(13 336 217)
Purchases		(68 894 752)	(172 039 810)
Closing stock		24 317 446	35 669 967
	13	(80 247 273)	(149 706 060)
Gross profit		44 516 028	36 360 581
Other income			
Commissions received		3 153 784	-
Royalties received		969 362	585 131
Management charges		3 840 000	3 840 000
Dividend revenue	14	33 500 000	-
Interest received	14	115 282	637 632
		41 578 428	5 062 763
Expenses (Refer to page 21)		(61 051 182)	(48 098 979)
Profit (loss) before taxation		25 043 274	(6 675 635)
Taxation		636 590	-
Profit (loss) for the year		24 406 684	(6 675 635)
Other comprehensive income		-	-
Total comprehensive income (loss) for the year		24 406 684	(6 675 635)

Aurobindo Pharma (Pty) Ltd

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Detailed Income Statement

Figures in Rand	Note(s)	2015	2014
Operating expenses			
Advertising and sales promotion		(795 636)	(638 732)
Auditors remuneration	15	(248 500)	(66 000)
Bank charges		(57 524)	(69 278)
Commission paid		(3 959 444)	(1 190 795)
Computer expenses		(587 083)	(499 848)
Depreciation, amortisation and impairments		(1 922 612)	(2 536 559)
Discount allowed and marketing fees		(17 534 822)	(9 119 996)
Employee costs		(19 370 239)	(16 109 809)
Freight expenses		(225 762)	-
Insurance		(318 928)	(230 384)
Legal and professional expenses		(703 666)	(528 406)
Licenses and renewals		(260 906)	(504 663)
Logistic fees		(6 614 686)	(4 158 323)
Loss on exchange differences		(3 749 441)	(8 295 982)
Miscellaneous expenses		(703)	(3 419)
Motor vehicle expenses		(1 002 431)	(773 627)
Office expenses		(355 971)	(409 280)
Postage, telegram and telephones		(341 415)	(338 650)
Printing and stationery		(124 292)	(141 324)
Recruitment and training expenses		(689 146)	(288 216)
Repairs and maintenance		(6 365)	(3 705)
Royalties		(155 519)	(454 702)
Samples and testing charges		(694 655)	(678 634)
Security		(5 357)	(160 780)
Staff welfare		(175 296)	(90 515)
Travel and conveyances		(740 635)	(405 213)
Water and electricity		(410 148)	(402 139)
		<u>(61 051 182)</u>	<u>(48 098 979)</u>

Aurobindo Pharma (Pty) Ltd

(Tax registration number 9298/660/15/1)

(Registration number 2005/002455/07)

Financial Statements for the year ended 31 March 2015

Tax Computation

Figures in Rand	2015
Net profit per income statement	25 043 274
Permanent differences (Non-deductable/Non taxable items)	
Local dividends excl. dividends mentioned in s 8E and 103(5)	(33 500 000)
Assessed loss for 2015 - carried forward	(8 456 726)
Tax thereon @ 28% in the Rand	Nil
Reconciliation of tax balance	
Prior year adjustment	636 590
Amount owing/(prepald) at the beginning of year	(1 672 280)
Amount owing/(prepald) in respect of prior year	(1 035 690)
Tax owing/(prepald) for the current year:	
Amount owing/(prepald) at the end of year	(1 035 690)

AURO HEALTHCARE (NIGERIA) LIMITED

**AUDITED FINANCIAL STATEMENTS
31 MARCH 2015**

DIRECTORS' REPORT

The directors present their report and the audited financial statements for the year ended March 31st 2015.

PRINCIPAL ACTIVITY

The principle object of the company is to trade and deal in pharmaceutical products and other allied products and services.

Unusual Items after the Financial Year:

No item, transaction or event of a Material nature has arisen during the period between the end of the financial year and the date of this report, which would affect substantially the operations of the company during the current year.

REVIEW OF OPERATIONS

During the year the company had registered a Profit of NGN 868,967 against a Total Revenue of NGN 11,391,353 and in previous year it made a Loss of NGN 9,946,227 against a Total Revenue of NGN 597,481.

Statement of Directors:

In the opinion of the Directors, the accompanying Financial statements were drawn up so as to give a true and fair view of the state of affairs of the Company as on 31st March 2015 and the results of the business for that period. Your Directors have taken all reasonable steps to prepare these financial statements on a going concern basis and suitable accounting policies have been adopted consistently. Further your Directors are confident that with the support and guidance of the Holding company, your Company can achieve better results in the future

DIRECTORS

The Directors at the date of the report are:

1. Mr. Okere George Ugwuanya
2. Mr. Phaneendra Prasad Gorla

By Order of the Board:



Mr. Phaneendra Prasad Gorla
Director
Nigeria

AURO HEALTHCARE (NIGERIA) LIMITED

STATEMENT OF ACCOUNTING POLICIES

6

The following are the significant accounting policies adopted by the company in the preparation of the statement of affairs:

1. BASIS OF ACCOUNTING

The financial statements are prepared under the historical cost basis.

2. Fixed Assets

Fixed assets are stated at cost less accumulated depreciation

3. Depreciation

Depreciation is provided by the straight-line method at percentage of cost on the estimated average useful lives of the assets. Estimated useful lives by major classes of depreciable assets are as follows:

Computers 15%
Office equipment 20%
Furniture and fittings 20%

4. Foreign currencies

Transactions in foreign currencies are converted into Naira at the exchange ruling on the day the transaction occurs. Assets and liabilities denominated in foreign currencies are converted into Naira at the rate of exchange ruling on the balance sheet date.

5. Registration costs of pharmaceutical products

Registration costs including laboratory costs of obtaining NAFDAC approval are to be written off over the period of approval of five years.

AURO HEALTHCARE (NIGERIA) LIMITED

NOTES TO THE ACCOUNTS CONTINUED

	2015 N	2014 N
8		
Accruals and other creditors		
Imprest	94,970	119,997
Professional fees	833,110	1,333,113
Salaries and Director's fees	471,501	213,777
Tax provision	52,262	-
	<u>1,451,843</u>	<u>1,666,887</u>
9		
Authorised share capital	<u>100,000,000</u>	<u>40,000,000</u>
Authorised share capital at inception was 10,000,000 ordinary shares of N1.00 each;		
Increased to 20,000,000 ordinary shares of N1.00 each on 27 October 2008;		
Increased to 30,000,000 ordinary shares of N1.00 each on 3 December 2009		
Increased to 40,000,000 ordinary shares of N1.00 each on 23 June 2011		
Increased to 100,000,000 ordinary shares of N1.00 each on 16 May 2014		
Issued and fully paid		
30,000,000 ordinary shares of N1.00 each	<u>30,000,000</u>	<u>30,000,000</u>
10		
Share application money		
Opening balance	28,503,536	17,380,536
Remittances	4,840,000	11,123,000
Closing balance	<u>33,343,536</u>	<u>28,503,536</u>
11		
Revenue reserve		
Opening balance	<u>(51,638,792)</u>	(41,692,565)
Transferred from Profit and Loss account	868,965	(9,946,227)
Closing balance	<u>(50,769,827)</u>	<u>(51,638,792)</u>
12		
Certain reclassifications have been made in these financial statements.		

AURO HEALTHCARE (NIGERIA) LIMITED

BALANCE SHEET AS AT 31 MARCH 2015

	Note	2015 N	2014 N
FIXED ASSETS	6	92,277	16,107
CURRENT ASSETS			
Prepayments and Other debit balances	7	3,182,680	5,392,766
Amount due from related company		7,091,882	597,481
Bank and cash balances		3,658,713	2,525,277
		<u>13,933,275</u>	<u>8,515,524</u>
CREDITORS: Amounts falling due within one year			
Accruals and other creditors	8	(1,451,843)	(1,666,887)
		<u>12,481,432</u>	<u>6,848,637</u>
NET CURRENT ASSETS			
		<u>12,481,432</u>	<u>6,848,637</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>12,573,709</u>	<u>6,864,744</u>
CAPITAL AND RESERVES			
Share capital	9	30,000,000	30,000,000
Share application money	10	33,343,536	28,503,536
Revenue reserve	11	(50,769,827)	(51,638,792)
		<u>12,573,709</u>	<u>6,864,744</u>

The financial statements on pages 2 to 8 were approved by the Board of Directors on 4 May 2015 and signed on its behalf by:

 _____ } Directors

The accounting policies on page 2 and the other explanatory notes on pages 6 to 8 form part of these financial statements.

AURO HEALTHCARE (NIGERIA) LIMITED

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2015

	2015 N	2014 N
Cash flows from operating activities		
Cash received from customers	9,298,518	2,957,115
Payments to suppliers and employees	<u>(11,840,934)</u>	<u>(12,522,040)</u>
	(2,542,416)	(9,564,925)
Tax paid	<u>(1,046,148)</u>	<u>-</u>
Net cash provided for operating activities	<u>(3,588,564)</u>	<u>(9,564,925)</u>
Cash flows from investing activities		
Purchase of Computer	(118,000)	-
Proceeds from sale of fixed assets	<u>-</u>	<u>-</u>
Net cash provided by investing activities	<u>(118,000)</u>	<u>-</u>
Cash flows from financing activities		
Share application money	4,840,000	11,123,000
Net cash provided by financing activities	<u>4,840,000</u>	<u>11,123,000</u>
Net increase in cash and cash equivalents	1,133,436	1,558,075
Cash balance at the beginning of the year	2,525,277	967,202
Cash and cash equivalents at 31 March	<u><u>3,658,713</u></u>	<u><u>2,525,277</u></u>

Reconciliation of net income to net cash provided by operating activities:

Net income after tax	868,965	(9,946,227)
Adjustment to reconcile net income to net cash provided:		
Depreciation	41,830	24,130
Loss on disposal of fixed asset		
Prepayments and other debit balances	2,210,086	(2,389,366)
Amount due from related company	(6,494,401)	2,359,634
Accruals	<u>(215,044)</u>	<u>386,904</u>
	<u><u>(3,588,564)</u></u>	<u><u>(9,564,925)</u></u>

AURO HEALTHCARE (NIGERIA) LIMITED

NOTES TO THE ACCOUNTS

1 The company

Auro Health (Nigeria) Limited was incorporated as a private limited liability company on 1 February 2007, to carry out business as a pharmaceutical company engaged in the manufacture and sale of pharmaceutical products both wholesale and retail.

The company commenced business on 1 April 2009.

2 Turnover

This is the commission earned on drugs produced for May & Baker Nigeria Limited and Philips Pharmaceuticals by Aurobindo Pharma Limited India.

3		2015 N	2014 N
	Operational costs		
	Personnel Expenses	2,695,482	3,157,324
	Depreciation	41,830	24,130
	Registrations & Subscriptions	127,750	12,500
	Trademark & Brand Registration	3,367,100	2,784,500
	Travelling Expenses	230,000	304,771
	Printing & Stationary	12,050	44,430
	Directors Remuneration	378,000	378,000
	Postage & Telegrams	161,600	180,154
	Electricity Charges	57,456	210,480
	Rent Service Charge	199,993	216,685
	Repairs & Maintenance	63,000	97,650
	Premises Licence	513,000	-
	Telephone and Internet Expenses	164,550	149,670
	Share registration	1,650,000	-
	Rent	649,993	704,149
	Professional Fees	1,269,372	2,330,363
	Bank charges and interest	34,282	48,509
		11,615,458	10,643,315

AURO HEALTHCARE (NIGERIA) LIMITED

NOTES TO THE ACCOUNTS CONTINUED

4	Loss on ordinary activities before taxation is stated after charging the following:	2015	2014		
		N	N		
	Depreciation :	41,830	24,130		
	Director's fee	<u>378,000</u>	<u>378,000</u>		
5	Taxation				
	Tax and penalty on previous years accounts paid	1,046,148	-		
	Current provision-Education Tax	<u>52,262</u>	<u>-</u>		
		<u>1,098,410</u>	<u>-</u>		
6	Fixed Assets	Computers	Office Equipment	Furniture and Fixtures	Total
	COST	N	N	N	N
	At 1 April 2014	160,864	165,000	1,234,984	1,560,848
	Additions	<u>118,000</u>	<u>-</u>	<u>-</u>	<u>118,000</u>
	At 31 March 2015	<u>278,864</u>	<u>165,000</u>	<u>1,234,984</u>	<u>1,678,848</u>
	Depreciation				
	At 1 April 2014	144,777	164,990	1,234,974	1,544,741
	During the year	<u>41,830</u>	<u>-</u>	<u>-</u>	<u>41,830</u>
	At 31 March 2015	<u>186,607</u>	<u>164,990</u>	<u>1,234,974</u>	<u>1,586,571</u>
	Net book value				
	At 31 March 2015	<u>92,257</u>	<u>10</u>	<u>10</u>	<u>92,277</u>
	At 31 March 2014	<u>16,087</u>	<u>10</u>	<u>10</u>	<u>16,107</u>
7	Prepayments and Other debit balances	2015	2014		
		N	N		
	Product registration	2,841,000	3,601,100		
	Share registration	-	1,650,000		
	Rent prepaid	108,340	108,333		
	Rental services	33,340	33,333		
	Salary advance	<u>200,000</u>	<u>-</u>		
		<u>3,182,680</u>	<u>5,392,766</u>		

AURO HEALTHCARE (NIGERIA) LIMITED
NOTES TO THE ACCOUNTS CONTINUED

	2015 N	2014 N
8		
Accruals and other creditors		
Imprest	94,970	119,997
Professional fees	833,110	1,333,113
Salaries and Director's fees	471,501	213,777
Tax provision	52,262	-
	<u>1,451,843</u>	<u>1,666,887</u>
9		
Authorised share capital	<u>100,000,000</u>	<u>40,000,000</u>
Authorised share capital at inception was 10,000,000 ordinary shares of N1.00 each; Increased to 20,000,000 ordinary shares of N1.00 each on 27 October 2008; Increased to 30,000,000 ordinary shares of N1.00 each on 3 December 2009 Increased to 40,000,000 ordinary shares of N1.00 each on 23 June 2011 Increased to 100,000,000 ordinary shares of N1.00 each on 16 May 2014		
Issued and fully paid		
30,000,000 ordinary shares of N1.00 each	<u>30,000,000</u>	<u>30,000,000</u>
	2015	2014
	N	N
10		
Share application money		
Opening balance	28,503,536	17,380,536
Remittances	4,840,000	11,123,000
Closing balance	<u>33,343,536</u>	<u>28,503,536</u>
11		
Revenue reserve		
Opening balance	<u>(51,638,792)</u>	(41,692,565)
Transferred from Profit and Loss account	868,965	(9,946,227)
Closing balance	<u>(50,769,827)</u>	<u>(51,638,792)</u>
12		
Certain reclassifications have been made in these financial statements		

Aurobindo Pharma Japan KK

FINANCIAL STATEMENTS

[For the fiscal year ended March 31, 2015]

DIRECTORS' REPORT

The directors present their report and the audited financial statements for the year ended March 31st 2015.

PRINCIPAL ACTIVITY

The principle object of the company is to trade and deal in pharmaceutical products and other allied products and services.

Unusual Items after the Financial Year:

No item, transaction or event of a Material nature has arisen during the period between the end of the financial year and the date of this report, which would affect substantially the operations of the company during the current year.

REVIEW OF OPERATIONS

During the year the company had registered a Profit of JPY 7,383,618 against a Total Revenue of JPY 105,207,726 and in previous year it made a Profit of JPY 98,108,745 against a Total Revenue of JPY 560,608,351.

Statement of Directors:

In the opinion of the Directors, the accompanying Financial statements were drawn up so as to give a true and fair view of the state of affairs of the Company as on 31st March 2015 and the results of the business for that period. Your Directors have taken all reasonable steps to prepare these financial statements on a going concern basis and suitable accounting policies have been adopted consistently. Further your Directors are confident that with the support and guidance of the Holding company, your Company can achieve better results in the future

DIRECTORS

The Directors at the date of the report are:

1. Mr. P Prabhakar Reddy
2. Mr. Toshihiko Koide
3. Mr. Phaneendra Prasad Gorla

By Order of the Board:



Mr. P Prabhakar Reddy.
Director
Japan


REPORT OF INDEPENDENT AUDITOR

To the Board of Directors and Shareholders
Aurobindo Pharma Japan KK

I have audited the accompanying balance sheet of Aurobindo Pharma Japan K.K. as of March 31, 2015 and the related statement of income, shareholders' equity and cash flow for the year then ended, expressed in Japanese yen. These financial statements are the solely responsibility of the Company's management. My responsibility is to express an opinion on these financial statements based on my audit.

I conducted my audit in accordance with generally accepted auditing standards. Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement based on the tolerable error. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. My audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. I believe that my audit provide a reasonable basis for my opinion.

In my opinion, the financial statements give a true and fair view of the Company of March 31, 2015, and of the results of its operation and cash flow for the year then ended in accordance with generally accepted accounting principles.



TAKASHI YAMAWAKE, Certified Public Accountant of Japan.

April 29, 2015

CONTENTS

page

FINANCIAL STATEMENTS:

Balance sheet	1
Profit and loss statement	3
Statement of shareholders' equity	4
Statements of cash flow	5
Notes to financial statements	7



Aurobindo Pharma Japan K.K.
BALANCE SHEET
As of March 31, 2015

ASSETS

	Note	As of March 31,	
		2015	2014
		(Yen)	
Current Assets:			
Cash and deposits		¥ 135,340,906	¥ 138,470,530
Account receivable - third party		19,311,800	2,929,500
Account receivable - related party	9	19,278,762	33,757,389
Other receivable - third party		1,200	-
Other receivable - related party	9	113,465	-
Inventory	9	2,610,000	-
Prepaid expenses		3,078,025	798,025
Consumption tax receivable		2,496,782	929,552
Corporate income tax refundable		1,006,700	-
Deferred tax assets - current		1,520,340	2,367,600
Total Current Assets		184,757,980	179,252,596
Fixed Assets:			
Tangible fixed assets			
Leasehold improvement		317,933	370,013
Furniture and fixture		126,878	147,662
Deferred tax assets - non current	4	444,090	487,600
Other assets		2,130,000	2,130,000
Total Fixed Assets		3,018,901	3,135,275
TOTAL ASSETS		¥ 187,776,881	¥ 182,387,871



BALANCE SHEET (continued)

LIABILITIES AND

SHAREHOLDERS' EQUITY

<u>SHAREHOLDERS' EQUITY</u>		<u>As of March 31,</u>	
		<u>2015</u>	<u>2014</u>
	Note	(Yen)	
Current Liabilities:			
Account payable, trade - related party	9	¥ 12,979,530	¥ 1,152,640
Account payable, others - third party		301,026	265,298
Account payable, others - related party	9	-	1,194,339
Income tax payable		-	12,411,300
Accrued expense		1,311,418	1,281,145
Vacation reserve		2,771,189	2,459,530
Withholding tax & social security tax		1,467,482	1,393,401
Other current liabilities		140	667,740
Total Current Liabilities:		<u>18,830,785</u>	<u>20,825,393</u>
Non - Current Liabilities:			
Assets retirement obligation		<u>1,201,931</u>	<u>1,201,931</u>
Total Non - Current Liabilities		<u>1,201,931</u>	<u>1,201,931</u>
TOTAL LIABILITIES		<u>¥ 20,032,716</u>	<u>¥ 22,027,324</u>
Shareholders' Equity:			
Common Stock		148,799,200	148,799,200
- Authorized 3,000,000 shares			
- Issued and outstanding 1,487,992 share	8		
Retained earnings		<u>18,944,965</u>	<u>11,561,347</u>
Total Shareholders' Equity		<u>167,744,165</u>	<u>160,360,547</u>
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		<u>¥ 187,776,881</u>	<u>¥ 182,387,871</u>

The accompanying notes are an integral part of these statements.



Aurobindo Pharma Japan K.K.
PROFIT AND LOSS STATEMENT
For the fiscal year ended March 31, 2015

		For the year ended March 31, 2015	For the year ended March 31, 2014
	Note	(Yen)	
Product sales		¥ 37,549,000	¥ 468,313,671
Sales commission revenue	9	67,658,726	92,294,680
Interest income		25,769	14,523
Foreign exchange gain (net)		8,927,368	-
Other income	6	716,770	206,480
Cost of goods sold	9	△32,386,694	△374,836,342
Selling, general and administrative expenses	5	△68,791,540	△65,431,630
Interest expenses	9	-	△115,548
Foreign exchange loss (net)		-	△1,672,741
Other loss	7	△825,711	-
Income (Loss) Before Income Tax		12,873,688	118,773,093
Income tax - Current	4	△4,599,300	△12,416,700
Income tax - Deferred	4	△890,770	△8,247,648
Net Income (Loss)		¥ 7,383,618	¥ 98,108,745

The accompanying notes are an integral part of these statements.



Aurobindo Pharma Japan K.K.
STATEMENT OF SHAREHOLDERS' EQUITY
For the fiscal year ended March 31, 2015

	For the year ended March 31, 2015		
		(Yen)	
	Common Stock	Retained earnings/ (Loss)	Total Shareholders' Equity
Balance as of April 1, 2014	¥ 148,799,200	¥11,561,347	¥ 160,360,547
Increase in Common Stock	-	-	-
Net Income (Loss)	-	7,383,618	7,383,618
Balance as of March 31, 2015	¥ 148,799,200	¥18,944,965	¥ 167,744,165

The accompanying notes are an integral part of these statements.



Aurobindo Pharma Japan K.K.
STATEMENT OF CASH FLOWS
For the fiscal year ended March 31, 2015

	For the year ended March 31, 2015	For the year ended March 31, 2014
	(Yen)	
Cash flows from operating activities:		
Net income (Loss) before income tax	¥ 12,873,688	¥ 118,773,093
Depreciation	72,864	131,820
Interest income	△25,769	△14,523
Interest expense	-	115,548
Decrease (increase) in account receivable	△1,903,673	△16,396,928
Decrease (increase) in inventory	△2,610,000	-
Decrease (increase) in prepaid expense	△2,280,000	1,309,350
Decrease (increase) in other receivable	△114,665	603,197
Decrease (increase) in consumption tax refundable	△1,567,230	-
Increase (decrease) in account payable - trade	11,826,890	1,152,640
Increase (decrease) in account payable - others	△1,158,611	245,670
Increase (decrease) in accrued expenses	30,273	△352,451
Increase (decrease) vacation reserve	311,659	43,062
Increase (decrease) other current liabilities	△667,600	-
Others	74,081	△73,854
Sub Total	14,861,907	105,536,624
Interest receive	25,769	14,523
Income tax paid	△18,017,300	△409,400
Net cash (used in) from operating activities	△3,129,624	105,141,747
Cash flows from investment activities:		
Net cash (used in) from investment activities	-	-
Cash flows from financial activities:		
Repayment of loan payable	-	△9,410,700



STATEMENT OF CASH FLOWS (continued)

	For the year ended March 31, 2015	For the year ended March 31, 2014
Net cash (used in) from financial activities	-	△9,410,700
Net increase (decrease) in cash and cash equivalents	△3,129,624	95,731,047
Cash and cash equivalent at beginning of the year	138,470,530	42,739,483
Cash and cash equivalent at end of the year	¥ 135,340,906	¥ 138,470,530



Aurobindo Pharma Japan K.K.
NOTES TO FINANCIAL STATEMENTS
For the fiscal year ended March 31, 2015

NOTE 1 GENERAL

The Company was incorporated on April 18, 2007 under the law of Japan as a subsidiary of Helix Healthcare B.V, which is a corporation in the Netherlands. The principal activity of the Company is an engaging primarily in the business of selling and marketing active pharmaceutical ingredients (bulk actives), intermediates and specialty generic formulations in Japan.

NOTE 2 SIGNIFICANT ACCOUNT POLICIES

BASIS OF ACCOUNTING – The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amount reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

FINANCIAL ASSETS – the Company's principal financial assets are bank balance, account receivable (trade and others), prepaid expenses, and fixed assets (tangible and other fixed assets).

Other current assets as prepaid expenses are stated at their nominal values or appropriate carrying amount.

Tangible fixed assets are stated at cost. Depreciation is computed under the straight-line method based on the estimated useful lives of the assets.

Other fixed assets are stated at cost after consideration of collectability.

The Company reviews their long-lived assets for impairment whenever events or changes in circumstance indicate the carrying amount of an asset or assets group may not be recoverable.

FINANCIAL LIABILITIES AND SHAREHOLDERS' EQUITY – Financial liabilities and shareholders' equity instrument are classified according to the substance of the contractual arrangements entered into. Financial



liabilities include trade and other payables. Trade and other payables are stated at their nominal values.

REVENUE RECOGNITION – Sales revenue commission is solely for the Company's ultimate parent company, Aurobindo Pharma Limited, India and is recognized at the timing when the Company's ultimate parent company collects the account receivable for the sales of their products in Japan from Japanese customer. The company started product purchase from Aurobindo Pharma Limited, India and sales to Japanese customers from the fiscal year ended March 31, 2011. Purchase and sales is recognized at the timing of delivery based on the contract.

INCOME TAX – Tax expense is determined on the basis of tax effect accounting, using the asset liability method, and it is applied to all significant temporary differences arising between the carrying amount of assets and liabilities in the financial statement and the corresponding tax bases used in computation of taxable profit except that the potential tax saving relating to tax loss carry forward is not recorded as an assets unless there is reasonable expectation of realization in the foreseeable future.

Deferred tax assets and liabilities are measured using the tax rate that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates and tax laws that have been enacted or substantially enacted by the balance sheet date. Deferred tax is charged or credited to the profit and loss statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when they relate to income tax levied by the same tax authority.

CASH – Cash for statement of cash flows includes cash and cash equivalents.

FOREIGN CURRENCY TRANSACTIONS – Foreign currency transactions (other than those relating to foreign branches) arising during the year are recorded at the exchange rates prevailing at the transaction dates. Monetary assets and liabilities related to foreign



currency transactions remaining unsettled at the end of the year are translated at year-end rates. The resultant gain/loss, if any, is recognized in the Statement of Profit and Loss, including exchange differences on liabilities incurred for acquisition of fixed assets. Non-monetary assets and liabilities related to foreign currency transactions are reported at the rate on the date of the transaction.

NOTE 3 FINANCIAL RISKS AND MANAGEMENT

The Company's overall risk management program seeks to minimize potential adverse effects on the financial performance of the group.

a. Liquidity risk

The Aurobindo group has adequate cash and credit facilities for its operating requirements. Then, the financial support from the group company is indispensable for the business of the stability of the Company.

b. Fair values of financial assets and financial liabilities

The fair values of financial assets and financial liabilities approximate their carrying amounts determined in accordance with the accounting policies stated in Note 2 to the financial statements except that is not practicable within the constraint of cost to reliably determine the fair value of amounts receivable and payable to related company at their balances have no fixed repayment terms.

NOTE 4 INCOME TAXES

	For the year ended March 31, 2015	For the year ended March 31, 2014
	(Yen)	
Income tax – Current		
- Current year accrued	¥ 4,599,300	¥ 12,416,700
- Adjustment of previous year paid	-	-
Income tax – Deferred	890,770	8,247,648
Total tax expense	¥ 5,490,070	¥ 20,664,348



The following is the details in deferred tax assets.

	For the year ended March 31, 2015	For the year ended March 31, 2014
	(Yen)	
Property & equipment (Fixed Assets)	¥ 444,090	¥ 487,600
Provision for Compensated absences	917,260	876,500
Accrued expense	434,080	456,600
Enterprise tax payable	△104,300	1,034,500
Inventory	273,300	-
Total temporary differences	1,964,430	2,855,200
Valuation loss	-	-
Total	¥ 1,964,430	¥ 2,855,200

Effective tax rate for FY2015 is 35.64%. The tax rate has been declined due to the change in the enacted tax laws, then the effective tax rate for and after FY2016 is 33.10%.

NOTE 5 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

	For the year ended March 31, 2015	For the year ended March 31, 2014
	(Yen)	
Compensation for directors	¥ 1,200,000	¥ 1,200,000
Salaries	36,373,920	35,242,309
Severance payment	-	1,036,424
Legal welfare expenses	4,702,959	4,594,349
Provision for vacation reserve	311,659	43,062
Other staff welfare expenses	85,272	218,082
Rent	5,652,288	5,652,288
Rates and tax	816,998	1,028,205
Printing , stationery and office supplies	1,448,749	2,144,804
Postage, telegram and telephones	1,597,052	1,529,844
Legal and professional charges	1,461,008	1,565,177



SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (continued)

	For the year ended March 31, 2015	For the year ended March 31, 2014
Remuneration to auditors	1,000,000	1,000,000
Carriage outwards	1,557,614	383,868
Travel and conveyance	7,784,001	6,523,956
Registration and filing charges	225,441	39,700
Office expenses	552,304	532,187
Entertainment	941,780	589,864
Meeting expense	313,283	325,532
Bank charge	345,461	322,843
Commission paid	216,769	741,769
Recruiting and training	71,779	-
Books and magazine	249,482	317,016
Membership	180,000	220,000
Depreciation	72,864	131,820
Insurance	45,170	16,080
Trade show	215,363	-
Sample expense	229,500	-
Bad debt loss	1,140,824	-
Miscellaneous expenses	-	32,451
Total	¥ 68,791,540	¥ 65,431,630

NOTE 6 OTHER INCOME

	For the year ended March 31, 2015	For the year ended March 31, 2014
	(Yen)	
Service for freight handling	¥ 714,170	¥ -
Consumption tax rounding	-	46
Interest on refunded consumption tax	2,600	9,100
Commission received	-	197,334



OTHER INCOME (continued)

	For the year ended March 31, 2015	For the year ended March 31, 2014
Total	¥ 716,770	¥ 206,480

NOTE 7 OTHER LOSS

	For the year ended March 31, 2015	For the year ended March 31, 2014
	(Yen)	
Damaged inventory write off	¥ 825,680	¥ -
Consumption tax rounding	31	-
Total	¥ 825,711	¥ -

NOTE 8 EARNING PER SHARE

	For the year ended March 31, 2015	For the year ended March 31, 2014
	(Yen)	
Net income (loss)	¥ 7,383,618	¥ 98,108,745
Number of shares (Shares)	1,487,992	1,487,992
Basic earnings per share (Yen)	¥ 4.96	¥ 65.93

Diluted net income (loss) per share is not disclosed because potentially dilutive securities are not issued.

NOTE 9 RELATED PARTY TRANSACTION

The transactions with related company during the fiscal year ended March 31, 2015 were as follows.



BALANCE:

		As of March 31,	
		2015	2014
		(Yen)	
Account receivable - trade			
Aurobindo Pharma Limited, India	¥	19,278,762	¥ 33,757,389
Total	¥	19,278,762	¥ 33,757,389
Account receivable - others			
Aurobindo Pharma Limited, India	¥	113,465	¥ -
Total	¥	113,465	¥ -
Account payable - trade			
Aurobindo Pharma Limited, India	¥	12,979,530	¥ 1,152,640
Total	¥	12,979,530	¥ 1,152,640
Account payable - Others			
Helix Healthcare B.V.	¥	-	¥ 1,194,339
Total	¥	-	¥ 1,194,339

TRANSACTIONS:

	For the year ended March 31, 2015	For the year ended March 31, 2014
	(Yen)	
Sales commission revenue		
Aurobindo Pharma Limited, India	¥ 67,013,271	¥ 92,060,903
Total	¥ 67,013,271	¥ 92,060,903
Other commission revenue		
Aurobindo Pharma Limited, India	¥ 645,455	¥ 233,777
Total	¥ 645,455	¥ 233,777



TRANSACTIONS (continued)

	For the year ended March 31, 2015	For the year ended March 31, 2014
Product purchase		
Aurobindo Pharma Limited, India		
Inventory at beginning of the year	¥ -	¥ -
Purchased during the year	¥ 34,996,694	374,836,342
Less: Inventory at end of the year	2,610,000	-
Cost of goods sold	¥ 32,386,694	¥ 374,836,342
Other purchase - Sample		
Aurobindo Pharma Limited, India	¥ 229,500	¥ -
Total	¥ 229,500	¥ -
Interest expense		
Helix Healthcare B.V.	¥ -	¥ 115,548
Total	¥ -	¥ 115,548



AUROBINDO PHARMA (SINGAPORE) PTE. LTD.
(Incorporated in the Republic of Singapore)
(Reg No:201019613C)

FINANCIAL STATEMENTS - 31 MARCH 2015

<u>CONTENTS</u>	<u>PAGE</u>
DIRECTORS' REPORT	2-3
STATEMENT BY DIRECTORS	4
INDEPENDENT AUDITOR'S REPORT	5
BALANCE SHEET	6
STATEMENT OF COMPREHENSIVE INCOME	7
STATEMENT OF CHANGES IN EQUITY	8
STATEMENT OF CASH FLOWS	9
NOTES TO THE FINANCIAL STATEMENTS	10-14

**AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)**

**DIRECTORS' REPORT
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015**

The directors present their report to the members together with the audited financial statements of the Company for the financial year ended 31 March 2015.

Directors:

The directors of the Company in office at the date of this report are: -

**GORLA PHANEEMDRA PRASAD
VENKATARAMAIYER SIVARAMAKRISHNAN**

Arrangements to enable director to acquire shares and debentures:

Neither at the end of nor at any time during the financial year was the Company a party to any arrangement whose object was to enable the directors of the Company to acquire benefits by means of the acquisition of shares or debentures of, the Company or any other body corporate.

Directors' interest in shares or debentures:

The following directors, who held office at the end of the financial year had, according to the register of the directors' shareholdings required to be kept under Section 164 of the Companies Act, an interest in shares of the Company as stated as below: -

Name of Directors	NUMBER OF SHARES	
	Beginning of financial year	End of financial year
Shares in Ultimate Holding Company Aurobindo Pharma India		
Gorla Phaneemdra Prasad	25,375	938

Directors' contractual benefits:

Since the end of previous financial year, the director has not received or become entitled to receive a benefit by reason of a contract made by the company or by a related corporation with the director or with a firm of which he is a member or with a company in which he has a substantial financial interest other than those disclosed in the financial statements.

Share options

No options were granted during the financial year to take up unissued shares of the Company.

No shares were issued during the financial year by virtue of the exercise of option.

There were no unissued shares of the Company under option at the end of the financial year.

**AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)**

**DIRECTORS' REPORT
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015**

Independent auditor

The independent auditor, MGI N Rajan Associates, has expressed its willingness to accept re-appointment.



**VENKATARAMAIYER SIVARAMAKRISHNAN
DIRECTOR**



**GORLA PHANEENDRA PRASAD
DIRECTOR**

Singapore/ India,
Date: - 8 MAY 2015

AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)

STATEMENT BY DIRECTORS
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015

In our opinion

- (a) the accompanying balance sheet, statement of comprehensive income, statement of changes in equity and statement of cash flows together with the notes thereon, are drawn up in accordance with and comply with the Singapore Financial Reporting Standards so as to give a true and fair view of the state of affairs of the Company as at 31 March 2015 and of the results of the business, changes in equity and cash flows of the Company for the financial year then ended; and
- (b) at the date of this statement there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.



VENKATARAMAIYER SIVARAMAKRISHNAN
DIRECTOR



GORLA PHANEENDRA PRASAD
DIRECTOR

Singapore/ India,
Date: - 8 MAY 2015



MGI N RAJAN ASSOCIATES
PUBLIC ACCOUNTANTS AND
CHARTERED ACCOUNTANTS SINGAPORE

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF
AUROBINDO PHARMA (SINGAPORE) PTE. LTD.
(Incorporated in the Republic of Singapore)

Report of financial statements

We have audited the accompanying financial statements of AUROBINDO PHARMA (SINGAPORE) PTE LTD. ("the Company") which comprise the balance sheet as at 31 March 2015 statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory notes.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Singapore Companies Act, Chapter 50 (the "Act") and Singapore Financial Reporting Standards and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair profit and loss accounts and balance sheets and to maintain accountability of assets.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Singapore Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements are properly drawn up in accordance with the provisions of the Act and Singapore Financial Reporting Standards so as to give a true and fair view of the state of affairs of the Company as at 31 March 2015 and of the results, changes in equity and cash flows of the Company for the year ended on that date.

Report on other Legal and Regulatory Requirements

In our opinion, the accounting and other records required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act.



MGI N RAJAN ASSOCIATES
PUBLIC ACCOUNTANTS AND CHARTERED ACCOUNTANTS

Singapore

Date: - 8 MAY 2015

10, JALAN BESAR #10-12, SIM LIM TOWER, SINGAPORE 208787.

TEL: (065) 6293 8089/6293 8370 / 6293 8047 / 6293 0732 FAX: (065) 6293 5756 Email: soma@nra.com.sg Web: www.nra.com.sg

G. Natarajan, P.S. Somasekharan, D. Govindaraj

MGI is a worldwide association of independent auditing, accounting and consulting firms.
Each member firm undertakes no responsibility for the activities, work, opinions or service of the other member firms.

AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)

BALANCE SHEET
AS AT 31 MARCH 2015

	Note	2015 S\$	2014 S\$
ASSETS			
Current assets			
Cash and cash equivalents	5	170	2,484
Prepayment		2,600	2,600
Total assets		2,770	5,084
LIABILITIES			
Current liabilities			
Accruals		1,900	1,177
Total liabilities		1,900	1,177
NET ASSETS		870	3,907
EQUITY			
Share capital	6	100,000	90,000
Accumulated (losses)		(99,130)	(86,093)
Total equity		870	3,907

(The annexed notes form an integral part of and should be read in conjunction with these financial statements.)

AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)

STATEMENT OF COMPREHENSIVE INCOME
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015

	Note	2015 S\$	2014 S\$
Revenue			-
Expenses			
Other operating expenses		(13,037)	(8,532)
(Loss) before tax	3	(13,037)	(8,532)
Tax expense	4	-	-
(Loss) after tax		(13,037)	(8,532)
Other comprehensive income		-	-
Total comprehensive (loss)		(13,037)	(8,532)

(The annexed notes form an integral part of and should be read in conjunction with these financial statements.)

AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)

STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015

	Share capital	Accumulated (losses)	Total
	S\$	S\$	S\$
Balance as at 31 March 2013	80,000	(77,561)	2,439
Issue of shares during the year	10,000	-	10,000
Total comprehensive (loss) for the year	-	(8,532)	(8,532)
Balance as at 31 March 2014	90,000	(86,093)	3,907
Issue of shares during the year	10,000	-	10,000
Total comprehensive (loss) for the year	-	(13,037)	(13,037)
Balance as at 31 March 2015	100,000	(99,130)	870

(The annexed notes form an integral part of and should be read in conjunction with these financial statements.)

AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)

STATEMENT OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015

	Note	2015 S\$	2014 S\$
Cash flows from operating activities			
Net(loss) for the year before taxation		(13,037)	(8,532)
Operating (loss) before working capital changes		(13,037)	(8,532)
(Increase) in prepayment		-	(50)
Increase in accruals		723	427
Net cash (used in) operating activities		(12,314)	(8,155)
Cash flows from financing activities			
Issue of shares		10,000	10,000
Net cash flows provided by financing activities		10,000	10,000
Net (decrease)/increase in cash and cash equivalents		(2,314)	1,845
Cash and cash equivalents at beginning of the year		2,484	639
Cash and cash equivalents at end of the year	5	170	2,484

(The annexed notes form an integral part of and should be read in conjunction with these financial statements.)

**AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)**

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015**

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

1 GENERAL INFORMATION

The Company is a limited liability Company and domiciled in the Republic of Singapore.

The financial statements of the Company for the financial year ended 31 March 2015 were authorised for issue in accordance with a resolution of the director on the date of the Statement by Directors.

The principal activity of the Company is that wholesale of medicinal and pharmaceutical products. However the Company has not started their business. The Company's registered office address is at 10, Jalan Besar, #10-10 Sim Lim Tower Singapore (208787).

The immediate holding Company is Helix Healthcare BV, Prins Berhadplein 200, 1097 JB Amsterdam, Netherlands.

The Ultimate holding company is Aurobindo Pharma India.

2 SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of preparation

The financial statements have been prepared in accordance with Singapore Financial Reporting Standards ("FRS"). The financial statements have been prepared under the historical cost convention, except as disclosed in the accounting policies below.

The preparation of these financial statements in conformity with FRS requires management to exercise its judgment in the process of applying the Company's accounting policies. It also requires the use of certain critical accounting estimates and assumptions. The company has assessed that there are no estimates or judgments used that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

Adoption of new and revised standards - In the current financial year, the company has adopted all the new and revised FRSs and Interpretations of FRS ("INT FRS") that are relevant to its operations and effective for annual periods beginning on or after April 1st, 2014. The adoption of these new / revised FRSs and INT FRSs does not result in changes to the company's accounting policies and has no material effect on the amounts reported for the current or prior years.

The financial statements are presented in Singapore dollars.

2.2. Revenue recognition

The Company has not started their business.

2.3 Income taxes

The current income tax is recognized at the amount expected to be paid to or recovered from the tax authorities.

Deferred income tax is recognized for all temporary differences except when the deferred income tax arises from the initial recognition of an asset or liability and affects neither accounting nor taxable profit nor loss at the time of the transaction.

Current and deferred income tax is measured using the tax rates and tax laws that have been enacted or substantially enacted by the balance sheet date, and are recognized as income or expense in the income statement, except to the extent that the tax arises from a transaction which is recognized directly in equity.

**AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)**

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015**

2. SIGNIFICANT ACCOUNTING POLICIES CONTD...

2.4 Cash and cash equivalents

For the purpose of presentation in the cash flow statement, cash and cash equivalents represent cash on hand/ bank.

2.5 Financial liabilities

Financial liabilities include trade payables, other payables and interest bearing loans. Financial liabilities are recognised on the balance sheet when, and only when, the company becomes a party to the contractual provisions of the financial instrument.. Financial liabilities are initially recognised at fair value of the consideration received less directly attributable transaction costs and subsequently measured at amortised cost using the effective interest rate method.

Gains and losses are recognised in the Income statement when the liabilities are derecognised as well as through the amortization process. The liabilities are derecognised when the obligation under the liability is discharged or cancelled or expired.

2.6 Financial assets

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets, except those maturing later than 12 months after the balance sheet date which are presented as non-current assets. Loans and receivables are presented as "trade and other receivables" and "cash and cash equivalents on the balance sheet.

Initial measurement

Financial assets are initially recognised at fair value plus transaction costs

Subsequent measurement

Loans and receivables are carried at amortised cost using the effective interest method.

Impairment

The Company assesses at each balance sheet date whether there is objective evidence that a financial asset or a company of financial assets is impaired.

Loans and receivables

An allowance for impairment of loans and receivables, including trade and other receivables is recognised when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganization and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of allowance is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. The amount of the allowance for impairment is recognised in the income statement within "Administrative expenses".

AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015

2. SIGNIFICANT ACCOUNTING POLICIES CONTD...

2.6 Financial assets Contd...

Classification

The Company classifies its financial assets as loans and receivables. The classification depends on the purpose for which the assets were acquired. Management determines the classification of its financial assets at initial recognition and re-evaluates this designation at every reporting date.

2.7 Share capital

Incremental external costs directly attributable to the issue of new shares, other than on a business combination, are shown in equity as a deduction, net of tax, from the proceeds. Share issue costs incurred directly in connection with a business combination are included in the cost of acquisition.

2.8 Going concern

The financial statements are prepared on a going concern basis on the assumption that the Company will be able to obtain the necessary financial support from the holding company to continue its operations as a going concern.

3. (LOSS) BEFORE TAX

	2015	2014
	S\$	S\$
Professional fees	8,450	6,772

4. TAX EXPENSE

No provision for tax has been made hence the Company has not been started their business.

The tax expense differs from the amount that would arise using the Singapore Standard Rate alignment of income tax as follows:

	2015	2014
	S\$	S\$
(Loss) before taxation	(13,037)	(8,532)
Tax at statutory rate of 17% (2014: 17%)	(2,216)	(1,451)
Tax effect on non-deductibles	2,216	1,451
	-	-

5. CASH AND CASH EQUIVALENTS

	2015	2014
	S\$	S\$
Cash at bank	170	2,484
	170	2,484

AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015

6. SHARE CAPITAL

The Company's share capital comprises of 100,000 (2014: 90,000) ordinary fully paid up shares with no par value with a total amounting to S\$100,000/- (2014: S\$90,000/-) The ordinary shares entitle for dividend as and when declared and carry one vote per share without restriction.

During the year the Company has increased its share capital from 90,000 to 100,000 by allotting 10,000 ordinary shares for cash consideration.

7. FINANCIAL RISK MANAGEMENT

Since the Company is not started their business, hence the financial risk management is not applicable.

8. FINANCIAL INSTRUMENTS BY CATEGORY

The carrying amount of the difference categories of financial instrument is as follows:

	2015	2014
	S\$	S\$
Loans and receivables	170	2,484
Financial liabilities at amortised cost	1,900	1,177

9. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to ensure that the Company is adequately capitalized and to maintain an optimal capital structure by issuing or redeeming additional equity and debt instruments when necessary.

The Board of Director's monitors its capital based on gearing ratio. Gearing ratio is computed as net debt divided by total capital. Net debt is calculated as borrowings plus trade and other payables less cash and bank deposits. Total capital is calculated as equity plus net debt.

The Company is not subject to any externally imposed capital requirements.

	2015	2014
	S\$	S\$
Net debt	1,730	-
Total equity	870	3,907
Total capital	2,600	3,907
Gearing ratio	67%	-

AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015

10. NEW OR REVISED STANDARDS AND INTERPRETATIONS

The Company has not adopted the following standards and interpretations that have been issued but not yet effective:

Annual periods commencing on	Description
1 July 2014	Amendments to FRS 19 (R) <i>Employee Benefits</i> - <i>Defined Benefit Plans:employee Contributions</i>
	Annual improvements 2012 -FRS 102 <i>Share-Based Payment</i> -FRS 103 <i>Business Combinations</i> -FRS 108 <i>Operating segments</i> -FRS 16 <i>Property, Plant & Equipment</i> -FRS 38 <i>Intangible Assets</i> -FRS 24 <i>Related Party Disclosures</i>
	Annual improvements 2013 -FRS 103 <i>Business Combinations</i> -FRS 113 <i>Fair Value Measurement</i> -FRS 40 <i>Investment Property</i>
1 January 2016	-FRS 114 <i>Regulatory Deferral</i>

The initial application of these standards and interpretations, where applicable, are not expected to have any material impact on the financial statements of the Company

AUROBINDO PHARMA (SINGAPORE) PTE .LTD.
(INCORPORATED IN THE REPUBLIC OF SINGAPORE)

This does not form part of audited financial statements

DETAILED PROFIT AND LOSS ACCOUNT FOR THE FINANCIAL YEAR ENDED 31 MARCH 2015

	2015	2014
	S\$	S\$
Revenue	-	-
Expenses		
Accounting fee	2,500	-
Audit fee	1,000	1,122
Bank charges	490	430
Fee for license under registration	1,200	900
Misc expenses	397	430
Nominee Director fees	3,000	3,000
Registered office fee	1,000	950
Secretarial service fees	1,700	1,700
Tax service fees	1,750	-
Net(loss) for the year	<u>(13,037)</u>	<u>(8,532)</u>

AUROBINDO PHARMA LIMITED, S. R. L.

**Independent Auditor's Report and Financial Statements
For the period of nine months and eighteen days ended on December 18, 2014
and one year ended on March 31, 2014**

AUROBINDO PHARMA LIMITED, S. R. L.

CONTENTS

FINANCIAL STATEMENTS FOR THE PERIOD OF NINE MONTHS AND EIGHTEEN DAYS ENDED ON DECEMBER 18, 2014 AND ONE YEAR ENDED ON MARCH 31, 2014

Independent Auditor's Report	1-2
Statements of Financial Position	3
Statements of Comprehensive Income	4
Statements of Changes in Equity	5
Statements of Cash Flow	6
 NOTES TO THE FINANCIAL STATEMENT	 7-11

INDEPENDENT AUDITORS REPORT

To the Liquidator of AUROBINDO PHARMA LIMITED, S.R.L.

We have audited the accompanying financial statements of AUROBINDO PHARMA LIMITED, S.R.L., which comprise the statements of financial position at December 18, 2014, and the statements of operations, changes in equity and cash flows for the period, and a summary of significant accounting policies and other explanatory notes.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with International Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

Auditor's Responsibility (continuation)

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of AUROBINDO PHARMA LIMITED, S.R.L., at December 18, 2014, its financial performance and its cash flows for the period ended in accordance with International Financial Reporting Standards.

Emphasis Matter

By the Extraordinary Shareholders Meeting held on October 5th 2014, the shareholders of Aurobindo Pharma Limited, S.R.L., agreed to and resolved to dissolve and liquidate the Company effective on the date of the meeting. As the subsidiary was liquidated, the leftover money by value of DOP 180,458 will be paid back to stockholder Helix Healthcare BV, Netherlands.

Baker Tilly R.D.

April 17, 2015
Santo Domingo,
Dominican Republic

AUROBINDO PHARMA LIMITED, S.R.L.

STATEMENTS OF FINANCIAL POSITION

**For the period of nine months and eighteen days ended on December 18, 2014
and one year ended on March 31, 2014
(Values in DOP)**

	Notes	December 2014	March 2014
ASSETS			
Current Assets:			
Cash	4	-	469,813
Other receivable		180,458	-
Prepaid expenses	5	-	197,119
Total current assets		<u>180,458</u>	<u>666,932</u>
LIABILITIES AND STOCHOLDERS'S EQUITY			
Current liabilities			
Accounts payable, suppliers	6	-	30,900
Tax payable		-	6,669
Total Current liabilities		<u>-</u>	<u>37,569</u>
STOCKHOLDER'S EQUITY			
Common Stock	7	-	100,000
Paid in capital		180,458	1,698,928
Net loss		-	(1,169,565)
Total Stockholder's Equity		<u>180,458</u>	<u>629,363</u>
		<u>180,458</u>	<u>666,932</u>

See accompanying notes to financial statements

AUROBINDO PHARMA LIMITED, S.R.L.

STATEMENTS OF COMPREHENSIVE INCOME

**For the period of nine months and eighteen days ended on December 18, 2014
and one year ended on March 31, 2014
(Values in DOP)**

	Notes	December 2014	March 2014
Revenue			
Revenue from operations		-	-
Operational expenses			
General and administrative expenses	8	444,261	544,089
Total operational expenses		<u>444,261</u>	<u>544,089</u>
Gross loss		<u>(444,261)</u>	<u>(544,089)</u>
Other income and (expenses)			
Financial expenses		-	(16,218)
Other income		680	17,793
Loss before income tax		<u>(443,581)</u>	<u>(542,514)</u>
Tax assets		<u>(5,324)</u>	<u>(6,669)</u>
		<u><u>(448,905)</u></u>	<u><u>(549,183)</u></u>

See accompanying notes to financial statements

AUROBINDO PHARMA LIMITED, S.R.L.

STATEMENT OF CHANGES IN EQUITY

**For the period of nine months and eighteen days ended on December 18, 2014
and one year ended on March 31, 2014
(Values in DOP)**

	Common Stock	Paid in capital	Retained Loss	Total
Balance as of March 31, 2013	100,000	683,391	(620,382)	163,009
Increase in paid capital		1,015,537		1,015,537
Net loss			(549,183)	(549,183)
Balance as of March 31, 2014	100,000	1,698,928	(1,169,565)	629,363.00
Results			(448,905)	(448,905)
Distribution of wealth	(100,000)	(1,518,470)	1,618,470	-
Balance as of December 18, 2014	-	180,458	-	180,458

See accompanying notes to financial statements

AUROBINDO PHARMA LIMITED, S.R.L.

STATEMENT OF CASH FLOW

**For the period of nine months and eighteen days ended on December 18, 2014
and one year ended on March 31, 2014
(Values in DOP)**

	December 2014	March 2014
Cash flow from operating activities		
Net loss	(448,905)	(549,183)
Changes in assets and liabilities:		
Other receivable	(180,458)	-
Prepaid expenses	197,119	(97,256)
Accounts payables suppliers	(30,900)	588
Tax payable	(6,669)	4,716
Net cash used in operating activities	<u>(469,813)</u>	<u>(641,135)</u>
Cash flow from financial activities		
Common Stock Increase		1,015,537
Distribution of wealth	-	-
Net cash (used in) provided by financial activities	<u>-</u>	<u>1,015,537</u>
Net increase in cash	<u>(469,813)</u>	<u>374,402</u>
Cash and cash equivalents, at the beginning of period	<u>469,813</u>	<u>95,411</u>
Cash and cash equivalents, at the end of period	<u><u>-</u></u>	<u><u>469,813</u></u>

See accompanying notes to financial statements

AUROBINDO PHARMA LIMITED, S.R.L.

NOTES TO THE FINANCIAL STATEMENTS

For the period of nine months and eighteen days ended on December 18, 2014

and one year ended on March 31, 2014

(Values expressed in DOP)

1. Entity

Aurobindo Pharma Limited, S.R.L., is a commercial entity incorporated pursuant to the laws of the Dominican Republic. The principal activity of the company is the importation, exportation, distribution and commercialization of pharmaceutical products.

As of December 18, 2014 the Company was liquidated and its name was struck from mercantile registry.

2. Summary of significant accounting policies

The significant accounting policies adopted by the Company to prepare its Financial Statements are described as follows:

2.1 Statement of conformity

These significant statements were prepared in accordance with International Financial Reporting Standards. These Financial statements have been prepared under historical cost measurement basis.

2.2 Measurement basis

Financial statement have been prepared under historical cost basis.

2.3 Functional currency and presentation

Financial statement are presented in Dominican pesos (RD\$), which is the functional currency of the company.

2.4 Use of estimates

Financial statements are prepared

Preparation of financial statement in accordance with the International Financial Reporting Standards requires that management perform judgments and estimates affecting the accounting policies and quantities reported of assets, liabilities, income and expenses. Result of these estimates could be different to real.

Estimated are reviewed continuously and the effect of these changes, if an, are recognize during the period of change and future periods, if they are affected.

AUROBINDO PHARMA LIMITED, S.R.L.

NOTES TO THE FINANCIAL STATEMENTS

For the period of nine months and eighteen days ended on December 18, 2014

and one year ended on March 31, 2014

(Values expressed in DOP)

3. Summary of Significant Accounting Policies

The significant accounting policies adopted by the Company to prepare its financial statements are described as follows:

3.1 Functional Currency and Foreign Currency Transactions.

The Dominican pesos is the functional currency of the Company's operations. Assets and liabilities have been translated at the rate of exchange on the balance sheet date. Revenues and expenses have been translated at the rate of exchange at the date of the transaction. The related foreign exchange gain and losses arising from the transactions are included in other income in the statement of comprehensive income. At December 18, 2014 and March 31, 2014 exchange rate was RD\$ 43.74 and RD\$43.03 per US\$ 1.00, respectively, in relation with US dollar.

3.2 Cash

For the purpose of the statements of cash flows, the Company considers as cash and cash equivalent all cash on hand, cash in banks, time deposits and highly liquid debt instruments with original maturities of three months or less. At the respective dates of the financial statements, there was no restriction over cash and cash equivalents balances.

Common stock

Common stock is classified as stockholder's equity. Cost of share is considered as a deduction from equity, net from any tributary effect.

3.3 Revenues Recognition

The Company's revenues are recognized under the accrual method.

3.4 Other Income (expense), net

Other income comprises investment interest and gain or loss in exchange rate. Interest income is recognized when occurred.

3.5 Income Tax

Current tax is the expected tax payable based on the taxable income for the year as established by the Tributary of the Dominican Republic and its modifications, using the tax rate in effect at the date of the statement of financial position.

AUROBINDO PHARMA LIMITED, S.R.L.

NOTES TO THE FINANCIAL STATEMENTS

For the period of nine months and eighteen days ended on December 18, 2014

and one year ended on March 31, 2014

(Values expressed in DOP)

Income taxes are accounted for under the asset and liabilities method. Deferred tax assets and liabilities are recognize for the future tax consequences attributable to different between the carrying amounts if exiting assets and liabilities and their respective tax based and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

3.6 Fair value of Financial Instruments

The fair value of financial instruments, consisting mainly of cash, currents accounts receivable, and accounts payable suppliers and related parties, approximate theirs carrying values due to their short maturity or short time until realization.

The Company deposits its excess cash in prime financial institutions, limiting credit risk.

3.7 Amendment power of Financial Statements

These financial statements were prepared by management in a voluntary manner, and consequently they have the ability to review the financial statements contained after the issuance of this report. General Management has approved and authorized the issuance of these financial statements and its accompanying notes on April 17, 2015.

4. Cash

Cash consist of:

	December 2014	March 2014
Cash in banks	-	469,813
	-	469,813

AUROBINDO PHARMA LIMITED, S.R.L.

NOTES TO THE FINANCIAL STATEMENTS

For the period of nine months and eighteen days ended on December 18, 2014

and one year ended on March 31, 2014

(Values expressed in DOP)

5. Prepaid expenses

Prepaid expenses consist of:

	December 2014	March 2014
ITBIS in advanced services	-	197,119
	-	197,119

6. Accounts payable, suppliers

Accounts payable suppliers consist of:

	December 2014	March 2014
Local suppliers	-	30,900
	-	30,900

7. Common Stock

At December 18, 2014, the Company was undergoing a dissolution. Therefore, its equity was distributed among the shareholders. The leftover paid in capital by the value of DOP 180,458 will be payable to the Stock Holder Helix Healthcare BV, Netherlands. As of March 31, 2014 the company's equity of 100,000 DOP consist of one hundred thousand (100) shares, each with the par value of one hundred Dominican Pesos (1,000 DOP) and all shares being of the same class and the same series, having equal rights in all matters.

AUROBINDO PHARMA LIMITED, S.R.L.

NOTES TO THE FINANCIAL STATEMENTS

For the period of nine months and eighteen days ended on December 18, 2014

and one year ended on March 31, 2014

(Values expressed in DOP)

8. General and administrative expenses

At December 18, 2014 and March 31, 2014, general and administrative expenses consist of:

	December 2014	March 2014
Accounting and auditing fees	-	272,937
Legal fees	108,439	271,152
Expenses dissolution	335,648	-
Other	174	-
	444,261	544,089



For the Board of directors and shareholders of

Aurovida Farmacéutica, S.A. de C.V.

Mexico, D.F. May 6th, 2015,

We have audited the financial statements of Aurovida Farmacéutica, S.A. de C.V., corresponding to the Balance Sheet and Income Statement for the period from April 1st 2014, as of March 31st, 2015 and a summary of significant accounting policies and other explanatory information.

The management is responsible for the preparation and fair presentation of these financial statements in accordance with Mexican Financial Reporting Standards and internal control that management deems necessary to permit preparation of financial statements free material deviation due to fraud or error.

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with International Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free material deviation.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks material deviation in the financial statements due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the preparation and fair presentation of the Company's financial statements in order to design audit procedures that are appropriate depending on the circumstances, and not for the purpose of expressing an opinion on the effectiveness of internal control of the Company. An audit also includes evaluating the appropriateness of accounting policies applied and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements as a whole.


We believe that the audit evidence we have obtained in our audits provide a sufficient and adequate for our audit opinion base.

Av. Col. Del Valle No. 318-401 Col. Del Valle CP. 03100 Benito Juárez México D.F. Tel 5536-1834 y 1107-8138 WEB: www.camsasesores.com

For the scope of this audit, we have compared the financial information presented by Aurovida Farmacéutica, SA de CV, related to the period from April 1st 2014 ending March 31st 2015, against the financial information for the same period as of 2013.

During the period audited, the company began commercial operation, thus, the costs that were recorded as pre operating according to the company policy began to be recorded directly to income, and be presented in the income statement.

In our opinion, the financial statements present fairly, in all material respects, the financial position of Aurovida Farmacéutica, SA de CV at March 31st, 2015 and its results and its cash flows for the years then ended, in accordance with Mexican Financial Reporting Standards.



C.P.R. Ricardo Tulio Cano Gonzalez

External Auditor

No. C.P.R. 2833

DIRECTORS' REPORT

The directors present their report and the audited financial statements for the year ended March 31st 2015.

PRINCIPAL ACTIVITY

The principle object of the company is to trade and deal in pharmaceutical products and other allied products and services.

REVIEW OF OPERATIONS

Your company had registered a loss of MXN 9,429,070 against a Sale of MXN 6,617,416. Your company had started its Commercial activities in the current financial year only. During the previous year the company had registered a loss of MXN 2,611,646.

Unusual Items after the Financial Year:

No item, transaction or event of a Material nature has arisen during the period between the end of the financial year and the date of this report, which would affect substantially the operations of the company during the current year.

Statement of Directors:


In the opinion of the Directors, the accompanying Financial statements were drawn up so as to give a true and fair view of the state of affairs of the Company as on 31st March 2015 and the results of the business for that period. Your Directors have taken all reasonable steps to prepare these financial statements on a going concern basis and suitable accounting policies have been adopted consistently. Further your Directors are confident that with the support and guidance of the Holding company, your Company can achieve better results in the future.

DIRECTORS

The Directors at the date of the report are:

1. Mr. Phaneendra Prasad Gorla
2. Mr. Michael Joseph Padvaiskas Ackerman
3. Mr. P.V. Ram Prasad Reddy

By Order of the Board:



Mr. Michael Joseph Padvaiskas Ackerman
Director
Mexico



Aurovida Farmacéutica, SA de CV
Balance Sheet as at March 31, 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

	Note	31 March, 2015 (MXP)	31 March, 2014 (MXP)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	85,516,360	52,492,722
Share application money			
Reserves and surplus	3	(12,070,705)	(2,641,635)
		<u>73,445,654</u>	<u>49,851,087</u>
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	52,474	54,431
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		<u>52,474</u>	<u>54,431</u>
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	4,424,686	1,729,474
Other current liabilities	9	-	-
Short-term provisions	7	-	-
		<u>4,424,686</u>	<u>1,729,474</u>
TOTAL		<u><u>77,922,814</u></u>	<u><u>51,634,992</u></u>
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	12,935,186	10,407,151
Intangible assets	11	8,183,703	1,304,701
Capital work-in-progress			
Intangible assets under development		25,176,418	21,417,681
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	106,660	98,160
Trade receivables	14.1	-	-
Other non-current assets	14.2	-	-
		<u>46,401,967</u>	<u>33,227,693</u>
Current assets			
Current investments	15	-	-
Inventories	16	7,239,474	1,811,593
Trade receivables	14.1	4,610,691	237,000
Cash and bank balances	17	1,375,559	303,079
Short-term loans and advances	13	35,646	2,071
Other current assets	14.2	18,259,478	16,053,556
		<u>31,520,847</u>	<u>18,407,299</u>
TOTAL		<u><u>77,922,814</u></u>	<u><u>51,634,992</u></u>
Summary of significant accounting policies	1		
The accompanying notes are an integral part of the financial statements.			


 C.P. Ricardo Tulio Cano Gonzalez
 External Auditor
 No. C.P.R. 2833

Industria, SA de CV
of profit and loss for the year ended March 31, 2015
(Units are in Local Currency except share data and unless otherwise stated)

	Note	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	March-15	Year ended March 31, 2015 (MXP)	Year ended March 31, 2014 (MXP)
Income															
Revenue from operations (gross)	18	998,400	-	(815,050)	308,500	721,175	693,018	963,420	386,300	563,888	1,063,856	918,676	815,233	6,617,416	737,000
Less: Excise duty/ Rebates		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from operations (net)		998,400	-	(815,050)	308,500	721,175	693,018	963,420	386,300	563,888	1,063,856	918,676	815,233	6,617,416	237,000
Other income	19	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenue (I)		998,400	-	(815,050)	308,500	721,175	693,018	963,420	386,300	563,888	1,063,856	918,676	815,233	6,617,416	237,000
Expenses															
Cost of raw material and components consumed	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods	21	739,831	6,274,516	1,297,458	-	-	-	994,228	95,000	555,982	-	-	-	9,957,015	2,040,323
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	(153,400)	(6,250,251)	(1,757,888)	240,951	471,834	455,400	(471,859)	149,891	16,122	733,913	661,627	475,721	(5,427,881)	(1,811,593)
Employee benefit expense	22	268,920	268,920	268,920	268,920	391,415	176,691	309,131	403,455	348,280	343,586	329,236	347,706	3,725,180	658,335
Other expenses	23	410,927	417,483	535,851	479,856	416,394	610,404	517,449	456,736	628,562	422,512	461,577	577,255	5,935,007	698,148
Exceptional items	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total (II)		1,266,279	710,668	344,341	989,726	1,279,643	1,242,495	1,348,950	1,105,083	1,548,945	1,500,011	1,452,441	1,400,683	14,189,321	1,585,212
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		(267,879)	(710,668)	(1,159,391)	(681,226)	(558,468)	(549,477)	(385,530)	(718,783)	(985,057)	(436,155)	(533,764)	(585,450)	(7,571,905)	(1,348,212)
Depreciation and amortization expense	25	130,912	137,489	142,031	142,315	143,921	144,383	144,452	146,393	146,697	146,827	166,435	259,807	1,851,660	1,263,434
Finance costs	26	387	196	382	406	230	228	248	29	250	2,708	212	229	5,505	-
Profit/(loss) before tax		(399,178)	(848,353)	(1,301,803)	(823,947)	(702,619)	(694,088)	(530,229)	(865,205)	(1,132,003)	(585,690)	(700,412)	(845,485)	(9,429,070)	(2,611,646)
Tax expenses															
Current tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: MAT credit entitlement		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fringe benefit tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax relating to previous years		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total tax expense		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Profit/(loss) for the year		(399,178)	(848,353)	(1,301,803)	(823,947)	(702,619)	(694,088)	(530,229)	(865,205)	(1,132,003)	(585,690)	(700,412)	(845,485)	(9,429,070)	(2,611,646)

Summary of significant accounting policies

The accompanying notes are an integral part of the financial statements.

C.P. Ricardo Tulio Cano Gonzalez
External Auditor
No. C.P.R. 2833

Aurovida Farmacéutica, SA de CV
 Notes to the Balance Sheet
 (All amounts are in Local Currency except share data and unless otherwise stated)

Note 1: Summary of significant accounting policies (Refer General Instructions Note No.1)

- 1.1
- 1.2
- 1.3
- 1.4
- 1.5

Note 2: Share capital (Refer General Instructions Note No.2)

	March 31, 2015	March 31, 2014
Authorized shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of XXXX each	85,516,360	52,492,722
XXXXXXXX (31 March, 2014: XXXXXXXX) preference shares of XXX each	85,516,360	52,492,722
Issued, Subscribed and Fully Paid-up shares:		
XXXXXXXX (31 March, 2014: XXXXXXXX) equity shares of XXXX each fully paid-up	85,516,360	52,492,722

C.P. Ricardo Tullio Cano Gonzalez
 External Auditor
 No. C.P.R. 2833

Aurovida Farmacéutica, SA de CV
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

Note 3 : Reserves and surplus (Refer General Instructions Note No.3)

	March 31, 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet		
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet		
General Reserve		
As per last Balance Sheet		
Add: Transferred from statement of profit and loss		
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	(2,641,635)	(29,989)
Profit for the quarter	(9,429,070)	(2,611,646)
Less: Appropriations		
Proposed final equity dividend (amount per share XX (31 March, 2014 XX)		
Tax on proposed equity dividend		
Interim dividend paid (amount per share XX (31 March, 2014 XX)		
Transfer to general reserve		
Total appropriations		
Net surplus in the statement of profit and loss	(12,070,705)	(2,641,635)
Total reserves and surplus	(12,070,705)	(2,641,635)

Note 4 : Long-term borrowings (Refer General Instructions Note No.4)

	Non-current Portion		Current maturities	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Term Loans				
From banks (Secured)				
Other Loans from banks				
Current account credit balance				
Loans and advances from related parties				
Other Loans and advances				
Sales tax deferment loan (Un Secured)				
The above amount includes				
Secured borrowings				
Unsecured borrowings				
Amount disclosed under the head				
"Other current liabilities"				
Net Amount				

C.P. Ricardo Tulio Cano González
External Auditor
No. C.P.R. 2833

Note 5 : Deferred tax liability (net)

	March 31, 2015	March 31, 2014
Deferred tax liability		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis	-	-
Provision for diminution in the value of investments	-	-
Provision for doubtful debts and advances	-	-
Fixed Assets (Depreciation)	-	-
Retirement Benefits	-	-
Others	52,474	54,431
Gross deferred tax liability	52,474	54,431
Deferred tax asset		
Earned Forward Business Losses	-	-
Others	-	-
Gross deferred tax asset	-	-
Net deferred tax liability	52,474	54,431

Note 6 : Other long-term liabilities (Refer General Instructions Note No.5)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances)	-	-
Other liabilities	-	-
Advances from related parties	-	-

Note 7 : Provisions (Refer General Instructions Note No.6 & 10)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Provision for employee benefits				
- Gratuity	-	-	-	-
- Leave encashment	-	-	-	-
Other Provisions				
For Taxation (net of advance payments)	-	-	-	-
For Proposed dividend	-	-	-	-
For revaluation of Liability	-	-	-	-
For Tax on proposed dividend	-	-	-	-

Provision for warranties

	March 31, 2015	March 31, 2014
At the beginning of the year	-	-
Arising during the period	-	-
Utilised during the period	-	-
Unused amounts reversed	-	-
At the end of the year	-	-
Current portion	-	-
Non-current portion	-	-

Note 8 : Short-term borrowings (Refer General Instructions Note No.7)

	March 31, 2015	March 31, 2014
Bank overdraft	-	-
Loans and advances from related parties	-	-
Working capital loans (Secured)	-	-
Short term loans (Un Secured)	-	-
Working capital loans	-	-
The above amount includes		
Secured borrowings	-	-
Unsecured borrowings	-	-

Note 9 : Other current liabilities (Refer General Instructions Note No.9)

	March 31, 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)	4,424,686	1,729,474
Other liabilities		
Current maturities of long-term borrowings	-	-
Advances from customers	-	-
Unclaimed dividends	-	-
Interest accrued but not due on loans	-	-
Trade deposits	-	-
	4,424,686	1,729,474

C.P. Ricardo Tulio Cano Gonzalez
External Auditor
No. C.P.R. 2833

Aurovida Farmacéutica, SA de CV

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 10: Tangible assets (Refer General Instructions Note No.11)

	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment	Computers	Computer Software	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation											
At 1 April 2013		6,102,669.0		478,520.0		184,253.7		255,870.5			7,021,313
Additions		2,388,523.6			1,018,552.0	59,036.0		137,285.0			3,603,397
Disposals											-
Other adjustments											-
- Exchange differences											-
- Borrowing costs											-
At 31 March 2014	-	8,491,193	-	478,520	1,018,552	243,290	-	393,156	-	-	10,624,710
Additions		2,597,953.0		23,203.5		40,183.0		90,483.2			2,751,823
Acquisitions through amalgamation											-
Disposals											-
Other adjustments											-
- Exchange differences											-
- Borrowing costs											-
At 31 March 2015	-	11,089,146	-	501,723	1,018,552	283,473	-	483,639	-	-	13,376,532
Depreciation											
At 1 April 2013				11,963.0		13,509.0		4,517.0			29,989
Charge for the year				47,851.0	38,747.0	69,601		31,371			187,570
Disposals											-
Other adjustments											-
- Exchange differences											-
At 31 March 2014	-	-	-	59,814	38,747	83,110	-	35,888	-	-	217,559
Charge for the period				49,777.0	50,927.1	76,998.9		46,084.8			223,788
Disposals											-
Other adjustments											-
- Exchange differences											-
At 31 March 2015	-	-	-	109,591	89,674	160,109	-	81,973	-	-	441,347
Impairment loss											
At 1 April 2013											
At 31 March 2014											
Charge for the period											
At 31 March 2015											
Net Block											
At 31 March 2014	-	8,491,193	-	418,706	979,805	160,180	-	357,268	-	-	10,407,151
At 31 March 2015	-	11,089,146	-	392,132	928,878	123,364	-	401,666	-	-	12,935,186

C.P. Ricardo Tulio Cano Gonzalez

External Auditor

No. C.P.R. 2833

602

Aurovida Farmacéutica, SA de CV

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 11 : Intangible assets (Refer General Instructions Note No.12)

	Goodwill	Product Development cost	Licences and patents	Total
Gross block				
At 1 April 2013			550,829	550,829
Purchase			792,488	792,488
Internal development			-	-
Disposals			-	-
Other adjustments			-	-
- Exchange differences			-	-
At 31 March 2014	-	-	1,343,317	1,343,317
Purchase			704,999.2	7,049,991
Acquisitions through amalgamation			-	-
Disposals			-	-
Other adjustments			-	-
- Exchange differences			-	-
At 31 March 2015	-	-	8,393,308	8,393,308
Amortization				
At 1 April 2013			2,295	2,295
Charge for the year			36,321	36,321
Disposals			-	-
Other adjustments			-	-
- Exchange differences			-	-
At 31 March 2014	-	-	38,616	38,616
Charge for the period			170,989.6	170,990
Disposals			-	-
Other adjustments			-	-
- Exchange differences			-	-
At 31 March 2015	-	-	209,606	209,606
Net Block				
At 31 March 2014	-	-	1,304,701	1,304,701
At 31 March 2015	-	-	8,183,703	8,183,703

C.P. Ricardo Tulio Cano Gonzalez

External Auditor

No. C.P.R. 2833

Note 12: Non-current investments (Refer General Instructions Note No.13)

	March 31, 2015	March 31, 2014
Unquoted equity instruments		
Investment in subsidiaries		
Investment in joint ventures		
Investment in associates		

Note 13: Loans and advances (Refer General Instructions Note No.14 & 21)

		Non-current		Current	
		March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Capital advances					
Secured, considered good		106,660	98,160		
Unsecured, considered good	(A)	106,660	98,160	-	-
Security deposit					
Secured, considered good					
Unsecured, considered good					
Doubtful					
Provision for doubtful security deposit	(B)	-	-	-	-
Loan and advances to related parties					
Unsecured, considered good	(C)	-	-	-	-
Advances recoverable in cash or kind					
Secured, considered good				31,650	2,071
Unsecured, considered good					
Doubtful					
Provision for doubtful advances	(D)	-	-	31,650	2,071
Other loans and advances					
Advance income-tax (net of provision for taxation)				3,996	
Prepaid expenses					
Loans to employees					
Loans to others					
Export incentives receivable					
Export incentives licenses					
Balances with Statutory / government authorities	(E)	-	-	3,996	-
Total (A+B+C+D+E)		106,660	98,160	35,646	2,071

Loans and advances due by directors or other officers, etc.

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Loans to employees include				
Dues from non-executive directors				
Dues from officers				
Dues from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner				
Dues from in which the company's managing director is a member				
Dues from the partnership firm in which the company's non-executive director is a partner				

C.P. Ricardo Tulio Cano Gonzalez
External Auditor
No. C.P.R. 2833

Note 14: Trade receivables and other assets

14.1 Trade receivable (Refer General Instructions Note No 15 & 19)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment			-	-
Secured, considered good				
Due from group companies				
Due from others			-	-
Unsecured, considered good				
Due from group companies				
Due from others			286,792	-
Doubtful				
Provision for doubtful receivables	-	-	286,792	-
(A)	-	-	286,792	-
Other receivables outstanding for a period less than six months from the date they are due for payment				
Secured, considered good				
Due from group companies				
Due from others				
Unsecured, considered good				
Due from group companies				
Due from others			4,323,899	237,000
Doubtful				
Provision for doubtful receivables	-	-	4,323,899	237,000
(B)	-	-	4,323,899	237,000
Total (A+B)	-	-	4,610,691	237,000

Trade receivables include:

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				
(A)	-	-	-	-
Unamortized expenditure				
Pre-operative expenditure to be written-off			10,094,232	10,762,666
Ancillary cost of arranging the borrowings				
(B)	-	-	10,094,232	10,762,666
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on investments in subsidiaries - long term			8,165,246	5,290,889
Others				
(C)	-	-	8,165,246	5,290,889
Total (A+B+C)	-	-	18,259,478	16,053,556

C.P. Ricardo Tulin Cano González
External Auditor
No. C.P.R. 2833

Aurovida Farmacéutica, SA de CV
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

Note 15: Current investments (Refer General Instructions Note No.17)

	March 31, 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any? (Please specify)		

Note 16: Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)

	March 31, 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2014 XXX)		
Work - in - Progress		
Finished goods		
Traded goods (including stock -in-transit XXXX (31 March, 2014 XXX)	7,239,474	1,811,593
Stores, spares, consumables and packing materials		
Loose tools		
	<u>7,239,474</u>	<u>1,811,593</u>

Note 17: Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	March 31, 2015	March 31, 2014	March 31, 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			1,372,559	300,079
Deposits with original maturity of less than 3 months				
Cash credit accounts				
On unpaid dividend account				
Cheques/drafts on hand			3,000	3,000
Unpaid matured deposits				
Cash on hand				
			<u>1,375,559</u>	<u>303,079</u>
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
Amount disclosed under non-current assets			<u>1,375,559</u>	<u>303,079</u>

C.P. Ricardo Tulio Cano Gonzalez
External Auditor
No. C.P.R. 2833

Aurovida Farmaceutica, SA de CV
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 18 : Revenue from operations (Refer General Instructions Note No.23)														
Revenue from operations														
Sale of products														
Finished goods	998,400		(815,050)	308,500	721,175	693,018	963,420	386,300	563,888	1,063,856	918,676	815,233	6,617,416	237,000
Traded goods													-	
Sale of services													-	
Sale of dossiers/licenses													-	
Other operating revenue													-	
Scrap sales													-	
Other													-	
Revenue from operations (gross)	998,400	-	(815,050)	308,500	721,175	693,018	963,420	386,300	563,888	1,063,856	918,676	815,233	6,617,416	237,000
Less: VAT/Excise duty/ Rebates													-	
Revenue from operations (net)	998,400	-	(815,050)	308,500	721,175	693,018	963,420	386,300	563,888	1,063,856	918,676	815,233	6,617,416	237,000

Note 19 : Other income (Refer General Instructions Note No.26)

Interest income on														
Bank deposits													-	
Long-term investments													-	
Current investments													-	
Loans to joint venture entities													-	
Others													-	
Dividend income on													-	
Investment in subsidiaries													-	
Current investments													-	
Long-term investments													-	
Net gain on sale of current investments													-	
Profit on sale of fixed assets (net)													-	
Foreign exchange gain (net)													-	
Balances no longer required written back													-	
Government grant													-	
Commission income													-	
Processing charges													-	
Other non-operating income (net of expenses directly attributable to such income of Rs.XXXXX (31 March, 2014:XXXX)													-	
	-	-	-	-	-	-	-	-	-	-	-	-	-	-

C.P. Ricardo Tulio Cano Gonzalez
External Auditor
No. C.P.R. 2833

Note 20 : Cost of raw material and components consumed
Inventory at the beginning of the period
Add: Purchases

Aurovida Farmaceutica, SA de CV

Notes to the statement of profit and loss

(All amounts are in Laxal Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Less: inventory at the end of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add: Packing material consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of raw material and components consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-

C.P. Ricardo Tullio Cano Gonzalez

External Auditor

No. C.P.R. 2833

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 21 : (Increase)/decrease in inventories														
Inventories at the end of the period														
Traded goods	1,964,935	8,215,187	9,973,074	9,732,124	9,260,290	8,804,890	9,276,748	9,126,857	9,110,735	8,376,822	7,715,195	7,239,474	7,239,474	1,811,593
Work-in-progress														
Finished goods														
	1,964,935	8,215,187	9,973,074	9,732,124	9,260,290	8,804,890	9,276,748	9,126,857	9,110,735	8,376,822	7,715,195	7,239,474	7,239,474	1,811,593
Inventories at the beginning of the period														
Traded goods	1,811,536	1,964,935	8,215,187	9,973,074	9,732,124	9,260,290	8,804,890	9,276,748	9,126,857	9,110,735	8,376,822	7,715,195	1,811,593	
Work-in-progress														
Finished goods														
	1,811,536	1,964,935	8,215,187	9,973,074	9,732,124	9,260,290	8,804,890	9,276,748	9,126,857	9,110,735	8,376,822	7,715,195	1,811,593	-
	153,400	6,250,251	1,757,888	(240,951)	(471,834)	(455,400)	471,859	(149,891)	(16,122)	(733,913)	(661,627)	(475,721)	5,427,881	1,811,593
Details of purchase of traded goods														
CEFOTAXIME														759,220
CEFTRIAXONA														1,281,103
WFI 10ml														
MEROPENEM INJ 1G	601,725	5,009,069											5,610,794	
MEROPENEM INJ 500MG	138,106	1,265,448											1,403,554	
TRAMADOL 100MG			1,095,537						454,685				1,550,223	
TRAMADOL 50MG			201,920						101,296				303,217	
IMPENEM & CILASTATINA							994,228						994,228	
WFI 4ml								95,000					95,000	
	739,831	6,274,516	1,297,458	-	-	-	994,228	95,000	555,982	-	-	-	9,957,015	2,040,323
Note 22 : Employee benefit expense														
Salaries, wages and bonus	268,920	268,920	268,920	268,920	268,920	176,691	309,131	403,455	333,280	308,466	329,236	347,706	3,552,566	647,736
Contribution to provident and other fund													-	
Employee stock option scheme													-	
Gratuity expense													-	
Other employee benefits					122,495				15,000	35,120			172,615	10,599
Post employment medical benefits													-	
Staff welfare expenses													-	
	268,920	268,920	268,920	268,920	391,415	176,691	309,131	403,455	348,280	343,586	329,236	347,706	3,725,180	658,335

C.P. Ricardo Tulio Cano Gonzalez
External Auditor
No. C.P.R. 2833

Leutica, SA de CV
Statement of profit and loss
(Amounts are in local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Note 23: Other expenses														
Consumption of stores and spares													-	-
Conversion charges													-	-
Chemicals consumed													-	-
Increase in VAT on finished goods													-	-
Customer service expenditure													-	-
Power and fuel							7,367		8,275		7,016		22,659	
Water charges			992	992		992		992		1,037		1,078	6,083	
Freight and forwarding charges		1,600	1,600	2,282	150	240		2,770	6,259	1,784	5,744	6,425	28,854	
Carriage inward													-	-
Carriage outwards													-	-
Rent	105,330	106,929	107,350	111,835	110,927	112,519	112,287	113,456	113,355	116,039	112,667	115,192	1,337,886	102,096
ii) Buildings				810									810	
iii) Others					30,959								30,959	
Advertising and sales promotion	56,685	62,080	35,000	35,000	35,000	35,000	35,815	35,000	35,000	10,567	50,000	55,000	480,147	355,774
Travelling and conveyance		27,500	11,514	18,809	3,596	7,649	9,313		3,560	8,790	12,057	25,491	128,279	
Communication costs	6,416	1,216	9,061	3,217	10,186	1,778	1,734	3,486	7,151	3,255	612	5,132	53,243	
Printing and stationery	10,394	4,000	9,058	4,915	7,395	4,000	5,328	9,538	13,526	23,342	9,482	4,575	105,553	
Legal and professional fees	26,000	26,000	26,000	26,000	26,000	26,000	26,000	43,395	43,395	45,250	45,224	65,280	424,544	
Directors sitting fees	131,039	129,425	130,174	129,878	131,382	134,541	135,288	136,152	147,429	148,414	149,228	151,542	1,654,492	
Provision for litigations (net of reversals)													-	-
Exchange differences (net)	(1,882)	(42,201)	88,978	25,765	30,323	230,290	34,641	52,796	153,566	20,054	22,766	58,889	673,985	15,955
Loss on derivative contracts (including provisions mark-to-market loss)													-	-
Product development expenses	14,123	1,525	5,945		1,600		80,160		58,850				162,203	
Registration and filing charges	40,000	71,844	80,764	71,245		26,924	12,285	4,095	247			41,711	349,115	224,322
Safety and security	16,500	16,500	16,500	16,500	16,500	16,500	16,500	16,500	16,500	16,500	16,500	16,500	198,000	
Office expenses	1,281	798	901	3,558	1,541	9,037	3,084	7,498	5,375	589	10,660	11,790	56,112	
Repairs and maintenance - others	5,042	7,317	9,064	4,935	4,935	4,935	6,382	4,935	4,935	4,935	4,935	4,935	67,285	
Management fees													-	-
Liquidated damages													-	-
Donations													-	-
Software license and implementation expenses				3,117									3,117	
Capital work-in-progress written off													-	-
Miscellaneous expenses		2,950	2,950	20,998	5,900		31,265	26,123	11,138	21,956	14,688	13,715	151,683	
	410,927	417,483	535,851	479,856	416,394	610,404	517,449	456,736	628,562	422,512	461,577	577,255	5,935,007	698,141

C.P. Ricardo Tulio Cano Gonzalez
External Auditor
No. C.P.R. 2833

Aurovida Farmacéutica, SA de CV
Notes to the statement of profit and loss
(All amounts are in Local Currency except share data and unless otherwise stated)

	Apr-14	May-14	Jun-14	Jul-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended March 31, 2015 (Currency)	Year ended March 31, 2014 (Currency)
Payment to Auditor														
As auditor:														
Audit fee													-	-
Tax audit fee													-	-
Limited review													-	-
In other capacity:														
Taxation matters													-	-
Company law matters													-	-
Management services													-	-
Other services (certification fees)													-	-
Reimbursement of expenses													-	-
Note 24 : Exceptional items														
Others (Specify if any)													-	-
Note 25 : Depreciation and amortization expense														
Depreciation of tangible assets	17,590	17,590	18,144	18,428	18,428	18,681	18,749	18,749	19,053	19,183	19,450	19,748	223,793	187,569
Amortization of intangible assets	5,597	5,597	9,584	9,584	11,191	11,400	11,400	13,342	13,342	13,342	32,683	33,927	170,989	38,616
Depreciation of investment property	107,725	114,302	114,302	114,302	114,302	114,302	114,302	114,302	114,302	114,302	114,302	206,132	1,456,879	1,037,248
	130,912	137,489	142,031	142,315	143,921	144,383	144,452	146,393	146,697	146,827	166,435	259,807	1,851,660	1,263,434
Note 26 : Finance costs (Refer General Instructions Note No.27)														
Interest													-	-
Bank charges	387	196	382	406	230	228	248	29	250	2,708	212	229	5,505	-
Amortization of ancillary borrowing costs													-	-
Exchange difference to the extent considered as an adjustment to borrowing costs	387	196	382	406	230	228	248	29	250	2,708	212	229	5,505	-

C.P. Ricardo Tulio Cano Gonzalez
External Auditor
No. C.P.R. 2833

Note 1 : Summary of significant accounting policies

a) Basis of preparation

The financial statements have been prepared under the historical cost convention on accrual basis.

b) Revenue Recognition

Revenue from sale of good is recognized on dispatch and is inclusive of local taxes and net of discounts and sales returns.

c) Fixed Assets and Depreciation

- (i) Fixed assets are stated at cost less accumulated depreciation. Cost includes freight, duties, taxes and any attributable costs of bringing the asset to its working condition for future use.
- (ii) Depreciation is provided on straight-line method as prescribed by the Income-Tax laws.

d) Intangible Assets and Amortisation

Cost relating to licenses, which are acquired, are capitalized and amortized on a straight-line basis over their useful life not exceeding five years. Research costs are expensed as incurred. Development expenditure incurred in respect of internally generated intangible assets such as product development is carried forward when the future recoverability can reasonably be regarded as assured.

e) Pre-operative expenses

These expenses are being valued at cost. There are product of expenditure on 2012 and 2013, less amortization on a straight-line basis as per Income-Tax law

f) Inventories

Trading Goods are valued at lower of cost or net realizable value, with cost being determined using Weighted Average method.

f) Foreign Exchange Transactions


Foreign currency transactions arising during the year are recorded at the exchange rates prevailing at the transaction dates. Profits and losses on foreign currency transactions are shown separately in the Profit & Loss Account.

2. Leases

The firm has no finance leases. Operating leases are mainly in the nature of lease of office premises with no restrictions and are renewable at mutual consent.

3. Partners Share Capital

The partners liability is limited by subscription to Capital. 100% of the paid up Share Capital is being held by Helix Healthcare BV.,


C.P. Ricardo Tulio Cano Gonzalez
External Auditor
No. C.P.R. 2833

**IVONNE PALACIOS C.
CONTADOR PÚBLICO**

Calle 189 45 30 Interior 1 Of 203
Tel 6679090-6679091 Cel 3002108857
E-mail: ivonne_palacios@hotmail.com

AUDITOR'S REPORT

To,
Shareholders of AUROBINDO PHARMA COLOMBIA SAS.


I have audited the balance sheet of the Company AUROBINDO PHARMA COLOMBIA SAS until March 31, 2015, the related statements of income for the period ended on that date.

The audit was conducted in accordance with auditing standards generally accepted in Colombia.

Those standards require that an audit be planned and carried out so as to obtain reasonable assurance as to the other statements are free of errors in its contents. An audit includes examining on a selective basis, evidence supporting the amounts and informative notes in the financial statements; Audit also includes assessing the accounting rules and principles used and significant estimates made by management, as well as the relative overall presentation of the financial statements. I believe that my audit provides a reasonable basis for my opinion.

In my opinion, the aforementioned accompanying financial statements present fairly the financial position of the company AUROBINDO PHARMA COLOMBIA SAS at 31 March 2015 and the results of its operations in accordance with accounting principles generally accepted in Colombia.

Bogotá DC April 30, 2015



IVONNE PALACIOS CORREDOR
Public Accountant
Professional License No. 26877-T

DIRECTORS' REPORT

The directors present their report and the audited financial statements for the year ended March 31st 2015.

PRINCIPAL ACTIVITY

The principle object of the company is to trade and deal in pharmaceutical products and other allied products and services.

Unusual Items after the Financial Year:

No item, transaction or event of a Material nature has arisen during the period between the end of the financial year and the date of this report, which would affect substantially the operations of the company during the current year.

REVIEW OF OPERATIONS

During the year the company had registered a Loss of COP 447,101,669 against a Total Revenue of COP 968,776,580. Your company had started its Commercial activities in the current financial year only. During previous year the company had registered a Loss of COP 9,359,895.

Statement of Directors:

In the opinion of the Directors, the accompanying Financial statements were drawn up so as to give a true and fair view of the state of affairs of the Company as on 31st March 2015 and the results of the business for that period. Your Directors have taken all reasonable steps to prepare these financial statements on a going concern basis and suitable accounting policies have been adopted consistently. Further your Directors are confident that with the support and guidance of the Holding company, your Company can achieve better results in the future

DIRECTORS

The Directors at the date of the report are:

1. Mr. Gopa Ravindranath
2. Mr. Kamlesh Thakkar
3. Mr. Arvind Vasudeva

By Order of the Board:



Mr. Gopa Ravindranath
Director
Colombia

AUROBINDO PHARMA COLOMBIA SAS
Balance Sheet as at March 31, 2015

(All amounts are in Local COP except share data and unless otherwise stated)

	Note	31 Mar, 2015 (COP)	31 Mar, 2014 (COP)
Equity and liabilities			
Shareholders' Funds			
Share capital	2	197.750.000	20.000.000
Share application money		303.239.039	671.718
Reserves and surplus	3	(456.461.565)	(9.359.895)
		44.527.474	11.311.823
Non-current liabilities			
Long-term borrowings	4	-	-
Deferred Tax Liabilities (net)	5	-	-
Trade payables	6	-	-
Other long-term liabilities	6	-	-
Long-term provisions	7	-	-
		-	-
Current liabilities			
Short-term borrowings	8	-	-
Trade payables	9	3.106.498.413	-
Other current liabilities	9	59.265.606	9.359.895
Short-term provisions	7	21.400.883	-
		3.187.164.902	9.359.895
TOTAL		3.231.692.377	20.671.718
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	19.542.429	-
Intangible assets	11	1.380.267	-
Capital work-in-progress		-	-
Intangible assets under development		-	-
Non-current investments	12	-	-
Deferred tax assets (net)	5	-	-
Long-term loans and advances	13	-	-
Trade receivables	14,1	-	-
Other non-current assets	14,2	-	-
		20.922.695	-
Current assets			
Current investments	15	-	-
Inventories	16	2.513.530.764	-
Trade receivables	14,1	677.373.613	-
Cash and bank balances	17	19.865.304	20.671.718
Short-term loans and advances	13	-	-
Other current assets	14,2	-	-
		3.210.769.681	20.671.718
TOTAL		3.231.692.377	20.671.718
Summary of significant accounting policies	1		

The accompanying notes are an integral part of the financial statements.


IVONNE PALACIOS C
Independent auditor
T.P 26.877 T

AUROBINDO PHARMA COLOMBIA SAS
Statement of profit and loss for the Period from April 1st, 2014 to Mar 31, 2015
(All amounts are in Local COP except share data and unless otherwise stated)

	Note	Apr-14	May-14	June-14	July-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended Mar 31, 2015 (COP)	Year ended Mar 31, 2014 (COP)
Income															
Revenue from operations (gross)	18	-	-	-	-	29,012,000	20,916,000	74,778,650	13,572,400	102,271,000	158,649,000	241,130,600	328,446,930	968,776,580	-
Less: Excise duty		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from operations (net)		-	-	-	-	29,012,000	20,916,000	74,778,650	13,572,400	102,271,000	158,649,000	241,130,600	328,446,930	968,776,580	-
Other income	19	-	-	-	-	-	34,860	-	-	-	-	-	-	34,860	-
Total revenue (I)		-	-	-	-	29,012,000	20,950,860	74,778,650	13,572,400	102,271,000	158,649,000	241,130,600	328,446,930	968,811,440	-
Expenses															
Cost of raw material and components const	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of trading goods	21	-	-	-	-	111,000,370	364,998,113	514,383,694	535,444,124	(211,186,216)	460,191,370	1,188,517,947	69,056,688	3,032,406,090	-
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	-	-	-	-	(105,340,261)	(335,793,969)	(446,036,231)	(524,685,359)	60,085,212	(345,125,295)	(1,043,656,330)	227,021,470	(2,513,530,764)	-
Employee benefit expense	22	-	677,618	14,262,062	17,509,192	16,409,792	18,177,562	35,113,454	41,825,550	65,200,701	45,498,265	47,137,277	53,640,782	355,452,255	-
Other expenses	23	4,965,800	5,493,266	14,688,987	13,434,549	23,489,363	27,843,795	13,652,857	22,590,248	304,861,290	74,120,527	111,866,157	(84,954,125)	532,052,714	9,359,895
Exceptional items	24	-	-	-	-	-	-	-	-	-	-	-	2,372,730	2,372,730	-
Total (II)		4,965,800	6,170,884	28,951,049	30,943,741	45,559,264	75,225,501	117,113,774	75,174,563	218,960,988	234,684,867	303,865,050	267,137,545	1,408,753,026	9,359,895
Earnings before interest, tax, depreciation and amortization		(4,965,800)	(6,170,884)	(28,951,049)	(30,943,741)	(16,547,264)	(54,274,641)	(42,335,124)	(61,602,163)	(116,689,988)	(76,035,867)	(62,734,450)	61,309,385	(439,941,586)	(9,359,895)
Depreciation and amortization expense	25	-	-	-	-	295,937	360,974	373,418	373,418	330,203	281,313	293,388	293,389	2,602,041	-
Finance costs	26	51,160	139,326	152,918	192,536	269,337	323,405	515,786	298,597	797,017	414,190	1,456,231	(52,459)	4,538,042	-
Profit(loss) before tax		(5,016,960)	(6,310,210)	(29,103,967)	(31,136,277)	(17,112,538)	(54,959,020)	(43,224,329)	(62,274,178)	(117,817,207)	(76,731,371)	(64,484,069)	61,068,455	(447,101,670)	(9,359,895)
Tax expenses															
Current tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: MAT credit entitlement		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fringe benefit tax		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax relating to previous years		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total tax expense		-	-	-	-	-	-	-	-	-	-	-	-	-	-
Profit(loss) for the year		(5,016,960)	(6,310,210)	(29,103,967)	(31,136,277)	(17,112,538)	(54,959,020)	(43,224,329)	(62,274,178)	(117,817,207)	(76,731,371)	(64,484,069)	61,068,455	(447,101,670)	(9,359,895)

Summary of significant accounting policies 1

The accompanying notes are an integral part of the financial statements.


IVONNE PALACIOS C
Independent auditor
T.P 26.877 T

Note 1 : Summary of significant accounting policies (Refer General Instructions Note No.1)

1,1
1,2
1,3
1,4
1,5

Note 2 : Share capital (Refer General Instructions Note No.2)

	Mar 31 2015	March 31, 2014
Authorised shares:		
XXXXXXXX (31 March, 2013: XXXXXXXX) equity shares of XXXX each	500.000.000	20.000.000
XXXXXXXX (31 March, 2013: XXXXXXXX) preference shares of XXX each		
Issued, Subscribed and Fully Paid-up shares:	197.750.000	20.000.000
Issued, Subscribed and Fully Paid-up shares: share application money	€ 40.000	€ 7.400
XXXXXXXX (31 March, 2013: XXXXXXXX) equity shares of XXXX each fully paid-up	303.239.039	671.718

a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Equity Shares

	Mar 31 2015		Mar 31 2014	
	No.	Rs.	No.	Rs.
At the beginning of the period	20.000	20.000.000	20.000	20.000.000
Issued during the period	177.750	177.750.000		
Outstanding at the end of the period	197.750	197.750.000	20.000	20.000.000

AUROBINDO PHARMA COLOMBIA SAS
Notes to the Balance Sheet
(All amounts are in Local COP except share data and unless otherwise stated)

Note 3 : Reserves and surplus (Refer General Instructions Note No.3)

	Mar 31 2015	March 31, 2014
Capital Reserve		
As per last Balance Sheet	-	-
Capital Redemption Reserve		
Securities Premium Account		
As per last Balance Sheet	-	-
General Reserve		
As per last Balance Sheet		
Add: Transferred from statement of profit and loss	-	-
Surplus/(deficit) in the statement of profit and loss		
Balance as per last financial statements	(9,359,895)	-
Profit for the quarter	(447,101,670)	(9,359,895)
Less: Appropriations		
Total appropriations	-	-
Net surplus in the statement of profit and loss	(456,461,565)	(9,359,895)
Total reserves and surplus	(456,461,565)	(9,359,895)

Note 4 : Long -term borrowings (Refer General Instructions Note No.4)

	Non-current Portion		Current maturities	
	Mar 31 2015	March 31, 2014	Mar 31 2015	March 31, 2014
Term Loans				
From banks (Secured)				
Other Loans from banks				
Current account credit balance				
Loans and advances from related parties				-
Other Loans and advances				
Sales tax deferment loan (Un Secured)				
	-	-	-	-
The above amount includes				
Secured borrowings				
Unsecured borrowings				
Amount disclosed under the head				
"Other current liabilities"				
Net Amount	-	-	-	-

AUROBINDO PHARMA COLOMBIA SAS
Notes to the Balance Sheet
(All amounts are in Local COP except share data and unless otherwise stated)

Note 5 : Deferred tax liability (net)

Deferred tax liability	
Impact of expenditure charged to the statement of profit and loss in the current	
Year but allowed for tax purposes on payment basis	
Provision for diminution in the value of investments	
Provision for doubtful debts and advances	
Fixed Assets (Depreciation)	
Retirement Benefits	
Others	
Gross deferred tax liability	
Deferred tax asset	
Carried Forward Business Losses	
Others	
Gross deferred tax asset	
Net deferred tax liability	

-	-

Note 6 : Other long-term liabilities (Refer General Instructions Note No.5)

	Mar 31 2015	March 31, 2014
Trade payables (including acceptances)		
Others,		
Advances from customers		
Unclaimed dividends		
Other liabilities		
Interest accrued but not due on loans		
Advances from related parties		
	-	-
	-	-
	-	-

Note 7 : Provisions (Refer General Instructions Note No.6 & 10)

	Non-current		Current	
	Mar 31 2015	March 31, 2014	Mar 31 2015	March 31, 2014
Provision for employee benefits				
- Gratuity			21,400.883	
- Leave encashment				
	-	-	21,400.883	-
Other Provisions				
For Taxation (net of advance payments)				
For Proposed dividend				
For Tax on proposed dividend				
	-	-	-	-
	-	-	21,400.883	-

Provision for warranties

	Mar 31 2015	March 31, 2014
At the beginning of the year		
Arising during the period		
Utilised during the period		
Unused amounts reversed		
At the end of the Quarter		
Current portion		
Non-current portion		
	-	-

Note 8 : Short-term borrowings (Refer General Instructions Note No.7)

	Mar 31 2015	March 31, 2014
Bank overdraft		
Loans and advances from related parties		
Working capital loans (Secured)		
Short term loans (Un Secured)		
Working capital loans		
	-	-
The above amount includes		
Secured borrowings		
Unsecured borrowings		
	-	-

Note 9 : Other current liabilities (Refer General Instructions Note No.9)

	Mar 31 2015	March 31, 2014
Trade payables (including acceptances) (Refer General Instructions Note No.8)	3,106,498.413	
Other liabilities		
Current maturities of long-term borrowings		
Trade deposits		
Other Payable for Expenses	59,265.606	9,359.895
Advances from related parties		
	59,265.606	9,359.895


3.165.764.019	9.359.895
---------------	-----------

AUROBINDO PHARMA COLOMBIA SAS
Notes to the Balance Sheet

(All amounts are in Local COP except share data and unless otherwise stated)

Note 10 : Tangible assets (Refer General Instructions Note No.11)

	Leasehold Buildings	Freehold Buildings	Computers & Software	Furniture & fixtures	Vehicles	Office Equipment	Total
Cost or valuation							
At 31st August 2013							-
Additions							-
Disposals							-
Other adjustments							-
- Exchange differences							-
- Borrowing costs							-
At 31st March 2014	-	-	-	-	-	-	-
Additions			8.077.674			12.593.462	20.671.136
Acquisitions through amalgamation							-
Disposals							-
Other adjustments							-
- Exchange differences							-
- Borrowing costs							-
At 31 Mar 2015	-	-	8.077.674	-	-	12.593.462	20.671.136
Depreciation							
At 31st August 2013							-
Charge for the year							-
Disposals							-
Other adjustments							-
- Exchange differences							-
At 31st March 2014	-	-	-	-	-	-	-
Charge for the year			768.718			359.989	1.128.707
Disposals							-
Other adjustments							-
- Exchange differences							-
At 31 Mar 2015	-	-	768.718	-	-	359.989	1.128.707
Impairment loss							
At 14 May 2012							
At 14 June 2013							
Charge for the year							
At 14 June 2014							
Net Block							
At 31 Mar 2014	-	-		-	-		
At 31 Mar 2015	-	-	7.308.956	-	-	12.233.473	19.542.429



IVONNE PALACIOS C
Independent auditor
T.P 26.877 T


AUROBINDO PHARMA COLOMBIA SAS

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 11 : Intangible assets

	Goodwill	Product Development cost	Licences. Patents and Software	Total
Gross block				
At April 1, 2013				-
Additions during the nine months				-
Internal development during the nine months				-
Disposals during the nine months				-
Other adjustments				-
- Exchange differences				-
At December 31, 2013	-	-	-	-
Additions during the three months				-
Internal development during the three months				-
Disposals during the three months				-
Other adjustments				-
- Exchange differences				-
At March 31, 2014	-	-	-	-
Additions during the nine months			2.853.600,0	2.853.600,0
Disposals during the nine months				-
Additions on acquisition				-
Other adjustments				-
- Exchange differences				-
At 31 Mar 2015	-	-	2.853.600,0	2.853.600,0
Amortization				
At April 1, 2013				-
Charge for the period				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At December 31, 2013	-	-	-	-
Charge for the period				-
Disposals				-
Other adjustments				-
- Exchange differences				-
At March 31, 2014	-	-	-	-
Charge for the period			1.473.333,4	1.473.333,4
Disposals				-
Other adjustments				-
- Exchange differences				-
At 31 Mar 2015	-	-	1.473.333,4	1.473.333,4
Net Block				
At December 31, 2013	-	-	-	-
At March 31, 2014	-	-	-	-
At 31 Mar 2015	-	-	1.380.266,6	1.380.266,6



IVONNE PALACIOS C
Independent auditor
T.P 26.877 T

AUROBINDO PHARMA COLOMBIA SAS
Notes to the Balance Sheet
 (All amounts are in Local COP except share data and unless otherwise stated)

Note 12: Non-current investments (Refer General Instructions Note No.13)

	Mar 31 2015	March 31, 2014
Unquoted equity instruments		
Investment in subsidiaries		
Investment in joint ventures		
Investment in associates		
	-	-

Note 13: Loans and advances (Refer General Instructions Note No.14 & 21)

	Non-current		Current	
	Mar 31 2015	March 31, 2014	Mar 31 2015	March 31, 2014
Capital advances				
Secured, considered good				
Unsecured, considered good				
(A)	-	-	-	-
Security deposit				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful security deposit				
(B)	-	-	-	-
Loan and advances to related parties				
Unsecured, considered good				
(C)	-	-	-	-
Advances recoverable in cash or kind				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful advances				
(D)	-	-	-	-
Other loans and advances				
Advance income-tax (net of provision for taxation)				
Prepaid expenses			-	
Loans to employees				
Loans to others				
Export incentives receivable				
Export incentives licenses				
Balances with Statutory/government authorities				
(E)	-	-	-	-
Total (A+B+C+D+E)	-	-	-	-
Loans and advances due by directors or other officers, etc.				
Loans to employees include				
Dues from non-executive directors				
Dues from officers				
Dues from non-executive and officers jointly with other persons				
Loans and advances to related parties include				
Dues from the partnership firm in which the company's executive director is a partner				
Dues from in which the company's managing director is a member				
Dues from the partnership firm in which the company's non-executive director is a partner				

Note 14 : Trade receivables and other assets

14.1 Trade receivable (Refer General Instructions Note No.15 & 19)

	Non-current		Current	
	Mar 31 2015	March 31, 2014	Mar 31 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Outstanding for a period exceeding six months from the date they are due for payment				
Due from related parties				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Provision for doubtful receivables	-	-	-	-
(A)	-	-	-	-
Other receivables				
Due from related parties				
Secured, considered good				
Unsecured, considered good			677.373.613	
Doubtful				
Provision for doubtful receivables	-	-	677.373.613	-
(B)	-	-	677.373.613	-
Total (A+B)	-	-	677.373.613	-

Trade receivables include:

	Non-current		Current	
	Mar 31 2015	March 31, 2014	Mar 31 2015	March 31, 2014
Due from non-executive directors				
Due from officers				
Due from non-executive directors and officers jointly with other persons				
Dues from partnership firm in which the company's non-executive director is a partner				
Dues from in which the company's non-executive director is a director				

14.2 Other assets (Refer General Instructions Note No.16 & 22)

	Non-current		Current	
	Mar 31 2015	March 31, 2014	Mar 31 2015	March 31, 2014
Unsecured, considered good (unless stated otherwise)				
Non-current bank balances				
(A)	-	-	-	-
Unamortized expenditure				
Unamortized premium on forward contract				
Ancillary cost of arranging the borrowings				
(B)	-	-	-	-
Others				
Interest accrued on fixed deposits				
Interest accrued on investments				
Dividend receivable on investments in subsidiaries - long term				
Others				
(C)	-	-	-	-
Total (A+B+C)	-	-	-	-

Note 15: Current investments (Refer General Instructions Note No.17)


	Mar 31 2015	March 31, 2014
Current investments (valued at lower of cost and fair value, unless stated otherwise)		
Quoted equity instruments - Non-trade		
Equity shares (fully paid-up)		
If any (Please specify)		

Note 16: Inventories (valued at lower of cost and net realizable value) (Refer General Instructions Note No.18)

	Mar 31 2015	March 31, 2014
Raw materials and components (includes in transit XXX (31 March, 2013 XXX)		
Work - in - Progress		
Finished goods		
Traded goods (including stock -in-transit XXXX (31 March, 2013 XXX)	2.513.530.764	
Stores, spares, consumables and packing materials		
Loose tools		
	2.513.530.764	-

Note 17: Cash and bank balances (Refer General Instructions Note No. 20)

	Non-current		Current	
	Mar 31 2015	March 31, 2014	Mar 31 2015	March 31, 2014
Cash and cash equivalents				
Balances with banks:				
On current accounts			19.477.563	20.671.718
Deposits with original maturity of less than 3 months				
Cash credit accounts				
On unpaid dividend account				
Cheques/ drafts on hand				
Unpaid matured deposits				
Cash on hand			387.741	
	-	-	19.865.304	20.671.718
Other bank balances				
Deposits with original maturity for more than 12 months				
Deposits with original maturity for more than 3 months but less than 12 months				
Margin money deposit				
	-	-	-	-
Amount disclosed under non-current assets				
	-	-	-	-


IVONNE PALACIOS C
Independent auditor
T.P 26.877 T

AUROBINDO PHARMA COLOMBIA SAS
Notes to the statement of profit and loss
(All amounts are in Local COP except share data and unless otherwise stated)

	Apr-14	May-14	June-14	July-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended Mar 31, 2015 (COP)	Year ended Mar 31, 2014 (COP)
Note 18 : Revenue from operations (Refer General Instructions Note No 26)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from operations	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of products	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Finished goods	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Traded goods	-	-	-	-	29,012,000	20,916,000	74,778,650	13,572,400	102,271,000	158,839,000	241,130,600	332,226,930	972,746,580	-
Sale of services	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of dossiers/licenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other operating revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Scrap sales	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue from operations (gross)	-	-	-	-	29,012,000	20,916,000	74,778,650	13,572,400	102,271,000	158,839,000	241,130,600	332,226,930	972,746,580	-
Less: VAT/Excise duty	-	-	-	-	-	-	-	-	-	190,000	-	3,780,000	3,970,000	-
Revenue from operations (net)	-	-	-	-	29,012,000	20,916,000	74,778,650	13,572,400	102,271,000	158,649,000	241,130,600	328,446,930	968,776,580	-
Note 19 : Other income (Refer General Instructions Note No 26)														
Interest income on														
Bank deposits	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loans to joint venture entities	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Others	-	-	-	-	-	34,860	-	-	-	-	-	-	34,860	-
Dividend income on														
Investment in subsidiaries	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net gain on sale of current investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Profit on sale of fixed assets (net)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Foreign exchange gain (net)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balances no longer required written back	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Government grant	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Commission income	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Processing charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other non-operating income (net of expenses dir to such income of Rs.XXXXX (14 June, 2013:XXX	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	34,860	-	-	-	-	-	-	34,860	-
Note 20 : Cost of raw material and components consumed														
Inventory at the beginning of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add: Purchases	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: inventory at the end of the period	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Add:Packing material consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of raw material and components consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-

AUROBINDO PHARMA COLOMBIA SAS
Notes to the statement of profit and loss
(All amounts are in Local COP except share data and unless otherwise stated)


	Apr-14	May-14	June-14	July-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended Mar 31, 2015 (COP)	Year ended Mar 31, 2014 (COP)
Note 21 : (Increase)/decrease in inventories														
Inventories at the end of the quarter														
Traded goods	-	-	-	-	105.340.261	441.134.231	887.170.462	1.411.855.821	1.351.770.609	1.696.895.904	2.740.552.234	2.513.530.764	11.148.250.285	-
Work-in-progress	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Finished goods	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	105.340.261	441.134.231	887.170.462	1.411.855.821	1.351.770.609	1.696.895.904	2.740.552.234	2.513.530.764	11.148.250.285	-
Inventories at the beginning of the quarter														
Traded goods	-	-	-	-	-	105.340.261	441.134.231	887.170.462	1.411.855.821	1.351.770.609	1.696.895.904	2.740.552.234	8.634.719.521	-
Work-in-progress	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Finished goods	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	105.340.261	441.134.231	887.170.462	1.411.855.821	1.351.770.609	1.696.895.904	2.740.552.234	8.634.719.521	-
	-	-	-	-	(105.340.261)	(335.793.969)	(446.036.231)	(524.685.359)	60.085.212	(345.125.295)	(1.043.656.330)	227.021.470	(2.513.530.764)	-
Details of purchase of traded goods														
Product A	-	-	-	-	111.000.370	364.998.113	514.383.694	535.444.124	(211.186.216)	460.191.370	1.188.517.947	69.056.688	3.032.406.090	-
Product B	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product C	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	111.000.370	364.998.113	514.383.694	535.444.124	(211.186.216)	460.191.370	1.188.517.947	69.056.688	3.032.406.090	-
Note 22 : Employee benefit expense														
Salaries, wages and bonus	-	518.400	11.022.000	12.522.000	12.522.000	14.022.000	23.972.000	29.132.000	49.202.000	33.174.000	33.146.000	35.758.000	254.990.400	-
Contribution to provident and other fund	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Employee stock option scheme	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gratuity expense	-	82.131	1.831.696	2.096.596	2.096.596	2.361.496	4.524.848	5.081.136	5.580.914	5.058.530	5.392.658	6.260.116	40.366.717	-
Other employee benefits	-	-	-	1.219.400	-	100.000	2.300.000	3.000.000	4.602.960	2.676.000	1.882.000	4.050.000	19.830.360	-
Vacations	-	19.393	518.600	593.600	593.600	668.600	1.281.102	1.438.600	1.580.100	1.432.200	1.526.800	1.772.400	11.424.995	-
Post employment medical benefits	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Staff welfare expenses	-	57.694	889.766	1.077.596	1.197.596	1.025.466	3.035.504	3.173.814	4.234.727	3.157.535	5.189.819	5.800.266	28.839.783	-
	-	677.618	14.262.062	17.509.192	16.409.792	18.177.562	35.113.454	41.825.550	65.200.701	45.498.265	47.137.277	53.640.782	355.452.255	-

AUROBINDO PHARMA COLOMBIA SAS
Notes to the statement of profit and loss
(All amounts are in Local COP except share data and unless otherwise stated)

	Apr-14	May-14	June-14	July-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended Mar 31, 2015 (COP)	Year ended Mar 31, 2014 (COP)
Note 23 : Other expenses														
Consumption of stores and spares	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Chemicals consumed	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in VAT on finished goods	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Customer service expenditure	-	-	-	-	2,734,945	2,591,312	8,066,894	1,684,190	5,510,512	2,086,961	5,333,941	4,502,153	32,510,909	
Power and fuel	-	23,160	27,350	42,690	38,370	39,140	51,890	199,980	71,970	70,130	73,970	77,890	716,540	
Gas	-	-	-	-	5,790	7,050	9,720	4,580	5,970	9,150	9,400	9,510	61,170	
Water charges	-	-	67,580	-	-	80,466	125,570	-	237,870	-	240,540	-	752,026	
Freight and forwarding charges	-	-	-	-	-	-	-	-	-	8,879,287	-	39,140,485	48,019,772	
Carriage inward	-	110,999	-	-	-	26,000	72,580	119,780	369,460	115,500	-	49,200	863,519	
Carriage outwards	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Rent	3,060,000	3,060,000	8,633,722	8,633,722	8,633,722	8,633,722	8,633,722	8,633,722	8,633,722	8,633,722	8,633,722	8,633,722	92,457,223	
Rates and taxes	-	-	-	-	-	82,502	433,784	56,190	423,402	656,807	998,281	1,359,770	4,010,735	
Insurance	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repairs and maintenance	-	-	-	-	-	-	-	-	-	-	-	-	-	-
i) Plant and machinery	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ii) Buildings	-	-	-	-	-	-	-	-	-	-	-	-	-	-
iii) Others	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Advertising and sales promotion	-	120,410	66,698	887,867	575,168	715,696	418,289	29,541	284,072	2,763,245	1,030,915	833,651	7,725,552	
Brokerage and discounts	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Remuneration to Auditors	1,905,800	819,200	2,207,762	-	7,034,861	6,354,621	(14,997,602)	511,680	409,600	-	102,080	-	4,348,202	
Sales commission	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Travelling and conveyance	-	33,950	1,533,611	1,598,984	1,560,534	1,912,711	4,388,571	4,477,484	7,095,185	5,635,434	6,824,014	6,571,040	41,631,515	
Communication costs	-	-	214,875	458,794	539,237	282,376	403,229	1,417,934	241,796	1,415,893	138,685	792,913	5,905,732	
Printing and stationery	-	-	-	12,000	1,077,640	-	-	-	-	381,200	26,000	984,149	2,480,989	
Legal and professional fees	-	-	492,018	7,000	1,949	56,584	(480,000)	-	-	30,000	-	656,036	763,587	9,243,795
Exchange differences (net)	-	-	-	-	-	-	-	-	263,955,901	44,623,593	86,195,914	(139,023,825)	255,751,582	
Vehicle maintenance expenses	-	-	-	308,617	305,328	250,908	-	-	185,087	630,041	609,973	349,682	2,639,636	
Vehicle parking	-	-	110,000	240,464	132,457	90,597	114,412	-	18,899	-	586	3,586	711,001	
Analytical charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product development expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Registration and filing charges	-	74,100	630,700	-	148,400	2,836,300	2,810,600	-	-	(2,832,000)	-	802,000	4,470,100	116,100
Safety and security	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Office expenses	-	374,587	128,873	1,135,337	577,294	1,513,948	1,272,764	4,856,939	5,680,797	328,902	1,347,841	2,394,978	19,612,260	
Repairs and maintenance - others	-	400,000	-	-	-	184,320	-	-	-	356,000	-	-	940,320	
Management fees	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liquidated damages	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Donations	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Software license and implementation expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital work-in-progress written off	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Miscellaneous expenses	-	476,860	575,798	109,074	123,668	2,185,341	2,328,433	598,230	11,737,047	336,663	300,296	(13,091,066)	5,680,343	
	4,965,800	5,493,266	14,688,987	13,434,549	23,489,363	27,843,795	13,652,857	22,590,248	304,861,290	74,120,527	111,866,157	(84,954,125)	532,052,714	9,359,895

AUROBINDO PHARMA COLOMBIA SAS
Notes to the statement of profit and loss
(All amounts are in Local COP except share data and unless otherwise stated)

	Apr-14	May-14	June-14	July-14	Aug-14	Sep-14	Oct-14	Nov-14	Dec-14	Jan-15	Feb-15	Mar-15	Year ended Mar 31, 2015 (COP)	Year ended Mar 31, 2014 (COP)
Payment to Auditor														
As auditor:														
Audit fee	409.600	819.200	819.200	-	409.600	409.600	409.600	511.680					3.788.480	
Tax audit fee	-	-	-	-	-	-	-	-					-	
Limited review	-	-	-	-	-	-	-	-					-	
In other capacity:	-	-	-	-	-	-	-	-					-	
Taxation matters	-	-	-	-	-	-	-	-					-	
Company law matters	-	-	-	-	-	-	-	-					-	
Management services	-	-	-	-	-	-	-	-					-	
Other services (certification fees)	1.496.200	-	1.388.562	-	6.625.261		(266.228)						9.243.795	
Reimbursement of expenses	-	-	-	-	-	-	-	-					-	
	1.905.800	819.200	2.207.762	-	7.034.861	409.600	143.372	511.680	-	-	-	-	13.032.275	-
Note 24 : Exceptional items														
Others (Specify if any)	-	-	-	-	-	-	-	-	-	-	-	2.372.730	2.372.730	
	-	-	-	-	-	-	-	-	-	-	-	2.372.730	2.372.730	-
Note 25 : Depreciation and amortization expense														
Depreciation of tangible assets	-	-	-	-	111.770	176.807	189.252	189.252	146.036	97.147	109.222	109.222	1.128.708	
Amortization of intangible assets	-	-	-	-	184.167	184.167	184.167	184.167	184.167	184.167	184.167	184.167	1.473.334	
Depreciation of investment property	-	-	-	-	-	-	-	-	-	-	-	-	-	
	-	-	-	-	295.937	360.974	373.418	373.418	330.203	281.313	293.388	293.389	2.602.041	-
Note 26 : Finance costs (Refer General Instructions Note No 27)														
Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	
Bank charges	51.160	139.326	152.918	192.536	269.337	323.405	515.786	298.597	797.017	414.190	1.456.231	(52.459)	4.558.042	-
Amortization of ancillary borrowing costs	-	-	-	-	-	-	-	-	-	-	-	-	-	
Exchange difference to the extent considered as :	-	-	-	-	-	-	-	-	-	-	-	-	-	
	51.160	139.326	152.918	192.536	269.337	323.405	515.786	298.597	797.017	414.190	1.456.231	(52.459)	4.558.042	-


IVONNE PALACIOS C
Independent auditor
T.P 26.877 T

AUROBINDO PHARMA COLOMBIA SAS
NOTES TO THE BALANCE SHEET
For the Period from April 1, 2014 to March 31, 2015

1. SOCIAL NATURE AND SCOPE

The Company was incorporated by private document, signed on the 28th January 2014 at Bogota Chamber of Commerce under number 01.800.844 Book IX and its legal duration is indefinite.

Purpose: Can develop any kind of lawful activity permitted by Colombian laws and in particular acting as buyer and seller of goods wholesale, retail or by mail, as promoter, importer, exporter, commodity broker, agent and commission broker, with respect to all types of pharmaceutical products and raw materials, without restrictions on the type and volume and nevertheless if its for immediate or future delivery, or through cash payments or marginal basis.

The Company started to invoice since August 2014.

Summary of Significant Accounting Policies

(a) Basis of Preparation and Presentation

The financial statements are prepared and presented in accordance with generally accepted accounting principles in Colombia.

The following practices and accounting standards used by the company in the register of its operations in accordance with accounting principles in Colombia issued by Decree 2649 of 1993 are summarized below.

(b) Criterion of Materiality

Economic events are recognized and presented according to their relative importance. In the preparation of the financial statements, materiality was determined in relation to the total assets and liabilities; the total assets and liabilities,

As a general rule, the criteria of 100% of the total value of assets and operating revenues continued.

(c) Accounting Framework

The company pursuant to the Decree 3022 of 2013 belongs to Group 2. Therefore the procedures of mandatory preparation period started to take place. As of January 1, 2015 began to develop the transition period.

(d) Cash Equivalents

For purposes of the statement of cash flows, investments of high liquidity achievable within a maximum period of 90 days and bank overdrafts are considered cash equivalents.

(e) Deferred

Deferred are represented by: Computer programs.

(f) Property, Plant & Equipment

Property, plant and equipment are recorded at cost and include the effect of inflation. Depreciation is calculated using the straight-line method over the cost adjusted for inflation, according to the estimated useful life of each asset.

	Years
Office equipment	5
Computers & communication equipment	5

(g) Taxes & Fees

The expense for current income tax is determined based on taxable income .

2. ON HAND

DETAILS	31/03/2015
Cash on hand	387.741
National bank	19.477.563
TOTAL	19.865.304

3. CUSTOMERS

This account is comprised of:

DETAILS	31/03/2015
Nationals	668.964.300
Provisions	-
TOTAL	- 668.964.300

4. DEBTORS

This account is comprised of:

DETAILS	31/03/2015
Advances	3.879.263
Advance Income Tax	4.530.050
TOTAL	- 8.409.313

5. INVENTORIES

This account is comprised of:

DETAILS	31/03/2015
Goods not manufactured by the Company	754.754.733
Inventories in transit	1.758.776.031
Provision for obsolescence	-
TOTAL	- 2.513.530.764

6. PROPERTY, PLANT & EQUIPMENT

This account balance has the following composition:

ASSETS YEAR 2014 - 2015

ASSETS	HISTORICAL COST	DEPRECIATION	TOTAL
Furniture & Fixtures	12.593.462	359.989	12.233.473
Computers & Communication Equipment	8.077.674	768.718	7.308.956
TOTALS	20.671.136	1.128.707	19.542.429

7. DEFERRED

Deferred shown in the balance sheet have the following composition:

DETAILS	31/03/2015
Deferred charges (software)	1.380.267
TOTAL	1.380.267

8. SUPPLIERS

Make this area the following balance sheet items:

DETAILS	31/03/2015
National Suppliers	7.083.071
Overseas Suppliers	3.106.498.413
TOTAL	3.113.581.484

THE ONLY OVERSEAS SUPPLIER IS THE PARENT COMPANY.

CORRESPONDS TO \$USD 1.199.298,25 AS ON 31ST MAR, 2015 TRM 2.590,26

9. ACCOUNTS PAYABLE

DETAILS	31/03/2015
Costs & Expenses Payable	28.108.593
Taxes - Retención en la fuente	2.001.083
Taxes - Retención Iva	259.290
Taxes - Retención en la fuente ICA	104.364
Taxes - Retención Cree	-
Wages taxes - Retenciones y Aportes de Nómina	9.586.572
Other creditors	-

TOTAL	-	<u><u>40.059.902</u></u>
--------------	---	--------------------------

10. TAXES

Make this area the following balance sheet items:

DETAILS

31/03/2015

Tax of Industry & Commerce	-	<u>1.359.770</u>
TOTAL	-	<u><u>1.359.770</u></u>

11. LABOUR OBLIGATIONS

Make this area the following balance sheet items:

DETAILS

31/03/2015

Wages payable		5.343.000
Consolidated vacations		5.419.862
Severance		7.865.845
Severance interest		946.113
Services bonus		7.865.845
Vacations provision		4.723.080
TOTAL	-	<u><u>32.163.745</u></u>

12. OTHER LIABILITIES

31/03/2015

Advances for capitalization		<u>303.239.039</u>
	-	<u><u>303.239.039</u></u>

13. CAPITAL SHARE

DETAILS

31/03/2015

Capital subscribed		<u>197.750.000</u>
TOTAL	-	<u><u>197.750.000</u></u>

The company is Colombian, with 100% foreign investment , with capital broken down as:

Authorized \$500.000.000 Shares 500.000 nominal value of \$1,000 each

Subscribed \$197.750.000

AUROBINDO PHARMA COLOMBIA SAS
NOTES TO THE PROFIT & LOSS STATEMENT
For the Period from April 1, 2014 to March 31, 2015

1. OPERATIONAL INCOME

Recorded operating revenues:

	31/03/2015
DETAILS	
Pharmaceutical products sales	968.776.580
TOTAL	- 968.776.580

2. SALES COSTS

	31/03/2015
DETAILS	
Pharmaceutical products sales	741.017.344
TOTAL	- 741.017.344

3. SELLING EXPENSES

	31/03/2015
DETAILS	
Employees expenses	127.482.432
Taxes	4.010.735
Services	2.542.733
Rent	78.042
Legals	24.935.993
Travel expenses	260.000
Other	41.952.329
TOTAL	- 201.262.264

4. EXPENSE MANAGEMENT

	31/03/2015
DETAILS	
Employees expenses	227.969.823
Professional fees	4.300.159
Rent	71.040.250
Services (phone, water, electricity)	92.457.224
Legal expenses	5.203.687
Maintenance & repairs	356.000
Adaptations & Facilities	584.320
Depreciation	1.128.707
Amortization	1.473.333
Other	28.579.660
TOTAL	- 433.093.163

5. OTHER INCOME

DETAILS	31/03/2015
Financials	34.860
TOTAL	- 34.860

6. OTHER EXPENSES

DETAILS	31/03/2015
Banking	356.627
Commissions	647.155
Taxing to the financial movement (GMF) 4/1000	3.537.861
Discounts	2.372.831
Exchange difference	33.609.564
Extraordinary expenses	16.437
TOTAL	- 40.540.475

7. INCOME TAX PROVISION

The company chose to benefit from the law 1429.

DETAILS	31/03/2015
PROFIT / (LOSS) BEFORE TAXES	- (447.101.806)
Nondeductible expenses	1.768.931
TAXABLE LOSS	- (445.332.875)
PROVISION OF INCOME	-

AUROBINDO PHARMA USA Inc.

Directors Reports

The Directors present their report and the audited financial statements for the year ended March 31, 2015.

PRINCIPAL ACTIVITY

The principle object of the Company is to Manufacture, Trade and deal in pharmaceuticals/health sector and other allied products and services. It may also acquire, participate in other companies with similar activities.

REVIEW OF OPERATIONS

During the year, your Company has registered a total turnover of \$613,970,239 and earned a profit after tax of \$33,907,559.

AUDITORS

The Auditors, Withum, Smith & Brown has expressed their willingness to accept re-appointment.

DIRECTORS

The Directors at the date of this report are:

1. Robert Cunard
2. Ron Quadrel
3. P.V. Ram Prasad Reddy

UNUSUAL ITEMS AFTER THE FINANCIAL YEAR

During the year the Company acquired the assets of Natrol Inc. to operate under the name of Natrol LLC as a wholly owned subsidiary of Aurobindo Pharma USA, Inc. on December 4, 2014. Barring this, No item, transaction or event of material nature has arisen during the period between the end of the financial year and the date of this report which would affect substantially the operations of the company during current year.

INVESTMENT IN SUBSIDIARY DURING CURRENT YEAR:

During the year the Company acquired the assets of Natrol Inc, to operate under the name of Natrol LLC as a wholly owned subsidiary of Aurobindo Pharma USA, Inc. on December 4, 2014 at a purchase price of \$131,750,000 in addition to certain assumed liabilities.

STATEMENT BY DIRECTORS

In the opinion if the Directors, the accompanying financial statements were down drawn up so as to give true and fair view of the state of affairs of the company as at March 31, 2015 and of the results of the business of the period. The Directors have taken all reasonable steps to prepare these financial statements on a going concern basis and that suitable accounting policies have been adopted consistently. Further, the Directors are confident that with the support and guidance of the parent company, your company can achieve better results in the future.

By Order of the Board

A handwritten signature in black ink, appearing to read 'Robert G. Cunard', written over a horizontal line.

Robert G. Cunard
Chief Executive Officer

New Jersey, May 21, 2015



465 South Street, Suite 200
Morristown, New Jersey 07960-6497 USA
973 898 9494 • fax 973 898 0856
www.withum.com

Additional offices in New Jersey,
New York, Pennsylvania, Maryland,
Florida, Colorado and Grand Cayman

Independent Auditors' Report on Special Purpose Financial Information Prepared for Consolidation Purposes

To the Board of Directors Aurobindo Pharma USA, Inc.
Dayton, New Jersey

As requested in your instructions to the Aurobindo Pharma Limited ("APL") Group Audit, we have audited, for purposes of the audit of the consolidated financial statements of APL, the accompanying special purpose financial information of Aurobindo Pharma USA, Inc. (collectively "APUSA" or the "Company") contained in the "Consolidated" Column of the attached Special Purpose Consolidated Financial Statements of APUSA as of and for the fiscal year ended March 31, 2015. These Special Purpose Consolidated Financial Statements and the accompanying Special Purpose Supplementary Information were extracted from the Company's Reporting System and are the responsibility of the Company's management. Such financial information and supplementary information has been prepared by Company management in conformity with generally accepted accounting principles in the United States of America ("US GAAP") and for use in the preparation of the consolidated financial statements of APL. Our responsibility is to express an opinion on the "Consolidated" Column of the Group Reporting Package based on our audit.

Management's Responsibility for the Special Purpose Financial Information

Management is responsible for the preparation and presentation of this special purpose financial information in accordance with US GAAP; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of special purpose financial information that is free from material misstatement, whether due to fraud or error. This special purpose financial information has been prepared solely to enable APL to prepare its consolidated financial statements.

Auditors' Responsibility

Our responsibility is to express an opinion on this special purpose financial information based on our audit. We did not audit the financial statements of Natrol, LLC, a wholly-owned subsidiary, whose statements reflect 26% of total consolidated assets as of March 31, 2015 and 5% of total consolidated revenue for the fiscal year then ended. Those statements were audited by other auditors, whose report has been furnished to us, and our opinion, insofar as it relates to the amounts



Board of Directors of Aurobindo Pharma USA, Inc.

Page 2 of 3

included for Natrol LLC, is based solely on the report of the other auditors. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the "Consolidated" Column of the Special Purpose Consolidated Financial Statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the "Consolidated" Column of the Special Purpose Consolidated Financial Statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the Special Purpose Consolidated Financial Statements. We believe that our audit provides a reasonable basis for our opinion.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the special purpose financial information. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the special purpose financial information, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and presentation of the special purpose financial information in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates, if any, made by management, as well as evaluating the overall presentation of the special purpose financial information.

Opinion

In our opinion, based on our audit and the report of the other auditors, the "Consolidated" Column of the Special Purpose Consolidated Financial Statements presents fairly, in all material respects, the financial position of Aurobindo Pharma USA, Inc. and Subsidiaries as of March 31, 2015 and the results of their operations for the fiscal year then ended in accordance with US GAAP. As discussed in the succeeding paragraph, and based on instructions from APL, the Group Reporting Package does not include a statement of cash flows for the fiscal year ended March 31, 2015.

Other Matters

In addition, the Condensed Notes to the Consolidated Special Purpose Financial Information have been prepared pursuant to instructions from APL to the Company. Such disclosures are intended to assist APL in the preparation of consolidated notes; accordingly the condensed notes are not intended to represent comprehensive note disclosures that are intended to comply with US GAAP. In addition, the Group Reporting Package does not include a statement of cash flows as required by US GAAP. The effects of this departure from US GAAP has not been determined. The preparation of such consolidated statement of cash flows and footnotes is the responsibility of APL.



Board of Directors of Aurobindo Pharma USA, Inc.
Page 3 of 3

The accompanying supplemental schedules (listed in the foregoing table of contents of the Company, prepared on a separate company basis) and notes thereto are presented for purposes of additional analysis and are not a required part of the basic special purpose consolidated financial statements. Such schedules and notes thereto are the responsibility of management and were derived from and relate directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the special purpose consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the special purpose consolidated financial statements themselves, and other additional procedures in accordance with the basis of US GAAP. In our opinion, based on our audit and the report of the other auditors, the information is fairly stated in all material respects in relation to the consolidated special purpose financial statements as a whole.

The Company's consolidated financial statements as of and for the fiscal year ended March 31, 2015 include the accounts of Natrol LLC. This wholly owned subsidiary was formed in connection with an Asset Purchase Agreement executed by the Company with a third party (Natrol, Inc. and Affiliates) dated November 10, 2014. In connection with such acquisition, the results of operations of Natrol LLC are included from the effective date of the acquisition (December 4, 2014) through March 31, 2015.

Restriction on Use and Distribution

The accompanying special purpose consolidated financial statements and related information has been prepared for purposes of providing information to APL to enable it to prepare its consolidated financial statements.

This report is intended solely for the Company, APL and S.R. Batliboi & Associates and should not be used by or distributed to other parties.

William Smith, Brown, PC

May 21, 2015

Name of the company : AUROBINDO PHARMA USA INC
 Balance Sheet As At 31st Mar 2015
 (All amounts are in Local Currency)

Balance Sheet As At 31st Mar 2015 (\$)							5	
	Note	APUSA	Asmirk	Ammurics	AumHealth	Nama	Adjustments	As of 31st Mar 2015
Equity and liabilities								
Shareholders' Funds								
Share capital	2	61,675,000	61,000,000	200,000	9,797	500,000	(61,950,000)	61,434,797
Share application money								
Reserves and surplus	3	55,923,969	23,109,763	2,098,362	(6,288,617)	(1,056,582)	(26,844,939)	46,941,976
		117,598,969	84,109,763	2,298,362	(6,278,820)	(556,582)	(88,794,919)	108,376,773
Non-current liabilities								
Long-term borrowings	4	80,947,576	11,841,634	-	20,614,452	133,087,484	(153,701,936)	92,789,210
Deferred Tax Liabilities	5	-	-	-	-	-	6,364,115	6,364,115
Trade payables	6	-	-	-	-	-	-	-
Other long-term liabilities	6	-	-	-	-	-	-	-
Long-term provisions	7	-	-	-	-	-	-	-
		80,947,576	11,841,634	-	20,614,452	133,087,484	(147,337,821)	99,153,325
Current liabilities								
Short-term borrowings	8	23,052,424	1,673,454	-	-	-	-	24,725,878
Trade payables	9	268,373,412	14,370,237	30,327,991	294,246	8,627,532	(28,379,302)	293,614,115
Other current liabilities	9	10,539,158	1,218,957	1,389,650	63,703	4,771,135	(135,401)	17,846,502
Short-term provisions	7	-	-	-	-	-	22,977,207	22,977,207
		301,964,994	17,262,648	31,717,641	357,949	13,399,966	(6,117,501)	358,583,698
TOTAL		500,511,539	113,214,046	34,015,023	14,693,580	145,929,869	(242,250,260)	566,113,796
Assets								
Non-current assets								
Fixed assets								
Tangible assets	10	4,888,073	60,718,231	27,237	13,256,237	4,146,183	-	83,035,961
Intangible assets	11	450,105	458,599	-	-	101,378,345	-	102,317,049
Capital work-in-progress		558,955	249,285	-	106,046	3,237,300	-	4,151,586
Intangible assets under development		-	-	-	-	-	-	-
Non-current investments	12	61,950,000	-	-	-	-	(61,950,000)	-
Long-term loans and advances	13	141,753,996	11,947,940	-	-	4,811,396	(153,701,936)	4,811,396
Trade receivables	14.1	-	-	-	-	-	-	-
Other non-current assets	14.2	200,000	25,417	-	-	-	-	225,417
		209,801,130	73,429,471	27,237	13,362,284	113,573,223	(215,651,936)	194,541,409
Current assets								
Deferred tax assets	5	-	-	-	-	-	7,079,719	7,079,719
Inventories	16	94,618,354	27,267,769	6,944,098	543,674	19,126,233	(5,183,341)	143,316,987
Trade receivables	14.1	155,897,777	40,632,383	25,179,624	203,737	8,779,324	(27,633,153)	203,059,903
Cash and bank balances	17	34,330,862	(30,445,056)	1,817,066	211,518	2,904,183	-	8,818,574
Short-term loans and advances	13	362,309	1,654,334	46,967	372,167	1,546,907	-	3,962,906
Other current assets	14.2	5,501,106	674,742	-	-	-	(881,549)	5,294,298
		290,710,409	39,794,574	33,987,766	1,331,297	32,156,646	(26,598,324)	371,572,387
TOTAL		500,511,539	113,214,045	34,015,023	14,693,580	145,929,869	(242,250,260)	566,113,796
Summary of significant accounting policies								
The accompanying notes are an integral part of the financial statements								

William Smith & Brown, PC

Name of the company : AUROBINDO PHARMA USA INC

Statement of profit and loss for the year ended 31st Mar 2015

(All amounts are in Local Currency except share data and unless otherwise stated)

		Period ended 31st Mar 2015						\$
	Note	APUSA	Aurolife	Auromedics	AuroHealth	Natrol	Adjustments	AUROBINDO PHARMA USA INC
Income								
Revenue from operations (gross)	18	478,442,985	117,389,615	68,678,071	297,145	30,784,385	(81,621,963)	613,970,239
Less: Excise duty								-
Revenue from operations (net)		478,442,985	117,389,615	68,678,071	297,145	30,784,385	(81,621,963)	613,970,239
Profit Share from Partners		-	-	-	-	-	-	-
Other income	19	14,468	1,401,342	64,327	452,946	25,153	(1,104,000)	854,236
Total revenue (I)		478,457,453	118,790,957	68,742,399	750,091	30,809,538	(82,725,963)	614,824,473
Expenses								
Cost of raw material and components consumed	20	-	52,191,820	-	182,640	11,688,374	(3,008,912)	61,053,922
Purchase of trading goods (Includes Short Dated Products of APUSA \$7,841,851 and Auromedics \$2,653,511 aggregating to \$10,495,362)	21	431,959,740	-	60,445,843	-	-	(81,621,963)	410,783,620
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	21	(27,109,474)	(5,041,390)	(1,635,222)	-	2,475,594	-	(31,310,492)
Employee benefit expense	22	11,294,079	18,631,502	4,300,491	1,877,197	5,094,128	-	41,197,399
Other expenses	23	39,221,159	12,215,875	4,827,904	1,636,715	7,337,543	(1,104,000)	64,135,195
Exceptional items	24	-	-	-	-	2,628,725	-	2,628,725
Total (II)		455,365,504	77,997,808	67,939,016	3,696,552	29,224,363	(85,734,875)	548,468,369
Earnings before interest, tax, depreciaton and amortizat		23,091,949	40,793,150	803,382	(2,946,461)	1,585,175	3,008,912	66,336,106
Depreciation and amortization expense	25	303,326	5,488,239	5,593	580,543	1,931,457	-	8,309,158
Finance costs	26	714,990	870,771	32,786	128,945	710,300	-	2,457,792
Profit/(loss) before tax		22,073,632	34,434,140	765,003	(3,655,948)	(1,056,582)	3,008,912	53,569,157
Tax expenses								
Current tax							22,397,202	22,397,202
Less: MAT credit entitlement								
Deferred tax							(2,852,430)	(2,852,430)
Fringe benefit tax								
Tax relating to previous years							2,116,826	2,116,826
Total tax expense		-	-	-	-	-	21,661,598	21,661,598
Profit/(loss) for the year		22,073,632	34,434,140	765,003	(3,655,948)	(1,056,582)	(18,652,686)	33,907,559
Summary of significant accounting policies	1							
The accompanying notes are an integral part of the financial statements.								

Withum Smith Brown & Brown PC

APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated balance	
APUSA												APUSA Consolidated	

<p> Table 3: Reserves and surplus (Part 3) Notes to the Balance Sheet AFSA amounts are in US\$ millions. All other data are in US\$ thousands. </p>												
	AFUSA		Aurilio		Aurionics		AuroHealth		Navid		Elimination - At 31st Mar 2015	AFUSA Consolidated Reserves
	At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015			At 31st Mar 2015
Table 3: Reserves and surplus (Part 3)												
Capital Reserve												
As per last Balance Sheet												
Capital Redemption Reserve												
Securities Premium Account												
As per last Balance Sheet												
General Reserve												
As per last Balance Sheet												
Add: Transferred from statement of profit and loss												
Surplus/(deficit) in the statement of profit and loss												
Balance as per last financial statement	33,830,337		(11,326,378)		1,332,379		(2,632,669)				(6,199,253)	13,034,417
Profit for the year	22,073,632		5,151,140		765,001		(1,655,948)		(1,034,567)		(18,657,686)	31,907,539
Less: Appropriations												
Proposed final equity dividend (amount per share XX (31 March, 2015 XX)												
Tax on proposed equity dividend												
Interim dividend paid (amount per share XX (31 March, 2015 XX)												
Transfer to general reserve												
Total appropriations												
Net surplus in the statement of profit and loss	55,923,969		23,109,763		2,098,382		(6,288,617)		(1,069,132)			44,941,976
Total reserves and surplus	55,923,969		23,109,763		2,098,382		(6,288,617)		(1,069,132)			44,941,976
Table 4: Long-term borrowings (Part 4)												
	Non-current Portion	Current maturities	Non-current Portion	Current maturities	Non-current Portion	Current maturities	Non-current Portion	Current maturities	Non-current Portion	Current maturities	Non-current Portion	Current maturities
	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015
Term loans												
From banks (Secured)			11,841,634									11,841,634
Other loans from banks												
Current account credit balances	80,947,576											80,947,576
Loans and advances from related parties - L1							20,614,451		133,067,684		(153,701,934)	
Other loans and advances												
Sek's us deferment loan (Un Secured)												
	80,947,576		11,841,634				20,614,451		133,067,684		(153,701,934)	92,789,230
The above amount includes												
Secured borrowings												
Unsecured borrowings												
Amount disclosed under the head												
"Other current liabilities"												
Net Assets												

William Smith & Brown, PC

Name of the company : AUROBINDO PHARMA USA INC

Notes to the Balance Sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

	APUSA		AuroLife		AuroMedica		AuroHealth		Natrol		Elimination - At 31st Mar 2015	APUSA Consolidated balance		
Note 5 : Deferred tax liability (net)		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015			At 31st Mar 2015	
Deferred tax liability														
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on an accrual basis														
Provision for diminution in the value of investments														
Provision for doubtful debts and advances														
Fixed Assets (Depreciation)														
Retention Benefits														
Others											6,364,115		6,364,115	
Gross deferred tax liability		-		-		-		-		-	6,364,115		6,364,115	
Deferred tax asset											7,099,719		7,099,719	
Earned Forward Business														
Others														
Gross deferred tax asset		-		-		-		-		-	7,099,719		7,099,719	
Net deferred tax liability		-		-		-		-		-	(735,604)		(735,604)	
Note 6 : Other long-term liabilities		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015			At 31st Mar 2015	
Trade payables (including advances)														
Others														
Advances from customers													-	
Unclaimed dividends													-	
Other liabilities													-	
Interest accrued but not due on loans													-	
Advances from related parties													-	
													-	
													-	
													-	
													-	
Note 7 : Provisions (Rs)		Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current		Non-current	Current
		At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015
Provision for employee benefits														
Gratuity														-
Leave encashment														-
Other Provisions														-
For Taxation (Current)												22,397,202		22,397,202
For Proposed dividend														-
For Tax on proposed dividend														-
												22,397,202		22,397,202
												22,397,202		22,397,202
Provision for warranties														
At the beginning of the year		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015				At 31st Mar 2015
Arising during the year														-
Utilised during the year														-
Unsettled amounts received														-
At the end of the Year														-
Current portion														-
Non-current portion														-

William Smith & Brown, PC

Name of the company : AUROBINDO PHARMA USA INC
Notes to the Balance Sheet
(All amounts are in Local Currency except share data and unless otherwise stated)

	APUSA		AuroLife		AuroMedica		AuroHealth		Natal		Elimination - At 31st Mar 2015	APUSA Consolidated balances		
Note 8 : Short-term borrowings		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015			At 31st Mar 2015	
Book overdraft		-		-		-		-		-			-	
Loans and advances from related parties		-		-		-		-		-			-	
Working capital loans (Secured)		-		-		-		-		-			-	
Short term loans (Un Secured)		23,852,424		1,672,454		-		-		-			24,725,878	
Working capital loans		0		-		-		-		-			0	
		23,852,424		1,672,454		-		-		-			24,725,878	
The above amount includes		-		-		-		-		-			-	
Secured borrowings		-		-		-		-		-			-	
Unsecured borrowings		0		-		-		-		-			0	
Note 9 : Other current liabilities		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015			At 31st Mar 2015	
Trade payables (including interest thereon)		266,312		14,120,232		30,327,991		294,216		8,627,532	(28,379,302)		293,614,113	
Other liabilities		10,539,158		1,218,957		1,368,680		-		4,771,435	(135,401)		17,846,502	
Current maturities of long term borrowings		-		-		-		-		-	-		-	
Trade deposits/Secured		10,539,158		1,218,957		1,368,680		63,703		4,771,435	(135,401)		17,846,502	
		278,912,570		15,549,194		31,716,641		357,949		13,998,966	(28,514,703)		311,440,617	
Note 12 : Non-current investments		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015			At 31st Mar 2015	
Unquoted equity instruments		-		-		-		-		-	-		-	
Investment in subsidiaries		61,950,000		-		-		-		-	(61,950,000)		-	
Investment in joint ventures		-		-		-		-		-	-		-	
Investment in associates		61,950,000		-		-		-		-	(61,950,000)		-	
Note 13 : Loans and advances		Non-current At 31st Mar 2015	Current At 31st Mar 2015	Non-current At 31st Mar 2015	Current At 31st Mar 2015	Non-current At 31st Mar 2015	Current At 31st Mar 2015	Non-current At 31st Mar 2015	Current At 31st Mar 2015	Non-current At 31st Mar 2015	Current At 31st Mar 2015		Non-current At 31st Mar 2015	Current At 31st Mar 2015
Capital advances		-	-	-	-	-	-	-	-	-	-		-	-
Secured, considered good		-	-	-	-	-	-	-	-	-	-		-	-
Unsecured, considered good		-	-	-	-	-	-	-	-	-	-		-	-
(A)		-	-	-	-	-	-	-	-	-	-		-	-
Secured, considered doubtful		-	-	-	50,224	-	-	-	-	-	-		-	50,224
Unsecured, considered doubtful		-	-	-	50,224	-	-	-	-	-	-		-	50,224
Doubtful		-	-	-	50,224	-	-	-	-	-	-		-	50,224
Provision for doubtful security deposit		-	-	-	50,224	-	-	-	-	-	-		-	50,224
(B)		-	-	-	50,224	-	-	-	-	-	-		-	50,224
Unsecured, considered good		141,753,996	-	11,947,940	(0)	-	-	-	-	-	(153,701,936)		(0)	-
(C)		141,753,996	-	11,947,940	(0)	-	-	-	-	-	(153,701,936)		(0)	-
Secured, considered ,and		-	41,543	-	1,285,904	-	-	303,343	4,811,396	-	-		4,811,396	1,630,809
Unsecured, considered		-	41,543	-	1,285,904	-	-	303,343	4,811,396	-	-		4,811,396	1,630,809
Doubtful		-	41,543	-	1,285,904	-	-	303,343	4,811,396	-	-		4,811,396	1,630,809
Provision for doubtful advances		-	41,543	-	1,285,904	-	-	303,343	4,811,396	-	-		4,811,396	1,630,809
(D)		-	41,543	-	1,285,904	-	-	303,343	4,811,396	-	-		4,811,396	1,630,809

William Smith & Browne, PC

Name of the company: AUROBINDO PHARMA USA INC
Notes to the Balance Sheet
(All amounts are in Local Currency except where data and unless otherwise stated)

	APUSA		AuroLife		AuroMedics		AuroHealth		Natal		Elimination - At 31st Mar 2015	APUSA Consolidated balance	
Other loans and advances													
Advance income tax (net of provision for taxation)													
Prepaid expenses		208,591		316,908		40,341		28,893		1,546,907			2,141,659
Loans to employees				1,500									1,500
Loans to others		112,178				6,626							118,803
Export incentives receivable													
Export incentives receivable													
Balance with Statutory / government authorities							34,912						34,912
Total (A+B+C+D+E)	(B)	320,769		318,408		46,967		68,806		1,546,907			2,301,873
		362,309	11,947,940	1,654,536		46,967		372,167	4,811,396	1,546,907	(153,701,936)	4,811,396	3,982,908
Loans and advances due by directors or other officers, etc.													
	Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current		Non-current	Current
	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015		At 31st Mar 2015	At 31st Mar 2015
Loans to employees include													
Dues from non-executive directors													
Dues from officers													
Dues from non-executive and officers' int. with other persons													
Loans and advances to related parties include													
Dues from the partnership firm in which the company's executive director is a partner													
Dues from in which the company's managing director is a member													
Dues from the partnership firm in which the company's non-executive director is a partner													
Note 14: Trade receivables and other assets													
14.1 Trade receivable													
	Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current		Non-current	Current
	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015		At 31st Mar 2015	At 31st Mar 2015
Secured, considered good (and stated otherwise)													
Outstanding for a period exceeding six months from the date they are due for payment													
Secured, considered good													
Due from group companies													
Due from others													
Unsecured, considered good													
Due from group companies													
Due from others													
Doubtful													
Provision for doubtful receivables													
(A)													
Other receivables outstanding for a period less than six months from the date they are due for payment													
Secured, considered good													
Due from group companies													
Due from others													
Unsecured, considered good													
Due from group companies													
Due from others		155,897,777		27,633,153		23,179,634		203,737		8,779,324	(27,633,153)		203,059,903
Doubtful													
Provision for doubtful receivables													
(B)													
Total (A+B)		155,897,777		40,632,583		25,179,634		203,737		8,779,324	(27,633,153)		203,059,903

William Smith & Brown, PC

Name of company: AUROMINDO PHARMA USA INC

Notes to the Balance sheet

(All amounts are in Local Currency except share data and unless otherwise stated)

	AU/USA		AuroLife		AuroMedics		AuroHealth		Nabot		Liquidation - At 31st Mar 2015	AU/USA Consolidated balance sheet	
	Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current		Non-current	Current
	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015		At 31st Mar 2015	At 31st Mar 2015
Trade receivables include:													
Due from non-executive directors													
Due from officers													
Due from non-executive directors and officers													
joint with other persons													
Due from partnership firm in which													
the company's non-executive director is a partner													
Due from in which the company's non-executive													
director is a director													
14.2 Other assets (Refer General Instructions para 16.6 & 2.1)													
	Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current		Non-current	Current
	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015		At 31st Mar 2015	At 31st Mar 2015
Unsecured, considered good (unless stated otherwise)													
Non-current bank balances	200,000		25,417									275,417	
(Non-current Deposits)													
Unamortized expenditure	(A)	200,000	25,417									225,417	
Unamortized premium on forward contract													
Auxiliary cost of arranging the borrowings													
(B)													
Others													
Interest accrued on fixed deposits		43,479											43,479
Interest accrued on investments		140,564		12,741							(135,101)		17,927
Dividend receivable on investments in													
subsidiaries - long term													
Others		5,317,083		661,998							(746,149)		5,232,932
(C)		5,501,106		674,742							(881,549)		5,294,290
Total (A+B+C)	200,000	5,501,106	25,417	674,742							(881,549)	225,417	5,294,290
Note 15: Current Investments		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015			At 31st Mar 2015
Current investments (valued													
unless stated otherwise)													
Quoted equity Instruments - Non-trade													
Equity shares (fully paid-up)													
If any (Please specify)													

William Smith & Brown, PC

Name: Amgen Pharmaceuticals Inc. APUSA (USA INC) Parent: Amgen Pharmaceuticals Inc. (All amounts are in Local Currency, except where indicated otherwise)														
	APUSA		Amgen		Acromedics		AuroHealth		Naze		Elimination - At 31st Mar 2015	APUSA Consolidated balances		
Note 16: Inventories (valued at lower of cost and net realizable value) (Refer to Note 12 for details, from Note 12)		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015		At 31st Mar 2015			At 31st Mar 2015	
Raw materials and components (includes in transit XXX (31 March, 2015 XXX))				12,628,980				119,161		4,753,678			17,311,819	
Work in Progress				9,839,641						7,399,714			17,124,375	
Finished goods		91,618,151		1,448,040		6,944,096		102,921		5,171,672	(5,183,341)		103,101,744	
Traded goods (including stock-in-transit XXXX (31 March, 2014 XXX))														
Stores, spare parts, consumables and packing materials				3,151,108				321,790		1,581,151			5,254,049	
Loose tools														
		94,618,354		27,267,769		6,944,096		543,874		19,126,233	(5,183,341)		143,316,587	
Note 17: Cash and bank balances (Refer General balance sheet Note 12)														
		Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current	Non-current	Current		Non-current	Current
		At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015	At 31st Mar 2015		At 31st Mar 2015	At 31st Mar 2015
Cash and cash equivalents														
Balances with banks:														
On current accounts			34,330,862		(30,345,056)		1,817,066		211,518		2,904,183			8,816,574
Deposits with original maturity of less than 3 months														
Cash credit accounts														
On unpaid dividend account														
Cheques/drafts on hand														
Unpaid matured deposits														
Cash on hand			34,330,862		(30,345,056)		1,817,066		211,518		2,904,183			8,816,574
Other bank balances														
Deposits with original maturity for more than 12 months														
Deposits with original maturity for more than 3 months but less than 12 months														
Margin money deposit														
Amount classified under non-current assets														
			34,330,862		(30,345,056)		1,817,066		211,518		2,904,183			8,816,574

William Smith & Brown, PC

Name of the company : AUROBINDO PHARMA USA INC
Notes to the statement of profit and loss for the year ended 31st Mar 2015
(All amounts are in Local Currency except share data and unless otherwise stated)

	AUROBINDO PHARMA USA INC						\$
	AUSA	AuroLife	AuroMedics	AuroHealth	Natrol	Adjustments	AUROBINDO PHARMA USA
Note 18 : Revenue from operations (Refer General Instructions Note No.25)							
Revenue from operations							
Sale of products							
Finished goods	478,442,985	117,389,615	68,678,071	297,145	30,784,385	(81,621,963)	613,970,239
Traded goods							-
Other operating revenue							
Scrap sales							
Other							
Revenue from operations (gross)	478,442,985	117,389,615	68,678,071	297,145	30,784,385	(81,621,963)	613,970,239
Less: VAT/Excise duty							
Revenue from operations (net)	478,442,985	117,389,615	68,678,071	297,145	30,784,385	(81,621,963)	613,970,239
Note 19 : Other income (Refer General Instructions Note No.26)							
Interest income on							
Bank deposits	-	-	-	-	-	-	-
Long-term investments	-	-	-	-	-	-	-
Current investments	-	-	-	-	-	-	-
Loans to joint venture entities	-	-	-	-	-	-	-
Income Others	14,468	1,401,342	64,327	452,946	25,153	(1,104,000)	854,236
Dividend income on							
Investment in subsidiaries	-	-	-	-	-	-	-
Current investments	-	-	-	-	-	-	-
Long-term investments	-	-	-	-	-	-	-
Net gain on sale of current investments	-	-	-	-	-	-	-
Profit on sale of fixed assets (net)	-	-	-	-	-	-	-
Foreign exchange gain (net)	-	-	-	-	-	-	-
Balances no longer required written back	-	-	-	-	-	-	-
Government grant	-	-	-	-	-	-	-
Commission income	-	-	-	-	-	-	-
Processing charges	-	-	-	-	-	-	-
Other non-operating income (net of expenses directly attributable to such income of Rs.XXXXX (31 March, 2015:XXXX)	-	-	-	-	-	-	-
	14,468	1,401,342	64,327	452,946	25,153	(1,104,000)	854,236

William Smith & Brown, PC

William Smith Brown & Brown PC

C-3

CEO, Aurobindo Pharma USA Inc

Name of the company : AUROBINDO PHARMA USA INC
Notes to the statement of profit and loss for the year ended 31st Mar 2015
(All amounts are in Local Currency except share data and unless otherwise stated)

	AUROBINDO PHARMA USA INC						\$
	APUSA	AuroLife	AuroMedics	AuroHealth	Natrol	Adjustments	AUROBINDO PHARMA USA
Note 20 : Cost of raw material and components consumed							
Inventory at the beginning of the Year		18,938,587		215,700	6,294,584	(8,192,253)	17,256,618
Inventory at the beginning of the Year							
Add: Purchases - Raw Materials & Excipients		49,210,509	-	510,814	11,738,616		61,459,940
Add: Purchases - Packing Materials	-	68,149,096	-	726,514	18,033,200	(8,192,253)	78,716,557
Less: inventory at the end of the Year		15,980,088		543,874	6,344,826	(5,183,341)	17,685,448
	-	52,169,007	-	182,640	11,688,374	(3,008,912)	61,031,109
Add: Other COGS		22,813	-				22,813
	-	52,191,820	-	182,640	11,688,374	(3,008,912)	61,053,922
Cost of raw material and components consumed - Includes Packing Mat \$6,503,970 of AuroLife)							
Note 21 : (Increase)/decrease in inventories							
Inventories at the end of the Year							
Traded goods	94,618,354		6,944,098				101,562,452
Work - in - Progress		9,839,641			7,309,734		17,149,375
Finished goods		1,448,040			5,471,672		6,919,712
	94,618,354	11,287,681	6,944,098	-	12,781,406	-	125,631,539
Inventories at the beginning of the Year							
Traded goods	67,508,880		5,308,876				72,817,756
Work-in-progress		6,012,173			4,322,000		10,334,173
Finished goods		234,118			10,935,000		11,169,118
	67,508,880	6,246,291	5,308,876	-	15,257,000	-	94,321,047
	(27,109,474)	(5,041,390)	(1,635,222)	-	2,475,594	-	(31,310,492)
Details of purchase of traded goods							
Product A							-
Product B							-
Product C							-
	-	-	-	-	-	-	-

William Smith + Brown, PC

Name of the company : AUROBINDO PHARMA USA INC
Notes to the statement of profit and loss for the year ended 31st Mar 2015
(All amounts are in Local Currency except share data and unless otherwise stated)

	AUROBINDO PHARMA USA INC						\$
	APUSA	AuroLife	AuroMedics	AuroHealth	Natrol	Adjustments	AUROBINDO PHARMA USA
Note 22 : Employee benefit expense							
Salaries, wages and bonus	10,135,860	16,422,004	3,908,342	1,739,692	3,845,565	-	36,051,463
Contribution to provident and other fund	204,238	214,030	66,857	25,912	-	-	511,038
Employee stock option scheme	-	-	-	-	-	-	-
Gratuity expense	-	-	-	-	-	-	-
Other employee benefits	904,916	1,992,880	325,292	111,593	1,199,021	-	4,533,701
Post employment medical benefits	-	-	-	-	-	-	-
Staff welfare expenses	49,066	2,589	-	-	49,542	-	101,197
	11,294,079	18,631,502	4,300,491	1,877,197	5,094,128	-	41,197,399
Note 23 : Other expenses							
Consumption of stores and spares	-	312,793	-	6,956	-	-	319,749
Conversion charges	-	81,487	-	-	2,180	-	83,667
Chemicals consumed	281,409	863,445	(87,609)	86,176	30,275	-	1,173,696
Increase in VAT on finished goods	-	-	-	-	-	-	-
Customer service expenditure	-	-	-	-	-	-	-
Power and fuel	-	1,496,653	-	177,790	-	-	1,674,443
Water charges	-	-	-	-	-	-	-
Carriage inward	832,437	1,889	-	-	177,375	-	1,011,701
Carriage outwards	5,771,806	845,466	1,020,644	23,258	1,130,643	-	8,791,817
Rent	963,415	52,519	144,000	-	568,222	(1,104,000)	624,156
Rates and taxes	987,877	720,169	3,300	455,104	140,549	-	2,306,998
Insurance	191,920	283,474	22,860	75,748	173,573	-	747,575
Repairs and maintenance	-	-	-	-	-	-	-
i) Plant and machinery	5,690	1,383,117	-	81,901	80,859	-	1,551,567
ii) Buildings	-	493,178	-	22,752	23,006	-	538,936
iii) Others	-	246,840	-	8,367	132,021	-	387,228
Advertising and sales promotion	248,544	-	228,233	94,882	3,184,392	-	3,756,050
Brokerage and discounts	-	-	-	-	-	-	-
Remuneration to Auditors	115,489	80,342	60,000	7,227	19,942	-	283,000
Sales commission	-	636	-	-	515,294	-	515,930
Travelling and conveyance	520,214	49,383	484,045	119,778	133,572	-	1,306,991
Communication costs	293,424	48,973	48,244	34,485	43,056	-	468,182
Printing and stationery	111,231	44,401	319	1,351	-	-	157,303
Legal and professional fees	462,582	115,410	47,738	29,693	310,791	-	966,214

William Smith Brown, PC

Name of the company : AUROBINDO PHARMA USA INC
Notes to the statement of profit and loss for the year ended 31st Mar 2015
(All amounts are in Local Currency except share data and unless otherwise stated)

	AUROBINDO PHARMA USA INC						\$
	APUSA	AuroLife	AuroMedics	AuroHealth	Natrol	Adjustments	AUROBINDO PHARMA USA
Directors sitting fees	-	-	-	-	-	-	-
Payment to auditor (Refer details below)	-	-	-	-	-	-	-
Provision for diminution in value of investment in subsid	-	-	-	-	-	-	-
Provision for other than temporary decline in the carrying amount of other long-term investments	-	-	-	-	-	-	-
Adjustment to the carrying amount of current investment	-	-	-	-	-	-	-
Provision for warranties (net of reversals)	-	-	-	-	-	-	-
Provision for litigations (net of reversals)	-	-	-	-	-	-	-
Exchange differences (net)	-	-	-	-	-	-	-
Loss on derivative contracts (including provisions mark-	-	-	-	-	-	-	-
Bad debts/advances written off	2	-	-	-	(4,282)	-	(4,280)
Impairment loss on fixed assets	-	-	-	-	-	-	-
Provision for doubtful debts and advances	-	-	-	-	-	-	-
Loss on sale of fixed assets (net)	-	-	-	-	-	-	-
Premium on forward exchange contract amortized	-	-	-	-	-	-	-
Factory maintenance	-	1,097,095	-	62,582	38,929	-	1,198,605
Waste Management expenses	63,036	59,243	-	6,065	10,755	-	139,099
Vehicle maintenance expenses	-	-	-	-	-	-	-
Analytical charges	6,111	695,527	69,994	135,300	101,575	-	1,008,507
Product development expenses	-	2,426,308	210,040	-	-	-	2,636,348
Registration and filing charges	56,874	20,409	448,300	11,654	-	-	537,237
Safety and security	40,861	454,903	-	69,999	4,958	-	570,721
Office expenses	456,203	185,450	79,514	21,731	56,728	-	799,627
Repairs and maintenance - others	238,709	245	-	-	-	-	238,954
Liquidated damages	-	-	-	-	-	-	-
Donations	5,150	-	-	-	-	-	5,150
Software license and implementation expenses	122,944	9,980	72,177	-	-	-	205,102
Capital work-in-progress written off	-	-	-	-	-	-	-
Sales Returns - Processing Fee	297,549	-	-	-	-	-	297,549
Supply Penalty - Delayed Supply	16,021,636	-	1,602,960	-	-	-	17,624,596
Product liability insurance	1,426,198	-	195,390	-	-	-	1,621,589
Recruitment and interview expenses	110,446	56,363	4,154	58,755	186,234	-	415,952
Medicaid expenses	9,312,636	-	59,946	-	-	-	9,372,582
Miscellaneous expenses	276,764	90,178	113,656	45,160	276,898	-	802,656
	39,221,159	12,215,875	4,827,904	1,636,715	7,337,543	(1,104,000)	64,135,195

William Smith & Brown, PC

Name of the company : AUROBINDO PHARMA USA INC
Notes to the statement of profit and loss for the year ended 31st Mar 2015
(All amounts are in Local Currency except share data and unless otherwise stated)

	AUROBINDO PHARMA USA INC						\$
	APUSA	AuroLife	AuroMedics	AuroHealth	Natrol	Adjustments	AUROBINDO PHARMA USA
Payment to Auditor							
As auditor:							
Audit fee	22,489	80,342	60,000	7,227	19,942	-	190,000
Tax audit fee							-
Limited review							-
In other capacity:							
Taxation matters							-
Company law matters							-
Management services							-
Other services (certification fees)	93,000						93,000
Reimbursement of expenses							
	115,489	80,342	60,000	7,227	19,942	-	283,000
Note 24 : Exceptional items							
Brokerage Fee					1,750,000		1,750,000
Legal Fee					430,000		430,000
Business Consulting & Due Diligence					230,761		230,761
Sales Tax					166,227		166,227
Other Expenses - Aquisition	-	-	-	-	51,737		51,737
	-	-	-	-	2,628,725	-	2,628,725
Note 25 : Depreciation and amortization expense							
Depreciation of tangible assets	234,540	5,335,239	5,593	580,543	312,195	-	6,468,110
Amortization of intangible assets	68,786	153,000	-	-	1,619,261	-	1,841,047
Depreciation of investment property	-	-	-	-	-	-	-
	303,326	5,488,239	5,593	580,543	1,931,457	-	8,309,158
Note 26 : Finance costs (Refer General Instructions Note No 22)							
Interest	369,917	794,453	-	124,568	666,837	-	1,955,776
Bank charges	345,074	76,318	32,786	4,376	43,463	-	502,017
Amortization of ancillary borrowing costs	-	-	-	-	-	-	-
Exchange difference to the extent considered as an adjust	-	-	-	-	-	-	-
	714,990	870,771	32,786	128,945	710,300	-	2,457,792

William Smith & Brown, PC

Name of the company : AUROBINDO PHARMA USA INC										
Notes to the Balance Sheet										
(All amounts are in Local Currency except share data and unless otherwise stated)										
Note 10 : Tangible assets (Refer General Instructions Note No.11)										
	Leasehold Land	Freehold Land	Leasehold Buildings	Freehold Buildings	Plant & Equipment (including Computers &c)	Computer	Furniture & fixtures	Vehicles	Office Equipment	Consolidated Total
Cost or valuation	-	6,211,390	-	40,612,572	42,629,804	-	1,090,663	2,926	1,461,287	92,008,642
At 31 March 2014	-	3,545,471	-	2,190,141	3,355,575	-	548,054	-	244,015	9,883,256
Additions	-	-	9,450	-	3,704,182	-	401,266	3,000	340,480	4,458,378
Through Acquisitions	-	-	-	-	-	-	-	-	-	-
Disposals	-	-	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	-	-	-	-	-	-
- Exchange differences	-	-	-	-	-	-	-	-	-	-
- Borrowing costs	-	-	-	-	-	-	-	-	-	-
At 31st Mar 2015	-	9,756,861	9,450	42,802,713	49,689,561	-	2,039,983	5,926	2,043,782	106,350,276
Depreciation	-	-	-	-	-	-	-	-	-	-
At 31 March 2014	-	-	-	4,008,778	11,251,016	-	596,492	2,779	987,136	16,846,201
Charge for the period	-	-	315	1,402,287	4,568,261	-	267,798	521	228,931	6,468,114
Disposals	-	-	-	-	-	-	-	-	-	-
Other adjustments	-	-	-	-	-	-	-	-	-	-
- Exchange differences	-	-	-	-	-	-	-	-	-	-
At 31st Mar 2015	-	-	315	5,411,065	15,819,278	-	864,289	3,300	1,216,068	23,314,315
Net Block	-	-	-	-	-	-	-	-	-	-
At 31 March 2014	-	6,211,390	-	36,603,794	31,378,787	-	494,171	147	474,151	75,162,440
At 31st Mar 2015	-	9,756,861	9,135	37,391,648	33,870,283	-	1,175,693	2,626	829,714	83,035,961

William Smith & Brown, PC

Consolidated APUSA Intangibles Schedule

Notes to the statement of profit and loss

(All amounts are in Local Currency except share data and unless otherwise stated)

Note 11 : Intangible assets

	Goodwill/Software & Other Intangibles	Product Development cost	Licences and patents	Consolidated Total
Gross block				
At March 31, 2014	1,427,564	-	40,660	1,468,224
Additions during the Twelve months	103,584,033	-	62,700	103,646,733
Disposals during the Twelve months	-	-	-	-
Additions on acquisition	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At 31st Mar 2015	105,011,597	-	103,360	105,114,957

Amortization

At March 31, 2014	916,201	-	40,660	956,861
Charge for the period	1,841,047	-	-	1,841,047
Disposals	-	-	-	-
Other adjustments	-	-	-	-
- Exchange differences	-	-	-	-
At 31st Mar 2015	2,757,248	-	40,660	2,797,908
Net Block				
At March 31, 2014	511,363	-	-	511,363
At 31st Mar 2015	102,254,349	-	62,700	102,317,049

William Smith & Brown, PC

Condensed Notes to Special Purpose Consolidated Financial Statements for the Year Ended March 31, 2015

(All amounts in United States Dollars, except otherwise stated)

1. GENERAL INFORMATION

Aurobindo Pharma USA, Inc. ("APUSA" or the "Company" or the "US parent company") is a corporation registered in the State of Delaware. The corporate office of the Company is located in Dayton, New Jersey. The Company is a wholly owned subsidiary of Aurobindo Pharma Limited ("APL"), a company incorporated and listed on various stock exchanges in India. The Company markets, sells, and distributes, in the United States of America, generic prescription drugs manufactured by APL and Aurolife Pharma, LLC, a wholly owned subsidiary of APUSA and through its Natrol, LLC subsidiary (from December 4, 2014 forward) dietary, herbal and hormonal supplements; vitamins, specialty formulations and sport nutritional products.

Effective on April 1, 2013, ownership of Aurohealth, LLC ("Aurohealth") was transferred to the Company. Prior to that date, Aurohealth was owned and managed by APL. Given the level of common control within the APL group, the assets and liabilities of Aurohealth were transferred to and recorded by the Company at historical cost values and the accounts of Aurohealth were consolidated from April 1, 2013 forward (see Note 5).

Effective December 4, 2014 pursuant to the terms and conditions of an Asset Purchase Agreement ("APA"), the Company acquired certain assets and assumed liabilities of Natrol Inc. for total cash consideration of \$ 131,750,000. The acquisition has been accounted for as a business combination, with Natrol, LLC ("Natrol", a newly formed and wholly owned subsidiary of the Company) as the successor entity. The acquired assets and assumed liabilities at December 4, 2014 have been recorded at the then relative fair values, which may be subject to change based on the resolution of a dispute among the parties to the APA (see Note 3). The accompanying consolidated financial statements reflect the operations of Natrol from December 4, 2014 through March 31, 2015.

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation

The special purpose consolidated financial statements of Aurobindo Pharma USA, Inc. are prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). Such special purpose consolidated financial statements and notes thereto are prepared in a format that is established by APL in accordance with US GAAP. The special purpose consolidated financial statements include the parent company and its subsidiaries, Aurohealth (effective April 1, 2013), Aurolife Pharma, LLC ("Aurolife") and Auromedics Pharma LLC ("Auromedics") and Natrol (effective December 4, 2014) collectively referred to as the "Group". All intercompany transactions and balances within the Group have been eliminated.

Estimates and Assumptions

In preparing the special purpose consolidated financial statements, certain estimates and assumptions are used that affect reported amounts and disclosures. These estimates and assumptions are evaluated using historical experience and other factors, including the economic environment. These estimates often are based on complex judgments, probabilities and assumptions that are believed to be reasonable but are inherently uncertain and unpredictable. Significant estimates used by the Company include: the valuation of receivables and revenue based on estimated allowances, the preliminary allocation of the Natrol purchase price, the useful lives ascribed to fixed and intangible assets, valuation of inventory and deferred tax assets and the measurement of accrued expenses.

As future events and their effects cannot be determined with precision, the estimates and assumptions may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Adjustment to estimates and assumptions are made when facts and circumstances indicate the need for change. Other risks and uncertainties may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, product quality, competition, litigation, legislation and regulations. The operations and product of Company and APL are regulated by the United States Food & Drug Administration ("FDA").

Concentrations

At present, the Company transacts business with a finite amount of third parties. The related concentrations, as a percentage of totals as of or for the year ended March 31, 2015, are:

Customers	As a Percentage of Revenue from Operations	As a Percentage Trade Receivables, Net
Customer A	11 %	15 %
Customer B	10 %	18 %
Customer C	23 %	24 %
Customer D	6 %	6 %
Manufacturer/Supplier	Purchases of Inventory	Trade Payables
APL	83%	96%

At March 31, 2015 the amount of APL purchased product and materials in inventory approximated \$101.6 million.

The Company has a significant level of its fixed assets and manufacturing plants concentrated in three distinct buildings. Management believes that the risks associated with such holdings are adequately insured by coverage provided by independent carriers.

Cash and cash equivalents

Cash and cash equivalents include cash at banks and interest bearing deposits at various banks.

Inventories

Inventories are valued at lower of cost or market. Inventories include raw materials, packing materials, stores, spares, and consumables.

Work-in-process and Finished goods

Based upon instructions from APL, effective April 1, 2013, the Company adopted a weighted average methodology in accounting for inventory. Cost of finished goods and work-in-process includes materials, labor and a proportion of appropriate overheads. Valuation allowances are provided, when appropriate, for off standard and dated or expired product. During Fiscal 2015, the Company recognized a provision of approximately \$7.8 million to provide for dated and expired product. Approximately 83% of the Company's Fiscal 2015 inventory purchases were transacted with APL.

Property, plant, and equipment

Property, plant, and equipment, are recorded at original cost and at fair value at for Natrol fixed assets. Property, plant and equipment assets, other than land and capital work-in-progress, are depreciated on a straight line basis over the estimated useful life of the individual assets. Useful lives of fixed assets at March 31, 2015 were as follows:

i	Buildings	30 Years
ii	Plant and machinery	5-15 Years
iii	Lab equipment	4-10 Years
iv	Warehouse Equipment	5 Years
v	Office equipment	5 Years
vi	Furniture and fixtures	5-6 Years
vii	Vehicles	5 Years

Repairs and maintenance expenses that do not extend the useful lives of property, plant, and equipment are charged to income in the year in which incurred.

At March 31, 2015, the Company was contractually committed to purchase or fund approximately \$ 1.2 million of various capital expenditures. In addition, the Company has announced plans to construct a new facility; at March 31, 2015, the expected amount of costs associated with completing this facility are estimated at \$30 million (unaudited).

The Company has also capitalized interest costs incurred in connection with the debt proceeds used to fund the development and installation of equipment to be utilized in Auroheath and the construction of the aforementioned facility. The capitalized interest cost at March 31, 2015 approximated \$184,000.

The Company has a solar power project at one of its facilities and has generated (and is the beneficiary of) 1,070 solar renewal energy credits ("SRECs") and had sold 122 SRECs in the exchange for an value of \$20,374 leaving a balance of 948 SRECs as of March 31, 2015 with a market value of \$196,331; such amount is recorded in other current assets at that date. The Company expects to receive the proceeds of the sale of such credits in Fiscal 2016.

Research and development costs

Research and development costs are charged to expense when incurred, such costs (including salaries and related benefits approximated \$4.4 million in Fiscal 2015. A significant amount of research and development costs in the development of the Company's products are incurred by APL and their affiliates. There are no allocated costs to the Company's Fiscal 2015 special purpose consolidated financial statements. Equipment acquired for research and development activities and having alternative future uses are capitalized as part of property, plant and equipment.

At March 31, 2015, the Company was contractually committed to purchase approximately \$752,000 of research and development expenditures.

Goodwill & Intangible assets

Goodwill represents the excess of cost over the fair value of net assets acquired in the Natrol acquisition. Goodwill has an indefinite life and is not amortized for US GAAP but is considered deductible for tax purposes.

Intangible assets with finite lives are amortized over their respective estimated useful lives to their estimated residual values. Intangible assets are comprised of the fair values ascribed to Natrol's customer relationships and acquired brand products. Customer relationships are amortized over 5 years and acquired brands over 13 to 20 year terms. The carrying values of intellectual property, product rights and associated development costs related to the Company's generic formulations are recorded at the APL level.

Impairment of Long-Lived Assets

Fixed and Intangible Assets - The Company evaluates the recoverability of such assets when indicators of impairment exist. US GAAP requires recognition of impairment of long-lived assets in the event the net carrying value of these assets exceeds the estimated future undiscounted cash flows attributable to such assets. Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of these assets in relation to the operating performance of the business and the future discounted cash flows expected to result from the use of these assets. If the carrying value of an asset exceeds its estimated future cash flows, an

impairment charge is recognized by the amount by which the carrying value of the asset exceeds the fair value of the asset. There were no impairment charges recognized in the year ended March 31, 2015.

Goodwill – US GAAP allows the Company to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If Management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management conducts a two-step quantitative goodwill impairment test. Given the recency of the Natrol acquisition and an assessment of other factors, the Company determined that there was no impairment of goodwill at March 31, 2015. However, as discussed in Note 3, the preliminary allocation of the Natrol purchase price is subject to change.

Revenue recognition

Revenue is recognized when the goods are received by the customer. Gross sales are subject to a variety of deductions such as chargebacks, sales rebates, discounts (including cash discounts) and incentives, and product returns that generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of the related obligation and concessions and, as such, past experience, judgment and knowledge of market conditions and practices are required when estimating the impact of these deductions on gross sales for a reporting period.

Sales returns are based on returns policies and practices, returns as a percentage of sales, estimated shelf life of product, and other factors that could impact the estimate of future returns, such as product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.

Income Taxes

The Company files a consolidated Federal tax return and returns in various states. Deferred income taxes are provided on a liability method whereby deferred income tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred income tax liabilities are recognized for taxable temporary differences. Temporary differences are the amounts between the reported amounts of assets and liabilities and their tax basis. Deferred income tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

US GAAP clarifies the accounting for uncertainty in income taxes recognized in an entity's financial statements and prescribes a recognition threshold of more-likely-than-not to be sustained upon a tax examination. Measurement of the tax uncertainty occurs if the recognition threshold has been met. This interpretation also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosures. There have been no tax related interest or penalties recognized for Fiscal 2015.

In the normal course of business, the Company and Parent are subject to examination by taxing authorities. The Company's tax returns for years subsequent to Fiscal 2011 are open, by statute, for review by authorities. The Internal Revenue Service ("IRS") conducted examinations of the Company's Federal income tax returns for Fiscal 2010 and Fiscal 2013. The examinations were completed and draft agreements are subject to the IRS' customary supervisory approval process, expected in Fiscal 2016. At present, the examinations' findings resulted in no material changes to the previously filed returns.

3. NATROL ACQUISITION

Allocation of the Purchase Price

The initial purchase price of Natrol on December 4, 2014 has been allocated based on estimated fair values at that date, for the various assets and liabilities assumed under the APA. The Company ascribed fair values based on its estimates and third party technical evaluation for the various tangible and intangible assets acquired. The following table summarizes the preliminary allocation of purchase price consideration, for the fair values of the assets acquired and liabilities assumed and the determination of goodwill:

Total Purchase Price	<u>\$131,750,000</u>
Fair Value of Net Assets Acquired:	
Cash equivalents	3,309,000
Accounts receivable, net	10,631,000
Inventory	21,600,000
Property and equipment (includes Construction in Progress)	6,747,000
Intangibles – customer relationships and brand products	45,600,000
Other assets	<u>5,398,000</u>
Total	<u>93,285,000</u>
Liabilities assumed:	
Accounts payable, accrued expenses and customer deposits	<u>18,669,000</u>
Less: Fair Value of Net Assets Acquired and Liabilities Assumed	<u>74,616,000</u>
Goodwill, as of December 4, 2014	<u>\$57,134,000</u>

The total cost associated with the acquisition was \$2,628,725, primarily comprised of professional and broker fees and investment advisor fees. This amount has been expensed as an operating charge in the statement of operations for Fiscal 2015. In addition, included in Cost of Goods Sold for Fiscal 2015 is a charge of \$ 4,500,000 related to the "step-up" (that is the December 4, 2014 fair value over historical cost) of acquired inventory subsequently sold.

The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values on December 4, 2014. The excess of the purchase consideration over the fair value of the net assets acquired has been allocated to goodwill. The preliminary purchase price allocation may be adjusted after obtaining more information regarding, among other items, valuations of assets acquired, liabilities assumed and revisions of preliminary estimates. The preliminary purchase price may also be adjusted for the resolution of legal matters (as discussed below) between the parties. Also see Note 4 for disclosure of the debt financing of this acquisition.

Dispute Among the Parties to the APA

On April 6, 2015 the Company filed a complaint against the sellers group regarding certain discrepancies in the value of acquired assets under the APA. The complaint sought specific monetary damages related to this action. Subsequent to that date, the parties reached a settlement on the complaint pursuant to which the Company is entitled to receive consideration in the form of cash; certain global intellectual property rights and other assets. The Company may also be obligated to assume certain disputed liabilities (not included in the initial purchase price allocation). The proposed settlement, as well as the receipt of the aforementioned consideration included therein, is: (a) subject to approval by the *Bankruptcy Court of the District of Delaware* and (b) dependent on the availability of cash to the sellers, which is subject to further due diligence, analysis and investigative efforts.

As the approvals and conditions have not been received or satisfied as of May 21, 2015 there is, at this time, no basis to record an adjustment to the initial purchase price allocation presented above. Due to the inherent uncertainties in resolving these type matters, there can be no assurances that the Company will be successful in enforcing the terms of the settlement. To the extent that the Company is successful in realizing the cash aspect of the settlement and is assigned the use of intellectual property within Fiscal 2016, the Company will be required to revalue the amounts ascribed to the initial purchase price allocation. Such amounts could be material.

4. FINANCING ARRANGEMENTS

Line of Credit

Short-term loan represents a line of credit of \$ 53 million (amount available as of March 31, 2015) sanctioned to the Company by Wells Fargo Bank. The line of credit is secured by current assets and non-current assets of the Group, excluding intangibles assets. Interest on this line is payable at one month London Interbank Offered Rate ("LIBOR") plus 250 basis points. The interest rate in effect and the amount outstanding at March 31, 2015 are 2.67% and \$ 0, respectively. The Company expects to terminate this line of credit in Fiscal 2016 and replace it with a successor facility syndicated with Wells Fargo Bank and Bank of Tokyo-Mitsubishi UFJ, LTD ("BOT").

Natrol Debt and Other Loans

Natrol Debt

In connection with the Natrol acquisition, the Company obtained unsecured debt financing from the Bank of Tokyo-Mitsubishi UFJ, LTD ("BTMU") and Australia and New Zealand Banking Group Limited ("ANZBG") in the amounts of \$60,000,000 and \$48,000,000 respectively.

With respect to the BOT agreement, quarterly principal payments of approximately \$3.5 million are required through the maturity date of December 3, 2019. Through March 3, 2015, interest on this debt accrued at a rate indexed to the BOT Term Fed Funds Rate plus 1.05% and, prospectively, interest accrues at the LIBOR plus 1.05%.

With respect to the ANZBG agreement, quarterly principal payments of approximately \$4 million are required through the maturity date of December 3, 2017. Interest on this debt accrues at a rate indexed to the defined LIBOR plus 1.25%.

In addition the Company is subject to certain reporting, financial and other covenants; including, but not limited to, the Company's defined Debt to Net Worth levels and Debt Service ratios. The Company is in compliance with such covenants at March 31, 2015.

Debt Summary

The amounts of short and long-term loans outstanding as of March 31, 2015, with interest rates, were as follows:

Payee	Classified as	Outstanding as of March 31, 2015	Interest Rate per Annum	Security
Mortgage	Short & Long Term	\$10,832,926	LIBOR+3%	All Fixed and Personal Assets - Aurobindo US Entities
Wells Fargo - Equipment 1	Short & Long Term	222,921	4.6%	All Fixed and Personal Assets - Aurobindo US Entities
Wells Fargo - Equipment 2	Short & Long Term	619,095	3.86%	All Fixed and Personal Assets - Aurobindo US Entities
Wells Fargo - Equipment 3	Short & Long Term	195,453	3.92%	All Fixed and Personal Assets - Aurobindo US Entities
Wells Fargo - Solar 1	Short & Long Term	602,504	4.10%	All Fixed and Personal Assets - Aurobindo US Entities
Wells Fargo - Solar 2	Short & Long Term	1,042,189	4.69%	All Fixed and Personal Assets - Aurobindo US Entities
BTMU	Short & Long Term	60,000,000	LIBOR+1.05%	Unsecured - Corporate Guarantee Provided by APL
ANZBG	Short & Long Term	44,000,000	LIBOR+1.25%	Unsecured Corporate Guarantee Provided by APL
Total		\$117,515,088		

Of the total amount of \$117,515,088 the short term portion of the loans was \$ 24,725,878 at March 31, 2015.

5. RELATED PARTIES

While APL provides a guarantee on the Natrol debt discussed in Note 4, the Company does not have any financing debts with Related Parties as of March 31, 2015:

The names of related parties and the nature of relationship are as follows:

Name of the related party	Country of incorporation	Relationship
Aurobindo Pharma Limited	India	APL – parent company
Aurolife Pharma, LLC	United States of America	100% owned subsidiary
Auromedics Pharma, LLC	United States of America	100% owned subsidiary
Pravesha Industries Private Limited	India	Significant influence exerted by APL – parent company
Aurohealth LLC	United States of America	100 % owned subsidiary
Natrol, LLC	United States of America	100 % owned subsidiary
Helix Healthcare B. V.	Netherlands	100 % owned subsidiary of APL

Statements of Profit and Loss– the details of transactions with related parties during Fiscal 2015 are as follows:

Name of related party	Nature of transaction	Amount
Aurobindo Pharma Limited	Equity contribution received	-
	Repayment of loan and guaranties	-
	Services provided	\$218,697
	Purchase of raw material	\$ 28,625,049
	Purchase of finished goods, net	\$409,835,978
	Purchase of fixed assets	-
	Sale of assets	\$456,685
	Interest expense	-
	Reimbursement of expenses	-
Pravesha Industries Private Limited	Reimbursement of product recall costs	\$241,640
	Purchase of packing material	\$1,911,711
Helix Healthcare B. V.	Interest expense for short term loan of \$20 million	\$14,282

Balance Sheet - the details of amounts receivable from (due to) related parties as of March 31, 2015 are as follows:

Name of related party	Nature of balance outstanding	
Aurobindo Pharma Limited	Accounts receivable	-
	Other receivables	\$135,401
	Accounts payable	(\$281,896,265)
	Interest payable	-
	Loan payable	-
Pravesha Industries Private Limited	Accounts payable	(\$ 456,199)

Equity Transactions and Transfer of Subsidiary

As discussed in Note 1, effective April 1, 2013, the assets (liabilities) of Aurohealth were contributed to (or assumed by) the Company. The related assets contributed and liabilities assumed were:

Fixed Assets	\$1,026,224
Current Assets	37,479
Current Liabilities	<u>(1,303,906)</u>
Net Liability Assumed	<u><u>\$ (240,203)</u></u>

A substantial portion of the current liabilities at April 1, 2013 were payable to the Company; such amounts are eliminated in the preparation of the consolidated financial statements. Additional paid in capital was charged for the effects of the assumed net liability.

6. TAXES

The components of income tax provision (benefit) are as follows for Fiscal 2015 follows:

Current :	
Federal	\$ 20,926,467
State	<u>1,470,735</u>
	<u>22,397,202</u>
Deferred:	
Federal	(698,522)
State	<u>(37,082)</u>
	<u>(735,604)</u>
Total	<u><u>\$ 21,661,598</u></u>

Income tax expense differs from the amounts that would be obtained by applying Federal statutory rates to income before provision for income taxes due to the effects of state taxes, estimated tax credits and differences prior year end estimates and actual tax liabilities.

7. LEGAL MATTERS

Aurobindo had filed an Abbreviated New Drug Application ("ANDA") for Minocycline ER tablets with "Paragraph IV" certification and had been sued by the brand manufacturer, Medicis. Subsequently, Aurobindo and Medicis settled the litigation in September 2011. As part of the settlement agreement, both the companies have submitted the agreement to the United States Federal Trade Commission ("FTC") who is currently reviewing the agreement. The FTC review has not been completed as of May 21, 2015 and management has responded to all information requests. Management does not expect, at present, that the outcome of this matter will have a material adverse effect on the Company's financial position, results or cash flows, as this product was not approved at the time of the FTC request and has not been commercially launched.

In February 2015, the State of Alaska served a Civil Investigative Demand on the Company related to an investigation concerning a settlement agreement the Company and a manufacturer entered into that terminated patent litigation on a specific brand drug. No allegations of wrongdoing have been made against the Company; management is cooperating with the investigation and intends to respond to requests for information.

In June 2014, the State of Texas served a Civil Investigative Demand on the Company related to an investigation concerning the pricing and marketing of the Company's products. No allegations of wrongdoing have been made against the Company and management has cooperated fully with this investigation. In May 2015, the State of Texas and the Company have negotiated a settlement in principle to resolve the matter at an amount that approximates the Company's recorded liability at March 31, 2015. The formal approval of settlement in principle is subject to certain conditions, as well as the approval of the State of Texas.

In the normal course of operations, the Company and APL have been named as defendants in legal actions related to patent infringement claims arising from the filing of generic products' *Abbreviated New Drug Applications* with the FDA. Since the Company and APL have not received regulatory approval and commenced the sale of these products; at present, the Company does not believe that the ultimate outcome of such matters will have an adverse material effect on the Company's financial position, results of operations and cash flows. However, prospective periods' forecasted revenue could be affected by the regulatory and legal process.

8. SUBSEQUENT EVENTS

The Company has evaluated subsequent events occurring after the consolidated financial statement date through the date of May 21, 2015 which is the date the consolidated financial statements were available to be issued. Based on the evaluation, other than the aforementioned settlement in principle with the State of Texas (see Note 7), the Company has determined that there are no additional subsequent events that require adjustment to or disclosure in the accompanying financial statements.

AurobindoPharma NZ Limited:

AurobindoPharma NZ Limited was incorporated as wholly owned subsidiary in New Zealand on 10th February, 2012 and there was no activity during the year ended 31st March, 2015. Therefore, no financial statements were drawn for the financial year ended 31st March, 2015.

ARROW GENERIQUES

A simplified joint stock company

Share capital: 36,945,840.47 Euros

Headquarters: 26, Avenue Tony Garnier 69007 LYON

Registered under n° 433 944 485 R.C.S. LYON

MANAGEMENT REPORT
ACCOUNTS CLOSED ON MARCH 31, 2015

Dear Shareholder,

We have invited you, in compliance with legal and statutory provisions, to present you the communications prescribed by the texts in force and specifically request that you approve the annual accounts for the statutory fiscal period ended as of March 31, 2015.

I HIGHLIGHTS

At the end of 2013, Actavis Group started negotiations with the Indian Group Aurobindo for the sale of the Western Europe generics' division of the group, including Arrow Generiques in France. Arrow Generiques was sold to the Aurobindo group, on April 1, 2014.

At the end of the latest statutory fiscal year, the amount of the net equity was below half of the share capital. Consequently, the following recapitalization operations took place in March 2014:

- Decrease in the share capital by M€ 30.0
- Increase in the share capital by offsetting an existing liability for M€ 21.1

After this operation that occurred in March 2014, the share capital amounted to M€ 35 and the net equity to M€ 18.5.

The Company changed its closing date from December 31, 2014 to March 31, 2015 to align with the Group closing date. Consequently, the statutory fiscal year closed as of March 31, 2015 lasted 15 months.

Aurobindo Pharma France's investments were transferred from Agile Pharma BV to Arrow Generiques generating an increase in the share capital by 1.9 m€ and a share premium of 0.5 m€. Following this transfer, Aurobindo Pharma France was merged into Arrow Generiques as of December 31, 2014 with retroactive effect as of April 1, 2014. This merger generated an intangible asset amounting to M€ 1.3.

II SIGNIFICANT EVENTS ARISEN SINCE FISCAL PERIOD CLOSING

No significant subsequent event to report since last closing date until the day of this report.



III COMPANY ACTIVITY

- Comparison of results

In M€	Statutory 31/03/2015 (15 months)	Statutory 31/12/2013 (12 months)
Turnover tax excl.	225.6	210.5
Net before tax income/(loss)	-3.8	-10.9
Net income/(loss)	-4.2	-10.9

The turnover reached in 2014-2015 increased by around M€ 15.1 meaning +7% as compared to the previous year.

This change is mainly linked to the length of the statutory fiscal year of 15 months compared to 12 months last year. By restating this difference, the turnover would have reached approximately M€ 180, meaning a decrease by approx. 15%.

This decrease is mainly linked to the retail business as the market share has slightly decreased during the year, in a total French market under recession caused by price decreases and lower substitution from branded to generic products at the pharmacies.

In addition, the company has strongly reinforced its positions on the "Hospital" segment, and confirmed itself as one of the major player in this market.

The gross margin of the company expressed in % is slightly lower, but increased in absolute value due to the turnover growth. This decrease in margin in % is linked to price decreases that we suffered all year long; the decrease was partially attenuated thanks to purchase prices slightly down.

Operating income before taxes improved significantly, moving from M€ -10.9 to M€ -4.2, thanks to the margin generated by growth in turnover, operating costs increased less than proportionately.

In addition, in line with the defined mid and long-term commercial strategy, the company has reinforced its various partnerships with key accounts, both on a regional and national level.

The company reached a financial loss of M€ 0.8 during the 15-month period ended March 31, 2015 resulting mainly from discounts granted that reached M€ 0.9, intra-group financing costs for M€ 0.2 and exchange gains for M€ 0.4.

The statutory net result amounted to M€ -4.2 as of March 31, 2015 as compared to -10.9 m€ as of December 31, 2013.

- **Situation and company trends during the reporting period**

Without the impact of the length of the fiscal year, the company reinforced its commercial positions and especially developed its sales to hospitals with a market share of 12% compared to 10% last year.

The retail business recorded a slow-down with a decrease in the turnover achieved by 10%.

During the previous fiscal period, average headcount was roughly 163 persons.

The company completed its product portfolio in successfully launching new products during 2014-2015, and actively positioned itself on the main patents that are coming into the public domain in the coming years.

- **Foreseeable trends and future perspectives**

The main objective for 2015-2016 is to reinforce our commercial positions acquired these last years on the hospital business, manage the different brands. The control of our commercialization costs is also a priority for the current fiscal period.

- **Payment cycles (statutory requirement)**

In compliance with the provisions of articles L. 441-6-1 and D. 441-4 of the French Code of commerce, we hereby indicate the breakdown of the balance of accounts payable with regard to our suppliers by due date, for the last fiscal period closed on March 31, 2015 and December 31, 2013:

Due dates (in M€)	31/03/2015	31/12/2013
Debts past due	7.4	18.7
Debts not due	16.8	32.1
- Between 0 and 30 days	13.6	27.7
- Between 30 and 60 days	3.2	4.4
- More than 60 days	0	0
Invoices not received and other accounts	12.2	17.2
TOTAL supplier debts and attached accounts	36.4	68

Past due debts are largely linked to companies from the group (Actavis France) for which payment facilities have been granted.

- **Research and development**

The costs of research and development totaled 0.1 M€ during the statutory fiscal year ended March 31, 2016. This amount was not booked as research expenses and has not been activated.

III SUBSIDIARIES AND HOLDINGS

Not applicable

IV FINANCIAL RESULTS – ALLOCATION

Examination of the accounts and results:

First of all, it is to be specified that the accounts that will be presented at the general meeting have been established according to the same accounting principles and methods as the preceding fiscal period.

- Proposal for allocation of the result

The annual accounts, as they will be presented and submitted for approval, show a loss of M€ 4.2, and we propose to allocate it as a debit to the gains/losses carried forward account.

Consequently, the gains/losses carried forward will amount to M€ 15.

In order to conform to the provisions of the French article 243b of the General Tax Code, we remind you that no dividend has been distributed during the last three years.

V CONVENTIONS RELATED TO ARTICLE L. 227-10 OF THE CODE OF COMMERCE

The additional special statutory report from the external auditors regarding the company's situation with regard to the conventions pursuant to article L.227-10 of the Code of Commerce will be remitted to you for your perusal.

We communicated them the list and purpose of the conventions in force signed under normal conditions pursuant to article L.227-11 of the Code of Commerce that took place during the fiscal period.

VI NON-DEDUCTIBLE EXPENSES

In compliance with the provisions of the French article 223c of the General Tax Code, we will request that you specifically approve the amount of tax non-deductible expenses booked during the previous statutory fiscal period pursuant to art. 39 - 4 of the General Tax Code.

These expenses amount to €65,139 for the statutory fiscal period closed on March 31, 2015 (15 months).

VI ADMINISTRATION AND CONTROL OF THE COMPANY

Arrow Generics was sold to the Aurobindo group, on April 1, 2014.

For statutory purposes, we will invite you to express your approval of the accounts and the proposals mentioned heretofore by adopting the resolutions submitted to you.

Vincent PONT
President

A handwritten signature in black ink, consisting of a stylized 'V' followed by a long horizontal stroke that extends to the right.

ARROW GENERIQUES SAS

**STATUTORY AUDITORS' REPORT
ON THE ANNUAL ACCOUNTS**

Fiscal period of 15 months closed as of March 31, 2015

**STATUTORY AUDITORS' REPORT
ON THE ANNUAL ACCOUNTS**

Fiscal period of 15 months closed as of March 31, 2015

For the the sole shareholder
Arrow Génériques SAS
Lyon

In execution of the mission that has been entrusted to us by your general meeting, we present our report relative to the 15-months fiscal period closed as of March 31, 2015 to you regarding:

- the control of the annual accounts of Arrow Génériques SAS, as they are attached to the present report;
- the justification for our appreciations;
- verifications and specific information required by law.

The annual accounts were closed by the president. It is our duty to express an opinion on these accounts on the basis of our audit.

I. OPINION ON THE ANNUAL ACCOUNTS

We have performed our audit according to the professional norms of practice applicable in France; these norms require the implementation of diligences allowing reasonable assurance to be obtained that the annual accounts do not contain any significant anomalies. An audit consists in verifying, by sampling or by the means of other methods of selection, the elements justifying the amounts and information stated in the annual accounts. It also consists in assessing the accounting principles followed, the significant estimations retained and the overall presentation of the accounts. We consider that the elements that we have collected are sufficient and appropriate to form our opinion.

We certify that the annual accounts are, with regard to French rules and accounting principles, regular and sincere and give a loyal picture of the results from operations covering the previous fiscal period as well as the company's financial situation and assets at the end of said fiscal period.

Without putting into question the opinion expressed here above, we draw your attention to note 2.1 that specifies that the continuity of business remains subordinate to the financial support of group that your company belongs to.

II. JUSTIFICATION OF OUR APPRECIATIONS

In application of the provisions of article L. 823-9 of the code of commerce relative to the justification of our appreciations, we inform you that the appreciations to which we have proceeded focused on the appropriate nature of the accounting principles applied as well as on the reasonable nature of the significant estimations retained.

The appreciations thus made are in line with the framework of our audit process on annual accounts, taken as a whole, and they therefore contributed to the forming of our opinion expressed in the first part of this report.

III. SPECIFIC VERIFICATIONS AND INFORMATION

We have also proceeded in compliance with the norms of professional practice applicable in France, to the specific verifications provided for by law.

We have no observations to formulate regarding the sincerity and concordance with the annual accounts of the information provided in the President's management report and the documents addressed to the sole shareholder on the financial situation and annual accounts.

In application of the law, we inform you in addition that due to late reception of certain documents, we were not able to issue the present report within the statutory deadlines.

Drafted in Lyon, May 29, 2015

The external auditors

PricewaterhouseCoopers Audit

ERNST & YOUNG Audit

Michel Bouzigues

Nicolas Perlier

BALANCE SHEET

	ASSETS	Fiscal period	31/03/2015	15	FY N-1 31/12/2013 12
		GROSS amount	Amortization and depreciation (to subtract)	NET	NET
	INTANGIBLE ASSETS				
	Establishment Set-up costs				
	Development costs				
FIXED	Concessions, patents and similar fees	7 549 034	5 078 820	2 470 214	1 905 483
ASSETS	Goodwill	4 452 194	3 142 000	1 310 194	3 142 000
	Other intangible assets	1 780 810		1 780 810	421 740
	Early payment and installments				
	TANGIBLE ASSETS				
	Land				
	Buildings				
	Technical installations, material and tooling	1 289 322	1 111 454	177 868	220 200
	Other tangible assets	734 286	667 366	66 920	76 786
	Capital expenditure underway				
	Early payment and installments				
	Financial Assets				
	Participations, equity method				
	Other participations				
	Debts linked to participations				
	Other immobilized securities				
	Loans	153 753	107 705	46 048	182 907
	Other financial assets	170 844		170 844	169 741
	TOTAL II	16 130 043	10 107 345	6 022 698	6 118 857
	STOCKS AND WORK IN PROGRESS				
	Raw materials, procurement	4 149 752	618 667	3 531 085	4 347 082
	Production of goods in progress				
	Production of services in progress				
	Semi-finished and finished products	38 925 454	8 241 899	30 683 555	33 584 419
Current	Merchandise	3 029 584	792 935	2 236 649	3 178 078
Assets	Early payment and installments made on orders	328 067		328 067	277 032
	Receivables				
	Customers and related accounts	28 633 198	1 584 038	27 049 159	29 350 163
	Other receivables	4 188 070		4 188 070	5 035 294
	Subscribed capital – called up, not paid in				
	Securities investments	618 483		618 483	1 697 558
	Cash on hand	2 921 760		2 921 760	17 131 985
	Deferred expenses	2 711 600		2 711 600	4 793 038
Regularization	TOTAL III	85 505 967	11 237 539	74 268 428	99 394 649
Accounts	Cost of issuing loans to be spread out (IV)				
	Reimbursement premiums on bonds (V)				
	Exchange rate accruals (VI)	2 144		2 144	435
	GRAND TOTAL (I+II+III+IV+V+VI)	101 638 154	21 344 884	80 293 270	105 513 941

BALANCE SHEET LIABILITIES AND SHAREHOLDERS' EQUITY

		FY N 31/03/2015 15	FY N-1 31/12/2013 12
	Share capital (including paid in 43 840 765)	36 945 840	43 840 765
Shareholders'	Premiums from stock issues, mergers, contributions	498 334	
Equity			
	RESERVES		
	Legal reserve	16 830	16 830
	Statutory or contractual reserves		
	Regulated reserves		
	Other reserves		
	Results carried forward	(10 876 733)	(30 004 333)
	Results from the fiscal period (profit or loss)	(4 161 036)	(10 876 733)
	Investment grants		
	Regulated provisions		
	TOTAL I	22 423 235	2 976 529
Other Equity	Proceeds from issues of participating securities		
	Conditional advances		
	TOTAL II		
PROVISIONS	Provisions for risks	2 873 985	2 015 611
	Provisions for future expenses		
	TOTAL III	2 873 985	2 015 611
	FINANCIAL LIABILITIES		
LIABILITIES	Convertible bond issues		
	Other bond issues		
	Loans through banking institutions		
	Current bank overdrafts		
	Various loans and financial debt	11 000 000	18 961 934
	Early payment or installments received on orders being processed	50 000	50 000
	CURRENT LIABILITIES		
	Accounts payable and related accounts	36 431 670	68 037 691
	Fiscal and social liabilities	4 578 511	6 043 881
	Amounts payable on fixed assets and related accounts		
	Other liabilities	1 471 155	4 385 320
Regularization accounts	Revenues collected in advance	1 464 714	2 472 878
	TOTAL IV	54 996 050	99 951 704
	Exchange rate accruals (v)	0	570 097
	OVERALL TOTAL (I+II+III+IV+V)	80 293 270	105 513 941

PROFIT AND LOSS STATEMENT

	FYN 31/03/2015		15	FYN-1
	France	Exports	Total	31/12/2013 12
OPERATING REVENUE (1)				
Sales of merchandise	1 795 976		1 796 976	1 222 585
Production of goods sold	214 276 906	7 755 235	222 032 141	207 761 143
Productions of services sold	1 701 585	43 997	1 745 082	1 467 306
NET REVENUE	217 775 467	7 798 732	225 574 199	210 451 033
Production in inventory			(3 126 620)	10 695 317
Production capitalized				
Operating subsidies				
Reversals on depreciation, provisions (amortizations) & deferred expenses			11 002 434	5 241 929
Other income			508 322	423 231
TOTAL OPERATING INCOME (I)			233 958 335	226 811 511
OPERATING EXPENSES				
Purchases of merchandise			4 200 176	4 487 662
Stock variations (merchandise)			1 181 742	(526 969)
Raw materials and other procurement			9 291 134	8 041 702
Stock variations (raw materials and other procurement)			203 987	(277 830)
Other purchases and external charges			170 810 716	174 767 000
Social contributions			6 987 943	7 444 220
Wages and salaries			13 232 765	9 554 538
Social contributions			5 765 016	4 436 323
Allowances for depreciation and amortization				
On assets: amortization allowances			602 270	475 039
On assets: amortization allowances			3 142 000	
On current assets: amortization allowances			9 798 895	9 833 078
Allowances for provisions			862 324	784 742
Other charges			10 870 386	17 270 783
TOTAL OPERATING EXPENSES (II)			236 949 354	236 291 289
1. OPERATING INCOME (I-II)			(2 991 019)	(9 479 778)

PROFIT AND LOSS STATEMENT

	FISCAL PERIOD N 31/03/2015 15	FISCAL PERIOD N-1 31/12/2013 12
FINANCIAL GAINS AND LOSSES		
Financial gains from participations		
Gains from other securities and current asset receivables	3 099	5 761
Other interests and assimilated gains	85 239	117
Depreciations and provisions no longer required, transfer of expenses	94	86 948
Gains from currency exchange	562 750	58 204
Net gains on transfers of securities and investments	20 923	7
TOTAL V	672 105	151 037
FINANCIAL EXPENSES		
Amortization allowances, depreciations and provisions	109 849	94
Assimilated interests and charges	1 206 711	1 525 756
Currency exchange losses	153 828	76 882
Net expenses on transfers of securities investments		
TOTAL VI	1 470 388	1 602 732
2. FINANCIAL GAINS AND LOSSES (V-VI)	(798 283)	(1 451 695)
3. NET PROFIT BEFORE TAX (I+II+III+IV+V+VI)	(3 789 302)	(10 931 473)
EXCEPTIONAL GAINS		
Exceptional gains on management operations		
Exceptional gains on shareholdings operations	16 118	9 284
Depreciations, provisions and deferred expenses no longer required		
TOTAL VII	16 118	9 284
EXCEPTIONAL GAINS		
Exceptional losses on management operations	(1 879)	11 122
Exceptional losses on shareholdings operations	456 901	9 275
Allowances for amortizations, depreciations and provisions		
TOTAL VIII	455 022	20 397
4. EXCEPTIONAL GAINS (LOSSES) (VII-VIII)	(438 904)	(11 113)
Participation by employees in company profits (IX)		
Corporate income tax (X)	(67 170)	(65 853)
TOTAL INCOME (I+III+V+VII)	234 646 558	226 971 832
TOTAL EXPENSES (II+IV+VI+VIII+IX+X)	238 807 594	237 848 565
5. PROFIT OR LOSS (total revenue – total expenses)	(4 161 036)	(10 876 733)

ARROW GENERIQUES SAS

Notes to the Financials Statements
15-month period ended March 31, 2015

1100

I – PRESENTATION OF THE COMPANY AND HIGHLIGHTS FOR THE FISCAL PERIOD

1.1 Presentation of the company

The company's activity consists in the manufacturing and commercialization of pharmaceutical specialties.

1.2 Highlights for the fiscal period

End 2013, the Actavis group engaged in discussions with the Indian group Aurobindo for the acquisition of the generics branch of the group on the Western Europe zone including Arrow Generics.

On April 1, 2014, the transaction was finalized and Arrow Generiques was sold to Aurobindo Group.

At the end of the latest fiscal year, the equity was below half of the share capital. To regularize the situation, the following operations were made in March 2014:

- Decrease of the share capital of M€30
- Increase in the share capital by compensating existing liabilities for M€21.1

At the end of these operations that occurred in March 2014, the share capital amounted to M€35 and the equity amounted to M€18.5.

The Company changed the closing date of its fiscal period from December 31 to March 31 in order to match with the group's closing date.

Consequently, the fiscal period ended March 31, 2015 lasted 15 months.

The shares of Aurobindo Pharma France, French subsidiary of Aurobindo group, have been transferred from Agile Pharma BV to Arrow Generiques, generating an increase in the share capital of M€1.9 and a share premium of M€0.5.

Following this transfer of shares, a merger was made as of December 31, 2014 with retroactive effect as of April 1, 2014. This merger generated a goodwill of M€1.3.

1.3 Subsequent events

Nothing to report.

II - ACCOUNTING PRINCIPLES AND METHODS

2.1 Principes comptables

The annual accounts for the fiscal period, established in euros, were prepared in compliance with the provisions of French legislation and the generally accepted accounting principles in France, meaning:

- The principle of prudence
- Continuity of exploitation
- Permanence of accounting methods
- Independence of fiscal periods

The basic method retained for the assessment of the elements booked in the accounting is the method of historical costs.

It is to be noted that the continuity of exploitation remains subordinate to the group's financial support materialized by a letter of support from the sole shareholder dated May 13, 2015.

2.2 Intangible and tangible assets

The intangible and tangible assets are evaluated based on their acquisition cost excluding financial costs.

Research and development expenses are recorded as an expense when they have occurred.

Goodwill has not been amortized.

Other assets are amortized over an estimated period of utilization of the element according to a linear model corresponding to the economic amortization of goods.

When there is an indication of an impairment loss, the depreciation is accounted for to reduce the value to the lowest cost of acquisition and the usual value.

2.3 Financial assets

Other financial assets are assessed based on their cost of acquisition. Depreciation is constituted when their usual value is lower than the accounting value.

2.4 Stocks

Stocks of raw materials and merchandise are evaluated at their cost of acquisition according to the method of weighted average of purchasing costs.

Stocks of finished products are valued at cost on the basis of purchasing costs of the active ingredients or bulk, increased by the transformation costs invoiced by subcontractors.

When the gross value defined under the aforementioned conditions is higher than the probable realizable value, depreciation is constituted for the amount of the difference.

2.5 Evaluation of receivables

Receivables are valued at their nominal value.

They are depreciated based on the risks of non-recovery, assessed on a case-by-case basis.

2.6 Investment securities

Investment securities are evaluated at their cost of acquisition.

If the market value on the date of closing is lower than the purchase price, depreciation is constituted in order to reduce the balance value to the realizable value.

2.7 Provisions

Each of the claims known at closing date and in which the company is involved, has been examined by management and external lawyers. When appropriate, the provisions deemed necessary have been constituted to cover the estimated risks.

2.8 Revenue

Turnover is booked when products have been delivered according to the specific terms and conditions of each contract and order.

2.9 Retirement indemnities (only mentioned in the notes to the Financial Statements as permitted under French GAAP)

Engagements in terms of retirement indemnities are evaluated at their probable current value for accrued rights by taking into account the provisions of the collective bargaining agreement, salary increases until the age of retirement, personnel turnover and mortality tables.

Retirement indemnities are not booked but mentioned as an off-balance sheet item.

Retirement indemnities are considered as an expense when they are incurred.

2.10 Foreign currency operations

Transactions in foreign currencies are recorded at the rate of exchange on the day of the operation.

Receivables and payables in foreign currencies are valued at the rate of closing date. The difference resulting from the actualization of the receivables and payables is recorded in the section "foreign currency translation difference".

Unrealized currency exchange losses are recorded as a provision.

III - NOTES ON THE BALANCE SHEET

3.1 Intangible assets

(en K€)	December 31, 2013	Acquisitions	Merger	Disposals	Transfers	March 31, 2015
Patents (including MAs)	6 833	199	1 259	-1 164	422	7 549
Goodwill	3 142	0	0	0	0	3 142
Goodwill (from merger)	0	0	1 310	0	0	1 310
Other intangible assets	422	222	1 559	0	-422	1 781
TOTAL	10 397	421	4 128	-1 164	0	13 782

Gross intangible assets amounted to K€ 13 782 as of March 31, 2015 (K€ 10 397 as of December 31, 2013).

Acquisitions of the period amounted to K€ 421 (K€ 3 316 as of December 31, 2013) et mainly relate to MAs fees for K€ 245 and dossiers for K€ 165.

The expenses for filing for marketing authorizations recorded in assets for the fiscal period came to K€ 444, they represent a flat fee per dossier of €14 000.

They enable the delivery of an AMM authorization renewable after 5 years. The dossier costs are representative of the costs engaged to create the files presented to AFSSAPS officials to obtain AMM authorizations.

These elements are amortized over their useful life:

Gross value in K€	Depreciation rate	31/03/2015	31/12/2013
Software and trademark	33.33%	192	413
Internet website	20%	129	129
MAs and dossiers	10%	7 228	6 291
Goodwill		3 142	3 142
Goodwill from merger		1 310	0
Other		1 781	422
Total		13 782	10 397

The gross value of assets disposed over the period amounted to K€ 1 164 and can be split as follows:

- K€ 232 for softwares,
- K€ 932 for MAs registration fees

The software disposed were fully depreciated and the MAs registration fees were depreciated for K€ 510 and have consequently generated a loss of K€ 422 as of March 31, 2015.

The intangible assets in progress amounted to K€ 1 781 and are composed of K€ 222 of registration fees and of K€ 1 559 of registration fees from the merger with Aurobindo Pharma France.

The merger with Aurobindo Pharma France generated the following impacts on intangible assets as of March 31, 2015:

- Registration fees for K€ 1 259, depreciated for K€ 513
- Registration fees in-progress for K€ 1 559
- Goodwill of K€ 1 310.

3.2 Tangible assets

(en K€)	December 31, 2013	Acquisitions	Merger	Disposals	Tranfers	March 31, 2015
Tooling	1 281	81	0	-73	0	1 289
Other tangible assets	977	27	7	-276	0	735
TOTAL	2 258	108	7	-349	0	2 024

The gross value of tangible assets amounted to K€ 2 024 as of March 31, 2015 (K€ 2 258 as of December 31, 2013).

Acquisitions of the period amounted to K€ 108 (K€ 138 as of December 31, 2013) and mainly relate to tooling, office and computer equipments.

The gross value of assets disposed over the period amounted to K€ 349 and can be split as follows:

- K€ 229 of office and computer equipments,
- K€ 73 of tooling
- K€ 31 of furniture and fixtures
- K€ 16 of vehicle

The entire assets disposed generated a loss of K€ 27 as of March 31, 2015.

The gross value of the elements of tangible fixed assets correspond to the entry value of the goods in assets taking into account the necessary expenses to put these goods into a working state, but excluding the expenses for their acquisition.

The cumulated depreciation amounted to K€ 1 779 as of March 31, 2015 (K€ 1 961 as of March 31, 2015). The depreciation of the period amounted K€ 132 (K€ 186 as of December 31, 2013).

The transfers from the merger with Aurobindo Pharma France are not significant (tangible assets transferred for K€ 7, already fully depreciated as of March 31, 2015).

The methods and periods of amortization retained are as follows:

Catégorie	Mode	Durée
Construction	Straight line	N/A
Agencies and amenities	Straight line	5 to 10 years
Technical installations	Straight line	N/A
Material and tooling	Straight line	5 to 10 years
Material and transportation	Straight line	3 years
Office equipment	Straight line	3 to 5 years
Furniture	Straight line	5 to 9 years

3.3 Other financial assets

Other Financials assets amounted to K€ 325 as of March 31, 2015 (K€ 353 as of December 31, 2013) and are mainly composed of deposits for a gross value of K€ 143 (including K€ 5 from the merger with Aurobindo Pharma France) and loans for K€ 154, depreciated for K€ 108.

3.4 Stocks

The inventory reserve amounted to K€ 9 654 as of March 31, 2015 (K€ 9 508 as of December 31, 2013).

3.5 Customer receivables and related accounts

The doubtful reserve amounted to K€ 1 584 as of March 31, 2015 (K€ 1 439 as of December 31, 2013).

3.6 Due dates on receivables

All receivables are at less than one year.

3.7 Other assets

Other assets can be split as follows:

(en K€)	31/03/2015	31/12/2013
Current income tax	176	0
Social organisms	408	0
VAT deductible	497	491
Refundable VAT	986	1 326
VAT on unreceived invoices	1 580	2 523
Other	541	695
Total	4 188	5 035

3.8 Share capital

As of March 31, 2015, the share capital amounted to € 36 945 840 and is composed of 14,603,099 shares of € 2.53 each, held at 100% by Agile Pharma BV, a company formed under Dutch law.

3.9 Equity

(en K€)	December 31, 2013	Increase	Decrease	Impact of the merger	Net result	March 31, 2015
Share capital	43 840	21 170	-30 004	1 940		36 946
Share premium				499		499
Legal reserve	17					17
Reserve	-30 004		30 004		-10 877	-10 877
Net result	-10 877					- 4 161
TOTAL	2 976	21 170	0	2 439	-10 877	22 424

All operations have an impact on the equity have been explained in note 1.2 of paragraph Highlights of the period.

3.10 Provisions

(en K€)	December 31, 2013	Accruals	Reversal for use	Reversal	Other	March 31, 2015
Litigations	149	512				661
Fines and penalties ¹	1 713	350				2 063
Exchange loss reserve		2				2
Other	154			-6		148
Total	2 016	864	0	-6	0	2 874

¹ Risk related to tax rules:

The company has to comply with various laws, especially tax rules.

Tax audit can lead to risk or unrealized liabilities.

These risks may be accrued, assessed on a risk-by-risk basis according to information and analysis available at closing date and according to applicable laws.

Risks accrued as of March 31, 2015 amounted to K€.2063.

3.11 Other liabilities

As of March 31, 2015, other liabilities of K€ 1 471 (K€ 4 385 as of December 31, 2013) are mainly composed of credit receivables for K€ 810 and of credit notes to issue for K€ 437.

3.12 Due dates on payables

All payables are due in less than one year.

The due date of the loan granted by Agile Pharma BV is in 5 years after November 1, 2014.

3.13 Charges to be paid included in following balance sheet items

K€	March 31, 2015
Payables	12 214
Tax and social liabilities	3 429
Other liabilities	188

3.14 Evaluation of invested securities

An evaluation made on the basis of the rate as of March 31, 2015 enabled it to be ascertained that no provision was necessary on the closing date.

3.15 Deferred income

The revenue collected in advance amounted to K€ 1 465 as of March 31, 2015 (K€ 2 472 as of December 31, 2013). It corresponds to the reprocessing of the sales revenue made by the company on year-end sales when the transfer of risks has not taken place by the end of the fiscal period closing.

3.16 Intercompany receivables and payables

The principle balance sheet items representative of transactions with associated companies are as follows:

(en K€)	March 31, 2015	December 31, 2013
Accounts receivables	915	1 420
Other assets	1	0
Accounts payables	(12 443)	(39 983)
Other liabilities	(74)	(4 278)
Loans	(11 000)	(18 962)
Net amount	(22 601)	(61 803)

The current accounts are considered in "loans and various financial debts" when they are creditors and "other receivables" when they are debtors.

3.17 Transactions with related parties

There were no significant transactions with related parties signed under abnormal market conditions and that should be mentioned in annex in compliance with regulations ANC N° 2010-02 and 2010-03. Transactions avec les parties liées

IV - NOTES ON THE INCOME STATEMENT

4.2 Breakdown of net turnover

(en K€)	31/03/2015	31/12/2013
France	217 775	204 253
Foreign countries	7 799	6 198
Total	225 574	210 451

4.3 Revenue and charges with associated companies

(en K€)	31/03/2015	31/12/2013
Sales	1 237	1 288
Purchases	(20 625)	-
Other operating expenses	(2 960)	(50 995)
Salaries and wages	-	(61)
Other expenses	(254)	(6 683)
Financial income	88	-
Financial expenses	(160)	(742)
Exceptional income	-	-
Exceptional expenses	-	-

4.4 Financial income and losses

(en K€)	31/03/2015	31/12/2013
Currency exchange result	409	(19)
Change in the exchange losses accrual	(2)	87
Cash discounts	(866)	(784)
Savings gains	21	
Accruals	(108)	
Interest expenses on loans	(247)	(742)
Other	(5)	6
Net	(798)	(1 452)

4.5 Exceptional result

(en K€)	31/03/2015	31/12/2013
Gains/losses on fixed assets disposed	(433)	9
Fines and penalties	2	(11)
Other	(8)	(9)
Net	(439)	(11)

4.6 Increase and decrease of the future tax expense

En K€	Amounts	Tax impact
Futur increases	-	-
Tax on turnover	(184)	(61)
Non-deductible accruals	(4 257)	(1 419)
Other accruals	(14)	(5)
Futures decreases	(4 455)	(1 485)
Losses carried forward (current year)	252	84
Losses carried forward (previous year)	(41 710)	(13 903)

Losses carried forward as of March 31, 2015 lead to a future decrease of the taxable income of K€ (13 819) calculated at a rate of 33,33 %.

V – OTHER INFORMATION

5.1 Identity of the consolidation entity

The company's individual accounts are included, following the method of overall integration, in the consolidated accounts of the company Aurobindo Pharma Limited (Inde), registered under number L24239AP1986PLC015190 located at Plot No.2, Maitri Vihar, Ameerpet, Hyderabad – 500 038, INDIA and whose share capital amounted to 291,982,275 Indian rupees as of March 31, 2015.

5.2 Tax credit (« CICE »)

The tax credit booked amount to K€ 168 over the period.
According to the request of the « Autorité des Normes Comptables », the income obtained was booked as a decrease of personnel expenses.

According to article 244 quater C of the « Code Général des Impôts », our company will use this tax credit through R&D, investments on pharmaceutical dossiers, research of new API sources, increase in batch size to decrease our production costs.

5.3 Off balance sheet items

Retirement

The engagements linked to retirement indemnities amounted to K€ 480 as of March 31, 2015. The calculation take into account departures on the employer's initiative, consequently, the indemnities are not increased by social charges.

The principle actuarial assumptions used are the following:

- Age of retirement: 67
- Financial discount rate: 1.5%

The turnover rate also takes into account the position and the year of birth.

Other

The other engagements made or received by the company can be analyzed as follows on March 31, 2015:

	Total
Pledges, sureties and guarantees	468
Total (en K€)	468

5.4 Average headcount

31/03/2015

- Managers	56
- Technicians and supervisors	75
- Employees	32
- Workers	0

Total	163
--------------	------------

5.5 Managing Directors compensations

This information is not given as it would lead to give the individual managing Directors wages.

ACTAVIS FRANCE
A joint stock company with share capital of 7,540,320 euros
Headquarters: 26 avenue Tony Garnier
69007 Lyon
Registered under N° 478 783 434 RCS LYON

PRESIDENT'S MANAGEMENT REPORT
FISCAL PERIOD CLOSED ON 31 MARCH 2015

Mr. Vincent PONT, non-shareholder President of ACTAVIS France, since 1 November 2013, a joint-stock company with share capital of 7 540 320 euros, has established the present management report on the Company's situation and business activity during the previous fiscal period in view of obtaining approval of the accounts for the fiscal period closed on 31 March 2015.

THE COMPANY'S BUSINESS ACTIVITY

1. The Company's situation and business trends during the fiscal period

On 21 March 2014, the company proceeded to make an increase in share capital of an amount of 23,428,650 Euros. This increase through the issue of new shares was entirely subscribed by its sole shareholder, Actavis Holding NWE, and was paid by compensation for debts. Successively and still on the date of 21 March 2014, the share capital of Actavis France was reduced to an amount of 19,384,790 Euros by the cancellation of shares, in view of clearing the losses stated in the "Carry forward" account. Subsequent to this operation, the share capital came to 7,540,320 euros and equity equaled 8,164,403.40 euros.

On 1st April 2014, given a level of profitability considered to be insufficient, the Actavis group sold off certain European subsidiaries, including Actavis France and Arrow Génériques, to the Indian group Aurobindo (Aurobindo Pharma Ltd). As such, the share capital of Actavis France has been held since that date wholly by the company Agile Pharma B.V., headquartered in the Netherlands.

2. Post-closing events

None.

3. Foreseeable trends and future perspectives

From an economic standpoint: the company has a reduced business scope. Its distribution activity was transferred to Arrow Génériques when the goodwill was sold off and it no longer has any employees. Solely its pharmaceutical activity has been maintained. Its revenue is

entirely made with Arrow Génériques, which buys the products from Actavis France for which the supply contracts have not yet been taken over by Arrow Génériques.

From a pharmaceutical standpoint: a transfer plan for the pharmaceutical activities of Actavis France to Arrow Génériques was defined with the National Agency for Medical Safety in early 2014. This plan foresees the termination of the activities at Actavis France in the 2016 timeframe.

4. Activity in terms of research and development

We inform you that the Company did not carry out any research and development activity during the previous fiscal period.

RESULTS - ALLOCATION

1. Examination of the accounts and financial results

We are going to present the annual accounts to you in detail that we submit for your approval and which were established in compliance with the rules of presentation and methods of assessment provided for by the regulations in force.

The rules and methods to establish the accounts closed on 31 March 2015 annual accounts are identical to those retained for the preceding fiscal periods.

The fiscal period lasted 15 months. This change was decided in order to allow the Company to be aligned with the closing calendar of the Aurobindo group, which also closed its accounts on 31 March 2015.

During the fiscal period closed on 31 March 2015, the net turnover came to 8,646,175 euros as compared to 30,581,696 euros during the preceding fiscal period.

The amount of purchases of merchandise and materials totaled 5,695,892 euros as compared to 9,593,865 euros for the preceding fiscal period.

The amount of other purchases and external charges amounted to 2,679,337 euros as compared to 10,622,151 euros for the preceding fiscal period.

The amount of taxes and duties came to 722,022 euros as compared to 1,794,021 euros for the preceding fiscal period.

The amount of remunerations and salaries amounted to 29,297 euros as compared to 3,290,926 euros during the preceding fiscal period.

The amount of social contributions and social benefits totaled 12,876 euros as compared to 889,500 euros for the preceding fiscal period.

The headcount on the closing date of the fiscal period was 0 just as at the end of the preceding fiscal period.

Total operating expenses came to 10,115,766 euros as compared to 38,922,445 euros for the preceding fiscal period.

Operating income for the fiscal period came to -923,264 euros as compared to -386,181 euros during the preceding fiscal period.

Given the financial result of -664,728 euros -1,636,923 euros for the preceding fiscal period, operating profit before tax for the fiscal period came to -1,587,992 euros as compared to -2,023,097 euros for the preceding fiscal period.

After taking into account:

- the exceptional loss of - 123,113 euros
- corporate income tax was nil,

The result of the fiscal period ended with a loss of 1,711,105 euros as compared to a profit of 624,089 euros relative to the preceding fiscal period.

2. Proposal for allocation of results

We propose that you approve the annual accounts (balance sheet, profit and loss statement and annexes) as they are presented to you and which show a loss of 1,711,105 euros.

We propose to allocate this financial result for the fiscal period in the following way:

- Entirely in the "carry forward" account

3. Fiscally non-deductible expenses

In compliance with the provisions of article 223c of the Tax Code, we request that you specially approve the fiscally non-deductible amount of charges booked during the previous fiscal period pursuant to art. 39 - 4 of the General Tax Code.

These charges amount to 1,535 euros for the fiscal period closed on 31 March 2015 relative to excess amortization of vehicles.

4. Table of results

A tableau of results for the last 5 fiscal periods is in annex to the present report.

5. Dividends paid out over the last 3 fiscal periods

There has been no payment of dividends relative to the last three fiscal periods.



CONVENTIONS OF ARTICLE L. 227-10 OF THE CODE OF COMMERCE

We request, in compliance with article L.227-10 of the Code of Commerce that you approve the conventions pursuant to this same article and signed during the previous fiscal period.

INFORMATION ON SUPPLIER PAYMENT CYCLES

In application of article L.441-6-1 of the Code of Commerce (originating in the law called "LME law" dated 4 August 2008), we inform you concerning the following information relative to supplier payment cycles and customer payment cycles.

On 31 March 2015, the balance of the Company's accounts payable with regard to its suppliers came to 3,178,163 euros including 972,286 euros constituted by the Group supplier account, these same elements came respectively to 4,964,148 euros and 2,064,441 euros on 31 December 2013.

The supplier accounts payable ex-group totaling 2,205,877 euros can be broken down as follows:

28% are payable at 60 days

72% are payable at 30 days

Excluding claims not yet resolved, these balances do not include any significant invoices past due.

Unless there is a claim or invoicing error, our supplier invoices are paid with respect to legal pay periods.

ADMINISTRATION AND CONTROL OF THE COMPANY AND GROUP


There are no other significant events to be mentioned outside of the points mentioned heretofore in the "The Company's Business Activity".

In conclusion, we hope that these various propositions meet your approval and that you will give your President discharge for his management during the fiscal period for the accounts that you have to vote on.

We invite you, after reading the reports presented by our External Auditors, to adopt the resolutions that we submit for your vote.

Dated 20/05/2015

President
Mr. Vincent PONT



ACTAVIS FRANCE

Fiscal period of 15 months closed as of March 31, 2015

STATUTORY AUDITORS' REPORT ON THE ANNUAL ACCOUNTS

Actavis France

Fiscal period of 15 months closed as of March 31, 2015

**STATUTORY AUDITORS' REPORT
ON THE ANNUAL ACCOUNTS**

For the the sole shareholder,

In execution of the mission that has been entrusted to us by your general meeting, we present our report relative to the 15-months fiscal period closed as of March 31, 2015 to you regarding:

- the control of the annual accounts of Actavis France, as they are attached to the present report;
- the justification for our appreciations;
- verifications and specific information required by law.

The annual accounts were closed by the president. It is our duty to express an opinion on these accounts on the basis of our audit.

I. OPINION ON THE ANNUAL ACCOUNTS

We have performed our audit according to the professional norms of practice applicable in France; these norms require the implementation of diligences allowing reasonable assurance to be obtained that the annual accounts do not contain any significant anomalies. An audit consists in verifying, by sampling or by the means of other methods of selection, the elements justifying the amounts and information stated in the annual accounts. It also consists in assessing the accounting principles followed, the significant estimations retained and the overall presentation of the accounts. We consider that the elements that we have collected are sufficient and appropriate to form our opinion.

We certify that the annual accounts are, with regard to French rules and accounting principles, regular and sincere and give a loyal picture of the results from operations covering the previous fiscal period as well as the company's financial situation and assets at the end of said fiscal period.

II. JUSTIFICATION OF OUR APPRECIATIONS

In application of the provisions of article L. 823-9 of the code of commerce relative to the justification of our appreciations, we inform you that the appreciations to which we have proceeded focused on the appropriate nature of the accounting principles applied as well as on the reasonable nature of the significant estimations retained.

The appreciations thus made are in line with the framework of our audit process on annual accounts, taken as a whole, and they therefore contributed to the forming of our opinion expressed in the first part of this report.

III. SPECIFIC VERIFICATIONS AND INFORMATION

We have also proceeded in compliance with the norms of professional practice applicable in France, to the specific verifications provided for by law.

We have no observations to formulate regarding the sincerity and concordance with the annual accounts of the information provided in the President's management report and the documents addressed to the sole shareholder on the financial situation and annual accounts.

In Paris and in Lyon, May 29, 2015

The Statutory Auditors

KPMG Audit ID

ERNST & YOUNG Audit

Hervé Michelet

Nicolas Perlier

ACTAVIS FRANCE
26 avenue Tony GARNIER
69007 LYON
SIRET n° 478 783 434 00044

FY of 15 months
Previous FY 12 months

	ASSETS				
		GROSS amount	Amortization and provisions	FY closed 31/03/2015	FY closed 31/12/2013
	Capital subscribed but not called up (1)				
	INTANGIBLE ASSETS				
	Establishment Set-up costs				
	Development costs				
FIXED ASSETS	Concessions, patents and similar fees	2 985 726	2 985 726	0	86 835
	Goodwill				
	Other intangible assets				
	Early payment and installments				
	TANGIBLE ASSETS				
	Land				
	Buildings				
	Technical installations, material and tooling	520 163	520 163	0	21 154
	Other tangible assets				
	Capital expenditure underway				
	Early payment and installments				
Financial Assets	Participations, evaluated using the equity method				
	Other participations				
	Debts linked to participations				
	Other immobilized securities				
	Loans				
	Other financial assets	1 830		1 830	51 383
	TOTAL II	3 507 719	3 505 889	1 830	159 373
Current Assets	Raw materials, procurement				234 621
	Production of goods in progress				
	Production of services in progress				
	Semi-finished and finished products				
	Merchandise				1 058
	Early payment and installments made on orders				
	Receivables				
	Customers and related accounts	11 707 800	1 428 614	10 279 187	20 539 062
	Other receivables	514 025	10 410	503 616	4 341 850
	Subscribed capital and called up, not paid in				
	Securities investments (including treasury stock)				
	Cash on hand	103 409		103 409	346 356
	Deferred expenses	106 710		106 710	261 409
	TOTAL III	12 431 945	1 439 024	10 992 922	25 724 359
Regularization Accounts	Cost of issuing loans to be spread out (IV)				
	Reimbursement premiums on bonds (V)				
	Exchange rate accruals (VI)				
	GRAND TOTAL (I to VI)	15 939 664	4 944 913	10 994 752	25 883 733

ACTAVIS FRANCE
 26 avenue Tony GARNIER
 69007 LYON
 SIRET n° 478 783 434 00044

FY of 15 months
 Previous FY 12 months

BALANCE SHEET – LIABILITIES AND SHAREHOLDERS' EQUITY before allocation

		FY N 31/03/2015 15	FY N 31/12/2013 12
	Share capital (including paid in 3 496 640)	7 540 320	3 496 640
Shareholders'	Premiums from stock issues, mergers, contributions		
Equity	Reassessment differences		
	Legal reserve	31 205	
	Statutory or contractual reserves		
	Regulated reserves including special reserves		
	Other reserves		
	Results carried forward	592 878	(19 384 976)
	Results from the fiscal period profit (or loss)	(1 711 105)	624 089
	Investment grants		
	Regulated provisions		
	TOTAL I	6 453 298	(15 264 246)
Other Equity	Proceeds from issues of participating securities		
	Conditional advances		
	TOTAL II		
PROVISIONS	Provisions for risks	181 203	103 710
	Provisions for future expenses		
	TOTAL III	181 203	103 710
	FINANCIAL LIABILITIES		
LIABILITIES	Convertible bond issues		
	Other bond issues		
	Loans and debts through banking institutions		24 663
	Various loans and financial debt including equity notes		33 184 257
	Early payment or installments received on orders being processed		
	Accounts payable and related accounts	3 178 163	4 964 144
	Fiscal and social liabilities	546 455	1 584 238
	Amounts payable on fixed assets and related accounts		
	Other liabilities	635 634	1 286 965
Regularization accounts	Revenues collected in advance		
	TOTAL IV	4 360 251	41 044 269
	Exchange rate accruals (V)		
	OVERALL TOTAL (I+II+III+IV+V)	10 994 752	25 883 733

ACTAVIS FRANCE
26 avenue Tony GARNIER
69007 LYON
SIRET n° 478 783 434 00044

FY of 15 months
Previous FY 12 months
PROFIT AND LOSS STATEMENT

	FY N 31/03/2015	15	12
	France	Exports	Total
OPERATING REVENUE (1)			
Sales of merchandise	5 889 410	5 889 410	30 198 330
Production of goods sold			
Productions of services sold	2 756 765	2 756 765	383 366
NET REVENUE	8 646 175	8 646 175	30 581 696
Production in inventory			
Production capitalized			
Operating subsidies			
Reversals on depreciation, provisions, transfers of charges		546 323	7 954 198
Other income		3	369
TOTAL OPERATING INCOME (I)		9 192 502	38 536 263
OPERATING EXPENSES			
Purchases of merchandise (including customs duties)		5 695 892	9 223 245
Stock variations (merchandise)		471 002	10 647 708
Raw materials and other procurement (including customs duties)		0	370 620
Stock variations (raw materials and procurement)		(82 820)	(353 313)
Other purchases and external charges		2 679 337	10 622 151
Taxes, duties and assimilated levies		722 022	1 794 021
Wages and salaries		29 297	3 290 926
Social contributions		12 876	889 500
Allowances for depreciation and amortization			
On assets: amortization allowances		419 277	437 827
On assets: allowances for provisions		38 029	624 688
On current assets: amortization allowances		130 759	1 111 478
Allowances for risks and charges		0	226 646
Other charges		95	36 944
TOTAL OPERATING EXPENSES (II)		10 115 766	38 922 445
1. OPERATING INCOME (I-II)		(923 264)	(386 181)
Part of financial results made jointly			
Profit attributed or loss transferred (III)			
Losses taken on or profit transferred (IV)			
Financial income			
Income other than security investments and security assets			
Other interests and assimilated income			
Reversals on provisions and transfers of charges			
Exchange rate gains		0	7
Net income on transfer of investment securities			
TOTAL FINANCIAL INCOME (V)		0	7
Financial allowances for amortization and provisions			
Interests and assimilated charges		664 728	1 636 923
Exchange rate losses			
Net charges on transfers of investment securities			
TOTAL FINANCIAL EXPENSES (VI)		664 728	1 636 923
2. FINANCIAL RESULT (V-VI)		(664 728)	(1 636 915)
3. CURRENT PROFIT BEFORE TAXES (I-II+III-IV+V-VI)		(1 587 992)	(2 023 097)

ACTAVIS FRANCE
 26 avenue Tony GARNIER
 69007 LYON
 SIRET n° 478 783 434 00044

FY of 15 months
 Previous FY 12 months

PROFIT AND LOSS STATEMENT (cont.)

	FISCAL PERIOD N	FISCAL PERIOD N-1
	31/03/2015 15	31/12/2013 12
FINANCIAL GAINS AND LOSSES		
Exceptional gains from management operations		
Exceptional gains on capital operations	0	3 142 000
Provisions no longer required, transfer of expenses		
TOTAL EXCEPTIONAL GAINS (VII)		
Exceptional losses on management operations	123 113	422 587
Exceptional losses on capital operations	0	72 224
Exceptional allowances for amortization and provisions		
TOTAL EXCEPTIONAL LOSSES (VIII)	123 113	494 812
4. EXCEPTIONAL GAINS AND LOSSES RESULT (VII-VIII)	(123 113)	2 647 187
Employee profit sharing		
Corporate income tax		
TOTAL REVENUE (I+III+V+VII)	9 192 502	41 678 271
TOTAL EXPENSES (II+IV+VI+VIII)	10 903 607	41 054 181
5. PROFIT OR LOSS (total revenue – total expenses)	(1 711 105)	624 089

Actavis France S.A.S.
26 avenue Tony Garnier 69007 Lyon
Siret (company registration number): 478 783 434 00044

NOTES TO THE FINANCIAL STATEMENTS

Before allocations, the balance sheet for the fiscal period closed on 31/03/2015 discloses a total of 10 994 752 euros and the profit and loss statement, presented in list form, showed a loss of 1 711 105 Euros.

The fiscal period lasted 15 months covering the period from 01/01/2014 to 31/03/2015.

The notes or tables hereinafter form an integral part of the annual accounts.

Significant facts of the fiscal year

At the end of 2013, the group Actavis has started discussions with the Indian Group Aurobindo for the sale of their Western Europe generic branch, including Actavis France.

On 1 April 2014, the sale was finalized and Actavis France was sold to the Indian group Aurobindo.

On 21 March 2014, the company proceeded to an increase in share capital of 23 428 650 euros in cash. This increase through the issue of new shares was integrally subscribed by its sole shareholder, Actavis Holding NWE, and was paid through debt compensation. Successively, and still on the date of 21 March 2014, the share capital of Actavis France was reduced to 19 384 790 euros by cancelling shares, in view of absorbing losses figuring in the "Profits (losses) carried forward account". Subsequent to this operation, the share capital stood at 7 540 320 euros and shareholders' equity stood at 8 164 403.40 euros.

Post-closing events

None

ACCOUNTING RULES AND METHODS

(decree N° 83-120 dated 29-11-1983 – articles 7.21.24 beginning and 24-1, 24-2 and 24-3)

The financial statements have been established in compliance with:

- The ANC n°2014 03
- Law n°83 353 dated 30 April 1983
- Decree 83 1020 dated 29 November 1983
- The applicable accounting regulations:
 - 2000-06 and 2003-07 regarding liabilities
 - 2002-10 on the amortization and depreciation of assets
 - 2004-06 on the definition, accounting and evaluation of assets.

The general accounting conventions have been applied in respect of the principle of prudence, in compliance with these basic assumptions:

- Continuity of business,
- Permanence of accounting methods from one fiscal period to another,
- Independence of fiscal periods,

and in compliance with the general rules for establishing and presenting the annual accounts.

The basic method retained for the evaluation of the elements booked in the accounting is the method of historical costs.

Assets

Assets are evaluated at their cost of acquisition (purchase price and incidental expenses) or their cost of production.

The incidental expenses (transfer duties, fees and legal costs) are incorporated in the cost of acquisition of assets.

Intangible assets, mainly constituted by MA dossiers (health authorities), are valued at their cost of purchase or production. Variations linked to the maintenance of MA (marketing authorizations) already existing were not placed in assets, but rather booked as expenses under the item 'other purchases and external expenses'.

Tangible assets are valued based on their cost of production, with the exception of assets acquired before December 1976 which were subject to reassessment. Amortizations for depreciation are calculated following straight-line or digressive modes depending on the expected life duration.

- | | |
|---------------------------------|----------|
| - Fixtures | 10 years |
| - Office and computer equipment | 4 years |
| - Office furniture | 5 years |

The intangible assets including the expenses for MA filings as well as the value of acquisition of dossiers are amortized using straight-line depreciation over a period of 5 years from an accounting standpoint of view and 7 years from a fiscal standpoint.

Inventory

Stocks are evaluated based on the method first in/first out.

The gross value of merchandise and procurements includes the purchase price and incidental expenses.

A reserve for inventory depreciation is booked depending on the probability that it may not be sold before its expiration date.

An additional reserve is also booked on products whose net realization value is inferior to their net book value.

Receivables

Receivables are valued at their nominal value. A provision for depreciation is booked when the realizable value is lower than book value.

Provisions

Provisions are accrued when booking criteria as prescribed in the CRC 2000-06 about liabilities are met.

Audit fees

The fees corresponding to the legal control of financials statements by auditors came to 26 319 euros.

Retirement accruals

Since there were no longer employees as at 31/03/2015, no provision for retirement has been calculated.

Off balance sheet commitments

DIF (individual rights to continuing education): On 31 March 2015, the company no longer has any DIF commitments.

Consolidation

The standalone financials statements of the company are included, in accordance with global integration method, in the consolidated financial statements of the company

Aurobindo Pharma Limited (India), registered under L24239AP1986PLC015190 at the address Plot No.2, Maitri Vihar, Ameerpet, Hyderabad – 500 038, INDIA and the share capital of which amounts to 291,982,275 indian rupees as at 31 march 2015.

Transactions with related parties

The list of transactions carried out by the company with associated parties has not been given since said transactions have been signed under normal market conditions.

Headcount

As at March 31, 2015, the company does not have any employees.

Taxes

The deficits carried forward on 31 March 2013 amounted to € 21 292 555.

Risks related to tax regulations

The company faces various regulations, in particular from a tax standpoint. The tax audits more specifically may generate risks or underlying liabilities. These risks may lead the company to book provisions, calculated on a standalone basis, and depending on information, notifications and analyses available at the date of closing and law in force.

NOTES ON BALANCE SHEET

Fixed assets

	31/12/2013	+	-	31/03/2015
Other intangibles	2 985 725			2 985 725
Tooling	520 163			520 163
Financial assets	51 383		49 553	1 830
Total fixed assets	3 557 271	0	49 553	3 507 718

Amortization

	31/12/2013	+	-	31/03/2015
Other intangibles	2 587 744	288 759		2 876 503
Tooling	185 466	130 518		315 984
Financial assets	0			0
Total amortization	2 773 210	419 277	0	3 192 487

Provisions and depreciations

31/12/2013	+	-	31/03/2015
------------	---	---	------------

Reserve for risk				
Other provision for risk	103 710	125 976	48 484	181 202
Total I	103 710	125 976	48 484	181 202
Depreciations & impairments				
Intangibles	311 145	23 293	225 216	109 222
Tangibles	313 543	14 736	124 100	204 180
Inventory	152 503		152 503	0
Trade Receivables	1 279 641	130 759		1 428 614
Other receivables	18 2013			0
Total II	2 075 045	168 788	501 819	1 742 016
TOTAL	2 178 755	294 764	550 303	1 923 218

Maturity of debts and receivables

All payables and receivables have a maturity less than one year.

Details on specific balance sheet categories

Accrued receivables **5 478**

Taxes – accrued receivables 5 478

Provisions **479 141**

Suppliers: invoices not yet received 464 538

Taxes – accruals 14 602

Prepaid **106 710**

MA registration fees 83 000

Other prepaid 23 710

Equity

<i>Opening</i>		<i>Balance</i>
Shareholders' equity before distributions from previous fiscal periods		(15 264 246)
Distributions from previous fiscal periods		
Shareholders' equity after distribution from previous fiscal periods		(15 264 246)
<i>Variations during the fiscal period</i>	<i>Decrease</i>	<i>Increase</i>
Variations in share capital	(19 384 790)	23 428 650
Variations in premiums linked to share capital		
Variations in reserves		
Variations in investment grants		
Variations in regulated provisions		
Other variations	(1 711 105)	
BALANCE		6 453 298
<i>Situation at fiscal period end</i>		<i>Balance</i>
Shareholders' equity before allocation		6 453 298

The nominal value of shares is €10.00 each.

Elements linked to several balance sheet line items

	Amount with		Amount of debt or receivables represented by bills of exchange
	Related	With which the company has a share	
Capital subscribed not called up			
Intangibles			
Advances and downpayments			
Tangibles			
Advances and downpayments			
Financial assets			
Holdings			
Receivables related to holdings			
Loans granted			
Other securities			
Other financials assets			
Total fixed assets			
Receivables			
Trade accounts receivables		10 194 609	
Other receivables			
Capital subscribed, called up, not paid in			
Total receivables		10 194 609	
Liabilities			
Convertible bond loans			
Other bond loans			
Loans and debts towards bank institutions			
Misc. Loans and financial debts			
Advances and installments		972 286	
Trade accounts payable			
Fixed Assets accounts payables			
Other payables			
Total Payables		972 286	

NOTES TO PROFIT AND LOSS STATEMENT

Details on exceptional result

Exceptional income: **0**

None

Exceptional expense **126 548**

Fines and penalties 126 741

Prior-period-related

Expense -194

Income and expense with related parties

(in K€)	31/03/2015	31/12/2013
Sales	8 282	18 443
Trade Purchases	(281)	(4 801)
Other services	(1 213)	(1 308)
Wages and salaries	0	0
Other expenses	0	0
Financial income	0	0
Financial expense	(150)	(1 634)
Exceptional income	0	3 142
Exceptional expense	0	0

APL RESEARCH CENTRE LIMITED

CIN: U24116TG2006PLC051171

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad, Telangana - 500 038, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

DIRECTORS' REPORT

Dear Members,

Your Directors are pleased to present the Ninth Annual Report of the Company together with the Audited Accounts for the year ended 31st March, 2015.

Review of Operations:

The Company is engaged in the business of research & development in both basic and applied branches of science in relation to all kinds of basic drugs, bulk drugs, pharmaceutical formulations, healthcare and bio technology and other related fields.

Dividend

No dividend has been declared for the year 2014-15

Reserves

No amount has been carried to General Reserves for the year 2014-15

Details of Subsidiary/Joint Ventures/Associate Companies

The Company has no Subsidiaries / Joint Venture / Associate Companies as on 31st March, 2015.

Deposits

The Company has not accepted any public deposits and as such, no amount on account of principal or interest on public deposits was outstanding as on the date of the balance sheet.

Statutory Auditors

M/s. G Pavan Kumar & Associates, Chartered Accountants, Hyderabad have been appointed as Statutory Auditors of the Company at the 8th Annual General Meeting held on 25th August, 2014 for a period of 5 years subject to ratification by the members at every Annual General Meeting (i.e. till 13th Annual General Meeting). Your Directors commend for the ratification of their appointment.

Auditors' Report

The observations made in the Auditors' Report read together with relevant notes thereon are self explanatory and hence do not call for any further comments under Section 134 of the Companies Act, 2013.

APL RESEARCH CENTRE LIMITED

CIN: U24116TG2006PLC051171

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad, Telangana - 500 038, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Share Capital

During the year, your Company has made further issue of 3,00,000 Equity Shares of Rs.10/- each at par to Aurobindo Pharma Limited, the holding company. Consequently, the paid-up equity share capital was increased to Rs.12,10,27,500.

Extract of the Annual Return

In accordance with Section 134(3)(a) of the Companies Act, 2013 the extract of Annual Return (Form MGT-9) of the Company is enclosed as **Annexure – I** to the Boards Report.

Material changes and commitments, if any.

There are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

Conservation of energy, technology absorption and foreign exchange earnings and outgo

There are no Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 and There are no foreign exchange earnings and outgo during the year.

Directors:

As per the provisions of the Companies Act, 2013 Mr. K Nityananda Reddy will retire in the ensuing annual general meeting and being eligible, seek re-appointment. The Board of Directors recommends his re-appointment.

Changes in Directors and Key Managerial Personnel:

During the year Mr. M Madan Mohan Reddy (DIN: 01284266) have been appointed as an Additional Director w.e.f. 30th March, 2015. Mr. K Venkateswara Rao (DIN:02907769) and Mr. A Vinod Kumar Reddy (DIN:02944453) have been appointed as an Additional Directors (Independent) w.e.f. 30th March, 2015. They hold office upto the date of the ensuing Annual General Meeting. The Company has received notice(s) in writing under the provisions of Section 160 of the Companies Act, 2013, proposing the candidature of Mr. M Madan Mohan Reddy, Mr. K Venkateswara Rao and Mr. A Vinod Kumar Reddy for appointment as Directors.

Mr. Sarath Chandra Reddy (DIN: 01608013) was resigned from the Board as Director of the Company w.e.f 30th March, 2015

APL RESEARCH CENTRE LIMITED

CIN: U24116TG2006PLC051171

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad, Telangana - 500 038, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Declaration by an Independent Director(s) and re- appointment, if any:

The Company has received necessary declaration(s) from each Independent Director of the Company under Section 149(7) of the Act, that they meet the criteria of independence as laid down in section 149(6) of the Act.

Number of meetings of the Board of Directors:

During the financial year 2014-15 the Board of Directors has met seven times viz., on 09.05.2014, 18.07.2014, 04.09.2014, 20.10.2014, 27.11.2014, 30.01.2015 and 30.03.2015.

Audit Committee:

pursuant to the provisions of Section 177 of the Companies Act, 2013 and the rules made thereunder an Audit Committee has been constituted with the following Directors of the Company.

- | | |
|------------------------------------|-----------|
| 1) Mr. Kondareddy Venkateswara Rao | :Chairman |
| 2) Mr. Vinod Kumar Reddy Aerva | :Member |
| 3) Mr. K.Nithyananda Reddy | :Member |

Nomination and Remuneration Committee:

pursuant to the provisions of Section 178 of the Companies Act, 2013 and the rules made thereunder a Nomination and Remuneration Committee has been constituted with the following Directors of the Company.

- | | |
|------------------------------------|-----------|
| 1) Mr. Vinod Kumar Reddy Aerva | :Chairman |
| 2) Mr. Kondareddy Venkateswara Rao | :Member |
| 3) Mr. K Nityananda Reddy | :Member |

Brief description of terms of reference of Nomination and Remuneration Committee:

- Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down
- Recommend to the Board for appointment and removal of directors and KMP
- Recommend to the Board a policy relating to the remuneration of the directors, KMP and other employees etc.

The objectives of the Nomination and Remuneration Policy:

- To lay down criteria and terms and conditions with regard to identifying persons who are qualified to become directors and who may be appointed in senior management and KMP
- To determine remuneration
- To carry out evaluation of the performance of the directors

APL RESEARCH CENTRE LIMITED

CIN: U24116TG2006PLC051171

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad, Telangana - 500 038, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Particulars of loans, guarantees or investments under section 186:

No loans, Guarantees or investment made by the company during the year 2014-15.

Particulars of contracts or arrangements with related parties:

There are no transactions as specified under section 188 of the Companies Act, 2013 with related parties entered by the Company during the financial year 2014-15.

Particulars of Employees

There are no employees whose information as required under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

Policy on Sexual Harassment

The Company has adopted policy on Prevention of Sexual Harassment of Women at Workplace in accordance with The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

During the financial year ended March 31, 2015, the Company has not received any Complaints pertaining to Sexual Harassment.

Business Risk Management

At present the company has not identified any element of risk which may threaten the existence of the Company.

Directors' Responsibility Statement

Pursuant to Section 134(5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

(a) in the preparation of the annual accounts for the year ended 31st March, 2015, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

APL RESEARCH CENTRE LIMITED

CIN: U24116TG2006PLC051171

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad, Telangana - 500 038, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) the directors had prepared the annual accounts on a going concern basis; and

(e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and are operating effectively.

(f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and are operating effectively.


Acknowledgements


Your Company will always keep interest of its customers, employees and the stakeholders as a priority and shall reciprocate their confidence reposed in the Company. It has been a mutually beneficial relationship and looks forward to their continued support.

For and on behalf of the Board



Place: Hyderabad
Date: 21.05.2015


K. Nityananda Reddy
Director
DIN: 01284195


M. Sivakumaran
Director
DIN: 01284320

ANNEXURE - I

Form No. MGT-9
EXTRACT OF ANNUAL RETURN
as on the financial year ended on 31.03.2015

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:		
i	CIN	U242116TG2006PLC051171
ii	Registration Date	15.09.2006
iii	Name of the Company	APL Research Centre Limited
iv	Category / Sub-Category of the Company	Company Limited by Shares/Public Limited Company
v	Address of the Registered office and contact details	Plot No. 2, Maitrivihar, Ameerpet, Hyderabad – 500 038, Telangana Ph No: 040 - 66725000 Fax No:040 - 67074059
vi	Whether listed company	No
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10% or more of the total turnover of the company shall be stated:-

The Company is yet start Commercial operations.

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
	NA	NA	NA

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S.No	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ASSOCIATE	% of shares held	Applicable Section
1	Aurobindo Pharma Limited Regd Off: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500038, Telangana	L24239TG1986PLC015190	HOLDING	100	2(46)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change During the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual /HUF	0	0	0	0	0	0	0	0	0
b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt (s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	11802150	11802150	100.00	0	12102150	12102150	100.00	2.54
e) Banks / FI									
f) Any Other (Nominees of holding Company)	0	600	600	0		600	600	0	0
Sub-total (A) (1):-	0	11802750	11802750	100.00	0	12102750	12102150	100.00	2.54

i) Individual shareholders holding nominal share capital upto Rs1 lakh	0	0	0	0	0	0	0	0	0
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	0	0	0	0	0	0	0	0	0
c) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	0	0	0	0	0	0	0	0
Total Public Shareholding (B)=(B)(1)+(B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	11802750	11802750	100.00	0	12102750	12102150	100.00	2.54

ii) Shareholding of Promoters

SI No	Shareholder's Name	Shareholding at the beginning of the year			Share holding at the end of the year			
		No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	
								% change in share Holding during the year

1	Aurobindo Pharma Ltd (APL)	11802150	11802150	100.00	12102150	100.00	0	2.54
2	M Sivakumaran (Nominee of APL)	100	0	0	100	0	0	0
3	M Madan Mohan Reddy (Nominee of APL)	100	0	0	100	0	0	0
4	Sudhir B Singhi (Nominee of APL)	100	0	0	100	0	0	0
5	T Sivasankara Reddy (Nominee of APL)	100	0	0	100	0	0	0
6	S S Yugandhar (Nominee of APL)	100	0	0	100	0	0	0
7	M Venkat Reddy (Nominee of APL)	100	0	0	100	0	0	0
	Total	11802750	11802750	100.00	12102750	1000	0	2.54

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl.No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	Aurobindo Pharma Ltd				
	At the beginning of the year	11802150	100.00		
	Allotment on 27.11.2014	300000		12102150	100.00
	At the End of the year			12102150	100.00

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	For Each of the Top 10 Shareholders				

	At the beginning of the year	NIL
	Date wise Increase /Decrease in Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus / sweat equity etc):	NIL
	At the End of the year (or on the date of separation, if separated during the year)	NIL

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total Shares of the company
	For Each of the Directors and KMP				
	At the beginning of the year			NIL	
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc):			NIL	
	At the End of the year			NIL	

V. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil

Total (i+ii+iii)	Nil	Nil	Nil	Nil
Change in Indebtedness during the financial year	Nil	Nil	Nil	Nil
• Addition	Nil	Nil	Nil	Nil
• Reduction	Nil	Nil	Nil	Nil
Indebtedness at the end of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl. no.	Particulars of Remuneration	Name of MD/WTD/ Manager				Total Amount
		---	---	---	---	
1	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	NIL				
2	Stock Option	NIL				
3	Sweat Equity	NIL				
4	Commission - as % of profit	NIL				

	- others, specify...	
5	Others, please specify	NIL
	Total (A)	NIL
	Ceiling as per the Act	NIL
		NIL

B. Remuneration to other directors:

Sl.no.	Particulars of Remuneration	Name of Directors	Total Amount

	Independent Directors • Fee for attending board / committee meetings • Commission • Others, please specify	NIL	
	Total (1)	NIL	
	Other Non-Executive Directors • Fee for attending board / committee meetings • Commission • Others, please specify	NIL	
	Total (2)	NIL	
	Total (B)=(1+2)	NIL	
	Total Managerial Remuneration	NIL	
	Overall Ceiling as per the Act	NIL	

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD:

Sl.no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary (a) Salary as per provisions contained	NIL.			

	in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Incometax Act, 1961	
2.	Stock Option	NIL.
3.	Sweat Equity	NIL.
4.	Commission - as % of profit - others, specify...	NIL.
5.	Others, please specify	NIL.
	Total	NIL.

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty /Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give details)
A. Company					
Penalty					
Punishment			NIL		
Compounding					
B. Directors					
Penalty					
Punishment			NIL		
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty					
Punishment			NIL		
Compounding					



INDEPENDENT AUDITOR'S REPORT

To the Members of
APL Research Centre Limited.

Report on the Financial Statements

We have audited the accompanying financial statements of M/s APL Research Centre Limited ("the Company"), which comprise the Balance sheet as at March 31, 2015, the Statement of Profit and Loss and Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements


The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedure to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the Assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.




duty, value added tax or cess and other material statutory dues, at the yearend, for a period of more than six months from the date they became payable.

- c) According to the information and explanations given to us, the company does not have any amount in the account to transfer investor education and protection fund in accordance with the relevant provisions of the Companies Act, 1956 and rules made there under.
- viii. The provision of clause 3(viii) of the Order is not applicable, since the incorporation of the company is less than five years
- ix. In our opinion, According to the information and explanations given to us, the Company has not accepted any loans from the financial institutions and banks. Accordingly, the provisions of clause 3(ix) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- x. In our opinion, according to the information and explanations given to us, the company has not given any guarantees for loans taken by others from banks or the financial institutions. Accordingly, the provisions of clause 3(x) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xi. According to the information and explanations given to us, the company has not accepted any term loans during the year. Accordingly, the provisions of clause 3(xi) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xii. Based upon the audit procedures performed for the purpose of reporting the true and fair view of financial statements and as per the information and explanations given by the management, we report that no fraud on or by the company was noticed or reported during the course of our audit.

Place: Hyderabad
Date:



For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants


(G Pavan Kumar Reddy)
Proprietor
M.No.229495

ANNEXURE TO AUDITORS REPORT
(Referred to in paragraph 3 & 4 of our report of even date)


- i. In respect of fixed assets:
 - a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - b) A major portion of the fixed assets has been physically verified during the year by the management in accordance with a programme of verification of all the fixed assets at reasonable intervals having regard to the size of the company and the nature of its assets. According to the information and explanations given to us, the discrepancies noticed on such verification were not material and have been properly dealt with in the books of accounts.
- ii. The Company has no inventory as on the balance sheet date
- iii. According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to Companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the provisions of clauses 3 (iii) (a), 3 (iii) (b) of the Companies (Auditor's Report) Order 2015 are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the company and the nature of its business, for the purchase of inventory and fixed assets and for the sale of goods and services. During the course of our audit, we have not observed any major weakness or continuing failure to correct any major weakness in the internal control system of the Company in respect of these areas.
- v. The Company has not accepted any deposits. Accordingly, the provisions of clause 3(v) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- vi. The company was started not commenced any commercial operations, maintenance of cost records under section 148(1) of the Companies Act, 2013 was not applicable.
- vii.
 - a) The company is regular in depositing with the appropriate authorities undisputed statutory dues including provident fund, employees' state insurance, income tax, sales - tax, wealth tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues applicable to it.
 - b) According to the information and explanations given to us, no undisputed amounts payable in respect of income tax, sale tax, wealth tax, service tax, customs duty, excise



duty, value added tax or cess and other material statutory dues, at the yearend, for a period of more than six months from the date they became payable.

- c) According to the information and explanations given to us, the company does not have any amount in the account to transfer investor education and protection fund in accordance with the relevant provisions of the Companies Act, 1956 and rules made there under.
- viii. The provision of clause 3(viii) of the Order is not applicable, since the incorporation of the company is less than five years
- ix. In our opinion, According to the information and explanations given to us, the Company has not accepted any loans from the financial institutions and banks. Accordingly, the provisions of clause 3(ix) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- x. In our opinion, according to the information and explanations given to us, the company has not given any guarantees for loans taken by others from banks or the financial institutions. Accordingly, the provisions of clause 3(x) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xi. According to the information and explanations given to us, the company has not accepted any term loans during the year. Accordingly, the provisions of clause 3(xi) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xii. Based upon the audit procedures performed for the purpose of reporting the true and fair view of financial statements and as per the information and explanations given by the management, we report that no fraud on or by the company was noticed or reported during the course of our audit.

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants



(G. Pavan Kumar Reddy)
Proprietor
M. No. 229495

Place: Hyderabad
Date:

APL RESEARCH CENTRE LIMITED

Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038

CIN:U24116TG2006PLC051171

BALANCE SHEET AS AT 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

PARTICULARS	Note No.	As at 31 March, 2015	As at 31 March, 2014
I. EQUITY AND LIABILITIES			
(1) Shareholders Funds			
(a) Share Capital	3	121,027,500	118,027,500
(b) Reserves and Surplus	4	(130,720)	-
		<u>120,896,780</u>	<u>118,027,500</u>
(2) Current Liabilities			
(a) Other Current Liabilities	5	10,000	27,987
		<u>10,000</u>	<u>27,987</u>
		<u>120,906,780</u>	<u>118,055,487</u>
II. ASSETS			
(1) Non- Current Assets			
(a) Fixed Assets			
(i) Tangible assets	6	115,089,012	112,535,312
(ii) Tangible assets-Capital work In Progress	8	2,305,985	2,305,985
(b) Long Term Loans and advances	7	1,000,000	1,500,000
		<u>118,394,997</u>	<u>116,341,297</u>
(2) Current Assets			
(a) Cash & Bank Balances	9	2,511,783	1,714,190
		<u>2,511,783</u>	<u>1,714,190</u>
		<u>120,906,780</u>	<u>118,055,487</u>

Corporate information & Summary of significant accounting policies 1&2

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES

Firm Registration Number:015343S

Chartered Accountants

(G.Pavan Kumar Reddy)

Proprietor

Membership No.229495

Place:Hyderabad

Date: 21-May-2015



(K. Nityananda Reddy)

Director

DIN:01284195

(M.Sivakumaran)

Director

DIN:01284320



APL RESEARCH CENTRE LIMITED
Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038
CIN:U24116TG2006PLC051171

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 MARCH, 2015
(All amounts are in Indian Rupees except share data and unless otherwise stated)


PARTICULARS	Note No	Year ended 31 March,2015	Year ended 31 March,2014
Income:			
Revenue from operations		-	-
Other Income			
Total Revenue		<u>-</u>	<u>-</u>
Expenses:			
Other Expenses	10	130,720	-
Total Expenses		<u>130,720</u>	<u>-</u>
Profit/(Loss) before tax		(130,720)	-
Tax Expense:			
Current Tax		-	-
Deferred tax Credit / Charge			
Total Tax Expenses		<u>-</u>	<u>-</u>
Profit/(Loss) for the year		<u>(130,720)</u>	<u>-</u>
Earning per equity share:	11		
Basic & Diluted		(0.01)	-
Nominal Value per Equity Share		10.00	10.00

Corporate Information & Significant accounting policies 1&2
The accompanying notes are an integral part of the financial statements.

As per our report of even date


For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES
Firm Registration Number:015343S
Chartered Accountants


(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place:Hyderabad
Date: 21-May-2015




(K. Nityananda Reddy)
Director
DIN:01284195


(M. Sivakumaran)
Director
DIN:01284320



APL RESEARCH CENTRE LIMITED
Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038
CIN:U24116TG2006PLC051171

Cash flow statement for the year ended 31 March, 2015
(All amounts in Indian Rupees, except for share data or as otherwise stated)

Particulars	Note No	Year ended 31 March,2015	Year ended 31 March,2014
1. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before tax		(130,720)	-
Operating Profit before Working Capital Changes		(130,720)	-
Movements in working capital:			
Decrease/(increase) in long-term loans and advances		500,000	-
Decrease/(increase) in short-term loans and advances		-	-
Decrease/(increase) in Other non-current assets		-	(13,796)
Decrease/(increase) other current assets		-	-
Increase/(decrease) in other current liabilities		(17,987)	-
Cash Generated from Operations		351,293	(13,796)
Direct taxes paid (net of refunds)		-	-
Net Cash flow from Operating Activities	(A)	351,293	(13,796)
2. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of fixed assets, including CWIP and capital advances		(2,553,700)	-
Investment in subsidiaries		-	-
Net Cash flow used in Investing Activities	(B)	(2,553,700)	-
3. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issuance of share capital/ Application Money		3,000,000	-
Net Cash flow from Financing Activities	(C)	3,000,000	-
Net Increase/(Decrease) in Cash and Cash Equivalents	(A+B+C)	797,593	(13,796)
Cash and Cash Equivalents at the beginning of the year		1,714,190	1,727,986
Cash and Cash Equivalents at the end of the year		2,511,783	1,714,190

As per our report of even date

For G.PAVAN KUMAR & ASSOCIATES
Firm Registration Number:015343S
Chartered Accountants

(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place:Hyderabad
Date: 21-May-2015



For and on behalf of the Board of Directors

(K. Nityananda Reddy)
Director
DIN:01284195

(M.Sivakumaran)
Director
DIN:01284320



APL RESEARCH CENTRE LIMITED

Notes to financial statements for year ended March 31, 2015

(All amounts in Indian Rupees, except for share data or as otherwise stated)

1. Corporate information

Apl Research centre Limited (the Company) is a limited Company domiciled in India and incorporated under the provisions of the Companies Act, 1956. The Company is engaged in the business of research & development in both basic and applied branches of science in relation to all kinds of basic drugs, bulk drugs, pharmaceutical formulations, healthcare and bio technology and other related fields.

The Company is a subsidiary of Aurobindo Pharma limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.

2. Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). The Company has prepared these financial statements to comply in all material respects with the accounting standards, specified under section 133 of the Companies Act, 2013 ("the Act"), read with the Rule 7 of the Companies (Accounts) Rules 2014 (as amended). The financial statements have been prepared on an accrual basis and under the historical cost convention.

The accounting policies adopted in the preparation of financial statements are consistent with those of previous year.

2.1 Summary of significant accounting policies

a. Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

b. Tangible fixed assets

Fixed assets are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price.

Subsequent expenditure related to an item of fixed asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. All other expenses on existing fixed assets, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which such expenses are incurred.

Gains or losses arising from derecognition of fixed assets are measured as the difference between the net disposal proceeds and the carrying amount of the asset and recognized in the statement of profit and loss when the asset is derecognized.

c. Depreciation on tangible fixed assets

Depreciation on fixed assets is calculated on straight line method as per the useful lives prescribed under schedule II of Companies Act 2013.



u. = Ce

APR



d. Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. Intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Internally generated intangible assets, excluding capitalized development costs, are not capitalized and expenditure is reflected in the statement of profit and loss in the year in which the expenditure is incurred. All intangible assets are assessed for impairment whenever there is an indication that the intangible asset may be impaired.

Cost of software is amortized on a straight line basis over the stipulated license period and for software without any stipulated license period over six years or estimated useful life whichever is lower. All Intangible assets are amortized on a straight line basis over the estimated useful economic life.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

e. Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.

Income from services rendered by the Company is recognised on accrual basis for services rendered and billed as per the terms of specific contract.

f. Foreign currency transactions

Foreign currency transactions and balances

Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; and non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

Exchange differences

The Company accounts for exchange differences arising on translation/ settlement of foreign currency monetary items as below:

1. Exchange differences arising on long-term foreign currency monetary items related to acquisition of a fixed asset are capitalized and depreciated over the remaining useful life of the asset.
2. All other exchange differences are recognised as income or expenses in the period in which they arise.

g. Retirement and other employee benefits

Gratuity or other retirement benefits are not provided because the provisions of Payment of Gratuity Act, 1972 were not applicable.

h. Income taxes

Tax expenses comprises of current and deferred tax. Current income tax has been measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961 enacted in India.

Deferred income taxes reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.



Handwritten signature and date 12-9-12.

Handwritten signature.



i. Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

j. Provisions

A provision has been recognized in respect of a present obligation as a result of past event i.e. based on the probability of there being an outflow of resources to settle the obligation, in respect of which a reliable estimate can be made. Provisions have not been discounted to its present value and have been determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

k. Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

l. Cash and Cash Equivalents

Cash and cash equivalents comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.

m. Cash flows

Cash flows are reported using indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities are segregated.

Cash and cash equivalents: Cash and Cash Equivalents, in the statement of cash flow, comprise cash at bank and in hand and fixed deposits with original maturity of maximum 90 days.



u. y

MPK



NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH, 2015.
(All amounts in Indian Rupees, except for share data or as otherwise stated)

3.SHARE CAPITAL

Authorised Capital:

13,000,000 (Previous Year: 12,000,000) Equity Shares of Rs. 10/- each

As at 31 March, 2015	As at 31 March, 2014
130,000,000	120,000,000

Issued, Subscribed and paid-up Capital

1,21,02,750 (Previous Year: 1,18,02,750) Equity Shares of Rs.10 /- each, fully paid up

Total Issued, Subscribed and Fully Paid-up shares

121,027,500	118,027,500
121,027,500	118,027,500

a. Reconciliation of number of shares:

Equity shares

Balance as at the beginning of year

Add: Shares issued during the year

Balance at the end of the year

As at 31 March, 2015	As at 31 March, 2014
11,802,750	11,802,750
300,000	-
12,102,750	11,802,750

b. Shares held by holding company:

Out of equity shares issued by the company, shares held by its holding company are as under:

Aurobindo Pharma Ltd, the holding Company

1,21,02,750 (Previous year: 1,18,02,750) Equity Shares of

Rs.10 /- each, fully paid up

As at 31 March, 2015	As at 31 March, 2014
121,027,500	118,027,500
121,027,500	118,027,500

c.Terms/rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10 per share. Each holder of Equity shares is entitled to one vote per share.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the share holders.

d. Details of shareholders holding more than 5% of the aggregate shares in the Company:

Name of the Equity shareholder	As at 31 March, 2015		As at 31 March, 2014	
	No. of shares	% of holding	No. of shares	% of holding
M/s Aurobindo Pharma Ltd	12,102,750	100%	11,802,750	100%
	12,102,750	100%	11,802,750	100%

4. Reserves & Surplus

Surplus/(defecit) in Statement of Profit & Loss:

Balance as per Last financial statements

Add:Profit/(loss) for the period

Total

As at 31 March, 2015	As at 31 March, 2014
(130,720)	-
(130,720)	-



Handwritten signature/initials.

Handwritten signature/initials.



5. Current Liabilities

Other Current Liabilities

Total

As at 31 March, 2015	As at 31 March, 2014
10,000	27,987
<u>10,000</u>	<u>27,987</u>

7. Loans and Advances

(Unsecured, considered good except stated otherwise
Capital Advance

Considered good

Total

As at 31 March, 2015	
Current	Non Current
-	1,000,000
<u>-</u>	<u>1,000,000</u>

As at 31 March, 2014	
Current	Non Current
-	1,500,000
<u>-</u>	<u>1,500,000</u>

8. Expenditure during construction period pending capitalization:

Balance brought forward
Add: Incurred During the year
Rates & Taxes
Printing & Stationary
Statutory Audit fee
Registration & Filing fee
Bank Charges
Preliminary expenses

Total

As at 31 March, 2015	As at 31 March, 2014
2,305,985	1,528,189
-	-
-	550
-	360
-	11,236
-	550
-	1,100
-	764,000
<u>2,305,985</u>	<u>2,305,985</u>

9. Cash and Bank Balances

Cash on hand
Balances with Banks
-Current Accounts

Total

As at 31 March, 2015	As at 31 March, 2014
38,470	63,059
2,473,313	1,651,131
<u>2,511,783</u>	<u>1,714,190</u>

10. Other Expenses

Rates & Taxes
Printing & stationery
Statutory Audit Fee
Postage, Telegram & Telephone
Staff Welfare
Conveyance
Registration and filing fee
Other expenses
Bank charges

Total

As at 31 March, 2015	As at 31 March, 2014
600	-
49	-
10,000	-
132	-
962	-
400	-
99,240	-
15,100	-
4,237	-
<u>130,720</u>	<u>-</u>



19

2



11. Earnings per share:

	Year ended 31 March, 2015	Year ended 31 March, 2014
Profit/Loss considered for calculation of basic & diluted earnings per share	(130,720)	-
Weighted average number of equity shares in calculating basic & diluted earnings per share	11,905,490	11,802,750
Basic & Diluted Earnings Per share	(0.01)	-
Face value per Share	10	10

12. Related Party Disclosures:

Name of the related parties and description of relationship

Aurobindo Pharma Limited, The Holding Company

Key Managerial personnel

K. Nityananda Reddy, Director

M. Sivakumaran, Director

M. Madan Mohan Reddy, Director

Transactions with related parties


	Year ended 31 March, 2015	Year ended 31 March, 2014
1. Aurobindo Pharma Limited, Holding Company Equity contribution received	30,00,000	-
13. Earning in foreign currency (accrual Basis)	-	-
14. Foreign exchange outflow	-	-
15. FOB value of exports	-	-
16. CIF value of Imports	-	-
17. Previous year figures are regrouped, reclassified wherever necessary to confirm with the current year presentations.		
18. There are no dues to Micro, Small and Medium size companies to which the company owe amount outstanding more than 30 days.		
19. Figures are rounded upto nearest Rupee.		
20. Contingent Liabilities	-	-

As per our report of even date

For G.PAVAN KUMAR & ASSOCIATES

Firm Registration Number: 015343S

Chartered Accountants



(G. Pavan Kumar Reddy)

Proprietor

Membership No. 229495

Place: Hyderabad

Date: 21-May-2015




For and on behalf of the Board of Directors


(K. Nityananda Reddy)

Director

DIN: 01284195



(M. Sivakumaran)


Director

DIN: 01284320



APL RESEARCH CENTRE LIMITED		
(All amounts are in Indian Rupees except share data and unless otherwise stated)		
Note 6: Tangible assets		
	Land(incl.land development)	Total
Cost or valuation		
At 1 April 2014	112,535,312	112,535,312
Additions	2,553,700	2,553,700
Disposals	-	-
As At 31 March, 2015	115,089,012	115,089,012
Depreciation		
At 1 April 2014	-	-
Charge for the year	-	-
Disposals	-	-
At 31 March 2015	-	-
At 31 March 2014	-	-
Net Block		
As At 31 March, 2015	115,089,012	115,089,012
At 31 March 2014	112,535,312	112,535,312

* Land to the extent of 100.44 Acres amounting to Rs.9,90,08,200(March 31,2014:Rs 9,90,08,200) has been attached by the Directorate of Enforcement in a legal case pertaining to the holding company.



R...-G
T

070K



APL HEALTHCARE LIMITED

CIN: U24239TG2006PLC052053

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India
Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

DIRECTORS' REPORT

Dear Members,

Your Directors are pleased to present the Ninth Annual Report of the Company together with the Audited Accounts for the year ended 31st March, 2015.

Review of Operations:

The Company is in the process to set up a project to manufacture OTC Monograph Solid dosage finished formulations in the form of Tablets, Capsules and Soft gel capsules. The main focus of the project is to market the products in highly lucrative premium regulated market of USA through the group selling arm for OTC Products in USA. The Project is being planned to be implemented in Two Phases.

The Company has completed the installation of all basic infrastructure/ utilities, process optimisation, production units of Module-A1 and A2 required in the first phase of activity and have taken 5 SKUs for exhibit batches and kept for stability.

Your company is gearing for commercial activity by second quarter of 2015-16.

Dividend

No dividend has been declared for the year 2014-15

Reserves

No amount has been carried to General Reserves for the year 2014-15

Details of Subsidiary/Joint Ventures/Associate Companies

The Company has no Subsidiaries / Joint Venture / Associate Companies as on 31st March, 2015.

Deposits

The Company has not accepted any public deposits and as such, no amount on account of principal or interest on public deposits was outstanding as on the date of the balance sheet.

Statutory Auditors

M/s. G Pavan Kumar & Associates, Chartered Accountants, Hyderabad have been appointed as Statutory Auditors of the Company at the 8th Annual General Meeting held on 25th August, 2014 for a period of 5 years subject to ratification by the members at every Annual General Meeting (i.e. till 13th Annual General Meeting). Your Directors commend for the ratification of their appointment.

APL HEALTHCARE LIMITED

CIN: U24239TG2006PLC052053

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Auditors' Report

The observations made in the Auditors' Report read together with relevant notes thereon are self explanatory and hence do not call for any further comments under Section 134 of the Companies Act, 2013.

Share Capital

During the year, your Company has made further issue of 4,15,00,000 Equity Shares of Rs.10/- each at par to Aurobindo Pharma Limited, the holding company. Consequently, the paid-up equity share capital was increased to Rs. 55,53,76,000

Extract of the Annual Return

In accordance with Section 134(3)(a) of the Companies Act, 2013 the extract of Annual Return (Form MGT-9) of the Company is enclosed as **Annexure – I** to the Boards Report.

Material changes and commitments, if any.

There are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

Conservation of energy, technology absorption and foreign exchange earnings and outgo

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014, is not applicable to the Company for the year 2014-15 except foreign exchange earnings and outgo which is furnished in as **Annexure – II**

Business Risk Management

At present the company has not identified any element of risk which may threaten the existence of the Company.

Directors:

As per the provisions of the Companies Act, 2013 Mr. P. Sarath Chandra Reddy will retire in the ensuing annual general meeting and being eligible, seek re-appointment. The Board of Directors recommends his re-appointment.

APL HEALTHCARE LIMITED

CIN: U24239TG2006PLC052053

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Changes in Directors and Key Managerial Personnel:

During the year Mr. K Venkateswara Rao (DIN:02907769) and Mr. A Vinod Kumar Reddy (DIN:02944453) have been appointed as an Additional Directors (Independent) w.e.f. 30th March, 2015. They hold office upto the date of the ensuing Annual General Meeting. The Company has received notices in writing under the provisions of Section 160 of the Companies Act, 2013, proposing the candidature for the office(s) of Independent Director(s).

Declaration by an Independent Director(s) and re- appointment, if any:

The Company has received necessary declaration(s) from each Independent Director of the Company under Section 149(7) of the Act, that they meet the criteria of independence as laid down in section 149(6) of the Act.

Formal Annual Evaluation:

Evaluation of all Board members is done on an annual basis, the evaluation is done by the Board, Nomination and Remuneration Committee with specific focus on the performance and effective functioning of the Board and Individual Directors.

The criteria for Evaluation of the Board are the frequency of meetings, length of meetings and the flow of the information to the Board members etc.

The criteria for Evaluation of the individual Directors are the core competencies, monitoring management performance and development, guiding strategy etc.

Number of meetings of the Board of Directors:

During the financial year 2014-15 the Board of Directors has met fourteen times viz., on 09.05.2014, 15.05.2014, 07.06.2014, 18.07.2014, 07.08.2014, 30.08.2014, 25.09.2014, 15.10.2014, 03.12.2014, 02.01.2015, 12.01.2015, 30.01.2015, 09.03.2015 and 30.03.2015.

Audit Committee:

pursuant to the provisions of Section 177 of the Companies Act, 2013 and the rules made thereunder an Audit Committee has been constituted with the following Directors of the Company.

- | | |
|------------------------------------|-----------|
| 1) Mr. Kondareddy Venkateswara Rao | :Chairman |
| 2) Mr. Vinod Kumar Reddy Aerva | :Member |
| 3) Mr. K.Nithyananda Reddy | :Member |

APL HEALTHCARE LIMITED

CIN: U24239TG2006PLC052053

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Nomination and Remuneration Committee:

pursuant to the provisions of Section 178 of the Companies Act, 2013 and the rules made thereunder a Nomination and Remuneration Committee has been constituted with the following Directors of the Company.

- | | |
|------------------------------------|-----------|
| 1) Mr. Vinod Kumar Reddy Aerva | :Chairman |
| 2) Mr. Kondareddy Venkateswara Rao | :Member |
| 3) Mr. K Nityananda Reddy | :Member |

Brief description of terms of reference of Nomination and Remuneration Committee

- Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down
- Recommend to the Board for appointment and removal of directors and KMP
- Recommend to the Board a policy relating to the remuneration of the directors, KMP and other employees etc.

The objectives of the Nomination and Remuneration Policy:

- To lay down criteria and terms and conditions with regard to identifying persons who are qualified to become directors and who may be appointed in senior management and KMP
- To determine remuneration
- To carry out evaluation of the performance of the directors

Particulars of loans, guarantees or investments under section 186:

No loans, Guarantees or investment made by the company during the year 2014-15.

Particulars of contracts or arrangements with related parties:

All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business. There were no materially significant related party transactions which could have had a potential conflict with the interests of the Company.

Transactions with related parties entered by the Company are periodically placed before the Board and the particulars of contracts entered during the financial year 2014-15 are enclosed in Form AOC-2 as **Annexure – III**

APL HEALTHCARE LIMITED

CIN: U24239TG2006PLC052053

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Particulars of Employees

There are no employees whose information as required to be disclosed under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

Policy on Sexual Harassment

The Company has adopted policy on Prevention of Sexual Harassment of Women at Workplace in accordance with The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

During the financial year ended March 31, 2015, the Company has not received any Complaints pertaining to Sexual Harassment.

Directors' Responsibility Statement

Pursuant to Section 134(5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

(a) in the preparation of the annual accounts for the year ended 31st March, 2015, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) the directors had prepared the annual accounts on a going concern basis; and

(e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and are operating effectively.

(f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and are operating effectively.

APL HEALTHCARE LIMITED

CIN: U24239TG2006PLC052053

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Acknowledgements

Your Company will always keep interest of its customers, employees and the stakeholders as a priority and shall reciprocate their confidence reposed in the Company. It has been a mutually beneficial relationship and looks forward to their continued support.

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015




K. Nityananda Reddy
Director
DIN: 01284195


M. Sivakumaran
Director
DIN: 01284320

ANNEXURE - I

**Form No. MGT-9
EXTRACT OF ANNUAL RETURN
as on the financial year ended on 31.03.2015**

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:		
i	CIN	U24239TG2006PLC052053
ii	Registration Date	19.12.2006
iii	Name of the Company	APL Healthcare Limited
iv	Category / Sub-Category of the Company	Company Limited by Shares/Public Limited Company
v	Address of the Registered office and contact details	Plot No. 2, Maitrivihaar, Ameerpet, Hyderabad – 500 038, Telangana Ph. No : 040 – 2373 6370 Fax No :040 - 2374 7340
vi	Whether listed company	No
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10% or more of the total turnover of the company shall be stated:-

The Company is yet to start Commercial operations.

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
	NIL	NIL	NIL

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S.No	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ASSOCIATE	% of shares held	Applicable Section
1	Aurobindo Pharma Limited Regd Off: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500038, Telangana	L24239TG1986PLC015190	HOLDING	100	2(46)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change During the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual /HUF	0	0	0	0	0	0	0	0	0
b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt (s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	14037000	14037000	100.00	0	55537000	55537000	100.00	295.65
e) Banks / FI									
f) Any Other (Nominees of holding	0	600	600	0		600	600	0	0

ii) Overseas	0	0	0	0	0	0	0	0	0
b) Individuals	0	0	0	0	0	0	0	0	0
i) Individual shareholders holding nominal share capital upto Rs1 lakh	0	0	0	0	0	0	0	0	0
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	0	0	0	0	0	0	0	0	0
c) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	0	0	0	0	0	0	0	0
Total Public Shareholding (B)=(B)(1)+(B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	14037600	14037600	100.00	0	55537600	55537600	100.00	295.65

ii) Shareholding of Promoters

Sl No	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in share Holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	

1	Aurobindo Pharma Ltd (APL)	14037000	100	0	55537000	100	0	295.65
2	M Sivakumaran (Nominee of APL)	100	0	0	100	0	0	0
3	M Madan Mohan Reddy (Nominee of APL)	100	0	0	100	0	0	0
4	Sudhir B Singhi (Nominee of APL)	100	0	0	100	0	0	0
5	T Sivasankara Reddy (Nominee of APL)	100	0	0	100	0	0	0
6	S S Yugandhar (Nominee of APL)	100	0	0	100	0	0	0
7	M Venkat Reddy (Nominee of APL)	100	0	0	100	0	0	0
	Total	14037600	100	0	55537600	100	0	295.65

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl.No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	Aurobindo Pharma Limited				
	At the beginning of the year	14037000	100.00		
	Allotment on 07.06.2014	4500000		18537000	100.00
	Allotment on 07.08.2014	6000000		24537000	100.00
	Allotment on 25.09.2014	8000000		32537000	100.00
	Allotment on 03.12.2014	6000000		38537000	100.00
	Allotment on 12.01.2015	9000000		47537000	100.00
	Allotment on 09.03.2015	6000000		53537000	100.00
	Allotment on 30.03.2015	2000000		55537000	100.00
	At the End of the year			55537000	100.00

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	For Each of the Top 10 Shareholders				
	At the beginning of the year				
	Date wise Increase /Decrease in Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus / sweat equity etc):	NIL			
	At the End of the year (or on the date of separation, if separated during the year)	NIL			

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total Shares of the company
	For Each of the Directors and KMP				
	At the beginning of the year	NIL			
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc):	NIL			
	At the End of the year	NIL			

V. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil
Change in Indebtedness during the financial year	Nil	Nil	Nil	Nil
• Addition	Nil	Nil	Nil	Nil
• Reduction	Nil	Nil	Nil	Nil
Indebtedness at the end of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl. no.	Particulars of Remuneration	Name of MD/WTM/ Manager				Total Amount
		---	---	---	---	
1	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	NIL				

	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	
2	Stock Option	NIL
3	Sweat Equity	NIL
4	Commission - as % of profit - others, specify...	NIL
5	Others, please specify	NIL
	Total (A)	NIL
	Ceiling as per the Act	NIL
		NIL

B. Remuneration to other directors:

Sl.no.	Particulars of Remuneration	Name of Directors	Total Amount
		---	---
	Independent Directors • Fee for attending board / committee meetings • Commission • Others, please specify		NIL
	Total (1)		NIL
	Other Non-Executive Directors • Fee for attending board / committee meetings • Commission • Others, please specify		NIL
	Total (2)		NIL
	Total (B)=(1+2)		NIL
	Total Managerial Remuneration		NIL
	Overall Ceiling as per the Act		NIL

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD:

Sl.no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Incometax Act, 1961	NIL			
2.	Stock Option	NIL			
3.	Sweat Equity	NIL			
4.	Commission - as % of profit - others, specify...	NIL			
5.	Others, please specify	NIL			
	Total	NIL			

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty /Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give details)
A. Company					
Penalty	NIL				
Punishment					
Compounding					
B. Directors					
Penalty	NIL				
Punishment					
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty	NIL				
Punishment					
Compounding					

APL HEALTHCARE LIMITED

CIN: U24239TG2006PLC052053

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Annexure-II

Foreign exchange earnings and Outgo:

	(in Rupees)	
	2014-15	2013-14
Foreign exchange earned		
Exports (FOB)	-	-
Others	-	-
	-	-
Foreign exchange outgo		
Materials	40,271	-
Capital Goods	52,208,780	-
	52,249,051	-

For and on behalf of the Board



Place: Hyderabad
Date: 21.05.2015

K.Nityananda Reddy
Director
DIN: 01284195

M.Sivakumaran
Director
DIN: 01284320

APL HEALTHCARE LIMITED

CIN: U24239TG2006PLC052053

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Annexure III

Form –AOC-2

DETAILS OF RELATED PARTY TRANSACTIONS

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis:

(a) Name(s) of the related party and nature of relationship	There were no transaction or arrangement which were not at arm's length
(b) Nature of contracts/arrangements/transactions	
(c) Duration of the contracts/arrangements/transactions	
(d) Salient terms of the contracts or arrangements or transactions including the value, if any arm's length.	
(e) Justification for entering into such contracts or arrangements or transactions	
(f) Date(s) of approval by the Board	
(g) Amount paid as advances, if any:	
(h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188	

2. Details of material contracts or arrangement or transactions at arm's length basis:


Name of the related party and nature of relationship	Aurobindo Pharma Ltd, Holding Company
Nature of contracts/ arrangements / transactions	Purchase of raw materials and capital goods
Duration of the contracts / arrangements / transactions	on going
Salient terms of the contracts or arrangements or transactions including the value, if any	Transactions: Purchase of raw materials and capital goods Rs. 17.69 Lakhs.
Justification for entering into such contracts or arrangements or transactions	Transactions are based on transfer pricing guidelines


Appropriate approvals have been taken for related party transactions. Advances paid if any have been adjusted against billing wherever applicable

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015




K. Nityananda Reddy
Director
DIN: 01284195


M. Sivakumaran
Director
DIN: 01284320



INDEPENDENT AUDITOR'S REPORT

To the Members of
APL Healthcare Limited.

Report on the Financial Statements

We have audited the accompanying financial statements of M/s APL Healthcare Limited ("the Company"), which comprise the Balance sheet as at March 31, 2015, and the Statement of Profit and Loss and Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedure to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the Assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Handwritten signature





Opinion


In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- a. In the case of the Balance Sheet, of the state of affairs of the Company as at March 31,2015;
- b. In the case of the Statement of Profit and Loss, of the loss for the year ended on that date; and
- c. In case of the Cash Flow Statement, of the cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

- 1) As required by the Companies (Auditor's Report) Order, 2015 ("the order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure a statement on the matters section in paragraphs 3 and 4 of the Order to the extent applicable.
- 2) As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to best of our knowledge and belief were necessary for the purpose of our audit;
 - b. In our opinion proper books of account as required by law have been kept by the company so far as appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the Balance Sheet , Statement of Profit and Loss and Cash Flow Statement comply with the Accounting Standards notified under Section 133 of the Companies Act,2013, read with the Rule 7 of the Companies (Accounts) Rules,2014;
 - e. On the basis of written representations received from the directors as on March 31,2015, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31,2015, from being appointed as a director In terms of sub-section (2) of section 164 of the Companies Act,2013.
 - f. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts in respect of which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants


(G Pavan Kumar Reddy)
Proprietor
M.No.229495

Place: Hyderabad

Date: 21-May-2015





ANNEXURE TO AUDITORS REPORT

(Referred to in paragraph 3 &4 of our report of even date)

- i. In respect of fixed assets:
 - a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - b) A major portion of the fixed assets has been physically verified during the year by the management in accordance with a programme of verification of all the fixed assets at reasonable intervals having regard to the size of the company and the nature of its assets. According to the information and explanations given to us, the discrepancies noticed on such verification were not material and have been properly dealt with in the books of accounts.
- ii. In respect of Inventories:
 - a) The management has conducted physical verification of inventory at reasonable intervals during the year.
 - b) The procedures of physical verification of inventory followed by the management are reasonable and adequate in relation to the size of the Company and nature of its business.
 - c) The Company is maintaining proper records of inventory and no material discrepancies were noticed on physical verification.
- iii.
 - a) According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to Companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the provisions of clauses 3 (iii) (a), 3 (iii) (b) of the Companies (Auditor's Report) Order 2015 are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the company and the nature of its business, for the purchase of inventory and fixed assets and for the sale of goods and services. During the course of our audit, we have not observed any major weakness or continuing failure to correct any major weakness in the internal control system of the Company in respect of these areas.
- v. The Company has not accepted any deposits. Accordingly, the provisions of clause 3(v) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- vi. The company has not started any commercial operations as on balance sheet date. Accordingly, the provisions of clause 3(vi) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.

Handwritten signature





vii.

- a) The company is regular in depositing with the appropriate authorities undisputed statutory dues including provident fund, income tax, sales - tax, wealth tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues applicable to it.
- b) According to the information and explanations given to us, no undisputed amounts payable in respect of income tax, sale tax, wealth tax, service tax, customs duty, excise duty, value added tax or cess and other material statutory dues, at the yearend, for a period of more than six months from the date they became payable.
- c) According to the information and explanations given to us, the company does not have any amount in the account to transfer investor education and protection fund in accordance with the relevant provisions of the Companies Act, 1956 and rules made there under.

viii. The Company has incurred cash losses at the end of the financial year but the accumulated losses at the end of the financial year are less than fifty percent of the net worth of the company.


ix. In our opinion, According to the information and explanations given to us, the Company has not accepted any loans from the financial institutions and banks. Accordingly, the provisions of clause 3(ix) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.

x. In our opinion, according to the information and explanations given to us, the company has not given any guarantees for loans taken by others from banks or the financial institutions. Accordingly, the provisions of clause 3(x) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.

xi. According to the information and explanations given to us, the company has not accepted any term loans during the year. Accordingly, the provisions of clause 3(xi) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.

xii. Based upon the audit procedures performed for the purpose of reporting the true and fair view of financial statements and as per the information and explanations given by the management, we report that no fraud on or by the company was noticed or reported during the course of our audit.

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants


(G Pavan Kumar Reddy)
Proprietor
M.No.229495

Place: Hyderabad

Date: 21 May 2015



Balance Sheet as at 31 March, 2015

(All amounts in Indian Rupees, except share data and where otherwise stated)

	Note	As at 31 Mar,2015	As at 31 Mar,2014
EQUITY AND LIABILITIES			
SHAREHOLDER'S FUNDS			
Share Capital	3	555,376,000	140,376,000
Reserves & Surplus	4	(1,578,935)	-
		<u>553,797,065</u>	<u>140,376,000</u>
NON CURRENT LIABILITIES			
Long Term Provisions	5	1,296,778	172,637
		<u>1,296,778</u>	<u>172,637</u>
CURRENT LIABILITIES			
Trade Payables	6	10,394,005	1,494,825
Other Current Liabilities	7	53,315,093	19,196,955
Short Term Provisions	5	-	61,683
		<u>63,709,098</u>	<u>20,753,463</u>
TOTAL		<u>618,802,941</u>	<u>161,302,100</u>
ASSETS			
NON-CURRENT ASSETS			
Fixed Assets			
(i) Tangible assets	8	18,804,838	18,804,838
(ii) Tangible assets - Capital work in progress	8	530,989,614	87,243,012
Deferred tax asset (Net)	9	706,065	-
Long Term Loans and Advances	10	36,357,482	45,287,354
		<u>586,857,999</u>	<u>151,335,204</u>
CURRENT ASSETS			
Inventories	11	12,776,234	-
Cash and Bank Balances	12	12,480,858	8,769,407
Short Term Loans and Advances	10	6,162,484	1,190,091
Other Current Assets	13	525,367	7,397
		<u>31,944,943</u>	<u>9,966,895</u>
TOTAL		<u>618,802,941</u>	<u>161,302,100</u>
Corporate Information & Summary of significant accounting policies	1&2		


The accompanying notes are an integral part of the financial statements

As per our report of even date.

For and on behalf of the Board of Directors

For G.Pavan kumar & Associates
Firm Registration Number:015343S
Chartered Accountants

(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place:Hyderabad
Date: 21-May-2015



(K.Nityananda Reddy)
Director
DIN:01284195

(M.Sivakumaran)
Director
DIN:01284320



APL HEALTHCARE LIMITED
PLOT NO.2, MAITRIVIHAR, AMEERPET, HYDERABAD-500038
CN: U24239TG2006PLC052053

Statement of profit and loss for the year ended 31 March, 2015
(All amounts are in Indian Rupees except share data and unless otherwise stated)

PARTICULARS	Note No.	Year ended 31 March,2015	Year ended 31 March,2014
Income:			
Revenue from operations		-	-
Other Income		-	-
Total Revenue		-	-
Expenses:			
Other Expenses	14	2,285,000	-
Total Expenses		2,285,000	-
Profit/(Loss) before tax		(2,285,000)	-
Tax Expense:			
Current Tax		-	-
Deffered Tax (charge)/Credit	9	706,065	-
Profit / (Loss)for the year		(1,578,935)	-
Earning per equity share:	18		
Basic & Diluted		(0.01)	-
Nominal Value per Equity Share		10	10


Corporate Information & Summary of significant accounting policies 1&2
The accompanying notes are an integral part of the financial statements.

As per our report of even date

For and on behalf of the Board of Directors

For G.Pavan kumar & Associates
Firm Registration Number:015343S
Chartered Accountants

(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place:Hyderabad
Date: 21-May-2015



(K.Nityananda Reddy)
Director
DIN:01284195

(M.Sivakumaran)
Director
DIN:01284320



APL HEALTHCARE LIMITED
PLOT NO.2, MAITRIVIHAR, AMEERPET, HYDERABAD-500038
CN: U24239TG2006PLC052053

Cash flow statement for the period ended 31 March, 2015.
(All amounts in Indian Rupees, except for share data or as otherwise stated)

Particulars	Notes	Year ended 31 March, 2015	Year ended 31 March, 2014
1. CASH FLOW FROM OPERATING ACTIVITIES			
Net (Loss) before tax and exceptional items		(2,285,000)	-
Adjustments to reconcile profit before tax to net cash flows			
Interest Income		-	-
Provision for Taxes and Deferred taxes		706,065	-
Operating Profit before Working Capital Changes		(1,578,935)	-
Movements in working capital:			
Decrease/(increase) in inventories		(12,776,234)	-
Decrease/(increase) in long-term loans and advances		8,929,872	(39,664,754)
Decrease/(increase) in short-term loans and advances		(4,972,393)	(1,178,193)
Decrease/(increase) Other Non Current Asset		(706,065)	(900,000)
Decrease/(increase) in other current assets		(517,970)	(7,397)
Increase/(decrease) in trade payables		8,899,180	1,432,109
Increase/(decrease) in provision for retirement benefits		1,124,141	-
Increase/(decrease) in other current liabilities		34,118,138	19,141,043
Cash Generated from Operations		32,519,735	(21,177,192)
Direct taxes paid (net of refunds)		(61,683)	(61,683)
Net Cash flow from Operating Activities	(A)	32,458,052	(21,115,509)
2. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of fixed assets, including CWIP and capital advances		(443,746,602)	(80,033,992)
Proceeds from sale of fixed assets		-	-
Purchase of non- current investments made in subsidiaries		-	-
Other non current assets		-	-
Net Cash flow used in Investing Activities	(B)	(443,746,602)	(80,033,992)
3. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issuance of share capital		415,000,000	107,500,000
Proceeds from long term borrowings		-	-
Net Cash flow from Financing Activities	(C)	415,000,000	107,500,000
Net Increase/(Decrease) in Cash and Cash Equivalents	(A+B+C)	3,711,450	6,350,499
Cash and Cash Equivalents at the beginning of the year		8,769,407	2,418,909
Cash and Cash Equivalents at the end of the year		12,480,858	8,769,407

As per our report of even date.

For and on behalf of the Board of Directors

For G.Pavan kumar & Associates

Firm Registration Number: 183435

Chartered Accountants


(G.Pavan Kumar Reddy)

Proprietor

Membership No.229495

Place:Hyderabad

Date: 21-May-2015



(K.Nityananda Reddy)

Director

DIN:01284195

(M.Sitakumaran)

Director

DIN:01284320



APL HEALTH CARE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

1. Background

APL Health Care Limited (the company) is a limited company domiciled in India and incorporated under provisions of the Companies Act, 1956. The company is engaged in the business of manufacture, refine, purchase, sell, prepare, import, export all classes and kinds of drugs including pharmaceutical preparations and formulations, fine chemicals, raw material, and intermediates, for drugs and all other pharmaceuticals such as tablets, injectables, syrups, powders, ointments, aerosols, capsules, liquids.

2. Summary of significant accounting policies

(a) Basis of preparation of financial statements

The Company maintains its accounts on accrual basis following the historical cost convention in accordance with generally accepted accounting principles (GAAP), in compliance with provisions of the Companies Act, 2013 and the Accounting Standards [as specified in the Companies (Accounting Standards) Rules, 2006 read with Section 133 of the Companies Act, 2013 and Rule 7 of the Companies (Accounts) Rules 2014 prescribed by the Central Government]. The other Accounting Standards as issued by ICAI, not yet notified are also considered, wherever applicable, except to the extent where compliance with the other statutory promulgations override the same requiring a different treatment. The accounting policies are consistent with those used in the previous year.

(b) Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting year. Examples of such estimates include provision for future obligation under employee benefit plans, net realizable value of inventory and estimated useful lives of fixed assets. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates.

(c) Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.

Revenue from sale of goods is recognized on dispatch (in respect of exports on the date of the bill of lading or airway bill) which coincides with transfer of significant risks and rewards to customer and is net of trade discounts, sales returns and sales tax, where applicable. Excise duty deducted from revenue (gross) is the amount that is included in revenue (gross) and not the entire amount of liability arising during the year.



Handwritten signature/initials

Handwritten signature/initials



APL HEALTH CARE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

Interest is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.

(d) Fixed assets and depreciation

Fixed assets are stated at cost less accumulated depreciation and impairment losses, if any. Cost comprises the purchase price and any attributable cost of bringing the asset to its working condition for its intended use. Borrowing costs relating to acquisition of fixed assets which take substantial period of time to get ready for use are included to the extent they relate to the period till such assets are ready for intended use. All other borrowing costs are expensed in the period they occur.

Expenditure directly relating to construction activity is capitalized. Indirect expenditure is capitalized to the extent those relate to the construction activity or is incidental thereto. Income earned during construction period is deducted from the total expenditure relating to construction activity.

Depreciation is provided using the Straight Line Method ('SLM') over the useful lives of the assets prescribed under Schedule II to the Companies Act, 2013

(e) Impairment


The carrying amounts of assets are reviewed at each balance sheet date to see if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the assets net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value at the weighted average cost of capital. After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

(f) Inventories

Raw materials, packing materials, stores, spares and consumables are valued at lower of cost, calculated on weighted average basis, and net realizable value. Items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost.


Finished goods and intermediates are valued at lower of cost and net realizable value. Cost includes materials, labour and a proportion of appropriate overheads based on normal operating capacity. Cost is determined on a weighted average basis.

Net realizable value is the estimated selling price in the ordinary course of business, reduced by the estimated costs of completion and costs to effect the sale.



[Handwritten signature]

[Handwritten signature]



APL HEALTH CARE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

(g) Employee benefits

Provident fund

A retirement benefit in the form of provident fund scheme is a defined contribution and the contribution is charged to the statement of profit and loss of the year when the contribution to the respective fund is due. There are no other obligations other than the contribution payable to the respective fund.

Gratuity

Retirement benefits in the form of gratuity is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to the statement of profit and loss.

Leave encashment

Employee benefits in the form of leave encashment is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to the statement of profit and loss.

(h) Leases

Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item are classified as operating leases. Operating lease payments are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term.

(i) Borrowing costs

Borrowing costs include interest and other ancillary costs incurred in connection with the arrangement of borrowing and exchange differences arising from the foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.


(j) Foreign Currency transactions

Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency



APL HEALTH CARE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

are reported using the exchange rate at the date of the transaction; and non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

Exchange differences

Exchange differences arising on the settlement of monetary items at rates different from those at which they were initially recorded during the period are recognized as income or as expenses in the period in which they arise.

(k) Export Benefits and Incentives.

Export benefits on account of duty drawback and export promotion schemes are accrued and accounted in the year of export, and are included in other operating revenue. Other benefits in the form of advance authorization for imports are accounted for on purchase of imported materials.

(l) Taxes on income

Tax expense comprises of current and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the provisions of the Income Tax Act, 1961. Deferred income taxes reflect the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.

Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the Balance Sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

Unrecognized deferred tax assets of earlier years are reassessed and recognized to the extent that it has become reasonably certain or virtually certain, as the case may be that future taxable income will be available against which such deferred tax assets can be realized.

The carrying amount of deferred tax assets are reviewed at each Balance Sheet date. The company writes-down the carrying amount of a deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

(m) Provisions

A provision is recognized when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on management estimate



APL HEALTH CARE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current management estimates.

(n) Earnings per equity share

Basic earnings per equity share are calculated by dividing the profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per equity share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

(o) Contingent Liabilities

A contingent liability is possible obligation that arises from past events whose existence will be confirmed by the occurrence or non occurrence of one or more uncertain future events beyond the control of Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize the contingent liability but discloses its existence in the financial statements.

(p) Cash flows

Cash flows are reported using indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities are segregated.

Cash and cash equivalents: Cash and cash equivalents, in the statement of cash flow, comprise cash at bank and in hand and fixed deposits with original maturity of maximum 90 days.



2-4

[Handwritten signature]



APL HEALTHCARE LIMITED
PLOT NO.2, MAITRIVIHAR, AMEERPET, HYDERABAD-500038

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015
(All amounts in Indian Rupees, except for share data or as otherwise stated)

Note 3 : Share capital

Authorised shares:

6,00,00,000 (PY:1,50,00,000) equity shares of
Rs.10/- each

As at 31 Mar,2015	As at 31 Mar,2014
600,000,000	150,000,000
600,000,000	150,000,000

Issued, Subscribed and Fully Paid-up shares:

5,55,37,600 (PY:1,40,37,600) equity shares of
Rs.10/- each

As at 31 Mar,2015	As at 31 Mar,2014
555,376,000	140,376,000
555,376,000	140,376,000

a. Reconciliation of number of shares:

Equity Shares

	As at 31 Mar,2015		As at 31 Mar,2014	
	No.	Value	No.	Value
At the beginning of the year	14,037,600	140,376,000	3,287,600	32,876,000
Issued during the year	41,500,000	415,000,000	10,750,000	107,500,000
Outstanding at the end of the year	55,537,600	555,376,000	14,037,600	140,376,000

b. Shares held by holding company

Out of equity shares issued by the company, shares held by its holding company are as under:

Aurobindo Pharma Ltd , the holding company

5,55,37,600 (PY: 1,40,37,600) equity shares of
Rs.10/- each

As at 31 Mar,2015	As at 31 Mar,2014
555,376,000	140,376,000
555,376,000	140,376,000

c. Terms/rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10 per share. Each holder of Equity shares is entitled to one vote per share.

In the event of liquidation of the company ,the holders of equity shares will be entitled to receive remaining assets of the company after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the share holders.

d Details of shareholders holding more than 5% of the aggregate shares in the Company:

Name of the Equity shareholder	As at 31 Mar,2015		As at 31 Mar,2014	
	No of shares	% of holding in the class	No of shares	% of holding in the class
Aurobindo Pharma Ltd , Holding company	555,376,000	100%	140,376,000	100%
	555,376,000	100%	140,376,000	100%

Note 4 : Reserves & Surplus

Surplus/Deficit In the Statement of profit and Loss

As per last financial statements

Add:- Profit/ (loss) during the year

As at 31 Mar,2015	As at 31 Mar,2014
-	-
(1,578,935)	-
(1,578,935)	-



u - 9

APL



APL HEALTHCARE LIMITED
PLOT NO.2, MAITRIVIHAR, AMEERPET, HYDERABAD-500038

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

	Non Current		Current	
	As at 31 Mar,2015	As at 31 Mar,2014	As at 31 Mar,2015	As at 31 Mar,2014
Note 5: Provisions				
For Employee Benefits				
- Gratuity(Refer Note No:20)	1,095,921	172,637	-	-
- Leave Encashment(Refer Note No:20)	200,857	-	-	-
Other Provisions				
-Provision for Income tax (net)	-	-	-	61,683
	<u>1,296,778</u>	<u>172,637</u>	<u>-</u>	<u>61,683</u>
Note 6: Trade Payables			<u>As at 31 Mar,2015</u>	<u>As at 31 Mar,2014</u>
Trade Payables for supplies and services			10,394,005	1,494,825
			<u>10,394,005</u>	<u>1,494,825</u>
Note 7: Other Current Liabilities			<u>As at 31 Mar,2015</u>	<u>As at 31 Mar,2014</u>
Creditors for Capital goods			52,052,366	18,905,452
Others paybles				
- Statutory liabilities			1,262,727	291,503
			<u>53,315,093</u>	<u>19,196,955</u>
Note 8: Fixed Assets			<u>As at 31 Mar,2015</u>	<u>As at 31 Mar,2014</u>
Tangible assets			18,804,838	18,804,838
Tangible assets - Capital work in progress			530,989,614	87,243,012
			<u>549,794,452</u>	<u>106,047,850</u>
Capital work in progress includes expenditure incurred during the construction period pending capitalization of Rs.4,90,38,052/- (PY.Rs.54,06,861/-) (Refer Note No:16)				
Note 9: Deferred Tax Asset			<u>As at 31 Mar,2015</u>	<u>As at 31 Mar,2014</u>
Deffered tax asset on Carry forwarded losses			706,065	-
			<u>706,065</u>	<u>-</u>
Note 10: Loans and Advances	<u>As at 31 Mar,2015</u>	<u>As At 31 Mar,2014</u>	<u>Non Current</u>	<u>Current</u>
Capital Advances				
Considered good	31,856,482	-	45,231,554	
Security Deposits	4,501,000	-	55,800	-
Balance with Statutory Authorities	-	510,402	-	168,384
Advances Recoverable in cash or kind	-	5,652,082	-	1,021,707
	<u>36,357,482</u>	<u>6,162,484</u>	<u>45,287,354</u>	<u>1,190,091</u>



← 9 →

APL



NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

Note 11: Inventories

(lower of cost or netrealizable value)

Raw materials
Packing Materials
Stores,spares and consumables

As at 31 Mar,2015	As at 31 Mar,2014
3,180,675	-
1,156,547	-
8,439,011	-
12,776,234	-

Note 12: Cash and Bank Balances

Cash and Cash equivalents Consists of

Cash on hand

Balances with banks

Margin Money Deposits*

As at 31 Mar,2015	As at 31 Mar,2014
27,869	14,428
5,227,989	4,754,979
7,225,000	4,000,000
12,480,858	8,769,407

*Given against FLC

Note 13: Other Current Assets

Interest Accrued but not due
Other Receivables

As at 31 Mar,2015	As at 31 Mar,2014
511,571	7,397
13,796	-
525,367	7,397

Note 14: Other Expenses

Statutory audit fees
Registration & Filing fee
Total

Year ended 31 Mar, 2015	Year ended 31 Mar, 2014
35,000	-
2,250,000	-
2,285,000	-

Note 15: Capital and other Commitments

Estimated amount of contracts (net of advances) remaining to be executed on Capital account and not provided for
Rs.12,62,87,030/- (PY:23,63,75,811)

Note 16: Expenditure during the construction period pending capitalization

A Preliminary Expenses
B Pre-Operative Expenses
Balance brought forward
Add: Incurred during the year
Salaries, Wages and other Benefits
Staff Welfare
Freight & Cartage
Stores, Spares & Consumables
Repairs and Maintenance
Power & fuel
Lease Rentals
Rates & taxes
Printing and Stationery
Postage and Telephone Charges
Insurance
Legal and Professional Charges
Auditor's Remuneration
Registration and filing fees
Travelling and Conveyance
Interest
Foreign Exchange loss/(gain)
Van Hire Charges
Bank Charges
Miscellaneous Expenses

As at 31 Mar,2015	As at 31 Mar,2014
940,600	940,600
4,508,287	993,545
26,528,324	2,586,991
909,982	33,352
1,171,682	-
4,670,784	-
362,774	20,631
5,209,331	293,772
182,000	182,000
996,787	4,737
593,499	19,861
385,383	5,625
655,567	200,610
526,426	43,500
-	11,236
59,038	13,625
918,589	73,903
3,625	-
592,531	34,424
334,295	-
186,738	62,184
90,278	60,401
49,826,520	5,580,997
698,238	161,870
90,230	90,135
788,468	252,005
-	77,869
788,468	174,136
49,038,052	5,406,861

Less:

Interest received/receivable
Other Income

Provision for tax

Handwritten signature

Handwritten signature



APL HEALTHCARE LIMITED
PLOT NO.2, MAITRIVIHAR, AMEERPET, HYDERABAD-500038

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

Note 17: Disclosure regarding derivatives financial instruments

Particulars of unhedged foreign currency exposure are detailed below at the exchange rate prevailing as at the Balance sheet date

	As at 31 Mar,2015	As at 31 Mar,2014
Loans & advances	4,734,450	-
Trade Payable (inculding creditors for capital goods)	14,566,679	-

Note 18: Earnings per Equity Shares

	Year ended 31 March,2015	Year ended 31 March,2014
Profit/ Loss considered for calculation of earnings per share	(1,578,935)	-
Weighted average no of equity shares in calculating EPS	205,493,151	107,500,000
Basic & Diluted Earnings Per share	(0.01)	-
Face value per Share	10	10

Note 19: Related Party Disclosures:

Names of related parties and description of relationship

Names

Aurobindo Pharma Limited
K. Nityananda Reddy
M.Sivakumaran
P.Sarath Chandra Reddy
Pravesha Industries Private Limited
Sri Sai Packaging works,Partnershipfirm
Pranit Packaging Private Limited .

Nature of relationship

Holding Company
Director
Director
Director
Enterprises where key managerial personnel
exercise significant influence
-- do --
-- do --

Transactions with related parties

Particulars	Year ended 31 March,2015	Year ended 31 March,2014
a.Transactions with holding company		
Aurobindo Pharma Limited		
Equity allotment	415,000,000	107,500,000
Purchases of capital goods & raw material	1,769,340	-
Balance payable	-	-
b.Transactions with enterprises over which key management personel or their relatives exercise significant influence		
1 .Pravesha Industries Private Limited		
Purchases of goods	130,885	-
Balance payable	130,885	-
2. Sri Sai Packaging works		
Purchases of goods	155,865	-
Balance payable	155,865	-
3.Pranit Packaging Private Limited		
Purchases of goods	136,850	-
Balance payable	136,850	-



Handwritten signature/initials.

Handwritten signature/initials.



NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

Note 20: Employee Benefits

a. Disclosures related to defined benefit plan-Gratuity

The company has a defined gratuity plan. Every employee who has completed five years or more of service get a gratuity on departure at 15 days last drawn salary for each completed year of service.

Statement of expenditure incurred during the construction period	Year ended 31 March, 2015	Year ended 31 March, 2014
Current Service Cost	246,949	62,656
Interest Cost on benefit obligation	13,811	-
Expected return on plan assets	-	-
Net Actuarial (gain)/ Loss recognized in the year	662,524	109,981
Net Benefit expense	923,284	172,637

Balance Sheet	As at 31 Mar, 2015	As at 31 Mar, 2014
Details of provision for Gratuity		
Defined benefit obligation	1,095,921	172,637

Changes in the present value of the defined benefit obligation are as follows

	Year ended 31 March, 2015	Year ended 31 March, 2014
Opening defined benefit obligation	172,637	-
Interest cost	13,811	-
Current services cost	246,949	62,656
Benefits paid	-	-
Actuarial (gains)/ losses on obligation	662,524	109,981
Closing defined benefit obligation	1,095,921	172,637

The principal assumptions used in determining gratuity and post employment medical benefit obligations for the company's plans are shown below:

Assumptions	As at 31 Mar, 2015	As at 31 Mar, 2014
Salary Rise (%)	4	10
Discount rate (%)	8	8
Attrition Rate (%)	5	10
Av Balance Service	28.10 Years	26.23 Years

b. Disclosures related to defined benefit plan-Leave Encashment

Statement of Profit and Loss	Year ended 31 March, 2015	Year ended 31 March, 2014
Current Service Cost	50,756	30,535
Interest Cost on benefit obligation	2,443	-
Expected return on plan assets	-	-
Net Actuarial (gain)/ Loss recognized in the year	117,123	30,535
Net Benefit expense	170,322	-
Actual return on plan assets	-	-

Balance Sheet	As at 31 Mar, 2015	As at 31 Mar, 2014
Details of provision for Leave encashment		
Defined benefit obligation	200,857	30,535

7 Changes in the present value of the defined benefit obligation are as follows

	Year ended 31 March, 2015	Year ended 31 March, 2014
Opening defined benefit obligation	30,535	-
Interest cost	2,443	-
Current services cost	50,756	30,535
Benefits paid	-	-
Actuarial (gains)/ losses on obligation	117,123	-
Closing defined benefit obligation	200,857	-

The principal assumptions used in determining gratuity and post employment medical benefit obligations for the company's plans are shown below:

Assumptions	As at 31 Mar, 2015	As at 31 Mar, 2014
Salary Rise (%)	4	10
Discount rate (%)	8	8
Attrition Rate (%)	5	10
Av Balance Service	28.10 Years	26.23 Years

The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotions and other relevant factors such as supply and demand in the employment market. The company evaluates these assumptions annually based on its long term plans of growth and industry standards.



Handwritten signature/initials.

Handwritten signature/initials.



APL HEALTHCARE LIMITED
PLOT NO.2, MAITRIVIHAR, AMEERPET, HYDERABAD-500038

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

Note 21: Leases

The APIIC has allotted 26 acres of land at Polepalley (village) in Green Industrial Park, Jedcherla, Mahaboob Nagar (Dist.) on lease basis vide their letter bearing no: ZM/SHSB/APIIC/SEZ/JDC/08/7463 dated 22.01.09, for a period of 35 years on as is where basis.

During the period under audit the company has paid annual rent of Rs. 1, 82,000/- (P.Y.:1,82,000/-)for the said lease

Note 22: Remuneration to Statutory auditors

	Year ended 31 March,2015	Year ended 31 March,2014
Statutory audit fee	35,000	11,236
	<u>35,000</u>	<u>11,236</u>

Note 23: Earning in foreign currency (accrual basis)

- -

Note 24: Expenditure in foreign currency (accrual basis)

- -

Note 25: CIF value of Imports

-Capital Goods

52,208,780

-

-Raw Material

40,271

-

Note 26: FOB value of exports

- -

Note 27: Pervious year figures are regrouped, reclassified wherever necessary to confirm with the current year presentations.

Note 28: There are no dues to Micro, Small and Medium size companies to which the company owe amount outstanding more than 30 days.

Note 29: Contingent Liabilities



- -

As per our report of even date

For and on behalf of the Board of Directors

For G.Pavan Kumār & Associates
Firm Registration Number:015343S
Chartered Accountants

(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place:Hyderabad
Date: 21-May-2015


(K.Nityananda Reddy)
Director
DIN:01284195

(M.Sivakumaran)
Director
DIN:01284320



AURONEXT PHARMA PRIVATE LIMITED

(CIN: U74999DL2009PTC191842)

Regd. Office: 89-A, Ground Floor, Zamrudpur, Greater Kailash-1, New Delhi – 110048

DIRECTORS' REPORT

Dear Members,

Your Directors are pleased to present the Sixth Annual Report of the Company together with the Audited Accounts for the year ended 31st March, 2015.

Financial Results:

	(in Rs.)	
	2014-15	2013-14
Gross Turnover	163,366,834	76,287,677
Profit before depreciation, interest, tax and exceptional items	(120,039,181)	(88,609,073)
Depreciation/amortization	63,957,688	28,722,486
Finance cost	18,874,790	27,577,756
Profit before tax	(202,871,659)	(144,909,315)
Provision for tax/deferred tax	-	-
Profit after tax before exception item	(202,871,659)	(144,909,315)
Less: Exceptional items	-	-
Net profit after exceptional items	(202,871,659)	(144,909,315)
Balance brought forward from previous year	(277,886,490)	(132,977,175)
Deficit carried to Balance sheet	(480,758,149)	(277,886,490)

Review of Operations:

Project Progress:

Formulation (PF) & Sterile Bulk Drugs (PB) blocks are fully operational. Inspection of Formulation & Sterile Bulk Drugs blocks by Auromedics USA team successfully completed.

Ertapenem (Lyophilizer) Block (PL) – All Civil work, Clean room panel work, outside painting and finishing work completed. All machineries including Lyophilizer are installed and commissioned. Area validation and one Scale up batch completed. 2nd Scale up & Exhibit batches are expected soon.

Marketing of Penems: Auronext will be the supplier for Penems Products of ROW, Europe and USA Markets requirements of Aurobindo Pharma Limited (APL). Launch orders of few ROW/EM countries like Mexico, Myanmar, Brazil, Ukraine and Tanzania etc. have been received & executed.

Following is status of filing of dossier & GMP approvals

For US Market: Audit by US is not yet scheduled. Internal audit from Auromedics – US completed successfully without any critical observation. DMF Filing completed for Imipenem Sterile, Cilastatin Sterile in December 2014. DMF filing of Meropenem (Blend Bulk), Sterile Doripenem also already completed.

AURONEXT PHARMA PRIVATE LIMITED

(CIN: U74999DL2009PTC191842)

Regd. Office: 89-A, Ground Floor, Zamrudpur, Greater Kailash-1, New Delhi – 110048

ANDA Filing completed for Meropenem for Injection 250 & 500mg and Doripenem for Injection 250 & 500mg. ANDA filing of Imipenem & Cilastatin for injection 250+250 & 500+500mg to be completed by June 2015

For EU Markets: Approval from EU GMP received, GMP Certificate for permission of Meropenem for Inj & Doripenem for Inj received. EDMF/CEP & dossier for Sterile Meropenem & Meropenem for inj. 500mg & 1 gm filing done in Q4. Doripenem is not planned for filing in EU. Sterile Imipenem, Cilastatin & Imipenem & Cilastatin for Injection 250+250mg & 500+500mg filing is expected by July 2015

For CANADA: Filing of dossier for Meropenem for Inj 500mg and 1g started.

For Korea Market: Initiated filing of Doripenem Monohydrate Sterile.

For EM/ROW Markets:

GMP Certificate received for followings

All GMP approvals: EU GMP, ANVISA (Brazil), Ukraine (PIC/S), Tanzania, Uganda, Ethiopia, Kenya, Ivory Coast, WHO GMP (India).

Following Dossiers approved

Meropenem for Injection 500mg & 1gm: Tanzania, Uzbekistan, Tajikistan, Kyrgyzstan, Moldova, Mexico, El Salvador, Brazil, Ukraine, Uganda, Myanmar, Ethiopia, Ivory Coast, Senegal.

Imipenem & Cilastatin for injection 250+250 & 500+500mg: El Salvador, Mexico, Myanmar, Ethiopia, Uzbekistan, Tanzania.

Tie ups with other Marketing Companies:

Ranbaxy: For supplying their Brands of Penems for exports to EM, EU & LRM. Since Ranbaxy is taken over & merged with Sunpharma, our agreement is also transferred to Sunpharma. However no business is started yet.

Alkem: For supplying their Brands of Penems for exports to EM & LRM. Business of LL for conversion of Rs 20 lac completed in Q4

Talks are in progress with Marksans for ROW, Mylan for Domestic requirements & Sandoz for their domestic requirements.

Dividend

No dividend has been declared for the year 2014-15

AURONEXT PHARMA PRIVATE LIMITED

(CIN: U74999DL2009PTC191842)

Regd. Office: 89-A, Ground Floor, Zamrudpur, Greater Kailash-1, New Delhi – 110048

Reserves

No amount has been carried to General Reserves for the year 2014-15

Details of Subsidiary/Joint Ventures/Associate Companies

The Company has no Subsidiaries / Joint Venture / Associate Companies as on 31st March, 2015.

Deposits

The Company has not accepted any public deposits and as such, no amount on account of principal or interest on public deposits was outstanding as on the date of the balance sheet.

Statutory Auditors

M/s. PKF SRIDHAR & SANTHANAM LLP, Chartered Accountants, have been appointed as Statutory Auditors of the Company at the 5th Annual General Meeting held on 23rd August, 2014 for a period of 5 years subject to ratification by the members at every Annual General Meeting (i.e. till 10th Annual General Meeting). Your Directors commend for the ratification of their appointment.

Auditors' Report

The observations made in the Auditors' Report read together with relevant notes thereon are self explanatory and hence do not call for any further comments under Section 134 of the Companies Act, 2013.

Internal Auditors

The Board of Directors of the Company has appointed 25th day of September, 2014 to conduct Internal Audit of the Company for the Financial Year ended 31st March, 2015.

Internal Control Systems and their Adequacy:

The Company has an Internal Control System, commensurate with the size, scale and complexity of its operations. To maintain its objectivity and independence, the Internal Audit Functions reports to the Chairman of the Audit Committee of the Board. Based on the report of internal audit function, process owners undertake corrective action in their respective areas and thereby strengthen the controls. Significant audit observations and recommendations along with corrective actions thereon are presented to the Audit Committee to the Board.

AURONEXT PHARMA PRIVATE LIMITED

(CIN: U74999DL2009PTC191842)

Regd. Office: 89-A, Ground Floor, Zamrudpur, Greater Kailash-1, New Delhi – 110048

Secretarial Audit

Pursuant to provisions of Section 204 of the Companies Act, 2013 and the Companies (appointment and Remuneration of Managerial Personnel) Rules 2014 the Company has appointed Mr. S. Chidambaram, Practising Company Secretary to undertake Secretarial Audit of the Company. Secretarial Audit Report dated 15.05.2015 issued by Mr. S.Chidambaram, Practicing Company Secretary in form MR-3 is enclosed as **Annexure - I** to this Report.

The Secretarial auditor in their report has observed that *"The Company has not complied with the provisions of Section 203 of the Companies Act, 2013."* Pursuant to section 204(3) of the Companies Act, 2013, the Board explains that the Company has complied with all the requirements under the new Companies Act, 2013 except the appointment of Key Managerial Personnel (KMP) and the Company is in the process of identifying suitable persons for the Key Managerial Positions and will be complied with in due course.

Share Capital

During the year, your Company has made further issue of 40,714,032 Equity Shares of Rs.10/- each at par to the existing shareholders of the Company. Consequently, the paid-up equity share capital was increased to Rs 113,01,40,280.

Extract of the Annual Return

In accordance with Section 134(3)(a) of the Companies Act, 2013 the extract of Annual Return (Form MGT-9) of the Company is enclosed as **Annexure – II** to the Boards Report.

Material changes and commitments, if any.

There are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

Conservation of energy, technology absorption and foreign exchange earnings and outgo

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 and foreign exchange earnings and outgo which is furnished in as **Annexure – III**

Directors:

As per the provisions of the Companies Act, 2013 Mr. K Nityananda Reddy and Mr. P. Sarath Chandra Reddy will retire in the ensuing annual general meeting and being eligible, seek re-appointment. The Board of Directors recommends their re-appointment.

AURONEXT PHARMA PRIVATE LIMITED

(CIN: U74999DL2009PTC191842)

Regd. Office: 89-A, Ground Floor, Zamrudpur, Greater Kailash-1, New Delhi – 110048

Changes in Directors and Key Managerial Personnel:

During the year Mr. K Venkateswara Rao (DIN:02907769) and Mr. A Vinod Kumar Reddy (DIN:02944453) have been appointed as an Additional Directors (Independent) w.e.f. 30th March, 2015. They hold office upto the date of the ensuing Annual General Meeting. The Company has received notice(s) in writing under the provisions of Section 160 of the Companies Act, 2013, proposing the candidature(s) for the office of Independent Director(s).

Declaration by an Independent Director(s) and re- appointment, if any:

The Company has received necessary declaration(s) from each Independent Director of the Company under Section 149(7) of the Act, that they meet the criteria of independence as laid down in section 149(6) of the Act.

Formal Annual Evaluation:

Evaluation of all Board members is done on an annual basis, the evaluation is done by the Board, Nomination and Remuneration Committee with specific focus on the performance and effective functioning of the Board and Individual Directors.

The criteria for Evaluation of the Board are the frequency of meetings, length of meetings and the flow of the information to the Board members etc.

The criteria for Evaluation of the individual Directors are the core competencies, monitoring management performance and development, guiding strategy etc.

Number of meetings of the Board of Directors:

During the financial year 2014-15 the Board of Directors has met fifteen times viz., on 26.05.2014, 05.06.2014, 04.08.2014, 11.08.2014, 30.08.2014, 06.09.2014, 25.09.2014, 13.10.2014, 26.11.2014, 10.12.2014, 12.01.2015, 02.02.2015, 25.02.2015, 02.03.2015 and 30.03.2015.

Audit Committee:

Pursuant to the provisions of Section 177 of the Companies Act, 2013 and the rules made thereunder an Audit Committee has been constituted with the following Directors of the Company.

- | | |
|------------------------------------|-----------|
| 1) Mr. Kondareddy Venkateswara Rao | :Chairman |
| 2) Mr. Vinod Kumar Reddy Aerva | :Member |
| 3) Mr. B R Sikri | :Member |

AURONEXT PHARMA PRIVATE LIMITED

(CIN: U74999DL2009PTC191842)

Regd. Office: 89-A, Ground Floor, Zamrudpur, Greater Kailash-1, New Delhi – 110048

Nomination and Remuneration Committee:

Pursuant to the provisions of Section 178 of the Companies Act, 2013 and the rules made thereunder a Nomination and Remuneration Committee has been constituted with the following Directors of the Company.

- | | |
|------------------------------------|-----------|
| 1) Mr. Vinod Kumar Reddy Aerva | :Chairman |
| 2) Mr. Kondareddy Venkateswara Rao | :Member |
| 3) Mr. B R Sikri | :Member |

Brief description of terms of reference of Nomination and Remuneration Committee

- Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down
- Recommend to the Board for appointment and removal of directors and KMP
- Recommend to the Board a policy relating to the remuneration of the directors, KMP and other employees etc.

The objectives of the Nomination and Remuneration Policy:

- To lay down criteria and terms and conditions with regard to identifying persons who are qualified to become directors and who may be appointed in senior management and KMP
- To determine remuneration
- To carry out evaluation of the performance of the directors

Particulars of loans, guarantees or investments under section 186:

No loans, Guarantees or investment made by the company during the year 2014-15.

Particulars of contracts or arrangements with related parties:

Related party transactions that were entered during the financial year were on an arm's length basis and were in the ordinary course of business. There were no materially significant related party transactions which could have had a potential conflict with the interests of the Company.

Transactions with related parties entered by the Company are periodically placed before the Board and the particulars of contracts entered during the financial year 2014-15 are enclosed in Form AOC-2 as **Annexure - IV**

Particulars of Employees

There are no employees whose information as required under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

AURONEXT PHARMA PRIVATE LIMITED

(CIN: U74999DL2009PTC191842)

Regd. Office: 89-A, Ground Floor, Zamrudpur, Greater Kailash-1, New Delhi – 110048

Business Risk Management

At present the company has not identified any element of risk which may threaten the existence of the Company.

Policy on Sexual Harassment

The Company has adopted policy on Prevention of Sexual Harassment of Women at Workplace in accordance with The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

During the financial year ended March 31, 2015, the Company has not received any Complaints pertaining to Sexual Harassment.

Directors' Responsibility Statement

Pursuant to Section 134(5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

(a) in the preparation of the annual accounts for the year ended 31st March, 2015, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) the directors had prepared the annual accounts on a going concern basis; and

(e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and are operating effectively.

(f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and are operating effectively.

Acknowledgements

Your Company will always keep interest of its customers, employees and the stakeholders as a priority and shall reciprocate their confidence reposed in the Company. It has been a mutually beneficial relationship and looks forward to their continued support.

For and on behalf of the Board

Place: Hyderabad
Date: 15.05.2015


K. Nityananda Reddy
Director
DIN: 01284195


B R Sikri
Director
DIN: 01134045





S. CHIDAMBARAM

B.Com., LL.B., F.C.S., A.I.C.W.A
Company Secretary in Practice

#6-3-855/10/A, Flat No .4A, Sampathji Apartments,
Near Niraj Public School,
Lane Opp.to Green Park Hotel,
Ameerpet, Hyderabad,A.P. - 500 016(India)
Phone : 91-040-23413376, Fax.040-23410449
Email : schid285@gmail.com

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2015

*[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the
Companies (Appointment and Remuneration Personnel) Rules, 2014]*

To,
The Members,
Auronext Pharma Private Limited
(Cin: U74999DL2009PTC191842)
89-A, Ground Floor,
Zamrudpur, Greater Kailash-I,
New Delhi – 110 048

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Auronext Pharma Private Limited. Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided and declarations made by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has, during the audit period covering the financial year ended on 31st March, 2015 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:



I have examined the books, papers, minute books, forms and returns filed and other records maintained by "the Company" for the financial year ended on 31st March, 2015 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) Delhi Shops and Establishment Act, 1954
- (iii) Employees' State Insurance Act, 1948 and Employees' State Insurance (General) Regulations, 1950;
- (iv) The Employees' Provident Funds and Miscellaneous Provisions Act, 1952 and The Employees' Provident Funds Scheme, 1952;
- (v) The Payment of Bonus Act, 1965 and the Payment of Bonus Rules, 1965;
- (vi) The Contract Labour (Regulation and Abolition) Act, 1970 and the Contract Labour (Regulation and Abolition) Central Rules, 1971;
- (vii) Income Tax Act, 1961 and rules made thereunder;
- (viii) Service Tax Act, 1994 and rules made thereunder;

I have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India;

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc., mentioned above subject to the following observations:

"The Company has not complied with the provisions of Section 203 of the Companies Act, 2013."



I further report that The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through in compliance with the provisions of the Act. ✕

I further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.


I further report that during the audit period:

- ✕ 1. The Company has allotted 4,07,14,032 shares of Rs. 10/- each at par by way of several right issues.

Place: Hyderabad

Date: 15.05.2015

Signature:



S. Chidambaram

Practicing Company Secretary:

FCS No. 3935

C P No: 2286

Form No. MGT-9
EXTRACT OF ANNUAL RETURN
as on the financial year ended on 31.03.2015

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:		
i	CIN	U74999DL2009PTC191842
ii	Registration Date	02.07.2008
iii	Name of the Company	Auronext Pharma Private Limited
iv	Category / Sub-Category of the Company	Company Limited by Shares / Private Limited
v	Address of the Registered office and contact details	89-A, GROUND FLOOR, ZAMRUDPUR, GREATER KAILASH -1, NEW DELHI -110 048.
vi	Whether listed company	No
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
1	Doripenem Sterile	21001 / 21002	15%
2	Imipenam & Cilastain	21001 / 21002	36%
3	Merogram	21001 / 21002	38%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S.No	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ASSOCIATE	% of shares held	Applicable Section
1	Aurobindo Pharma Limited Regd Off: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500038, Telangana	L24239TG1986PLC015190	HOLDING	83.42	2(46)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change During the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual /HUF	0	18074996	18074996	25.00	0	18740028	18740028	16.58	-8.42
b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt (s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	54225000	54225000	75.00	0	94274000	94274000	83.42	8.42
e) Banks / FI									
f) Any Other	0	0	0	0	0	0	0	0	0
Sub-total (A) (1):-	0	72299996	72299996	100.00	0	113014028	113014028	100.00	0

i) Individual shareholders holding nominal share capital upto Rs1 lakh	0	0	0	0	0	0	0	0	0
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	0	0	0	0	0	0	0	0	0
c) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	0	0	0	0	0	0	0	0
Total Public Shareholding (B)=(B)(1)+ (B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	72299996	72299996	100.00	0	113014028	113014028	100.00	0

ii) Shareholding of Promoters

SI No	Shareholder's Name	Shareholding at the beginning of the year			Share holding at the end of the year			% change in share Holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	

1	Aurobindo Pharma Ltd	54225000	75.00	0	94274000	83.42	0	8.42
2	Bodh Raj Sikri	10845000	15.00	0	11244020	9.94	0	-5.06
3	Anil Munjal	3614998	5.00	0	3748004	3.32	0	-1.68
4	P H Subba Rao	3614998	5.00	0	3748004	3.32	0	-1.68
	Total	72299996	100.00	0	113014028	100.00	0	0

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl.No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
A.	Aurobindo Pharma Limited	No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
A.	At the beginning of the year	54225000	75.00		
1	Allotment on 05.06.2014	1995100		56220100	75.00
2	Allotment on 04.08.2014	4750000		60970100	76.49
3	Allotment on 06.09.2014	800000		61770100	76.72
4	Allotment on 25.09.2014	5223900		66994000	78.14
5	Allotment on 26.11.2014	8580000		75574000	80.13
6	Allotment on 12.01.2015	5450000		81024000	81.24
7	Allotment on 25.02.2015	3250000		84274000	81.81
8	Allotment on 30.03.2015	10000000		94274000	83.42
	At the End of the year			94274000	83.42
B.	Bodh Raj Sikri				
	At the beginning of the year	10845000	15.00		
	Allotment on 05.06.2014	399020		11244020	15.00
	At the End of the year			11244020	9.94
C.	Anil Munjal				
	At the beginning of the year	3614998	5.00		
	Allotment on 05.06.2014	133006		3748004	5.00
	At the End of the year			3748004	3.32
D.	P H Subba Rao				
	At the beginning of the year	3614998	5.00		
	Allotment on 05.06.2014	133006		3748004	5.00

	At the End of the year			3748004	3.32
--	------------------------	--	--	---------	------

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
	For Each of the Top 10 Shareholders	No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	At the beginning of the year	NIL			
	At the End of the year (or on the date of separation, if separated during the year)				

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
	For Each of the Directors and KMP	No. of shares	% of total shares of the company	No. of shares	% of total Shares of the company
	At the beginning of the year	14459998	20.00		
1	Bodh Raj Sikri	10845000	15.00	11244020	9.94
2	Anil Munjal	3614998	5.00	3748004	3.32
	At the End of the year			14992024	13.26

V. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment:

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	195,694,798	-	-	195,694,798
ii) Interest due but not paid	-	-	-	-

iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	195,694,798	-	-	195,694,798
Change in Indebtedness during the financial year				
• Addition	-	-	-	-
• Reduction	117,601,845	-	-	117,601,845
Indebtedness at the end of the financial year				
i) Principal Amount	78,092,953	-	-	78,092,953
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	78,092,953	-	-	78,092,953

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl. no.	Particulars of Remuneration	Name of MD/WTDI/ Manager				Total Amount
		----	----	----	----	
1	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	NIL				
2	Stock Option	NIL				
3	Sweat Equity	NIL				
4	Commission	NIL				

	- as % of profit - others, specify...	
5	Others, please specify	NIL
	Total (A)	NIL
	Ceiling as per the Act	NIL
		NIL

B. Remuneration to other directors:

Sl.no.	Particulars of Remuneration	Name of Directors				Total Amount
		----	----	----	----	
	Independent Directors • Fee for attending board / committee meetings • Commission • Others, please specify	NIL				
	Total (1)	NIL				
	Other Non-Executive Directors • Fee for attending board / committee meetings • Commission • Others, please specify	NIL				
	Total (2)	NIL				
	Total (B)=(1+2)	NIL				
	Total Managerial Remuneration	NIL				
	Overall Ceiling as per the Act	NIL				

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/MTD:

Sl.no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary	NIL			

	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Incometax Act, 1961	
2.	Stock Option	NIL
3.	Sweat Equity	NIL
4.	Commission - as % of profit - others, specify...	NIL
5.	Others, please specify	NIL
	Total	NIL

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty /Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give details)
A. Company					
Penalty					
Punishment			NIL		
Compounding					
B. Directors					
Penalty					
Punishment			NIL		
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty					
Punishment			NIL		
Compounding					

AURONEXT PHARMA PRIVATE LIMITED

(CIN: U74999DL2009PTC191842)

Regd. Office: 89-A, Ground Floor, Zamrudpur, Greater Kailash-1, New Delhi – 110048

Annexure-III

The conservation of energy, technology absorption, foreign exchange earnings and outgo pursuant to the provisions of section 134(3) (m) of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014.

(A) Conservation of energy-

(i) the steps taken or impact on conservation of energy;

1) Action Taken

- a) Installed temperature sensor in cooling tower so that unnecessary running of fan is avoided once wet bulb temperature is reached.
- b) Training Program for Energy Saving Awareness is given to all employee of Auronext. This includes the awareness to all to switch of all lights, appliances & air conditioning at the time of leaving the work place.

2) Action in Progress.

- a) Usage of gas (PNG) for Boiler instead of Furnace Oil to save wastage of FO in start up of Boiler.
- b) Use of LED Light instead of CFL Light. Approx 300 light shall be replaced with LED having ROI 2 years.
- c) Plan to stop the AHU's when no man movement in unclassified & D grade area this will result in considerable energy saving.
- d) Plan to start re-cycling of water used in water ring vacuum pumps. This will save energy as well as water.

(ii) the steps taken by the company for utilising alternate sources of energy;

NIL

(iii) the capital investment on energy conservation equipments;

NIL

B) Technology absorption-

(i) the efforts made towards technology absorption;

Success fully used technology of APL RC-II & APL RC-I for taking Exhibit Batches of followings for US & EU

- Sterile Imipenem Trihydrate
- Sterile Cilastatin Sod.
- Vials of Imipenem & Cilastatin for Injection

AURONEXT PHARMA PRIVATE LIMITED

(CIN: U74999DL2009PTC191842)

Regd. Office: 89-A, Ground Floor, Zamrudpur, Greater Kailash-1, New Delhi – 110048

(ii) the benefits derived like product improvement, cost reduction, product development or import substitution;

The product listed in point i) above are Import substitution & for export to US / Europe

(iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)- NA

(a) the details of technology imported; NIL

(b) the year of import; NIL

(c) whether the technology been fully absorbed; Local Technology of APL RC-I & II is fully absorbed

(d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof; and

(iv) the expenditure incurred on Research and Development. NA

(C) Foreign exchange earnings and Outgo-

	(in Rupees)	
	2014-15	2013-14
Foreign exchange earned		
Exports (FOB)	35,486,910	28,999,390
Others	-	-
	35,486,910	28,999,390
Foreign exchange outgo		
Materials	32,170,062	6,161,769
Other expenses	26,746,362	34,368,155
	58,916,425	40,529,924

For and on behalf of the Board

Place: Hyderabad

Date: 15.05.2015

K.Nityananda Reddy

Director

DIN: 01284195

B R Sikri

Director

DIN:01134045



AURONEXT PHARMA PRIVATE LIMITED

(CIN: U74999DL2009PTC191842)

Regd. Office: 89-A, Ground Floor, Zamrudpur, Greater Kailash-1, New Delhi – 110048

Annexure IV

AOC-2

DETAILS OF RELATED PARTY TRANSACTIONS

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis:

(a) Name(s) of the related party and nature of relationship (b) Nature of contracts/arrangements/transactions (c) Duration of the contracts/arrangements/transactions (d) Salient terms of the contracts or arrangements or transactions including the value, if any arm's length. (e) Justification for entering into such contracts or arrangements or transactions (f) Date(s) of approval by the Board (g) Amount paid as advances, if any: (h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188	There were no transaction or arrangement which were not at arm's length
--	---

2. Details of material contracts or arrangement or transactions at arm's length basis:


Name of the related party and nature of relationship	Aurobindo Pharma Ltd, Holding Company	Aurobindo Pharma Ltd, Holding Company	Aurobindo Pharma Ltd, Holding Company
Nature of contracts/ arrangements / transactions	Lease of Factory Premises at Bhiwadi	Sale of goods	Purchase of materials
Duration of the contracts / arrangements / transactions	Taken Factory Premises on Lease for 10 years from January 2010 with an option to renew the lease contract for further period	on going	on going
Salient terms of the contracts or arrangements or transactions including the value, if any	Transactions: Paid rent Rs.16.02 Lakhs for lease of Factory premises	Transactions: Sold goods Rs. 757.06 Lakhs	Transactions: Purchase of raw materials Rs. 441.65 Lakhs.
Justification for entering into such contracts or arrangements or transactions	Aurobindo offered premises suited our requirement	Transactions are based on transfer pricing guidelines	Transactions are based on transfer pricing guidelines


Appropriate approvals have been taken for related party transactions. Advances paid if any have been adjusted against billing wherever applicable			
Name of the related party and nature of relationship	Aurobindo Pharma Ltd. Holding Company	Aurovida Farmaceutica SA De CV –Fellow Subsidiary	Silicon Life Sciences Private Limited-Fellow Subsidiary
Nature of contracts/ arrangements / transactions	Reimbursement of expenses	Sale of goods	Purchase of materials
Duration of the contracts / arrangements / transactions	on going	on going	on going
Salient terms of the contracts or arrangements or transactions including the value, if any	Transactions: Reimbursement of expenses Rs. 162.40 Lakhs	Transactions: Sold goods Rs. 75.95 Lakhs.	Transactions: Purchase of raw materials Rs. 401.93 Lakhs.
Justification for entering into such contracts or arrangements or transactions		Transactions are based on transfer pricing guidelines	Transactions are based on transfer pricing guidelines

Appropriate approvals have been taken for related party transactions. Advances paid if any have been adjusted against billing wherever applicable

For and on behalf of the Board

Place: Hyderabad
Date: 15.05.2015


K. Nityananda Reddy
Director
DIN: 01284195


B R Sikri
Director
DIN: 01134045



PKF SRIDHAR & SANTHANAM LLP
Chartered Accountants

INDEPENDENT AUDITOR'S REPORT

To the members of Auronext Pharma Private Limited

Report on the Standalone Financial Statements

We have audited the accompanying standalone financial statements of Auronext Pharma Private Ltd. ("The Company"), which comprise the Balance Sheet as at 31st March, 2015, the Statement of Profit and Loss, the Cash Flow Statement for the year then ended, and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over

91/92 VII Floor, Dr Radhakrishnan Road, Mylapore, Chennai- 600004, India
Tel: +91 44 28112985 - 88 Fax: +91 44 28112989 Email: sands@pkfindia.in Web: www.pkfindia.in

PKF SRIDHAR & SANTHANAM has been converted into a limited liability partnership PKF SRIDHAR & SANTHANAM LLP FROM 21ST APRIL 2015.
REGISTRATION NO. WITH ICAI IS 003990S/S200018



financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2015 and its loss and its cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2015 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure, a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143 (3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - (e) On the basis of the written representations received from the directors as on 31st March, 2015 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2015 from being appointed as a director in terms of Section 164 (2) of the Act.
 - (f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts



in respect of which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For PKF Sridhar & Santhanam LLP
Chartered Accountants
Firm's Registration No.003990S / S200018

S. Ramakrishnan

S.Ramakrishnan
Partner
Membership No.018967
Place of Signature: Mumbai
Date: 15 May 2015



Annexure

Referred to in paragraph 1 on 'Report on Other Legal and Regulatory Requirements' of our report of even date

- (i)
 - (a) The Company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.
 - (b) The company has a regular program of verifying fixed assets every year which, in our opinion, is reasonable having regard to the size of the company and nature of its assets. All Fixed assets have been physically verified by the management during the year. As informed, discrepancies noticed on such verification were not material and have been properly dealt with in the books of account.
- (ii)
 - (a) The Company has conducted physical verification of inventories at reasonable intervals.
 - (b) The procedures followed for physical verification of inventories by the management were reasonable and adequate in relation to the size of the company and nature of its business.
 - (c) The company is maintaining proper records of inventory and the differences noticed on physical verification, which were not material, have been properly dealt with in the books of account.
- (iii) The company has not granted loans, secured or unsecured to companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act.
- (iv) In our opinion and according to the information and explanations given to us, there is an internal control system with regard to the purchase of inventory, fixed assets and sale of goods and services commensurate with the size of the Company and the nature of its business which however needs further improvements. On the basis of our examination and according to the information and explanations given to us, there is no continuing failure to correct major weaknesses in the aforesaid internal control system.
- (v) The Company has not accepted any deposits from the public within the meaning of the Act and the rules made there under.
- (vi) We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under Section 148 (1) of the Act and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.
- (vii)
 - (a) According to the information and explanations given to us and the records of



the Company examined by us, the Company has generally been regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues applicable to it with the appropriate authorities. According to the information and explanation given to us and the records of the Company examined by us, no undisputed amounts payable in respect of provident fund, employees' state insurance, income-tax, sales tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues were in arrears, as at 31st March 2015 for a period of more than six months from the date they became payable.

- (b) There are no dues relating to income tax / sales tax / wealth tax / service tax / duty of customs / duty of excise / value added tax / cess, which have not been deposited on account of disputes with the related authorities .
- (c) There are no amounts which require to be transferred to Investor Education and Protection Fund in accordance with the provisions of the Companies Act 1956 and the rules made thereunder.
- (viii) The Company's accumulated losses as at the end of the year is more than 50% of the networth of the company and it has incurred cash losses in the current year and the immediately preceding financial year.
- (ix) Based on our audit procedure and as per the information and explanations given by the management, we are of the opinion that the company has not defaulted in repayment of dues to financial institutions, banks or debenture holders.
- (x) According to the information and explanations given to us, the company has not given any guarantee during the year for loans taken by others from banks or financial institutions.
- (xi) In our opinion and according to the information and explanations given to us, the company has applied the term loans for the purpose for which it was obtained.
- (xii) Based upon the audit procedures performed and information and explanations given by the management, we report that no fraud on or by the Company has been noticed or reported during the year ended 31st March 2015.

For PKF Sridhar & Santhanam LLP
Chartered Accountants
Firm's Registration No.0039905 / S200018

S. Ramakrishnan

S.Ramakrishnan
Partner

Membership No 018967

Place of Signature: *Mumbhai*

Date: *15/5/15*



AURONEXT PHARMA PVT LTD
Balance Sheet as at 31st March, 2015

(All amounts are in INR (Rs.) unless otherwise stated)

	Notes	As at 31 March, 2015	As at 31 March, 2014
Equity and liabilities			
Shareholders' Funds			
Share capital	3	1,130,140,280	722,999,960
Reserves and surplus	4	(480,758,149)	(277,886,490)
		649,382,131	445,113,470
Non-current liabilities			
Long-term borrowings	5	33,475,126	116,004,798
Long-term provisions	6	10,530,465	5,187,389
		44,005,591	121,192,187
Current liabilities			
Short-term borrowings		-	-
Trade payables	7	122,625,740	121,673,462
Other current liabilities	8	67,171,950	93,955,754
Short-term provisions	9	4,249,401	2,080,451
		194,047,091	217,709,667
TOTAL		887,434,813	784,015,324
Assets			
Non-current assets			
Fixed assets			
Tangible assets	10	504,355,614	561,815,676
Intangible assets		-	-
Capital work-in-progress	10	118,429,894	4,223,968
Intangible assets under development		-	-
Non-current investments		-	-
Deferred tax assets (net)		-	-
Long-term loans and advances	11	55,159,184	41,729,666
Other non-current assets		-	-
		677,944,692	607,769,310
Current assets			
Current investments		-	-
Inventories	12	105,929,526	117,567,960
Trade receivables	13	48,395,782	34,595,236
Cash and bank balances	14	47,554,842	21,719,517
Short-term loans and advances	15	7,609,971	2,363,301
Other current assets		-	-
		209,490,121	176,246,014
TOTAL		887,434,813	784,015,324
Summary of significant accounting policies & Note to accounts	1 & 2		

The accompanying notes are an integral part of the financial statements.

As per our report on even date.

For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm's Registration No. 003990S / S200018

S. Ramakrishnan

Partner

Membership No. 018967

Place: Gurgaon, Haryana

Date: May 15, 2015


 For and on behalf of Board of Directors of
Auronext Pharma Private Limited

B.R. Sikri

Director

Place: Gurgaon

Date: May 15, 2015

K. Nithyananda Reddy

Director

Place: Gurgaon

Date: May 15, 2015

AURONEXT PHARMA PVT LTD
Statement of profit and loss for the year ended 31st March 2015

(All amounts are in INR (Rs.) unless otherwise stated)

	Note	Year ended March 31, 2015	Year ended March 31, 2014
Income			
Revenue from operations (gross)	16	163,366,834	76,287,677
Less: Excise duty		8,544,882	1,493,343
Revenue from operations (net)		154,821,952	74,794,334
Other income	17	2,657,347	1,249,135
Total revenue (I)		157,479,299	76,043,469
Expenses			
Cost of raw material and components consumed	18	75,024,228	110,818,727
Purchase of trading goods		-	-
(Increase)/decrease in inventories of finished goods, work-in-progress and traded goods	19	26,709,027	(78,731,501)
Employee benefit expense	20	57,838,071	42,465,544
Other expenses	21	117,947,154	90,099,772
Exceptional items		-	-
Total (II)		277,518,480	164,652,542
Earnings before interest, tax, depreciation and amortization (EBITDA) (I)-(II)		(120,039,181)	(88,609,073)
Depreciation and amortization expense		63,957,688	28,722,486
Finance costs	22	18,874,790	27,577,756
Profit/(loss) before tax		(202,871,659)	(144,909,315)
Tax expenses			
Current tax		-	-
Total tax expense		-	-
Profit/(loss) for the Year		(202,871,659)	(144,909,315)
Earnings or Loss Per Equity Share (EPS):			
Weighted average number of shares (face value of Rs.10 per share)		84,445,198	52,213,011
Earnings per share :			
Basic and diluted		(2.40)	(2.78)

Summary of significant accounting policies & Note to accounts
1 & 2

The accompanying notes are an integral part of the financial statements.

As per our report on even date.

 For and on behalf of Board of Directors of
Auronext Pharma Private Limited
For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm's Registration No.003990S / S200018

S. Ramakrishnan

Partner

Membership No. 018967

Place: Gurgaon Mumbai

Date: May 15, 2015


 B.R.Sikri
 Director

 Place: Gurgaon
 Date: May 15, 2015

 K.Nithyananda Reddy
 Director

 Place: Gurgaon
 Date: May 15, 2015

Auronext Pharma Private Limited**Cash Flows Statement for the year ended 31 March 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

	For the year ended 31 March	
	2015	2014
Cash flows from operating activities		
Loss before tax	(202,871,659)	(144,909,315)
Adjustments to reconcile loss before tax to net cash flows:		
- Depreciation	63,957,688	28,722,486
- Interest expense	18,763,303	27,577,756
- Interest income	(1,154,432)	(315,996)
- Liability written back	(302,739)	(933,139)
- Provision for gratuity	2,270,914	2,072,014
- Provision for leave Encashment	3,265,021	-
- Provision for leave travel allowance	339,293	287,508
- Provision for medical allowance	175,637	287,508
- Provision for bonus	391,791	1,443,903
- Loss on sale of asset	-	185,301
- Provision for Entry Tax	1,069,370	-
- Adjustment to fixed asset	-	-
- Foreign exchange fluctuation loss on financing activities	2,461,815	4,415,729
Operating loss before working capital changes	(111,633,998)	(81,166,245)
<i>Changes in working capital:</i>		
Decrease/(Increase) in inventories	11,638,434	(107,391,415)
Decrease/(Increase) in trade receivables	(13,800,546)	(23,021,838)
Decrease/(Increase) in long-term loans and advances	(13,429,518)	653,200
Decrease/(Increase) in short-term loans and advances	(5,339,628)	(17,387,546)
Increase/(Decrease) in other current liabilities	(26,783,804)	39,208,505
Increase/(Decrease) in trade payables	1,255,017	97,295,070
Cash used in operations	(158,094,043)	(91,810,269)
Taxes paid	92,958	(30,815)
Net cash used in operating activities (A)	(158,001,085)	(91,841,084)
Cash flows from investing activities		
Purchase of tangible assets	(120,703,551)	(19,356,976)
Sale of tangible assets	-	3,679,120
Investment in Fixed Deposits	(2,821,000)	-
Interest received	1,154,432	315,996
Net cash used in investing activities (B)	(122,370,119)	(15,361,860)



Handwritten signature/initials

Auronext Pharma Private Limited**Cash Flows Statement for the year ended 31 March 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

	For the year ended 31 March	
	2015	2014
Cash flows from financing activities		
Proceeds from issue of equity shares	407,140,320	257,999,980
Repayment of long term borrowings	(84,991,487)	(111,078,236)
Proceeds from long term borrowings	-	-
Repayment from short-term borrowings	-	-
Proceeds of short-term borrowings	-	-
Interest paid	(18,763,303)	(28,116,109)
Net cash generated from financing activities (C)	303,385,530	118,805,635
Net increase in cash and cash equivalent (A+B+C)	23,014,325	11,602,691
Opening balance of cash and cash equivalents	20,929,517	9,326,826
Closing balance of cash and cash equivalents	43,943,842	20,929,517
<i>Cash and cash equivalents comprise of:</i>		
Cash on hand	15,854	677,081
Balances with banks	43,927,988	20,252,436
Total cash and cash equivalents	43,943,842	20,929,517

As per our report on even date.

For and on behalf of Board of Directors of
Auronext Pharma Private Limited**For PKF Sridhar & Santhanam LLP**

Chartered Accountants

Firm's Registration No. 003990S / S200018


S. Ramakrishnan

Partner

Membership No. 018967

Place: Gurgaon *Mumbai*


Date: May 15, 2015


B.R. Sikri

Director

Place: Gurgaon

Date: May 15, 2015


K.Nithyananda Reddy

Director

Place: Gurgaon

Date: May 15, 2015

Auronext Pharma Private Limited

Notes to Financial Statement for the year ended March 31, 2015

(All amounts are in INR (Rs.) unless otherwise stated)

1. Background

Auronext Pharma Private Limited ('the Company') was incorporated on 2 July 2009 with its registered office in New Delhi, India. The Company is a subsidiary of Aurobindo Pharma Limited, Hyderabad, India ('the Parent'). The Company was incorporated with an objective of carrying out Research, Developing, Manufacturing and Marketing of Pharmaceutical Substances and Finished Dosage forms for Indian and International markets.

2. Summary of significant accounting policies

(a) Basis of preparation of financial statements

The Company maintains its accounts on accrual basis following the historical cost convention in accordance with generally accepted accounting principles (GAAP), in compliance with provisions of the Companies Act, 2013 and the Accounting Standards [as specified in the Companies (Accounting Standards) Rules, 2006 read with Section 133 of the Companies Act, 2013 and Rule 7 of the Companies (Accounts) Rules 2014 prescribed by the Central Government]. The other Accounting Standards as issued by ICAI, not yet notified are also considered, wherever applicable, except to the extent where compliance with the other statutory promulgations override the same requiring a different treatment. The accounting policies are consistent with those used in the previous year.

(b) Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting year. Examples of such estimates include provision for future obligation under employee benefit plans, net realizable value of inventory and estimated useful lives of fixed assets. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates.

(c) Revenue recognition

Revenue from sale of goods is recognized on dispatch (in respect of exports on the date of the bill of lading or airway bill) which coincides with transfer of significant risks and rewards to customer and is net of trade discounts, sales returns and sales tax, where applicable. Excise duty deducted from revenue (gross) is the amount that is included in revenue (gross) and not the entire amount of liability arising during the year.

Interest is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.

Export entitlements are recognized as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds and utilization of such assets within its validity.

(d) Fixed assets and depreciation

Fixed assets are stated at cost less accumulated depreciation and impairment losses, if any. Cost comprises the purchase price and any attributable cost of bringing the asset to its working condition for its intended use. Borrowing costs relating to acquisition of fixed assets which take substantial period of time to get ready for use are included to the extent they relate to the period till such assets are ready for intended use. All other borrowing costs are expensed in the period they occur.

Expenditure directly relating to construction activity is capitalized to the extent those relate to the construction activity or is incidental thereto



Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

Depreciation is provided using the Straight Line Method ('SLM') over the useful lives of the assets considered by the management, as given below:

S. No.	Nature of assets	Useful Life As per Company Policy
1	Factory buildings	30 Years
	Office, Stores & canteen other than RCC	30 Years
	Office, Stores & canteen RCC	60 Years
2	Roads (RCC)	15 Years
3	Furniture and fittings	10 Years
4	Cars and Vans	8 Years
	Tractors	8 Years
	Battery trucks	8 Years
5	Office equipment	5 Years
6	Servers and networks	5 Years
	Desktops/laptops/printer/scanners etc.,	5 Years
7	General Laboratory equipment	12 Years
8	Electrical installations and Equipment	15 Years
10	Reactors	15 Years
	Distillation Columns & Pipelines*	12 Years
	Drying equipments/Centrifuges & Decanters	15 Years
	Storage tanks	15 Years
	Formulation Process Equipment	15 Years
11	General rate to P&M	10 Years
12	Power plant turbine at unit-11	20 Years

The above stated Useful life is estimated by management and supported by technical evaluation of the useful life which are generally comparable or lower than the rates prescribed under Schedule II to the Companies Act 2013 except for the items as stated here under:

Asset Type	Life as per Companies Act 2013	Life Considered
General Laboratory Equipment	10 years	12 years
Electrical installations and Equipment	10 years	15 years

Residual value is considered to be Nil.

Assets costing below Rs.5,000 are depreciated in full in the same year.

Additions during the year are depreciated on a pro-rata basis.

Capital work in progress includes the cost of fixed assets which are not yet ready for its intended use.

(e) Impairment

The carrying amounts of assets are reviewed at each balance sheet date to see if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount



Handwritten signature/initials

Auronext Pharma Private Limited

Notes to Financial Statement for the year ended March 31, 2015

(All amounts are in INR (Rs.) unless otherwise stated)

of an asset exceeds its recoverable amount. The recoverable amount is the greater of the assets net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value at the weighted average cost of capital. After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

(f) Inventories

Raw materials, packing materials, stores, spares and consumables are valued at lower of cost, calculated on weighted average basis, and net realizable value. Items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost.

Finished goods and intermediates are valued at lower of cost and net realizable value. Cost includes materials, labour and a proportion of appropriate overheads based on normal operating capacity. Cost is determined on a weighted average basis.

Net realizable value is the estimated selling price in the ordinary course of business, reduced by the estimated costs of completion and costs to effect the sale.

(g) Employee benefits

Provident fund

A retirement benefit in the form of provident fund scheme is a defined contribution and the contribution is charged to the statement of profit and loss of the year when the contribution to the respective fund is due. There are no other obligations other than the contribution payable to the respective fund.

Gratuity

Retirement benefits in the form of gratuity is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to the statement of profit and loss.

Leave encashment

Employee benefits in the form of leave encashment is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to the statement of profit and loss.

(h) Leases

Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item are classified as operating leases. Operating lease payments are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term.

(i) Borrowing costs

Borrowing costs include interest and other ancillary costs incurred in connection with the arrangement of borrowing and exchange differences arising from the foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.



204

Auronext Pharma Private Limited

Notes to Financial Statement for the year ended March 31, 2015

(All amounts are in INR (Rs.) unless otherwise stated)

(j) Foreign Currency transactions

Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; and non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

Exchange differences

Exchange differences arising on the settlement of monetary items at rates different from those at which they were initially recorded during the period are recognized as income or as expenses in the period in which they arise.

(k) Taxes on income

Tax expense comprises of current and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the provisions of the Income Tax Act, 1961. Deferred income taxes reflect the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.

Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the Balance Sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

(l) Provisions

A provision is recognized when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on management estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current management estimates.

(m) Earnings per equity share

Basic earnings per equity share are calculated by dividing the profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per equity share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

(n) Segment reporting

Identification of reportable segments

Segments are identified in line with AS-17 "Segment Reporting", taking into consideration the internal organization and management structure as well as the different risk and returns of the segment.



Handwritten signature/initials

Auronext Pharma Private Limited

Notes to Financial Statement for the year ended March 31, 2015

(All amounts are in INR (Rs.) unless otherwise stated)

Based on the company's business model, pharmaceuticals have been considered as the only reportable business segment and hence no separate financial disclosures provided in respect of its single business segment.

(o) Contingent Liabilities

A contingent liability is possible obligation that arises from past events whose existence will be confirmed by the occurrence or non occurrence of one or more uncertain future events beyond the control of Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize the contingent liability but discloses its existence in the financial statements.

(p) Cash flows

Cash flows are reported using indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities are segregated.

Cash and cash equivalents: Cash and cash equivalents, in the statement of cash flow, comprise cash at bank and in hand and fixed deposits with original maturity of maximum 90 days.



Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

3. Share capital

	31 March 2015		31 March 2014	
	No. of shares	Amount (Rs.)	No. of shares	Amount (Rs.)
Authorized				
Equity shares of Rs.10/- each	1,200,000,000	12,000,000,000	80,000,000	800,000,000
Issued, subscribed and fully paid-up				
Equity shares of Rs.10/- each	113,014,028	1,130,140,280	72,299,996	722,999,960
	113,014,028	1,130,140,280	72,299,996	722,999,960

(a) Reconciliation of the equity shares capital outstanding at the beginning and at the end of the reporting year

	31 March 2015		31 March 2014	
	No. of shares	Amount (Rs.)	No. of shares	Amount (Rs.)
Equity shares				
At the beginning of the year	72,299,996	722,999,960	46,499,998	464,999,980
Issued during the year	40,714,032	407,140,320	25,799,998	257,999,980
Outstanding at the end of the year	113,014,028	1,130,140,280	72,299,996	722,999,960

(b) Terms/rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs. 10/- per share. Each holder of equity shares is entitled to one vote per share.

(c) Shareholders holding more than 5% shares in the Company:

	31 March 2015		31 March 2014	
	No. of shares	% of holding	No. of shares	% of holding
Aurobindo Pharma Limited - Holding Company	94,274,000	83.42%	54,225,000	75.00%
B.R.Sikri	11,244,020	9.95%	10,845,000	15.00%

As per records of the Company, including its register of shareholders/members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownership of shares.

(d) Shareholding of holding company

	31 March 2015		31 March 2014	
	No. of shares	Amount (Rs.)	No. of shares	Amount (Rs.)
Aurobindo Pharma Limited	94,274,000	942,740,000	54,225,000	542,250,000



[Handwritten signature]

Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

4. Reserves and surplus

	As at 31 March	
	2015	2014
Deficit in the statement of profit and loss		
Balance at the beginning of the year	(277,886,490)	(132,977,175)
Add: Profit/(Loss) during the year	(202,871,659)	(144,909,315)
Balance at the end of the year	(480,758,149)	(277,886,490)

5. Long-term borrowings

	Non-current		Current	
	As at 31 March		As at 31 March	
	2015	2014	2015	2014
Secured				
Loan From Banks				
Term Loan in Indian Currency	-	90,516,542	-	66,475,564
Term Loan in Foreign currency loan	33,475,126	25,488,256	44,617,827	13,214,436
Amount disclosed under the head "other Current Liabilities"	-	-	(44,617,827)	(79,690,000)
(Refer note 8)				
Total	33,475,126	116,004,798	-	-

Notes:

- a) Indian rupee term loans were all paid off during the year.
- b) Foreign currency term loans carry an interest of 6 month LIBOR + 500 basis points with interest payments at monthly intervals current interest rate being 5.09% per annum). The foreign currency term loans are repayable in 7 quarterly installments of Rs. 1,10,00,000 each starting from 01.04.2015. The entire term loans are secured by a first charge on entire fixed assets of the company (both present and future) and collateral security of present and future current assets of the Company.

6. Long-term provisions

	As at 31 March	
	2015	2014
Provision for employee benefits		
Gratuity (Refer note 25)	7,366,907	5,187,389
Leave Encashment (Refer note 26)	3,163,558	-
Total	10,530,465	5,187,389



Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

7. Trade payables

	As at 31 March	
	2015	2014
Trade payables (including acceptances)		
-Creditor for trade	122625740	121673462
Total	122,625,740	121,673,462

There are no micro and small enterprises, as defined under the provisions of the Micro, Small and Medium Enterprises Development Act, 2006 to whom the Company owes dues, as at the reporting date. The micro and small enterprises have been identified by management on the basis of information available with the Company and have been relied upon by the auditors.

8. Other current liabilities

	As at 31 March	
	2015	2014
Other Payables		
Interest accrued and due on borrowings	-	2,014,198
Current Maturity of Long Term Borrowings	44,617,827	79,690,000
Creditors for capital goods	12,929,800	2,531,504
Statutory liabilities	490,338	430,904
Creditors for expenses and general goods	3,185,841	4,312,044
Salary Payable	3,976,084	3,135,933
Expenses Payable (Including Audit fees payable)	1,972,060	1,841,171
Total	67,171,949	93,955,754

9. Short-term provisions

	As at 31 March	
	2015	2014
Provision for employee benefits		
Bonus	1,835,694	1,443,903
Gratuity (refer note 25)	152,928	61,532
Leave Encashment (refer note 26)	101,463	-
Leave travel allowance	626,801	287,508
Medical allowance	463,145	287,508
Total (a)	3,180,031	2,080,451
Others		
Provision for Entry Tax (Refer Note 27)	1,069,370	-
Total (b)	1,069,370	-
Total Short-term provisions (a+b)	4,249,401	2,080,451





Auronext Pharma Private Limited

Notes to Financial Statement for the year ended March 31, 2015

(All amounts are in INR (Rs.) unless otherwise stated)

Note 10 : Tangible assets for the year ended 31st March 2015

Particulars	Leasehold Buildings	Plant & Equipment	Furniture & fixtures	Vehicles	Office Equipment	Computer	Total
Gross Block							
As at 1 April 2013	46,142,932	536,178,422	19,106,310	484,129	177,405	1,654,242	603,743,440
Additions made during the year	7,630,476	6,793,038	333,158	-	109,313	427,453	15,293,438
Disposals/adjustments made during the year	-	(3,864,421)	-	-	-	-	(3,864,421)
At 1 April 2014	53,773,408	539,107,039	19,439,468	484,129	286,718	2,081,695	615,172,457
Additions made during the year	181,303	5,687,068	419,120	-	22,950	187,185	6,497,626
Disposals/adjustments made during the year	-	-	-	-	-	-	-
At 31st March 2015	53,954,711	544,794,107	19,858,588	484,129	309,668	2,268,880	621,670,083
Accumulated depreciation							
As at 1 April 2013	1,374,934	21,881,676	814,021	121,668	52,286	389,710	24,634,295
Charge for the year	1,673,547	25,475,541	1,218,027	45,992	12,500	296,879	28,722,486
Adjustments or disposals	-	-	-	-	-	-	-
At 1 April 2014	3,048,481	47,357,217	2,032,048	167,660	64,786	686,589	53,356,781
Charge for the year	1,792,949	59,285,662	2,115,138	72,794	181,800	509,345	63,957,688
Adjustments or disposals	-	-	-	-	-	-	-
At 31st March 2015	4,841,430	106,642,879	4,147,186	240,454	246,586	1,195,934	117,314,469
Net Block							
At 31 March 2014	50,724,927	491,749,822	17,407,420	316,469	221,932	1,395,106	561,815,676
At 31st March 2015	49,113,281	438,151,228	15,711,402	243,675	63,082	1,072,946	504,355,614

B. Capital Work in Progress

At 1 April 2014	4,223,968
Additions upto 31.03.2015	114,205,926
Adjustments made during the year	-
At 31st March 2015	118,429,894
Total	622,785,508

Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

11. Long-term loans and advances

	As at 31 March	
	2015	2014
<i>Advance recoverable in cash or kind</i>		
Unsecured, considered good		
Security Deposits	4,864,679	3,575,379
Total (a)	4,864,679	3,575,379
<i>Other Loan & advances</i>		
Unsecured, considered good		
Advance Tax	-	109,054
Cenvat & Service Tax Receivable	50,294,505	38,045,233
Total (b)	50,294,505	38,154,287
Total (a+b)	55,159,184	41,729,666

12. Inventories

	As at 31 March	
	2015	2014
Raw materials (including packing material)	51,626,652	36,556,059
Intermediates	42,434,330	76,415,034
Finished goods	11,868,544	4,596,867
Total	105,929,526	117,567,960

13. Trade receivables (Unsecured, considered good)

	As at 31 March	
	2015	2014
Outstanding for a period exceeding six months from the date they are due for payment		
Considered Good	335,137	1,038,222
Doubtful	-	-
Total (a)	335,137	1,038,222
Other receivables		
Considered Good	48,060,645	33,557,014
Doubtful	-	-
Total (b)	48,060,645	33,557,014
Total (a+b)	48,395,782	34,595,236



✓ 1004

Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

14. Cash and bank balances

	As at 31 March	
	2015	2014
Cash and Cash equivalents		
<i>i) Balance With Bank</i>		
Balance with bank in current Account	43,927,988	20,252,436
<i>ii) Cash in Hand</i>	15,854	677,081
Total (a)	43,943,842	20,929,517
Other Bank Balances		
i) Fixed Deposits #	2,821,000	-
ii) Fixed Deposits *	790,000	790,000
Total (b)	3,611,000	790,000
Total (a+b)	47,554,842	21,719,517

Held as security against Foreign Currency Loan

* Held as lien against Bank Guarantees

15. Short-term loans and advances

	As at 31 March	
	2015	2014
Unsecured, considered good		
Vat & others Receivable	110,392	-
Prepaid expenses	2,746,114	2,363,301
Loans & Advances	2,047,856	-
Export incentives receivable	2,705,609	-
Total	7,609,971	2,363,301

16. Revenue from operations, gross

	For the year ended 31 March	
	2015	2014
Sale of goods	161,488,179	73,434,711
Sale of services	-	1,200,000
Sale of Scrap	151,607	-
Other operating revenues		
- Export incentives	1,727,048	1,652,966
Total	163,366,834	76,287,677

Details of sale of goods and services:**(a) Sale of goods**

Description	For the year ended 31 March	
	2015	2014
Merogram	59,817,464	8,145,168
Meromny	11,434,242	28,999,390
Doripenem	25,116,091	32,143,832
Imipenem & Cilastain	55,887,037	-
Others	9,233,345	4,146,321
Total	161,488,179	73,434,711



Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

17. Other income

	For the year ended 31 March	
	2015	2014
Interest Income		
Bank Deposits	827,558	-
Other Deposits	326,874	315,996
Foreign Exchange Gain	1,200,176	-
Liability written back	302,739	933,139
Total	2,657,347	1,249,135

18. Cost of materials consumed

	For the year ended 31 March	
	2015	2014
Raw material at the beginning of the year	36,556,059	7,896,145
Add: Purchases during the year	90,094,821	139,478,641
Less: Raw material at the end of the year	(51,626,652)	(36,556,059)
Total	75,024,228	110,818,727

Notes:**(a) Details of materials consumed**

	For the year ended 31 March	
	2015	2014
Meropenem (Sterile)	10,520,290	25,732,450
Meropenem (Non-Sterile)	22,036,648	49,207
Imipenem and cilastatin for Injection	10,713,245	229,034
Cilastatin Sodium Non-Sterile	15,362,111	-
Others	16,391,934	84,808,036
Total	75,024,228	110,818,727

19. Changes in inventories of finished good and intermediates

	For the year ended 31 March	
	2015	2014
Opening stock	81,011,901	2,280,400
Closing stock	54,302,874	81,011,901
Total	26,709,027	(78,731,501)

20. Employee benefits expense

	For the year ended 31 March	
	2015	2014
Salaries and wages	50,068,571	38,556,887
Contribution to provident and other funds	1,128,728	1,093,666
Staff welfare expenses	1,104,837	742,977
Gratuity	2,270,914	2,072,014
Leave Encashment	3,265,021	-
Total	57,838,071	42,465,544



Handwritten signature/initials

Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

21. Other expenses

	For the year ended 31 March	
	2015	2014
Consumption of Store & Spares	13,006,686	14,545,411
Power, Fuel & Electricity	48,691,675	38,285,282
Labour Charges	4,216,470	3,541,984
Other Manufacturing Related Expenses	7,833,050	-
Factory Related Expenses	2,494,816	-
Repairs and maintenance		
i) Buildings, Plant & Machinery	10,965,335	9,932,343
ii) Factory Maintenance	692,073	-
iii) Others	2,529,587	1,261,921
Commissioning & Installation	331,503	214,061
Rent	1,602,000	1,602,000
Rates and taxes	5,587,816	975,000
Printing and stationery	981,284	829,966
Communication costs	412,164	291,908
Postage & courier	132,150	-
Insurance	918,387	1,052,652
Legal & Professional Fees	1,320,980	6,868,279
Remuneration to Auditor	433,500	160,000
Carriage Outward	922,849	1,231,900
Travelling and conveyance	936,154	744,438
Advertising and sales promotion	434,271	550,272
Membership, Subscription & Periodicals	536,230	-
Security Charges	839,228	699,243
Loss on Sale of Fixed Assets	-	185,301
Software license and implementation expenses	-	1,920,500
USFDA/ DMF Fees	8,608,481	-
Foreign Exchange Fluctuation	2,573,726	4,415,729
Miscellaneous expenses	946,741	791,582
Total	117,947,154	90,099,772

22. Finance cost

	For the year ended 31 March	
	2015	2014
Interest expense on term loans	18,763,303	27,577,756
Bank Charges	111,487	0
Total	18,874,790	27,577,756

23. Capital & Other Commitments

	For the year ended 31 March	
	2015	2014
Estimated amount of contracts remaining to be executed and not provided for (net of advances)	-	2,140,000
Total	-	2,140,000



Handwritten signature/initials

Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

24. Related party disclosures**Names of related parties and nature of relationship**

Names	Nature of relationship
Aurobindo Pharma Limited	Holding company
B.R. Sikri	Key management personnel
Anshul Sikri	Key management personnel
Anil Munjal	Key management personnel
Alok Munjal	Relative of key management personnel
Silicon Life Sciences Private Limited	Fellow subsidiary
Aurobindo Pharma (Malta) Limited	Fellow subsidiary
Aurovida Farmaceutica SA De CV, Mexico	Fellow subsidiary
ABS Mercantiles Private Limited	Enterprises where key managerial personnel exercise significant influence
Veritaz Healthcare Limited	Enterprises where Director exercises significant influence

X APL Director?

Nature of transactions and year end balances

	For the year ended 31 March	
	2015	2014
Transactions with KMP:		
Anil Munjal		
Amount received towards equity contribution	1,330,060	12,899,990
B.R. Sikri		
Amount received towards equity contribution	3,990,200	38,700,000
Unsecured loan received and repaid	0	45,000
Alok Munjal		
Salary paid	460,601	515,044
Anshul Sikri		
Salary paid	1,052,062	-
Transactions with holding company- Aurobindo Pharma Limited		
Amount received towards equity contribution	400,490,000	193,500,000
Rent	1,602,000	1,602,000
Purchase of raw materials	44,165,360	45,565,954
Unsecured loan received and repaid		
Reimbursement of expenses	16,240,016	25,300,988
Sales of capital goods	-	1,908,113
Sale of goods	75,706,379	33,607,884
Transactions with enterprises where Director exercises significant influence:		
Veritaz Healthcare Limited		
Sale of goods	17,956,103	6,578,609



Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

	For the year ended 31 March	
	2015	2014
Transactions with fellow subsidiary:		
Silicon Lifescience Private Limited		
Purchase of raw materials	40,193,005	83,870,540
Aurovida Farmaceutica SA De CV		
Sale of goods	7,595,145	28,999,390
Aurobindo Pharma (Malta) Limited		
ASMF Filing Fees Reimbursement	49,503	-
Transaction with enterprises where key management personnel have significant		
ABS Mercantiles Private Limited		
Unsecured Loan received and repaid	-	-
Purchase of raw materials	-	-
Reimbursement of expenses	6,789,844	1,499,115
Balances receivable /(payable)		
Aurobindo Pharma Limited	(29,686,217)	(51,860,071)
Aurovida Farmaceutica SA De CV	4,326,248	28,999,390
Silicon Lifescience Private Limited	(89,764,598)	(65,009,108)
Aurobindo Pharma (Malta) Limited	49,503	-
Veritaz Healthcare Limited	13,183,767	5,076,181

25. Gratuity**Defined benefit plan – gratuity****Changes in present value of defined benefit obligation representing reconciliation of opening and closing**

	As at 31 March	
	2015	2014
PVO at the beginning of the period	5,248,921	3,176,907
Interest cost	419,914	253,973
Adjustment	-	(2,250)
Current service cost	2,966,341	2,349,203
Past service cost (non vested benefit)	-	-
Actuarial/losses on obligation	(1,115,341)	(528,912)
Obligation at the end of the year	7,519,835	5,248,921

Net gratuity expense

	As at 31 March	
	2015	2014
Current service cost	2,966,341	2,349,203
Interest cost on benefit obligation	419,914	253,973
Adjustment	-	(2,250)
Net actuarial (gain)/loss recognized in the year	(1,115,341)	(528,912)
Past service cost	-	-
Net Employee benefit expense	2,270,914	2,072,014



Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

Liability recognized in the balance sheet

	As at 31 March	
	2015	2014
Defined benefit obligation	7,519,835	5,248,921
Liability recognized in the balance sheet	7,519,835	5,248,921

The assumptions used in accounting for the gratuity plan are set out as below:

	As at 31 March	
	2015	2014
Discount rate	7.77%	8%
Retirement age	58 years	58 years
Future salary increase	15%	15%
Attrition Rate	5%	5%

The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotions and Experience adjustment and expected contribution in the next year have not been disclosed as these have not been provided

26. Leave Encashment**Changes in present value of defined benefit obligation representing reconciliation of opening and closing**

	As at 31 March	
	2015	2014
PVO at the beginning of the period	-	-
Interest cost	-	-
Adjustment	-	-
Current service cost	1,975,522	-
Past service cost (non vested benefit)	-	-
Actuarial/losses on obligation	1,289,499	-
Obligation at the end of the year	3,265,021	0

Net leave encashment expense

	As at 31 March	
	2015	2014
Current service cost	1,975,522	-
Interest cost on benefit obligation	-	-
Adjustment	-	-
Net actuarial (gain)/loss recognized in the year	1,289,499	-
Past service cost	-	-
Net Employee benefit expense	3,265,021	0

Liability recognized in the balance sheet

	As at 31 March	
	2015	2014
Defined benefit obligation	3,265,021	-
Liability recognized in the balance sheet	3,265,021	0



Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

The assumptions used in accounting for the leave encashment plan are set out as below:

	As at 31 March	
	2015	2014
Discount rate	7.77%	-
Rate of increase in compensation	15.00%	-
Attrition Rate	5.00%	-

The estimates of rate of increase in compensation, considered in actuarial valuation, take account of inflation, seniority,

27. Provision for Entry tax:

	As at 31 March	
	2015	2014
Opening Balance of Provision for Entry Tax	-	-
Addition During the Year (Refer Note 9)	10,69,370	-
Withdrawal during the Year	-	-
Closing Balance	10,69,370	-

Out of this above provision company has paid Rs. 3,35,765/- in the April, 2015. The balance amount is expected to be paid in the F.Y. 2015-16 upon receipt of demand from the concerned authority.

28. Disclosure regarding derivative financial instruments

Particular of un-hedged foreign currency exposure are detailed below at the exchange rate prevailing as at the Balance Sheet

	31 March 2015		31 March 2014	
	USD	Rs.	USD	Rs.
Foreign currency loan	1,235,844	78,092,953	649,542	38,883,523
Trade receivables	363,352	22,742,662	468,110	28,999,390

The company has not entered into any derivative instruments during the year.

29. Expenditure and earnings in foreign currency

	Year Ended 31 March	
	2015	2014
a. CIF Value of imports		
- Raw material and packing material	2,331,716	2,141,871
- Capital goods	29,838,346	4,019,898
b. Expenditure in foreign currency		
- Filing fees paid to USFDA	19,758,932	30,659,301
- Drug master filing fees	5,303,690	1,240,789
- Interest expense	1,683,740	2,468,065
c. Earnings in foreign currency		
- Sale of goods (FOB)	35,486,910	28,999,390

30. Imported and indigenous raw materials, including packing materials, consumed:

	Year Ended 31 March			
	2015		2014	
	Amount(Rs.)	%	Amount(Rs.)	%
Raw materials and packing material				
- Imported	2,331,716	3%	1,663,230	2%
- Indigenous	72,692,512	97%	109,155,497	98%
	75,024,228	100%	110,818,727	100%



Auronext Pharma Private Limited**Notes to Financial Statement for the year ended March 31, 2015**

(All amounts are in INR (Rs.) unless otherwise stated)

31. Contingent Liabilities

	As at 31 March	
	2015	2014
a. Guarantees		
- Outstanding Bank Guarantees for EPCG Licences	790,000	790,000
b. Commitments		
- Export Commitment against Import of machinery without duty	49,769,465	55,294,213

32. Domestic transfer pricing:

The Company has established a comprehensive system of maintenance of information and documents as required by the

33. Current Assets, Loans & Advances:

In the opinion of the management current assets, loans and advances have a value on realization in the ordinary course of business.

34. Change in Useful life of Assets:

Company has reassessed the useful lives of its tangible fixed assets on and from April 1, 2014 and based on technical evaluation, revised the useful lives to match those specified in Part C of Schedule II to the companies act 2013, for all classes of assets, other than servers and networks, desktop / laptops / printers, general lab equipment, electrical installation, sewage tanks and general Plant and machinery. Management believes that the revised useful lives reflect the periods over which the assets are to be used. As a result of this revision, the charge on account of depreciation for the year ended March 31, 2015, is increase by Rs 34,744,900 as compared to earlier periods.

35. Previous year figures have been reworked, regrouped, reclassified and rearranged wherever necessary to make them


This is the summary of significant accounting policies and other explanatory information referred to in our report of even

As per our report on even date.

For PKF Sridhar and Santhanam LLP

Chartered Accountants

Firm's Registration No.003990S / S200018


S. Ramakrishnan

Partner


Membership No. 018967

Place: Gurgaon Mumbai

Date: May 15, 2015




For and on behalf of Board of Directors of

Auronext Pharma Private Limited

B.R. Sikri

Director

Place: Gurgaon

Date: May 15, 2015


K. Nithyananda Reddy

Director

Place: Gurgaon

Date: May 15, 2015

AURO PEPTIDES LIMITED

CIN: U24232TG2012PLC078350

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

DIRECTORS' REPORT

Dear Members,

Your Directors are pleased to present the Third Annual Report of the Company together with the Audited Accounts for the year ended 31st March, 2015.

Financial Results:

	(Rs. In Millions)	
	2014-15	2013-14
Gross Turnover	24.26	-
Profit before depreciation, interest, tax and exceptional items	(45.68)	-
Depreciation/amortization	20.16	-
Finance cost	25.98	-
Profit before tax	(91.82)	-
Provision for tax/deferred tax	30.36	-
Profit after tax before exception item	(61.46)	-
Less: Exceptional items	-	-
Net profit after exceptional items	(61.46)	-
Balance brought forward from previous year	-	-
Deficit carried to Balance sheet	(61.46)	-

Review of Operations:

We are pleased to report that your company has commenced its operations during the year. The Company is currently running two modules and is in the process of commissioning the third module. The status of the various products is as follows:

- Octreotide - The Process validation batches are completed and the analytical aspects are under progress.
- Linacotide – One batch is completed and two more batches have to be progressed. Plan is to file the DMF by June'2015
- Desmopressin – Validation is under progress. The plan is to file the DMF by June'2015
- Glatiramer – Validation is under progress.
- Leuprolide – Validation is under progress
- Paserotide – Lab RM's are awaited to initiate the development.

AURO PEPTIDES LIMITED

CIN: U24232TG2012PLC078350

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Manufacturing of high quality peptides under GMP (Good Manufacturing Practice) requires purification by reverse phase chromatography. To manufacture large quantities (multi kilograms) of such quality peptides in a short period of time, it is impossible to achieve with small or medium scale equipment. Therefore, equipment like Hipersep M and LC 45 cm column is required.

Currently the Company has columns which can facilitate one kilo batches. Hipersep M and LC 45 CM Column would facilitate Two Kgs Batch.

The parent company M/s. Aurobindo Pharma Ltd, Formulations Division as well as external customers requirements run into few kilos. We propose to go ahead with the procurement of Hipersep M and LC 45 cm column. To commercialize Products in large scale a typical payback of 2 to 3 Years can be considered.

Dividend

No dividend has been declared the year 2014-15

Reserves

No amount has been carried to General Reserves during the year 2014-15

Details of Subsidiary/Joint Ventures/Associate Companies

The Company has no Subsidiaries as on 31st March, 2015.

Deposits

The Company has not accepted any public deposits and as such, no amount on account of principal or interest on public deposits was outstanding as on the date of the balance sheet.

Statutory Auditors

M/s. G Pavan Kumar & Associates, Chartered Accountants, Hyderabad have been appointed as Statutory Auditors of the Company at the 2nd Annual General Meeting held on 25th August, 2014 for a period of 5 years subject to ratification by the members at every Annual General Meeting (i.e. till 7th Annual General Meeting). Your Directors commend for the ratification of their appointment.

Auditors' Report

The observations made in the Auditors' Report read together with relevant notes thereon are self explanatory and hence do not call for any further comments under Section 134 of the Companies Act, 2013.

AURO PEPTIDES LIMITED

CIN: U24232TG2012PLC078350

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Share Capital

During the year, your Company has issued 50,00,000 (Fifty Lakhs) 9.5% Cumulative Redeemable Preference Shares of Rs.100/- each at par to Aurobindo Pharma Limited, the holding company. Consequently, the paid-up share capital was increased to Rs. 50,10,00,000.

Extract of the Annual Return

In accordance with Section 134(3)(a) of the Companies Act, 2013 the extract of Annual Return (Form MGT-9) of the Company is enclosed as **Annexure – I** to the Boards Report.

Material changes and commitments, if any.

There are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

Conservation of energy, technology absorption and foreign exchange earnings and outgo

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014, is not applicable to the Company for the year 2014-15 except foreign exchange earnings and outgo which is furnished in as **Annexure - II**

Directors:

As per the provisions of the Companies Act, 2013 Mr. N Govindarajan will retire in the ensuing Annual General Meeting and being eligible, seek re-appointment. The Board of Directors recommends his re-appointment.

Number of meetings of the Board of Directors:

During the financial year 2014-15 the Board of Directors has met Six times viz., on 08.05.2014, 18.07.2014, 20.10.2014, 30.01.2015, 09.02.2015 and 30.03.2015.

Particulars of loans, guarantees or investments under section 186:

No loans, Guarantees or investment made by the company during the year 2014-15.

AURO PEPTIDES LIMITED

CIN: U24232TG2012PLC078350

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Particulars of contracts or arrangements with related parties:

Related party transactions that were entered during the financial year were on an arm's length basis and were in the ordinary course of business. There were no materially significant related party transactions which could have had a potential conflict with the interests of the Company.

Transactions with related parties entered by the Company are periodically placed before the Board and the particulars of contracts entered during the financial year 2014-15 are enclosed in Form AOC-2 as **Annexure - III**

Particulars of Employees

Information as required under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are enclosed as **Annexure – IV**

Policy on Sexual Harassment

The Company has adopted policy on Prevention of Sexual Harassment of Women at Workplace in accordance with The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

During the financial year ended March 31, 2015, the Company has not received any Complaints pertaining to Sexual Harassment.

Risk Management

There are no elements of risks identified during the financial year

Directors' Responsibility Statement

Pursuant to Section 134(5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

(a) in the preparation of the annual accounts for the year ended 31st March, 2015, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

AURO PEPTIDES LIMITED

CIN: U24232TG2012PLC078350

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

(d) the directors had prepared the annual accounts on a going concern basis; and

(e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and are operating effectively.

(f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and are operating effectively.

Acknowledgements

Your Company will always keep interest of its customers, employees and the stakeholders as a priority and shall reciprocate their confidence reposed in the Company. It has been a mutually beneficial relationship and looks forward to their continued support.

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015


K. Nityananda Reddy
Director
DIN: 01284195


N. Govindarajan
Director
DIN: 00050482

ANNEXURE - I

Form No. MGT-9
EXTRACT OF ANNUAL RETURN
as on the financial year ended on 31.03.2015

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:		
i	CIN	U24232TG2012PLC078350
ii	Registration Date	02.01.2012
iii	Name of the Company	Auro Peptides Limited
iv	Category / Sub-Category of the Company	Company Limited by Shares/Public Limited Company
v	Address of the Registered office and contact details	Plot No. 2, Maitrivihar, Ameerpet, Hyderabad – 500 038, Telangana Ph: 040 - 2373 6370 Fax:040 - 2374 7340
vi	Whether listed company	No
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
1	Linacotide	21001/21002	60%
2	Octreotide Acetate		19%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S.No	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ASSOCIATE	% of shares held	Applicable Section
1	Aurobindo Pharma Limited Regd Off: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500038, Telangana	L24239TG1986PLC015190	HOLDING	95.00	2(46)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change During the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual /HUF	0								
b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt (s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	94400	94400	95.00	0	94400	94400	95.00	0
e) Banks / FI									
f) Any Other (Nominees of holding Company)	0	600	600	0		600	600	0	0
Sub-total (A) (1):-	0	95000	95000	95.00	0	95000	95000	95.00	0

i) Individual shareholders holding nominal share capital upto Rs1 lakh	0	5000	5000	5.00	0	5000	5000	5.00	0
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	0	0	0	0	0	0	0	0	0
c) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	5000	5000	5.00	0	5000	5000	5.00	0
Total Public Shareholding (B)=(B)(1)+(B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	100000	100000	100.00	0	100000	100000	100.00	0

ii) Shareholding of Promoters

SI No	Shareholder's Name	Shareholding at the beginning of the year			Share holding at the end of the year			% change In share Holding during the year
		No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	%of Shares Pledged / Encumbered to total shares	
1	Aurobindo Pharma Ltd (APL)	94400	95.00	0	94400	95.00	0	0

2	K Nityananda Reddy (Nominee of APL)	100	0	0	100	0	0	0
3	N Govindarajan (Nominee of APL)	100	0	0	100	0	0	0
4	P Sarath Chandra Reddy (Nominee of APL)	100	0	0	100	0	0	0
5	A Mohan Rami Reddy(Nominee of APL)	100	0	0	100	0	0	0
6	G Phaneendra Prasad (Nominee of APL)	100	0	0	100	0	0	0
7	T S Sankara Reddy (Nominee of APL)	100	0	0	100	0	0	0
	Total	95000	95.00	0	95000	95.00	0	0

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl.No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	At the beginning of the year	No Change			
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus/ sweat equity etc):				
	At the End of the year				

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	For Each of the Top 10 Shareholders				
	At the beginning of the year Dr. Nagana A Goud	5000	5%	0	0
	Date wise Increase /Decrease in Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus / sweat equity etc):	Nil			
	At the End of the year (or on the date of separation, if separated during the year) Dr. Nagana A Goud	5000 Equity Shares consisting of 5% of Total Equity Share Capital of the Company			

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total Shares of the company
	For Each of the Directors and KMP				
	At the beginning of the year				
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc):	Nil			
	At the End of the year	Nil			

V. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	-	288,000,000	-	288,000,000
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)		288,000,000	-	288,000,000
Change in Indebtedness during the financial year				
• Addition	-	174,100,000	-	174,100,000
• Reduction	-	462,100,000	-	462,100,000
Indebtedness at the end of the financial year				
i) Principal Amount	-	-	-	-
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	-	-	-	-

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl.no.	Particulars of Remuneration	Name of MD/WTD/Manager				Total Amount
1						
2	Stock Option	-	-	-	-	-
3	Sweat Equity	-	-	-	-	-
4	Commission - as % of profit	-	-	-	-	-

	- others, specify...					
5	Special Allowance	-	-	-	-	-
	Total (A)	-	-	-	-	-
	Ceiling as per the Act	-	-	-	-	-

B. Remuneration to other directors:

Sl.no.	Particulars of Remuneration	Name of Directors				Total Amount
		----	----	----	----	
	Independent Directors • Fee for attending board / committee meetings • Commission • Others, please specify	Nil				
	Total (1)	Nil				
	Other Non-Executive Directors • Fee for attending board / committee meetings • Commission • Others, please specify	Nil				
	Total (2)	Nil				
	Total (B)=(1+2)	Nil				
	Total Managerial Remuneration	Nil				
	Overall Ceiling as per the Act	Nil				

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD:

Sl.no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	Nil			

	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Incometax Act, 1961	
2.	Stock Option	Nil
3.	Sweat Equity	Nil
4.	Commission - as % of profit - others, specify...	Nil
5.	Others, please specify	Nil
	Total	Nil

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty /Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give details)
A. Company					
Penalty			Nil		
Punishment					
Compounding					
B. Directors					
Penalty			Nil		
Punishment					
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty			Nil		
Punishment					
Compounding					

i) Category-wise Share Holding:

[illegible]

(B)=(B)(1)+ (B)(2)									
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	0	0	0	0	5000000	5000000	100.00	100.00

ii) Shareholding of Promoters

SI No	Shareholder's Name	Shareholding at the beginning of the year			Share holding at the end of the year			
		No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	No. of Shares of Rs. 100/- each	% of total Shares of the company	%of Shares Pledged / encumbere d to total shares	
1	Aurobindo Pharma Ltd (APL)	0	0	0	5000000	100.00	0	100.00
	Total	0	0	0	5000000	100.00	0	100.00

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl.No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	At the beginning of the year	<p>The Company has allotted 50,00,000 9.5% Cumulative Redeemable Preference Shares of Rs. 100/- each at par to the Holding Company on 30.03.2015</p>			
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus/ sweat equity etc):				
	At the End of the year				

AURO PEPTIDES LIMITED

CIN: U24232TG2012PLC078350

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Annexure- II

The conservation of energy, technology absorption, foreign exchange earnings and outgo pursuant to the provisions of section 134(3) (m) of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014.

(A) Conservation of energy-

- (i) the steps taken or impact on conservation of energy; - Nil
- (ii) the steps taken by the company for utilizing alternate sources of energy; - Nil
- (iii) the capital investment on energy conservation equipments; - Nil

B) Technology absorption-

- (i) the efforts made towards technology absorption; -Nil
- (ii) the benefits derived like product improvement, cost reduction, product development or import substitution; - Nil
- (iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)- - Nil
 - (a) the details of technology imported; - Nil
 - (b) the year of import; - Nil
 - (c) whether the technology been fully absorbed; - Nil
 - (d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof- Nil
- (iv) the expenditure incurred on Research and Development. - Nil

AURO PEPTIDES LIMITED

CIN: U24232TG2012PLC078350

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

(C) Foreign exchange earnings and Outgo-


	(Rs in Millions)	
	2014-15	2013-14
Foreign exchange earned		
Exports (FOB)	9.68	-
Others	-	-
	<u>9.68</u>	<u>-</u>
Foreign exchange outgo		
Materials	52.11	70.48
Other expenses	0.67	0.23
	<u>52.77</u>	<u>70.71</u>

For and on behalf of the Board

Place: Hyderabad

Date: 21.05.2015


K. Nityananda Reddy
Director
DIN: 01284195


N. Govindarajan
Director
DIN: 00050482

AURO PEPTIDES LIMITED

CIN: U24232TG2012PLC078350

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Annexure III AOC-2

DETAILS OF RELATED PARTY TRANSACTIONS

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis:

(a) Name(s) of the related party and nature of relationship (b) Nature of contracts/arrangements/transactions (c) Duration of the contracts/arrangements/transactions (d) Salient terms of the contracts or arrangements or transactions including the value, if any arm's length. (e) Justification for entering into such contracts or arrangements or transactions (f) Date(s) of approval by the Board (g) Amount paid as advances, if any: (h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188	There were no transaction or arrangement which were not at arm's length
--	---

2. Details of material contracts or arrangement or transactions at arm's length basis:

Name of the related party and nature of relationship	Aurobindo Pharma Ltd, Holding Company	Aurobindo Pharma Ltd , Holding Company.	Aurobindo Pharma Ltd , Holding Company.	Aurobindo Pharma Ltd , Holding Company.
Nature of contracts/ arrangements / transactions	Loan Agreement	Lease of Factory Premises at Medak	Sale of goods	Purchase of materials

Duration of the contracts / arrangements / transactions	Entered 2nd April 2012 including supplementary agreements thereon. Loan granted is unsecured payable on demand for a period of 3 years from date of each disbursement and can be extended and rescheduled with mutual agreement.	Taken Factory Premises on Lease for 5 years from May 2012 with an option to renew the lease contract for further period	on going	on going
Salient terms of the contracts or arrangements or transactions including the value, if any	Salient Terms: Loan carries an interest rate of 9.5% p.a. Transactions: during the year Rs. 17.41 Crores Loan was availed and the total outstanding of Rs. 46.21 Crores with interest of Rs. 3.43 Crores was repaid in full as on 31.03.2015	Transactions: Paid of Rs.53.98 Lakhs towards lease of premises and reimbursement of electricity payment 249.69 Lakhs.	Transactions: Sold goods amounting to Rs.146.09 Lakhs.	Transactions: Purchase of raw materials amounting to Rs.41.36 Lakhs.
Justification for entering into such contracts or arrangements or transactions	To avail financial assistance for the project of the company.	Aurobindo offered premises suited to the Company's requirement	Transactions are based on transfer pricing guidelines	Transactions are based on transfer pricing guidelines

Appropriate approvals have been taken for related party transactions. Advances paid if any have been adjusted against billing wherever applicable

For and on behalf of the Board

Place: Hyderabad

Date: 21.05.2015


K.Nityananda Reddy
Director
DIN: 01284195


N Govindarajan
Director
DIN: 00050482

AURO PEPTIDES LIMITED

CIN: U24232TG2012PLC078350

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340


Annexure-IV


Information as required under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

Name of the Employee	Designation of employee	Remuneration Received (Rs.) (per annum)	Nature of Employment (Contractual or otherwise)	Qualifications and Experience of the employee	Date of Commencement of employment	Age of Employee	Last employment held before joining the Company	The % of Equity shares held by the employee	Whether employee is relative of any Director, if so. Name of such Director
Dr. Nagana A Goud	Sr. Vice-President	1,16,41,698/-	Contractual	M.Sc, Ph.D (Organic Chemistry)	13.01.2012	DOB:11.07.1937 (78 Years)	Poly Peptide Group, Torrance, USA as Executive Vice President	5% of Equity Shares	No

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015


K.Nityananda Reddy
Director
DIN: 01284195


N.Govindarajan
Director
DIN: 00050482



INDEPENDENT AUDITOR'S REPORT

To the Members of
Auro Peptides Limited.

Report on the Financial Statements

We have audited the accompanying financial statements of M/s Auro Peptides Limited ("the Company"), which comprise the Balance sheet as at March 31, 2015, and the Statement of Profit and Loss and Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedure to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the Assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion


In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- a. In the case of the Balance Sheet, of the state of affairs of the Company as at March 31,2015;
- b. In the case of the Statement of Profit and Loss, of the loss for the year ended on that date; and
- c. In case of the Cash Flow Statement, of the cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

- 1) As required by the Companies (Auditor's Report) Order, 2015 ("the order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure a statement on the matters section in paragraphs 3 and 4 of the Order.
- 2) As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to best of our knowledge and belief were necessary for the purpose of our audit;
 - b. In our opinion proper books of account as required by law have been kept by the company so far as appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the Balance Sheet , Statement of Profit and Loss and Cash Flow Statement comply with the Accounting Standards notified under Section 133 of the Companies Act,2013, read with the Rule 7 of the Companies (Accounts) Rules2014;
 - e. On the basis of written representations received from the directors as on March 31,2015,and taken on record by the Board of Directors, none of the directors is disqualified as on March31,2015,from being appointed as a director In terms of sub-section (2) of section 164 of the Companies Act,2013.
 - f. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts in respect of which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.


Place: Hyderabad
Date:



For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants
(G Pavan Kumar Reddy)
Proprietor
M.No.229495

ANNEXURE TO AUDITORS REPORT
(Referred to in paragraph 3 & 4 of our report of even date)

- i. In respect of fixed assets:
 - a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - b) A major portion of the fixed assets has been physically verified during the year by the management in accordance with a programme of verification of all the fixed assets at reasonable intervals having regard to the size of the company and the nature of its assets. According to the information and explanations given to us, the discrepancies noticed on such verification were not material and have been properly dealt with in the books of accounts.
- ii. In respect of Inventories:
 - a) The management has conducted physical verification of inventory at reasonable intervals during the year.
 - b) The procedures of physical verification of inventory followed by the management are reasonable and adequate in relation to the size of the Company and nature of its business.
 - c) The Company is maintaining proper records of inventory and no material discrepancies were noticed on physical verification.
- iii.
 - a) According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to Companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the provisions of clauses 3 (iii) (a), 3 (iii) (b) of the Companies (Auditor's Report) Order 2015 are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the company and the nature of its business, for the purchase of inventory and fixed assets and for the sale of goods and services. During the course of our audit, we have not observed any major weakness or continuing failure to correct any major weakness in the internal control system of the Company in respect of these areas.
- v. The Company has not accepted any deposits. Accordingly, the provisions of clause 3(v) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- vi. We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under sub section (1) of section 148 of the Act and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.



vii.

- a) The company is regular in depositing with the appropriate authorities undisputed statutory dues including provident fund, employees' state insurance, income tax, sales tax, wealth tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues applicable to it.
- b) According to the information and explanations given to us, no undisputed amounts payable in respect of income tax, sale tax, wealth tax, service tax, customs duty, excise duty, value added tax or cess and other material statutory dues, at the yearend, for a period of more than six months from the date they became payable.
- c) According to the information and explanations given to us, the company does not have any amount in the account to transfer investor education and protection fund in accordance with the relevant provisions of the Companies Act, 1956 and rules made there under.

viii. The provision of clause 3(viii) of the Order is not applicable, since the incorporation of the company is less than five years.

ix. In our opinion, According to the information and explanations given to us, the Company has not accepted any loans from the financial institutions and banks. Accordingly, the provisions of clause 3(ix) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.

x. In our opinion, according to the information and explanations given to us, the company has not given any guarantees for loans taken by others from banks or the financial institutions. Accordingly, the provisions of clause 3(x) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.


xi. According to the information and explanations given to us, the company has not accepted any term loans during the year. Accordingly, the provisions of clause 3(xi) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.

xii. Based upon the audit procedures performed for the purpose of reporting the true and fair view of financial statements and as per the information and explanations given by the management, we report that no fraud on or by the company was noticed or reported during the course of our audit.

For M/s. G Pavan Kumar & Associates

Firm Registration No: 015343S

Chartered Accountants



(G. Pavan Kumar Reddy)

Proprietor

M.No.229495

Place: Hyderabad

Date:

AURO PEPTIDES LIMITED

CIN- U24232TG2012PLC078350

Balance Sheet as at March 31, 2015

(All amounts in Indian Rupees, except share data and where otherwise stated)

Particulars	Note	As at March 31, 2015	As at March 31, 2014
EQUITY AND LIABILITIES			
SHAREHOLDER'S FUNDS			
Share Capital	3	501,000,000	1,000,000
Reserves & Surplus	4	(61,458,449)	-
		<u>439,541,551</u>	<u>1,000,000</u>
NON-CURRENT LIABILITIES			
Long Term Borrowings	5	-	288,000,000
Long Term Provisions	6	554,694	-
		<u>554,694</u>	<u>288,000,000</u>
CURRENT LIABILITIES			
Trade Payables	7	23,728,467	14,317,465
Other Current Liabilities	8	4,051,643	13,248,896
Short - Term provisions	6	27,226	31,761
		<u>27,807,336</u>	<u>27,598,122</u>
TOTAL		<u>467,903,581</u>	<u>316,598,122</u>
ASSETS			
NON-CURRENT ASSETS			
Fixed Assets	9		
Tangible Assets		303,122,877	-
Tangible Assets-Capital work in progress		37,594,251	275,254,968
Deferred Tax Asset (Net)	10	30,365,671	-
Loans and advances	11	6,237,898	17,402,314
Other non - current assets	12	2,922,560	2,610,360
		<u>380,243,257</u>	<u>295,267,642</u>
CURRENT ASSETS			
Inventories	13	34,772,882	11,193,333
Trade Receivables	14	2,149,049	-
Cash and Bank Balances	15	20,489,419	9,074,162
Loans and advances	11	29,089,547	702,127
Other Current Assets	16	1,159,427	360,858
		<u>87,660,325</u>	<u>21,330,480</u>
TOTAL		<u>467,903,581</u>	<u>316,598,122</u>

Corporate Information & Significant accounting policies 1 & 2

The accompanying notes are an integral part of the financial statements

As per our report of even date.

For G.PAVAN KUMAR & ASSOCIATES

Chartered Accountants

ICAI Firm Registration Number: 0153435


G PAVAN KUMAR REDDY


Proprietor

Membership No.229495

Hyderabad,

For and on behalf of the Board of Directors of
Auro Peptides Limited


K. NITYANANDA REDDY
Director
DIN No.01284195


N.GOVINDARAJAN
Director
DIN No.-00050482



AURO PEPTIDES LIMITED

CIN- U24232TG2012PLC078350

Statement of profit and loss for the year ended March 31, 2015

(All amounts in Indian Rupees, except share data and where otherwise stated)

Particulars	Note	Year ended 31st March, 2015	Year ended 31st March, 2014
I. INCOME			
Revenue from operations (gross)	17	24,259,646	-
Less: Excise duty		1,582,674	-
Revenue from operations (net)		22,676,972	-
Other income	18	961,456	-
TOTAL REVENUE		23,638,429	-
II EXPENSES			
Cost of materials consumed	19	11,580,391	-
(Increase)/decrease in Inventories of Finished goods, work-in-progress	20	(9,220,732)	-
Employee benefit expense	21	22,706,744	-
Other expenses	22	44,255,464	-
Depreciation	9	20,161,097	-
Finance costs	23	25,979,585	-
TOTAL EXPENSES		115,462,548	-
III Profit before extraordinary and exceptional items and taxes		(91,824,119)	-
IV Extraordinary and Exceptional items		-	-
V PROFIT/(LOSS) BEFORE TAX		(91,824,119)	-
VI TAX EXPENSE		-	-
Current tax		-	-
Deferred tax		30,365,671	-
TOTAL TAX EXPENSE		30,365,671	-
VI PROFIT/(LOSS) FOR THE YEAR		(61,458,449)	-
VI EARNINGS PER EQUITY SHARE	24		
Basic & Diluted		(615)	-
Nominal Value per share		10	10
Corporate Information & Significant accounting policies 1 & 2			
The accompanying notes are an integral part of financial statements			

As per our report of even date.

For **G.PAVAN KUMAR & ASSOCIATES**

Chartered Accountants

ICAI Firm Registration Number: 015343S

G PAVAN KUMAR REDDY

Proprietor

Membership No.229495

Hyderabad,

For and on behalf of the Board of Directors of
Auro Peptides Limited**K. NITYANANDA REDDY**

Director

DIN No.01284195

N.GOVINDARAJAN

Director

DIN No.-00050482



AURO PEPTIDES LIMITED

CIN- U24232TG2012PLC078350

Cash flow statement for the year ended March 31, 2015

(All amounts in Indian Rupees, except share data and where otherwise stated)

	Year ended 31st March, 2015	Year ended 31st March, 2014
CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and exceptional items	(91,824,119)	-
Adjustments to reconcile profit before tax to net cash flows		-
Depreciation	20,161,097	-
Unrealised foreign exchange loss/(gain) (net)	(259,308)	-
Interest Expense	25,979,585	-
Operating Profit before Working Capital Changes	(45,942,746)	-
Movements in working capital:		-
Decrease/(increase) in trade receivables	(2,149,049)	-
Decrease/(increase) in inventories	(23,579,549)	(11,193,333)
Decrease/(increase) in long-term loans and advances	11,164,416	(5,300,649)
Decrease/(increase) in short-term loans and advances	(28,387,420)	3,314,398
Decrease/(increase) in other noncurrent assets	(312,200)	(1,822,600)
Decrease/(increase) in other current assets	(798,569)	(218,644)
Increase/(decrease) in trade payables	9,670,310	9,898,709
Increase/(decrease) in provision for retirement benefits	581,920	-
Increase/(decrease) in other current liabilities	(9,197,253)	(215,692)
Cash Generated from Operations	(88,950,140)	(5,537,811)
Direct taxes paid (net of refunds)	31,761	85,252
NET CASH FLOW FROM OPERATING ACTIVITIES (A)	(88,981,901)	(5,623,063)
CASH FLOW USED IN INVESTING ACTIVITIES		
Purchase of fixed assets, including CWIP and capital advances	(85,623,257)	(217,376,784)
NET CASH FLOW USED IN INVESTING ACTIVITIES (B)	(85,623,257)	(217,376,784)
CASH FLOW USED IN FINANCING ACTIVITIES		
Proceeds from issuance of Preference share capital	500,000,000	-
Proceeds from long term borrowings	174,100,000	213,000,000
Repayment of long term borrowings	(462,100,000)	-
Interest paid on long term borrowings	(25,979,585)	-
NET CASH FLOW USED IN FINANCING ACTIVITIES (C)	186,020,415	213,000,000
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)	11,415,257	(9,999,847)
Cash and Cash Equivalents at the beginning of the year	9,074,162	19,074,009
Cash and Cash Equivalents at the end of the year	20,489,419	9,074,162
<i>Cash and cash equivalents comprise of:</i>		
Cash on hand	87,969	87,730
Balances with banks	20,401,450	8,986,432
Total cash and cash equivalents	20,489,419	9,074,162

As per our report of even date.

For G.PAVAN KUMAR & ASSOCIATES

Chartered Accountants

ICAI Firm Registration Number: 0153435

C PAVAN KUMAR REDDY

Proprietor

Membership No.229495

Hyderabad,

For and on behalf of the Board of Directors of
Auro Peptides Limited

K. NITYANANDA REDDY

Director

DIN No.01284195

N.GOVINDARAJAN

Director

DIN No.-00050482



AUROPEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

1. Background

AUROPEPTIDES LIMITED ('the Company') was incorporated on 2 January 2012 with its registered office in Hyderabad, India. The Company is a subsidiary of Aurobindo Pharma Limited, Hyderabad, India ('the Parent'). The Company was incorporated with an objective of (i) carrying out Research, Developing, Manufacturing, trading, and Dealing of Peptides, Peptide based Pharmaceutical Ingredients and related biologically active molecules, their intermediaries and reagents (ii) Carry on business of manufacturing, importing, exporting, buying, selling or dealing in all kinds of drugs, pharmaceuticals, Medical chemical and other preparations, articles and compounds.

2. Summary of significant accounting policies

(a) Basis of preparation of financial statements

The Company maintains its accounts on accrual basis following the historical cost convention in accordance with generally accepted accounting principles (GAAP), in compliance with provisions of the Companies Act, 2013 and the Accounting Standards [as specified in the Companies (Accounting Standards) Rules, 2006 read with Section 133 of the Companies Act, 2013 and Rule 7 of the Companies (Accounts) Rules 2014 prescribed by the Central Government]. The other Accounting Standards as issued by ICAI, not yet notified are also considered, wherever applicable, except to the extent where compliance with the other statutory promulgations override the same requiring a different treatment. The accounting policies are consistent with those used in the previous year.

(b) Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting year. Examples of such estimates include provision for future obligation under employee benefit plans, net realizable value of inventory and estimated useful lives of fixed assets. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates.

(c) Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.

Revenue from sale of goods is recognized on dispatch (in respect of exports on the date of the bill of lading or airway bill) which coincides with transfer of significant risks and rewards to customer and is net of trade discounts, sales returns and sales tax, where applicable. Excise duty deducted from revenue (gross) is the amount that is included in revenue (gross) and not the entire amount of liability arising during the year.

Interest is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.



AUROPEPTIDES LIMITED**NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015**

(All amounts are in Indian Rupees except share data and where otherwise stated)

(d) Fixed assets and depreciation

Fixed assets are stated at cost less accumulated depreciation and impairment losses, if any. Cost comprises the purchase price and any attributable cost of bringing the asset to its working condition for its intended use. Borrowing costs relating to acquisition of fixed assets which take substantial period of time to get ready for use are included to the extent they relate to the period till such assets are ready for intended use. All other borrowing costs are expensed in the period they occur.

Expenditure directly relating to construction activity is capitalized. Indirect expenditure is capitalized to the extent those relate to the construction activity or is incidental thereto. Income earned during construction period is deducted from the total expenditure relating to construction activity.

Depreciation is provided using the Straight Line Method ('SLM') over the useful lives of the assets considered by the management, as given below:

S. No.	Nature of assets	Useful Life As per Company Policy
1	Factory buildings	30 Years
	Office, Stores & canteen other than RCC	30 Years
	Office, Stores & canteen RCC	60 Years
2	Roads (RCC)	15 Years
3	Furniture and fittings	10 Years
4	Cars and Vans	8 Years
	Tractors	8 Years
	Battery trucks	8 Years
5	Office equipment	5 Years
6	Servers and networks	5 Years
	Desktops/laptops/printer/scanners etc.,	5 Years
7	General Laboratory equipment	12 Years
8	Electrical installations and Equipment	15 Years
10	Reactors	15 Years
	Distillation Columns & Pipelines*	12 Years
	Drying equipments/Centrifuges & Decanters	15 Years
	Storage tanks	15 Years
	Formulation Process Equipment	15 Years
11	General rate to P&M	10 Years



—4



AUROPEPTIDES LIMITED**NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015**

(All amounts are in Indian Rupees except share data and where otherwise stated)

The above stated Useful life is estimated by management and supported by technical evaluation of the useful life which are generally comparable or lower than the rates prescribed under Schedule II to the Companies Act 2013 except for the items as stated here under:

Asset Type	Life as per Companies Act 2013	Life Considered
General Laboratory Equipment	10 years	12 years
Electrical installations and Equipment	10 years	15 years

Residual value is considered to be Nil.

Assets costing below Rs.5,000 are depreciated in full in the same year.

Additions during the year are depreciated on a pro-rata basis.

Capital work in progress includes the cost of fixed assets which are not yet ready for its intended use.

(e) Impairment

The carrying amounts of assets are reviewed at each balance sheet date to see if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the assets net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value at the weighted average cost of capital. After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

(f) Inventories

Raw materials, packing materials, stores, spares and consumables are valued at lower of cost, calculated on weighted average basis, and net realizable value. Items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost.

Finished goods and intermediates are valued at lower of cost and net realizable value. Cost includes materials, labour and a proportion of appropriate overheads based on normal operating capacity. Cost is determined on a weighted average basis.

Net realizable value is the estimated selling price in the ordinary course of business, reduced by the estimated costs of completion and costs to effect the sale.



u. - 9

28



AUROPEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

(g) Employee benefits

Provident fund

A retirement benefit in the form of provident fund scheme is a defined contribution and the contribution is charged to the statement of profit and loss of the year when the contribution to the respective fund is due. There are no other obligations other than the contribution payable to the respective fund.

Gratuity

Retirement benefits in the form of gratuity is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to the statement of profit and loss.

Leave encashment

Employee benefits in the form of leave encashment is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to the statement of profit and loss.

(h) Leases

Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item are classified as operating leases. Operating lease payments are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term.

(i) Borrowing costs

Borrowing costs include interest and other ancillary costs incurred in connection with the arrangement of borrowing and exchange differences arising from the foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.



(j) Foreign Currency transactions

Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; and non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.



AUROPEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

Exchange differences

Exchange differences arising on the settlement of monetary items at rates different from those at which they were initially recorded during the period are recognized as income or as expenses in the period in which they arise.

(k) Export Benefits and Incentives.

Export benefits on account of duty drawback and export promotion schemes are accrued and accounted in the year of export, and are included in other operating revenue. Other benefits in the form of advance authorization for imports are accounted for on purchase of imported materials.

(l) Taxes on income

Tax expense comprises of current and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the provisions of the Income Tax Act, 1961. Deferred income taxes reflect the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.

Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the Balance Sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

Unrecognized deferred tax assets of earlier years are reassessed and recognized to the extent that it has become reasonably certain or virtually certain, as the case may be that future taxable income will be available against which such deferred tax assets can be realized.


The carrying amount of deferred tax assets are reviewed at each Balance Sheet date. The company writes-down the carrying amount of a deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

(m) Provisions

A provision is recognized when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on management estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current management estimates.


(n) Earnings per equity share

Basic earnings per equity share are calculated by dividing the profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.



4

78



AUROPEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

For the purpose of calculating diluted earnings per equity share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

(o) Segment reporting

Identification of reportable segments

Segments are identified in line with AS-17 "Segment Reporting", taking into consideration the internal organization and management structure as well as the different risk and returns of the segment.

Based on the company's business model, pharmaceuticals have been considered as the only reportable business segment and hence no separate financial disclosures provided in respect of its single business segment.

(p) Contingent Liabilities

A contingent liability is possible obligation that arises from past events whose existence will be confirmed by the occurrence or non occurrence of one or more uncertain future events beyond the control of Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize the contingent liability but discloses its existence in the financial statements.

(q) Cash flows

Cash flows are reported using indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities are segregated.

Cash and cash equivalents: Cash and cash equivalents, in the statement of cash flow, comprise cash at bank and in hand and fixed deposits with original maturity of maximum 90 days.



28
4



AURO PEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

3. SHARE CAPITAL

	As at 31st Mar, 2015	As at 31st Mar, 2014
Authorised		
100,000 (March 31, 2014: 100,000) equity shares of Rs.10/- each	1,000,000	1,000,000
6,000,000 (March 31, 2014 : 0) preference shares of Rs.100/- each	600,000,000	-
	<u>601,000,000</u>	<u>1,000,000</u>
Issued, Subscribed and Fully Paid-up		
100,000 (March 31, 2014: 100,000) Equity shares of Rs.10/- each	1,000,000	1,000,000
5,000,000 (March 31, 2014 : 0) 9.5% Cumulative Redeemable Preference shares of Rs.100/- each	500,000,000	-
TOTAL	<u>501,000,000</u>	<u>1,000,000</u>

a. Reconciliation of the shares outstanding at the beginning and at the end of the Reporting period:

	As at 31st Mar, 2015		As at 31st Mar, 2014	
	No. of shares	Value	No. of shares	Value
Equity shares				
At the beginning of the year	100,000	1,000,000	100,000	1,000,000
Issued during the year	-	-	-	-
Outstanding at the end of the year	<u>100,000</u>	<u>1,000,000</u>	<u>-</u>	<u>-</u>
	As at 31st Mar, 2015		As at 31st Mar, 2014	
	No. of shares	Value	No. of shares	Value
9.5% Cumulative Redeemable Preference shares				
At the beginning of the year	-	-	-	-
Issued during the year	5,000,000	500,000,000	-	-
Outstanding at the end of the year	<u>5,000,000</u>	<u>500,000,000</u>	<u>-</u>	<u>-</u>

b (i). Terms/Rights attached to Equity Shares

The Company has only one class of Equity shares having a par value of Rs.10/- per share . Each holder of Equity Shares is entitled to one vote per share.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholder.



28/3/15

28/3/15



AURO PEPTIDES LIMITED
NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

b(ii). Terms/Rights attached to Preference Shares:

The Company has only one class of Preference shares having a par value of Rs.100/- per share .

Preferences shareholders will be paid dividend @ 9.5% p.a. on a cumulative basis and carry a preferential right vis-à-vis Equity Shares of the Company with respect to payment of dividend or repayment of capital in case of a winding up.

The Cumulative Redeemable Preference Shares shall be redeemable at par not later than five years from the date of allotment and company has option to redeem at any time after 2 years from the date of allotment. These class of shares need to be compulsorily redeemed but shall not be convertible and are non-participating in the surplus funds and carry voting rights as per the provisions of Section 47(2) of the Act.

c. Shares held by holding company

	As at 31st Mar, 2015		As at 31st Mar, 2014	
	No. of shares	Value	No. of shares	Value
Aurobindo Pharma Ltd , the holding company				
Equity shares of Rs.10/- each	95,000	950,000	95,000	950,000
9.5% Cumulative Redeemable Preference shares of Rs.100/- each	5,000,000	500,000,000	-	-
	5,095,000	500,950,000	95,000	950,000

d. Details of shareholders holding more than 5% shares in the company

	As at 31st Mar, 2015		As at 31st Mar, 2014	
	No. of Shares	% of holding in the class	No. of Shares	% of holding in the class
Equity shares of Rs. 10/- each				
Aurobindo Pharma Ltd , holding company	95,000	95%	95,000	95%
Dr.A. Nagana Goud	5,000	5%	5,000	5%
	100,000	100%	100,000	100%
9.5% Cumulative Redeemable Preference shares of Rs.100/- each				
Aurobindo Pharma Ltd , holding company	5,000,000	100%	-	-
	5,000,000	100%	-	-


4. RESERVES AND SURPLUS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Surplus/(Deficit) in the Statement of Profit&Loss		
As per last financial statements	-	-
Add: Profit/(Loss) for the year	(61,458,449)	-
TOTAL	(61,458,449)	-



Handwritten signature

Handwritten signature



AURO PEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

5. LONG-TERM BORROWINGS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Intercompany Loans from related parties Aurobindo Pharma Ltd, Holding Co.	-	288,000,000
TOTAL	-	288,000,000

Terms :

The Intercompany loan which was unsecured carrying an interest rate of 9.5% p.a was fully repaid during current financial year.

6. PROVISIONS

	Non Current		Current	
	As at 31st Mar, 2015	As at 31st Mar, 2014	As at 31st Mar, 2015	As at 31st Mar, 2014
For employee benefits				
-Gratuity (Refer Note no.31(b))	467,564	-	-	-
-Leave Encashment (Refer Note no. 31 (c))	87,130	-	27,226	-
Other Provisions				
Provision for Income tax(net)	-	-	-	31,761
TOTAL	554,694	-	27,226	31,761

7. TRADE PAYABLES

	As at 31st Mar, 2015	As at 31st Mar, 2014
Trade Payables for supplies and services	23,728,467	14,317,465
TOTAL	23,728,467	14,317,465

8. OTHER CURRENT LIABILITIES

	As at 31st Mar, 2015	As at 31st Mar, 2014
Creditors for Capital goods	1,639,678	6,225,474
Interest accrued and due	-	5,651,433
Other Payables		
-Statutory Liabilities	1,792,326	1,371,989
-Others	619,639	-
TOTAL	4,051,643	13,248,896



AURO PEPTIDES LIMITED


NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

Note 9 :TANGIBLE ASSETS

Particulars	Freehold Land	Freehold Buildings	Plant & Equipment	Lab Equipments	Electrical equipment	Furniture & fixtures	Vehicles	Office Equipment	Computer	Total
Gross Block										
At 1 April 2013	-	-	-	-	-	-	-	-	-	-
Additions made during the year	-	-	-	-	-	-	-	-	-	-
Disposals/adjustments made during the year	-	-	-	-	-	-	-	-	-	-
At 1 April 2014	-	-	-	-	-	-	-	-	-	-
Additions made during the year	-	43,583,143	177,204,620	71,297,876	13,250,306	7,909,204	2,957,196	2,316,494	4,765,135	323,283,974
Disposals/adjustments made during the year	-	-	-	-	-	-	-	-	-	-
At 31st March 2015	-	43,583,143	177,204,620	71,297,876	13,250,306	7,909,204	2,957,196	2,316,494	4,765,135	323,283,974
Accumulated depreciation										
At 1 April 2013	-	-	-	-	-	-	-	-	-	-
Charge for the year	-	-	-	-	-	-	-	-	-	-
Adjustments or disposals	-	-	-	-	-	-	-	-	-	-
At 1 April 2014	-	-	-	-	-	-	-	-	-	-
Charge for the year	-	1,034,851	12,620,642	4,232,294	628,881	563,395	81,019	330,021	669,994	20,161,097
Adjustments or disposals	-	-	-	-	-	-	-	-	-	-
At 31st March 2015	-	1,034,851	12,620,642	4,232,294	628,881	563,395	81,019	330,021	669,994	20,161,097
Net Block										
At 31 March 2014	-	-	-	-	-	-	-	-	-	-
At 31st March 2015	-	42,548,292	164,583,978	67,065,582	12,621,425	7,345,809	2,876,177	1,986,473	4,095,141	303,122,877

Capital Work in Progress Rs. 37,594,251 (March 31,2014: Rs. 275,254,968)



g

28/3/15

76

826

AURO PEPTIDES LIMITED
NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015
(All amounts are in Indian Rupees except share data and unless otherwise stated)

10. DEFERRED TAX ASSETS (NET)

	As at 31st Mar, 2015	As at 31st Mar, 2014
Deferred tax asset arising on account of timing differences relating to		
Business Loss	23,186,928	-
Unabsorbed Depreciation	33,829,067	-
Employee Benefits	201,391	-
Deferred tax Liability on account of differences in depreciation as per tax books and financial books	26,851,715	-
TOTAL	30,365,671	-

11. LOANS AND ADVANCES

	Non Current		Current	
	As at 31st Mar, 2015	As at 31st Mar, 2014	As at 31st Mar, 2015	As at 31st Mar, 2014
(Unsecured, considered good except stated other wise)				
Capital Advances	6,119,748	39,007	-	-
Trade Deposits	118,150	10,500	-	-
Balance with Statutory/Govt. Authorities	-	17,352,807	25,999,111	559,165
Advances recoverable in cash or kind	-	-	2,141,304	142,962
Satff Loans & Advances	-	-	949,132	-
TOTAL	6,237,898	17,402,314	29,089,547	702,127

12. OTHER NON CURENT ASSETS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Non - Current bank balances (Refer Note.15)	2,922,560	2,610,360
TOTAL	2,922,560	2,610,360

13. INVENTORIES

	As at 31st Mar, 2015	As at 31st Mar, 2014
(Valued at lower of cost or net realisable value)		
Raw materials		
-in stock	20,780,961	5,385,157
-in transit	571,010	-
Packing Materials	511,390	-
Stores ,spares and consumables	3,688,789	5,808,176
Work-in-progress	8,655,573	-
Finished Goods	565,159	-
TOTAL	34,772,882	11,193,333



AURO PEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

14. TRADE RECEIVABLES

	Non Current		Current	
	As at 31st Mar, 2015	As at 31st Mar, 2014	As at 31st Mar, 2015	As at 31st Mar, 2014
Unsecured, considered good except stated otherwise				
Debts outstanding for a period exceeding six months from the date they are due	-	-	-	-
Due from group companies	-	-	-	-
Others	-	-	-	-
Other debts	-	-	-	-
Due from group companies	-	-	1,867,911	-
Others	-	-	281,138	-
TOTAL			2,149,049	-

15. CASH AND BANK BALANCES

	Non Current		Current	
	As at 31st Mar, 2015	As at 31st Mar, 2014	As at 31st Mar, 2015	As at 31st Mar, 2014
Cash and cash equivalents consists of				
Cash on hand			87,969	87,730
Balance with Banks			19,509,850	3,930,466
- Current Accounts				
- Margin Money/ Fixed Deposits*	2,922,560	2,610,360	891,600	5,055,966
	2,922,560	2,610,360	20,489,419	9,074,162
Amount disclosed under non - current assets(Refer Note 12)	(2,922,560)	(2,610,360)	-	-
TOTAL			20,489,419	9,074,162

* Given against bank guarantees & FLC

16. OTHER CURRENT ASSETS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Prepaid Expenses	491,203	220,331
Interest Accrued but not due	331,678	140,527
Other receivables (Considered good)	336,547	-
TOTAL	1,159,427	360,858



2-4

28



AURO PEPTIDES LIMITED
NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015
(All amounts are in Indian Rupces except share data and unless otherwise stated)

17. REVENUE FROM OPERATIONS

	Year ended March 31, 2015	Year ended March 31, 2014
Sales of Products	24,134,531	-
Sale of Services	-	-
Other Operating Income	-	-
Scrap Sales	-	-
Export Incentives	125,115	-
Total	24,259,646	-
Details of Sales of Products		
- Active Pharmaceutical Ingredients	24,134,531	-
- Others	-	-
TOTAL	24,134,531	-

18. OTHER INCOME

	Year ended March 31, 2015	Year ended March 31, 2014
Interest Income on		
Bank Deposits	435,246	-
Others Advances and deposits	8,800	-
Exchange Fluctuation Gain (Net)	517,410	-
TOTAL	961,456	-

19. COST OF MATERIALS CONSUMED

	Year ended March 31, 2015	Year ended March 31, 2014
Raw Materials consumed		
Opening Stock:	4,924,902	-
Purchases	27,674,793	-
	32,599,695	-
Less: Closing Stock	21,351,971	-
Cost of Materials Consumed	11,247,724	-
Packing Materials consumed		
Opening Stock:	460,255	-
Purchases	383,802	-
	844,057	-
Less: Closing Stock	511,390	-
Packing Materials consumed	332,667	-
TOTAL	11,580,391	-
Details of Cost of Materials Consumed		
Material Name		
Fmoc-Cys-(Trityl) [CAS NO. 103213-32-7]	1,442,607	-
Dithiothretol [CAS No. 3483-12-3]	1,310,701	-
Others	8,827,083	-
TOTAL	11,580,391	-



Handwritten signature and number 981.



AURO PEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

20. (INCREASE)/DECREASE IN WORK IN PROGRESS & FINISHED GOODS


	Year ended March 31, 2015	Year ended March 31, 2014
Inventories at the end of the year		
Finished Goods	565,159	-
Work in Progress	8,655,573	-
	9,220,732	-
Inventories at the beginning of the year		
Finished Goods	-	-
Work in Progress	-	-
	-	-
TOTAL	(9,220,732)	

21. EMPLOYEE BENEFIT EXPENSES

	Year ended March 31, 2015	Year ended March 31, 2014
Salaries, Wages & Bonus	21,098,468	-
Contribution to Provident Fund & Other Funds	542,849	-
Gratuity & Leave Encashment (Refer Note. 31)	581,920	-
Staff Welfare Expenses	483,507	-
TOTAL	22,706,744	-

22. OTHER EXPENSES

	Year ended March 31, 2015	Year ended March 31, 2014
Consumption of Stores & Spares	8,860,292	-
Chemicals consumed	1,411,488	-
Power & Fuel	17,222,030	-
Carriage Inward	719,433	-
Factory maintenance	2,134,861	-
Water Charges	215,967	-
(Increase)/Decrease of excise duty on inventory (Refer Note.33)	58,468	-
Repairs and Maintenance		-
- Plant & Machinery	933,175	-
- Others	55,359	-
Rent	3,846,556	-
Rates and taxes	5,500	-
Printing and Stationery	507,570	-
Postage and Telephones	94,304	-
Insurance	223,131	-
Legal and Professional Charges	31,850	-
Remuneration to Statutory Auditor	35,000	-
Carriage outward	226,219	-
Travelling and conveyance	1,891,314	-
Analytical charges	16,000	-
Registration, Membership & Filing fees	5,545,594	-
Office Maintenance	221,354	-
TOTAL	44,255,464	-



AURO PEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

23. FINANCE COSTS

	Year ended March 31, 2015	Year ended March 31, 2014
Interest	25,881,841	-
Bank charges	97,744	-
TOTAL	25,979,585	-

24. EARNING PER EQUITY SHARE

Particulars	As at 31st Mar, 2015	As at 31st Mar, 2014
Profit/(Loss) after taxation considered for calculation of basic and diluted earning per share	(61,458,449)	-
Weighted average number of equity shares considered for calculation of basic earnings per share	100,000	100,000
Basic and Diluted Earning Per Share	(615)	-

25. CAPITAL AND OTHER COMMITMENTS

Estimated amount of contracts (net of advances) remaining to be executed on capital account and not provided for Rs.27,924,356 (March 31,2014: Rs.9,304,115)

26. CONTINGENT LIABILITIES

	Year ended March 31, 2015	Year ended March 31, 2014
Outstanding Bank Guarantees	2,922,560	2,610,360
TOTAL	2,922,560	2,610,360


27. IMPORTED AND INDIGENOUS RAW MATERIALS, STORES AND SPARES CONSUMED (EXCLUDING EXPENSES INCURRED DURING CONSTRUCTION PERIOD)

	Year ended March 31, 2015	Year ended March 31, 2014
Raw Materials and Packing Material		
- Imported	7,213,401	-
- Indigenous	4,034,323	-
TOTAL	11,247,724	-
Stores and Spares		
- Imported	3,002,847	-
- Indigenous	5,857,445	-
TOTAL	8,860,292	-



4

983



AURO PEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

28. REMUNERATION TO STATUTORY AUDITORS

	As at 31st Mar, 2015	As at 31st Mar, 2014
As auditors		
Statutory audit	35,000	16,854
TOTAL	35,000	16,854

29. EXPENDITURE DURING CONSTRUCTION PERIOD :

	As at 31st Mar, 2015	As at 31st Mar, 2014
Preliminary expenses	25,670	25,670
Pre-Operative Expenses		
Opening balance	55,088,802	7,495,959
Add: Incurred during the year		
Salaries, wages & Other Benefits to Employees	7,109,393	10,686,788
Staff Welfare Expenses	65,764	164,828
Employer contribution to PF	123,582	-
Lab Chemicals	1,626,945	1,458,510
Repairs & Maintenance - Others	124,350	22,614
Power Charges	7,241,775	6,269,973
Carriage Inwards	36,564	64,736
Factory Maintenance	680,859	1,511,390
Rent	1,502,466	600,000
Lease Rentals	1,630,340	5,141,391
Rates and Taxes	38,795	105,675
Printing and Stationery	69,009	329,456
Telephone Charges	17,733	109,092
Insurance		273,074
Professional Charges	35,202	32,891
Remuneration to auditors		16,854
Registration and filing fees	74,995	111,735
Travelling and conveyance	652,189	1,621,352
Membership & Subscription	-	36,179
Office Maintenance	232,646	131,972
Miscellaneous expenses	313,341	28,333
Interest paid	8,463,484	18,811,957
Bank charges	170,522	169,050
	85,324,426	55,219,479
Less: Interest on Deposits	-	151,964
Provision for Taxation	-	(46,957)
Total	85,324,426	55,114,472
Less: Pre-Operative Expenses capitalised to Fixed assets during the year	85,324,426	-
Balance Carried forward	-	55,114,472



AURO PEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)



30. RELATED PARTY DISCLOSURES

Names of related parties and description of relationship

Names	Nature of relationship
Aurobindo Pharma Limited	Holding company
Mr.K.Nityananda Reddy, Director	Key management personnel
Mr.N.Govindarajan, Director	Key management personnel
Mr. P.Sarath Chandra Reddy, Director	Key management personnel
All Pharma (Shanghai) Trading Co.,Ltd	Fellow subsidiary
Eugia Pharma Specialities Limited	Fellow subsidiary
Aurobindo Pharma Usa., Inc	Fellow subsidiary
Trident Chemphar Limited, India	Enterprises where key managerial personnel exercise significant influence

Transaction with related parties

Particulars	Year ended March 31, 2015	Year ended March 31, 2014
a. Transactions with holding company		
Aurobindo Pharma Limited, India		
Preference shares allotment	500,000,000	-
Lease rentals Paid	5,398,456	5,141,391
Power Charges Paid	24,356,322	6,377,456
Purchase of raw materials	4,136,252	4,932,807
Purchase of capital goods	-	469,758
Unsecured loan received	174,100,000	288,000,000
Unsecured loan repaid	462,100,000	-
Reimbursement of expenses	624,134	23,119
Sales of capital goods	146,796	-
Sale of goods	14,609,535	-
Interest on Unsecured loans	34,338,986	18,795,296
Balance payable	10,707,835	305,072,407
b. Transactions with fellow subsidiary		
Eugia Pharma Specialities Limited, India		
Sales of capital goods	146,796	-
Balance receivable	146,796	-
Aurobindo Pharma Usa., Inc, U.S.A.		
Sale of goods	3,199,500	-
Balance receivable	-	-
All Pharma (Shanghai) Trading Co.,Ltd, China		
Purchase of materials	507,970	-
Balance payable	49,803	-
c. Transactions with enterprises over which key management personnel or their relative exercise significant influence		
Trident Chemphar Limited, India		
Purchase of raw materials	506,416	-
Balance payable	405,132	-



AURO PEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

31. EMPLOYEE BENEFITS

	Year ended March 31, 2015	Year ended March 31, 2014
a Disclosures related to defined contribution plan		
Provident fund contribution recognized as expense in the statement of Profit and Loss	492,338	-

b Disclosures related to defined benefit plan -Gratuity

The Company has a defined gratuity plan. Every employee who has completed five years or more of service gets a gratuity on departure at 15 days last drawn salary for each completed year of service

Statement of Profit and Loss

	Year ended March 31, 2015	Year ended March 31, 2014
Current Service Cost	64,316	-
Interest Cost on benefit obligation	-	-
Expected return on plan assets	-	-
Net Actuarial (gain)/Loss recognized in the year	403,248	-
Net Benefit expense	467,564	-
Actual return on plan assets	-	-

Balance Sheet

	As at 31st Mar, 2015	As at 31st Mar, 2014
Details of provision for Gratuity		
Defined benefit obligation	467,564	-

Change in the present value of the defined benefit obligation are as follows

	Year ended March 31, 2015	Year ended March 31, 2014
Opening defined benefit obligation	-	-
Interest cost	-	-
Current services cost	64,316	-
Benefits paid	-	-
Actuarial (gains)/losses on obligation	403,248	-
Closing defined benefit obligation	467,564	-

The principal assumptions used in determining gratuity obligations for the Company's plans are shown below:

	As at 31st Mar, 2015	As at 31st Mar, 2014
Discount rate (p.a) (%)	8	-
Salary Rise (%)	4	-
Attrition Rate (%)	5	-
Av Balance Service	27.60 Years	-

The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotions and other relevant factors such as supply and demand in the employment market. The Company evaluates these assumptions annually based on its long term plans of growth and industry standards.



AURO PEPTIDES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

C Disclosures related to defined benefit plan -Leave Encashment

Statement of Profit and Loss

	Year ended March 31, 2015	Year ended March 31, 2014
Current Service Cost	34,078	-
Interest Cost on benefit obligation	-	-
Expected return on plan assets	-	-
Net Actuarial (gain)/ Loss recognized in the year	80,278	-
Net Benefit expense	114,356	-
Actual return on plan assets	-	-

Balance Sheet

	As at 31st Mar, 2015	As at 31st Mar, 2014
Details of provision for Leave encashment		
Defined benefit obligation	114,356	-

Change in the present value of the defined benefit obligation are as follows

	Year ended March 31, 2015	Year ended March 31, 2014
Opening defined benefit obligation	-	-
Interest cost	-	-
Current services cost	34,078	-
Benefits paid	-	-
Actuarial (gains)/losses on obligation	80,278	-
Closing defined benefit obligation	114,356	-

The principal assumptions used in determining leave encashment obligations for the Company's plans are shown below:


	As at 31st Mar, 2015	As at 31st Mar, 2014
Discount rate (p.a) (%)	8	-
Salary Rise (%)	4	-
Attrition Rate (%)	5	-

The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotions and other relevant factors such as supply and demand in the employment market. The Company evaluates these assumptions annually based on its long term plans of growth and industry standards.

32. LEASES

The company has entered into Operating lease with Aurobindo Phrama Limited for Factory premises with no restrictions and are renewable/cancellable at the option of either of the parties. There is an escalation of 5% over the previous year rent after completion of each year. There are no sub-leases. The aggregate amount of operating lease payments recognized in the the Statement of Profit and Loss is Rs.5,398,456 (March 31,2014- Rs.5,141,391)

33. In accordance with paragraph 10 of Notified Accounting Standard 9 on Revenue Recognition, excise duty on sales amounting to Rs.1,582,764 (March 31, 2014: Rs. 0) has been reduced from sales in Statement of Profit and Loss and excise duty on (increase)/decrease in closing stock of finished goods amounting to Rs. 58,468 (March 31,2014-Rs.0)has been debited to the Statement of Profit and Loss.



AURO PEPTIDES LIMITED

CIN- U24232TG2012PLC078350

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

34. VALUE OF IMPORTS CALCULATED ON CIF BASIS

	Year ended March 31, 2015	Year ended March 31, 2014
Raw materials and Packing materials	19,968,675	-
Capital Goods	20,324,736	70,482,512
Stores and spares, lab chemicals and other consumables	11,812,716	-
TOTAL	52,106,127	70,482,512

35. EXPENDITURE IN FOREIGN CURRENCY (ACCRUAL BASIS)

	Year ended March 31, 2015	Year ended March 31, 2014
Travelling and Conveyance	669,384	209,483
Membership & Subscriptions	-	26,136
TOTAL	669,384	235,619

36. EARNINGS IN FOREIGN CURRENCY (ACCRUAL BASIS)

	Year ended March 31, 2015	Year ended March 31, 2014
Exports on F.O.B. basis	9,680,846	-
TOTAL	9,680,846	-

37. DISCLOSURE REGARDING DERIVATIVE FINANCIAL INSTRUMENTS

Particulars of unhedged foreign currency exposure are detailed below at the exchange rate prevailing as at the Balance Sheet date:

	As at 31st Mar, 2015	As at 31st Mar, 2014
Trade receivables	-	-
Trade payables (including creditors for capital goods)	(2,142,500)	(1,180,975)
Advances to Creditors	8,341,474	-

38. There are no dues to micro, small and medium size companies to which the company owe amount outstanding more than 30 days

39. The figures of previous year have been regrouped/rearranged, wherever necessary to conform to those of the current year.


As per our report of even date.


For G.PAVAN KUMAR & ASSOCIATES

Chartered Accountants

ICAI Firm Registration Number: 015343S


G PAVAN KUMAR REDDY

 Proprietor
 Membership No.229495
 Hyderabad,
For and on behalf of the Board of Directors of
Auro Peptides Limited

K. NITYANANDA REDDY
 Director
 DIN No.01284195


N.GOVINDARAJAN
 Director
 DIN No.-00050482


AUROBINDO ANTIBIOTICS LIMITED

CIN: U24232TG2012PLC081892

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

DIRECTORS' REPORT

Dear Members,

Your Directors are pleased to present the Third Annual Report of the Company together with the Audited Accounts for the year ended 31st March, 2015

Review of Operations:

The Company is yet to start its commercial operations

Dividend

No dividend has been declared, as the company is yet to start commercial operations.

Reserves

No amount has been carried to General Reserves during the year 2014-15

Details of Subsidiary/Joint Ventures/Associate Companies

The Company has no Subsidiaries / Joint Venture / Associate Companies as on 31st March, 2015.

Deposits

The Company has not accepted any public deposits and as such, no amount on account of principal or interest on public deposits was outstanding as on the date of the balance sheet.

Statutory Auditors

M/s. G Pavan Kumar & Associates, Chartered Accountants, Hyderabad have been appointed as Statutory Auditors of the Company at the 2nd Annual General Meeting held on 25th August, 2014 for a period of 5 years subject to ratification by the members at every Annual General Meeting (i.e. till 7th Annual General Meeting). Your Directors commend for the ratification of their appointment.

Share Capital

During the year there is no further issue of shares.

Extract of the Annual Return

In accordance with Section 134(3)(a) of the Companies Act, 2013 the extract of Annual Return (Form MGT-9) of the Company is enclosed as **Annexure – I** to the Boards Report.

AUROBINDO ANTIBIOTICS LIMITED

CIN: U24232TG2012PLC081892

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Material changes and commitments, if any.

There are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

Conservation of energy, technology absorption and foreign exchange earnings and outgo

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014, is not applicable to the Company for the year 2014-15. There are no foreign exchange earnings and outgo during the year.

Directors:

As per the provisions of the Companies Act, 2013 Mr. N Govindarajan will retire in the ensuing Annual General Meeting and being eligible, seek re-appointment. The Board of Directors recommends his re-appointment.

Changes in Directors and Key Managerial Personnel:

During the year Mr. M. Madan Mohan Reddy (DIN:01284266) has been appointed as an Additional Director of the Company w.e.f. 30th March, 2015. He hold office upto the date of the ensuing Annual General Meeting. The Company has received notice in writing under the provisions of Section 160 of the Companies Act, 2013, proposing the candidature of Mr. M. Madan Mohan Reddy for the office of Director.

Mr. Sarath Chandra Reddy (DIN: 01608013) was resigned from the Board as Director of the Company w.e.f 30th March, 2015.

Number of meetings of the Board of Directors:

During the financial year 2014-15 the Board of Directors has met five times viz., on 09.05.2014, 18.07.2014, 20.10.2014, 30.01.2015 and 30.03.2015.

Particulars of loans, guarantees or investments under section 186:

No loans, Guarantees or investment made by the company during the year 2014-15.

Particulars of contracts or arrangements with related parties:

Related party transactions that were entered during the financial year were on an arm's length basis and were in the ordinary course of business. There were no materially significant related party transactions which could have had a potential conflict with the interests of the Company.

AUROBINDO ANTIBIOTICS LIMITED

CIN: U24232TG2012PLC081892

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340'

Particulars of Employees

There are no employees whose information as required under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

Policy on Sexual Harassment

The Company has adopted policy on Prevention of Sexual Harassment of Women at Workplace in accordance with The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. During the financial year ended March 31, 2015, the Company has not received any Complaints pertaining to Sexual Harassment.

Business Risk Management

At present the company has not identified any element of risk which may threaten the existence of the Company.

Directors' Responsibility Statement

Pursuant to Section 134(5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

(a) in the preparation of the annual accounts for the year ended 31st March, 2015, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) the directors had prepared the annual accounts on a going concern basis; and

(e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and are operating effectively.

(f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and are operating effectively.

AUROBINDO ANTIBIOTICS LIMITED

CIN: U24232TG2012PLC081892

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Acknowledgements

Your Company will always keep interest of its customers, employees and the stakeholders as a priority and shall reciprocate their confidence reposed in the Company. It has been a mutually beneficial relationship and looks forward to their continued support.

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015


K. Nityananda Reddy
Director
DIN: 01284195


N. Govindarajan
Director
DIN: 00050482

ANNEXURE - I

Form No. MGT-9
EXTRACT OF ANNUAL RETURN
as on the financial year ended on 31.03.2015

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:		
i	CIN	U24232TG2012PLC081892
ii	Registration Date	10.07.2012
iii	Name of the Company	Aurobindo Antibiotics Limited
iv	Category / Sub-Category of the Company	Company Limited by Shares/Public Limited Company
v	Address of the Registered office and contact details	Plot No. 2, Maitrivihar, Ameerpet, Hyderabad – 500 038, Telangana Ph. No : 040 – 2373 6370 Fax No :040 - 2374 7340
vi	Whether listed company	No
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10% or more of the total turnover of the company shall be stated:-

The Company is yet to start Commercial operations.

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
	NA	NA	NA

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S.No	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ASSOCIATE	% of shares held	Applicable Section
1	Aurobindo Pharma Limited Regd Off: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500038, Telangana	L24239TG1986PLC015190	HOLDING	100	2(46)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change During the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual /HUF	0	0	0	0	0	0	0	0	0
b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt (s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	49400	49400	100.00	0	49400	49400	100.00	0
e) Banks / FI									
f) Any Other (Nominees of holding Company)	0	600	600	0		600	600	0	0

b) Individuals	0	0	0	0	0	0	0	0	0
i) Individual shareholders holding nominal share capital upto Rs1 lakh	0	0	0	0	0	0	0	0	0
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	0	0	0	0	0	0	0	0	0
c) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	0	0	0	0	0	0	0	0
Total Public Shareholding (B)=(B)(1)+ (B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	50000	50000	100.00	0	50000	50000	100.00	0

ii) Shareholding of Promoters

Sl No	Shareholder's Name	Shareholding at the beginning of the year			Share holding at the end of the year			
		No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	
								% change In share Holding during the year

1	Aurobindo Pharma Ltd (APL)	49400	100	0	4900	100	0	0
2	K Nityananda Reddy (Nominee of APL)	100	0	0	100	0	0	0
3	N Govindarajan (Nominee of APL)	100	0	0	100	0	0	0
4	P Sarath Chandra Reddy (Nominee of APL)	100	0	0	100	0	0	0
5	M Venkat Reddy (Nominee of APL)	100	0	0	100	0	0	0
6	A Mohan Rami Reddy (Nominee of APL)	100	0	0	100	0	0	0
7	T S Sankara Reddy (Nominee of APL)	100	0	0	100	0	0	0
	Total	50000	100	0	50000	100	0	0

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl.No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	At the beginning of the year	NIL			
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus/ sweat equity etc):				
	At the End of the year				

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	For Each of the Top 10 Shareholders				
	At the beginning of the year				
	Date wise Increase /Decrease in Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus / sweat equity etc):	NIL			
	At the End of the year (or on the date of separation, if separated during the year)	NIL			

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total Shares of the company
	For Each of the Directors and KMP				
	At the beginning of the year				
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc):	NIL			
	At the End of the year	NIL			

V. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil
Change in Indebtedness during the financial year	Nil	Nil	Nil	Nil
• Addition	Nil	Nil	Nil	Nil
• Reduction	Nil	Nil	Nil	Nil
Indebtedness at the end of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl. no.	Particulars of Remuneration	Name of MD/WTD/ Manager	Total Amount

1	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	NIL	

	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	
2	Stock Option	NIL
3	Sweat Equity	NIL
4	Commission - as % of profit - others, specify...	NIL
5	Others, please specify	NIL
	Total (A)	NIL
	Ceiling as per the Act	NIL
		NIL

B. Remuneration to other directors:

Sl.no.	Particulars of Remuneration	Name of Directors	Total Amount
		---	---
	Independent Directors • Fee for attending board / committee meetings • Commission • Others, please specify		NIL
	Total (1)		NIL
	Other Non-Executive Directors • Fee for attending board / committee meetings • Commission • Others, please specify		NIL
	Total (2)		NIL
	Total (B)=(1+2)		NIL
	Total Managerial Remuneration		NIL
	Overall Ceiling as per the Act		NIL

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD:

Sl.no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Incometax Act, 1961	N.A.			
2.	Stock Option	N.A.			
3.	Sweat Equity	N.A.			
4.	Commission - as % of profit - others, specify...	N.A.			
5.	Others, please specify	N.A.			
	Total	N.A.			

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty /Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give details)
A. Company					
Penalty			NIL		
Punishment					
Compounding					
B. Directors					
Penalty			NIL		
Punishment					
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty			NIL		
Punishment					
Compounding					



INDEPENDENT AUDITOR'S REPORT

To the Members of
Aurobindo Antibiotics Limited.

Report on the Financial Statements

We have audited the accompanying financial statements of M/s Aurobindo Antibiotics Limited ("the Company"), which comprise the Balance sheet as at March 31, 2015, the Statement of Profit and Loss and Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedure to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the Assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion


In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- a. In the case of the Balance Sheet, of the state of affairs of the Company as at March 31,2015;
- b. In the case of the Statement of Profit and Loss, of the loss for the year ended on that date; and
- c. In case of the Cash Flow Statement, of the cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

- 1) As required by the Companies (Auditor's Report) Order, 2015 ("the order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure a statement on the matters section in paragraphs 3 and 4 of the Order.
- 2) As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to best of our knowledge and belief were necessary for the purpose of our audit;
 - b. In our opinion proper books of account as required by law have been kept by the company so far as appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the Balance Sheet, Statement of Profit and Loss and Cash Flow Statement comply with the Accounting Standards notified under Section 133 of the Companies Act,2013, read with the Rule 7 of the Companies (Accounts) Rules2014;
 - e. On the basis of written representations received from the directors as on March 31,2015,and taken on record by the Board of Directors, none of the directors is disqualified as on March 31,2015,from being appointed as a director In terms of sub-section (2) of section 164 of the Companies Act,2013.
 - f. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts in respect of which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants



G Pavan Kumar Reddy)
Proprietor
M.No.229495

Place: Hyderabad
Date:

ANNEXURE TO AUDITORS REPORT
(Referred to in paragraph 3 & 4 of our report of even date)


- i. The Company has no fixed assets as on the balance sheet date
- ii. The Company has no inventory as on the balance sheet date
- iii. According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to Companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the provisions of clauses 3 (iii) (a), 3 (iii) (b) of the Companies (Auditor's Report) Order 2015 are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the company and the nature of its business, for the purchase of inventory and fixed assets and for the sale of goods and services. During the course of our audit, we have not observed any major weakness or continuing failure to correct any major weakness in the internal control system of the Company in respect of these areas.
- v. The Company has not accepted any deposits. Accordingly, the provisions of clause 3(v) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- vi. The company was started not commenced any commercial operations, maintenance of cost records under section 148(1) of the Companies Act, 2013 was not applicable.
- vii.
 - a) The company is regular in depositing with the appropriate authorities undisputed statutory dues including provident fund, employees' state insurance, income tax, sales - tax, wealth tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues applicable to it.
 - b) According to the information and explanations given to us, no undisputed amounts payable in respect of income tax, sale tax, wealth tax, service tax, customs duty, excise duty, value added tax or cess and other material statutory dues, at the yearend, for a period of more than six months from the date they became payable.
 - c) According to the information and explanations given to us, the company does not have any amount in the account to transfer investor education and protection fund in accordance with the relevant provisions of the Companies Act, 1956 and rules made there under.
- viii. The provision of clause 3(viii) of the Order is not applicable, since the incorporation of the company is less than five years



- ix. In our opinion, According to the information and explanations given to us, the Company has not accepted any loans from the financial institutions and banks. Accordingly, the provisions of clause 3(ix) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- x. In our opinion, according to the information and explanations given to us, the company has not given any guarantees for loans taken by others from banks or the financial institutions. Accordingly, the provisions of clause 3(x) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xi. According to the information and explanations given to us, the company has not accepted any term loans during the year. Accordingly, the provisions of clause 3(xi) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xii. Based upon the audit procedures performed for the purpose of reporting the true and fair view of financial statements and as per the information and explanations given by the management, we report that no fraud on or by the company was noticed or reported during the course of our audit.

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants

Place: Hyderabad
Date:



AUROBINDO ANTIBIOTICS LIMITED

PLOT.NO.2, MAITHRI VIHAR,AMEERPET, HYDERABAD 500 038

CIN:U24232TG2012PLC081892

BALANCE SHEET AS AT 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

PARTICULARS	Note No.	As at 31 March, 2015	As at 31 March, 2014
I. EQUITY AND LIABILITIES			
(1) Shareholders Funds			
(a) Share Capital	3	500,000	500,000
(b) Reserves and Surplus	4	(82,976)	-
		417,024	500,000
(2) Current Liabilities			
(a) Other Current Liabilities	5	10,000	11,236
		10,000	11,236
		427,024	511,236
II. ASSETS			
(1) Non- Current Assets			
(a) Non current assets	6	-	67,696
			67,696
(2) Current Assets			
(a) Cash & Bank Balances	7	427,024	443,540
		427,024	443,540
		427,024	511,236

Corporate information & Summary of significant accounting policies 1&2

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES

Firm Registration Number:015343S

Chartered Accountants


(G. Pavan Kumar Reddy)


Proprietor

Membership No.229495

Place:Hyderabad


Date: 21-May-2015




(K. Nityanaanda Reddy)


Director

DIN:01284195


(N. Govindarajan)

Director

DIN:00050482



AUROBINDO ANTIBIOTICS LIMITED
PLOT.NO.2, MAITHRI VIHAR,AMEERPET, HYDERABAD 500 038
CIN:U24232TG2012PLC081892

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 MARCH, 2015
(All amounts are in Indian Rupees except share data and unless otherwise stated)


PARTICULARS	Note No.	Year ended 31 March,2015	Year ended 31 March,2014
Income:			
Revenue from operations		-	-
Other Income		-	-
Total Revenue		-	-
Expenses:			
Other Expenses	8	82,976	-
Total Expenses		82,976	-
Profit before tax		(82,976)	-
Tax Expense:			
Current Tax		-	-
Deferred Tax (charge)/Credit		-	-
Profit / (Loss)for the year		(82,976)	-
Earning per equity share:	9		
Basic & Diluted		(0.17)	-
Nominal Value per Equity Share		10.00	10.00

Corporate Information & Significant accounting policies 1&2
The accompanying notes are an integral part of the financial statements.



As per our report of even date

For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES
Firm Registration Number:015343S
Chartered Accountants


(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place;Hyderabad
Date: 21-May-2015




(K. Nityananda Reddy)
Director
DIN:01284195

(N. Govindarajan)
Director
DIN:00050482



AUROBINDO ANTIBIOTICS LIMITED
PLOT.NO.2, MAITHRI VIHAR, AMEERPET, HYDERABAD 500 038
CIN:U24232TG2012PLC081892

Cash flow statement for the year ended 31 March, 2015
(All amounts in Indian Rupees, except for share data or as otherwise stated)

Particulars	Note No	Year ended 31 March, 2015	Year ended 31 March, 2014
1. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before tax		(82,976)	-
Operating Profit before Working Capital Changes		(82,976)	-
Movements in working capital:			
Decrease/(increase) in long-term loans and advances		-	-
Decrease/(increase) in short-term loans and advances		-	-
Decrease/(increase) in other non current assets		67,696	(29,320)
Decrease/(increase) other current assets		-	-
Increase/(decrease) in other current liabilities		(1,236)	-
Cash Generated from Operations		(16,516)	(29,320)
Direct taxes paid (net of refunds)		-	-
Net Cash flow from Operating Activities	(A)	(16,516)	(29,320)
2. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of fixed assets, including CWIP and capital advances		-	-
Investment in subsidiaries		-	-
Net Cash flow used in Investing Activities	(B)	-	-
3. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issuance of share capital/ Application Money		-	-
Net Cash flow from Financing Activities	(C)	-	-
Net Increase/(Decrease) in Cash and Cash Equivalents	(A+B+C)	(16,516)	(29,320)
Cash and Cash Equivalents at the beginning of the year		443,540	472,860
Cash and Cash Equivalents at the end of the year		427,024	443,540

As per our report of even date

For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES
Firm Registration Number:015343S
Chartered Accountants

(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place:Hyderabad
Date: 21-May-2015



(K. Nityananda Reddy)
Director
DIN:01284195

(N. Govindarajan)
Director
DIN:00050482



AUROBINDO ANTIBIOTICS LIMITED

Notes to financial statements for the year ended March 31, 2015

(All amounts in Indian Rupees, except for share data or as otherwise stated)

1. Corporate information

Aurobindo Antibiotics Limited (the Company) is a limited Company domiciled in India and incorporated under the provisions of the Companies Act, 1956. The Company is engaged in the business of pharmaceutical Antibiotics, Chemicals, Intermediates, drugs, formulations, dyestuffs, colours and pigments.

The Company is a subsidiary of Aurobindo Pharma limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.

2. Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). The Company has prepared these financial statements to comply in all material respects with the accounting standards specified under section 133 of the Companies Act, 2013 ("the Act"), read with the Rule 7 of the Companies (Accounts) Rules 2014 (as amended). The financial statements have been prepared on an accrual basis and under the historical cost convention.

The accounting policies adopted in the preparation of financial statements are consistent with those of previous year.

2.1 Summary of significant accounting policies

a. Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

b. Tangible fixed assets

Fixed assets are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price.

Subsequent expenditure related to an item of fixed asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. All other expenses on existing fixed assets, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which such expenses are incurred.

Gains or losses arising from derecognition of fixed assets are measured as the difference between the net disposal proceeds and the carrying amount of the asset and recognized in the statement of profit and loss when the asset is derecognized.


c. Depreciation on tangible fixed assets

Depreciation on fixed assets is calculated on straight line method as per the useful lives prescribed under schedule II of Companies Act 2013.



Handwritten signature and date 28/11/15.

Handwritten signature and date 28/11/15.



d. Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. Intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any. Internally generated intangible assets, excluding capitalized development costs, are not capitalized and expenditure is reflected in the statement of profit and loss in the year in which the expenditure is incurred. All intangible assets are assessed for impairment whenever there is an indication that the intangible asset may be impaired.

Cost of software is amortized on a straight line basis over the stipulated license period and for software without any stipulated license period over six years or estimated useful life whichever is lower. All Intangible assets are amortized on a straight line basis over the estimated useful economic life.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognized.

d. Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.

Income from services rendered by the Company is recognised on accrual basis for services rendered and billed as per the terms of specific contract.

f. Foreign currency transactions

Foreign currency transactions and balances

Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; and non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

Exchange differences

The Company accounts for exchange differences arising on translation of settlement of foreign currency monetary items as below:

1. Exchange differences arising on long-term foreign currency monetary items related to acquisition of a fixed asset are capitalized and depreciated over the remaining useful life of the asset.
2. All other exchange differences are recognised as income or expenses in the period in which they arise.

e. Retirement and other employee benefits

Gratuity or other retirement benefits are not provided because the provisions of Payment of Gratuity Act, 1972 were not applicable

f. Income taxes


Tax expenses comprises of current and deferred tax. Current income tax has been measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961 enacted in India.

Deferred income taxes reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.



4

8



g. Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

h. Provisions

A provision has been recognized in respect of a present obligation as a result of past event i.e. based on the probability of there being an outflow of resources to settle the obligation, in respect of which a reliable estimate can be made. Provisions have not been discounted to its present value and have been determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.


i. Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. The Company does not recognize a contingent liability but discloses its existence in the financial statements.



5/11

2/11



AUROBINDO ANTIBIOTICS LIMITED
PLOT.NO.2, MAITHRI VIHAR,AMEERPET, HYDERABAD 500 038
CIN: U24232TG2012PLC081892

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31,MARCH 2015
(All amounts in Indian Rupees, except for share data or as otherwise stated)

3.SHARE CAPITAL

Authorised Capital:

50,000 (Previous Year: 50,000) Equity Shares of Rs. 10/- each

As at 31 March, 2015	As at 31 March, 2014
500,000	500,000
500,000	500,000

Issued, Subscribed and paid-up Capital

50,000 (Previous Year: 50,000) Equity Shares of Rs.10 / - each, fully paid up

Total Issued, Subscribed and Fully Paid-up shares

As at 31 March, 2015	As at 31 March, 2014
500,000	500,000
500,000	500,000

a. Reconciliation of number of shares:

Equity shares

Balance as at the beginning of year

Add: Shares issued during the year

Balance at the end of the year

As at 31 March, 2015	As at 31 March, 2014
50,000	50,000
-	-
50,000	50,000

b. Shares held by holding company:

Out of equity shares issued by the company, shares held by its holding company are as under:

Aurobindo Pharma Ltd, the holding Company

50,000 (Previous year: 50,000)Equity Shares of Rs.10 / - each, fully paid up

As at 31 March, 2015	As at 31 March, 2014
500,000	500,000
500,000	500,000

c.Terms/rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10 per share. Each holder of Equity shares is entitled to one vote per share.

In the event of liquidation of the company ,the holders of equity shares will be entitled to receive remaining assets of the company after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the share holders.

d. Details of shareholders holding more than 5% of the aggregate shares in the Company:

Name of the Equity shareholder	As at 31 March, 2015		As at 31 March, 2014	
	No. of shares	% of holding	No. of shares	% of holding
M/s Aurobindo Pharma Ltd	50,000	100%	50,000	100%
	50,000	100%	50,000	100%

4. Reserves & Surplus

Surplus/(defecit) in Statement of Profit & Loss:

Balance as per last financial statements

Add:Profit/(loss) during the year


Total

As at 31 March, 2015	As at 31 March, 2014
-	-
(82,976)	-
(82,976)	-

5. Current Liabilities


Other Current Liabilities

As at 31 March, 2015	As at 31 March, 2014
10,000	11,236
10,000	11,236



12 - 9

28



6. Other Non Current assets

Balance brought forward

Add: Incurred during year

Rates & Taxes

Statutory Audit Fee

Legal & Professional Charges

Preliminary Expenses

As at 31 March, 2015	As at 31 March, 2014
-	13,876
-	330
-	11,236
-	17,754
-	24,500
-	67,696

7. Cash and Bank Balances

Cash on hand

Balances with Banks

-Current Accounts

Total

As at 31 March, 2015	As at 31 March, 2014
7,250	2,530
419,774	441,010
427,024	443,540

8. Other Expenses

Preoperative Expenses

Statutory Audit Fee

Registration and filing fee

Preliminary Expenditure

Total

Year ended 31 March, 2015	Year ended 31 March, 2014
43,196	-
10,000	-
5,280	-
24,500	-
82,976	-

9. Earnings per Equity share

Profit/Loss considered for calculation of basic & diluted earnings per share

Weighted average number of equity shares in calculating basic & diluted earnings per

Basic & Diluted Earnings Per share

Face value per Share

Year ended 31 March, 2015	Year ended 31 March, 2014
(82,976)	-
500,000	500,000
(0.17)	-
10	10

10. Related Party Disclosures:

Name of the related parties and description of relationship

Aurobindo Pharma Limited, The Holding Company

Transactions with related parties

1. Aurobindo Pharma Limited, Holding Company

Equity contribution received

Key managerial personnel

K. Nityananda Reddy, Director

N. Govindarajan, Director

M. Madan Mohan Reddy, Director

As at 31 March, 2015	As at 31 March, 2014
-	-


11. Earning in foreign currency (accrual Basis)

12. Foreign exchange outflow

13. FOB value of exports


14. CIF value of exports

-	-
-	-
-	-
-	-



Handwritten signature/initials.

Handwritten signature/initials.



15. Pervious year figures are regrouped, reclassified wherever necessary to confirm with the current year presentations.

16. There are no dues to Micro, Small and Medium size companies to which the company owe amount outstanding morethan 30 days.

17. Contingent Liabilities

As per our report of even date

For G.PAVAN KUMAR & ASSOCIATES
Firm Registration Number:015343S
Chartered Accountants

(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place:Hyderabad
Date: 21-May-2015



For and on behalf of the Board of Directors

(K. Nityananda Reddy)
Director
DIN:01284195

(N. Govindarajan)
Director
DIN:00050482



CUREPRO PARENTERALS LIMITED

CIN: U24232TG2013PLC087101

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

DIRECTORS' REPORT

Dear Members,

Your Directors are pleased to present the Second Annual Report of the Company together with the Audited Accounts for the year ended 31st March, 2015.

Financials summary:

The financial performance of your company for the year ended March 31, 2015 is summarized below:
(in Rs.)

Particulars	2014-15	2013-14
Other Income	2,766,617	231,109
Other Expenses	26,995	1,671,861
Finance cost	46,971	1,447
Profit before tax	2,692,651	557,801
Current Tax	743,276	582,200
Deferred tax Credit / (Charge)	101,960	(409,839)
Profit for the year	1,847,415	385,440

Review of Operations:

The Company is yet to establish the Project..

Dividend

No dividend has been declared for the year 2014-15

Reserves

No amount has been carried to General Reserves for the year 2014-15

Details of Subsidiary/Joint Ventures/Associate Companies

Eugia Pharma Specialties Limited is the only Subsidiary of the Company. The financials of Eugia Pharma Specialties Limited and a statement pursuant to section 129 of the Companies Act, 2013 are annexed to this report.

CUREPRO PARENTERALS LIMITED

CIN: U24232TG2013PLC087101

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Deposits

The Company has not accepted any public deposits and as such, no amount on account of principal or interest on public deposits was outstanding as on the date of the balance sheet.

Statutory Auditors

M/s. G Pavan Kumar & Associates, Chartered Accountants, Hyderabad have been appointed as Statutory Auditors of the Company at the 1st Annual General Meeting held on 25th August, 2014 for a period of 5 years subject to ratification by the members at every Annual General Meeting (i.e. till 6th Annual General Meeting). Your Directors commend for the ratification of their appointment.

Auditors' Report

The observations made in the Auditors' Report read together with relevant notes thereon are self explanatory and hence do not call for any further comments under Section 134 of the Companies Act, 2013.

Share Capital

During the year, your Company has made further issue of 6,00,000 Equity Shares of Rs.10/- each for cash at premium of Rs. 140/- per share to Aurobindo Pharma Limited, the holding company. Consequently, the paid-up equity share capital was increased to Rs. 2,15,00,000.

Extract of the Annual Return

In accordance with Section 134(3)(a) of the Companies Act, 2013 the extract of Annual Return (Form MGT-9) of the Company is enclosed as **Annexure – I** to the Boards Report.

Material changes and commitments, if any.

There are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

Conservation of energy, technology absorption and foreign exchange earnings and outgo

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is not applicable for financial year 2014-15 and there are no foreign exchange earnings during the year

CUREPRO PARENTERALS LIMITED

CIN: U24232TG2013PLC087101

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Business Risk Management

At present the company has not identified any element of risk which may threaten the existence of the Company.

Directors:

As per the provisions of the Companies Act, 2013 Mr. M Madan Mohan Reddy will retire in the ensuing annual general meeting and being eligible, seek re-appointment. The Board of Directors recommends his re-appointment.

Changes in Directors and Key Managerial Personnel:

During the year Dr. M. Sivakumaran (DIN:01284320) has been appointed as an Additional Director w.e.f. 25th June, 2015. He hold office upto the date of the ensuing Annual General Meeting. The Company has received notice in writing under the provisions of Section 160 of the Companies Act, 2013, proposing the candidature for the office of Director.

Mr. Arvind Vasudeva (DIN: 00669039) was resigned from the Board as Director of the Company w.e.f 25th June, 2015.

Number of meetings of the Board of Directors:

During the financial year 2014-15 the Board of Directors has met seven times viz., on 09.05.2014, 18.07.2014, 13.10.2014, 30.12.2014, 30.01.2015, 18.02.2015 and 13.03.2015.

Particulars of loans, guarantees or investments under section 186:

No loans or Guarantees made by the company during the year 2014-15. Details of investments made by the company is attached in **Annexure-II**

Particulars of contracts or arrangements with related parties:

There are no materially significant related party transactions made by the Company with Promoters, Directors, Key Managerial Personnel or other designated persons which may have a potential conflict with the interest of the Company at large.

Particulars of Employees

There are no employees whose information as required to be disclosed under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

CUREPRO PARENTERALS LIMITED

CIN: U24232TG2013PLC087101

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India
Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Policy on Sexual Harassment

The Company has adopted policy on Prevention of Sexual Harassment of Women at Workplace in accordance with The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

During the financial year ended March 31, 2015, the Company has not received any Complaints pertaining to Sexual Harassment.

Directors' Responsibility Statement

Pursuant to Section 134(5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

(a) in the preparation of the annual accounts for the year ended 31st March, 2015, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) the directors had prepared the annual accounts on a going concern basis; and

(e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and are operating effectively.


(f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and are operating effectively.

Acknowledgements

Your Company will always keep interest of its customers, employees and the stakeholders as a priority and shall reciprocate their confidence reposed in the Company. It has been a mutually beneficial relationship and looks forward to their continued support.

For and on behalf of the Board

Place: Hyderabad
Date: 25.06.2015



M Madan Mohan Reddy
Director
DIN: 01284266



P Sarath Chandra Reddy
Director
DIN: 01628013

ANNEXURE-III

Form No. MGT-9 EXTRACT OF ANNUAL RETURN as on the financial year ended on 31.03.2015

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:		
i	CIN	U24232TG2013PLC087101
ii	Registration Date	19.04.2013
iii	Name of the Company	Curepro Parenterals Limited
iv	Category / Sub-Category of the Company	Company Limited by Shares/Public Limited Company
v	Address of the Registered office and contact details	Plot No. 2, Maitrivihar, Ameerpet, Hyderabad – 500 038, Telangana Ph.No: 040 - 66725000 Fax.No:040 -67074059
vi	Whether listed company	No
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

The Company is yet to start Commercial operations.

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
	Nil	Nil	Nil

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S.No	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ASSOCIATE	% of shares held	Applicable Section
1	Aurobindo Pharma Limited Regd Off: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500038, Telangana	L24239TG1986PLC015190	HOLDING	100	2(46)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual /HUF	0	0	0	0	0	0	0	0	0
b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt (s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	1549400	1549400	100.00	0	2149400	2149400	100.00	38.72
e) Banks / FI									
f) Any Other (Nominees)	0	600	600	0		600	600	0	0
Sub-total (A) (1):-	0	1550000	1550000	100.00	0	2150000	2150000	100.00	38.72
(2) Foreign									

shareholders holding nominal share capital upto Rs1 lakh									
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	0	0	0	0	0	0	0	0	0
c) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	0	0	0	0	0	0	0	0
Total Public Shareholding (B)=(B)(1)+(B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	1550000	1550000	100.00	0	2150000	2150000	100.00	38.72

ii) Shareholding of Promoters

SI No	Shareholder's Name	Shareholding at the beginning of the year			Share holding at the end of the year			
		No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	
								% change In share Holding during the year

1	Aurobindo Pharma Ltd (APL)	1549400	100	0	2149400	100	0	38.72
2	K Nityananda Reddy (Nominee of APL)	100	0	0	100	0	0	0
3	N Govindarajan (Nominee of APL)	100	0	0	100	0	0	0
4	P Sarath Chandra Reddy (Nominee of APL)	100	0	0	100	0	0	0
5	A Mohan Rami Reddy (Nominee of APL)	100	0	0	100	0	0	0
6	M Venkat Reddy (Nominee of APL)	100	0	0	100	0	0	0
7	T S Sankara Reddy (Nominee of APL)	100	0	0	100	0	0	0
	Total	1550000	100	0	2150000	100	0	38.72

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl.No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	At the beginning of the year	1549400	100.00		
	Allotment on 30.01.2015	100000		1649400	100.00
	Allotment on 13.03.2015	500000		2149400	100.00
	At the End of the year			2149400	100.00

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	For Each of the Top 10 Shareholders				
	At the beginning of the year	NIL			
	Date wise Increase /Decrease in Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus / sweat equity etc):	NIL			
	At the End of the year (or on the date of separation, if separated during the year)	NIL			

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total Shares of the company
	For Each of the Directors and KMP				
	At the beginning of the year	NIL			
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc):	NIL			
	At the End of the year	NIL			

V. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil
Change in Indebtedness during the financial year	Nil	Nil	Nil	Nil
• Addition	Nil	Nil	Nil	Nil
• Reduction	Nil	Nil	Nil	Nil
Indebtedness at the end of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL**A. Remuneration to Managing Director, Whole-time Directors and/or Manager:**

Sl. no.	Particulars of Remuneration	Name of MD/WTM/ Manager				Total Amount
		----	----	----	----	
1	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act,	NIL				

	1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	
2	Stock Option	NIL
3	Sweat Equity	NIL
4	Commission - as % of profit - others, specify...	NIL
5	Others, please specify	NIL
	Total (A)	NIL
	Ceiling as per the Act	NIL
		NIL

B. Remuneration to other directors:

Sl.no.	Particulars of Remuneration	Name of Directors				Total Amount
		----	----	----	----	
	Independent Directors • Fee for attending board / committee meetings • Commission • Others, please specify	NIL				
	Total (1)	NIL				
	Other Non-Executive Directors • Fee for attending board / committee meetings • Commission • Others, please specify	NIL				
	Total (2)	NIL				
	Total (B)=(1+2)	NIL				

Total Managerial Remuneration	NIL
Overall Ceiling as per the Act	NIL

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD:

Sl.no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Incometax Act, 1961	N.A			
2.	Stock Option	N.A			
3.	Sweat Equity	N.A			
4.	Commission - as % of profit - others, specify...	N.A			
5.	Others, please specify	N.A			
	Total	N.A			

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty /Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give details)
A. Company					
Penalty	NIL				
Punishment					

Compounding	
B. Directors	
Penalty	NIL
Punishment	
Compounding	
C. OTHER OFFICERS IN DEFAULT	
Penalty	NIL
Punishment	
Compounding	

CUREPRO PARENTERALS LIMITED

CIN: U24232TG2013PLC087101

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Annexure-II

Details of Investments:


(in Rupees)


Particulars of Investments	Face Value	Qty	As at 31 March, 2015	As at 31 March, 2014
Investments in Subsidiaries:				
Eugia Pharma Specialties Limited, India	Rs.10	62%(P.Y:60%) of paid in capital	315,000,000	180,000,000
Total			315,000,000	180,000,000

Investment made in Eugia Pharma Specialties Limited during the year is Rs. 135,000,000.

For and on behalf of the Board

Place: Hyderabad
Date: 25.06.2015


M Madan Mohan Reddy
Director
DIN: 01284266


P Sarath Chandra Reddy
Director
DIN: 01628013

CUREPRO PARENTERALS LIMITED

CIN: U24232TG2013PLC087101

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Form AOC-I

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

Part "A": Subsidiaries

(Information in respect of each subsidiary to be presented with amounts in Rs)

- | | |
|--|---------------------------------|
| 1. Name of the subsidiary | : Eugia Pharma Specialities Ltd |
| 2. Reporting period for the subsidiary concerned, if different from the holding company's reporting Period | : Same as Holding Company |
| 3. Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries | : NA |
| 4. Share capital | : Rs. 47,50,00,000 |
| 5. Reserves & surplus | : Rs. (14,46,615) |
| 6. Total assets | : Rs.1,07,48,78,784 |
| 7. Total Liabilities | : Rs. 1,07,48,78,784 |
| 8. Investments | : Rs.Nil |
| 9. Turnover | : Rs.Nil |
| 10. Profit before taxation | : Rs.(20,93,909) |
| 11. Provision for taxation | : Rs.(6,46,894) |
| 12. Profit after taxation | : Rs. (14,46,615) |
| 13. Proposed Dividend | : Rs.Nil |
| 14. % of shareholding | : 66.32% |

Notes: The following information shall be furnished at the end of the statement:

1. Names of subsidiaries which are yet to commence operations
2. Names of subsidiaries which have been liquidated or sold during the year.

CUREPRO PARENTERALS LIMITED

CIN: U24232TG2013PLC087101


Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340


Part "B": Associates and Joint Ventures

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures is **Nil**

For and on behalf of the Board



M Madan Mohan Reddy
Director
DIN: 01284266



P Sarath Chandra Reddy
Director
DIN: 01628013

Place: Hyderabad
Date: 25.06.2015



INDEPENDENT AUDITOR'S REPORT

**To the Members of
Curepro Parenterals Limited.**

Report on the Financial Statements

We have audited the accompanying financial statements of M/s Curepro Parenterals Limited ("the Company"), which comprise the Balance sheet as at March 31, 2015, the Statement of Profit and Loss and Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedure to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the Assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- a. In the case of the Balance Sheet, of the state of affairs of the Company as at March 31,2015;
- b. In the case of the Statement of Profit and Loss, of the profit for the year ended on that date; and
- c. In case of the Cash Flow Statement, of the cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

- 1) As required by the Companies (Auditor's Report) Order, 2015 ("the order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure a statement on the matters section in paragraphs 3 and 4 of the Order.
- 2) As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to best of our knowledge and belief were necessary for the purpose of our audit;
 - b. In our opinion proper books of account as required by law have been kept by the company so far as appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the Balance Sheet, Statement of Profit and Loss and Cash Flow Statement comply with the Accounting Standards notified under Section 133 of the Companies Act,2013, read with the Rule 7 of the Companies (Accounts) Rules,2014;
 - e. On the basis of written representations received from the directors as on March 31,2015, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31,2015, from being appointed as a director in terms of sub-section (2) of section 164 of the Companies Act,2013.
 - f. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts in respect of which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For M/s. G Pavan Kumar & Associates

Firm Registration No: 015343S

Chartered Accountants



G Pavan Kumar Reddy)

Proprietor


M.No.229495

Place: Hyderabad

Date:


ANNEXURE TO AUDITORS REPORT
(Referred to in paragraph 3 & 4 of our report of even date)

- i. The Company has no fixed assets as on the balance sheet date.
- ii. The Company has no inventory as on the balance sheet date
- iii. According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to Companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the provisions of clauses 3 (iii) (a), 3 (iii) (b) of the Companies (Auditor's Report) Order 2015 are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the company and the nature of its business, for the purchase of inventory and fixed assets and for the sale of goods and services. During the course of our audit, we have not observed any major weakness or continuing failure to correct any major weakness in the internal control system of the Company in respect of these areas.
- v. The Company has not accepted any deposits. Accordingly, the provisions of clause 3(v) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- vi. The company was started not commenced any commercial operations, maintenance of cost records under section 148(1) of the Companies Act, 2013 was not applicable.
- vii.
 - a) The company is regular in depositing with the appropriate authorities undisputed statutory dues including provident fund, employees' state insurance, income tax, sales - tax, wealth tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues applicable to it.
 - b) According to the information and explanations given to us, no undisputed amounts payable in respect of income tax, sale tax, wealth tax, service tax, customs duty, excise duty, value added tax or cess and other material statutory dues, at the yearend, for a period of more than six months from the date they became payable.
 - c). According to the information and explanations given to us, the company does not have any amount in the account to transfer investor education and protection fund in accordance with the relevant provisions of the Companies Act, 1956 and rules made there under.
- viii. The provision of clause 3(viii) of the Order is not applicable, since the incorporation of the company is less than five years.



- ix. In our opinion, According to the information and explanations given to us, the Company has not accepted any loans from the financial institutions and banks. Accordingly, the provisions of clause 3(ix) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- x. In our opinion, according to the information and explanations given to us, the company has not given any guarantees for loans taken by others from banks or the financial institutions. Accordingly, the provisions of clause 3(x) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xi. According to the information and explanations given to us, the company has not accepted any term loans during the year. Accordingly, the provisions of clause 3(xi) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xii. Based upon the audit procedures performed for the purpose of reporting the true and fair view of financial statements and as per the information and explanations given by the management, we report that no fraud on or by the company was noticed or reported during the course of our audit.

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants



(G Pavan Kumar Reddy)
Proprietor
M.No.229495

Place: Hyderabad
Date:

CUREPRO PARENTERALS LIMITED

Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038

CIN:U24232TG2013PLC087101

BALANCE SHEET AS AT 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

PARTICULARS	Note No.	As at 31 March, 2015	As at 31 March, 2014
I. EQUITY AND LIABILITIES			
(1) Shareholders Funds			
(a) Share Capital	3	21,500,000	15,500,000
(b) Reserves and Surplus	4	296,232,855	210,385,440
		<u>317,732,855</u>	<u>225,885,440</u>
(3) Current Liabilities			
(a) Other Current Liabilities	5	10,000	11,709
(b) Short term provisions	6	-	359,089
		<u>10,000</u>	<u>370,798</u>
		<u>317,742,855</u>	<u>226,256,238</u>
II. ASSETS			
(1) Non- Current Assets			
(a) Non current investments	7	315,000,000	180,000,000
(b) Deferred Tax Asset (Net)	8	307,879	409,839
		<u>315,307,879</u>	<u>180,409,839</u>
(2) Current Assets			
(a) Cash & Bank Balances	9	2,431,383	45,846,399
(b) Loans and advances	10	3,593	-
		<u>2,434,976</u>	<u>45,846,399</u>
		<u>317,742,855</u>	<u>226,256,238</u>

Corporate information & Summary of significant accounting policies 1&2

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES

Firm Registration Number:015343S

Chartered Accountants

(G.Pavan Kumar Reddy)

Proprietor

Membership No.229495

Place: Hyderabad

Date: 21-May-2015



(M.Madan Mohan Reddy)
Director

DIN NO: 00050482


(Arvind Vasudeva)
Director

DIN NO:00669039

CUREPRO PARENTERALS LIMITED

Plot.No.2, Maithri Vihar, Ameerpet, Hyderabad 500 038

CIN:U24232TG2013PLC087101

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

PARTICULARS	Note No.	Year ended 31 March, 2015	Year ended 31 March, 2014
Income:			
Revenue from operations		-	-
Other Income	11	2,766,617	2,231,109
Total Revenue		2,766,617	2,231,109
Expenses:			
Other Expenses	12	26,995	1,671,861
Finance cost	13	46,971	1,447
Total Expenses		73,966	1,673,308
Profit before tax		2,692,651	557,801
Tax Expense:			
Current Tax		743,276	582,200
Deferred tax Credit / (Charge)		101,960	(409,839)
Profit for the year		1,847,415	385,440
Earning per equity share:	14		
Basic & Diluted		1.16	0.44
Nominal Value per Equity Share		10	10

Corporate Information & Significant accounting policies 1&2

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For G.PAVAN KUMAR & ASSOCIATES

Firm Registration Number:015343S

Chartered Accountants

(G.Pavan Kumar Reddy)

Proprietor

Membership No.229495

Place: Hyderabad

Date: 21-May-2015



For and on behalf of the Board of Directors

(M.Madan Mohan Reddy)

Director

DIN NO: 00050482

(Arvind Vasudeva)

Director

DIN NO:00669039

CUREPRO PARENTERALS LIMITED

Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038

CIN:U24232TG2013PLC087101

Cash flow statement for the year ended 31 March, 2015

(All amounts in Indian Rupees, except for share data or as otherwise stated)

Particulars	Note No	Year ended 31 March,2015	Year ended 31 March,2014
1. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before tax		2,692,651	557,801
Operating Profit before Working Capital Changes		2,692,651	557,801
Movements in working capital:			
Decrease/(increase) in long-term loans and advances		-	-
Decrease/(increase) in short-term loans and advances		(3,593)	-
Decrease/(increase) other current assets		-	-
Increase/(decrease) in other current liabilities		(1,709)	11,709
Cash Generated from Operations		2,687,349	569,510
Direct taxes paid (net of refunds)		(1,102,364)	(223,112)
Net Cash flow from Operating Activities	(A)	1,584,985	346,398
2. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of fixed assets, including CWIP and capital advances		-	-
Investment in subsidiaries including securities premium		(135,000,000)	(180,000,000)
Net Cash flow used in Investing Activities	(B)	(135,000,000)	(180,000,000)
3. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issuance of share capital including security Premium		90,000,000	225,500,000
Net Cash flow from Financing Activities	(C)	90,000,000	225,500,000
Net Increase/(Decrease) in Cash and Cash Equivalents	(A+B+C)	(43,415,015)	45,846,398
Cash and Cash Equivalents at the beginning of the year		45,846,398	-
Cash and Cash Equivalents at the end of the year		2,431,383	45,846,398

As per our report of even date

For G.PAVAN KUMAR & ASSOCIATES

Firm Registration Number:015343S

Chartered Accountants

(G.Pavan Kumar Reddy)

Proprietor

Membership No.229495

Place: Hyderabad

Date: 21-May-2015



For and on behalf of the Board of Directors

(M.Madan Mohan Reddy)

Director

DIN NO: 00050482

(Arvind Vasudeva)

Director

DIN NO:00669039

CUREPRO PARENTERALS LIMITED

Notes to financial statements for the year ended March 31, 2015

(All amounts in Indian Rupees, except for share data or as otherwise stated)

1. Corporate information

Curepro Parenterals Limited (the company) is a limited company domiciled in India and incorporated under provisions of the Companies Act, 1956. The company is engaged in the business of manufacture, prepare, import, export, buy, sell, supply, distribute, store, stock, maintain and otherwise handle, deal in and carry on the business in all kinds and varieties of pharmaceutical drugs, patents and non patent medicines, common medical preparations, drugs, mixtures, elixirs, drops, tonics, other liquid drugs and medicines, formulations, capsules, tablets, pills, powders, medical ointments, chemical, sterilized injections, vaccines, immunogens, phylacogens, chemicals and surgical dressings.

The Company is a subsidiary of Aurobindo Pharma limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.

2. Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). The Company has prepared these financial statements to comply in all material respects with the accounting standards, specified under section 133 of the Companies Act, 2013 ("the Act"), read with the Rule 7 of the Companies (Accounts) Rules 2014 (as amended). The financial statements have been prepared on an accrual basis and under the historical cost convention.

The accounting policies adopted in the preparation of financial statements are consistent with those of previous year.

2.1 Summary of significant accounting policies

a. Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

b. Tangible fixed assets

Fixed assets are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price.

Subsequent expenditure related to an item of fixed asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. All other expenses on existing fixed assets, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which such expenses are incurred.

Gains or losses arising from derecognition of fixed assets are measured as the difference between the net disposal proceeds and the carrying amount of the asset and recognized in the statement of profit and loss when the asset is derecognized.

c. Depreciation on tangible fixed assets

Depreciation on fixed assets is calculated on a straight line method, as per useful lives prescribed under Schedule II to the Companies Act, 2013

d. Investments :

Investments that are readily realizable and intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as long term investments. Current investments are carried at lower of cost and fair value determined on individual investment basis.



A handwritten signature in black ink, consisting of a large, stylized 'G' followed by a horizontal line.

A handwritten signature in black ink, consisting of a large, stylized 'A' followed by a horizontal line.

Long term Investments are carried at cost .However diminution in value is provided to recognize a decline, other than temporary ,in the value of the investments.

e. Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.

Income from services rendered by the Company is recognized on accrual basis for services rendered and billed as per the terms of specific contract.

f. Retirement and other employee benefits

Gratuity or other retirement benefits are not provided because the provisions of Payment of Gratuity Act, 1972 were not applicable.

g. Income taxes

Tax expenses comprises of current and deferred tax. Current income tax has been measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961 enacted in India.

Deferred income taxes reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.

Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred tax assets and deferred tax liabilities relate to the taxes on income levied by same governing taxation laws. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

At each reporting date, the Company re-assesses unrecognized deferred tax assets. It recognizes unrecognized deferred tax asset to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized.

The carrying amount of deferred tax assets are reviewed at each reporting date. The Company writes-down the carrying amount of deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

h. Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

i. Provisions

A provision has been recognized in respect of a present obligation as a result of past event i.e. based on the probability of there being an outflow of resources to settle the obligation, in respect of which a reliable estimate can be made. Provisions have not been discounted to its present value and have been determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.



A handwritten signature in black ink, appearing to be "Dmy".

A handwritten signature in black ink, appearing to be "CJ".

j. Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

k. Cash and Cash Equivalents

Cash and cash equivalents comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.

i. Cash flows

Cash flows are reported using indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities are segregated.

Cash and cash equivalents: Cash and Cash Equivalents, in the statement of cash flow, comprise cash at bank and in hand and fixed deposits with original maturity of maximum 90 days.



A handwritten signature in black ink, appearing to be "P. K. Kumar", written over a diagonal line.

A handwritten signature in black ink, appearing to be "V. S. Kumar", written over a horizontal line.

CUREPRO PARENTERALS LIMITED
Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038
CIN:U24232TG2013PLC087101

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH,2015
(All amounts in Indian Rupees, except for share data or as otherwise stated)

3.SHARE CAPITAL

	As at 31 March, 2015	As at 31 March, 2014
Authorised Capital:		
20,000,000 (Previous Year: 20,000,000) Equity Shares of Rs. 10/- each	200,000,000	200,000,000
Issued, Subscribed and paid-up Capital		
21,50,000 (Previous Year: 15,50,000) Equity Shares of Rs.10 /- each, fully paid up	21,500,000	15,500,000
Total Issued, Subscribed and Fully Paid-up shares	21,500,000	15,500,000

a. Reconciliation of number of shares:

Equity shares	As at 31 March, 2015	As at 31 March, 2014
Balance as at the beginning of year	1,550,000	-
Add: Shares issued during the year	600,000	1,550,000
Balance at the end of the year	2,150,000	1,550,000

b. Shares held by holding company:

Out of equity shares issued by the company, shares held by its holding company are as under:

	As at 31 March, 2015	As at 31 March, 2014
Aurobindo Pharma Ltd, the holding Company		
21,50,000 (Previous year: 15,50,000)Equity Shares of Rs.10 /- each, fully paid up	21,500,000	15,500,000
	21,500,000	15,500,000

c:Terms/rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10 per share. Each holder of equity shares is entitled to one vote per share.

In the event of liquidation of the company ,the holders of equity shares will be entitled to receive remaining assets of the company ,after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the share holders.

d. Details of shareholders holding more than 5% of the aggregate shares in the Company:

Name of the Equity shareholder	As at 31 March, 2015		As at 31 March, 2014	
	No. of shares	% of holding	No. of shares	% of holding
M/s Aurobindo Pharma Ltd	2,150,000	100%	1,550,000	100%
	2,150,000	100%	1,550,000	100%

4. Reserves & Surplus

Securities Premium Account

	As at 31 March, 2015	As at 31 March, 2014
As per last Balance Sheet	210,000,000	-
Add: Premium on Fresh allotment of shares	84,000,000	210,000,000
	294,000,000	210,000,000

Surplus/(deficit) in Statement of Profit & Loss:

	As at 31 March, 2015	As at 31 March, 2014
Balance as per last financial statements	385,440	-
Add: Profit/(loss) during the year	1,847,415	385,440
	2,232,855	385,440
	296,232,855	210,385,440



[Handwritten signature]

[Handwritten signature]

5. Current Liabilities

Other Current Liabilities

As at 31 March, 2015	As at 31 March, 2014
10,000	11,709
10,000	11,709

6. Short Term Provisions

Provision for income Tax (Net)

As at 31 March, 2015	As at 31 March, 2014
-	359,088
-	359,088

7. Non Current Investments

Trade Investments

Long-Term, unquoted, in fully paid equity shares
(at cost unless stated otherwise)

In Subsidiaries

Eugia Pharma Specialties Limited, India

66.32%(P.Y:60%) of paid up capital,Face value Rs.10 Each

As at 31 March, 2015	As at 31 March, 2014
315,000,000	180,000,000
315,000,000	180,000,000

8. Deferred Tax Asset:

Deferred Tax Asset on account of Temporary disallowance

As at 31 March, 2015	As at 31 March, 2014
307,879	409,839
307,879	409,839

9. Cash and Bank Balances

Cash on hand

Balances with Banks

-Current Accounts

-In Deposit accounts

As at 31 March, 2015	As at 31 March, 2014
5,290	7,285
2,426,093	1,839,114
-	44,000,000
2,431,383	45,846,399

10. Short term Loan and advances:

Balances with government authorities

As at 31 March, 2015	As at 31 March, 2014
3,593	-
3,593	-

11. Other Income

Interest Earned

Year ended 31 March, 2015	Year ended 31 March, 2014
2,766,617	2,231,109
2,766,617	2,231,109

12. Other Expenses

Rates & Taxes

Printing & stationery

Legal & professional charges

Statutory Audit Fee

Registration and filing fee

Other expenses

Year ended 31 March, 2015	Year ended 31 March, 2014
660	1,418,040
600	720
5,000	216,225
10,000	11,236
10,735	1,980
-	23,660
26,995	1,671,861

13. Finance Cost

Interest -Others

Bank charges

Year ended 31 March, 2015	Year ended 31 March, 2014
44,358	-
2,613	1,447
46,971	1,447



[Signature]

[Signature]

14. Earnings per share:

	Year ended 31 March, 2015	Year ended 31 March, 2014
Profit/ Loss considered for calculation of basic & diluted earnings per share	1,847,415	385,440
Weighted average number of equity shares in calculating basic & diluted earnings	1,592,740	1,550,000
Basic & Diluted Earnings Per share	1.16	0.25
Face value per Share	10	10

15. Related Party Disclosures:**Name of the related parties and description of relationship**

Aurobindo Pharma Limited, The Holding Company

Eugia Pharma Specialties Limited, The Subsidiary Company

Key Managerial persons

M.Madan Mohan Reddy, Director

Arvind Vasudeva, Director

P.Sarath Chandra Reddy, Director

Transactions with related parties

	Year ended 31 March, 2015	Year ended 31 March, 2014
1. Aurobindo Pharma Limited, Holding Company Equity contribution received including securities premium	90,000,000	225,500,000
2. Eugia Pharma Specialties Limited, The Subsidiary Company Equity allotment	135,000,000	180,000,000
16. Earning in foreign currency (accrual Basis)	-	-
17. Foreign exchange Earnings & outflow	-	-
18. FOB value of exports	-	-
19. CIF value of imports	-	-

20. Previous year figures are regrouped, reclassified wherever necessary to confirm with the current year presentations.

21. There are no dues to Micro, Small and Medium size companies to which the company owe amount outstanding more than 30 days.

22. Contingent Liabilities

As per our report of even date

For G.PAVAN KUMAR & ASSOCIATES

Firm Registration Number:0153435

Chartered Accountants

(G.Pavan Kumar Reddy)

Proprietor

Membership No.229495

Place: Hyderabad

Date: 21-May-2015



For and on behalf of the Board of Directors

(M.Madan Mohan Reddy)

Director

DIN NO: 00050482

(Arvind Vasudeva)

Director

DIN NO:00669039

EUGIA PHARMA SPECIALITIES LIMITED

CIN: U24297TG2013PLC087048

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

DIRECTORS' REPORT

Dear Members,

Your Directors are pleased to present the Second Annual Report of the Company together with the Audited Accounts for the year ended 31st March, 2015.

Review of Operations:

The JV partners in the Company Curepro Parenterals Ltd (a wholly owned subsidiary of Aurobindo Pharma Ltd) and Celon Laboratories Limited have made investments in the equity share capital of the Company.

The Company has availed facilities from Exim Bank to finance the project. The company is in the process of establishing a project for manufacture of Hormonal & Oncology Products. The company is yet to start commercial operations.

In Hormonal Block, we have completed Plant Commissioning, Water system & other utilities, Personal & Microbiological qualification. Media fills runs completed (vials under incubation). Facility is ready for Exhibit batches.

Dividend

No dividend has been declared for the year 2014-15.

Reserves

No amount has been carried to General Reserves for the year 2014-15.

Details of Subsidiary/Joint Ventures/Associate Companies

The Company has no Subsidiaries / Joint Venture / Associate Companies as on 31st March, 2015.

Deposits

The Company has not accepted any public deposits and as such, no amount on account of principal or interest on public deposits was outstanding as on the date of the balance sheet.

Statutory Auditors

M/s. G Pavan Kumar & Associates, Chartered Accountants are not seeking re-appointment as Statutory Auditors of the Company. M/s. G Pavan Kumar & Associates, Chartered Accountants have expressed their unwillingness to act as Statutory Auditors of the Company. M/s. Walker Chandiok & Co LLP, Chartered Accountants have confirmed their eligibility to accept office of the Statutory Auditors, if appointed. Your Directors recommend for the approval of their appointment.

EUGIA PHARMA SPECIALITIES LIMITED

CIN: U24297TG2013PLC087048

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Auditors' Report

The observations made in the Auditors' Report read together with relevant notes thereon are self explanatory and hence do not call for any further comments under Section 134 of the Companies Act, 2013.

Share Capital

During the year, your Company has made further issue of 17,500,000 Equity Shares of Rs.10/- each at par to par to the existing Shareholders of the company. Consequently, the paid-up equity share capital was increased to Rs. 47,50,00,000.

Extract of the Annual Return

The extract of the Annual Return in Form MGT-9 forming part of Boards report is enclosed as **Annexure - I**

Material changes and commitments, if any.

There are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

Conservation of energy, technology absorption and foreign exchange earnings and outgo

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014, is not applicable to the Company for the year 2014-15 except foreign exchange earnings and outgo which is furnished in as **Annexure - II**

Business Risk Management

At present the company has not identified any element of risk which may threaten the existence of the Company.

Directors:

As per the provisions of the Companies Act, 2013 Mr. M Madan Mohan Reddy and Mr. Vijay Kumar Vasireddy Directors of the Company will retire in the ensuing annual general meeting and being eligible, seek re-appointment. The Board of Directors recommends their re-appointment.

EUGIA PHARMA SPECIALITIES LIMITED

CIN: U24297TG2013PLC087048

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Changes in Directors and Key Managerial Personnel:

During the year Mr. K Venkateswara Rao (DIN:02907769) and Mr. A Vinod Kumar Reddy (DIN:02944453) have been appointed as an Additional Directors (Independent) w.e.f. 30th March, 2015 and Dr. M Sivakumaran (DIN: 01284320) has appointed as an Additional Director w.e.f. 25th June, 2015. They hold office upto the date of the ensuing Annual General Meeting. The Company has received notices in writing under the provisions of Section 160 of the Companies Act, 2013, proposing Mr. K Venkateswara Rao, Mr. A Vinod Kumar Reddy and Dr. M Sivakumaran as the candidature for the office of Directors.

Mr. Arvind Vasudeva and Mr N Govindarajan were resigned from the Board as Directors of the Company w.e.f 25th June, 2015

Declaration by an Independent Director(s) and re- appointment, if any:

The Company has received necessary declaration(s) from each Independent Director of the Company under Section 149(7) of the Act, that they meet the criteria of independence as laid down in section 149(6) of the Act.

Formal Annual Evaluation:

Evaluation of all Board members is done on an annual basis, the evaluation is done by the Board, Nomination and Remuneration Committee with specific focus on the performance and effective functioning of the Board and Individual Directors.

The criteria for Evaluation of the Board are the frequency of meetings, length of meetings and the flow of the information to the Board members etc.

The criteria for Evaluation of the individual Directors are the core competencies, monitoring management performance and development, guiding strategy etc.

Number of meetings of the Board of Directors:

During the financial year 2014-15 the Board of Directors has met twelve times viz., on 09.05.2014, 31.05.2014, 18.07.2014, 10.09.2014, 20.10.2014, 26.11.2014, 22.12.2014, 20.01.2015, 30.01.2015, 18.02.2015, 17.03.2015 and 30.03.2015.

Audit Committee:

pursuant to the provisions of Section 177 of the Companies Act, 2013 and the rules made thereunder an Audit Committee has been constituted with the following Directors of the Company.

- | | |
|------------------------------------|-----------|
| 1) Mr. Kondareddy Venkateswara Rao | :Chairman |
| 2) Mr. Vinod Kumar Reddy Aerva | :Member |
| 3) Mr. M Madan Mohan Reddy | :Member |

EUGIA PHARMA SPECIALITIES LIMITED

CIN: U24297TG2013PLC087048

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Nomination and Remuneration Committee:

pursuant to the provisions of Section 178 of the Companies Act, 2013 and the rules made thereunder a Nomination and Remuneration Committee has been constituted with the following Directors of the Company.

- | | |
|------------------------------------|-----------|
| 1) Mr. Vinod Kumar Reddy Aerva | :Chairman |
| 2) Mr. Kondareddy Venkateswara Rao | :Member |
| 3) Mr. M Madan Mohan Reddy | :Member |

Brief description of terms of reference of Nomination and Remuneration Committee

- Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down
- Recommend to the Board for appointment and removal of directors and KMP
- Recommend to the Board a policy relating to the remuneration of the directors, KMP and other employees etc.

The objectives of the Nomination and Remuneration Policy:

- To lay down criteria and terms and conditions with regard to identifying persons who are qualified to become directors and who may be appointed in senior management and KMP
- To determine remuneration
- To carry out evaluation of the performance of the directors

Particulars of loans, guarantees or investments under section 186:

No loans, Guarantees or investment made by the company during the year 2014-15.

Particulars of contracts or arrangements with related parties:

All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business. There were no materially significant related party transactions which could have had a potential conflict with the interests of the Company.

Transactions with related parties entered by the Company are periodically placed before the Board and the particulars of contracts entered during the financial year 2014-15 are enclosed in Form AOC-2 as **Annexure – III**

Particulars of Employees

Information as required to be disclosed under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are enclosed as **Annexure IV**

EUGIA PHARMA SPECIALITIES LIMITED

CIN: U24297TG2013PLC087048

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Policy on Sexual Harassment

The Company has adopted policy on Prevention of Sexual Harassment of Women at Workplace in accordance with The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

During the financial year ended March 31, 2015, the Company has not received any Complaints pertaining to Sexual Harassment.

Directors' Responsibility Statement

Pursuant to Section 134(5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

(a) in the preparation of the annual accounts for the year ended 31st March, 2015, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) the directors had prepared the annual accounts on a going concern basis; and

(e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and are operating effectively.

(f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and are operating effectively.

Acknowledgements


Your Company will always keep interest of its customers, employees and the stakeholders as a priority and shall reciprocate their confidence reposed in the Company. It has been a mutually beneficial relationship and looks forward to their continued support.

Place: Hyderabad

Date: 25.06.2015



For and on behalf of the Board


M Madan Mohan Reddy
Director
DIN: 01284266


V Vijay Kumar
Director
DIN: 03262782

ANNEXURE - I

Form No. MGT-9
EXTRACT OF ANNUAL RETURN
as on the financial year ended on 31.03.2015

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:		
i	CIN	U24297TG2013PLC087048
ii	Registration Date	17.04.2013
iii	Name of the Company	Eugia Pharma Specialities Limited
iv	Category / Sub-Category of the Company	Company Limited by Shares/Public Limited Company
v	Address of the Registered office and contact details	Plot No. 2, Maitrivihar, Ameerpet, Hyderabad – 500 038, Telangana Ph.No: 040 - 66725000 Fax.No:040 -67074059
vi	Whether listed company	No
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
	Nil	Nil	Nil

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S.No	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ASSOCIATE	% of shares held	Applicable Section
1	Curepro Parenterals Limited Regd Off: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500038, Telangana	U24232TG2013PLC087101	HOLDING	66.32	2(46)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual /HUF	0	0	0	0	0	0	0	0	0
b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt (s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	29999400	29999400	100.00	0	47499400	47499400	100.00	58.33
e) Banks / FI									
f) Any Other (Nominees)	0	600	600	0	0	600	600	0	0
Sub-total (A) (1):-	0	30000000	30000000	100.00	0	47500000	47500000	100.00	58.33
(2) Foreign									

a) NRIs - Individuals	0	0	0	0	0	0	0	0	0
b) Other -Individuals	0	0	0	0	0	0	0	0	0
c) Bodies Corp.	0	0	0	0	0	0	0	0	0
d) Banks / FI	0	0	0	0	0	0	0	0	0
e) Any Other....	0	0	0	0	0	0	0	0	0
Sub-total (A) (2):-	0	0	0	0	0	0	0	0	0
Total shareholding of Promoter (A) = (A)(1)+(A)(2)	0	30000000	30000000	100.00	0	47500000	47500000	100.00	58.33
B. Public Shareholding									
1. Institutions									
a) Mutual Funds	0	0	0	0	0	0	0	0	0
b) Banks / FI	0	0	0	0	0	0	0	0	0
c) Central Govt	0	0	0	0	0	0	0	0	0
d) State Govt(s)	0	0	0	0	0	0	0	0	0
e) Venture Capital Funds	0	0	0	0	0	0	0	0	0
f) Insurance Companies	0	0	0	0	0	0	0	0	0
g) FIs	0	0	0	0	0	0	0	0	0
h) Foreign Venture Capital Funds	0	0	0	0	0	0	0	0	0
i) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(1):-	0	0	0	0	0	0	0	0	0
2. Non-Institutions									
a) Bodies Corp.	0	0	0	0	0	0	0	0	0
i) Indian	0	0	0	0	0	0	0	0	0
ii) Overseas	0	0	0	0	0	0	0	0	0
b) Individuals	0	0	0	0	0	0	0	0	0
i) Individual	0	0	0	0	0	0	0	0	0

shareholders holding nominal share capital upto Rs1 lakh									
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	0	0	0	0	0	0	0	0	0
c) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	0	0	0	0	0	0	0	0
Total Public Shareholding (B)=(B)(1)+(B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	30000000	30000000	100.00	0	47500000	47500000	100.00	58.33

ii) Shareholding of Promoters

Sl No	Shareholder's Name	Shareholding at the beginning of the year			Share holding at the end of the year			
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
								% change in share Holding during the year

1	Curepro Parenterals Ltd (CPL)	17999600	60.00	0	31499600	66.32	0	75.00
2	Celon Laboratories Ltd (CLL)	11999800	40.00	0	15999800	33.68	0	33.33
3	M Madan Mohan Reddy (Nominee of CPL)	100	0	0	100	0	0	0
4	Arvind Vasudeva (Nominee of CPL)	100	0	0	100	0	0	0
5	Phaneendra Prasad (Nominee of CPL)	100	0	0	100	0	0	0
6	A Mohan Rami Reddy(Nominee of CPL)	100	0	0	100	0	0	0
7	V Vijay Kumar (Nominee of CLL)	100	0	0	100	0	0	0
8	K Vimal Kumar (Nominee of CLL)	100	0	0	100	0	0	0
	Total	30000000	100	0	47500000	100	0	58.33

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl.No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	Curepro Parenterals Ltd				
	At the beginning of the year	17999600	60.00		
	Allotment on 20.01.2015	6000000		23999600	60.00
	Allotment on 13.03.2015	7500000		31499600	66.32
	At the End of the year			31499600	66.32
	Celon Laboratories Ltd				
	At the beginning of the year	11999800	40.00		

	Allotment on 20.01.2015	4000000		15999800	40.00
	At the End of the year			15999800	33.68

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	For Each of the Top 10 Shareholders				
	At the beginning of the year	NIL			
	Date wise Increase /Decrease in Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus / sweat equity etc):	NIL			
	At the End of the year (or on the date of separation, if separated during the year)	NIL			

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total Shares of the company
	For Each of the Directors and KMP				
	At the beginning of the year	NIL			
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc):	NIL			
	At the End of the year	NIL			

V. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	236,000,000.00	-	-	236,000,000.00
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due				
Total (i+ii+iii)	236,000,000.00	-	-	236,000,000.00
Change in Indebtedness during the financial year	-	-	-	-
• Addition	267,497,192.00	50,000,000.00	-	317,497,192.00
• Reduction	-	-	-	-
Indebtedness at the end of the financial year	-	-	-	-
i) Principal Amount	503,497,192.00	50,000,000.00	-	553,497,192.00
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	503,497,192.00	50,000,000.00	-	553,497,192.00

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl.no.	Particulars of Remuneration	Name of MD/WTD/ Manager				Total Amount
1	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	Nil	Nil	Nil	Nil	Nil
2	Stock Option	Nil	Nil	Nil	Nil	Nil
3	Sweat Equity	Nil	Nil	Nil	Nil	Nil
4	Commission - as % of profit - others, specify...	Nil	Nil	Nil	Nil	Nil
5	Special Allowance	Nil	Nil	Nil	Nil	Nil
	Total (A)	Nil	Nil	Nil	Nil	Nil
	Ceiling as per the Act	Nil	Nil	Nil	Nil	Nil
		Nil	Nil	Nil	Nil	Nil

B. Remuneration to other directors:

Sl.no.	Particulars of Remuneration	Name of Directors				Total Amount
		---	---	---	---	
	Independent Directors • Fee for attending board / committee meetings • Commission • Others, please specify	NIL				
	Total (1)	NIL				
	Other Non-Executive Directors • Fee for attending board / committee meetings • Commission • Others, please specify	NIL				
	Total (2)	NIL				
	Total (B)=(1+2)	NIL				
	Total Managerial Remuneration	NIL				
	Overall Ceiling as per the Act	NIL				

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD:

Sl.no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Incometax Act, 1961	NIL			

2.	Stock Option	NIL
3.	Sweat Equity	NIL
4.	Commission - as % of profit - others, specify...	NIL
5.	Others, please specify	NIL
	Total	NIL

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty /Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give details)
A. Company					
Penalty			NIL		
Punishment					
Compounding					
B. Directors					
Penalty			NIL		
Punishment					
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty			NIL		
Punishment					
Compounding					

EUGIA PHARMA SPECIALITIES LIMITED

CIN: U24297TG2013PLC087048

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Annexure-II

Foreign exchange earnings and Outgo:

	(in Rupees)	
	2014-15	2013-14
Foreign exchange earned		
Exports (FOB)	-	-
Others	-	-
Foreign exchange outgo		
Materials	86,874,396	-
Other expenses	-	-
	86,874,396	-

Place: Hyderabad
Date: 25.06.2015



For and on behalf of the Board

M Madan Mohan Reddy
Director
DIN: 01284266

V Vijay Kumar
Director
DIN: 03262782

V. Vijay Kumar

EUGIA PHARMA SPECIALITIES LIMITED

CIN: U24297TG2013PLC087048

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Annexure III

Form -AOC-2

DETAILS OF RELATED PARTY TRANSACTIONS

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis:

(a) Name(s) of the related party and nature of relationship	There were no transaction or arrangement which were not at arm's length.
(b) Nature of contracts/arrangements/transactions	
(c) Duration of the contracts/arrangements/transactions	
(d) Salient terms of the contracts or arrangements or transactions including the value, if any arm's length.	
(e) Justification for entering into such contracts or arrangements or transactions	
(f) Date(s) of approval by the Board	
(g) Amount paid as advances, if any:	
(h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188	

2.Details of material contracts or arrangement or transactions at arm's length basis:

Name of the related party and nature of relationship	Aurobindo Pharma Ltd, Holding Company
Nature of contracts/ arrangements / transactions	Purchase of materials
Duration of the contracts / arrangements / transactions	on going
Salient terms of the contracts or arrangements or transactions including the value, if any	Transactions: Purchase of raw materials and capital goods Rs. 9.09 Lakhs.
Justification for entering into such contracts or arrangements or transactions	Transactions are based on transfer pricing guidelines


Appropriate approvals have been taken for related party transactions. Advances paid if any have been adjusted against billing wherever applicable

For and on behalf of the Board

Place: Hyderabad
Date: 25.06.2015




M Madan Mohan Reddy
Director
DIN: 01284266


V Vijay Kumar
Director
DIN: 03262782

EUGIA PHARMA SPECIALITIES LIMITED

CIN: U24297TG2013PLC087048

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India
Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Annexure-IV

Information as required under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

Name of the Employee	Designation of employee	Remuneration Received (Rs.)	Nature of Employment (Contractual or otherwise)	Qualifications and Experience of the employee	Date of Commencement of employment	Age of Employee	Last employment held before joining the Company	The % of Equity shares held by the employee	Whether employee is relative of any Director, if so. Name of such Director
Mr. Sushil Baukhandi	Sr. Vice-President	11,65,563 *	Contractual	M Sc., & 30 years work exp	2 nd Feb 2015	51 years	M/s Famy Care Limited	Nil	No

* Part of the year

Place: Hyderabad
Date: 25.06.2015



For and on behalf of the Board

M Madan Mohan Reddy
Director
DIN: 01284266

V Vijay Kumar
Director
DIN: 03262782



INDEPENDENT AUDITOR'S REPORT

To the Members of
Eugia Pharma Specialities Limited.

Report on the Financial Statements

We have audited the accompanying financial statements of M/s Eugia Pharma Specialities Limited ("the Company"), which comprise the Balance sheet as at March 31, 2015, and the Statement of Profit and Loss and Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedure to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the Assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.





Opinion


In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- a. In the case of the Balance Sheet, of the state of affairs of the Company as at March 31,2015;
- b. In the case of the Statement of Profit and Loss, of the loss for the year ended on that date; and
- c. In case of the Cash Flow Statement, of the cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

- 1) As required by the Companies (Auditor's Report) Order, 2015 ("the order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure a statement on the matters section in paragraphs 3 and 4 of the Order.
- 2) As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to best of our knowledge and belief were necessary for the purpose of our audit;
 - b. In our opinion proper books of account as required by law have been kept by the company so far as appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the Balance Sheet , Statement of Profit and Loss and Cash Flow Statement comply with the Accounting Standards notified under Section 133 of the Companies Act,2013, read with the Rule 7 of the Companies (Accounts) Rules2014;
 - e. On the basis of written representations received from the directors as on March 31,2015,and taken on record by the Board of Directors, none of the directors is disqualified as on March31,2015,from being appointed as a director In terms of sub-section (2) of section 164 of the Companies Act,2013.
 - f. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts in respect of which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants



(Pavan Kumar Reddy)
Proprietor
M.No.229495


Place: Hyderabad
Date:



ANNEXURE TO AUDITORS REPORT

(Referred to in paragraph 3 & 4 of our report of even date)

- i. In respect of fixed assets:
 - a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - b) A major portion of the fixed assets has been physically verified during the year by the management in accordance with a programme of verification of all the fixed assets at reasonable intervals having regard to the size of the company and the nature of its assets. According to the information and explanations given to us, the discrepancies noticed on such verification were not material and have been properly dealt with in the books of accounts.
- ii. In respect of Inventories:
 - a) The management has conducted physical verification of inventory at reasonable intervals during the year.
 - b) The procedures of physical verification of inventory followed by the management are reasonable and adequate in relation to the size of the Company and nature of its business.
 - c) The Company is maintaining proper records of inventory and no material discrepancies were noticed on physical verification.
- iii.
 - a) According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to Companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the provisions of clauses 3 (iii) (a), 3 (iii) (b) of the Companies (Auditor's Report) Order 2015 are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the company and the nature of its business, for the purchase of inventory and fixed assets and for the sale of goods and services. During the course of our audit, we have not observed any major weakness or continuing failure to correct any major weakness in the internal control system of the Company in respect of these areas.
- v. The Company has not accepted any deposits. Accordingly, the provisions of clause 3(v) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- vi. The Company has not started any commercial operations as on Balance Sheet date. So the reporting provisions clause 3(vi) is not applicable.





vii.

- a) The company is regular in depositing with the appropriate authorities undisputed statutory dues including provident fund, employees' state insurance, income tax, sales - tax, wealth tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues applicable to it.
- b) According to the information and explanations given to us, no undisputed amounts payable in respect of income tax, sale tax, wealth tax, service tax, customs duty, excise duty, value added tax or cess and other material statutory dues, at the yearend, for a period of more than six months from the date they became payable.
- c) According to the information and explanations given to us, the company does not have any amount in the account to transfer investor education and protection fund in accordance with the relevant provisions of the Companies Act, 1956 and rules made there under.

viii. The provision of clause 3(viii) of the Order is not applicable, since the incorporation of the company is less than five years.

ix. In our opinion, According to the information and explanations given to us, the Company has not accepted any loans from the financial institutions and banks. Accordingly, the provisions of clause 3(ix) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.


x. In our opinion, according to the information and explanations given to us, the company has not given any guarantees for loans taken by others from banks or the financial institutions. Accordingly, the provisions of clause 3(x) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.

xi. Based on the information and explanations given to us by the management, term loan were applied for the purpose for which loans were obtained

xii. Based upon the audit procedures performed for the purpose of reporting the true and fair view of financial statements and as per the information and explanations given by the management, we report that no fraud on or by the company was noticed or reported during the course of our audit.

Place: Hyderabad
Date:

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants



(G Pavan Kumar Reddy)
Proprietor
M.No.229495

Balance Sheet as at March 31, 2015

(All amounts in Indian Rupees, except share data and where otherwise stated)

Particulars	Note	As at March 31, 2015	As at March 31, 2014
EQUITY AND LIABILITIES			
SHAREHOLDER'S FUNDS			
Share Capital	3	475,000,000	300,000,000
Reserves & Surplus	4	(1,446,615)	-
		473,553,385	300,000,000
NON-CURRENT LIABILITIES			
Long-term borrowings	5	503,497,192	236,000,000
Long-term provisions	6	1,931,534	365,414
		505,428,726	236,365,414
CURRENT LIABILITIES			
Short-term borrowings	7	50,000,000	-
Trade Payables	8	18,048,081	-
Other Current Liabilities	9	27,790,899	1,450,407
Short term Provisions	6	57,693	-
		95,896,673	1,450,407
TOTAL		1,074,878,784	537,815,821
ASSETS			
NON-CURRENT ASSETS			
Fixed Assets			
(i).Tangible assets	10	43,141,972	43,141,972
(ii).Tangible Assets- Capital Work-In-Progress	10	709,004,061	246,103,636
Deferred tax asset	11	646,894	-
Long-term Loans and Advances	12	130,947,205	6,987,135
		883,740,133	296,232,743
CURRENT ASSETS			
Inventory	13	42,919,069	-
Cash and Bank Balances	14	136,924,810	210,685,170
Short-term Loans and Advances	12	11,092,758	30,592,549
Other current assets	15	202,014	305,359
		191,138,651	241,583,078
TOTAL		1,074,878,784	537,815,821

Corporate Information & Summary of significant accounting policies
The accompanying notes are an integral part of financial statements

1&2

As per our report of even date.

For G.PAVAN KUMAR & ASSOCIATES


Chartered Accountants

ICAI Firm Registration Number: 016343S

G PAVAN KUMAR REDDY
Proprietor

Membership No.229495
Hyderabad

Date: 21-May-2015



For and on behalf of the Board of Directors of
Eugia Pharma Specialities Limited

(M. Madan Mohan Reddy)
Director

DIN NO: 00050482

(Vijay Kumar Vasireddy)
Director

DIN NO: 03262782


Statement of profit and loss for the year ended March 31, 2015
(All amounts in Indian Rupees, except share data and where otherwise stated)


Particulars	Note	Year ended 31st March, 2015	Year ended 31st March, 2014
INCOME			
Revenue from operations		-	-
Other Income		-	-
TOTAL REVENUE		-	-
EXPENSES			
Other Expenses	16	2,093,509	-
TOTAL EXPENSES		2,093,509	-
PROFIT/(LOSS) BEFORE TAX		(2,093,509)	-
TAX EXPENSE			
Current tax		-	-
Deferred tax		(646,894)	-
TOTAL TAX EXPENSE		(646,894)	-
PROFIT/(LOSS) FOR THE YEAR		(1,446,615)	-
EARNINGS PER EQUITY SHARE			
Basic & Diluted		(0.07)	-
Nominal Value per Equity Share		10.00	10.00

Corporate Information & Summary of significant accounting policies
The accompanying notes are an integral part of financial statements


1&2


As per our report of even date.

For G.PAVAN KUMAR & ASSOCIATES
Chartered Accountants
ICAI Firm Registration Number MA 3438

G PAVAN KUMAR REDDY
Proprietor
Membership No.229495
Hyderabad
Date: 21-May-2015



For and on behalf of the Board of Directors of
Eugia Pharma Specialities Limited


(M. Madan Mohan Reddy)
Director
DIN NO: 00050482


(Vijay Kumar Vasireddy)
Director
DIN NO: 03262782

Cash flow statement for the period ended 31st Mar, 2015
(All amounts in Indian Rupees, except share data and where otherwise stated)

	Year ended 31st March, 2015	Year ended 31st March, 2014
CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and exceptional & extraordinary items	(2,093,509)	-
Adjustments to reconcile profit before tax to net cash flows	-	-
Depreciation and amortisation	-	-
Provision for trade receivables	-	-
Bad debts written off	-	-
Provision for diminution on investment	-	-
Profit on sale of investment	-	-
Balances no longer required written back	-	-
Unrealised foreign exchange loss/(gain) (net)	-	-
Operating Profit before Working Capital Changes	(2,093,509)	-
<i>Movements in working capital:</i>		
Decrease/(increase) in short-term loans and advances	19,499,791	(53,499)
Decrease/(increase) in trade receivables	-	-
Decrease/(increase) in inventories	(42,919,069)	-
Decrease/(increase) in other current assets	103,345	(19,777,328)
Increase/(decrease) in trade payables	18,048,081	-
Increase/(decrease) in other current liabilities	26,340,492	1,450,407
Increase/(decrease) in Short term borrowings	50,000,000	-
Increase/(decrease) in Provisions	1,566,120	365,414
Cash Generated from Operations	72,638,760	(18,015,006)
Direct taxes paid (net of refunds)	-	-
Net Cash flow from Operating Activities (A)	70,545,251	(18,015,006)
CASH FLOW FROM INVESTING ACTIVITIES		
Additions to Fixed assets, CWIP	(462,900,425)	(289,245,608)
Decrease/(increase) in long-term loans and advances	(123,960,070)	(18,054,216)
Investments	-	-
Other non current assets	-	-
Net Cash flow used in Investing Activities (B)	(586,860,495)	(307,299,824)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issuance of share capital including share premium	175,000,000	300,000,000
Proceeds from long-term Borrowings	267,497,191	236,000,000
Net Cash flow from Financing Activities (C)	442,497,191	536,000,000
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(73,818,053)	210,685,169
Cash and Cash Equivalents at the beginning of the year	210,685,170	-
Cash and Cash Equivalents at the end of the year	136,924,810	210,685,170
Cash and cash equivalents comprise of:		
Cash on hand	43,363	45,813
Balances with banks	136,881,447	210,639,357
Total cash and cash equivalents	136,924,810	210,685,170

As per our report of even date.

For G.PAVAN KUMAR & ASSOCIATES
Chartered Accountants

ICAI Firm Registration Number: 015343S

G PAVAN KUMAR REDDY

Proprietor

Membership No.229495

Hyderabad

Date: 21-May-2015

For and on behalf of the Board of Directors of
Eugia Pharma Specialities Limited

(M. Madan Mohan Reddy)

Director

DIN NO: 00050482

(Vijay Kumar Vasireddy)

Director

DIN NO: 03262782

EUGIA PHARMA SPECIALITIES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

1. Background

EUGIA PHARMA SPECIALITIES LIMITED ('the Company') was incorporated on 17 April 2013 with its registered office in Hyderabad, India. The Company is a joint-venture between Curepro Parenterals Ltd, (100% subsidiary of Aurobindo Pharma Limited, one of the leading pharmaceutical company in India) and Celon Laboratories Ltd, a research based speciality Pharma company. The Company was incorporated to carry on business in all kinds and varieties of pharmaceutical drugs, patent and non-patent medicines, common medical preparations, drugs, mixtures, elixirs, drops, tonics, other liquid drugs and medicines, formulations, capsules, tablets, pills, powders, medical ointments, pharmaceuticals, chemical medical products, preparations and materials, sterilized injections, vaccines, immunogens, phylacogens, chemicals and surgical dressings.

2. Summary of significant accounting policies

(a) Basis of preparation of financial statements

The Company maintains its accounts on accrual basis following the historical cost convention in accordance with generally accepted accounting principles (GAAP), in compliance with provisions of the Companies Act, 2013 and the Accounting Standards [as specified in the Companies (Accounting Standards) Rules, 2006 read with Section 133 of the Companies Act, 2013 and Rule 7 of the Companies (Accounts) Rules 2014 prescribed by the Central Government]. The other Accounting Standards as issued by ICAI, not yet notified are also considered, wherever applicable, except to the extent where compliance with the other statutory promulgations override the same requiring a different treatment. The accounting policies are consistent with those used in the previous year.

(b) Use of estimates


The preparation of financial statements in conformity with Indian GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting year. Examples of such estimates include provision for future obligation under employee benefit plans, net realizable value of inventory and estimated useful lives of fixed assets. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates.

(c) Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.

Revenue from sale of goods is recognized on dispatch (in respect of exports on the date of the bill of lading or airway bill) which coincides with transfer of significant risks and rewards to customer and is net of trade discounts, sales returns and sales tax, where applicable. Excise duty deducted from revenue (gross) is the amount that is included in revenue (gross) and not the entire amount of liability arising during the year.

Interest is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.



Handwritten signature

EUGIA PHARMA SPECIALITIES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

(d) Fixed assets and depreciation

Fixed assets are stated at cost less accumulated depreciation and impairment losses, if any. Cost comprises the purchase price and any attributable cost of bringing the asset to its working condition for its intended use. Borrowing costs relating to acquisition of fixed assets which take substantial period of time to get ready for use are included to the extent they relate to the period till such assets are ready for intended use. All other borrowing costs are expensed in the period they occur.

Expenditure directly relating to construction activity is capitalized. Indirect expenditure is capitalized to the extent those relate to the construction activity or is incidental thereto. Income earned during construction period is deducted from the total expenditure relating to construction activity.

Capital work in progress includes the cost of fixed assets which are not yet ready for its intended use.

(e) Impairment


The carrying amounts of assets are reviewed at each balance sheet date to see if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the assets net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value at the weighted average cost of capital. After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

(f) Inventories

Raw materials, packing materials, stores, spares and consumables are valued at lower of cost, calculated on weighted average basis, and net realizable value. Items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost.

Finished goods and intermediates are valued at lower of cost and net realizable value. Cost includes materials, labour and a proportion of appropriate overheads based on normal operating capacity. Cost is determined on a weighted average basis.

Net realizable value is the estimated selling price in the ordinary course of business, reduced by the estimated costs of completion and costs to effect the sale.



Handwritten signature

EUGIA PHARMA SPECIALITIES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

(g) Employee benefits

Provident fund

A retirement benefit in the form of provident fund scheme is a defined contribution and the contribution is charged to the statement of profit and loss of the year when the contribution to the respective fund is due. There are no other obligations other than the contribution payable to the respective fund.

Gratuity

Retirement benefits in the form of gratuity is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to the statement of profit and loss.

Leave encashment

Employee benefits in the form of leave encashment is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to the statement of profit and loss.

(h) Leases

Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item are classified as operating leases. Operating lease payments are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term.

(i) Borrowing costs

Borrowing costs include interest and other ancillary costs incurred in connection with the arrangement of borrowing and exchange differences arising from the foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.


(j) Foreign Currency transactions

Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; and non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.



[Handwritten signature]



[Handwritten signature]

EUGIA PHARMA SPECIALITIES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

Exchange differences

Exchange differences arising on the settlement of monetary items at rates different from those at which they were initially recorded during the period are recognized as income or as expenses in the period in which they arise.

(k) Export Benefits and Incentives.

Export benefits on account of duty drawback and export promotion schemes are accrued and accounted in the year of export, and are included in other operating revenue. Other benefits in the form of advance authorization for imports are accounted for on purchase of imported materials.

(l) Taxes on income

Tax expense comprises of current and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the provisions of the Income Tax Act, 1961. Deferred income taxes reflect the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.

Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the Balance Sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

Unrecognized deferred tax assets of earlier years are reassessed and recognized to the extent that it has become reasonably certain or virtually certain, as the case may be, that future taxable income will be available against which such deferred tax assets can be realized.


The carrying amount of deferred tax assets are reviewed at each Balance Sheet date. The company writes-down the carrying amount of a deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

(m) Provisions

A provision is recognized when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on management estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current management estimates.

(n) Earnings per equity share

Basic earnings per equity share are calculated by dividing the profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.



Handwritten signature

EUGIA PHARMA SPECIALITIES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

For the purpose of calculating diluted earnings per equity share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.


(o) Contingent Liabilities

A contingent liability is possible obligation that arises from past events whose existence will be confirmed by the occurrence or non occurrence of one or more uncertain future events beyond the control of Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize the contingent liability but discloses its existence in the financial statements.

(p) Cash flows

Cash flows are reported using indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities are segregated.

Cash and cash equivalents: Cash and cash equivalents, in the statement of cash flow, comprise cash at bank and in hand and fixed deposits with original maturity of maximum 90 days.



A handwritten signature in black ink, appearing to be "D. My" or similar, with a long horizontal line extending to the right.



A handwritten signature in black ink, appearing to be "V. Vijay" or similar.

EUGIA PHARMA SPECIALITIES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

3. SHARE CAPITAL

	As at 31st Mar, 2015	As at 31st Mar, 2014
Authorised share Capital		
52,50,000 equity shares (Previous year 30,000,000) of Rs.10/- each	525,000,000	300,000,000
	<u>525,000,000</u>	<u>300,000,000</u>
Issued, Subscribed and Fully Paid-up share Capital		
47,50,000 equity shares (Previous year 30,000,000) of Rs.10/- each	475,000,000	300,000,000
TOTAL	<u>475,000,000</u>	<u>300,000,000</u>

a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting year.

	As at 31st Mar, 2015		As at 31st Mar, 2014	
Equity Shares	No. of shares	Value	No. of shares	Value
At the beginning of the year	30,000,000	300,000,000	-	-
Issued during the year	17,500,000	175,000,000	30,000,000	300,000,000
Outstanding at the end of the year	<u>47,500,000</u>	<u>475,000,000</u>	<u>30,000,000</u>	<u>300,000,000</u>

b. Shares held by holding company

	As at 31st Mar, 2015		As at 31st Mar, 2014	
	No. of shares	Value	No. of shares	Value
Curepro Parenterals Ltd, The Holding Company				
Equity shares of Rs.10/- each	31,500,000	315,000,000	18,000,000	180,000,000
TOTAL	<u>31,500,000</u>	<u>315,000,000</u>	<u>18,000,000</u>	<u>180,000,000</u>

c. Details of shareholders holding more than 5% shares in the company

	As at 31st Mar, 2015		As at 31st Mar, 2014	
	No. of shares	% of holding in class	No. of shares	% of holding in class
Equity shares of Rs. 10/- each				
Curepro Parenterals Ltd, The Holding Company	31,500,000	66.32%	18,000,000	60%
Celon Laboratories Ltd, The Associate Company	16,000,000	33.68%	12,000,000	40%
TOTAL	<u>47,500,000</u>	<u>100%</u>	<u>30,000,000</u>	<u>100%</u>

4. RESERVES & SURPLUS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Surplus/Deficit In the Statement of profit and Loss		
As per last financial statements	-	-
Add:- Profit/(loss) during the year	(1,446,615)	-
TOTAL	<u>(1,446,615)</u>	<u>-</u>

5. LONG-TERM BORROWINGS

	As at 31st Mar, 2015	As at 31st Mar, 2014
From Banks (Secured)		
Term loans	503,497,192	236,000,000
TOTAL	<u>503,497,192</u>	<u>236,000,000</u>

a) Secured Term Loan are secured by first charge on entire fixed assets incl. intangibles, both present and future and Second charge on the current assets, both present and future.

b) Pledge of shares held by Celon Laboratories Ltd.

c) The term loan carries the interest rate of 11.25% and is repayable in 15 quarterly installments starting from Sep '17.



[Handwritten signature]



[Handwritten signature]

EUGIA PHARMA SPECIALITIES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

6. PROVISIONS

	Non current		Current	
	As at 31st Mar, 2015	As at 31st Mar, 2014	As at 31st Mar, 2015	As at 31st Mar, 2014
For employee benefits				
-Gratuity (Refer Note no.19)	1,633,831	365,414	-	-
-Leave Encashment (Refer Note no. 19)	297,703	-	57,693	-
TOTAL	1,931,534	365,414	57,693	-

7. SHORT TERM BORROWINGS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Loan from related party	50,000,000	-
TOTAL	50,000,000	-

Unsecured loan from Celon Laboratories Limited, Associate company is repayable on demand & carries an interest rate of 12% p.a.

8. TRADE PAYABLES

	As at 31st Mar, 2015	As at 31st Mar, 2014
Trade Payables for supplies and services	18,048,081	-
TOTAL	18,048,081	-

9. OTHER CURRENT LIABILITIES

	As at 31st Mar, 2015	As at 31st Mar, 2014
Creditors for Capital goods	25,515,439	1,004,134
Other Payables		
Statutory Liabilities	2,158,374	348,524
Others	117,085	97,749
TOTAL	27,790,899	1,450,407

10. TANGIBLE FIXED ASSETS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Land	43,141,972	43,141,972
Capital Work in Progress	709,004,061	246,103,636
TOTAL	752,146,033	289,245,608

Capital work in progress includes expenditure incurred during the construction period pending capitalization of Rs.13,71,60,851/- (PY.1,68,97,989)
(Refer Note No.20)

11. DEFERRED TAX ASSET

	As at 31st Mar, 2015	As at 31st Mar, 2014
On account of carried forward losses	646,894	-
TOTAL	646,894	-

12. LOANS AND ADVANCES

	Non Current		Current	
	As at 31st Mar, 2015	As at 31st Mar, 2014	As at 31st Mar, 2015	As at 31st Mar, 2014
(Unsecured, considered good except stated otherwise)				
Capital Advances	79,667,654	-	-	18,054,216
Security Deposits	1,985,199	-	-	-
Advance receivable in cash or kind	-	-	10,860,922	53,499
Balances with Govt. Authorities	49,294,352	6,987,135	-	12,484,834
Prepaid insurance	-	-	231,836	-
TOTAL	130,947,205	6,987,135	11,092,758	30,592,549



[Handwritten signature]



[Handwritten signature]

EUGIA PHARMA SPECIALITIES LIMITED
NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

13. INVENTORIES

	As at 31st Mar, 2015	As at 31st Mar, 2014
(Lower of cost or net realisable value)		
Raw materials	28,769,699	-
Packing Materials	5,034,535	-
Stores, spares, consumables & others	9,114,835	-
TOTAL	42,919,069	-

14. CASH AND BANK BALANCES

	As at 31st Mar, 2015	As at 31st Mar, 2014
Cash and Cash equivalents consist of		
Cash on hand	43,363	45,813
Balance with Scheduled Banks		
- in Current Accounts	31,436,447	639,357
Deposits against margin money	105,445,000	210,000,000
TOTAL	136,924,810	210,685,170

15. OTHER CURRENT ASSETS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Interest accrued but not due	202,014	305,359
TOTAL	202,014	305,359

16. OTHER EXPENSES

	Year ended March 31, 2015	Year ended March 31, 2014
Rates and Taxes	2,058,509	-
Statutory Audit Fees	35,000	-
TOTAL	2,093,509	-

17. CAPITAL AND OTHER COMMITMENTS

Estimated amount of contracts (net of advances) remaining to be executed on Capital account and not provided for Rs.313,192,741/- (March, 2014 Rs.2,52,44,626/-)

18. CONTINGENT LIABILITIES

	Year ended March 31, 2015	Year ended March 31, 2014
Outstanding Bank Guarantees	445,000	-

19. EMPLOYEE BENEFIT EXPENSES

Particulars	As at 31st Mar, 2015	As at 31st Mar, 2014
A. Disclosures related to defined benefit plan - GRATUITY		
Statement of Profit and Loss		
Current Service Cost	427,850	126,243
Interest Cost on benefit obligation	29,233	-
Expected return on plan assets	-	-
Net Actuarial (gain)/Loss recognized in the year	811,334	239,171
Net Benefit expense	1,268,417	365,414
Actual return on plan assets		




EUGIA PHARMA SPECIALITIES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

Balance Sheet

	As at 31st Mar, 2015	As at 31st Mar, 2014
Details of provision for Gratuity		
Defined benefit obligation	16,33,831	365,414

Change in the present value of the defined benefit obligation are as follows

	As at 31st Mar, 2015	As at 31st Mar, 2014
Opening defined benefit obligation	365,414	-
Interest cost	29,233	-
Current services cost	427,850	126,243
Benefits paid	-	-
Actuarial (gains)/losses on obligation	811,334	239,171
Closing defined benefit obligation	1,633,831	365,414

The principal assumptions used in determining leave encashment obligations for the Company's plans are shown below:

Discount rate (p.a) (%)	8%	8%
Salary Rise (%)	4%	10%
Attrition Rate (%)	5%	10%
Av Balance Service	26.44 years	25.22 years

The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotions and other relevant factors such as supply and demand in the employment market. The Company evaluates these assumptions annually based on its long term plans of growth and industry standards.

B. Disclosures related to defined benefit plan - LEAVE ENCASHMENT

Statement of Profit and Loss

	Year ended March 31, 2015	Year ended March 31, 2014
Current Service Cost	80,516	-
Interest Cost on benefit obligation	6,817	-
Expected return on plan assets	-	-
Net Actuarial (gain)/ Loss recognized in the year	182,856	-
Net Benefit expense	270,189	-
Actual return on plan assets	-	-

	Year ended March 31, 2015	Year ended March 31, 2014
--	------------------------------	------------------------------

Balance Sheet

Details of provision for Leave encashment

Defined benefit obligation	355,396	-
----------------------------	---------	---

Change in the present value of the defined benefit obligation are as follows

	Year ended March 31, 2015	Year ended March 31, 2014
Opening defined benefit obligation	85,207	-
Interest cost	6,817	-
Current services cost	80,516	-
Benefits paid	-	-
Actuarial (gains)/losses on obligation	182,856	-
Closing defined benefit obligation	355,396	-

The principal assumptions used in determining leave and post employment medical benefit


obligations for the company's plans are shown below:

Assumptions	%	%
Salary Rise	4	-
Discount rate	8	-
Attrition Rate	5	-

The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotions and other relevant factors such as supply and demand in the employment market. The Company evaluates these assumptions annually based on its long term plans of growth and industry standards.



Handwritten signature



Handwritten signature

EUGIA PHARMA SPECIALITIES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

20. EXPENDITURE INCURRED DURING THE CONSTRUCTION PERIOD

	As at 31st Mar, 2015	As at 31st Mar, 2014
Balance brought forward	16,897,989	-
Add : Incurred during the year		
Salaries, wages and other benefits	46,696,106	8,906,980
Staff Welfare Expenses	1,107,530	546,624
Stores, Spares And Consumables	9,513,460	-
Freight & Cartage	375,247	6,797
Power & fuel	11,292,171	432,515
Rent	457,742	263,976
Rates and Taxes	7,573,000	3,210
Printing and Stationery	228,576	23,264
Postage, telegram, telephones	1,614,917	22,446
Repairs & maintenance	2,555,571	1,166,239
Legal & Professional Charges	323,318	604,882
Travelling & Conveyance	2,287,996	42,488
Miscellaneous Expenses	1,217,699	292,181
Product Development Expenses	6,679,034	300,000
Land Development Expenses	23,833	-
Security Charges	313,882	-
Registration and filing fees	1,334,030	2,565,976
Van Hire Charges	564,667	-
Statutory Audit Fees	-	11,236
Bank Charges	623,551	1,396,272
Interest on Loans (net)	25,480,532	312,904
TOTAL	137,160,851	16,897,989

21. DISCLOSURE REGARDING DERIVATIVE FINANCIAL INSTRUMENTS

Particulars of unhedged foreign currency exposure are detailed below at the exchange rate prevailing as at the Balance Sheet date:

	As at 31st Mar, 2015	As at 31st Mar, 2014
Advances to Creditors	22,576,537	-

22. RESEARCH & DEVELOPMENT EXPENSES:-

a. Details of Research & development expense incurred during the year, debitted under various heads is given below:-

Particulars	Year ended March 31, 2015	Year ended March 31, 2014
Employees Benefits	12,641,590	-
Power & fuel	910,235	-
Stores, Spares & Consumables	5,211,985	-
Product Development Expenses	20,003,482	-
Repairs & Maintenance	404,552	-
Other Expenses	2,045,917	3,271,558
TOTAL	41,217,761	3,271,558

b. Details of capital expenditure incurred for Research & Development are given under:-

Particulars	Year ended March 31, 2015	Year ended March 31, 2014
CWIP-Plant & Machinery	29,846,051	-
CWIP-Factory Equipment	5,524,416	-
CWIP-Lab Equipment	31,013,356	-
CWIP-Furniture & Fixtures	1,343,978	-
CWIP-Data Processing Equipment	1,618,989	-
TOTAL	69,346,790	-



[Handwritten signature]



[Handwritten signature]

EUGIA PHARMA SPECIALITIES LIMITED
NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

23. Related party disclosures

	Year ended March 31, 2015	Year ended March 31, 2014
Names of related parties and description of relationship		
Name		
1. Aurobindo Pharma Limited, ultimate holding company		
2. Curepro Parenterals Limited, Holding Company		
3. Celon Laboratories Ltd, Associate Company		
4. Auropetides Ltd, Fellow Subsidiary		
Key Managerial Personnel		
M. Madan Mohan Reddy		
Arvind Vasudeva		
Vijay Kumar Vasireddy		
Transactions with Related Parties:		
a. Transactions with Ultimate holding company- Aurobindo Pharma Limited		
Purchase of goods	909,888	-
Balance Payable O/s	909,888	-
b. Transactions with fellow subsidiary		
1. Celon Laboratories Ltd		
Equity Contribution Received	40,000,000	120,000,000
Fixed Assets Purchased	-	266,435,514
Loan	50,000,000	-
Interest	174,247	-
Rent	457,742	263,976
Electricity Charges Reimbursed	462,511	392,870
Telephone Charges Reimbursed	1,200	1,167
Balance Payable O/s	281,574	192,947
2. Curepro Parenterals Limited		
Equity Contribution Received	135,000,000	180,000,000
Balance Payable O/s	-	-
3. Auro Peptides Limited		
Purchase of capital goods	146,796	-
Balance Payable O/s	146,796	-
c. Transactions with enterprises over which key management personnel or their relative exercise significant influence		
1. Pravesha Industries Private Limited		
Purchases of Materials	352,988	-
Balance Payable O/s	249,461	-

24. EARNING PER EQUITY SHARE

Particulars	Year ended March 31, 2015	Year ended March 31, 2014
Profit/(Loss) after taxation considered for calculation of basic and diluted earning per share	(2,093,509)	-
Weighted average number of equity shares considered for calculation, of basic earnings per share (a)	32,205,479	-
Basic earning per share	(0.07)	-

25. VALUE OF IMPORTS CALCULATED ON CIF BASIS

	Year ended March 31, 2015	Year ended March 31, 2014
Raw materials and Packing materials	17,666,869	-
Capital Goods	69,207,527	-
TOTAL	86,874,396	-




EUGIA PHARMA SPECIALITIES LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

26. EXPENDITURE IN FOREIGN CURRENCY (ACCRUAL BASIS)

	Year ended March 31, 2015	Year ended March 31, 2014
Registration & filing fees	-	-
TOTAL	-	-

27. EARNINGS IN FOREIGN CURRENCY (ACCRUAL BASIS)

	Year ended March 31, 2015	Year ended March 31, 2014
Exports on F.O.B. basis	-	-
TOTAL	-	-

28. There are no dues to Micro, Small & Medium size companies to which the company owe amount outstanding more than 30 days.

29. The figures of pervious year have been regrouped/re arranged, wherever necessary to confirm to those of current year presentations.

As per our report of even date.

For G.PAVAN KUMAR & ASSOCIATES

Chartered Accountants

ICAI Firm Registration Number

33435

G.PAVAN KUMAR REDDY

Proprietor

Membership No.229495

Hyderabad

Date: 21-May-2015



For and on behalf of the Board of Directors of

Eugia Pharma Specialities Limited

(M.Madan Mohan Reddy)
Director

DIN NO: 00050482

(Vijay Kumar Vasireddy)
Director

DIN NO: 03262782

HYACINTHS PHARMA PRIVATE LIMITED

CIN: U24232TG2010PTC069638

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

DIRECTORS' REPORT

Dear Members,

Your Directors are pleased to present the Fifth Annual Report of the Company together with the Audited Accounts for the year ended 31st March, 2015.

Financials summary:

The Financial Performance of your Company for the year ended March 31, 2015 is summarized below:

	Year ended March 31, 2015 Rs.	Year ended March 31, 2014 Rs.
Profit/ (Loss) for the Year	(98,185)	(2,53,553)

Review of Operations:

The Company is established to engage in the business of manufacture, process, sell, buy, deal, export & import in all types of drugs, drugs intermediates, pharmaceutical and medical preparations, chemical and other connected materials. The Company is yet to establish the project.

Dividend

No dividend has been declared the year 2014-15.

Reserves

No amount has been carried to General Reserves during the year 2014-15

Details of Subsidiary/Joint Ventures/Associate Companies

The Company has no Subsidiaries / Joint Venture / Associate Companies as on 31st March, 2015.

Deposits

The Company has not accepted any public deposits and as such, no amount on account of principal or interest on public deposits was outstanding as on the date of the balance sheet.

8

HYACINTHS PHARMA PRIVATE LIMITED

CIN: U24232TG2010PTC069638

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India
Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Statutory Auditors

M/s. G Pavan Kumar & Associates, Chartered Accountants, Hyderabad have been appointed as Statutory Auditors of the Company at the 4th Annual General Meeting held on 25th August, 2014 for a period of 5 years subject to ratification by the members at every Annual General Meeting (i.e. till 9th Annual General Meeting). Your Directors commend for the ratification of their appointment.

Auditors' Report

The observations made in the Auditors' Report read together with relevant notes thereon are self explanatory and hence do not call for any further comments under Section 134 of the Companies Act, 2013.

Share Capital

During the year, your Company has made further issue of 3,80,000 Equity Shares of Rs.10/- each at par to Aurobindo Pharma Limited, the holding company. Consequently, the paid-up equity share capital was increased to Rs. 8,49,09,980.

Extract of the Annual Return

In accordance with Section 134(3)(a) of the Companies Act, 2013 the extract of Annual Return (Form MGT-9) of the Company is enclosed as **Annexure – I** to the Boards Report.

Material changes and commitments, if any.

There are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

Conservation of energy, technology absorption and foreign exchange earnings and outgo

There are no Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 and there are no foreign exchange earnings during the year

Business Risk Management

At present the company has not identified any element of risk which may threaten the existence of the Company.

HYACINTHS PHARMA PRIVATE LIMITED

CIN: U24232TG2010PTC069638

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Directors:

As per the provisions of the Companies Act, 2013 Mr. N Govindarajan will retire in the ensuing annual general meeting and being eligible, seek re-appointment. The Board of Directors recommends his re-appointment.

Number of meetings of the Board of Directors:

During the financial year 2014-15 the Board of Directors has met Seven times viz., on 09.05.2014, 05.06.2014, 18.07.2014, 25.09.2014, 20.10.2014, 30.01.2015, and 31.03.2015.

Particulars of loans, guarantees or investments under section 186:

No loans, Guarantees or investment made by the company during the year 2014-15.

Particulars of contracts or arrangements with related parties:

There are no materially significant related party transactions made by the Company with Promoters, Directors, Key Managerial Personnel or other designated persons which may have a potential conflict with the interest of the Company at large.

Particulars of Employees

There are no employees whose information as required to be disclosed under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

Policy on Sexual Harassment

The Company has adopted policy on Prevention of Sexual Harassment of Women at Workplace in accordance with The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. During the financial year ended March 31, 2015, the Company has not received any Complaints pertaining to Sexual Harassment.

Directors' Responsibility Statement

Pursuant to Section 134(5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

(a) in the preparation of the annual accounts for the year ended 31st March, 2015, the applicable accounting standards had been followed along with proper explanation relating to material departures;

HYACINTHS PHARMA PRIVATE LIMITED

CIN: U24232TG2010PTC069638

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) the directors had prepared the annual accounts on a going concern basis; and

(e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and are operating effectively.

(f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and are operating effectively.

Acknowledgements

Your Company will always keep interest of its customers, employees and the stakeholders as a priority and shall reciprocate their confidence reposed in the Company. It has been a mutually beneficial relationship and looks forward to their continued support.

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015


K. Nityananda Reddy
Director
DIN: 01284195


N. Govindarajan
Director
DIN: 00050482

ANNEXURE - I
Form No. MGT-9
EXTRACT OF ANNUAL RETURN
as on the financial year ended on 31.03.2015

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:		
i	CIN	U24232TG2010PTC069638
ii	Registration Date	23.07.2010
iii	Name of the Company	Hyacinths Pharma Private Limited
iv	Category / Sub-Category of the Company	Company Limited by Shares/Private Limited Company
v	Address of the Registered office and contact details	Plot No. 2, Maitrivihar, Ameerpet, Hyderabad – 500 038, Telangana Ph.No: 040 - 66725000 Fax.No:040 - 67074059
vi	Whether listed company	No
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
	N.A.	N.A.	N.A.

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S.No	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ASSOCIATE	% of shares held	Applicable Section
1	Aurobindo Pharma Limited	L24239TG1986PLC015190	HOLDING	100	2(46)

Regd Off: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500038, Telangana					
--	--	--	--	--	--

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual /HUF	0	0	0	0	0	0	0	0	0
b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt (s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	8110498	8110498	100.00	0	8490498	8490498	100.00	4.68
e) Banks / FI	0	0	0	0	0	0	0	0	0
f) Any Other (Nominee of holding Company)	0	500	500	0	500	500	500	0	0
Sub-total (A) (1):-	0	8110998	8110998	100.00	0	8490998	8490998	100.00	4.68
(2) Foreign									
a) NRIs - Individuals	0	0	0	0	0	0	0	0	0
b) Other –Individuals	0	0	0	0	0	0	0	0	0
c) Bodies Corp.	0	0	0	0	0	0	0	0	0
d) Banks / FI	0	0	0	0	0	0	0	0	0
e) Any Other....	0	0	0	0	0	0	0	0	0
Sub-total (A) (2):-	0	0	0	0	0	0	0	0	0

Total shareholding of Promoter (A) = (A)(1)+(A)(2)	0	8110498	8110498	100.00	0	8490998	8490998	100.00	4.68
B. Public Shareholding									
1. Institutions									
a) Mutual Funds	0	0	0	0	0	0	0	0	0
b) Banks / FI	0	0	0	0	0	0	0	0	0
c) Central Govt	0	0	0	0	0	0	0	0	0
d) State Govt(s)	0	0	0	0	0	0	0	0	0
e) Venture Capital Funds	0	0	0	0	0	0	0	0	0
f) Insurance Companies	0	0	0	0	0	0	0	0	0
g) FIs	0	0	0	0	0	0	0	0	0
h) Foreign Venture Capital Funds	0	0	0	0	0	0	0	0	0
i) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(1):-									
2. Non-Institutions									
a) Bodies Corp.	0	0	0	0	0	0	0	0	0
i) Indian	0	0	0	0	0	0	0	0	0
ii) Overseas	0	0	0	0	0	0	0	0	0
b) Individuals	0	0	0	0	0	0	0	0	0
i) Individual shareholders holding nominal share capital upto Rs1 lakh	0	0	0	0	0	0	0	0	0
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	0	0	0	0	0	0	0	0	0

c) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	0	0	0	0	0	0	0	0
Total Public Shareholding (B)=(B)(1)+(B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	8110498	8110498	100.00	0	8490998	8490998	100.00	4.68

ii) Shareholding of Promoters

Sl No	Shareholder's Name	Shareholding at the beginning of the year			Share holding at the end of the year			% change in share Holding during the year
		No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	
1	Aurobindo Pharma Ltd(APL)	8110498	100.00	0	8490498	100.00	0	4.68
2	K Nityananda Reddy (Nominee of APL)	500	0	0	500	0	0	0
	Total	8140998	100.00	0	8490998	100.00	0	4.68

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl.No.	Aurobindo Pharma Ltd	Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	At the beginning of the year	8110498	100.00		
	Allotment on 05.06.2014	30000		8140498	100.00
	Allotment on 25.09.2014	150000		8290498	100.00
	Allotment on 31.03.2015	200000		8490498	100.00
	At the End of the year			8490498	100.00

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	For Each of the Top 10 Shareholders				
	At the beginning of the year	NIL			
	Date wise Increase /Decrease in Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus / sweat equity etc):	NIL			
	At the End of the year (or on the date of separation, if separated during the year)	NIL			

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total Shares of the company
	For Each of the Directors and KMP				

	At the beginning of the year	NIL
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc):	NIL
	At the End of the year	NIL

V. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil
Change in Indebtedness during the financial year	Nil	Nil	Nil	Nil
• Addition	Nil	Nil	Nil	Nil
• Reduction	Nil	Nil	Nil	Nil
Indebtedness at the end of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl. no.	Particulars of Remuneration	Name of MD/WTD/ Manager				Total Amount
		---	---	---	---	
1	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	NIL				
2	Stock Option	NIL				
3	Sweat Equity	NIL				
4	Commission - as % of profit - others, specify...	NIL				
5	Others, please specify	NIL				
	Total (A)	NIL				
	Ceiling as per the Act	NIL				
		NIL				

B. Remuneration to other directors:

Sl.no.	Particulars of Remuneration	Name of Directors				Total Amount
		---	---	---	---	
	Independent Directors • Fee for attending board / committee meetings • Commission	NIL				

	• Others, please specify	
	Total (1)	NIL
	Other Non-Executive Directors • Fee for attending board / committee meetings • Commission • Others, please specify	NIL
	Total (2)	NIL
	Total (B)=(1+2)	NIL
	Total Managerial Remuneration	NIL
	Overall Ceiling as per the Act	NIL

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD:

Sl.no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income tax Act, 1961	N.A.			
2.	Stock Option	N.A.			
3.	Sweat Equity	N.A.			
4.	Commission - as % of profit - others, specify...	N.A.			
5.	Others, please specify	N.A.			
	Total	N.A.			

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty /Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give details)
A. Company					
Penalty			NIL		
Punishment					
Compounding					
B. Directors					
Penalty			NIL		
Punishment					
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty			NIL		
Punishment					
Compounding					



INDEPENDENT AUDITOR'S REPORT

To the Members of
Hyacinths Pharma Private Limited.

Report on the Financial Statements

We have audited the accompanying financial statements of M/s Hyacinths Pharma Private Limited ("the Company"), which comprise the Balance sheet as at March 31, 2015, the Statement of Profit and Loss and Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedure to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the Assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:


- a. In the case of the Balance Sheet, of the state of affairs of the Company as at March 31,2015;
- b. In the case of the Statement of Profit and Loss, of the loss for the year ended on that date; and
- c. In case of the Cash Flow Statement, of the cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2015 ("the order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure a statement on the matters section in paragraphs 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to best of our knowledge and belief were necessary for the purpose of our audit;
 - b. In our opinion proper books of account as required by law have been kept by the company so far as appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the Balance Sheet, Statement of Profit and Loss and Cash Flow Statement comply with the Accounting Standards notified under Section 133 of the Companies Act,2013, read with the Rule 7 of the Companies (Accounts) Rules,2014;
 - e. On the basis of written representations received from the directors as on March 31,2015, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31,2015, from being appointed as a director In terms of sub-section (2) of section 164 of the Companies Act,2013.
 - f. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts in respect of which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants




(G Pavan Kumar Reddy)
Proprietor
M.No.229495

Place: Hyderabad
Date:

ANNEXURE TO AUDITORS REPORT
(Referred to in paragraph 3 & 4 of our report of even date)


- i. In respect of fixed assets:
 - a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - b) A major portion of the fixed assets has been physically verified during the year by the management in accordance with a programme of verification of all the fixed assets at reasonable intervals having regard to the size of the company and the nature of its assets. According to the information and explanations given to us, the discrepancies noticed on such verification were not material and have been properly dealt with in the books of accounts.
- ii. The Company has no inventory as on the balance sheet date
- iii. According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to Companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the provisions of clauses 3 (iii) (a), 3 (iii) (b) of the Companies (Auditor's Report) Order 2015 are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the company and the nature of its business, for the purchase of inventory and fixed assets and for the sale of goods and services. During the course of our audit, we have not observed any major weakness or continuing failure to correct any major weakness in the internal control system of the Company in respect of these areas.
- v. The Company has not accepted any deposits. Accordingly, the provisions of clause 3(v) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- vi. The company was started not commenced any commercial operations, maintenance of cost records under section 148(1) of the Companies Act, 2013 was not applicable.
- vii.
 - a) The company is regular in depositing with the appropriate authorities undisputed statutory dues including provident fund, employees' state insurance, income tax, sales - tax, wealth tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues applicable to it.
 - b) According to the information and explanations given to us, no undisputed amounts payable in respect of income tax, sale tax, wealth tax, service tax, customs duty, excise



duty, value added tax or cess and other material statutory dues, at the yearend, for a period of more than six months from the date they became payable.

- c) According to the information and explanations given to us, the company does not have any amount in the account to transfer investor education and protection fund in accordance with the relevant provisions of the Companies Act, 1956 and rules made there under.
- viii. The Company has incurred cash losses at end of the financial year and also accumulated losses at end of the financial year but which does not exceeds 50% of net worth of the company.
- ix. In our opinion, According to the information and explanations given to us, the Company has not accepted any loans from the financial institutions and banks. Accordingly, the provisions of clause 3(ix) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- x. In our opinion, according to the information and explanations given to us, the company has not given any guarantees for loans taken by others from banks or the financial institutions. Accordingly, the provisions of clause 3(x) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xi. According to the information and explanations given to us, the company has not accepted any term loans during the year. Accordingly, the provisions of clause 3(xi) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xii. Based upon the audit procedures performed for the purpose of reporting the true and fair view of financial statements and as per the information and explanations given by the management, we report that no fraud on or by the company was noticed or reported during the course of our audit.

Place: Hyderabad
Date:

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants

(G. Pavan Kumar Reddy)
Proprietor
M.No.229495

HYACINTHS PHARMA PRIVATE LIMITED
Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038
CIN:U24232TG2010PTC069638

BALANCE SHEET AS AT 31 MARCH,2015

(All amounts in Indian Rupees, except for share data or as otherwise stated)

PARTICULARS	Note No.	As At 31 Mar, 2015	As At 31 Mar, 2014
EQUITY AND LIABILITIES			
Shareholders Funds			
(a) Share Capital	3	84,909,980	81,109,980
(b) Reserves and Surplus	4	(563,196)	(465,011)
		<u>84,346,784</u>	<u>80,644,969</u>
Current Liabilities			
(a) Other Current Liabilities	5	10,000	202,883
		<u>10,000</u>	<u>202,883</u>
Total		<u><u>84,356,784</u></u>	<u><u>80,847,852</u></u>
ASSETS			
Non- Current Assets			
(a) Fixed Assets			
(i) Tangible Assets	6	73,355,286	71,311,986
(ii) Tangible assets - Capital Work In Progress	7	7,393,750	7,068,750
(b) Deferred Tax Asset (Net)	8	-	72,582
(c) Long-term Loans and Advances	9	1,159,700	2,059,700
		<u>81,908,736</u>	<u>80,513,018</u>
Current Assets			
(a) Cash & Bank Balances	10	2,150,274	37,060
(b) Short-term Loans & Advances	11	297,774	297,774
		<u>2,448,048</u>	<u>334,834</u>
Total		<u><u>84,356,784</u></u>	<u><u>80,847,852</u></u>


Corporate Information & Summary of significant accounting policies 1&2

The accompanying notes are an integral part of the financial statements.


As per our report of even date

For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES
Firm Registration Number:-015343S
Chartered Accountants


(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place:Hyderabad
Date:21-May-2015




(K.Nithyananda Reddy)

Director
DIN:012841951


(N.Govindarajan)
Director
DIN:00050482



HYACINTHS PHARMA PRIVATE LIMITED
Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038
CIN:U24232TG2010PTC069638


STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 MARCH, 2015
(All amounts in Indian Rupees, except for share data or as otherwise stated)

PARTICULARS	Note No.	Year ended 31 Mar, 2015	Year ended 31 Mar, 2014
Income:			
Revenue from operations		-	-
Other Income		-	-
Total Revenue		<u>-</u>	<u>-</u>
Expenses:			
Other Expenses	12	25,603	234,892
Total Expenses		<u>25,603</u>	<u>234,892</u>
Profit/(Loss) before tax		<u>(25,603)</u>	<u>(234,892)</u>
Tax Expense:			
Deffered tax Credit / (Charge)		72,582	(18,661)
Profit/(Loss) for the year		<u>(98,185)</u>	<u>(253,553)</u>
Earning per equity share:	13		
Basic & Diluted		(0.00)	(0.03)
Nominal Value per Equity Share		10	10



Corporate Information & Summary of significant accounting policies 1&2
The accompanying notes are an integral part of the financial statements.

As per our report of even date

For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES
Firm Registration Number:-015343S
Chartered Accountants

(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place:Hyderabad
Date:21-May-2015




(K.Nithyananda Reddy)
Director
DIN:01284195

(N.Govindarajan)
Director
DIN:00050482



HYACINTHS PHARMA PRIVATE LIMITED
Plot.No.2, Maithri Vihar, Ameerpet, Hyderabad 500 038
CIN:U24232TG2010PTC069638

CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH, 2015
(All amounts in Indian Rupees, except for share data or as otherwise stated)

Particulars	Notes	Year ended 31 Mar, 2015	Year ended 31 Mar, 2014
1. CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before tax		(25,603)	(234,892)
Operating Profit before Working Capital Changes		(25,603)	(234,892)
Movements in working capital:		-	-
Decrease/ (increase) in trade receivables		-	-
Decrease/ (increase) in inventories		-	-
Decrease/ (increase) in long-term loans and advances		900,000	-
Decrease/ (increase) in short-term loans and advances		-	(7,829)
Decrease/ (increase) in other current assets		-	-
Increase/ (decrease) in trade payables		-	-
Increase/ (decrease) in provision for retirement benefits		-	-
Increase/ (decrease) in other current liabilities		(192,883)	102,826
Cash Generated from Operations		681,514	(139,895)
Direct taxes paid (net of refunds)		-	-
Net Cash flow from Operating Activities	(A)	681,514	(139,895)
2. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of fixed assets, including CWIP and capital advances		(2,368,300)	(730,340)
Net Cash flow used in Investing Activities	(B)	(2,368,300)	(730,340)
3. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issuance of share capital		3,800,000	800,000
Net Cash flow from Financing Activities	(C)	3,800,000	800,000
Net Increase/(Decrease) in Cash and Cash Equivalents	(A+B+C)	2,113,214	(70,235)
Cash and Cash Equivalents at the beginning of the year		37,060	107,295
Cash and Cash Equivalents at the end of the year		2,150,274	37,060

As per our report of even date

For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES
Firm Registration Number:-015343S
Chartered Accountants

(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place:Hyderabad
Date:21-May-2015



(K.Nithyananda Reddy)
Director
DIN:01284145
(N.Govindarajan)
Director
DIN:00050482



HYACINTHS PHARMA PRIVATE LIMITED

Notes to financial statements for the year ended March 31, 2015

(All amounts in Indian Rupees, except for share data or as otherwise stated)

1. Corporate information

Hyacinths Pharma Private Limited was incorporated in 23rd July' 2010 and incorporated under the provisions of the Companies Act, 1956. The Company is engaged in the business of manufacture, process, sell, buy, deal, export & import in all types of drugs, drugs intermediates, pharmaceutical and medical preparations, chemical and other connected materials and to obtain patents for them.

The Company is a subsidiary of Aurobindo Pharma limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.

2. Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). The Company has prepared these financial statements to comply in all material respects with the accounting standards, specified under section 133 of the Companies Act, 2013 ("the Act"), read with the Rule 7 of the Companies (Accounts) Rules 2014 (as amended). The financial statements have been prepared on an accrual basis and under the historical cost convention.

The accounting policies adopted in the preparation of financial statements are consistent with those of previous year.

2.1 Summary of significant accounting policies

a. Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

b. Tangible fixed assets

Fixed assets are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price.


Subsequent expenditure related to an item of fixed asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. All other expenses on existing fixed assets, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which such expenses are incurred.

Gains or losses arising from derecognition of fixed assets are measured as the difference between the net disposal proceeds and the carrying amount of the asset and recognized in the statement of profit and loss when the asset is derecognized.



4

28



c. Depreciation on tangible fixed assets

Depreciation on fixed assets is calculated on straight line method as per the useful lives prescribed under schedule II of Companies Act 2013.

d. Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.

Income from services rendered by the Company is recognised on accrual basis for services rendered and billed as per the terms of specific contract.

e. Retirement and other employee benefits

Gratuity or other retirement benefits are not provided because the provisions of Payment of Gratuity Act, 1972 were not applicable

f. Income taxes

Tax expenses comprises of current and deferred tax. Current income tax has been measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961 enacted in India.

Deferred income taxes reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.

g. Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

h. Provisions

A provision has been recognized in respect of a present obligation as a result of past event i.e. based on the probability of there being an outflow of resources to settle the obligation, in respect of which a reliable estimate can be made. Provisions have not been discounted to its present value and have been determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

i. Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

j. Cash flows


Cash flows are reported using indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities are segregated.

Cash and cash equivalents: Cash and Cash Equivalents, in the statement of cash flow, comprise cash at bank and in hand and fixed deposits with original maturity of maximum 90 days.



28/4

28/4



HYACINTHS PHARMA PRIVATE LIMITED

Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038

CIN:U24232TG2010PTC069638

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH,2015

(All amounts in Indian Rupees, except for share data or as otherwise stated)

3. Share Capital	As at Mar 31, 2015	As at Mar 31, 2014
Authorised Capital:		
10,000,000 (Previous Year : 10,000,000) Equity Shares of Rs. 10/- each	100,000,000	100,000,000
Issued, Subscribed and paid-up Capital		
84,90,998 (Previous Year: 81,10,998) Equity Shares of Rs.10 /- each, fully paid up	84,909,980	81,109,980
Total Issued, Subscribed and Fully Paid-up shares	84,909,980	81,109,980

a. Reconciliation of number of shares:

Equity shares	As at Mar 31, 2015	As at Mar 31, 2014
Balance as at the beginning of year	8,110,998	8,030,998
Add: Shares issued during the year	380,000	80,000
Balance at the end of the year	8,490,998	8,110,998

b. Shares held by holding company:

Out of equity shares issued by the company, shares held by its holding company are as under:

	As at Mar 31, 2015	As at Mar 31, 2014
Aurobindo Pharma Ltd, the holding Company		
84,90,998 (Previous Year: 81,10,998)Equity Shares of Rs.10 /- each, fully paid	84,909,980	8,110,998
	84,909,980	8,110,998

c.Terms/rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10 per share. Each holder of equity shares is entitled to one vote per share.

In the event of liquidation of the company ,the holders of equity shares will be entitled to receive remaining assets of the company ,after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the share holders

d. Details of shareholders holding more than 5% of the aggregate shares in the Company:


Name of the Equity shareholder	As at Mar 31, 2015		As at Mar 31, 2014	
	No. of shares	% of holding in class	No. of shares	% of holding in class
M/s Aurobindo Pharma Ltd	8,490,998	100%	8,110,998	100%
	8,490,998	100%	8,110,998	100%

4. Reserves & Surplus
Surplus/Deficit in the Statement of Profit & Loss:

	As at Mar 31, 2015	As at Mar 31, 2014
Balance as per last financial statements	(465,011)	(211,458)
Add: Profit/(Loss) for the year	(98,185)	(253,553)
Total	(563,196)	(465,011)



u... 4



5. Other Current Liabilities

Other Payables

Total

As at Mar 31, 2015	As at Mar 31, 2014
10,000	202,883
10,000	202,883

7. Capital Work-in Progress

Capital Work-in-Progress

Add : Pre-operative Expenses

Bank Charges

Registration & Filing Fees

Travelling & Conveyance

Rates & Taxes

Total

As at Mar 31, 2015	As at Mar 31, 2014
7,068,750	7,068,750
-	-
-	-
-	-
325,000	-
7,393,750	7,068,750

8. Deferred Tax Asset:

Deferred Tax Asset on account of carried forward losses

Total

As at Mar 31, 2015	As at Mar 31, 2014
-	72,582
-	72,582

9. Long term Loans and Advances

Advance paid for Land

Total

As at Mar 31, 2015	As at Mar 31, 2014
1,159,700	2,059,700
1,159,700	2,059,700

10. Cash and Bank Balances

Cash & cash equivalents

Balances with Banks

Cash on hand

Total

As at Mar 31, 2015	As at Mar 31, 2014
2,121,034	24,810
29,240	12,250
2,150,274	37,060

11. Short-term Loans & Advances

Balance with the Revenue Authorities

Total

As at Mar 31, 2015	As at Mar 31, 2014
297,774	297,774
297,774	297,774

12. Other Expenses

Rates & Taxes

Printing & stationery

Postage & telephone charges

Legal & professional charges

Registration & Filing Fees

Statutory Audit Fee


Travelling & Conveyance

Other expenses

Business promotion expenses


Total

Year ended 31 Mar, 2015	Year ended 31 Mar, 2014
1,280	11,320
600	1,909
-	22,751
-	58,754
11,880	-
10,000	10,000
950	75,817
-	20,000
893	32,500
25,603	234,892



4

28



	Year ended 31 Mar, 2015	Year ended 31 Mar, 2014
13. Earnings per share:		
Profit/Loss considered for calculation of basic & diluted earnings per share	(25,603)	(234,892)
Weighted average number of equity shares in calculating basic & diluted	8,213,464	8,110,998
Basic & Diluted Earnings Per share	(0.00)	(0.03)
Face value per Share	10	10

14. Related Party Disclosures:

Name of the related parties and description of relationship

Aurobindo Pharma Limited, The Holding Company

Key managerial personnel

Transactions with related parties	Year ended 31 Mar, 2015	Year ended 31 Mar, 2014
1. Aurobindo Pharma Limited, Holding Company		
Equity contribution received	3,800,000	800,000

15. Earning in foreign currency (accrual Basis) - -
16. Foreign exchange outflow - -
17. FOB value of exports - -
18. CIF value of imports - -
19. Previous year figures are regrouped, reclassified wherever necessary to confirm with the current year presentations.

20. There are no dues to Micro, Small and Medium size companies to which the company owe amount outstanding more than 30 days.

21. Contingent Liabilities - -


As per our report of even date

For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES

Firm Registration Number:-015343S

Chartered Accountants



(G.Pavan Kumar Reddy)

Proprietor

Membership No.229495

Place: Hyderabad

Date: 21-May-2015




(K.Nithyananda Reddy)

Director

DIN:01284195


(N.Govindarajan)

Director

DIN:00050482



HYACINTHS PHARMA PRIVATE LIMITED

(All amounts in Indian Rupees, except for share data or as otherwise stated)

Note 6: FIXED ASSETS

Particulars	Gross Block			As at 31 Mar, 2015	Accumulated Depreciation			As at 31 Mar, 2015	Net Block	
	As at 1st April, 2014	Additions	Deletions		As at 1st April, 2014	For the year	As at 31 Mar, 2015		As at 31 Mar, 2015	As at 31st Mar, 2014
I.Tangible Assets										
Free hold land	71,311,986	2,043,300	-	73,355,286	-	-	-	73,355,286	71,311,986	
Total	71,311,986	2,043,300	-	73,355,286	-	-	-	73,355,286	71,311,986	
Previous Year	70,581,646	730,340	-	71,311,986	-	-	-	71,311,986	70,581,646	

Capital work-in-progress Rs. 7,393,750 (Previous Year :Rs.70,68,750)



K. J. G.

28



SILICON LIFE SCIENCES PRIVATE LIMITED

CIN: U85100TG2008PTC057669

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

DIRECTORS' REPORT

Dear Members,

Your Directors are pleased to present the Seventh Annual Report of the Company together with the Audited Accounts for the year ended 31st March, 2015.

Financial Results:

The financial performance of your company for the year ended March 31, 2015 is summarized below:

	(in Rs.)	
	2014-15	2013-14
Gross Turnover	142,889,846	194,099,896
Profit before depreciation, interest, tax and exceptional items	(11,088,233)	10,483,182
Depreciation/amortization	23,463,717	24,135,910
Finance cost	3,194,674	25,225,206
Profit before tax	(37,746,624)	(38,877,934)
Provision for tax/deferred tax	34,611,503	5,535,083
Profit after tax before exception item	(3,135,120)	(33,342,852)
Less: Exceptional items	-	-
Net profit after exceptional items	(3,135,120)	(33,342,852)
Balance brought forward from previous year	(55,651,757)	(22,308,905)
Deficit carried to Balance sheet	(58,786,877)	(55,651,757)

Review of Operations

The Company is presently manufacturing Non-Sterile APIs. Out of one production block, one product can be manufactured at a time. The Company is manufacturing Meropenem, Ertapenem, Imipenem and also Cilastatin Acid.

Specification revision work (Residual solvent, Water content & XRD limits) and final TTD preparation work is going on in APL-RC-II for Validation batches.

Dividend

No dividend has been declared the year 2014-15.

Reserves

No amount has been carried to General Reserves during the year 2014-15

SILICON LIFE SCIENCES PRIVATE LIMITED

CIN: U85100TG2008PTC057669

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India
Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Details of Subsidiary/Joint Ventures/Associate Companies

The Company has no Subsidiaries / Joint Venture / Associate Companies as on 31st March, 2015.

Deposits

The Company has not accepted any public deposits and as such, no amount on account of principal or interest on public deposits was outstanding as on the date of the balance sheet.

Statutory Auditors

M/s. G Pavan Kumar & Associates, Chartered Accountants, Hyderabad have been appointed as Statutory Auditors of the Company at the 6th Annual General Meeting held on 25th August, 2014 for a period of 5 years subject to ratification by the members at every Annual General Meeting (i.e. till 11th Annual General Meeting). Your Directors commend for the ratification of their appointment.

Auditors' Report

The observations made in the Auditors' Report read together with relevant notes thereon are self explanatory and hence do not call for any further comments under Section 134 of the Companies Act, 2013.

Share Capital

The Company is a wholly owned subsidiary of Aurobindo Pharma Limited. During the year, your Company has made further issue of 1,56,30,000 Equity Shares of Rs.10/- each at par to Aurobindo Pharma Limited, the holding company. Consequently, the paid-up equity share capital was increased to Rs. 43,61,75,000 as on March 31, 2015.

Extract of the Annual Return

In accordance with Section 134(3)(a) of the Companies Act, 2013 the extract of Annual Return (Form MGT-9) of the Company is enclosed as **Annexure – I** to the Boards Report.

Material changes and commitments, if any.

There are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

SILICON LIFE SCIENCES PRIVATE LIMITED

CIN: U85100TG2008PTC057669

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India
Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Conservation of energy, technology absorption and foreign exchange earnings and outgo

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 and foreign exchange earnings and outgo which is furnished in as **Annexure – II**

Business Risk Management

At present the company has not identified any element of risk which may threaten the existence of the Company.

Directors:

As per the provisions of the Companies Act, 2013 Mr. K Nityananda Reddy will retire in the ensuing Annual General Meeting and being eligible, seek re-appointment. The Board of Directors recommends his re-appointment.

Changes in Directors and Key Managerial Personnel:

During the year Mr. K Venkateswara Rao (DIN:02907769) and Mr. A Vinod Kumar Reddy (DIN:02944453) have been appointed as Additional Directors (Non-Executive Independent) w.e.f. 30th March, 2015. They hold office upto the date of the ensuing Annual General Meeting. The Company has received notices in writing under the provisions of Section 160 of the Companies Act, 2013, proposing the candidature of Mr. K Venkateswara Rao and Mr. A Vinod Kumar Reddy for appointment as Directors.

Declaration by an Independent Director(s) and re- appointment, if any:

The Company has received necessary declaration(s) from each Independent Director of the Company under Section 149(7) of the Act, that they meet the criteria of independence as laid down in section 149(6) of the Act.

Formal Annual Evaluation:

Evaluation of all Board members is done on an annual basis, the evaluation is done by the Board, Nomination and Remuneration Committee with specific focus on the performance and effective functioning of the Board and Individual Directors.

The criteria for Evaluation of the Board are the frequency of meetings, length of meetings and the flow of the information to the Board members etc.

SILICON LIFE SCIENCES PRIVATE LIMITED

CIN: U85100TG2008PTC057669

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India
Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

The criteria for Evaluation of the individual Directors are the core competencies, monitoring management performance and development, guiding strategy etc.

Number of meetings of the Board of Directors:

During the financial year 2014-15 the Board of Directors has met Ten times viz., on 28.04.2014, 09.05.2014, 05.06.2014, 05.07.2014, 18.07.2014, 25.08.2014, 20.10.2014, 17.01.2015, 30.01.2015, and 30.03.2015.

Audit Committee:

pursuant to the provisions of Section 177 of the Companies Act, 2013 and the rules made thereunder an Audit Committee has been constituted with the following Directors of the Company.

- | | |
|------------------------------------|-----------|
| 1) Mr. Kondareddy Venkateswara Rao | :Chairman |
| 2) Mr. Vinod Kumar Reddy Aerva | :Member |
| 3) Mr. K.Nithyananda Reddy | :Member |

Nomination and Remuneration Committee:

pursuant to the provisions of Section 178 of the Companies Act, 2013 and the rules made thereunder a Nomination and Remuneration Committee has been constituted with the following Directors of the Company.

- | | |
|------------------------------------|-----------|
| 1) Mr. Vinod Kumar Reddy Aerva | :Chairman |
| 2) Mr. Kondareddy Venkateswara Rao | :Member |
| 3) Mr. K Nityananda Reddy | :Member |

Brief description of terms of reference of Nomination and Remuneration Committee

- Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down
- Recommend to the Board for appointment and removal of directors and KMP
- Recommend to the Board a policy relating to the remuneration of the directors, KMP and other employees etc.

The objectives of the Nomination and Remuneration Policy:

- To lay down criteria and terms and conditions with regard to identifying persons who are qualified to become directors and who may be appointed in senior management and KMP
- To determine remuneration
- To carry out evaluation of the performance of the directors

SILICON LIFE SCIENCES PRIVATE LIMITED

CIN: U85100TG2008PTC057669

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91-40 2373 6370 Fax: +91 40 2374 7340

Particulars of loans, guarantees or investments under section 186:

No loans, Guarantees or investment made by the company during the year 2014-15.

Particulars of contracts or arrangements with related parties:

All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business. There were no materially significant related party transactions which could have had a potential conflict with the interests of the Company.

Transactions with related parties entered by the Company are periodically placed before the Board and the particulars of contracts entered during the financial year 2014-15 are enclosed in Form AOC-2 as **Annexure – III**

Particulars of Employees

There are no employees whose information as required to be disclosed under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

Policy on Sexual Harassment

The Company has adopted policy on Prevention of Sexual Harassment of Women at Workplace in accordance with The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

During the financial year ended March 31, 2015, the Company has not received any Complaints pertaining to Sexual Harassment.

Directors' Responsibility Statement

Pursuant to Section 134(5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

(a) in the preparation of the annual accounts for the year ended 31st March, 2015, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

SILICON LIFE SCIENCES PRIVATE LIMITED

CIN: U85100TG2008PTC057669

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

(d) the directors had prepared the annual accounts on a going concern basis; and

(e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and are operating effectively.

(f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and are operating effectively.

Acknowledgements

Your Company will always keep interest of its customers, employees and the stakeholders as a priority and shall reciprocate their confidence reposed in the Company. It has been a mutually beneficial relationship and looks forward to their continued support.

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015


K.Nityananda Reddy
Director
DIN: 01284195


N Govindarajan
Director
DIN: 00050482

ANNEXURE - I

Form No. MGT-9
EXTRACT OF ANNUAL RETURN
as on the financial year ended on 31.03.2015

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:		
i	CIN	U85100TG2008PTC057669
ii	Registration Date	19.02.2008
iii	Name of the Company	Silicon Life Sciences Private Limited
iv	Category / Sub-Category of the Company	Company Limited by Shares/Private Limited Company
v	Address of the Registered office and contact details	Plot No. 2, Maitrivihar, Ameerpet, Hyderabad – 500 038, Telangana Ph. No : 040 – 2373 6370 Fax No :040 - 2374 7340
vi	Whether listed company	No
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
1	10% Palladium on Carbon	21001 / 21002	42%
2	Meropenem Trihydrate Non Sterile		17%
3	Job Work		20%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S.No	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ASSOCIATE	% of shares held	Applicable Section
1	Aurobindo Pharma Limited Regd Off: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500038, Telangana	L24239TG1986PLC015190	HOLDING	100	2(46)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual /HUF	0	0	0	0	0	0	0	0	0
b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt (s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	27986657	27986657	100.00	0	43616657	43616657	100.00	55.85
e) Banks / FI	0	0	0	0	0	0	0	0	0
f) Any Other (nominee)	0	843	843	0	0	843	843	0	0
Sub-total (A) (1):-	0	27987500	27987500	100.00	0	43617500	43617500	100.00	55.85

i) Individual shareholders holding nominal share capital upto Rs1 lakh	0	0	0	0	0	0	0	0	0
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	0	0	0	0	0	0	0	0	0
c) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	0	0	0	0	0	0	0	0
Total Public Shareholding (B)=(B)(1)+ (B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	27987500	27987500	100.00	0	43617500	43617500	100.00	55.85

ii) Shareholding of Promoters

SI No	Shareholder's Name	Shareholding at the beginning of the year			Share holding at the end of the year			
		No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	%of Shares Pledged / Encumbere d to total shares	
								% change In share Holding during the year

1	Aurobindo Pharma Ltd (APL)	27986657	100.00	0	43616657	100.00	0	55.85
2	K Nityananda Reddy (Nominee of APL)	843	0	0	843	0	0	0
	Total	27987500	100.00	0	43617500	100.00	0	55.85

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl.No.	Name of the Shareholder	Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	Aurobindo Pharma Ltd				
	At the beginning of the year	27986657	100.00		
	Allotment on 05.07.2014	15130000		43116657	100.00
	Allotment on 25.08.2014	500000		43616657	100.00
	At the End of the year			43616657	100.00

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	For Each of the Top 10 Shareholders				
	At the beginning of the year	NIL			
	Date wise Increase /Decrease in Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus / sweat equity etc):	NIL			
	At the End of the year (or on the date of separation, if separated during the year)	NIL			

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total Shares of the company
	For Each of the Directors and KMP				
	At the beginning of the year	NIL			
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc):	NIL			
	At the End of the year	NIL			

V. INDEBTEDNESS:**Indebtedness of the Company including interest outstanding/accrued but not due for payment**

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	69,221,183.00	-	-	69,221,183.00
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	69,221,183.00	-	-	69,221,183.00
Change in Indebtedness during the financial year				
• Addition	-	7,500,000.00	-	7,500,000.00
• Reduction	69,221,183.00	-	-	69,221,183.00
Indebtedness at the end of the financial year				
i) Principal Amount	-	7,500,000.00	-	7,500,000.00
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	-	7,500,000.00	-	7,500,000.00

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl. no.	Particulars of Remuneration	Name of MD/WTM/ Manager				Total Amount
		----	----	----	----	
1	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	NIL				
2	Stock Option	NIL				
3	Sweat Equity	NIL				
4	Commission - as % of profit - others, specify...	NIL				
5	Others, please specify	NIL				
	Total (A)	NIL				
	Ceiling as per the Act	NIL				
		NIL				

B. Remuneration to other directors:

Sl.no.	Particulars of Remuneration	Name of Directors				Total Amount
		----	----	----	----	
	Independent Directors • Fee for attending board / committee meetings	NIL				

	• Commission • Others, please specify	
	Total (1)	NIL
	Other Non-Executive Directors • Fee for attending board / committee meetings • Commission • Others, please specify	NIL
	Total (2)	NIL
	Total (B)=(1+2)	NIL
	Total Managerial Remuneration	NIL
	Overall Ceiling as per the Act	NIL

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD:

Sl.no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income tax Act, 1961	NIL			
2.	Stock Option	NIL			
3.	Sweat Equity	NIL			
4.	Commission - as % of profit - others, specify...	NIL			
5.	Others, please specify	NIL			
	Total	NIL			

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty /Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give details)
A. Company					
Penalty	NIL				
Punishment					
Compounding					
B. Directors					
Penalty	NIL				
Punishment					
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty	NIL				
Punishment					
Compounding					

SILICON LIFE SCIENCES PRIVATE LIMITED

CIN: U85100TG2008PTC057669

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

ANNEXURE-I

Information on conservation of energy, technology absorption, foreign exchange earnings and outgo pursuant to the provisions of section 134(3) (m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014.

(A) Conservation of energy-

- (i) the steps taken or impact on conservation of energy;
Nil
- (ii) the steps taken by the company for utilising alternate sources of energy;
NIL
- (iii) the capital investment on energy conservation equipments;
NIL

B) Technology absorption-

- (i) the efforts made towards technology absorption;-NIL
- (ii) the benefits derived like product improvement, cost reduction, product development or import substitution; NIL
- (iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-NIL
- (a) the details of technology imported; - Nil
- (b) the year of import; - Nil
- (c) whether the technology been fully absorbed; - Nil
- (d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof- Nil
- (iv) the expenditure incurred on Research and Development. - Nil


(C) Foreign exchange earnings and Outgo

	(in Rupees)	
	2014-15	2013-14
Foreign exchange earned		
Exports (FOB)	-	-
Others	-	-
Foreign exchange outgo		
Materials	-	-
Other expenses	3,477,164	-
	3,477,164	-

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015


K. Nityananda Reddy
Director
DIN: 01284195


N. Govindarajan
Director
DIN: 00050482

SILICON LIFE SCIENCES PRIVATE LIMITED

CIN: U85100TG2008PTC057669

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Annexure III Form AOC-2 DETAILS OF RELATED PARTY TRANSACTIONS

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis:

(a) Name(s) of the related party and nature of relationship	There were no transaction or arrangement which were not at arm's length
(b) Nature of contracts/arrangements/transactions	
(c) Duration of the contracts/arrangements/transactions	
(d) Salient terms of the contracts or arrangements or transactions including the value, if any arm's length.	
(e) Justification for entering into such contracts or arrangements or transactions	
(f) Date(s) of approval by the Board	
(g) Amount paid as advances, if any:	
(h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188	

2. Details of material contracts or arrangement or transactions at arm's length basis:

Name of the related party and nature of relationship	Aurobindo Pharma Ltd, Holding Company	Aurobindo Pharma Ltd, Holding Company	Auro Next Pharma Pvt. Ltd, Fellow Subsidiary	Aurobindo Pharma Ltd, , Holding Company
Nature of contracts/arrangements/transactions	Loan Agreement	Sale of goods	Sale of goods	Purchase of materials
Duration of the contracts/arrangements/transactions	Entered on 21 st January 2015 including supplementary agreements thereon. Loan granted is unsecured payable on demand for a period of 3 years from date of each disbursement and can be extended and reschedules with mutual agreement.	on going	on going	on going

Salient terms of the contracts or arrangements or transactions including the value, if any	Salient Terms: Loan carries an interest rate of 9.5% p.a. Transactions: during the year Rs. 75 Lakhs loan availed and Interest accrued there on was 0.84 Lakhs.	Transactions: Sold goods amounting to Rs.970.34 Lakhs.	Transactions: Sold goods amounting to Rs.450.55 Lakhs.	Transactions: Purchase of raw materials amounting to Rs. 1261.41 Lakhs.
Justification for entering into such contracts or arrangements or transactions	To avail financial assistance for the project of the company.	Transactions are based on transfer pricing guidelines	Transactions are based on transfer pricing guidelines	Transactions are based on transfer pricing guidelines

Appropriate approvals have been taken for related party transactions. Advances paid if any have been adjusted against billing wherever applicable

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015


K. Nityananda Reddy
Director
DIN: 01284195


N. Govindarajan
Director
DIN: 00050482



INDEPENDENT AUDITOR'S REPORT

To the Members of
Silicon Life Sciences Pvt Ltd.

Report on the Financial Statements

We have audited the accompanying financial statements of M/s Silicon Life Sciences Pvt Ltd ("the Company"), which comprise the Balance sheet as at March 31, 2015, and the Statement of Profit and Loss and Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedure to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the Assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:


- a. In the case of the Balance Sheet, of the state of affairs of the Company as at March 31,2015;
- b. In the case of the Statement of Profit and Loss, of the loss for the year ended on that date; and
- c. In case of the Cash Flow Statement, of the cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

- 1) As required by the Companies (Auditor's Report) Order, 2015 ("the order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure a statement on the matters section in paragraphs 3 and 4 of the Order to the extent applicable.
- 2) As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to best of our knowledge and belief were necessary for the purpose of our audit;
 - b. In our opinion proper books of account as required by law have been kept by the company so far as appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the Balance Sheet , Statement of Profit and Loss and Cash Flow Statement comply with the Accounting Standards notified under Section 133 of the Companies Act,2013, read with the Rule 7 of the Companies (Accounts) Rules2014;
 - e. On the basis of written representations received from the directors as on March 31,2015,and taken on record by the Board of Directors, none of the directors is disqualified as on March31,2015,from being appointed as a director In terms of sub-section (2) of section 164 of the Companies Act,2013.
 - f. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts in respect of which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

Place: Hyderabad

Date: 21-May-2015

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants

(G Pavan Kumar Reddy)
Proprietor
M.No.229495



ANNEXURE TO AUDITORS REPORT

(Referred to in paragraph 3 & 4 of our report of even date)

- i. In respect of fixed assets:
 - a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - b) A major portion of the fixed assets has been physically verified during the year by the management in accordance with a programme of verification of all the fixed assets at reasonable intervals having regard to the size of the company and the nature of its assets. According to the information and explanations given to us, the discrepancies noticed on such verification were not material and have been properly dealt with in the books of accounts.
- ii. In respect of Inventories:
 - a) The management has conducted physical verification of inventory at reasonable intervals during the year.
 - b) The procedures of physical verification of inventory followed by the management are reasonable and adequate in relation to the size of the Company and nature of its business.
 - c) The Company is maintaining proper records of inventory and no material discrepancies were noticed on physical verification.
- iii.
 - a) According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to Companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the provisions of clauses 3 (iii) (a), 3 (iii) (b) of the Companies (Auditor's Report) Order 2015 are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the company and the nature of its business, for the purchase of inventory and fixed assets and for the sale of goods and services. During the course of our audit, we have not observed any major weakness or continuing failure to correct any major weakness in the internal control system of the Company in respect of these areas.
- v. The Company has not accepted any deposits. Accordingly, the provisions of clause 3(v) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- vi. We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under sub section (1) of section 148 of the Act and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.

5



vii.

- a) The company is regular in depositing with the appropriate authorities undisputed statutory dues including provident fund, income tax, sales - tax, wealth tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues applicable to it.
- b) According to the information and explanations given to us, no undisputed amounts payable in respect of income tax, sale tax, wealth tax, service tax, customs duty, excise duty, value added tax or cess and other material statutory dues, at the yearend, for a period of more than six months from the date they became payable.
- c) According to the information and explanations given to us, the company does not have any amount in the account to transfer investor education and protection fund in accordance with the relevant provisions of the Companies Act, 1956 and rules made there under.

viii. The Company has incurred cash losses at the end of the financial year but the accumulated losses at the end of the financial year are less than fifty percent of the net worth of the company.

ix. In our opinion, According to the information and explanations given to us, the Company has not accepted any loans from the financial institutions and banks. Accordingly, the provisions of clause 3(ix) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.

x. In our opinion, according to the information and explanations given to us, the company has not given any guarantees for loans taken by others from banks or the financial institutions. Accordingly, the provisions of clause 3(x) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.


xi. According to the information and explanations given to us, the company has not accepted any term loans during the year. Accordingly, the provisions of clause 3(xi) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.

xii. Based upon the audit procedures performed for the purpose of reporting the true and fair view of financial statements and as per the information and explanations given by the management, we report that no fraud on or by the company was noticed or reported during the course of our audit.

Place: Hyderabad

Date: 21-May-2015

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants


(G Pavan Kumar Reddy)
Proprietor
M.No.229495

SILICON LIFE SCIENCES PRIVATE LIMITED
Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038
CIN:U85100TG2008PTC057669

Balance Sheet as at March 31, 2015

(All amounts in Indian Rupees, except share data and where otherwise stated)

Particulars	Note	As at March 31, 2015	As at March 31, 2014
EQUITY AND LIABILITIES			
SHAREHOLDER'S FUNDS			
Share capital	3	436,175,000	279,875,000
Reserves and surplus	4	(52,786,877)	(49,651,757)
		383,388,123	230,223,243
NON-CURRENT LIABILITIES			
Long term borrowings	5		69,221,183
Long term provisions	6	493,992	363,936
		493,992	69,585,119
CURRENT LIABILITIES			
Short term borrowings	7	7,500,000	-
Trade payables	8	166,845,729	72,451,937
Other current liabilities	9	8,625,126	82,430,449
Short - Term provisions	6	258,363	-
		183,229,218	154,882,386
TOTAL		567,111,333	454,690,747
ASSETS			
NON-CURRENT ASSETS			
Fixed assets	10		
Tangible assets		288,594,689	300,314,692
Tangible Assets- Capital Work-In-Progress		11,539,799	-
Deferred tax asset(Net)	11	49,009,924	14,398,423
Loans and advances	12	48,057,550	2,322,145
		397,201,961	317,035,260
CURRENT ASSETS			
Inventory	13	71,184,126	19,694,771
Trade receivables	14	91,748,954	80,169,172
Cash and bank balances	15	2,340,403	5,198,936
Loans and advances	12	1,883,680	32,592,609
Other current assets	16	2,752,209	-
		169,909,371	137,655,487
TOTAL		567,111,333	454,690,747

Corporate Information & summary of Significant Accounting Policies

1 & 2

The accompanying notes are an integral part of the financial statements

As per our report of even date.

For G.PAVAN KUMAR & ASSOCIATES

Chartered Accountants


ICAI Firm Registration Number: 1062425

G PAVAN KUMAR REDDY

Proprietor

Membership No.229495

Hyderabad



For and on behalf of the Board of Directors of
Silicon Life Sciences Private Limited


K. NITYANANDA REDDY

Director

DIN:01284195


N.GOVINDARAJAN

Director

DIN:00050482

SILICON LIFE SCIENCES PRIVATE LIMITED

Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038

CIN:U85100TG2008PTC057669

Statement of profit and loss for the year ended March 31, 2015

(All amounts in Indian Rupees, except share data and where otherwise stated)

Particulars	Note	Year ended 31st March, 2015	Year ended 31st March, 2014
I INCOME			
Revenue from operations (Gross)	17	142,889,846	194,099,896
Less: Excise Duty		12,450,093	15,842,632
Revenue from operations (Net)		130,439,753	178,257,264
Other income	18	165,233	211,953
TOTAL REVENUE		130,604,986	178,469,217
II EXPENSES			
Cost of materials Consumed	19	93,199,360	122,305,239
(Increase)/Decrease in Work in Progress, Traded & Finished goods	20	(2,044,431)	4,261,896
Employee benefits expenses	21	21,559,082	18,226,347
Depreciation	10	23,463,717	24,135,910
Other expenses	22	28,979,208	23,192,553
Finance costs	23	3,194,674	25,225,206
TOTAL EXPENSES		168,351,610	217,347,151
III Profit before extraordinary and exceptional items and taxes		(37,746,624)	(38,877,934)
IV Extraordinary and Exceptional items			
V PROFIT/(LOSS) BEFORE TAX		(37,746,624)	(38,877,934)
VI TAX EXPENSE			
Current tax			
Deferred tax (Charge) / Credit		34,611,504	5,535,083
TOTAL TAX EXPENSE		34,611,504	5,535,083
VII PROFIT/ (LOSS) FOR THE YEAR		(3,135,120)	(33,342,852)
VIII EARNINGS PER EQUITY SHARE	25		
Basic & Diluted		(0.08)	(2.50)
Nominal Value per Share		10.00	10.00

Corporate Information & summary of Significant Accounting Policies

1 & 2

The accompanying notes are an integral part of financial statements

As per our report of even date.

For G.PAVAN KUMAR & ASSOCIATES

Chartered Accountants

ICAI Firm Registration Number: 015543

G PAVAN KUMAR REDDY
Chartered Accountants
Hyderabad

Proprietor

Membership No.229495

Hyderabad,

For and on behalf of the Board of Directors of
Silicon Life Sciences Private Limited

K. NITYANANDA REDDY

Director

DIN:01284195

N.GOVINDARAJAN

Director

DIN:00050482

SILICON LIFE SCIENCES PRIVATE LIMITED

Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038

CIN:U85100TG2008PTC057669

CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH, 2015

(All amounts in Indian Rupees, except share data and where otherwise stated)

	Year end March 31, 2015	Year end March 31, 2014
CASH FLOW FROM OPERATING ACTIVITIES		
Net profit/ (loss) before taxes	(37,746,624)	(38,877,934)
Adjustments for :		
Depreciation	23,463,717	24,135,910
Interest expenses	3,102,258	24,925,049
Operating Profit before working capital changes	(11,180,649)	10,183,025
Adjustments for :		
Decrease/ (increase) in inventories	(51,489,355)	40,210,869
Decrease/ (increase) in trade receivables	(11,579,782)	(52,418,762)
Decrease/ (increase) in short term loans and advances	30,708,929	(914,217)
Decrease/ (increase) in long term loans and advances	(45,735,405)	2,162,551
Increase/ (decrease) in trade payables	94,393,792	6,648,998
Increase/ (decrease) in other current liabilities	(2,005,323)	(19,450,836)
Increase/ (decrease) in provisions	130,056	-
Cash generated from operations	14,422,911	(23,761,396)
Income tax paid	-	-
NET CASH FROM OPERATING ACTIVITIES (A)	3,242,262	(13,578,372)
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of fixed assets	(23,283,513)	(9,460,647)
Proceeds from sale of fixed assets	-	-
Sale of investments	-	-
NET CASH FROM INVESTING ACTIVITIES (B)	(23,283,513)	(9,460,647)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of Share Capital	156,300,000	147,875,000
Share Application money received	-	(6,597,330)
Proceeds from short term borrowings	7,500,000	-
Repayment of long term borrowings	(141,021,183)	(92,380,028)
Interest paid	(3,102,258)	(24,925,049)
NET CASH FROM FINANCING ACTIVITIES (C)	19,676,559	23,972,593
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)	(364,689)	933,571
Cash and cash equivalents at beginning of the year	5,198,936	4,265,365
Cash and cash equivalents at end of the year	2,340,403	5,198,936
<i>Cash and cash equivalents comprise of:</i>		
Cash on hand	21,482	30,004
Balances with banks	2,318,921	5,168,932
Total cash and cash equivalents	2,340,403	5,198,936

As per our report of even date.

For G.PAVAN KUMAR & ASSOCIATES

Chartered Accountants


ICAI Firm Registration Number: 0153435

G PAVAN KUMAR REDDY

Proprietor

Membership No.229495

Hyderabad,



For and on behalf of the Board of Directors of
Silicon Life Sciences Private Limited

K. NITYANANDA REDDY

Director

DIN:01284195

N.GOVINDARAJAN

Director

DIN:00050482

SILICON LIFE SCIENCES PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

1. Background

SILICON LIFE SCIENCES PRIVATE LIMITED ('the Company') was incorporated on 2 January 2012 with its registered office in Hyderabad, India. The Company is a subsidiary of Aurobindo Pharma Limited, Hyderabad, India ('the Parent'). The Company was incorporated with an objective to manufacture, produce, process compound, mix, pack, formulate, develop, treat, refine, manipulate, job work, commercialize, export, import buy and sell or otherwise to deal in all types, descriptions, specifications, strengths, and applications of pharmaceuticals and chemical products of medicaments in all the branches including basic drugs, vitamins, hormones, medical products in all forms such as capsules, tablets, powders, ointments, syrups, injectable, pills, fluids, granules and their by products, intermediates, residues, mixtures and compounds.

2. Summary of significant accounting policies

(a) Basis of preparation of financial statements

The Company maintains its accounts on accrual basis following the historical cost convention in accordance with generally accepted accounting principles (GAAP), in compliance with provisions of the Companies Act, 2013 and the Accounting Standards [as specified in the Companies (Accounting Standards) Rules, 2006 read with Section 133 of the Companies Act, 2013 and Rule 7 of the Companies (Accounts) Rules 2014 prescribed by the Central Government]. The other Accounting Standards as issued by ICAI, not yet notified are also considered, wherever applicable, except to the extent where compliance with the other statutory promulgations override the same requiring a different treatment. The accounting policies are consistent with those used in the previous year.

(b) Use of estimates


The preparation of financial statements in conformity with Indian GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting year. Examples of such estimates include provision for future obligation under employee benefit plans, net realizable value of inventory and estimated useful lives of fixed assets. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates.

(c) Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.

Revenue from sale of goods is recognized on dispatch (in respect of exports on the date of the bill of lading or airway bill) which coincides with transfer of significant risks and rewards to customer and is net of trade discounts, sales returns and sales tax, where applicable. Excise duty deducted from revenue (gross) is the amount that is included in revenue (gross) and not the entire amount of liability arising during the year.

Interest is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.



u - 4

→ 8

SILICON LIFE SCIENCES PRIVATE LIMITED**NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015**

(All amounts are in Indian Rupees except share data and where otherwise stated)


(d) Fixed assets and depreciation

Fixed assets are stated at cost less accumulated depreciation and impairment losses, if any. Cost comprises the purchase price and any attributable cost of bringing the asset to its working condition for its intended use. Borrowing costs relating to acquisition of fixed assets which take substantial period of time to get ready for use are included to the extent they relate to the period till such assets are ready for intended use. All other borrowing costs are expensed in the period they occur.

Expenditure directly relating to construction activity is capitalized. Indirect expenditure is capitalized to the extent those relate to the construction activity or is incidental thereto. Income earned during construction period is deducted from the total expenditure relating to construction activity.

Depreciation is provided using the Straight Line Method ('SLM') over the useful lives of the assets considered by the management, as given below:

S. No.	Nature of assets	Useful Life As per Company Policy
1	Factory buildings	30 Years
	Office, Stores & canteen other than RCC	30 Years
	Office, Stores & canteen RCC	60 Years
2	Roads (RCC)	15 Years
3	Furniture and fittings	10 Years
4	Cars and Vans	8 Years
	Tractors	8 Years
	Battery trucks	8 Years
5	Office equipment	5 Years
6	Servers and networks	5 Years
	Desktops/laptops/printer/scanners etc.,	5 Years
7	General Laboratory equipment	12 Years
8	Electrical installations and Equipment	15 Years
10	Reactors	15 Years
	Distillation Columns & Pipelines*	12 Years
	Drying equipments/Centrifuges & Decanters	15 Years
	Storage tanks	15 Years
	Formulation Process Equipment	15 Years
11	General rate to P&M	10 Years



Handwritten signature/initials.

Handwritten signature/initials.

SILICON LIFE SCIENCES PRIVATE LIMITED**NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015**

(All amounts are in Indian Rupees except share data and where otherwise stated)

The above stated Useful life is estimated by management and supported by technical evaluation of the useful life which are generally comparable or lower than the rates prescribed under Schedule II to the Companies Act 2013 except for the items as stated here under:

Asset Type	Life as per Companies Act 2013	Life Considered
General Laboratory Equipment	10 years	12 years
Electrical installations and Equipment	10 years	15 years

Residual value is considered to be Nil.

Assets costing below Rs.5,000 are depreciated in full in the same year.

Additions during the year are depreciated on a pro-rata basis.

Capital work in progress includes the cost of fixed assets which are not yet ready for its intended use.

(e) Impairment

The carrying amounts of assets are reviewed at each balance sheet date to see if there is any indication of impairment based on internal/external factors. An impairment loss is recognized wherever the carrying amount of an asset exceeds its recoverable amount. The recoverable amount is the greater of the assets net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value at the weighted average cost of capital. After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

(f) Inventories

Raw materials, packing materials, stores, spares and consumables are valued at lower of cost, calculated on weighted average basis, and net realizable value. Items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost.

Finished goods and intermediates are valued at lower of cost and net realizable value. Cost includes materials, labour and a proportion of appropriate overheads based on normal operating capacity. Cost is determined on a weighted average basis.

Net realizable value is the estimated selling price in the ordinary course of business, reduced by the estimated costs of completion and costs to effect the sale.



[Handwritten signature]

[Handwritten signature]

SILICON LIFE SCIENCES PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

(g) Employee benefits

Provident fund

A retirement benefit in the form of provident fund scheme is a defined contribution and the contribution is charged to the statement of profit and loss of the year when the contribution to the respective fund is due. There are no other obligations other than the contribution payable to the respective fund.

Gratuity

Retirement benefits in the form of gratuity is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to the statement of profit and loss.

Leave encashment

Employee benefits in the form of leave encashment is a defined benefit obligation and is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of each financial year. Actuarial gains/losses are immediately taken to the statement of profit and loss.

(h) Leases

Leases, where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item are classified as operating leases. Operating lease payments are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term.

(i) Borrowing costs

Borrowing costs include interest and other ancillary costs incurred in connection with the arrangement of borrowing and exchange differences arising from the foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.


(j) Foreign Currency transactions

Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; and non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.



SILICON LIFE SCIENCES PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

Exchange differences

Exchange differences arising on the settlement of monetary items at rates different from those at which they were initially recorded during the period are recognized as income or as expenses in the period in which they arise.

(k) Export Benefits and Incentives.

Export benefits on account of duty drawback and export promotion schemes are accrued and accounted in the year of export, and are included in other operating revenue. Other benefits in the form of advance authorization for imports are accounted for on purchase of imported materials.

(l) Taxes on income

Tax expense comprises of current and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the provisions of the Income Tax Act, 1961. Deferred income taxes reflect the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.

Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the Balance Sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

Unrecognized deferred tax assets of earlier years are reassessed and recognized to the extent that it has become reasonably certain or virtually certain, as the case may be, that future taxable income will be available against which such deferred tax assets can be realized.


The carrying amount of deferred tax assets are reviewed at each Balance Sheet date. The company writes-down the carrying amount of a deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

(m) Provisions

A provision is recognized when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on management estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current management estimates.

(n) Earnings per equity share

Basic earnings per equity share are calculated by dividing the profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.



Handwritten signature/initials.

Handwritten signature/initials.

SILICON LIFE SCIENCES PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and where otherwise stated)

For the purpose of calculating diluted earnings per equity share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

(o) Segment reporting

Identification of reportable segments

Segments are identified in line with AS-17 "Segment Reporting", taking into consideration the internal organization and management structure as well as the different risk and returns of the segment.

Based on the company's business model, pharmaceuticals have been considered as the only reportable business segment and hence no separate financial disclosures provided in respect of its single business segment.


(p) Contingent Liabilities

A contingent liability is possible obligation that arises from past events whose existence will be confirmed by the occurrence or non occurrence of one or more uncertain future events beyond the control of Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize the contingent liability but discloses its existence in the financial statements.

(q) Cash flows

Cash flows are reported using indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities are segregated.

Cash and cash equivalents: Cash and cash equivalents, in the statement of cash flow, comprise cash at bank and in hand and fixed deposits with original maturity of maximum 90 days.



SILICON LIFE SCIENCES PRIVATE LIMITED

Plot.No.2, Maithri Vihar,Ameerpet, Hyderabad 500 038

CIN:U85100TG2008PTC057669

NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015

(All amounts are in Indian Rupees except share data and unless otherwise stated)

3 SHARE CAPITAL

	As at 31st Mar, 2015	As at 31st Mar, 2014
Authorised		
45,000,000 (PY 30,000,000) equity shares of Rs. 10/- each	450,000,000	300,000,000
Issued subscribed and paid-up:		
43,617,500 (PY 27,987,500) equity shares of Rs. 10/- each	436,175,000	279,875,000
TOTAL	436,175,000	279,875,000

a. Reconciliation of number of shares outstanding at the beginning and end of the year

	As at 31st Mar, 2015		As at 31st Mar, 2014	
	No of shares	Value	No of shares	Value
Equity Shares at the beginning of the Year	27,987,500	279,875,000	13,200,000	132,000,000
Equity Shares issued during the Year	15,630,000	156,300,000	14,787,500	147,875,000
Equity Shares outstanding at the end of the Year	43,617,500	436,175,000	27,987,500	279,875,000

b. Terms/rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10 per share. Each holder of equity shares is entitled to one vote per share.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the share holders. In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the share holders.

c. Shares held by holding company

Out of the equity shares issued by the company, shares held by its holding company are as under :

	As at 31st Mar, 2015		As at 31st Mar, 2014	
	No. of shares	Value	No. of shares	Value
Aurobindo Pharma Ltd, the holding Company				
43,617,500 (PY 27,987,500) equity shares of Rs. 10/- each	43,617,500	436,175,000	27,987,500	27,987,500
TOTAL	43,617,500	436,175,000	27,987,500	27,987,500

d. Details of shareholders holding more than 5% shares in the company

	As at 31st Mar, 2015		As at 31st Mar, 2014	
	No. of Shares	% of holding in the class	No. of Shares	% of holding in the class
Aurobindo Pharma Limited, the holding company	43617500	100%	27987500	100%
TOTAL	43617500	100%	27987500	100%

4 RESERVES AND SURPLUS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Securities Premium Account	6,000,000	6,000,000
Surplus/(Deficit) in the Statement of Profit&Loss		
As per last balance sheet	(55,651,757)	(22,308,905)
Add: Profit/(Loss) for the year	(3,135,120)	(33,342,852)
	(58,786,877)	(55,651,757)
TOTAL	(52,786,877)	(49,651,757)



5 LONG-TERM BORROWINGS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Term loans from State bank of Hyderabad	-	69,221,183
TOTAL	-	69,221,183

Loan from State Bank of Hyderabad is fully repaid during the financial year which carries an interest rate of 12% P.A.

6 PROVISIONS

	Non Current		Current	
	As at 31st Mar, 2015	As at 31st Mar, 2014	As at 31st Mar, 2015	As at 31st Mar, 2014
For employee benefits				
-Gratuity (Refer Note no.28)	441,007	363,936	-	-
-Leave Encashment (Refer Note no. 28)	52,985	-	258,363	-
TOTAL	493,992	363,936	258,363	-

7 SHORT-TERM BORROWINGS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Unsecured		
Loan from related party	7,500,000	-
TOTAL	7,500,000	-

Unsecured loan from Aurobindo Pharma Limited, holding company repayable on demand for a period of 3 years from the date of each disbursement and can be extended and rescheduled with mutual agreement and carries an interest rate of 9.5% p.a.

8 TRADE PAYABLES

	As at 31st Mar, 2015	As at 31st Mar, 2014
Trade payables for supplies and services	166,845,729	72,451,937
TOTAL	166,845,729	72,451,937

9 OTHER CURRENT LIABILITIES


	As at 31st Mar, 2015	As at 31st Mar, 2014
Current maturities of long term debt	-	71,800,000
Creditors for Capital goods	8,001,295	2,339,024
Other Payables		
-Statutory Liabilities	226,449	1,223,566
-Others	397,382	7,067,860
TOTAL	8,625,126	82,430,449

11 DEFERRED TAX ASSETS/LIABILITY (NET)

	As at 31st Mar, 2015	As at 31st Mar, 2014
Deferred tax Liability on account of differences in		
On account of depreciation	5,566,451	13,649,034
Deferred tax asset arising on account of timing differences relating to		
On account of employee benefits	260,372	112,458
On account of carried forward loss	54,316,003	27,934,998
TOTAL	49,009,924	14,398,423

12 LOANS AND ADVANCES

	Non Current		Current	
	As at 31st Mar, 2015	As at 31st Mar, 2014	As at 31st Mar, 2015	As at 31st Mar, 2014
(Unsecured and Considered good)	-	-	-	-
Capital advances	2,641,437	1,602,145	-	-
Security deposits	1,070,875	720,000	-	-
Advance recoverable in cash or kind	-	-	1,681,248	31,971,891
Balances with statutory/government authorities	44,345,238	-	-	438,482
Prepaid expenses	-	-	202,432	182,236.00
TOTAL	48,057,550	2,322,145	1,883,680	32,592,609



13 INVENTORIES

	As at 31st Mar, 2015	As at 31st Mar, 2014
(Valued at lower of cost or net realisable value)		
Raw materials	52,627,780	6,510,032
Work in progress	15,053,698	13,117,321
Finished goods	175,471	67,418
Stores,spares and consumables	3,327,176	-
TOTAL	71,184,126	19,694,771

14 TRADE RECEIVABLES

	As at 31st Mar, 2015	As at 31st Mar, 2014
Unsecured, considered good except stated otherwise		
Debts outstanding for a Year exceeding six months from the date they are due for payment		
Due from group companies	69,379,454	38,079,205
Others	1,984,356	-
Other debts		
Due from group companies	20,385,144	-
Others	-	42,089,967
TOTAL	91,748,954	80,169,172

15 CASH AND BANK BALANCES

	As at 31st Mar, 2015	As at 31st Mar, 2014
Cash and cash equivalents consists of		
Cash on hand	21,482	30,004
Balances with banks		
- Current Accounts	2,318,921	5,168,932
TOTAL	2,340,403	5,198,936

16 OTHER CURRENT ASSETS


	As at 31st Mar, 2015	As at 31st Mar, 2014
Intrest accrued bu not due	75,444	-
Other receivables	2,676,765	-
	2,752,209	-

17 REVENUE FROM OPERATIONS

	Year ended March 31, 2015	Year ended March 31, 2014
Sales of products-Domestic	116,819,706	175,160,326
Process Income	26,070,140	18,939,570
TOTAL	142,889,846	194,099,896
Details of Sales of Products		
10% Palladium on Carbon	54,721,360	46,142,778
Doirpenam	-	40,460,200
Ertapenem	-	34,742,496
Meropenem Trihydrate Non Sterile	21,526,000	-
Imipenem Monohydrate	11,048,880	36,529,280
Others	29,523,466	17,285,572
TOTAL	116,819,706	175,160,326

18 OTHER INCOME

	Year ended March 31, 2015	Year ended March 31, 2014
Interest earned/accrued	147,233	62,794
Others	18,000	149,159
TOTAL	165,233	211,953



19 COST OF MATERIAL CONSUMED

	Year ended March 31, 2015	Year ended March 31, 2014
Raw Material Consumed		
Opening stock	6,510,031	42,459,004
Add:- Purchases	139,317,109	86,356,267
	145,827,140	128,815,271
Less:- Closing Stock	52,627,780	6,510,031
Cost of material consumed	93,199,360	122,305,239
Details of cost of material consumed		
Palladium group	10,715,607	39,337,910
Bycyclic Ketoeaster	6,600,000	13,247,500
Dorepenam sidechain	-	18,624,410
Methyl Vinyl Phosphate (MAP)	13,856,400	12,849,950
Acetone	4,336,701	3,510,535
Beta- Methyl Vinyl Phosphate	13,856,400	-
Others	43,834,252	34,734,934
	93,199,360	122,305,239

20 (INCREASE)/DECREASE IN WORK IN PROGRESS, TRADED & FINISHED GOODS


	Year ended March 31, 2015	Year ended March 31, 2014
Inventories at the end of the year		
Finished Goods	175,471	67,418
Work in Progress	15,053,698	13,117,321
	15,229,170	13,184,739
Inventories at the beginning of the year		
Finished Goods	67,418	2,966,844
Work in Progress	13,117,321	14,479,791
	13,184,739	17,446,635
TOTAL	(2,044,431)	4,261,896

21 EMPLOYEE BENEFIT EXPENSES

	Year ended March 31, 2015	Year ended March 31, 2014
Salaries, wages and bonus	18,995,024	15,680,354
Contribution to provident & other funds	693,235	227,147
Gratuity & Leave Encashment (Refer Note. 28)	388,419	1,249,981
Staff welfare expenses	1,482,404	1,068,865
TOTAL	21,559,082	18,226,347

22 OTHER EXPENSES

	Year ended March 31, 2015	Year ended March 31, 2014
Consumption of Stores & Spares	1,078,484	3,024,094
Power and fuel	12,778,766	12,212,469
Carriage Inward	170,284	73,874
Repairs & Maintenance:-		
-Plant & Machinery	2,133,631	1,015,498
-Building	954,760	1,004,939
-Others	882,138	-
Processing charges	1,171,680	137,500
Increase/ (Decrease) of Excise duty on Finishedgoods(refer note no.27)	21,934	(314,980)
Other manufacturing expenses	1,003,129	535,363
Rent	-	69,000
Rates and taxes	885,174	1,122,685
Printing and stationary	265,084	195,360
Postage,telegram and telephones	382,581	169,680
Insurance	423,304	350,808
Legal and professional fee	127,500	282,354
Audit Fee - Statutory audit	35,000	30,000
Audit Fee - Tax Audit	15,000	15,000
Carriage outwards	691,932	261,750
Travelling and conveyance	97,171	189,020
Vehicle maintenance.	17,869	16,659
General Expenses	424,887	189,192
Registration, membership and filing fee	5,289,119	2,491,405
Office Maintenance	129,781	120,884
TOTAL	28,979,208	23,192,553



u. -4

28

23 FINANCIAL COST

	Year ended March 31, 2015	Year ended March 31, 2014
Interest expenses		
-for term loans	3,102,258	24,925,049
-for others	83,938	96,661
Bank charges	8,478	203,496
TOTAL	3,194,674	25,225,206

24 CAPITAL AND OTHER COMMITMENTS

Estimated amount of contracts(net of advances) remaining to be executed on capital account and not provide for Rs.42,95,216/- (Mar ,2014 Rs.40,11,000/-)

25 CONTINGENT LIABILITIES

	Year ended March 31, 2015	Year ended March 31, 2014
Outstanding Bank Guarantees	-	-
TOTAL	-	-

26 IMPORTED AND INDIGENOUS RAW MATERIALS, STORES AND SPARES CONSUMED

	Year ended March 31, 2015	Year ended March 31, 2014
Raw Materials and Packing Material		
- Imported		
- Indigenous	93,199,360	122,305,239
TOTAL	93,199,360	122,305,239
Stores and Spares		
- Imported		
- Indigenous	1,078,484	3,024,094
TOTAL	1,078,484	3,024,094

In accordance with paragraph 10 of Notified Accounting Standard 9 on Revenue Recognition, excise duty on sales amounting to Rs.12,450,093/- (March 31, 2014: Rs. 15,842,632) has been reduced from sales in Statement of Profit and Loss and excise duty on (increase)/decrease in closing stock of finished goods amounting to Rs. 21,934/- (March 31,2014-Rs.-314,980/-)has been debited to the Statement of Profit and Loss.

28 EMPLOYEE BENEFITS

	Year ended March 31, 2015	Year ended March 31, 2014
a Disclosures related to defined contribution plan		
Provident fund contribution recognized as expense in the statement of Profit and Loss	693,235	179,043

b Disclosures related to defined benefit plan -Gratuity

The Company has a defined gratuity plan. Every employee who has completed five years or more of service gets a gratuity on departure at 15 days last drawn salary for each completed year of service

	Year ended March 31, 2015	Year ended March 31, 2014
Statement of Profit and Loss		
Expenses recognized in statement of profit and loss		
Current service cost	70,011	47,948
Interest cost	29,115	37,212
Expected return on plan assets		
Net Actuarial (gain)/ Loss recognized in the Year	(22,055)	(186,371)
Net Benefit expense	77,071	(101,211)



Balance Sheet

	Year ended March 31, 2015	Year ended March 31, 2014
Details of provision for Gratuity		
Defined benefit obligation	441,007	363,936
Amount shown in the balancesheet		
Opening defined benefit obligation	3,63,936	465,147
Interest cost	29,115	37,212
Current services cost	70,011	47,948
Benefits paid	-	-
Actuarial (gains)/losses on obligation	(22,055)	(186,371)
Closing defined benefit obligation	4,41,007	363,936
The principal assumptions used in determining gratuity obligations for the Company's plans are shown below:		
Assumptions		
Salary Rise	4%	4%
Discount rate	8%	8%
Attrition Rate	5%	5%
Av Balance Service	25.18 Years	26.72 Yrs
The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotions and other relevant factors such as supply and demand in the employment market. The Company evaluates these assumptions annually based on its long term plans of growth and industry standards.		

C Disclosures related to defined benefit plan -Leave Encashment**Statement of Profit and Loss**

	Year ended March 31, 2015	Year ended March 31, 2014
Current Service Cost	8,958	-
Interest Cost on benefit obligation	22,503	-
Expected return on plan assets	-	-
Net Actuarial (gain)/Loss recognized in the year	24,893	-
Net Benefit expense	56,354	-

	Year ended March 31, 2015	Year ended March 31, 2014
Balance Sheet		
Details of provision for Leave encashment		
Defined benefit obligation	311,348	-


Change in the present value of the defined benefit obligation are as follows

	Year ended March 31, 2015	Year ended March 31, 2014
Opening defined benefit obligation	281,288	-
Interest cost	22,503	-
Current services cost	8,958	-
Benefits paid	(26,294)	-
Actuarial (gains)/losses on obligation	24,893	-
Closing defined benefit obligation	311,348	-

The principal assumptions used in determining leave encashment obligations for the Company's plans are shown below:

	Year ended March 31, 2015	Year ended March 31, 2014
Discount rate (p.a)	4%	0%
Salary Rise	8%	0%
Attrition Rate	5%	0%

The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotions and other relevant factors such as supply and demand in the employment market. The Company evaluates these assumptions annually based on its long term plans of growth and industry standards.



u. - 9

29 RELATED PARTY DISCLOSURES
Names of related parties and description of relationship

Names	Nature of relationship
Aurobindo Pharma Ltd	Holding company
Auro Next Pharma Pvt. Ltd	Fellow subsidiary
Sri K. Nityananda Reddy	Director
Sri N.Govindarajan	Director
Mr.V.S.Nagi Reddy*	Director
Mr.A.S.R.Prasad*	Director
Mr.G.C.Bakki Reddy*	Director
VVR Organics Private Limited**	Enterprises where key managerial personnel exercise significant influence
Silicon Drugs & Intermediates Pvt Ltd**	Enterprises where key managerial personnel exercise significant influence
Pravesha Industries Private Limited	Enterprises where key managerial personnel exercise significant influence
Trident chemphar Limited	Enterprises where key managerial personnel exercise significant influence

* resigned w.e.f. 1-11-2013.


*ceased w.e.f. 1-11-2013.

Transaction with related parties

Particulars	Year ended March 31, 2015	Year ended March 31, 2014
a. Transactions with holding company- Aurobindo Pharma Limited		
Equity allotment	15,630,000	147,875,000
Unsecured Loan	7,500,000	-
Interest on unsecured loan	83,938	-
Sales & Jobwork of Goods	90,899,948	70,020,162
Purchase of Goods/ Assets	127,063,809	93,446,775
Balance Payable	156,155,399	54,682,598
b. Transactions with fellow subsidiary-Auro Next Pharma Pvt. Ltd		
Sale of Goods	39,309,565	94,009,108
Balance Receivable	89,764,598	65,009,108
c. Transactions with directors		
Mr.V.S.Nagi Reddy - Director		
Managerial Remuneration	-	216,000
Balance Payable	165,840	165,840
Mr.A.S.R.Prasad - Director		
Managerial Remuneration	-	216,000
Balance Payable	355,401	355,401
Mr.G.C.Bakki Reddy - Director		
Managerial Remuneration	-	216,000
Balance Payable	355,401	355,401
d. Transactions with enterprises over which key management personnel or their relative exercise significant influence		
Pravesha Industries Pvt Ltd		
Purchase of Goods, Assets & Services	97,818	-
Balance Payable / (Receivable)	13,925	-
Trident Chemphar Ltd		
Purchase of Goods, Assets & Services	3,812,937	-
Balance Payable / (Receivable)	-	-
VVR Organics Private Limited - Associate Company		
Purchase of Goods, Assets & Services	-	8,623,544
Balance Payable / (Receivable)	-	-

30 EARNING PER EQUITY SHARE

	As at 31st Mar, 2015	As at 31st Mar, 2014
Profit/ (Loss) after taxation considered for calculation of basic and diluted earning per share	(3,135,120)	(33,342,852)
Weighted average number of equity shares considered for calculation of basic earnings per share (a)	39,479,555	13337141
Basic earning per share	(0.08)	(2.50)



31 VALUE OF IMPORTS CALCULATED ON CIF BASIS

	As at 31st Mar, 2015	As at 31st Mar, 2014
Raw materials and Packing materials	-	-
Capital Goods	-	-
Stores and spares, lab chemicals and other consumables	-	-
TOTAL	-	-

32 EXPENDITURE IN FOREIGN CURRENCY (ACCRUAL BASIS)

	Year ended March 31, 2015	Year ended March 31, 2014
Registration & filing fees	3,477,164	-
TOTAL	3,477,164	-

33 EARNINGS IN FOREIGN CURRENCY (ACCRUAL BASIS)

	Year ended March 31, 2015	Year ended March 31, 2014
FOB value of exports	-	-
TOTAL	-	-

34 CIF VALUE OF EXPORTS

	Year ended March 31, 2015	Year ended March 31, 2014
	-	-
TOTAL	-	-

35 There are no dues to Micro, Small and Medium size companies to which the company owe amount outstanding more than 30 days.


36 The figures of previous year have been regrouped/rearranged wherever necessary to confirm to those of current year presentations.

As per our report of even date.


For G.PAVAN KUMAR & ASSOCIATES

Chartered Accountants

ICAI Firm Registration Number: 012841



G PAVAN KUMAR REDDY
Proprietor
Membership No.229495
Hyderabad



For and on behalf of the Board of Directors of
Silicon Life Sciences Private Limited


K. NITYANANDA REDDY

Director

DIN:012841


N.GOVINDARAJAN

Director

DIN:00050482

SILICON LIFE SCIENCES PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2015

(All amounts in Indian Rupees, except share data and where otherwise stated)

Note 10 : Tangible Assets

Particulars	Land	Buildings	Plant & Machinery	Electrical Installation	Lab Equipment	Computers	Furniture & Fixtures	Vehicles	Total
Gross Block									
As at 1 April 2013	17,763,803	111,696,729	145,211,619	25,345,812	21,767,422	1,519,855	108,000	107,960	323,521,200
Additions made during the year	1,515,754	4,766,207	1,321,393	239,208	678,533	50,400	889,153	-	9,460,648
Disposals/adjustments made during the year	-	-	-	-	-	-	-	-	-
As At 1 April 2014	19,279,557	116,462,936	146,533,012	25,585,020	22,445,955	1,570,255	997,153	107,960	332,981,848
Additions made during the year	-	6,079,370	4,566,737	465,442	312,449	319,715	-	-	11,743,713
Disposals/adjustments made during the year	-	-	-	-	-	-	-	-	-
At 31st March 2015	19,279,557	122,542,306	151,099,749	26,050,462	22,758,404	1,889,970	997,153	107,960	344,725,561
Accumulated depreciation									
As at 1 April 2013	-	2,362,423	4,512,835	801,518	679,672	163,388	4,581	6,828	8,531,245
Charge for the year	-	3,864,484	15,065,043	2,628,112	2,285,222	247,033	34,854	11,163	24,135,911
Adjustments or disposals	-	-	-	-	-	-	-	-	-
As At 1 April 2014	-	6,226,907	19,577,878	3,429,630	2,964,894	410,421	39,435	17,991	32,667,156
Charge for the year	-	3,917,571	15,550,635	1,683,248	1,802,475	371,032	102,182	36,573	23,463,716
Adjustments or disposals	-	-	-	-	-	-	-	-	-
At 31st March 2015	-	10,144,478	35,128,513	5,112,878	4,767,369	781,453	141,617	54,564	56,130,872
Net Block									
At 31 March 2014	19,279,557	110,236,029	126,955,134	22,155,390	19,481,061	1,159,835	957,718	89,969	300,314,693
At 31st March 2015	19,279,557	112,397,828	115,971,236	20,937,584	17,991,035	1,108,517	855,536	53,396	288,594,689

Capital Work in Progress Rs.1,15,37,799(Mar 31, 2014: Rs.NIL)

*Note : Agreement for sale of land is executed, however the registration in the name of the company of the same is pending.



u. - 9

128

AUROZYMES LIMITED

CIN: U24232TG2013PLC091383

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

DIRECTORS' REPORT

Dear Members,

Your Directors are pleased to present the Second Annual Report of the Company together with the Audited Accounts for the year ended 31st March, 2015.

Review of Operations:

The Company is yet to start commercial operations

Dividend

No dividend has been declared, as the company is yet to start commercial operations.

Reserves

No amount has been carried to General Reserves during the year 2014-15

Details of Subsidiary/Joint Ventures/Associate Companies

The Company has no Subsidiaries / Joint Venture / Associate Companies as on 31st March, 2015.

Deposits

The Company has not accepted any public deposits and as such, no amount on account of principal or interest on public deposits was outstanding as on the date of the balance sheet.

Statutory Auditors

M/s. G Pavan Kumar & Associates, Chartered Accountants, Hyderabad have been appointed as Statutory Auditors of the Company at the 1st Annual General Meeting held on 25th August, 2014 for a period of 5 years subject to ratification by the members at every Annual General Meeting (i.e. till 6th Annual General Meeting). Your Directors commend for the ratification of their appointment.

Auditors' Report

The observations made in the Auditors' Report read together with relevant notes thereon are self explanatory and hence do not call for any further comments under Section 134 of the Companies Act, 2013.

AUROZYMES LIMITED

CIN: U24232TG2013PLC091383

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Share Capital

There is no further issue of shares during the year.

Extract of the Annual Return

In accordance with Section 134(3)(a) of the Companies Act, 2013 the extract of Annual Return (Form MGT-9) of the Company is enclosed as **Annexure – I** to the Boards Report.

Material changes and commitments, if any.

There are no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

Conservation of energy, technology absorption and foreign exchange earnings and outgo

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014, is not applicable to the Company for the year 2014-15 except foreign exchange earnings and outgo which is furnished in as **Annexure – II**

Business Risk Management

At present the company has not identified any element of risk which may threaten the existence of the Company.

Directors:

As per the provisions of the Companies Act, 2013 Mr. K Nityananda Reddy will retire in the ensuing Annual General Meeting and being eligible, seek re-appointment. The Board of Directors recommends his re-appointment.

Changes in Directors and Key Managerial Personnel:

During the year Mr. M. Madan Mohan Reddy (DIN:01284266) has been appointed as an Additional Director of the Company w.e.f. 30th March, 2015. He holds office upto the date of the ensuing Annual General Meeting. The Company has received notice in writing under the provisions of Section 160 of the Companies Act, 2013, proposing the candidature of Mr. M. Madan Mohan Reddy for the office of Director.

Mr. Sarath Chandra Reddy (DIN: 01608013) was resigned from the Board as Director of the Company w.e.f 30th March, 2015

AUROZYMES LIMITED

CIN: U24232TG2013PLC091383

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Number of meetings of the Board of Directors:

During the financial year 2014-15 the Board of Directors has met five times viz., on 09.05.2014, 18.07.2014, 21.10.2014, 30.01.2015, and 30.03.2015.

Particulars of loans, guarantees or investments under section 186:

No loans, Guarantees or investment made by the company during the year 2014-15.

Particulars of contracts or arrangements with related parties:

All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business. There were no materially significant related party transactions which could have had a potential conflict with the interests of the Company.

Particulars of Employees

Information as required to be disclosed under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 which is furnished in as **Annexure – III**

Policy on Sexual Harassment

The Company has adopted policy on Prevention of Sexual Harassment of Women at Workplace in accordance with The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. During the financial year ended March 31, 2015, the Company has not received any Complaints pertaining to Sexual Harassment.

Directors' Responsibility Statement

Pursuant to Section 134(5) of the Companies Act, 2013, Directors of your Company hereby state and confirm that:

(a) in the preparation of the annual accounts for the year ended 31st March, 2015, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

AUROZYMES LIMITED

CIN: U24232TG2013PLC091383

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India
Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) the directors had prepared the annual accounts on a going concern basis; and

(e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and are operating effectively.


(f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and are operating effectively.


Acknowledgements

Your Company will always keep interest of its customers, employees and the stakeholders as a priority and shall reciprocate their confidence reposed in the Company. It has been a mutually beneficial relationship and looks forward to their continued support.

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015


K.Nityananda Reddy
Director
DIN: 01284195


N Govindarajan
Director
DIN: 00050482

AUROZYMES LIMITED

CIN: U24232TG2013PLC091383

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Annexure-II

Foreign exchange earnings and Outgo:

	(in Rupees)	
	2014-15	2013-14
Foreign exchange earned		
Exports (FOB)	-	-
Others	-	-
Foreign exchange outgo		
Materials	-	-
Other expenses	189,942	-
	189,942	-

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015


K. Nityananda Reddy
Director
DIN: 01284195


N. Govindarajan
Director
DIN: 00050482

ANNEXURE - I

**Form No. MGT-9
EXTRACT OF ANNUAL RETURN
as on the financial year ended on 31.03.2015**

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:		
i	CIN	U24232TG2013PLC091383
ii	Registration Date	28.11.2013
iii	Name of the Company	AuroZymes Limited
iv	Category / Sub-Category of the Company	Company Limited by Shares/Public Limited Company
v	Address of the Registered office and contact details	Plot No. 2, Maitrivihar, Ameerpet, Hyderabad – 500 038, Telangana Ph.No: 040 - 66725000 Fax.No:040 - 67074059
vi	Whether listed company	No
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

The Company is yet start Commercial operations.

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
	N.A.	N.A.	N.A.

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S.No	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ASSOCIATE	% of shares held	Applicable Section
1	Aurobindo Pharma Limited Regd Off: Plot No.2, Maitrivihar, Ameerpet, Hyderabad – 500038, Telangana	L24239TG1986PLC015190	HOLDING	100	2(46)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):

i) Category-wise Share Holding:

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual /HUF	0	0	0	0	0	0	0	0	0
b) Central Govt	0	0	0	0	0	0	0	0	0
c) State Govt (s)	0	0	0	0	0	0	0	0	0
d) Bodies Corp.	0	49400	49400	100.00	0	49400	49400	100.00	0
e) Banks / FI									
f) Any Other (Nominees of holding Company)	0	600	600	0	0	600	600	0	0
Sub-total (A) (1):-	0	50000	50000	100.00	0	50000	50000	100.00	0

i) Individual shareholders holding nominal share capital upto Rs1 lakh	0	0	0	0	0	0	0	0	0
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	0	0	0	0	0	0	0	0	0
c) Others (specify)	0	0	0	0	0	0	0	0	0
Sub-total (B)(2):-	0	0	0	0	0	0	0	0	0
Total Public Shareholding (B)=(B)(1)+(B)(2)	0	0	0	0	0	0	0	0	0
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	0	50000	50000	100.00	0	50000	50000	100.00	0

ii) Shareholding of Promoters

Sl No	Shareholder's Name	Shareholding at the beginning of the year			Share holding at the end of the year			
		No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	%of Shares Pledged / encumbered to total shares	
								% change in share Holding during the year

1	Aurobindo Pharma Ltd (APL)	49400	100	0	4900	100	0	0
2	K Nityananda Reddy (Nominee of APL)	100	0	0	100	0	0	0
3	N Govindarajan (Nominee of APL)	100	0	0	100	0	0	0
4	P Sarath Chandra Reddy (Nominee of APL)	100	0	0	100	0	0	0
5	A Mohan Rami Reddy (Nominee of APL)	100	0	0	100	0	0	0
6	M Venkat Reddy (Nominee of APL)	100	0	0	100	0	0	0
7	T S Sankara Reddy (Nominee of APL)	100	0	0	100	0	0	0
	Total	50000	100	0	50000	100	0	0

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl.No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	At the beginning of the year	NIL			
	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus/ sweat equity etc):	NIL			
	At the End of the year	NIL			

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	For Each of the Top 10 Shareholders				
	At the beginning of the year	NIL			
	Date wise Increase /Decrease in Share holding during the year specifying the reasons for increase /decrease (e.g. allotment /transfer / bonus / sweat equity etc):	NIL			
	At the End of the year (or on the date of separation, if separated during the year)	NIL			

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total Shares of the company
	For Each of the Directors and KMP				
	At the beginning of the year	NIL			
	Date wise Increase / Decrease in Share holding during the year specifying the reasons for increase / decrease (e.g. allotment /transfer / bonus/ sweat equity etc):	NIL			
	At the End of the year	NIL			

V. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil
Change in Indebtedness during the financial year	Nil	Nil	Nil	Nil
• Addition	Nil	Nil	Nil	Nil
• Reduction				
Indebtedness at the end of the financial year	Nil	Nil	Nil	Nil
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid				
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl.no.	Particulars of Remuneration	Name of MD/WTD/ Manager				Total Amount

1	Gross salary (a) Salary as per provisions contained in section 17(1) of the	Nil	Nil	Nil	Nil	Nil

	Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961					
2	Stock Option	Nil	Nil	Nil	Nil	Nil
3	Sweat Equity	Nil	Nil	Nil	Nil	Nil
4	Commission - as % of profit - others, specify...	Nil	Nil	Nil	Nil	Nil
5	Special Allowance	Nil	Nil	Nil	Nil	Nil
	Total (A)	Nil	Nil	Nil	Nil	Nil
	Ceiling as per the Act	Nil	Nil	Nil	Nil	Nil

B. Remuneration to other directors:

Sl.no.	Particulars of Remuneration	Name of Directors				Total Amount
		----	----	----	----	
	Independent Directors • Fee for attending board / committee meetings • Commission • Others, please specify	NIL				
	Total (1)	NIL				
	Other Non-Executive Directors • Fee for attending board / committee meetings • Commission	NIL				

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty /Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give details)
A. Company					
Penalty			NIL		
Punishment					
Compounding					
B. Directors					
Penalty			NIL		
Punishment					
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty			NIL		
Punishment					
Compounding					

	• Others, please specify	
	Total (2)	NIL
	Total (B)=(1+2)	NIL
	Total Managerial Remuneration	NIL
	Overall Ceiling as per the Act	NIL

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD:

Sl.no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Incometax Act, 1961	N.A			
2.	Stock Option	N.A			
3.	Sweat Equity	N.A			
4.	Commission - as % of profit - others, specify...	N.A			
5.	Others, please specify	N.A			
	Total	N.A			

AUROZYMES LIMITED

CIN: U24232TG2013PLC091383

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India

Tel: +91 40 2373 6370 Fax: +91 40 2374 7340

Annexure-III

Information as required under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014


Name of the Employee	Designation of employee	Remuneration Received (Rs.)	Nature of Employment (Contractual or otherwise)	Qualifications and Experience of the employee	Date of Commencement of employment	Age of Employee	Last employment held before joining the Company	The % of Equity shares held by the employee	Whether employee is relative of any Director, if so. Name of such Director
Mr. Jonathan Wiffen	Sr. Vice-President	1,50,90,940*	Contractual	Professional Certificate in Management (2001-02)&University Level : Applied Chemistry (1990-95) & Total 23.8 Yrs.	12.06. 2014	19.03.1972 (43 Yrs.)	Almac Group, UK	Nil	No

*Part of the year

For and on behalf of the Board

Place: Hyderabad
Date: 21.05.2015


K. Nityananda Reddy
Director
DIN: 01284195


N. Govindarajan
Director
DIN: 00050482



INDEPENDENT AUDITOR'S REPORT

To the Members of
Aurozymes limited.

Report on the Financial Statements

We have audited the accompanying financial statements of M/s Aurozymes limited ("the Company"), which comprise the Balance sheet as at March 31, 2015, the Statement of Profit and Loss and Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements


The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedure to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the Assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- a. In the case of the Balance Sheet, of the state of affairs of the Company as at March 31,2015;
- b. In the case of the Statement of Profit and Loss, of the loss for the year ended on that date; and
- c. In case of the Cash Flow Statement, of the cash flows for the year ended on that date.


Report on Other Legal and Regulatory Requirements

- 1) As required by the Companies (Auditor's Report) Order, 2015 ("the order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure a statement on the matters section in paragraphs 3 and 4 of the Order.
- 2) As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to best of our knowledge and belief were necessary for the purpose of our audit;
 - b. In our opinion proper books of account as required by law have been kept by the company so far as appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the Balance Sheet , Statement of Profit and Loss and Cash Flow Statement comply with the Accounting Standards notified under Section 133 of the Companies Act,2013, read with the Rule 7 of the Companies (Accounts) Rules,2014;
 - e. On the basis of written representations received from the directors as on March 31,2015, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31,2015, from being appointed as a director In terms of sub-section (2) of section 164 of the Companies Act,2013.
 - f. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts in respect of which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For M/s. G Pavan Kumar & Associates

Firm Registration No: 015343S

Chartered Accountants



(G. Pavan Kumar Reddy)

Proprietor

M.No.229495

Place: Hyderabad

Date:

ANNEXURE TO AUDITORS REPORT
(Referred to in paragraph 3 & 4 of our report of even date)

- i. In respect of fixed assets:
 - a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - b) A major portion of the fixed assets has been physically verified during the year by the management in accordance with a programme of verification of all the fixed assets at reasonable intervals having regard to the size of the company and the nature of its assets. According to the information and explanations given to us, the discrepancies noticed on such verification were not material and have been properly dealt with in the books of accounts.
- ii. The Company has no inventory as on the balance sheet date
- iii. According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to Companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the provisions of clauses 3 (iii) (a), 3 (iii) (b) of the Companies (Auditor's Report) Order 2015 are not applicable to the Company and hence not commented upon.
- iv. In our opinion and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the company and the nature of its business, for the purchase of inventory and fixed assets and for the sale of goods and services. During the course of our audit, we have not observed any major weakness or continuing failure to correct any major weakness in the internal control system of the Company in respect of these areas.
- v. The Company has not accepted any deposits. Accordingly, the provisions of clause 3(v) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- vi. The company was started not commenced any commercial operations, maintenance of cost records under section 148(1) of the Companies Act, 2013 was not applicable.
- vii.
 - a) The company is regular in depositing with the appropriate authorities undisputed statutory dues including provident fund, employees' state insurance, income tax, sales - tax, wealth tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues applicable to it.
 - b) According to the information and explanations given to us, no undisputed amounts payable in respect of income tax, sale tax, wealth tax, service tax, customs duty, excise



duty, value added tax or cess and other material statutory dues, at the yearend, for a period of more than six months from the date they became payable.

- c) According to the information and explanations given to us, the company does not have any amount in the account to transfer investor education and protection fund in accordance with the relevant provisions of the Companies Act, 1956 and rules made there under.
- viii. The provision of clause 3(viii) of the Order is not applicable, since the incorporation of the company is less than five years
- ix. In our opinion, According to the information and explanations given to us, the Company has not accepted any loans from the financial institutions and banks. Accordingly, the provisions of clause 3(ix) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- x. In our opinion, according to the information and explanations given to us, the company has not given any guarantees for loans taken by others from banks or the financial institutions. Accordingly, the provisions of clause 3(x) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xi. According to the information and explanations given to us, the company has not accepted any term loans during the year. Accordingly, the provisions of clause 3(xi) of the companies (Auditor's Report) Order, 2015 are not applicable to the Company.
- xii. Based upon the audit procedures performed for the purpose of reporting the true and fair view of financial statements and as per the information and explanations given by the management, we report that no fraud on or by the company was noticed or reported during the course of our audit.

For M/s. G Pavan Kumar & Associates
Firm Registration No: 015343S
Chartered Accountants



(G Pavan Kumar Reddy)
Proprietor

No. 229495

Place: Hyderabad
Date:

AUROZYMES LIMITED

PLOT.NO.2, MAITHRI VIHAR,AMEERPET, HYDERABAD 500 038

CIN:U24232TG2013PLC091383

BALANCE SHEET AS AT 31 MARCH, 2015

(All amounts in Indian Rupees, except for share data or as otherwise stated)

PARTICULARS	Note No.	As at 31 Mar, 2015	As at 31 Mar, 2014
I. EQUITY AND LIABILITIES			
(1) Shareholders Funds			
(a) Share Capital	3	500,000	500,000
(b) Reserves & Surplus	4	(76,088)	-
		423,912	500,000
(2) Non-Current Liabilities			
(a) Deferred tax liabilities (Net)	5	15,683	-
		15,683	-
(3) Current Liabilities			
(a) Short term borrowings	6	20,500,000	-
(b) Other Current Liabilities	7	982,053	11,236
		21,482,053	11,236
Total		21,921,648	511,236
II. ASSETS			
(1) Non- Current Assets			
(a) Fixed Assets			
(i) Tangible Assets	8	1,586,533	-
(ii) Tangible Assets-Capital work In Progress	8	18,121,574	37,348
(b) Long term Loans & advances	9	323,140	-
		20,031,247	37,348
(2) Current Assets			
(a) Short Term Loans & Advances	9	10,904	-
(b) Cash & Bank Balances	10	1,879,497	473,888
		1,890,401	473,888
Total		21,921,648	511,236

Corporate information & Summary of significant accounting policies 1& 2

The accompanying notes are an integral part of the financial statements.

As per our report of even date

For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES

Firm Registration Number:015343S

Chartered Accountants


(G.Pavan Kumar Reddy)

Proprietor

Membership No.229495

Place: Hyderabad

Date:21-May-2015



(K.Nithyananda Reddy)


Director

DIN:01284195

(N.Govindarajan)

Director

DIN:00050482



AUROZYMES LIMITED
PLOT.NO.2, MAITHRI VIHAR, AMEERPET, HYDERABAD 500 038
CIN:U24232TG2013PLC091383

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 MARCH,2015

(All amounts in Indian Rupees, except for share data or as otherwise stated)


PARTICULARS	Note	Year ended	Year ended
Income:			
Revenue from operations		-	-
Other Income		-	-
Total Revenue		-	-
Expenses:			
Other Expenses	11	60,405	-
Total Expenses		60,405	-
Profit/(Loss) before tax		(60,405)	-
Tax Expense:			
Differed tax Credit / (Charge)	5	(15,683)	-
Profit/(Loss) for the year		(76,088)	-
Earning per equity share:	12		
Basic & Diluted		(1.52)	-
Nominal Value per Equity Share		10	-

Corporate information & Summary of significant accounting policies 1& 2
The accompanying notes are an integral part of the financial statements.

As per our report of even date


For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES
Firm Registration Number:015343S
Chartered Accountants


(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place: Hyderabad
Date:21-May-2015




(K.Nithyananda Reddy)
Director
DIN:01284195


(N.Govindarajan)
Director
DIN:00050482



AUROZYMES LIMITED
PLOT.NO.2, MAITHRI VIHAR, AMEERPET, HYDERABAD 500 038
CIN:U24232TG2013PLC091383


Cash flow statement for the year ended 31 March, 2015
(All amounts in Indian Rupees, except for share data or as otherwise stated)

Particulars	Year ended 31 Mar, 2015	Year ended 31 Mar, 2014
1. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and exceptional items	(76,088)	-
Adjustments to reconcile profit before tax to net cash flows		
Operating Profit before Working Capital Changes	(76,088)	-
Movements in working capital:		
Decrease/(increase) in long-term loans and advances	(323,140)	-
Decrease/(increase) in short-term loans and advances	(10,904)	-
Increase/(decrease) in other noncurrent assets	-	(37,348)
Increase/(decrease) in other noncurrent liabilities	15,683	-
Increase/(decrease) in other current liabilities	982,093	11,236
Cash Generated from Operations	587,604	(26,112)
Direct taxes paid (net of refunds)	-	-
Net Cash flow from Operating Activities (A)	587,604	(26,112)
2. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of fixed assets, including CWIP and capital advances	(19,670,759)	-
Net Cash flow used in Investing Activities (B)	(19,670,759)	-
3. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issuance of share capital	-	500,000
Proceeds from Long term/Short term Borrowings	20,488,764	-
Net Cash flow from Financing Activities (C)	20,488,764	500,000
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	1,405,609	473,888
Cash and Cash Equivalents at the beginning of the year	473,888	-
Cash and Cash Equivalents at the end of the year	1,879,497	473,888

As per our report of even date


For G.PAVAN KUMAR & ASSOCIATES
Firm Registration Number:0153435
Chartered Accountants

(G.Pavan Kumar Reddy)
Proprietor
Membership No.229495
Place: Hyderabad
Date:21-May-2015



For and on behalf of the Board of Directors

K. Nithyananda Reddy
(K.Nithyananda Reddy)
Director
DIN:01284116
N. Govindarajan
(N.Govindarajan)
Director
DIN:00050482



AUROZYMES LIMITED

Notes to financial statements for the year ended March 31, 2015

(All amounts in Indian Rupees, except for share data or as otherwise stated)

1. Corporate information

Aurozymes Limited (the Company) is a limited Company domiciled in India and incorporated under the provisions of the Companies Act, 1956. The Company is engaged in the business of researching, receiving, manufacturing, processing, producing, accruing, distributing, marketing, selling, releasing, commissioning, purchasing, licensing, importing, dealing, trading, using & exporting all types of enzymes, biocatalysts, biobased products & products utilising, biocatalytic steps including biotech, pharmaceutical, nutraceutical, cosmeceutical and agro chemical ingredients, intermediates and finished products and other preparations of any nature and in whatsoever into the chemical and allied industries.

The Company is a subsidiary of Aurobindo Pharma limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.

2. Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). The Company has prepared these financial statements to comply in all material respects with the accounting standards, specified under section 133 of the Companies Act, 2013 ("the Act"), read with the Rule 7 of the Companies (Accounts) Rules 2014 (as amended). The financial statements have been prepared on an accrual basis and under the historical cost convention.

2.1 Summary of significant accounting policies

a. Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

b. Tangible fixed assets

Fixed assets are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discounts and rebates are deducted in arriving at the purchase price.

Subsequent expenditure related to an item of fixed asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. All other expenses on existing fixed assets, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which such expenses are incurred.

Gains or losses arising from derecognition of fixed assets are measured as the difference between the net disposal proceeds and the carrying amount of the asset and recognized in the statement of profit and loss when the asset is derecognized.

c. Depreciation on tangible fixed assets

Depreciation on fixed assets is calculated on a straight line method, based on useful life prescribed under Schedule II to the Companies Act, 2013.



Handwritten signature

Handwritten signature



d. Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured.

Income from services rendered by the Company is recognised on accrual basis for services rendered and billed as per the terms of specific contract.

e. Retirement and other employee benefits

Gratuity or other retirement benefits are not provided because the provisions of Payment of Gratuity Act, 1972 were not applicable

f. Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

g. Provisions

A provision has been recognized in respect of a present obligation as a result of past event i.e. based on the probability of there being an outflow of resources to settle the obligation, in respect of which a reliable estimate can be made. Provisions have not been discounted to its present value and have been determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

h. Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

i. Cash and Cash Equivalents

Cash and cash equivalents comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.



Handwritten signature and a horizontal line.

Handwritten signature.



NOTES TO FINANCIAL STATEMENTS FOR YEAR ENDED 31 MARCH, 2015
(All amounts in Indian Rupees, except for share data or as otherwise stated)

3. Share Capital

	As at 31 Mar, 2015	As at 31 Mar, 2014
50,000 (Previous Year : 50,000) Equity Shares of Rs. 10/- each	500,000	500,000
Issued, Subscribed and paid-up Capital		
50,000 (Previous Year: 50,000) Equity Shares of Rs.10 /- each, fully paid up	500,000	500,000
Total issued, subscribed and fully paid-up share capital	500,000	500,000

a. Reconciliation of number of shares:

	As at 31 Mar, 2015	As at 31 Mar, 2014
Balance as at the beginning of year	50,000	-
Add: Shares issued during the year	-	50,000
Balance at the end of the year	50,000	50,000

b. Shares held by holding company:

Out of equity shares issued by the company, shares held by its holding company are as under:

	As at 31 Mar, 2015	As at 31 Mar, 2014
Aurobindo Pharma Ltd, the holding Company		
50,000 (Previous Year:50,000)Equity Shares of Rs.10 /- each, fully paid up	500,000	500,000
	500,000	500,000

c. Terms/rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10 per share. The equity shares carry equal voting rights

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the share holders.

c. Shares held by holding/ultimate holding company and/ or their subsidiaries/associates

Out of the equity shares issued by the Company, Shares held by its holding company, ultimate holding company and their subsidiaries/associates are as below:

	As at 31 Mar, 2015		As at 31 Mar, 2014	
	No. of shares	Value	No. of shares	Value
Aurobindo Pharma Limited, the holding company	50,000	500,000	50,000	500,000
	50,000	500,000	50,000	500,000

d. Details of shareholders holding more than 5% of the aggregate shares in the Company:


	As at 31 Mar, 2015		As at 31 Mar, 2014	
Name of the Equity shareholder	No. of shares	% of holding in class	No. of shares	% of holding in class
M/s Aurobindo Pharma Ltd , The Holding company	50,000	100%	50,000	100%
	50,000	100%	50,000	100%

4. Reserves & Surplus

	As at 31 Mar, 2015	As at 31 Mar, 2014
Surplus In the Statement of profit and Loss		
Profit/(Loss) for the year	(76,088)	-
Total	(76,088)	-



2. = 9



5. Deferred Tax Asset/Liability (Net)

	As at 31 Mar, 2015	As at 31 Mar, 2014
Deferred tax liability on account of difference in depreciation	34,348	-
Deferred tax Asset arising on account of timing differences relating to: Business loss	(18,665)	-
Total	15,683	-

6. Short Term Borrowings

	As at 31 Mar, 2015	As at 31 Mar, 2014
Unsecured		
Loans from Related parties	20,500,000	-
Total	20,500,000	-

i. Unsecured Loan from Aurobindo Pharma Limited, The holding company shall be repayable on demand for a period of 3 years from the date of each disbursement and carries an interest rate of 9.5%

7. Other Current Liabilities

	As at 31 Mar, 2015	As at 31 Mar, 2014
Other Payables		
Statutory Liabilities	932,782	-
Others	49,271	11,236
Total	982,053	11,236

9. Loans & Advances

	As at 31 Mar, 2015		As at 31 Mar, 2014	
	Current	Non Current	Current	Non Current
Security Deposits & Advances	-	323,140	-	-
Pre-paid Insurance	10,904	-	-	-
Total	10,904	323,140	-	-

10. Cash and Bank Balances


	As at 31 Mar, 2015	As at 31 Mar, 2014
Cash & cash equivalents consists of		
Balances with Banks	1,868,873	473,888
Cash on hand	10,624	-
Total	1,879,497	473,888

11. Other Expenses

	Year ended 31 Mar, 2015	Year ended 31 Mar, 2014
Statutory Audit Fee	21,236	-
Registration & Filing fee	11,490	-
Bank Charges	1,679	-
Preliminary Expenses	26,000	-
Total	60,405	-


12. Earnings per share:

	Year ended 31 Mar, 2015	Year ended 31 Mar, 2014
Profit/Loss considered for calculation of basic & diluted earnings per share	(76,088)	-
No. of shares	No. of shares	No. of shares
Weighted average number of equity shares in calculating basic & diluted EPS	50,000	50,000
Face value per Share	10	10
Basic & Diluted Earnings Per share	(1.52)	-



Handwritten signature

Handwritten signature



13. Expenditure during construction period pending capitalization

	As at 31 Mar, 2015	As at 31 Mar, 2014
Preliminary Expenses	-	26,000
Pre-Operative Expenses		
Salaries & Other Benefits	16,136,018	-
Rates & Taxes	17,600	-
Postage ,telegram& telephones	150,343	-
Insurance	24,007	-
Legal & Professional Charges	224,412	11,236
Travelling Expenses	645,547	-
Interest	774,445	-
Depreciation	149,202	-
Bank Charges	-	112
Total	18,121,574	37,348

15. Related Party Disclosures:

Name of the related parties and description of relationship

Aurobindo Pharma Limited, The Holding Company

Key managerial personnel

K.Nithyananda Reddy, Director

N.Govindarajan, Director

P.Madan Mohan Reddy, Director

Transactions with related parties

1. Aurobindo Pharma Limited, Holding Company

	As at 31 Mar, 2015	As at 31 Mar, 2014
Equity contribution received	-	500,000
Unsecured Loan received	20,500,000	-
Interest Paid	697,001	-
Balance Outstanding	20,500,000	-

16. Earning in foreign currency (accrual Basis)

Export at FOB Value	-	-
17. Foreign exchange outflow		
i. Travelling expenses	189,942	-
18.FOB value of exports	-	-
19.CIF value of imports	-	-
20. Pervious year figures are regrouped, reclassified wherever necessary to confirm with the current year presentations.		
21. There are no dues to Micro, Small and Medium size companies to which the company owe amount outstanding more than 30 days.		
22. Contingent Liabilities		

As per our report of even date

For and on behalf of the Board of Directors

For G.PAVAN KUMAR & ASSOCIATES

Firm Registration Number:015343S

Chartered Accountants

(G.Pavan Kumar Reddy)

Proprietor

Membership No.229495

Place: Hyderabad

Date:21-May-2015



(K.Nithyananda Reddy)

Director

DIN:01284145

(N.Govindarajan)

Director

DIN:00050482



AUROZYMES LIMITED**Notes to financial statements for the Year ended March 31, 2015**

(All amounts in Indian Rupees, except for share data or as otherwise stated)

8. Tangible assets

	Vehicle	Total Tangible Assets
Cost		
As on April 1, 2014	-	-
Additions	1,735,735	1,735,735
Disposals	-	-
As at March 31, 2015	1,735,735	1,735,735
As at March 31, 2014	-	-
Depreciation / Amortization		
As at April 1, 2014	-	-
Charge for the year	149,202	149,202
Disposals	-	-
As at March 31, 2015	149,202	149,202
As at March 31, 2014	-	-
Net Block		
As at March 31, 2015	1,586,533	1,586,533
As at March 31, 2014	-	-

Note: Capital Work in Progress included Expenditure during construction period pending capitalization Rs 1,81,21,574 (PY:37,348)



[Handwritten signature]

[Handwritten signature]



Depreciation as per IT Act

Sl.No	Particulars	Rate %	W.D.V As On 01.04.2014	>180 days	<180 days	Deletions	Total as on 31.03.2015	Depreciation For the year	Additional	Total	W.D.V As On 31.03.2015
1	Car	15%	-		1,735,735	-	1,735,735	260,360	-	260,360	1,475,375
Total			-	-	1,735,735	-	1,735,735	260,360	-	260,360	1,475,375

-1178



1-19

3/28

